

# 2022

SCIENTIFIC REPORT

**INCLIVA | VLC**  
Biomedical Research Institute

Published by:

*Fundación Investigación Hospital Clínico Universitario de Valencia*  
INCLIVA Biomedical Research Institute  
Avd. Menéndez Pelayo, 4 Accesorio – 46010 Valencia

Managing direction:

Mr. Vicente de Juan Martín

Coordination and writing:

Scientific Management Department  
*Fundación Investigación Hospital Clínico Universitario de Valencia*  
INCLIVA Biomedical Research Institute

Design: Marta Ballester Collado

Layout: Ideas Estratégicas de Marketing y Comunicación S.L.

<b>1. Introduction</b>	5
<b>2. INCLIVA origin and structure</b>	9
2.1 History	11
2.2 Organizational structure	12
2.3 Core facilities	17
<b>3. INCLIVA global analysis</b>	19
3.1 Scientific production global analysis	21
3.2 Financial resources	24
3.3 Cooperative research networks	28
3.4 Knowledge transfer activities	29
3.5 Gender perspective	38
<b>4. Scientific activity</b>	45
4.1 Scientific structure	47
4.2 Scientific translational programs	48
4.2.1 Overweight and cardiovascular and renal risk	48
4.2.2 Detection and control of ventricular dysfunction	50
4.2.3 Rare Diseases	52
4.2.4 Neurological Decline	54
4.2.5 Translational Oncology	57
4.2.6 Reproductive Medicine	59
4.2.7 Ageing and associated diseases	61
4.3 Research areas	65
4.3.1 Cardiovascular Area	67
4.3.2 Oncology Area	100
4.3.3 Metabolism Area	135
4.3.4 Reproductive Medicine Area	187
4.3.5 Clinical Associated Groups	197
4.4 Hospital division research area	211
4.5 Other scientific contributions from scientific platforms	232
4.5.1 Biobank	232
4.5.2 Oncology Phase I Oncology Clinical Trials Unit	239
4.5.3 Spanish Clinical Research Network (SCReN), Clinical Research and Clinical Trials of the Clinical Trials Platform (UICEC INCLIVA)	241
4.5.4 Precision Medicine Unit	246
4.5.5 Bioinformatics Unit	249
4.5.6 Biostatistics Unit	251
<b>5. Clinical trials and other studies</b>	255
5.1 Activity of the Ethical Committee for investigation with medicinal products (CEIm)	257
5.2 Clinical research activity performed by Valencia Clínico-Malvarrosa Health Department	259
<b>6. Initiatives for research promotion</b>	265
6.1 Grants for external fellowships	267
6.2 Training and teaching activities	269
<b>7. Communication</b>	271
7.1 Highlights	273
7.2 Communication Indicators 2021	275
<b>8. INCLIVA social initiatives</b>	277
8.1 Philanthropic projects	283
8.2 Private philanthropic donations and acknowledgments	284
<b>9. Publication list.</b>	287



# intro- duc- tion



We are pleased to once again present the INCLIVA Annual Scientific Report, which summarizes the extensive scientific activity and achievements in 2022 of the research groups of the *Hospital Clínico Universitario de València* and the INCLIVA-affiliated groups of scientific excellence of the University of Valencia Faculty of Medicine and Dentistry and the Carlos Simón Foundation.

In 2022, the joint effort of our staff has brought us further in establishing INCLIVA as one of the predominant Biomedical Research Institutes in the country, internationally acclaimed and with a prolific research output.

This boost in INCLIVA's research activity can be observed in the formal recognition of a new emerging group in the priority research line in metabolism [Medical Chemistry Research Group for Drug Development] and a new consolidated group within the priority research line in oncology [Research Group in Molecular Microbiology and Microbial Pathogenesis], as well as in the creation of five associated clinical groups: Associated Clinical Group in Urology, Associated Clinical Group in Digestive Medicine, Associated Clinical Group in Traumatology and Orthopedics, Associated Clinical Group in Neurology and Associated Clinical Group in Pharmacy.

INCLIVA has continued to strengthen its reputation for high-quality, competitive projects, confirming the upward trend of recent years by securing almost five million euros in funding for 44 new national and regional projects. In terms of the Carlos III Health Institute-funded call for personnel, INCLIVA staff have received overall two Joan Rodés scholarships, two Río Hortega scholarships, two Miguel Servet scholarships, and one Sara Borrell scholarship. Furthermore, a national pre-doctoral scholarship from the Ministry of Science and Innovation and the Ministry of Universities and three grants from the Department of Innovation, Universities, Science and Digital Society of the Department of Health of the Generalitat Valenciana have been awarded.

Among our achievements on an international level, the Ministry of Economic Affairs and Digital Transformation has provided funding to the sum of over five million euros for the INTEGRA-CLOUD project, which will implement real time integration of health data for the Malvarrosa Department of Clinical Health in the Valencia province.

Our researchers have been highly successful in competitive calls from the European Commission, accumulating funding of almost nine million euros for projects in the fields of big data and artificial intelligence, oncology, nephrology, hypertension, digital innovation and for the Mediterranean Researchers' Night. One of these projects, AlDA (An Artificially Intelligent Diagnostic Assistant for gastric inflammation) is coordinated by INCLIVA over a four-year term and has secured over seven million euros in total funding.

# 1 introduction

Another key achievement of 2022 is our participation in international networks such as the Big Data Value Association (BDVA/DAIRO), the European infrastructure for translational medicine (EATRIS), the European high-capacity screening network (EU-OPENSCREEN) and the Worldwide innovative networking (WIN) in personalized cancer medicine.

Regarding scientific output, our research staff published 786 articles in 2022, with a cumulative impact factor of over 8,500 points. The quality of our research output should also be highlighted: around 80% of the published articles are in the first and second quartiles, 20% in the first decile and 29% have an impact factor above 7. Furthermore, 52% of scientific output involved international collaboration. A total of 51 doctoral theses were also defended in 2022, 11 of which received European mention.

Turning to clinical trials, our Drug Research Ethics Committee (CEIm) at the *Hospital Clínico Universitario de Valencia*, the first in the Valencian Community and among the first nationally to receive this certification, has been a review board of reference in 91 clinical studies since the new legislation was approved in 2016. During 2022 INCLIVA has initiated 105 new clinical studies and has participated in 687 active studies.

The Innovation Unit has been further consolidated both in INCLIVA and within the business community. Together with the Maxillofacial Surgery Unit of the *Hospital Clínico Universitario de Valencia*, this unit has supported the creation of the Advanced Diagnostics Unit, which uses 3D printing and medical imaging to improve patient care and reduce the side effects of complex surgeries. In addition, it has promoted innovative projects with companies and technology centres and has actively collaborated with four INCLIVA spin-offs.

Finally, in 2022 we also published the Interim Report of the II INCLIVA Equality Plan (2020–2024), which includes a General Employee Training Plan, reflecting the institute's commitment to equality policies.



Mr. Andrés Cervantes Ruipérez  
INCLIVA Scientific Director

# origin & struc- ture

INCLIVA SCIENTIFIC REPORT 2022



# INCLIVA origin and structure

## 2.1. History

The *Hospital Clínico Universitario de Valencia* Research Foundation was constituted in the year 2000 as the first Valencian research foundation affiliated to a public hospital. Ten years later, various centers of excellence in biomedical research from the University of Valencia and Carlos Simón Foundation joined the Foundation through the establishment of specific agreements, and thus INCLIVA Biomedical Research Institute was created.

INCLIVA's main aims are to manage the biomedical research carried out by the *Hospital Clínico Universitario de Valencia* and its Health Department, and to encourage teaching and scientific activities, thus improving patient treatment and knowledge sharing.

In 2011 INCLIVA was accredited as a Biomedical Research Institute by the Ministry of Science and Innovation (*Ministerio de Ciencia e Innovación*) thus obtaining preferential treatment from the Carlos III Health Institute (*Instituto de Salud Carlos III*), in recognition of its excellence in research.

In 2021 INCLIVA received the official notification of renewal of its accreditation as Biomedical Research Institute for the next five years.



# INCLIVA origin and structure

## 2.2. Organizational structure

### 2.2.1. Government structure

The highest government body in the Foundation, the Board of Trustees is headed by the Regional Minister for Health of the Valencian Government. This body appoints a Board of Governors – headed by the Chief Executive Officer of the Health Department –, the Managing Director and the Scientific Director. These are guided by two Research Committees: the External Scientific Committee and the Internal Scientific Committee.

#### 2.2.1.1 Board of Trustees

**President**, Mr. Miguel Minguez, Honorable Counselor of the High Sanitary Inspection of the *Conselleria de Sanidad Universal y Salud Pública* (Autonomous Public Health Department) of the Valencian Government

**Vice-president**, Mr. Álvaro Bonet, Chief Executive Officer of the *Hospital Clínico Universitario of Valencia* and of the Valencia Clínico – Malvarrosa Health Department

##### Board members

- Mrs. María Vicenta Mestre, Distinguished Dean of the University of Valencia
- Mr. Francisco Javier Chorro, Distinguished Dean of the Faculty of Medicine of the University of Valencia
- Mrs. Emilia Adán García, President of the Social Council of the University of Valencia
- Mr. Juan López-Trigo Pichó, Cañada Blanch Foundation
- Mr. Rafael Alcón Traver, President of Bancaja Foundation
- Mr. José Bernardo Noblejas Pérez, Valencia Chamber of Commerce, Industry and Navigation
- Mrs. Concha Andrés Sanchis, Autonomous Secretary of Efficiency and Health Technology of the *Conselleria de Sanidad Universal y Salud Pública* (Autonomous Public Health Department) of the Valencian Government

cency and Health Technology of the *Conselleria de Sanidad Universal y Salud Pública* (Autonomous Public Health Department) of the Valencian Government

- General Director of Research and High Sanitary Inspection of the *Conselleria de Sanidad Universal y Salud Pública* (Autonomous Public Health Department) of the Valencian Government
- Mrs. Núria Vizcarro Boix, Valencian Council of Culture
- Mr. Carlos Simón, Scientific Director of the Carlos Simón Foundation
- Mr. Rubén Ventura, Fero Foundation
- Mrs. Bárbara Congost Mirón, FEDER (Spanish Federation of Rare Diseases) representative

##### Board members under own name

- Mr. Carlos Pascual de Miguel
- Mr. Joaquín Ortega Serrano
- Mr. Tomás Trénor Puig
- Mrs. Ana Lluch Hernández
- Mrs. Àngela Nieto Toledano

#### 2.2.1.2 Board of Governors

**President**, Mr. Álvaro Bonet Pla, Chief Executive Officer of the *Hospital Clínico Universitario of Valencia* and of the Valencia Clínico – Malvarrosa Health Department

**Vice-president**, Mr. Francisco Javier Chorro, Distinguished Dean of the Faculty of Medicine of University of Valencia

##### Vocals

- Mr. Andrés Cervantes Ruipérez, INCLIVA Scientific Director
- Mr. Vicente de Juan Martín, Managing Director

• Mrs. Ana Sanmartín Almenar, Primary Care Director of the *Hospital Clínico Universitario of Valencia* and of the Valencia Clínico – Malvarrosa Health Department

• Mr. Jorge Navarro Pérez, Medical Director of the *Hospital Clínico Universitario of Valencia* and of the Valencia Clínico – Malvarrosa Health Department

• Director of Research and High Sanitary Inspection of the *Conselleria de Sanidad Universal y Salud Pública* (Autonomous Public Health Department) of the Valencian Government

# INCLIVA origin and structure

- Mr. Pascual Medina Besó, Coordinator of Central Medical Research Unit of the Faculty of Medicine of University of Valencia
- Mr. Manuel Alós, Head of the Pharmacy Service of *Hospital Clínico Universitario de Valencia* and of the Valencia Clínico – Malvarrosa Health Department
- Mrs. Marisa Luisa Calabuig, President of Ethic Committee for Investigation with medicinal products
- Mr. Federico Pallardó, Professor of the Department of Physiology of the University of Valencia
- Mr. Carlos Simón, Scientific Director of the Carlos Simón Foundation
- Mrs. Maite Sáenz, Secretary General

## 2.2.1.3 Managing Director

Mr. Vicente de Juan Martín, INCLIVA IIS Economic Director from 2016 to 2022, this year he has been appointed managing director of the institution by the Board of Trustees, at the proposal of the Governing Board. His functions are included in article 20 of the Statutes dated 3 May 2022. He is an ex officio member of the Governing Board and advisory member of the Board of Trustees. He is the designated representative of the Foundation in the absence of the President and Vice Presidents, and directs the Foundation's economic policy, following the decisions of the governing bodies of the Foundation. He formulates the entity's Action Plan and Annual Accounts for approval by the Board of Trustees, holding the position of chief of staff.

## 2.2.1.4 Scientific Director

Professor Andrés Cervantes Ruipérez is Full Professor of Medicine at the University of Valencia, Head of the Oncology Service of the *Hospital Clínico Universitario de Valencia* and Director of the Cancer Area at the INCLIVA Biomedical Research Institute.

His training as a resident medical intern took place at the *Hospital Clínico Universitario de Valencia*. After completing this residency, he obtained a predoctoral fellowship at the Free University Hospital in Amsterdam, where he obtained his Doctorate in the laboratory of cellular pharmacology, with work on multidrug resistance.

His areas of interest and research are gastrointestinal and gynecological cancer, as well as phase I trials and new drugs development.

As a clinical researcher in rectal cancer, he has published several papers on the quality of multidisciplinary work as well as on evaluating the quality of mesorectal surgery, how to optimize initial therapy choices and especially, how to treat cancer of the upper third of the rectum.

He is the President of the European Society of Medical Oncology (ESMO) since July 2019.

## 2.2.1.5 External Scientific Committee

**President**, Mr. Javier Díez. Professor of Medicine, University of Navarra. Director of the Cardiovascular Sciences Area, Center for Applied Medical Research (CIMA). University of Navarra

### Vocals

- Mr. Antonio Vidal-Puig. Professor of Molecular Nutrition and Metabolism, University of Cambridge. Honorary consultant in metabolic medicine. Metabolic research laboratories. Addenbrooke's Hospital, Cambridge, United Kingdom
- Mr. Josep Tabernero Caturla. Head of the Medical Oncology Service. Vall d'Hebrón Hospital.
- Mr. Juan Carlos Laca Sanjuán. Research Professor at the CSIC. Institute of Biomedical Research, Madrid
- Mr. Manuel Tena Sempere. Professor of University. Department of Cell Biology, Physiology and Immunology. University of Cordoba
- Mr. M Roser Torra Balcells. Nephrologist, Fundació Puigvert. Research line in the study of Hereditary Kidney Diseases
- Mrs. Laura Saucék. Group leader at VHIO (Oncology Institute of the Vall d'Hebron Hospital). Head of Modeling of Anti-tumor Therapies in mice. Founder executive director (CEO) at Peptomyics SL
- Mrs. Pura Muñoz Cánoves. Professor of Medicine, Department of Experimental and Health Sciences at Pompeu Fabra University. ICREA Research Professor

# INCLIVA origin and structure

## 2.2.1.6 Internal Scientific Committee

- Mr. Andrés Cervantes Ruipérez, INCLIVA Scientific Director
- Mrs. Ana Sanmartín Almenar, Primary Care Director of the *Hospital Clínico Universitario of Valencia* and of the Valencia Clínico-Malvarrosa Health Department
- Mr. Jorge Navarro Pérez, Medical Director of the *Hospital Clínico Universitario of Valencia* and of the Valencia Clínico-Malvarrosa Health Department
- Mr. Julio Núñez, Associate Professor of the Department of Medicine of the University of Valencia, attached to the Scientific Direction
- Mr. Vicente Bodí, Full Professor of the Department of Medicine of the University of Valencia
- Mr. Josep Redón, INCLIVA Emeritus Researcher
- Mr. Federico Pallardó, Full Professor of the Department of Physiology of the University of Valencia
- Mrs. María Jesús Sanz Ferrando, Full Professor of the Department of Pharmacology at the University of Valencia
- Mrs. Ana Lluch Hernández, Emeritus Professor of the Department of Medicine of the University of Valencia
- Mrs. María del Mar Tormo García, Oncologist at the *Hospital Clínico Universitario of Valencia* and of the Valencia Clínico - Malvarrosa Health Department Hematology Service
- Mr. Felip Vilella Mitjana, researcher at INCLIVA
- Mrs. Isabel Gabaldón Sánchez, Valencia Clínico-Malvarrosa Health Department
- Mr. David Moro Valdezate, General Surgery Associate Physician
- Mrs. Laura Piquerias Ruiz, researcher at INCLIVA
- Mrs. Patricia Roselló, Pediatrics Associated Physician
- Mr. Sergio Martínez Hervás, Endocrinology and Nutrition Associated Physician
- Mrs. Herminia González Navarro, researcher at INCLIVA
- Mrs. Pilar Eroles Asensio, researcher at INCLIVA
- Mrs. M<sup>a</sup> Cruz González Villaescusa, Neumology Associate Physician
- Mrs. Carmina Montoliu Félix, researcher at INCLIVA
- Mr. José Real Collado, Head of the Endocrinology and Nutrition Service
- Mr. Raúl Gómez Gallego, researcher at INCLIVA
- Mr. F. Javier Chaves Martínez, researcher at INCLIVA
- Mr. Daniel Monleón Salvadó, researcher at INCLIVA
- Mrs. Desamparados Roda Pérez, Oncology Associate Physician
- Mr. Carlos Tornero Tornero, Head of the Anesthesia/ Reanimation Service
- Mrs. Nuria Cabedo Escrig, researcher at INCLIVA
- Mrs. Pilar Rentero Garrido, coordinator of Precision Medicine Unit
- Mrs. Ana Belén Paes, researcher at INCLIVA
- Mr. José Luis Górriz Teruel, Head of the Nephrology Service
- Mr. Antonio Martínez Sabater, general supervisor at the *Hospital Clínico Universitario de Valencia*
- Mr. César Ríos Navarro, researcher at INCLIVA
- Mrs. Lorena Peiró Chova, researcher at Biobank

### RESEARCH COMMISSION

**President:** Mr. Luis Sabater Ortí, Section Head of the General Surgery

#### Vocals:

- Mrs. Marta Peiró Signes, Scientific Subdirector at INCLIVA
- Mr. Julio Núñez Villota, Cardiology Associate Physician
- Mr. Jaime Signes-Costa, Neumology Service Head
- Mrs. Rosa Zaragozá Colom, researcher at INCLIVA
- Mr. Vicente José Bodí Peris, Professor of the Department of Medicine of the University of Valencia
- Mrs. M<sup>a</sup> José Terol Castera, Hematology and Hemotherapy Associated Physician
- Mrs. Gema Miñana Escrivá, Cardiology Associate Physician

**Commission Management Unit:** Mrs. Sofía Galant

# INCLIVA origin and structure

## INNOVATION COMMISSION

**President:** Mr. Andrés Cervantes Ruipérez, INCLIVA Scientific Director

**Commission Management:** Mrs. Rita Pastor, Head of UAI

- Mr. Vicente de Juan Martín, Managing Director
- Mr. Jorge Navarro Pérez, Medical Director of the *Hospital Clínico Universitario de Valencia* and of the Valencia Clínico – Malvarrosa Health Department
- Mrs. Marta Peiró Signes, Scientific Subdirector at INCLIVA
- Mrs. Maite Sáenz González, Secretary General at INCLIVA
- Mr. Josep Redón, INCLIVA Emeritus Researcher
- Mr. Miguel Puche Torres, Clinical researcher with experience in

the field of innovation

- Mr. Jose Luis García, Basic researcher with experience in the field of innovation
- Mr. Rubén Artero Allepuz, Basic researcher with experience in the field of innovation
- Mrs. Consuelo Borrás Blasco, Basic researcher with experience in the field of innovation
- Mr. Felip Vilella Mitjana, Basic researcher with experience in the field of innovation
- Mrs. Carolina Mir Sánchez, Clinical researcher with experience in the field of innovation
- Mrs. Maite Sánchez, Clinical researcher with experience in the

field of innovation

## 2.2.1.7. Ethics Committee for Investigation with Medicinal Products

**President:** Mrs. M<sup>a</sup> Luisa Calabuig Muñoz, Specialist of the Hematology Department

**Vice-president:** Mr. Esteban Morcillo Sánchez, Clinical pharmacologist

**Technical Secretary:** Mr. Manuel Alós Almiñana, Head of the Pharmacy Department

**Vocals:**

- Mr. Diego V. Cano Blanquer, Hospital Pharmacist
- Mr. José Luis Trillo Mata, Primary Care Pharmacist
- Mr. David Juan López Ortega, Law Degree
- Mrs. Carmen Celda Ortega, Nurse
- Mr. Luis González Luján, Primary Attention doctor
- Mr. Joaquín Ortega Serrano, Head of the General Surgery Service
- Mrs. Patricia Roselló Millet, Specialist of the Pediatrics Department
- Mrs. M<sup>a</sup> Jesús Puchades Montesa, Specialist of the Nephrology Department
- Mr. José Alejandro Pérez Fidalgo, Specialist of the Oncology Department

- Mrs. Tania Fleitas Kanonnikoff, Specialist of the Oncology Department
- Mr. Antonio Peláez Hernández, Allergy Specialist
- Mr. Francisco Dasí Fernández, Stabilized Miguel Servet Researcher
- Mr. Ángel Martínez Brotons, Assistant Physician of Cardiostimulation of Cardiology Department
- Mrs. Carolina Mir Sánchez, Primary Care Team Family Physician
- Mr. Manuel Corell Raga, Health Council of the CS of the Argentine Republic, Salvador Pau I Xile
- Mr. Rafael Barajas Cenobio, Responsible for Quality and Data Protection INCLIVA

**Administrative Secretary:** Mrs. Sofía Galant, Mr. Carlos Ballesteros

**Administrative:** Mrs. Maialen Llopis


# INCLIVA origin and structure

## 2.2.2. Management structure

The organizational chart, approved at the Board of Trustees, is comprised of two sub-directorates, economical and scientific.

The first sub-directorate is in charge of the administrative area, which deals with the financial and administrative matters as well as with human resource management.

The second sub-directorate is in the charge of scientific activity management and innovation. It is responsible for integral scientific management that includes controlling and monitoring clinical trials and research projects, organizing courses, conferences and seminars, and several tasks related to general administration. Furthermore, it acts as an administrative support to the different affiliated scientific committees and to the Medical Research Central Unit. It comprises the innovation area in charge of quality and planning, innovation management, international programs and scientific and innovative culture promotion (UCCI).



# INCLIVA origin and structure

## ADMINISTRATIVE AREA:

- Managing Director: Vicente de Juan
- Budget Control and Economic Management: Consuelo López
- Human Resources and Equality Unit: Ruth Cano, Anabel Gil, Lucía Toledo
- Invoicing and Project Justify: Vera Marín, Lorena Munuera
- Accounting: M<sup>a</sup> José Rosalén, M<sup>a</sup> Pilar Boix
- Records Unit: Alicia Belenguer
- Purchasing Unit: Isabel Gomis, Karen Iglesias
- General Services Unit: Cristina García
- Receptionists: Inmaculada Montalt, Alicia Gumié

## SCIENTIFIC MANAGEMENT AREA:

- Scientific Subdirector and Project Management: Marta Peiró
- Scientific Culture Unit: Mercedes Navarro, Natividad Paz
- International Projects Unit: Ana Ferrer, Ana Duarte, Eugenia Flores
- Innovation Management Unit: Marta de Olmo, Carlos Guerrero, Rita Pastor
- Clinical Trials Management Unit: Alexandra Pons, M<sup>a</sup> Carmen Román
- Clinical Trials Platform: Ana Portolés, Mercedes Peris, Mireya Ferrandis, Carlos Peris, Patricia Caunedo

- Training and Events Unit: Cristina García, Mercedes Navarro, Natividad Paz, Clara Soriano
- CElm Administrative Management: Sofía Galant, Maialen Llopis, Carlos Ballesteros
- Data Quality and Protection: Rafael Barajas, María Domínguez
- Scientific Production Unit: Patricia Mañas
- Communication: Alexandra Muñoz, Arantxa Martín

## COMPUTING UNIT:

- Head of Information Systems and High Performance Computing: Miguel Herreros
- Software engineer and IT system administrator: Enrique Herreras
- Computer technicians: Joan Josep Bruno Ramírez, Ángel Antonio Hernández, Antonio Macías, Francisco Sánchez, Germán Sánchez

## SECRETARY GENERAL

- Head: Maite Saenz
- Technician: Lorena Munuera, Irene Collado


## 2.3. Core facilities

### RESEARCH SUPPORT PLATFORMS

- Animal Housing and Experimental Operating Theaters Unit
- Biomedical imaging and metabolomics Section
- Flow Cytometry and Cell Culture Section
- Multigenic Analysis Unit
- Microscopy Unit
- Personal Autonomy, Dependence and Severe Mental Disorders Assessment Unit

### INCLIVA PLATFORMS

- Biobank
- Bioinformatics Unit
- Biostatistics Unit
- Big Data and Artificial Intelligence
- Body Composition Unit
- Cytogenetics Laboratory
- Precision Medicine Unit



# global analy- sis

INCLIVA SCIENTIFIC REPORT 2022





# global analysis

## 3.1 Scientific production global analysis

As in previous year, INCLIVA continued in 2022 with the upward trend in the quality of scientific production. The number of publications this year is 786, with a cumulative impact factor of 8.511,685 which translates into an average impact factor 10.829.


The following figures depict the number and quality of the published manuscripts expressed in terms of total and average impact factor.

**786**  
Publications




# 3 global analysis

The distribution by quartiles within their thematic categories is shown below. In 2022, about 80% of the papers that were published in indexed journals belong to the first and second quartiles of their corresponding thematic categories:





The number and percentage of scientific publications according to category are:

Category	Value
Articles	654
Case reports	10
Corrections	11
Editorials	35
Letters	31
Practice Guideline	8
Reviews	48




The percentage of originals in first decile and first quartile publications in 2022 are:




Cardiovascular   Oncology   Metabolism   Reproductive   Associated Clinical Groups   Hospital divisions

# global analysis

One of the main success factors for a biomedical research institution has to do with its potential to establish high level scientific collaborations. The percentage of national and international collaborations which led to scientific output in 2022 is listed below.




Another key performance indicator is the leadership role in scientific publications. The chart below shows the number of published articles in which INCLIVA researchers sign as corresponding author, first and last author.



# 3 global analysis



## 3.2. Financial resources

INCLIVA's funding during 2022 totaled €15.669.321. The funds raised from competitive sources were still higher than the average of recent years.



Funding source in the indicated period is shown below.

The remaining income corresponds to private sources of funding, clinical trial revenues and grants among others. The graph below shows this distribution of the year 2022.



# global analysis

The analysis of the income obtained by the Foundation in its last fiscal year (2022) is shown in the table.

INCOME	AMOUNT	OVERHEADS	TOTAL
TURNOVER	6.174.197,83	1.343.956,79	7.518.154,62
DONATIONS	346.781,22	14.044,07	360.825,29
GRANTS	5.882.663,77	663.785,70	6.546.449,47
CAPITAL GRANTS	1.230.115,68		1.230.115,68
FINANCIAL	0,00		0,00
EXTRAORDINARY	13.776,42		13.776,42
<b>TOTAL INCOME</b>	<b>13.647.534,92</b>	<b>2.021.786,56</b>	<b>15.669.321,48</b>

Also used as a source of information the Annual Accounts of 2022 approved by the Board of Trustees of the Foundation and audited by the General Intervention of the Generalitat Valenciana [through the audit firm DULA Auditores] the information of the expenses executed is provided, with the explanation of the use of the corresponding indirect costs.

EXPENSES	TOTAL
CASH FUNDING	148.495,41
SUPPLIES	1.343.354,75
OTHER FUNCIONAL EXPENSES (ACTIVITY)	2.493.007,70
STAFF COSTS	7.807.898,46
OTHER FUNCIONAL EXPENSES (STRUCTURAL)	441.151,94
EXTRAORDINARY EXPENSES	182.319,30
INVENTORY ITEM DONATION EXPENSES	49.489,58
AMORTIZATION OF FIXED ASSETS	1.488.855,74
<b>TOTAL EXPENSES</b>	<b>13.954.572,88</b>

# 3 global analysis

Finally, this is the balance sheet of the foundation in official format, extracted from the Annual Accounts of 2022:

		ASSETS	FISCAL YEAR	FISCAL YEAR
			2022	2021
A)		NON-CURRENT ASSETS	<b>16.887.219,94</b>	<b>16.571.327,92</b>
	I.	Intangible assets	2.358.857,93	2.453.753,52
	2.	Concessions	2.353.336,42	2.443.818,38
	3.	Patents, licences, trademarks and similar rights	5.521,51	6.057,50
	5.	Computer Software	0,00	3.877,64
	III.	Investment property	5.989.060,62	6.946.953,82
	2.	Technical facilities and other tangible fixed assets	5.972.680,62	6.946.953,82
	3.	Fixed assets in progress and advances	16.380,00	
	VI.	Deferred tax assets	8.539.301,39	7.170.620,58
	1.	Other government loans	1.592.291,02	3.298.442,07
	2.	Other government loans group and associated companies	362.455,10	944.443,16
	3.	Other loans from private entities	418.377,38	547.826,75
	4.	Other loans from private entities group and associated companies	100.000,00	238.706,62
	5.	Other European Union loans	6.066.177,89	2.141.201,98
B)		CURRENT ASSETS	<b>37.436.524,47</b>	<b>26.406.646,77</b>
	III.	Trade and other receivables	4.817.935,36	5.341.276,58
	1.	Trade and other receivables	4.659.582,58	5.197.271,07
	2.	Trade and other receivables group and associated companies	158.352,78	144.005,51
	IV.	Current Investments in group companies and associates	14.785.902,39	7.121.236,16
	1.	Other government loans	10.004.515,78	4.352.505,41
	2.	Other government loans group and associated companies	4.781.386,61	2.768.730,75
	VI.	Prepayments for current assets	16.416,00	2.416,00
	5.	Other financial assets	16.416,00	2.416,00
	VII.	Short-term periodicities	63.207,45	
	VIII.	Cash and cash equivalents	17.753.063,27	13.941.718,03
	1.	Cash	17.753.063,27	13.941.718,03
<b>TOTAL ASSETS (A + B)</b>			<b>54.323.744,41</b>	<b>42.977.974,69</b>

# global analysis

3

EQUITY AND LIABILITIES			FISCAL YEAR	FISCAL YEAR
			2022	2021
A)		EQUITY	19.562.182,56	18.989.637,34
		Capital and reserves without valuation adjustments	13.828.334,80	12.113.586,20
I.		Endowments	617.482,67	617.482,67
II		Reserves	11.496.103,53	8.954.504,50
2.		Other reserves		
IV.		Profit/[loss] for the period	1.714.748,60	2.541.599,03
		Grants, donations or gifts and legacies received	5.733.847,76	6.876.051,14
B)		NON-CURRENT LIABILITIES	11.311.436,15	6.151.112,04
II.		Non-current payables	11.311.436,15	6.151.112,04
5.		Other financial liabilities	10.848.981,05	5.006.668,88
6.		Other short-term debts with group companies and associates	462.455,10	1.144.443,16
C)		CURRENT LIABILITIES	23.450.125,70	17.837.225,31
II		Current provisions	493.084,63	403.165,16
1.		Other provisions	98.030,75	98.030,75
2.		Other provisions with group companies and associates	395.053,88	305.134,41
III.		Current payables	16.652.347,16	11.170.599,37
5.		Other financial liabilities	13.741.966,43	9.761.987,65
6.		Other short-term debts with group companies and associates	2.910.380,73	1.408.611,72
V.		Beneficiaries-Creditors	3.256.523,90	1.330.461,39
VI.		Trade creditors and other accounts payable	3.048.170,01	4.865.913,38
1.		Suppliers	109.704,82	169.342,41
3.		Other payables	284.253,88	145.589,02
4.		Personnel [salaries payable]	-11,29	-0,80
5.		Current tax liabilities	74,32	0,00
6.		Public entities, other	2.451.877,54	4.550.982,75
7.		Advances from customers	202.270,74	67.086,01
TOTAL EQUITY AND LIABILITIES (A + B + C)			54.323.744,41	42.977.974,69

# 3 global analysis

## 3.3 Cooperative research networks

The Carlos III Health Institute (*Instituto de Salud Carlos III*) develops – through the General Subdirection of Networks and Centers for the Cooperative Research – the creation of stable research network structures such as CIBER (Network of Centres for Biomedical Research). INCLIVA participates in this research structure through its associated groups.

The following table shows the participation in scientific networks according to the prioritized research area, the center and its principal investigator.

### CIBER

Research Area	INCLIVA PI		Scientific Network	Reference
Cardiovascular	Mr. José Tomás Real Collado	CIBERdem		CB07/08/0018
	Mrs. Empar Lurbe i Ferrer	CIBERRobn		CB06/03/0039
	Mr. Francisco Javier Chorro Gascó	CIBERcv		CB16/11/00486
	Mr. Juan Sanchis Forés	CIBERcv		CB16/11/00420
Metabolism and Organ Damage	Mr. Esteban Morcillo Sánchez	CIBERes		CB06/06/0027
	Mr. Federico V. Pallardó Calatayud	CIBERer		CB06/07/0073
	Mr. Juan Nacher Roselló	CIBERSam		CB07/09/006
	Mr. Rafael Tabarés Seisdedos	CIBERSam		CB07/09/0021
	Mr. José Viña Ribes	CIBERfes		CB16/10/00435
Oncology	Mr. Andrés Cervantes Ruipérez	CIBERonc		CB16/12/00473
	Mrs. Rosa Noguera Salvá	CIBERonc		CB16/12/00484

# global analysis

## 3.4 Knowledge transfer activities

INCLIVA Biomedical Research Institute is fully committed to transfer the knowledge created both to the National Health System and to the industrial sector in order to fulfil its organizational mission.

### 3.4.1 Knowledge transfer to the National Health System

Clinical guidelines and consensus documents are one of the best indicators of knowledge transfer from research to clinical practice. The following table shows the guidelines published in indexed journals in which authors affiliated with INCLIVA have participated.

Clinical guidelines	IF
8	198,789

- Bergeron A, Mikulska M, De Greef J, Bondeelle L, Franquet T, Herrmann J, Lange C, Spriet I, Akova M, Donnelly J, Maertens J, Maschmeyer G, Rovira M, Goletti D, de la Camara R. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia. *Lancet Infectious Diseases*. 2022 Dec;22(12):e359-e369. doi: 10.1016/S1473-3099(22)00227-4. PMID: 35636446. IF: 71,421
- Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth E. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology*. 2022 Oct;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. PMID: 35914639. IF: 51,769
- Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology*. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. PMID: 35914638. IF: 51,769
- SEC Working Group for the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and SEC Guidelines Committee. Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Revista Espanola de Cardiologia* (English Ed.). 2022 Jun;75(6):458-465. doi: 10.1016/j.rec.2021.11.023. PMID: 35190290. IF: 6,975
- Arrarte V, Campuzano R, Duque J, Aldama G, Barrios V, Bonanad C, Conde A, Olmo R, Gamez J, Guzman-Martinez G, Rey C, Vivas D, Avanzas P, Congost G, Boraite A, Bueno H, Calvo D, Delgado V, Dos L, Ferreira-Gonzalez I, Doblas J, Figal D, Sambola A, Tejedor A, Ferreiro J, Alfonso F. Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. *Revista Española de Cardiología*. 2022 May;75(5):364-369. doi: 10.1016/j.rec.2021.10.023. PMID: 35165071. IF: 6,975
- Barretina Ginesta MP, Quindos M, Alarcon JD, Esteban C, Gaba L, Gomez C, Perez Fidalgo JA, Romero I, Santaballa A, Rubio Perez MJ. SEOM-GEICO clinical guidelines on endometrial cancer [2021]. *Clinical & Translational Oncology*. 2022 Apr;24(4):625-634. doi: 10.1007/s12094-022-02799-7. PMID: 35312947. IF: 3,34
- Capdevila J, Gomez MA, Guillot M, Paez D, Pericay C, Safont MJ, Tarazona N, Vera R, Vidal J, Sastre J. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer [2021]. *Clinical & Translational Oncology*. 2022 Apr;24(4):646-657. doi: 10.1007/s12094-022-02816-9. PMID: 35303269. IF: 3,34
- Mingot Castellano M, Pascual Izquierdo C, Gonzalez A, Viejo Llorente A, Valcarcel Ferreiras D, Sebastian E, Garcia Candel F, Sarmiento Palao H, Gomez Segui I, de la Rubia J, Cid J, Martinez Nieto J, Hernandez Mateo L, Goterris Viciedo R, Fidalgo T, Salinas R, Del Rio-Garma J, Grupo Espanol de Aferesis (GEA). Recommendations for the diagnosis and treatment of patients with thrombotic

# global analysis

thrombocytopenic purpura. Medicina Clinica. 2022 Jun 24;158(12):630.e1-630.e14. doi: 10.1016/j.medcli.2021.03.040. PMID: 34266669. IF: 3,2

Consensus documents	IF
9	115,762

- Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski R, Curigliano G, Felip E, Ferreira A, Ganz P, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge A, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Annals of Oncology. 2022 Nov;33(11):1119-1133. doi: 10.1016/j.annonc.2022.07.1941. PMID: 35963481. IF: 51,769
- de Simone G, Mancusi C, Hanssen H, Genovesi S, Lurbe E, Parati G, Sendzikaitė S, Valerio G, Di Bonito P, Di Salvo G, Ferrini M, Leeson P, Moons P, Weismann C, Williams B. Hypertension in children and adolescents a consensus document from ESC Council on Hypertension, European Association of Preventive Cardiology, European Association of Cardiovascular Imaging, Association of Cardiovascular Nursing & Allied Professions, ESC Council for Cardiology Practice and Association for European Paediatric and Congenital Cardiology. European Heart Journal. 2022 Sep 14;43(35):3290-3301. doi: 10.1093/eurheartj/ehac328. PMID: 35896123. IF: 35,855
- Mediano O, Gonzalez Mangado N, Montserrat J, Alonso-Alvarez M, Almendros I, Alonso-Fernandez A, Barbe F, Borsini E, Caballero-Eraso C, Cano-Pumarega I, de Carlos Villafranca F, Carmona-Bernal C, Carrillo Alduenda J, Chiner E, Cordero Guevara J, de Manuel L, Duran-Cantolla J, Farre R, Franceschini C, Gaig C, Garcia Ramos P, Garcia-Rio F, Garmendia O, Gomez Garcia T, Gonzalez Pondal S, Hoyo Rodrigo M, Lecube A, Antonio Madrid J, Maniegas Lozano L, Martinez Carrasco J, Masa J, Masdeu Margalef M, Mayos Perez M, Mirabet Lis E, Monasterio C, Navarro Soriano N, Olea de la Fuente E, Plaza G, Puertas Cuesta F, Rabec C, Resano P, Rigau D, Roncero A, Ruiz C, Salord N, Saltijeral A, Sampol Rubio G, Sanchez Quiroga M, Sans Capdevila O, Teixeira C, Tinahones Madueno F, Maria Togeiro S, Troncoso Acevedo M, Vargas Ramirez L, Winck J, Zabala Urionaguena N, Egea C. International consensus document on obstructive sleep apnea. Archivos de Bronconeumología. 2022 Jan;58(1):T52-T68. doi: 10.1016/j.arbres.2021.03.027. PMID: 35245183. IF: 6,333
- Mediano O, Gonzalez Mangado N, Montserrat J, Alonso-Alvarez M, Almendros I, Alonso-Fernandez A, Barbe F, Borsini E, Caballero-Eraso C, Cano-Pumarega I, de Carlos Villafranca F, Carmona-Bernal C, Carrillo Alduenda J, Chiner E, Cordero Guevara J, de Manuel L, Duran-Cantolla J, Farre R, Franceschini C, Gaig C, Garcia Ramos P, Garcia-Rio F, Garmendia O, Gomez Garcia T, Gonzalez Pondal S, Hoyo Rodrigo M, Lecube A, Madrid J, Maniegas Lozano L, Martinez Carrasco J, Masa J, Masdeu Margalef M, Mayos Perez M, Mirabet Lis E, Monasterio C, Navarro Soriano N, Olea de la Fuente E, Plaza G, Puertas Cuesta F, Rabec C, Resano P, Rigau D, Roncero A, Ruiz C, Salord N, Saltijeral A, Sampol Rubio G, Sanchez Quiroga M, Sans Capdevila O, Teixeira C, Tinahones Madueno F, Maria Togeiro S, Troncoso Acevedo M, Vargas Ramirez L, Winck J, Zabala Urionaguena N, Egea C, el Spanish Sleep Network. International Consensus Document on obstructive sleep apnea. Archivos de Bronconeumología. 2022 Jan;58(1):52-68. doi: 10.1016/j.arbres.2021.03.017. PMID: 33875282. IF: 6,333
- Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, Castro A, Cebrian-Cuenca A, De Torres-Sanchez A, Garcia-de-Lucas MD, Nunez J, Obaya JC, Soler MJ, Gorrioz JL, Rubio-Herrera MA. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. Journal of Clinical Medicine. 2022 Dec 24;12(1):145. doi: 10.3390/jcm12010145. PMID: 36614945. IF: 4,964
- Barrios V, Beato P, Brotons C, Campuzano R, Merino-Torres J, Mostaza J, Plana N, Rubio J, Comellas M. Comprehensive management of risk factors in peripheral vascular disease. Expert consensus. Revista Clinica Espanola. 2022 Feb;222(2):82-90. doi: 10.1016/j.rceng.2020.11.011. PMID: 34217671. IF: 3,064

# global analysis

7. Pinana J, Vazquez L, Martino R, de la Camara R, Sureda A, Rodriguez-Veiga R, Garrido A, Sierra J, Ribera J, Torrent A, Mateos M, de la Rubia J, Tormo M, Diez-Campelo M, Garcia-Gutierrez V, Alvarez-Larran A, Sancho J, MartinGarcia-Sancho A, Yanez L, Simon J, Barba P, Abrisqueta P, Alvarez-Twose I, Bonanad S, Lecumberri R, Ruiz-Camps I, Navarro D, Hernandez-Rivas J, Cedillo A, Garcia-Sanz R, Bosch F. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. *Leukemia & Lymphoma*. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. PMID: 34668835. IF: 2,996
8. Cilleruelo Ramos Á, Figueroa Almánzar S, López Castro R, Martínez Hernández NJ, Mezquita Pérez L, Moreno Casado P, Zabaleta Jiménez J. Spanish Society of Thoracic Surgery (SECT) consensus document. Long-term follow-up for operated patients with lung cancer. *Cirugía Espanola*. 2022 Jun;100(6):320-328. doi: 10.1016/j.cireng.2022.05.024. PMID: 35643357. IF: 2,242
9. Ejarque Domenech I, Marin Reina P, Garcia-Minaur Rica S, Chirivella Gonzalez I, Martinez Martinez M, Garcia Rodriguez A, Alvarez de Andres S, Telleria Orriols J. Referral criteria to clinical genetics from primary care: consensus document. *Atencion Primaria*. 2022 Nov 11;54(12):102501. doi: 10.1016/j.aprim.2022.102501. PMID: 36375295. IF: 2,206

Intitutional Documents	IF
9	117,91

1. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. *Annals of Oncology*. 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. PMID: 35809752. IF: 51,769
2. Bayes-Genis A, Aimo A, Jhund P, Richards M, de Boer RA, Arfsten H, Fabiani I, Lupon J, Anker SD, Gonzalez A, Castiglione V, Metra M, Mueller C, Nunez J, Rossignol P, Barison A, Butler J, Teerlink J, Filippatos G, Ponikowski P, Vergaro G, Zannad F, Seferovic P, Rosano G, Coats AJS, Emdin M, Januzzi JL. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*. 2022 Oct;24(10):1767-1777. doi: 10.1002/ejhf.2675. PMID: 36073112. IF: 17,349
3. Nunez J, de la Espriella R, Rossignol P, Voors AA, Mullens W, Metra M, Chioncel O, Januzzi JL, Mueller C, Richards AM, de Boer RA, Thum T, Arfsten H, Gonzalez A, Abdelhamid M, Adamopoulos S, Anker SD, Gal TB, Biegus J, Cohen-Solal A, Boehm M, Emdin M, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Jhund PS, Lopatin Y, Lund LH, Milicic D, Moura B, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Tocchetti CG, Van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Bayes-Genis A. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. *European Journal of Heart Failure*. 2022 Oct;24(10):1751-1766. doi: 10.1002/ejhf.2664. PMID: 36039656. IF: 17,349
4. Aimo A, Vergaro G, Gonzalez A, Barison A, Lupon J, Delgado V, Richards AM, de Boer RA, Thum T, Arfsten H, Hulsmann M, Falcao-Pires I, Diez J, Foo RSY, Chan MYY, Anene-Nzelu CG, Abdelhamid M, Adamopoulos S, Anker SD, Belenkov Y, Gal TB, Cohen-Solal A, Bohm M, Chioncel O, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Januzzi JL, Jhund P, Lopatin Y, Lund LH, Metra M, Milicic D, Moura B, Mueller C, Mullens W, Nunez J, Piepoli MF, Rakisheva A, Ristic AD, Rossignol P, Savarese G, Tocchetti CG, van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Emdin M, Bayes-Genis A. Cardiac remodelling-Part 2: clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*. 2022 Jun;24(6):944-958. doi: 10.1002/ejhf.2522. PMID: 35488811. IF: 17,349

# global analysis

5. Mendibe Bilbao M, Ezpeleta Echavarri D, Lainez Andres J. The SEN and the Spanish model of recertification promoted by the Spanish Federation of Medical and Scientific Associations and its members. *Neurologia*. 2022 Sep 29;S2173-5808(22)00102-X. doi: 10.1016/j.nrleng.2022.09.001. PMID: 36183954. IF: 5,486
6. Martinez D, Quilez-Cutillas A, Jimenez-Labaig P, Sesma A, Tarazona N, Pacheco-Barcia V, Obispo B, Paez D, Quintanar T, Sanchez-Canovas M, Montes A, Felip E, Rodriguez-Lescure A, Elez E. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology+MIR section. *Clinical & Translational Oncology*. 2022 Nov 23;1-7. doi: 10.1007/s12094-022-02989-3. PMID: 36418642. IF: 3,34
7. Luis Recuero Diaz J, Almanzar S, Munoz C, Sierra J, Porras M, Medina D, Vicuna M, Moreno L, Cantalejo M, Porcel J. Recommendations of the Spanish Society of Thoracic Surgery for the management of malignant pleural effusion. *Cirugia Espanola*. 2022 Nov;100(11):673-683. doi: 10.1016/j.cireng.2022.06.009. PMID: 35667609. IF: 2,242
8. Orozco-Beltran D, Brotons Cuixart C, Banegas Banegas J, Gil Guillen V, Cebrian Cuenca A, Martin Rioboo E, Jordà Baldo A, Vicuna J, Navarro Perez J. Cardiovascular preventive recommendations. PAPPS 2022 thematic updates. Working groups of the PAPPS. *Atencion Primaria*. 2022 Oct;54 Suppl 1(Suppl 1):102444. doi: 10.1016/j.aprim.2022.102444. PMID: 36435583. IF: 2,206
9. Wandschneider L, Namer Y, Davidovitch N, Nitzan D, Otok R, Leighton L, Signorelli C, Middleton J, Martin-Moreno JM, Chambaud L, Lopes H, Razum O. The role of Europe's schools of public health in times of war: ASPHER Statement on the War Against Ukraine. *Public Health Reviews*. 2022 Mar 16;43:1604880. doi: 10.3389/phrs.2022.1604880. PMID: 35371592. IF: 0,82

Position statements	IF
2	9,677

1. MHT Eligibility Criteria Group. Mendoza N, Ramirez I, de la Viuda E, et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. *Maturitas*. 2022 Aug 30;166:65-85. doi: 10.1016/j.maturitas.2022.08.008. PMID: 36081216. IF: 5,11
2. Leigh D, Cram D, Rechitsky S, Handyside A, Wells D, Munne S, Kahraman S, Grifo J, Katz-Jaffe M, Rubio C, Viotti M, Forman E, Xu K, Gordon T, Madjunkova S, Qiao J, Chen Z, Harton G, Gianaroli L, Simon C, Scott R, Simpson J, Kuliev A. PGDIS position statement on the transfer of mosaic embryos 2021. *Reproductive Biomedicine Online*. 2022 Jul;45(1):19-25. doi: 10.1016/j.rbmo.2022.03.013. PMID: 35523707. IF: 4,567

# global analysis


## 3.4.2. Innovation and Knowledge transfer

The Innovation Unit of INCLIVA supports INCLIVA professionals with the development of translational research, which is one of the main objectives of INCLIVA. In this way, a greater impact into society can be achieved. The unit promotes innovation and collaboration with research centres and industrial partners. The unit is responsible of the so-called innovation funnel, evaluating the viability of the innovative ideas at different stages to ensure that only the best ideas are launched to the market. Then, the main services are the following:

- Identification and analysis of ideas.
- Evaluation and management of intellectual property rights
- Commercialisation and technology transfer to the market
- Project management of innovation projects
- Training activities to promote innovation culture.

Consequently, INCLIVA innovation funnel in 2022 is shown in Table:

Innovation Funnel	ITC Health	Device	Pharma	Bio and diagnosis	Imaging	Organizational	Total
Detection	3	1	0	6	0	2	12
Assessment	1	3	3	12	1	0	20
Development	4	3	3	7	0	1	18
Transfer	1	1	3	3	0	1	9
Market	2	2	1	3	1	2	11



# 3 global analysis

## 3.4.2.1 Intellectual Assets

The protection of knowledge is the first step to move scientific findings and ideas from researchers to the industry. Patents are the most common way to protect technologies that are new, inventive and have industrial application. Thus, research institutions can exploit the patents they hold by licensing them to companies.

The following family patents were active on 2022:

Invention	Priority number	IP/% INCLIVA	Status
2022. Dispositivo de Lubricación Intrauretral pediátrica	ES1290053U	100%	ES
2022. Method for assessing the activity of nicotinamida N-Methyl Transferase	EP22382866	10%	EP
2021. Use of Musashi 2 [msi2] as therapeutic target for the treatment of the characteristic myopathy of type 1 myotonic dystrophy	EP21382133	5%	EP
2021. Compound comprising ruthenium(iii) and 2,2'-biimidazole (Runat-bi) and the therapeutic use thereof	P202130624	40%	ES
2021. APC protein for the detection and prediction of septic shock	EP21382173	10%	EP
2021. Epigenetic signature for the diagnosis and prognosis of Spitzoides cutaneous melanocytic tumors	EP21382569	66,67%	EP
2019. Moxifloxacin for use in the treatment of spinal muscular atrophy	ES201930436	23%	PCT
2019. Oropharyngeal obturation device	ES20190003	100%	PCT
2018. Injectable material for the regeneration of the articular cartilage	ES201830730	29%	ES
2017. Prenylated benzopyranes as PPAR agonists	P201731470	40%	PCT

# global analysis

2016. Mass spectrometry-based methods for the detection of circulating histones h3 and h2b in plasma from sepsis or septic shock [ss] patients	EP16382509.4	6%	EU, USA, JP, CN, CA [Licensed]
2016. Intramedullary fixation device	P201631220	2,5%	EU, EEUU, Brasil [Licensed]
2016. Device for the exo-prosthetisation of limbs and other percutaneous applications	P201631218	2,5%	EU, EEUU [Licensed]
2013. Maxillomandibular prosthesis and production method	ES20130030734	33,33%	Licensed

## 3.4.2.2 Competitive innovation

Competitive calls offer technical and financial support for developing innovation ideas. Then, INCLIVA submits proposals to autonomic, national and international funding calls. In 2022, 11 innovation projects were granted for a total of €1.104.190,39.

INNOVATION COMPETITIVE PROJECTS	TOTAL AMMOUNT (€)
<i>Identificación y validación de biomarcadores mediante el uso de las ómicas y la Inteligencia Artificial para el diagnóstico temprano y mejora del manejo clínico de la sepsis [MICINN-CPP]</i>	150.269,00
<i>Tratamiento innovador con ABT-0812 para el cáncer pancreático metastásico: acortando los tiempos para su aprobación – INNOPANC [MICINN-CPP]</i>	266.860,49
<i>Optimización de parámetros PK/PD de una terapia farmacológica reutilizada para pacientes con AME [ISCIII-DTS22]</i>	134.200,00
<i>Test basados en péptidos spike-in y espectroscopía de masas para la cuantificación de histonas circulantes y la proteína APC para la mejora del paciente crítico [GVA-ClAPOTIP]</i>	24.000,00
<i>Desarrollo de estrategias para el silenciamiento génico de Musashi2 en distrofia miotónica [GVA-APOTIP]</i>	24.000,00
<i>Exploraciones radiológicas especiales [GVA-APOTIP]</i>	36.000,00
InnDIH - Valencia Region Digital Innovation Hub [European Union]	225.395,50

# 3 global analysis

Especialización en fenotipado y caracterización molecular de modelos biomédicos murinos (GVA-INNVEST)	44.811,88
Utilización de <i>Drosophila melanogaster</i> en el desarrollo de oligonucleótidos antisentido como medicamentos (GVA-INNVEST)	66.217,84
Programa de formación y ocupabilidad de psicólogo/a en evaluaciones clínicas y uso seguimiento del aplicativo Remindcare en proyectos de investigación (GVA-INNVEST)	66.217,84
Investigación en enfermedades inflamatorias (GVA-INNVEST)	66.217,84
<b>Total</b>	<b>1.104.190,39</b>

## 3.4.2.3 Entrepreneurship

When the knowledge generated in INCLIVA is disruptive and the researchers are willing to exploit it by themselves, the knowledge transfer is direct. Consequently, a new venture [also known as a spin-off or start-up] is created. INCLIVA counts with the following companies officially recognized as spin-offs:



### Epidesase S.L.

Company created in 2014 as a result of a project led by researchers from INCLIVA and the Center for Research in Biomedicine Network (CIBER) in the area of Rare Diseases to transfer knowledge in the field of epigenetics and biomedical sciences at the service of society.

**Founding year:** 2014

**INCLIVA entrepreneurial team:** Mr. José Luis García Giménez and Mr. Federico Pallardó

<http://www.epidisease.com/>



### Sequencing Multiplex S.L.

Company created in 2013, which was born from the idea of generating solutions for research and clinical applications, using as a basis the introduction of new techniques and advanced genetic platforms, mainly next-generation sequencing (NGS).

**Founding year:** 2013

**INCLIVA entrepreneurial team:** Mr. Javier Chaves

<https://www.seqplexing.com/es>



### Nela BioDynamics S.L.

The company arises from the results of a Final Master Thesis in Biomedical Engineering, which lead to two patents on a novel intramedullary fixation system for joint endoprostheses, nails for fractures and exoprostheses; and a percutaneous ostomy collar. Both patents are currently licensed to the spin-off itself.

**Founding year:** 2020

**INCLIVA entrepreneurial team:** Mr. José Expósito Ollero

<http://www.nelabiodynamics.com/>

# global analysis



## ArtHex Biotech S.L.

Company created in 2020 at the University of Valencia that develops advanced RNA treatments against genetic diseases. ARTHEx Biotech's mission is to find effective treatments for unmet medical needs. As a result, the company investigates anti-microRNAs for the treatment of myotonic dystrophy type 1 [DM1].

**Founding year:** 2020

**INCLIVA entrepreneurial team:** Mr. Rubén Artero

<http://www.arthexbiotech.com/>

## PLATFORMS

INCLIVA has the status of Adhered Center of the **ITEMAS** Platform of the IDIBELL Node for 2021 to 2023. Moreover, INCLIVA is part of the Alliance for Health Innovation and Industrialization of the Mediterranean Axis (**AISEM**) coordinated by the IDIBELL Foundation and created by the following institutions: IIS La Fe, FISABIO, IDIBELL, ISABIAL, IISPV, IdISBa, IDIAP and IMIB. AISEM nodes meet once a month, both the Technical Commission and the Strategic Commission. The Alliance has a 3-year Action or Work Plan divided into 5 key objectives:

- I) promote collaboration with industry
- II) create a portfolio of innovative initiatives
- III) improve the translation of solutions to the National Health System (NHS)
- IV) improve training and resources in innovation
- V) improve coordination and complementarity with other innovation units


# 3 global analysis

## 3.5 Gender perspective

As part of its commitment to contribute towards guaranteeing real equality between women and men, INCLIVA's Board of Trustees has approved the II INCLIVA Equality Plan (2020-2024) following approval by the Equality Committee. Through INCLIVA's II Equality Plan, the different planned actions will be implemented throughout its four-year duration following the timeline established for each one.

Currently, 87,64% of INCLIVA employees are women. The data corresponding to activity in 2022 is as follows:


Total cost of INCLIVA staff	2022
Men	€2.105.703
Women	€5.701.367
<b>TOTAL</b>	<b>€7.807.070</b>



A total of 305 employees joined INCLIVA in 2022, of whom 74,10% are women. The percentage of women hired has increased every year for the last three years.

The following graphs differentiate between personnel hired for administration tasks and research staff:

- Women comprise 91,43% of staff contracted to carry out administration tasks and 71,85% of those who carry out research tasks
- Within the administrative area, 88,46% of Managerial/Technician positions are women and 100% of Auxiliary and Nursing staff contracts are for women
- In research, 94,12% of those hired as Nursing staff, 75% of Administrative staff and 67,92% of Research staff are women




# global analysis

## Distribution by contract type


The breakdown of contracts granted to women is shown in the following graphs:

- 87,71% of permanent contracts for administration tasks and 50% of permanent contracts for research tasks are for women.
- 92,86% of temporary contracts for administration tasks and 72,35% of temporary contracts for research tasks are for women.
- In administration: 81,25% of contracts for women are temporary contracts. Of these, 73,91% are contracts to carry out Managerial/Technician tasks and 100% for Auxiliary and Subordinate staff jobs. Fixed contracts for women within the administration are 100% for positions such as Managerial/Technician.
- In research: 98,45% of contracts awarded to women are temporary contracts. Of these, 98,61% of temporary contracts for research tasks, 100% of temporary contracts for nursing tasks and 94,44% for research administration tasks are for women.

**Administrative Staff - women**



**Research Staff - women**



## Shared parental leave

Maternity/paternity leave was requested by only 10 employees throughout 2022: 2 by men, 7 by women.

# 3 global analysis


## Organizational structure

Unlike within our staff structure, women are clearly underrepresented in governing bodies and scientific committees. The distribution of each is summarized below:


	Men	Women	Total 2022
Board of Governors	9	3	12
Board of Trustees	11	7	18
Ethical Committee in Clinical Research	13	8	21
External Scientific Committee	6	2	8
Innovation Committe	8	6	14
Internal Scientific Committee	6	4	10
Research areas	4	0	4
Research Committe	15	17	32
Research Groups	40	19	59
Scientific translational programs	12	3	15

## Breakdown of Research Group staff

A total of 810 researchers belong to consolidated, emerging and associated research groups, and whose EURAXESS profile distribution is as follows. Distribution by group of research staff in 2022:



Distribution by group of research staff hired with public funding in 2022



# global analysis

## Research projects

Throughout 2022, competitive tendering began for 46 new public projects, making a total of 117 currently active public projects under competitive tender. The Principal Investigators are distributed as shown in the table. In total, 39.39% of regional projects are led by women, compared with 44.28% of national projects and 7.14% of international projects.

	Men	Women	Total 2022
<b>Autonomous Regions</b>	12	13	33
<b>National</b>	32	31	70
<b>International/European</b>	13	1	14

## Clinical studies and trials

A total of 105 studies have been managed throughout 2022. The tables below indicate the distribution of Principal Investigators, and number of male and female evaluators.

	Men	Women	Total 2022
<b>Managed Studies</b>	46	59	105
<b>CEIm Evaluators</b>	13	7	20

## Transfer to the Productive Sector

Calls for proposals, innovation awards and patent portfolios during 2022 are distributed by gender as shown in the table:

	Men	Women	Total 2022
<b>External calls for innovation proposals requested in 2022</b>	16	12	28
<b>Patents in portfolio [IPs that have co-ownership of a patent]</b>	6	5	11
<b>Vlc-Bioclinic Applications 2022</b>	14	16	30
<b>Vlc-Bioclinic Concessions 2022</b>	6	7	13
<b>Applicants for Innovation Awards 2022</b>	11	23	34

## Bibliometric analysis: Biomedical Research Institute (IIS) corresponding author, first and last author

Of the 786 INCLIVA publications in 2022, the distribution of men to women according to the relevant position of signature (first, last or corresponding author) it is 15,44% for female researchers and 31% for male researchers.

## Training Activities

In total, 1829 people participated in training activities carried out during 2022. According to registration questionnaires, 68,45% of participation was female (1252) and 31% male (570). In 57% of activities, participation was mainly female.

# 3 global analysis

Of the 72 activities, the 2 listed below provided training on equality, and their content and participant data are summarized in the following table.

Title	Date	Scope	Activity Type	Modality	Hours	Participants	Men	Women
Importance of gender differences. Mrs. Chelo Borrás Blasco	03/08/2022	Local	INCLIVA Seminar	Hybrid	1	17	2	15
I Meeting of women for health research	05/06/2022	Local	Scientific Conferences	Hybrid	2	41	0	41

## Importance of gender differences. Mrs. Chelo Borrás Blasco

YouTube link: <https://www.youtube.com/watch?v=H40WFE59w6Y>

## I Meeting of women for health research

The goals of this information day were to:

- Make women visible within the research sector
- Empower women to assume positions of responsibility within the research sector
- Create synergies with other health institutions to promote the role of women in health research together

## External stays

Of a total of 5 external stays, 4 were granted to women, while of the 19 external stays funded by INCLIVA, 13 were women. In total, 73% of stays were completed by women.

## Internal Stays

Of a total of 5 internal stays, 1 was granted to women, entailing 20% of total internal stays.

## Training placements

The classification and distribution by gender of training placements in 2022 is shown in the following table:

	Men	Women	Total 2022
Secondary school and vocational training placements	0	1	1
Bachelor's placements	6	21	27
Master's placements	16	30	46
Bachelor's final project (TFG) agreements (including INCLIVA Calls)	2	16	18
Master's final project (TFM) agreements (including INCLIVA Calls)	5	13	18
<b>Total</b>	<b>29</b>	<b>81</b>	<b>110</b>

# global analysis

## Doctoral theses

Below is a breakdown by gender of the 51 doctoral theses defended or supervised by INCLIVA research staff: 57,14% of predoctoral researchers who defended their thesis in 2022 were women, and 33,75% of those supervising the theses defended in 2022 were women.

	Men	Women	Total 2022
INCLIVA Doctoral students	12	16	28
INCLIVA Doctoral Supervisors	51	29	80



# scienc- tific activi- ty

INCLIVA SCIENTIFIC REPORT 2022

## 4. Scientific activity

### 4.1 Scientific structure

### 4.2 Scientific translational programs

4.2.1 Overweight and cardiovascular and renal risk

4.2.2 Detection and control of ventricular dysfunction

4.2.3 Rare Diseases

4.2.4 Neurological Decline

4.2.5 Translational Oncology

4.2.6 Reproductive Medicine

4.2.7 Ageing and associated diseases

### 4.3. Research areas

4.3.1 Cardiovascular Area

4.3.2 Oncology Area

4.3.3 Metabolism and Organ Damage Area

4.3.4 Reproductive Medicine Area

4.3.5 Clinical Associated Groups

### 4.4. Hospital divisions research area

### 4.5 Other scientific contributions from scientific platforms

4.5.1 Biobank

4.5.2 Oncology Phase I Oncology Clinical Trials Unit

4.5.3 Spanish Clinical Research Network (SCReN),

Clinical Research and Clinical Trials of the Clinical  
Trials Platform (UICEC INCLIVA)

4.5.4 Precision Medicine Unit

4.5.5 Bioinformatic Unit

4.5.6 Biostatistics Unit

## 4.1 Scientific structure

INCLIVA articulates its research in 4 areas of research, 7 scientific programs, 5 platforms and 6 associated clinical groups.

**Areas of research constitute the basis on which to articulate the scientific work of the groups:**

- Research area in cardiovascular
- Research area in oncology
- Research area in metabolism and organ damage
- Research area in reproductive medicine
- Associated clinical groups

**Scientific programs are aimed at specific diseases from a translational perspective:**

- Program in Overweight and cardiovascular and renal risk
- Program in Detection and control of ventricular dysfunction
- Program in Rare Diseases
- Program in Neurological Decline
- Program in Translational Oncology
- Program in Reproductive Medicine
- Program in Aging and associated diseases

**Platforms are based on the provision of research services to the whole institute:**

- Central Unit for Medical Research (UCIM)
- Biobank
- Precision Medicine Unit
- Bioinformatics Unit
- Biostatistics Unit

# scientific activity

## 4.2 Scientific translational programs

### 4.2.1 Overweight and cardiovascular and renal risk

Obesity and overweight is a field in which new strategies are developed both for prevention and treatment with the use of traditional resources and the new technologies. The present program is focused on the study of pathology on the first stages of obesity (overweight with or without metabolic syndrome) integrating different clinical and experimental research studies.

**Coordinators:** Mr. José Tomás Real and Mr. Josep Redon

**Objectives:**

- To deepen in the early alterations, mechanisms and biomarkers that contribute to the development of obesity, vascular and renal alterations as a complication, from its fetal, biological, genetic and environmental origins
- To know potential signaling pathways susceptible to be therapeutic targets
- Early application of new technologies for the prevention and treatment of obesity and vascular and renal alterations in overweight subjects
- Research Group on Cardiometabolic Risk and Diabetes (Mr. José Tomás Real Collado, Mr. Sergio Martínez Hervás)
- Research Group on General and Digestive Surgery (Mr. Joaquín Ortega Serrano)
- Research Group on Pediatric Nutrition (Mrs. Cecilia Martínez Costa)
- Research Group in Care. INVESTENF-INCLIVA (Mrs. M<sup>a</sup> José Gastaldo Zaragozá)
- Research Group in Medical Chemistry for Drug Development (Mrs. Nuria Cabedo Escrig)

**Research lines:**

- To identify early vascular and renal changes in overweight subjects and in animal models
- To study the state, mechanisms of vascular inflammation and endothelial injury in overweight and animal models
- To analyze the relationship of “omic” markers (genomic, epigenetic and metabolomic) with obesity and vascular and renal alterations in overweight and animal models
- Interaction of biomarkers (biological, genomic and metabolic) and intervention in progression to obesity and vascular and renal complications

**Clinical groups:**

- Research Group on the Study of Cardiometabolic and Renal Risk (Mr. Josep Redón i Mas)
- Cardiometabolic Research Group on Primary Care (Mr. Jorge Navarro Pérez)
- Research Group for the Prevention of Cardiovascular Risk in Children and Adolescents (Mrs. Empar Lurbe i Ferrer)

**Experimental groups:**

- Research Group on Endothelial Cells (LINCE) (Mr. Carlos Hernández Caudeville, Mrs. Susana Novella del Campo)
- Research Group on Molecular Imaging and Metabolomics (Mr. Daniel Monleón Salvadó)
- Research Group on Inflammation (Mr. Esteban Morcillo Sánchez, Mrs. M<sup>a</sup> Jesús Sanz Ferrando)
- Genomics and Diabetes Unit (Mr. Felipe Javier Chaves Martínez)
- Research Group on Nuclear Receptors in Cardiometabolic Pathology (Mrs. Laura Piqueras Ruiz)
- Research Group on Metabolic Diseases (Mrs. Herminia González Navarro)
- Research Group on Exercise, Nutrition and Healthy Lifestyle (Mrs. M<sup>a</sup> Carmen Gómez Cabrera)

# scientific activity

4

OVERWEIGHT AND CARDIOVASCULAR AND RENAL RISK				
OBJECTIVES	STATE			ACTIONS
	Achieve	Partially achieved	Not achieved	
Metabolic, vascular and renal evaluation of overweight patients (children and adults)			X	
Characterization of the relationship between overweight and vascular inflammation / endothelial function		X		
Identification of molecular markers that relate overweight with its associated diseases		X		<ul style="list-style-type: none"> <li>• Metabolomic measurements (80 spectral features) of 3 cohorts (4500 subjects) for associations between obesity, associated diseases and morbidities and early alterations of metabolism. Focus on the metabolic interaction between host and gut microbiota. Cohorts: Rio Hortega (general population), AWHS (working population) and PIANCAVALLO (obese and morbid obese)</li> </ul>
Identification of metabolomic markers that relate overweight with its associated morbidities		X		<ul style="list-style-type: none"> <li>• Metabolomic measurements (80 spectral features) of 3 cohorts (4500 subjects) for associations between obesity, associated diseases and morbidities and early alterations of metabolism. Focus on the metabolic interaction between host and gut microbiota. Cohorts: Rio Hortega (general population), AWHS (working population) and PIANCAVALLO (obese and morbid obese)</li> </ul>
Development of new early detection systems for obesity and its associated complications		X		<ul style="list-style-type: none"> <li>• Metabolomic measurements (80 spectral features) of 3 cohorts (4500 subjects) for associations between obesity, associated diseases and morbidities and early alterations of metabolism. Focus on the metabolic interaction between host and gut microbiota. Cohorts: Rio Hortega (general population), AWHS (working population) and PIANCAVALLO (obese and morbid obese)</li> </ul>
Identification of molecular targets of obesity and its associated complications and development of new therapies			X	

# scientific activity

## 4.2.2 Detection and control of ventricular dysfunction

The program focuses on the study of the pathophysiological mechanisms involved in myocardial ischemic damage, on its structural, functional and electrophysiological repercussions on the evaluation of diagnostic tools and markers and prognoses and on the study of new therapeutic approaches that may help to prevent their adverse consequences.

It is a truly and translational research program that capitalizes the synergies between clinical and experimental research groups and also includes specialists in cardiac imaging techniques and technological development experts. The multidisciplinary approach extends the possibilities of collaboration between groups, strengthens those already existing and incorporates other groups into the activities of the program. Innovation through the development of analytical tools [imaging techniques such as cardiac magnetic resonance, cardiac electrical signals or cartographic techniques], allows the generalize of patents in the field of technological development.

**Coordinators:** Mr. Francisco J. Chorro, Mr. Vicente Bodí and Mr. Juan Sanchis

**Objectives:**

- Electrical remodeling: experimental studies on the protective effect against the arrhythmic vulnerability of modifications of the signaling pathways
- Ventricular remodeling: evaluation of the role of microvascular damage, prediction of postinfarction clinical evolution
- Biomarkers: clinical studies aimed at the validation of biomarkers related to the degradation of components of the extracellular matrix

**Research lines:**

- Characterization of the direct electrophysiological effects of the active metabolite of sacubitril
- Study of the modifications of the electrophysiological effects of overload sharp mechanics
- Analysis of the protective effects produced by chronic treatment with inhibitors
- Mechanisms involved in the deterioration of systolic function, fibrosis and the inducibility of arrhythmias
- Development of useful working instruments in the study of cardiac electrophysiology
- Basic research related to ischemia and myocardial infarction
- Prospective and multicenter registry (*Hospital Clínico Universitario de Valencia* and *Hospital Clínic de Barcelona* and *Hospital Vall d'Hebrón de Barcelona*) of patients
- Prognostic value of geriatric conditions in older patients admitted for acute coronary syndrome

- Prospective Evaluation of the European Society of Cardiology 0/1h-algorithm's Safety and Efficacy for Triage of Patients with Suspected Myocardial Infarction (PRESC1SE-MI)

**Clinical groups:**

- Research Group on Clinical Cardiology (Mr. Juan Sanchis Forés)
- Research Group on Cardiac Experimental Electrophysiology (Mr. Francisco Javier Chorro Gascó)
- Research Group on Heart Failure (Mr. Julio Núñez Villota)
- Group on Translational Research in Ischemic Heart Disease (Mr. Vicente Bodí Peris)
- Cardiometabolic Research Group on Primary Care (Mr. Jorge Navarro Pérez)
- Research Group in Care. INVESTENF-INCLIVA (Mrs. M<sup>a</sup> José Gastaldo Zaragoza)

**Experimental groups:**

- Research Group on Endothelial Cells (LINCE) (Mr. Carlos Hernández Caudevilla, Mrs. Susana Novella del Campo)
- Research Group on Molecular Imaging and Metabolomics (Mr. Daniel Monleón Salvadó)
- Research Group on Inflammation (Mr. Esteban Morcillo Sánchez, Mrs. M<sup>a</sup> Jesús Sanz Ferrando)
- Research Group on Nuclear Receptors in Cardiometabolic Pathology (Mrs. Laura Piqueras Ruiz)

# scientific activity

4

MYOCARDIAL ISCHAEMIA INJURY DETECTION AND CONTROL OF VENTRICULAR DYSFUNCTION				
OBJECTIVES	STATE			ACTIONS
	Achieve	Partially achieved	Not achieved	
Study of the basic mechanisms involved in myocardial damage	X  X	X		<ul style="list-style-type: none"> <li>Oxidative stress during reperfusion in acute myocardial infarction</li> <li>Neoangiogenesis, the appearance of micro-vascular obstruction and impaired function systolic</li> <li>Deregulation of the immune system in acute myocardial infarction</li> </ul>
Diagnosis through new RM tools	X  X  X	X  X  X		<ul style="list-style-type: none"> <li>RM micro-image for the development of combinations of RM sequences without contrast</li> <li>Analysis of myocardial textures</li> <li>Offline evaluation of myocardial tension</li> <li>CMR for risk stratification and decision making in STEMI</li> <li>Stress CMR for risk stratification and decision making in chronic coronary syndromes</li> </ul>
Prediction through new biomarkers		X  X  X		<ul style="list-style-type: none"> <li>Definition of new serological indicators with NMR-S to predict DR and fibrosis</li> <li>Serum CA125, galectin-1 and galectin-3 markers</li> <li>0/1h-algorithm's Safety and Efficacy for Triage and Troponin extraction of Patients with Suspected Myocardial Infarction</li> </ul>
Prevention		X  X		<ul style="list-style-type: none"> <li>DR prevention through multiple antioxidant treatment</li> <li>Prevention of deterioration of systolic function, fibrosis and arrhythmias</li> </ul>

# scientific activity

## 4.2.3 Rare Diseases

The program's main objectives are to improve the diagnosis and current treatments of rare diseases (RDs). To this end, we will proceed to identify and validate rare disease biomarkers for which we do not have effective diagnostic and/or prognostic indicators. On the other hand, new therapeutic strategies will be developed to treat these diseases. Human and animal model samples will be used to understand the molecular basis of disease, evaluate the activity of candidate drugs, and discover new biomarkers.

The program seeks to fill the gap between basic research and commercial development of diagnostic systems and treatments, so it aims to transfer this knowledge to companies to transform biomedical knowledge into products and services that improve human health. With these objectives, contacts with biotechnology and pharmaceutical companies have been established. On the other hand, the program aims to disseminate its findings to society to get feedback about actual patients' needs.

**Coordinators:** Mr. Francisco Dasí and Mr. Federico Pallardó

**Objectives:**

- Development of 2D and 3D (organoids) cell or organ models derived from cells of patients diagnosed with the RDs being studied obtained either through the genetic manipulation of healthy cells to mimic the mutations associated with these diseases or from animal models in order to improve the knowledge of the pathophysiology of each disease
- Discover new therapeutic targets and propose new pharmacological strategies for the treatment of these pathologies
- Promote collaboration with services of the Clinical Hospital involved in the treatment of these RDs, emphasizing primary care to improve its diagnostic potential
- Development of new diagnostic and prognostic methods
- Development of "omics" technologies to advance research in RRDD

**Research lines:**

- Study of the physiopathology of rare neuromuscular diseases
- Epigenetic regulation of neonatal sepsis
- Pathophysiology of telomeres
- Pathophysiology of alpha-1 antitrypsin deficiency, primary ciliary dyskinesia, childhood interstitial diseases and Prader-Willi syndrome
- Genetic and epigenetic modifiers in Friedreich's ataxia
- Gene therapy for the treatment of rare respiratory diseases
- Design and testing of new biomarkers for rare diseases
- Characterization of the cellular and molecular mechanisms associated with the pathology of neuromuscular diseases like Myotonic Dystrophy and Friedreich's ataxia and identification of molecular targets for the development of new therapies

**Clinical groups:**

- Research Group on Respiratory Diseases (Mr. Jaime Signes Costa Miñana)
- Research Group on Psychiatry and Neurodegenerative Diseases (Mr. Julio Sanjuán Arias)
- Cardiometabolic Research Group on Primary Care (Mr. Jorge Navarro Pérez)
- Clinical Associated Group in Traumatology and Orthopedics (Mr. Antonio Silvestre Muñoz)

**Experimental groups:**

- Research Group on Human Translational Genomics (Mr. Rubén D Artero Allepuz)
- Research Group on Rare Respiratory Diseases (RRD) (Mr. Francisco Dasí Fernández)
- Research Group on Cellular and Organic Physiopathology of Oxidative Stress (Mr. Federico V. Pallardó Calatayud)
- Research Group on Epigenomics and translational epigenetics (Mr. José Luis García Giménez)
- Research Group on Neurobiology and Molecular Physiopathology in Rare Diseases – NeurFisER (Mrs. Pilar González Cabo)

**Clinical Services Associated with the Program**

- Department of Pediatrics
- Department of Pneumology

# scientific activity

4

RARE DISEASES				
OBJECTIVES	STATE			ACTIONS
	Achieve	Partially achieved	Not achieved	
Extension to the PCT phase of the European patent "Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (ss) patients" (PCT/EP2017/078362)	X			EP, US, CA, JP y CN
Acquisition of budget and resources from different programs	X			Counseling of Innovation, Universities, Science and Digital Society [2 new projects], Carlos III Health Institute - Co-financed FEDER [4 new projects], Ministry of Science and Innovation [4 new projects], Center of Excellence ALBA synchrotron [1 new project], Society of Pneumology [2 projects], Alpha-1 antitrypsin deficiency patients' association [1 project]
Carry out teaching and outreach activities	X			<ul style="list-style-type: none"> <li>• Subject "Enfermedades Raras": Medicine degree (UV)</li> <li>• Master course in Biomedical Research</li> <li>• Master "Enfermedades raras"</li> <li>• 2nd edition of the online course "<i>Introducción a las EERR: investigación y atención clínica</i>"</li> <li>• "Introduction to rare diseases". Program of the University of Valencia La Nau Gran.</li> <li>• "<i>Máster online de formación permanente en déficit de alfa-1 antitripsina</i>". SEPAR-University CEU San Pablo.</li> </ul>

# scientific activity

## 4.2.4 Neurological Decline

Inflammation, which is associated with many chronic diseases (diabetes, liver cirrhosis, etc.), aging or major surgeries, leads to neuroinflammation and brain alterations that eventually lead to cognitive and functional impairment. This deterioration reduces the quality of life and increases the risk of accidents, falls, fractures and adverse consequences, which implies an increase in hospitalizations and the use of public resources.

Cognitive and functional impairment associated with aging and many chronic diseases is one of the most important challenges in order to improve the quality of life of the population and secure the sustainability of health systems. Early detection and treatment and prevention of cognitive and functional impairment would improve the quality of life of the elderly or with chronic diseases and reduce the demand for resources to the health system, improving its sustainability. Therefore, it is necessary to design new approaches to address these challenges, based on advances in knowledge on mechanisms, early diagnosis, prevention and treatment of cognitive and functional impairment.

**Coordinators:** Mrs. Carmina Montoliu and Mr. Vicente Felipó

**Objectives:**

- Characterize the alterations in inflammation, neuroinflammation, neurotransmission, function and brain structure associated with the appearance of cognitive and functional impairment
- Characterize cognitive and functional disturbances in detail
- Identify biomarkers for the early detection of cognitive and functional impairment
- Identify the mechanisms by which:
  - a) peripheral inflammation leads to neuroinflammation
  - b) neuroinflammation leads to functional, structural and neurotransmission alterations in the brain
  - c) brain disorders lead to cognitive and functional impairment
- Identify therapeutic targets to reverse or prevent cognitive and functional impairment
- Design and test new therapeutic procedures to reverse or prevent cognitive and functional impairment

**Research lines:**

- Develop new early diagnostic procedures for cognitive and functional impairment
- Try to transfer the new diagnostic procedures developed to clinical practice
- Evaluate in patients the efficacy and usefulness of new therapeutic procedures to prevent or reverse cognitive and functional impairment that has been effective in animal models
- Transfer to clinical practice the new validated therapeutic procedures

**Clinical groups:**

- Associated Clinical Group in Digestive Medicine (Mrs. Isabel Pascual Moreno)
- Research Group on Anesthesiology and Reanimation (Mr. Rafael Badenes Quiles)
- Research Group on Cardiometabolic Risk and Diabetes (Mr. José Tomás Real, Mr. Sergio Martínez Hervás)
- Research Group in Care. INVESTENF-INCLIVA (Mrs. M<sup>a</sup> José Gastaldo Zaragozá)
- Research Group on the Study of Cardiometabolic and Renal Risk (Mr. Josep Redón i Mas)

**Experimental groups:**

- Research Group on Neurological Impairment (Mrs. Carmina Montoliu Félix)
- Research Group on Personal Autonomy, Dependence and Severe Mental Disorders (TMAP) (Mr. Rafael Tabarés Seis-dedos)
- Research Group on Aging and Physical Activity (Mr. José Viña Ribes)
- Research Group on Inflammation (Mr. Esteban Morcillo Sánchez, Mrs. M<sup>a</sup> Jesús Sanz Ferrando)

**Clinical Services Associated to the Program:**

- Department of Neurophysiology

**University Department Associated with the Program:**

- Biology Unit. Department of Pathology

# scientific activity

4

OBJECTIVES	NEUROLOGICAL DECLINE			ACTIONS	
	Achieve	STATE			
		Partially achieved	Not achieved		
1. Characterize the alterations in inflammation, neuroinflammation, neurotransmission, function and brain structure associated with the appearance of cognitive and functional impairment		X		<p>We analyzed the presence of neuroinflammation in post-mortem samples of the cerebellum from patients died with different grades of liver disease, from mild steatohepatitis to cirrhosis.</p> <p>We are analysing alterations in neural connectivity by functional magnetic resonance imaging.</p>	
2. Characterize cognitive and functional disturbances in detail		X		<p>Gait, balance, hand strength and motor speed performance were evaluated in cirrhotic patients.</p> <p>Evaluation and characterization of sensory thresholds was also performed by quantitative sensory testing using a CASE IV.</p> <p>We are characterizing cognitive and functional disturbances in patients with other pathologies: NASH (non-alcoholic steatohepatitis), diabetes mellitus, schizophrenia, bipolar disorder, and post-surgery patients.</p> <p>We are better characterizing executive functions in cirrhotic patients by computerized tests.</p>	
3. Identify biomarkers for the early detection of cognitive and functional impairment		X		<p>We are studying the altered genes in peripheral blood cells and the involved pathways associated with the appearance of cognitive impairment; we are characterizing the changes in inflammation and metabolites associated to cognitive impairment.</p> <p>We are performing an integrated multiomics analysis to identify biomarkers of cognitive and functional impairment.</p> <p>We are characterizing eye movements in patients with different pathologies: cirrhosis, NASH, and diabetes mellitus.</p>	

# scientific activity

4. Identify the mechanisms by which:  a) peripheral inflammation leads to neuroinflammation  b) neuroinflammation leads to functional, structural and neurotransmission alterations in the brain  c) brain disorders lead to cognitive and functional impairment		X		We have identified alterations of the immune system associated with the appearance of neurological alterations in cirrhotic patients with MHE.  We have identified, in animal models, mechanisms by which peripheral inflammation induces neuroinflammation, and how this alters neurotransmission and cognitive and motor function.  We have shown that there is a dysregulation in the urea cycle in non-alcoholic fatty liver disease.  We are analyzing the role of exosomes as mediators of neuroinflammation and of alterations in neurotransmission and cognitive and motor function in animal models of MHE.
5. Identify therapeutic targets to reverse or prevent cognitive and functional impairment		X		We have identified several therapeutic targets in animal models of MHE.
6. Design and test new therapeutic procedures to reverse or prevent cognitive and functional impairment		X		We are testing the effect of treatments on cognitive impairment and immunophenotype in patients to reverse or prevent cognitive and functional impairment.  We have designed several treatments that improve cognitive and motor function in animal models.
7. Programme activity: Seminars of the Neurological Impairment Program		X		Seminars are scheduled for the third Thursday of each month. Time: 13:30h

## 4.2.5 Translational Oncology

The translational oncology program called "Identification of oncogenic biomarkers: mechanisms and clinical implications, detection in non-invasive samples, omics analysis" tries to apply to the clinical practice the genomic screening in human tumors.

Its main objective is to assess cancer dynamics through non-invasive samples in order to detect minimal residual disease, early onset of markers after surgery and patient response to different treatments.

The high heterogeneity of cancer results in inefficiency of treatments, even when they are directed against specific molecular targets. The low availability of tumor specimens makes genomic studies difficult.

In this sense, the use of liquid biopsies would facilitate the serial collection of samples to carry out molecular analysis and would guarantee a minimum risk for the patient. Thus, improving the follow-up and allowing a dynamic understanding of the evolution of the genomic parameters of the patient.

This point of view benefits the National Health System as a whole since it allows the application of more specific treatments to patients, thus avoiding those that would have been less effective, reducing hospitalization and improving life expectancy and quality thereof. It could also prevent generalized treatments, secondary toxicities and rapid treatment adequacy responses.

Finally, it would improve the inclusion of patients in clinical trials which are stratified by molecular mutations.

**Coordinator:** Mr. Andrés Cervantes

**Objectives:**

- Identification of diagnostic biomarkers that help the early identification of patients
- Identification of biomarkers of resistance to treatment or relapses
- Development of functional models mimetic to the characteristics of the patient
- Development of decision support systems through data analysis

**Research lines:**

- Liquid biopsy as a diagnostic tool
- Functional models of organoids, murine and 3D bioprinted for the study of resistance and drug screening
- Integration of molecular and image data for the development of decision support systems
- Promote the development and implementation of programs in advanced therapies, particularly, CAR-T cells cell therapy and other models
- Continuous improvement of the inclusion of patients in clinical trials, in coordination with primary care
- Economic evaluation of innovative therapies and digital health

**Clinical Groups:**

- Research Group on Breast Cancer Biology [Mrs. Ana Lluch Hernández, Mrs. Pilar Eroles Asensio]
- Research Group of Innovative Diagnostic and Therapeutic Developments in Solid Tumors - InDeST [Mr. Andrés Cervantes Ruipérez]
- Research Group on Hematopoietic Transplantation [Mr. Carlos Solano Vercet]
- Research Group on Myeloid Neoplasms [Mrs. Mar Tormo Díaz]
- Research Group on Lymphoproliferative Disorders [Mrs. Mª José Terol Casterá]
- Translational Research Group on Pediatric Solid Tumors [Mr. Samuel Navarro Fos, Mrs. Rosa Noguera Salvá]
- Research Group on General and Digestive Surgery [Mr. Luis Sabater]
- Associated Clinical Group in Urology [Mr. José Martínez Jabaloyas]
- Associated Clinical Group in Pharmacy [Mr. Manuel Alós Almiñana]

# scientific activity

## Clinical Services Associated to the Program

- Department of Pathology
- Department of Radiology
- Central Laboratory

## Associated program platforms:

- Biobank
- Bioinformatics Unit
- Biostatistics Unit
- Precision Medicine Unit

TRANSLATIONAL ONCOLOGY				
OBJECTIVES	STATE			ACTIONS
	Achieve	Partially achieved	Not achieved	
Identify biomarkers	X  X  X  X			<ul style="list-style-type: none"> <li>• Clinical recruitment-characterization and storage Biobank-Data Management</li> <li>• Subclassify tumours according to their profile</li> <li>• Identify biomarkers of inflammation / angiogenesis; miRs-detox from oxidative stress</li> <li>• Perform comprehensive omics data analysis with search of altered routes using Biology of systems</li> </ul>
Validate promising biomarkers / mechanistic analysis	X	X  X  X		<ul style="list-style-type: none"> <li>• Proof of concept on commercial cell lines</li> <li>• Establishment of cell lines with patient tumours</li> <li>• Establishment of tumours in mouse models [xenografts]</li> <li>• IHC antibodies in FFPE to validate expression / western blot in cell lines / xenotumours</li> </ul>
Detect biomarkers in liquid biopsies to monitor disease progression (BEAMing PCR)	X  X			<ul style="list-style-type: none"> <li>• Start on biopsies of patients with advanced disease or disease progression</li> <li>• Implement technology optimized for initial detection, detection of residual disease, and disease evolution and response to treatment</li> </ul>

## 4.2.6 Reproductive Medicine

This program comprises two main lines:

1. Molecular characterization at single-cell resolution of the human uterus as a basis for both understanding uterus health and disease, and improving diagnosis, monitoring and new therapies.
2. Study of maternal-embryonic communication mechanisms and their impact on reproductive health.

**Coordinators:** Mr. Carlos Simón and Mr. Felip Vilella

**Objectives:**

- To create comprehensive reference map at single-cell resolution of the human uterus
- To study the origin of fibroids at the single-cell level
- To study the origin of late gestational pathology focuses on decidualization deficiency
- To establish the maternal-fetal communication mechanisms before embryo implantation
- To provide early diagnosis and treatment of endometriosis and endometrial cancer
- To study the molecular mediators in hormone-dependent oncogenesis in endometrium and ovary
- To establish a success strategy in the implementation of physical activity to reduce the risk of chronic disease in women

**Research lines:**

- Study of endometrial receptivity and cell map of the human uterus. Previous research in our laboratory using microarray technology has established a transcriptomic signature of human endometrial receptivity
- Maternal-fetal communication
- Role of the endometrial microbiome in reproduction
- Early diagnosis of preeclampsia and other complications of pregnancy

- Study at the single-cell level of the origin of uterine fibroids
- Early Diagnosis and treatment of endometriosis and endometrial cancer
- Molecular factors involved in the initiation and progression of hormone-dependent tumours in the endometrium and ovary
- Implementation of physical activity as a strategy to improve health indicators in women
- Deciphering interactions at the single-cell level of the human endometrial microbiome in health and disease

**Clinical groups:**

- Research Group on Women's Health [Mr. Antonio Cano Sánchez]
- Research Group on Endometriosis and Endometrial Cancer Therapies (Mr. Raúl Gómez Gallego)

**Experimental groups:**

- Research Group on Maternal Fetal Communication (Mr. Felip Vilella Mitjana)
- Research Group on Reproductive Medicine (Mr. Carlos Simón Vallés)

**Clinical Services Associated to the Program**

- Department of Gynaecology and Obstetrics

# 4 scientific activity

OBJECTIVES	STATE			ACTIONS
	Achieve	Partially achieved	Not achieved	
Advance in the understanding of the mechanisms that regulate maternal-fetal communication		X		Project is ongoing. Results published
Single cell resolving molecular characterization of the human uterus with its implications for health and disease		X		Project is finished. Results to be published
Single cell study of the origin of fibroids		X		Project is ongoing
Study of resistance to decidualization at the origin of late gestational disease		X		Project is finished. Results to be published
Early diagnosis and treatment of endometriosis and endometrial cancer		X		Project is ongoing
Molecular mediators in hormone-dependent oncogenesis in endometrium and ovary		X		Project is ongoing
Success strategy in the implementation of physical activity to reduce the risk of chronic disease in women		X		Project is ongoing

## 4.2.7 Ageing and associated diseases

This program has the priority of improving the quality of life of the elderly and promoting longevity as much as possible. The aging population is a challenge for current health systems since the population over 65 years old contributes, in a very significant percentage, to health expenditure. As life expectancy increases, so do age-associated diseases.

In this context, the concept of "healthspan" (quality of life) has emerged. The program is formed by many researchers and health professionals who consider that efforts to extend life at the expense of causing a severe physical or psychic disability are undesirable and, on the contrary, they should focus on lengthening the part of life during which we are able to maintain autonomy, independence, productivity, and well-being.

A central guiding idea in this program is that people who achieve exceptional longevity (i.e., centenarians) serve as a model of satisfactory aging. On the other hand, it is considered that the most problematic expression of the population aging is the clinical condition of frailty since an important part of the people over 65 and older fulfill several frailty criteria. Approximately one-fourth of people over the age of 85 are estimated to be frail. Frailty is a geriatric syndrome characterized by increased vulnerability to external aggressions as a result of an alteration in the physiological reserves of multiple systems, leading to difficulties in maintaining homeostasis. The program tries to identify specific molecular targets to be able to intervene concretely and rationally to improve the quality of life of the elderly.

For this, INCLIVA has an enormous advantage because of the great integration that exists, by proximity and interests, between the *Hospital Clínico Universitario de Valencia* and the Faculty of Medicine of the University of Valencia. This framework allows intense collaboration between basic research groups, that analyze possible biomarkers associated with healthy aging, frailty, or age-associated diseases and clinical research groups that provide biological human samples and, on the other hand, can transfer to the patient those studies that have been successfully developed at the bench.

In addition to this, INCLIVA has registered the first and only Spanish Group for the Study of Centenarians, which includes research groups working in this field distributed in different Spanish communities.

**Coordinators:** Mr. José Viña, Mrs. Consuelo Borrás, Mrs. María Carmen Gómez

### Objectives:

- Determination of oxidative stress and inflammation parameters associated with healthy aging, frailty, and age-associated diseases
- Determination of genetic biomarkers (microRNAs, mRNAs, and SNPs) associated with healthy aging, frailty, and age-associated diseases
- Determination of epigenetic biomarkers associated with healthy aging, frailty, and age-associated diseases
- Determination of metabolomic biomarkers associated with healthy aging, frailty, and age-associated diseases
- Protocols of physical exercise and other healthy life interventions for the treatment and prevention of frailty

### Research topics:

- Biomarkers of aging
- Mechanisms of aging with special attention to exceptional aging: centenarians
- Healthy aging: frailty and prevention of disability
- Intervention for successful aging: physical exercise, nutrition, molecular interventions (extracellular vesicles)
- Age-associated diseases: cardiovascular and neurodegenerative diseases
- Mitochondrial implications in age-associated frailty
- Skeletal muscle repair, exercise, frailty, and sarcopenia
- Regenerative medicine in aging and age-associated diseases

# 4 scientific activity

## Clinical research groups:

- Research Group on the Study of Cardiometabolic and Renal Risk [Mr. Josep Redón i Mas]
- Cardiometabolic Research Group on Primary Care [Mr. Jorge Navarro Pérez]
- Research Group on Clinical Cardiology [Mr. Juan Sanchis Forés]
- Research Group on Women Health [Mr. Antonio Cano Sánchez]
- Research Group in Care. INVESTENF-INCLIVA [Mrs. M<sup>a</sup> José Gastaldo Zaragozá]

## Experimental research groups

- Research Group on Neurological Impairment [Mrs. Carmina Montoliu Félix]
- Research Group on Endothelial Cells (LINCE) [Mr. Carlos Hermenegildo Caudevilla, Mrs. Susana Novella del Campo]

- Research Group on Exercise, Nutrition and Healthy Lifestyle [Mrs. M<sup>a</sup> Carmen Gómez Cabrera]
- Research Group on Healthy Aging [Mrs. Consuelo Borrás Blasco]
- Research Group on Aging and Physical Activity [Mr. José Viña Ribes]
- Research Group on Cellular and Organic Physiopathology of Oxidative Stress [Mr. Federico V. Pallardó Calatayud]
- Research Group on Inflammation [Mr. Esteban Morcillo Sánchez, Mrs. M<sup>a</sup> Jesús Sanz Ferrando]
- Research Group on Genetics of Osteoporosis [Mr. Miguel Ángel García Pérez]
- Research Group on Molecular Imaging and Metabolomics [Mr. Daniel Monleón Salvadó]

AGING AND AGE-ASSOCIATED DISEASES				
OBJECTIVES	STATE			ACTIONS
	Achieve	Partially achieved	Not achieved	
Determination of parameters of oxidative stress and inflammation associated with aging healthy, frailty and diseases associated with aging (mainly cardiovascular and neurodegenerative)	X			<ul style="list-style-type: none"><li>Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer's disease patients</li><li>Reductive Stress: a New Concept in Alzheimer's Disease</li><li>Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease</li><li>Glucose 6-P dehydrogenase delays the onset of frailty by protecting against muscle damage</li><li>Frailty is associated with oxidative stress in older patients with Type 2 Diabetes</li><li>Redox-related biomarkers in physical exercise</li></ul> <p><b>Project:</b> CIBER de Fragilidad y envejecimiento (CIBERfes)</p> <p><b>Project:</b> Evolution-Age-Gender-Lifestyle-Environment: mitochondrial fitness mapping</p> <p><b>Thesis title:</b> Role of p16ink4a and bmi-1 in oxidative stress-induced premature senescence in human dental pulp stem cells</p> <p><b>Thesis title:</b> Regulation of antioxidant defenses in the prevention of skeletal muscle deconditioning</p>

# scientific activity

4

Determination of genetic biomarkers [microRNAs, mRNAs and SNPs] associated with healthy aging, frailty and diseases associated with aging [mainly cardiovascular and neurodegenerative]	X			<ul style="list-style-type: none"> <li>In Search of 'Omics'-Based Biomarkers to Predict Risk of Frailty and Its Consequences in Older Individuals: The FRAILOMIC</li> <li>Human exceptional longevity: transcriptome from centenarians is distinct from septuagenarians and reveals a role of Bcl-xL in successful aging. Aging [Albany NY]</li> <li>A translational approach from an animal model identifies CD80 as a candidate gene for the study of bone phenotypes in postmenopausal women</li> <li>Centenarians maintain miRNA biogenesis pathway while it is impaired in octogenarians. Mechanisms of ageing and development</li> </ul> <p><b>Thesis title:</b> <i>Transcriptómica en centenarios: un ejemplo de envejecimiento satisfactorio</i></p>
Determination of epigenetic biomarkers associated with healthy aging, frailty, and diseases associated with aging [mainly cardiovascular and neurodegenerative]		X		<ul style="list-style-type: none"> <li>Epigenetic biomarkers for human sepsis and septic shock: insights from immunosuppression</li> <li>Epigenetic regulation in the pathogenesis of Sjögren Syndrome and Rheumatoid Arthritis</li> <li>Exercise training as a modulator of epigenetic events in prostate tumors</li> <li>Implementing precision medicine in human frailty through epigenetic biomarkers</li> <li>Epigenetic biological age in mice models in aging and frailty</li> </ul>
Determination of metabolomic biomarkers associated with healthy aging, frailty, and diseases associated with aging [mainly cardiovascular and Neurodegenerative]		X		<ul style="list-style-type: none"> <li>Sex differences in age-associated Type 2 Diabetes in Rats-Role of Estrogens and Oxidative Stress</li> </ul>

# 4 scientific activity

Physical exercise protocols for the prevention of frailty	<ul style="list-style-type: none"><li>• A multicomponent exercise intervention that reverses frailty and improves cognition, emotion, and social networking in the community-dwelling frail elderly</li><li>• Exercise training as a drug to treat age-associated frailty</li><li>• Copenhagen consensus statement 2019: physical activity and aging</li><li>• Muscle repair after physiological damage relies on nuclear migration for cellular reconstruction</li></ul> <p><b>Project:</b> Novel multidomain therapeutic interventions to delay frailty and disability. Identification of molecular mechanisms with translational relevance</p> <p><b>Project:</b> Personalized physical exercise as an intervention to reverse disability in older adults living in residences [RESIFIT]</p> <p><b>Thesis title:</b> A multicomponent exercise program to prevent frailty, and for cognitive, emotional, and social improvement in frail elderly people</p> <p><b>Thesis title:</b> Moderate overexpression of glucose-6-phosphate dehydrogenase improves healthspan in mice. Implications in skeletal muscle regeneration</p> <p><b>Thesis title:</b> Impact of long-term physical exercise on neuroprotection in middle-aged subjects: study of the molecular mechanisms involved</p>
---	--

# scientific activity

## 4.3. Research areas

INCLIVA Biomedical Research Institute has four research areas in order to organize its scientific activity. Despite their independence, they have a common objective: meeting health needs and improving R&D&i system.

Their main aim is to establish a common reference framework to promote collaboration between INCLIVA attached researchers.

Each of the lines counts on the participation of one or several advisers from the External Scientific Committee. These lines are led by the following coordinators:

### Cardiovascular Area

- **Coordinator:** Mr. Francisco Javier Chorro
- **Mission:** to contribute to the study of different aspects of cardiovascular disease (CVD) from its origins to its consequences.

### Oncology Area

- **Coordinator:** Mr. Andrés Cervantes
- **Mission:** to contribute to the study of different aspects of oncological diseases, at the stage of diagnosis and molecular characterization and selection of specific molecular targets of therapeutic interest.

### Metabolism and Organic Damage Area


- **Coordinator:** Mr. José Viña
- **Mission:** to contribute to the study of the etiology, pathophysiology and diagnosis mechanisms or treatment of various metabolic diseases; or those that generate organ damage as a fundamental link of its trigger action.

### Reproductive Medicine Area

- **Coordinator:** Mr. Carlos Simón
- **Mission:** to advance in knowledge of human reproduction for translational application, improving the efficiency of assisted reproduction treatment and reducing adverse effects.


## Scientific production analysis by research area

The following charts and figures summarize the main scientific activity indicators of the four areas of research and the other divisions from *Hospital Clínico de Valencia*.



# 4 scientific activity

Since there are some scientific articles which are shared by two or more areas, it is worth mentioning that the sum of publications by area exceeds INCLIVA's total scientific output. Additionally, the next tables shows scientific publications distribution by area in terms of number of articles and impact factor.




# scientific activity

## 4.3.1 Cardiovascular area


### Groups

- Research Group on Cardiometabolic Risk and Diabetes
- Genomics and Diabetes Unit
- Research Group on Cardiac Experimental Electrophysiology
- Research Group on Endothelial Cells (LINCE)
- Research Group on Clinical Cardiology
- Research Group for the Prevention of Cardiovascular Risk in Children and Adolescents
- Cardiometabolic Research Group on Primary Care
- Research Group on the Study of Cardiometabolic and Renal Risk
- Research Group on Vascular Function
- Research Group on Pediatric Nutrition
- Group on Translational Research in Ischemic Heart Disease
- Research Group on Heart Failure



# scientific activity

## Research Group on Cardiometabolic Risk and Diabetes Consolidated group



### Strategic aims

In terms of scientific activity of the research group during 2022, our group is participating in the development of this competitive and multidisciplinary research projects that include the following aims:

- Project: Immunopharmacological modulation of the systemic inflammation associated to metabolic disorders. Search for new therapeutic targets and synthesis of novel drugs
- Project: Study of new inflammatory and angiogenic mechanisms associated to severe morbid obesity
- Project: Role of the inflammatory processes in metabolic diseases and associated complications
- Project: Evaluation of the efficacy of pharmacogenetics to improve the response to treatment in subjects with insufficiently controlled type 2 diabetes

### Main lines of research

- Role of inflammatory axes in the modulation of metabolic and vascular dysfunctions in obesity, insulin resistance and diabetes
- Primary dyslipidemias: molecular mechanisms, insulin resistance and novel therapeutic targets
- Ageing, frailty, sarcopenia and neurodegeneration in people with diabetes
- New diabetes technologies
- Pharmacogenetic-based personalized treatment in diabetes
- Applying Big Data and Artificial Intelligence technologies to analyze cardiovascular risk in dyslipidemia and diabetes
- Adipokines, inflammatory axes, new therapeutic targets and cardiovascular risk in metabolic fatty liver disease
- Body composition analysis

# scientific activity

4

- effect of body composition analysis, vascular risk and treatment in people with diabetes
- impact of body composition analysis on prognosis, quality of life and therapeutic response in onco-hematological patients
- NAFLD (non-alcoholic fatty liver disease) and metabolic diseases

## Emerging Researcher

Vera Lucía Gomes Francisco

Her work focuses on establishing new biomarkers and therapeutic targets in metabolic and cardiovascular diseases, highlighting the role of new adipokines and inflammatory axes.<sup>78</sup>

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Danne T, Ampudia-Blasco FJ, Mathieu C. Diabetes and the WHO Model List of Essential Medicines. *Lancet Diabetes & Endocrinology*. 2022 Jan;10(1):18-19. doi: 10.1016/S2213-8587(21)00322-3. PMID: 34919865. IF: 44,867
2. Palanca A, van Nes F, Pardo F, Ampudia Blasco FJ, Mathieu C. Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with Type 1 Diabetes: an European two-center experience. *Diabetes Care*. 2022 Mar 1;45(3):650-658. doi: 10.2337/dc21-1584. PMID: 35061022. IF: 17,152
3. Martinez-Hervas S, Morales-Suarez-Varela MM, Andres-Blasco I, Lara-Hernandez F, Peraita-Costa I, Real JT, Garcia-Garcia AB, Chaves FJ. Developing a simple and practical decision model to predict the risk of incident type 2 diabetes among the general population: the Di@bet.es Study. *European Journal of Internal Medicine*. 2022 Aug;102:80-87. doi: 10.1016/j.ejim.2022.05.005. PMID: 35570127. IF: 7,749
4. Marques P, Domingo E, Rubio A, Martinez-Hervas S, Ascaso JF, Piqueras L, Real JT, Sanz MJ. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. *Biomedicine & Pharmacotherapy*. 2022 Jan;145:112460. doi: 10.1016/j.biopharm.2021.112460. PMID: 34864314. IF: 7,419
5. Garcia-Garcia A, Martinez-Hervas S, Vernia S, Ivorra C, Pulido I, Martin-Escudero J, Casado M, Carretero J, Real J, Chaves F. A very rare variant in SREBF2, a possible cause

of hypercholesterolemia and increased glycemic levels. *Biomedicines*. 2022 May 19;10(5):1178. doi: 10.3390/biomedicines10051178. PMID: 35625914. IF: 4,757

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI21/00220

**Title:** Estudio de nuevos ejes de quimiocinas como potenciales dianas de intervención en la obesidad y la resistencia a la insulina

**Principal Investigator:** Laura Piqueras Ruiz and José Tomas Real Collado

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €204.490

**Reference:** ICI21/00020

**Title:** Evaluación de la eficacia de la farmacogenética para mejorar la respuesta al tratamiento en sujetos con diabetes tipo 2 insuficientemente controlada

**Principal Investigator:** Sergio Martinez Hervás

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2025

**Total budget:** €267.300

# scientific activity

**Reference:** PMP21/00076

**Title:** *ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2*

**Principal Investigator:** Felipe Javier Chaves Martínez and Sergio Martínez Hervás

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2025

**Total budget:** €106.700

**Reference:** PI19/00169

**Title:** *Papel de los procesos inflamatorios en las enfermedades metabólicas y en las complicaciones asociadas*

**Principal Investigator:** Herminia González Navarro and Sergio Martínez Hervás

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €159.720

**Reference:** PI18/00209

**Title:** *Identificación de nuevos mecanismos implicados en la angiogénesis e inflamación en pacientes obesos. Modulación por ligandos de receptores nucleares constitutivos de androstano*

**Principal Investigator:** Laura Piqueras Ruiz and José Tomas Real Collado

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2022

**Total budget:** €173.332,50

**Reference:** CB07/08/0018

**Title:** *CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem)*

**Principal Investigator:** José Tomas Real Collado

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2008-

**Reference:** PROMETEO/2019/032

**Title:** *Una aproximación traslacional desde la clínica a la experimentación animal: estudio del papel del eje CCL11/CCR3 y la inflamación eosinofílica en la patología cardiovascular asociada a*

*desórdenes metabólicos*

**Principal Investigator:** M<sup>a</sup> Jesús Sanz Ferrando (José Tomás, Sergio Martínez as collaborating researchers)

**Funding Body:** Conselleria de Educación Cultura y Deporte

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2023

**Total budget:** €211.736

**Reference:** INVEST/2022/470

**Title:** *Investigación en Enfermedades Inflamatorias*

**Principal Investigator:** Vera Lucía Gomes Francisco

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €66.217,84

## THESIS

**Thesis title:** *La ecografía Doppler con flujo en color en el diagnóstico, tratamiento y pronóstico de la enfermedad de Graves-Basedow*

**Doctoral candidate:** Olalla Rubio Puchol

**Director(s):** Agustín Ángel Merchante Alfaro, Sergio Martínez Hervás

**Date of the defense:** 25/01/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** *Effect of SGLT-2 inhibition in abdominal aortic aneurysm development. Role of rora in adipose tissue inflammation associated to obesity*

**Doctoral candidate:** Rebeca Ortega Herráiz

**Director(s):** Laura Piqueras Ruiz, María Jesús Sanz Ferrando, José Tomás Real Collado

**Date of the defense:** 21/02/2022

**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD

**Thesis title:** *Estudio de la sarcopenia y la fragilidad en una población diabética de edad avanzada y su relación con parámetros de estrés oxidativo*

**Doctoral candidate:** Blanca Alabadí Pardiñas

**Director(s):** Jose Tomás Real Collado, Miguel Civera Andrés

**Date of the defense:** 11/11/2022



**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD

# scientific activity

4

## Genomics and Diabetes Unit Consolidated group




# scientific activity

with phenotypes present five years later, as pertains to type 2 diabetes

- Monitoring and molecular characterization of chronic lymphocytic leukaemia and study of molecular markers
- Identification of relationships between different genes, essential metals and pollutants in relation to type 2 diabetes and related traits

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Galvez-Fernandez M, Sanchez-Saez F, Domingo-Relloso A, Rodriguez-Hernandez Z, Tarazona S, Gonzalez-Marrachelli V, Grau-Perez M, Morales-Tatay J, Amigo N, Garcia-Barrera T, Gomez-Ariza J, Chaves F, Garcia-Garcia A, Melero R, Tellez-Plaza M, Martin-Escudero J, Redon J, Monleon D. Gene-environment interaction analysis of redox-related metals and genetic variants with plasma metabolic patterns in a general population from Spain: the Hortega Study. *Redox Biology*. 2022 Jun;52:102314. doi: 10.1016/j.redox.2022.102314. PMID: 35460952. IF: 10,787
2. Moya-Gonzalvez E, Pena-Gil N, Rubio-del-Campo A, Coll-Marques J, Gozalbo-Rovira R, Monedero V, Rodriguez-Diaz J, Yebra M. Infant gut microbial metagenome mining of alpha-1-fucosidases with activity on fucosylated human milk oligosaccharides and glycoconjugates. *Microbiology Spectrum*. 2022 Aug 31;10(4):e0177522. doi: 10.1128/spectrum.01775-22. PMID: 35943155. IF: 9,043
3. Martinez-Hervas S, Morales-Suarez-Varela MM, Andres-Blasco I, Lara-Hernandez F, Peraita-Costa I, Real JT, Garcia-Garcia AB, Chaves FJ. Developing a simple and practical decision model to predict the risk of incident type 2 diabetes among the general population: The Di@bet.es Study. *European Journal of Internal Medicine*. 2022 Aug;102:80-87. doi: 10.1016/j.ejim.2022.05.005. PMID: 35570127. IF: 7,749
4. Garcia-Garcia A, Martinez-Hervas S, Vernia S, Ivorra C, Pulido I, Martin-Escudero J, Casado M, Carretero J, Real J, Chaves F. A very rare variant in SREBF2, a possible cause of hypercholesterolemia and increased glycemic levels. *Biomedicines*. 2022 May 19;10(5):1178. doi: 10.3390/biomedicines10051178. PMID: 35625914. IF: 4,757
5. Usategui-Martin R, Perez-Castrillon J, Mansego M, Lara-Hernandez F, Manzano I, Briongos L, Abadia-Otero J, Martin-Vallejo J, Garcia-Garcia A, Martin-Escudero J, Chaves F. Association between genetic variants in oxidative stress-related genes and osteoporotic bone fracture. *Gene*. 2022 Jan 30;809:146036. doi: 10.1016/j.gene.2021.146036. PMID: 34688818. IF: 3,913

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PMP21/00076

**Title:** *ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2*

**Principal Investigator:** Felipe Javier Chaves Martínez

**Funding Body:** *Instituto de Salud Carlos III - Co-financed FEDER*

**Beneficiary Institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2022-2025

**Total budget:** €106.700

**Reference:** PI21/00506

**Title:** *Estudio multifactorial para la identificación de nuevos factores genéticos y no genéticos mediante la secuenciación del exoma y técnicas de inteligencia artificial*

# scientific activity

4

**Principal Investigator:** Felipe Javier Chaves Martínez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico

Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €183.920

**Reference:** PID2020-115403RB-C22

**Title:** Glicosil hidrolasas bacterianas y su función en la infectividad

viral

**Principal Investigator:** Jesús Rodríguez Díaz

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2021-2024

**Total budget:** €160.930

**Reference:** AICO/2021/033

**Title:** Role of host mucosal glycosylation in SARS-CoV-2 infectivity

**Principal Investigator:** Jesús Rodríguez Díaz

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia  
y Sociedad Digital

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2022-2024

**Total budget:** €90.000

# scientific activity

## Research Group on Cardiac Experimental Electrophysiology Consolidated group

### Group members

#### Leading Researchers, R4

Francisco Javier Chorro Gascó  
Hospital. University  
Antonio M. Alberola Aguilar. University  
Luis Such Belenguer. University

#### Researchers by categories



Researchers financed by competitive public calls or networks



#### Recognised Researchers, R2

Irene del Canto Serrano. INCLIVA  
Isabel Trapero Gimeno. University  
Luis Such Miquel. University  
Manuel Zarzoso Muñoz. University

#### Team involved in



#### First Stage Researcher, R1

Óscar Julián Arias Mutis. CIBER

### Strategic aims

- Publication of the results obtained on using the 1,4-benzothiazepine derivative JTV-519 to modify the proarrhythmogenic manifestations of mechanoelectric feedback and continuation of the programmed experimental series to analyze the effects of KN-93, carvedilol and analogues, late Na<sup>+</sup> current inhibitors and the Nitric Oxide carrier S-nitrosoglutathione
- Continuation of the analysis of the effects of modifications of the basic electrophysiological properties on the processes involved in the induction and maintenance of ventricular fibrillation
- Analysis of the electrophysiological effects of chronic physical exercise and its protective effect against arrhythmias, the influence of the cardiac nervous system and mitochondrial oxidative stress and the involvement of the IKATP current
- Development of instruments for recording, processing and analysing cardiac electrophysiological signals obtained with mapping systems
- Progressive development of the experimental series aimed to study the mechanisms involved in the deterioration of the systolic function, fibrosis and the inducibility of arrhythmias in a chronic model of infarction
- Progressive development of an experimental model of metabolic syndrome to analyze the electrophysiological modifications and the inducibility of cardiac arrhythmias

### Main lines of research


- Myocardial stretching: analysis of electrophysiological changes induced by mechanical stretching. Autocrine/paracrine influences and study of protective actions by means of drugs
- Clinical and basic research on heart failure: role of calcium homeostasis in arrhythmogenesis. Study on the effects of drugs acting on intracellular Ca<sup>2+</sup> dynamics
- Analysis of the effects of modifications in basic electrophysiological properties on the processes involved in induction and maintenance of ventricular fibrillation

# scientific activity

4

- Study of electrophysiological effects of chronic physical activity by: a) analysis of the protection against arrhythmias or scientific activity facilitation of its reversion; b) study of the influence of heart's nervous system and mitochondrial oxidative stress; and c) analysis of the effects on the electrical instability induced by myocardial ischemia and the implication of IKATP current
- Development and extension of tools for the registration, processing and analysing of cardiac electrophysiological signals based on multielectrodes and optical mapping systems able to analyze voltage and calcium signals
- Study of mechanisms involved in the deterioration of the systolic function, fibrosis and the inducibility of arrhythmias in a chronic model of infarction
- Study of electrophysiological modifications and inducibility of cardiac arrhythmias in an experimental model of metabolic syndrome

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Gabaldón-Pérez A, Marcos-Garcés V, Gavara J, López-Lereu MP, Monmeneu JV, Pérez N, Ríos-Navarro C, De Dios E, Merenciano-González H, Cànoves J, Racugno P, Bonanad C, Minana G, Núñez J, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Ortiz-Pérez JT, Rodríguez-Palomares JF, Bodí V. Prognostic value of cardiac magnetic resonance early after ST-segment elevation myocardial infarction in older patients. *Age and Ageing*. 2022 Nov;51(11):afac248. doi: 10.1093/ageing/afac248. PMID: 36436010. IF: 12,782
2. Gavara J, Perez N, Marcos-Garcés V, Monmeneu J, Lopez-Lereu M, Ríos-Navarro C, de Dios E, Bonanad C, Canoves J, Moratal D, Palau P, Minana G, Nunez J, Chorro F, Bodí V. Combined assessment of stress cardiovascular magnetic resonance and angiography to predict the effect of revascularization in chronic coronary syndrome patients. *European Journal of Preventive Cardiology*. 2022 Mar;11;29(2):407-416. doi: 10.1093/eurjpc/zwab170. PMID: 34686874. IF: 8,526
3. Del Canto I, Santas E, Cardells I, Minana G, Palau P, Llacer P, Facila L, Lopez-Vilella R, Almenar L, Bodí V, Lopez-Lereu M, Monmeneu J, Sanchis J, Moratal D, Maceira A, de la Espriella R, Chorro F, Bayes-Genis A, Nunez J. Short-term changes in left and right ventricular cardiac magnetic resonance feature tracking strain following ferric carboxymaltose in patients with heart failure: a substudy of the Myocardial-IRON Trial. *Journal of the American Heart Association*. 2022 Apr;51(7):e022214. doi: 10.1161/JAHA.121.022214. PMID: 35301854. IF: 6,106
4. Gavara J, Marcos-Garcés V, Lopez-Lereu, MP, Monmeneu JV, Ríos-Navarro C, de Dios E, Perez N, Merenciano H, Gabaldón A, Canoves J, Racugno P, Bonanad C, Minana G, Nunez J, Nunez E, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Rodriguez-Palomares JF, Ortiz-Perez JT, Bodí V. Magnetic resonance assessment of left ventricular ejection fraction at any time post-infarction for prediction of subsequent events in a large multicenter STEMI Registry. *Journal of Magnetic Resonance Imaging*. 2022 Aug;56(2):476-487. doi: 10.1002/jmri.27789. PMID: 34137478. IF: 5,119
5. Palau P, Nunez J, Monmeneu J, Lopez-Lereu M, Gavara J, Ríos-Navarro C, de Dios E, Perez-Sole N, Marcos-Garcés V, Dominguez E, Moratal D, Canoves J, Minana G, Chorro F, Bodí V. Sex effect in the decision to perform invasive coronary angiography in patients with chronic coronary syndrome after undergoing vasodilator stress MRI. *Journal of Magnetic Resonance Imaging*. 2022 Dec;56(6):1680-1690. doi: 10.1002/jmri.28163. PMID: 35344231. IF: 5,119

# 4 scientific activity

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI21/01984

**Title:** *Efectos de la inhibición de SGLT2 sobre el remodelado auricular producido por el síndrome metabólico y su sustrato arritmogénico. Estudio experimental*

**Principal Investigator:** Francisco Javier Chorro Gascó and Manuel Zarzoso Muñoz

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €99.220

**Reference:** CB16/11/00486

**Title:** *Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV)*

**Principal Investigator:** Francisco Javier Chorro Gascó

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2017-

**Title:** *Resonancia magnética cardíaca de estrés con vasodilatadores para predecir la mortalidad a largo plazo en un amplio registro retrospectivo de pacientes con cardiopatía isquémica conocida o sospechada*

**Principal Investigator:** Vicent Bodí Peris (Francisco J Chorro Gascó as collaborating researcher)

**Funding body:** Sociedad Española de Cardiología


**Beneficiary Institution:** Fundación Investigación del Hospital Clínico Universitario de Valencia

**Duration:** 2021-2022


**Total budget:** €15.000

# scientific activity

## Research Group on Endothelial Cells (LINCE) Consolidated group



## PUBLICATIONS



## SELECTED PUBLICATIONS

- Perez-Cremades D, Chen J, Assa C, Feinberg M. MicroRNA-mediated control of myocardial infarction in diabetes. *Trends in Cardiovascular Medicine*. 2022 Jan 17:S1050-1738(22)00006-8. doi: 10.1016/j.tcm.2022.01.004. PMID: 35051592. IF: 8,049
- Mompeon A, Perez-Cremades D, Paes A, Sanchis J, Ortega-Paz L, Andrea R, Brugaletta S, Sabate M, Novella S, Dantas A, Hermenegildo C. Circulating miRNA fingerprint and endothelial function in myocardial infarction: comparison at acute event and one-year follow-up. *Cells*. 2022 Jun 2;11(11):1823. doi: 10.3390/cells11111823. PMID: 35681518. IF: 7,666

# scientific activity

3. Robinson EL, Novella S. Editorial: Genetic and gene regulation underlying sex differences in cardiovascular disease. *Frontiers in Cardiovascular Medicine*. 2022 Apr 11;9:881154. doi: 10.3389/fcvm.2022.881154. PMID: 35479282. IF: 5,848
4. McCoy MG, Perez Cremades D, Belkin N, Peng W, Zhang B, Chen J, Sachan M, Wara AKMK, Zhuang R, Cheng HS, Feinberg MW. A miRNA cassette reprograms smooth muscle cells into endothelial cells. *FASEB Journal*. 2022 Apr;36(4):e22239. doi: 10.1096/fj.202101872R. PMID: 35235229. IF: 5,834
5. Perez-Cremades D, Bueno-Beti C, Garcia-Gimenez J, Ibanez-Cabellos J, Pallardo F, Hermenegildo C, Novella S. Extracellular histones trigger oxidative stress-dependent induction of the NF- $\kappa$ B/CAM pathway via TLR4 in endothelial cells. *Journal of Physiology and Biochemistry*. 2022 Dec 5. doi: 10.1007/s13105-022-00935-z. PMID: 36464762. IF: 5,08

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** COST Action CA21153

**Title:** Network for implementing multiomics approaches in atherosclerotic cardiovascular disease prevention and research [AtheroNET]

**Principal Investigator:** Paolo Magni (Susana Novella as collaborating researcher)

**Funding body:** European Commission

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2025

**Reference:** COST Action CA17129

**Title:** Catalysing transcriptomics research in cardiovascular disease

**Principal Investigator:** Yvan Devaux (Susana Novella as collaborating researcher)

**Funding body:** European Commission

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2018-2023

**Reference:** PI19/01714

**Title:** Regulación dependiente de sexo y estrógenos en el síndrome coronario agudo e impacto funcional en células endoteliales humanas. Nuevos biomarcadores para prevención primaria

**Principal Investigator:** Carlos Hermenegildo and Susana Novella

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2023

**Total Budget:** €159.720

**Reference:** CIGE/2021/158

**Title:** Caracterización de un modelo murino experimental de insuficiencia cardiaca para estudios transcriptómicos

**Principal Investigator:** Daniel Pérez Cremades

**Funding body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary institution:** Universidad de Valencia

**Duration:** 2022-2023

**Total Budget:** €20.000

**Reference:** AICO/2021/211

**Title:** Análisis funcional de las rutas de señalización vascular reguladas por miRNA sensibles a estrógenos

**Principal Investigator:** Susana Novella Del Campo and Carlos Hermenegildo Caudeville

**Funding body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital



**Beneficiary institution:** Universidad de Valencia

**Duration:** 2022-2024

**Total Budget:** €90.000


# scientific activity

## Research Group on Clinical Cardiology Consolidated group



# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Castellano J, Pocock S, Bhatt D, Quesada A, Owen R, Fernandez-Ortiz A, Sanchez P, Ortuno F, Rodriguez J, Domingo-Fernandez A, Lozano I, Roncaglioni M, Baviera M, Foresta A, Ojeda-Fernandez L, Colivicchi F, Di Fusco S, Doehner W, Meyer A, Schiele F, Ecarnot F, Linhart A, Lubanda J, Barczi G, Merkely B, Ponikowski P, Kasprzak M, Alvira J, Andres V, Bueno H, Collier T, Van de Werf F, Perel P, Rodriguez-Manero M, Garcia A, Proietti M, Schoos M, Simon T, Ferro J, Lopez N, Beghi E, Bejot Y, Vivas D, Cordero A, Ibanez B, Fuster V. Polypill strategy in secondary cardiovascular prevention. *New England Journal of Medicine.* 2022 Sep 15;387(11):967-977. doi: 10.1056/NEJMoa2208275. PMID: 36018037. IF: 176,079
2. Romaguera R, Salinas P, Gomez-Lara J, Brugaletta S, Gomez-Menchero A, Romero M, Garcia-Blas S, Ocaranza R, Bordes P, Kockar M, Salvatella N, Jimenez-Diaz V, Alameda M, Trillo R, Lee D, Martin P, Lopez-Benito M, Freites A, Pascual-Tejerina V, Hernandez-Hernandez F, Del Blanco B, Mohandes M, Bosa F, Pinar E, Roura G, Comin-Colet J, Fernandez-Ortiz A, Macaya C, Rossello X, Sabate M, Pocock S, Gomez-Hospital J, SUGAR Trial Investigators. Amphilius- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. *European Heart Journal.* 2022 Mar 31;43(13):1320-1330. doi: 10.1093/eurheartj/ehab790. PMID: 34735004. IF: 35,855
3. De la Espriella R, Amiguet M, Minana G, Rodriguez JC, Moyano P, Segarra D, Fernandez J, Santas E, Nunez G, Lorenzo M, Bonanad C, Alania E, Valle A, Sanchis J, Bodi V, Gorrioz JL, Navarro J, Codina P, Voors AA, Bayes-Genis A, Nunez J. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure. *European Journal of Heart Failure.* 2022 Nov;24(11):2108-2117. doi: 10.1002/ejhf.2651. PMID: 36054502. IF: 17,349
4. Palau P, Amiguet M, Dominguez E, Sastre C, Mollar A, Seller J, Pinilla J, Larumbe A, Valle A, Doblas J, de la Espriella R, Minana G, Mezcua A, Santas E, Bodi V, Sanchis J, Pascual-Figal D, Gorrioz J, Bayes-Genis A, Nunez J. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial. *European Journal of Heart Failure.* 2022 Oct;24(10):1816-1826. doi: 10.1002/ejhf.2560. PMID: 35604416. IF: 17,349
5. Amat-Santos I, Sanchez-Luna J, Abu-Assi E, Melendo Viu M, Cruz-Gonzalez I, Nombela-Franco L, Munoz Garcia A, Garcia Blas S, de la Torre Hernandez J, Romaguera R, Sanchez-Recalde A, Diez Gil J, Lopez Otero D, Gheorge L, Ibanez B, Iniguez Romo A, Raposeiras-Roubin S, Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI), investigators. Rationale and design of the dapagliflozin after transcatheter aortic valve implantation (DapaTAVI) randomized trial. *European Journal of Heart Failure.* 2022 Mar;24(3):581-588. doi: 10.1002/ejhf.2370. PMID: 34693613. IF: 17,349

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI18/01138

**Title:** Efecto de la modificación de los niveles de antígeno carbohidrato 125 antes del implante de prótesis valvular aórtica percutánea sobre el pronóstico tras el implante

**Principal Investigator:** Juan Sanchis Forés

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2022

**Total budget:** €57.475

**Reference:** CB16/11/00420

**Title:** Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV)

**Principal Investigator:** Juan Sanchis Forés

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2017-

**Reference:** AP-2021-016

**Title:** BREIC: Identificación de biomarcadores del eje corazón-microbiota-sistema inmune por RMN para la estratificación de pacientes con insuficiencia cardiaca

# scientific activity

4

**Principal Investigator:** Vannina González Marrachelli and Anna

Mollar Fernández

**Funding Body:** Universidad de Valencia - INCLIVA

**Beneficiary Institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total budget:** €4.750

## THESIS

**Thesis title:** *Historia clínica y niveles indetectables de troponina de alta sensibilidad en la evaluación del riesgo de pacientes con dolor torácico agudo y primera determinación de troponina normal*

**Doctoral candidate:** Ernesto Valero Picher

**Director(s):** Juan Sanchis Forés, Julio Núñez Villota

**Date of the defense:** 28/01/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group for the Prevention of Cardiovascular Risk in Children and Adolescents Consolidated group

### Group members

#### Leading Researcher, R4

Empar Lurbe i Ferrer

University

#### Established Researchers, R3

Francisco Aguilar Bacallado. University

Isabel Torró Doménech. University

#### Recognised Researchers, R2

Christine Deutsch. CIBER

Julio Álvarez Pitti. University

#### First Stage Researcher, R1

Ana de Blas Zapata. University

#### Staff. Collaborating Researchers

Juan José Alcón Sáez. University

Nuria García Carbonell. University

Rafael Gómez Zafra. University

### Researchers by categories



Researchers financed by competitive public calls or networks



### Team involved in

*ciberobn*

#### Staff. Technician

Francisco Ponce Zanón. CIBER

### Strategic aims

- The iPEDITEC Unit brings healthcare workers into daily contact with engineers developing software for signal capture through mobile devices. Studying the psychological parameters that facilitate personalized therapy has been a priority aim during 2022, resulting in improved treatment of obese pediatric patients in the Unit
- The PAIDO Program is focused on personalized medical care extended through initiatives involving family, educators, nutritionists, physical education teachers and other social agents. Treatment goes beyond the hospital setting to include the child's environment and personal sphere and is supported by state-of the art artificial intelligence technologies
- To improve the knowledge of fetal life and postnatal growth on the development of cardiometabolic risk factors early in life. The KITE cohort is a prospective study starting at birth and assessing the determinants of cardiometabolic risk factors in the first decades of life. Omics data from umbilical cord are available and the analysis of the interaction between clinical data and omics may help to introduce actions in critical periods of life and the potential contribution to reduce cardiometabolic disease later in life. Mrs. Lurbe is the coordinator of the new document of the European Guidelines on Arterial Hypertension in Children and Adolescents

### Main lines of research

- New technologies applied to the detection of congenital heart diseases and sepsis in asymptomatic newborn babies
- Childhood obesity: new insights in the personalized treatment: study of the cardiorespiratory capacity
- New technologies applied to the treatment of obesity: physical exercise preventing and treating obesity
- Arterial hypertension in children and adolescents
- Cardiovascular and renal risk in diabetes
- Early origins of cardiometabolic risk factors assessed in a prospective study starting at birth (Cohort KITE)
- HyperChildNET: European Network for Research on Blood Pressure in Children and Adolescents

# scientific activity

4

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. De Simone G, Mancusi C, Hanssen H, Genovesi S, Lurbe E, Parati G, Sendzikaitė S, Valerio G, Di Bonito P, Di Salvo G, Ferrini M, Leeson P, Moons P, Weismann C, Williams B. Hypertension in children and adolescents a consensus document from ESC Council on Hypertension, European Association of Preventive Cardiology, European Association of Cardiovascular Imaging, Association of Cardiovascular Nursing & Allied Professions, ESC Council for Cardiology Practice and Association for European Paediatric and Congenital Cardiology. European Heart Journal. 2022 Sep 14;43(35):3290-3301. doi: 10.1093/euroheartj/ehac328. PMID: 35896123. IF: 35,855
2. Lurbe E, Redon J, Alvarez J, Grau-Perez M, Martinez F, Mancia G. Insights from matched office and ambulatory blood pressure in youth: clinical relevance. Hypertension. 2022 Mar 29;101161HYPERTENSIONAHA12218993. doi: 10.1161/HYPERTENSIONAHA.122.18993. PMID: 35345885. IF: 9,897
3. Borghi C, Agnoletti D, Cicero A, Lurbe E, Virdis A. Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk. Hypertension. 2022 Sep;79(9):1927-1936. doi: 10.1161/HYPERTENSIONAHA.122.17956. PMID: 35658505. IF: 9,897
4. Desdentado L, Navarrete J, Folgado-Alufre M, de Blas A, Navarro-Siurana J, Ponce F, Molinari G, Jimeno-Martinez A, Ruperez A, Bueno-Lozano G, Cuenca-Royo A, Corbella E, Aguera Z, Banos R, Alvarez-Pitti J. Are peripheral biomarkers determinants of eating styles in childhood and adolescence obesity?. A cross-sectional study. Nutrients. 2022 Jan 12;14(2):305. doi: 10.3390/nu14020305. PMID: 35057485. IF: 6,706
5. Alvarez-Pitti J, Herceg-Cavrak V, Wojcik M, Radovanovic D, Brzezinski M, Grabitz C, Wuhl E, Drozd D, Melk A. Blood pressure response to exercise in children and

adolescents. Frontiers in Cardiovascular Medicine. 2022 Sep 30;9:1004508. doi: 10.3389/fcvm.2022.1004508. PMID: 36247478. IF: 5,846

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** COST CA19115

**Title:** Network for blood pressure research in children and adolescents. HyperChildNET

**Principal Investigator:** Empar Lurbe i Ferrer

**Funding Body:** European Commision

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2024

**Reference:** PI20/00269

**Title:** Impacto del peso al nacer y el patrón de crecimiento en los factores de riesgo cardiom metabólico en adolescentes postpuberales: aproximación clínica y molecular

**Principal Investigator:** Empar Lurbe i Ferrer

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total budget:** €174.845

**Reference:** CB06/03/0039

**Title:** Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn)

**Principal Investigator:** Empar Lurbe i Ferrer

**Funding Body:** Instituto de Salud Carlos III-Co-financed FEDER

**Beneficiary Institution:** Consorcio Hospital General Universitario de Valencia

**Duration:** 2006-

# scientific activity

## Cardiometabolic Research Group on Primary Care Consolidated group


Group members	Researchers by categories
<b>Leading Researcher, R4</b>	<b>R3</b> 4
Jorge Navarro Pérez University. Hospital	<b>R4</b> 1
<b>Established Researchers, R3</b>	<b>STAFF</b> 44
Alvaro Bonet Pla. Hospital Carolina Mir Sánchez. University. Clínico-Malvarrosa Health Department Desamparados Garcés Sánchez. Hospital Ruth Usó Talamantes. Hospital	José Luis Trillo Mata. Hospital Laura Almudéver Campo. Clínico-Malvarrosa Health Department Lucía Navarro Salvador. Clínico-Malvarrosa Health Department Mª Dolores Seligra Borrull. Hospital Mª José Puchades Company. Clínico-Malvarrosa Health Department Margarita Giménez Loreiro. Clínico-Malvarrosa Health Department María Aóda Andreu Lledó. Hospital María Ferrus Domingo. Clínico-Malvarrosa Health Department María José Garzón Nieto. Clínico-Malvarrosa Health Department Marina Gimeno Gimeno. Hospital Marisa Calabuig Muñoz. Clínico-Malvarrosa Health Department Nidia Ruiz Varea. Clínico-Malvarrosa Health Department Óscar Pérez Quintana. Hospital Pablo Sabater Arnaldos. Clínico-Malvarrosa Health Department Pilar Botija Yagüe. Hospital Pilar Roca Navarro. University. Clínico-Malvarrosa Health Department Ricardo González Espadas. University. Hospital Ruth Uribe Fillo. Clínico-Malvarrosa Health Department Sofía Bauer Izquierdo. Clínico-Malvarrosa Health Department Svitlana Nikitina Osadcha. Clínico-Malvarrosa Health Department Tamara Miravalls Pérez. Hospital Tomás Sánchez Ruiz. University. Clínico-Malvarrosa Health Department Verónica Audina Márquez. Clínico-Malvarrosa Health Department Verónica Lozano Rodríguez. Hospital Vibiana Blanco Alvarado. Clínico-Malvarrosa Health Department Victoria Gosalbes Soler. Clínico-Malvarrosa Health Department
<b>Staff. Collaborating Researchers</b>	
Aaron Piera Torró. Clínico-Malvarrosa Health Department Alberto Belenguer Guillot. Clínico-Malvarrosa Health Department Alex David Misle Morales. Clínico-Malvarrosa Health Department Alexandre Sorribes Ramírez. Clínico-Malvarrosa Health Department Carlos Fluixá Carrascosa. University. Clínico-Malvarrosa Health Department Carlos Momparler Martínez. Clínico-Malvarrosa Health Department Carmina Martínez Vernia. Clínico-Malvarrosa Health Department Celia Poveda Rocamora. Hospital Cristina Más Lázaro. Clínico-Malvarrosa Health Department Diana Vicente Miralles. Clínico-Malvarrosa Health Department Eduardo Rovira Cabrera. Clínico-Malvarrosa Health Department Enrique Guinot Martínez. Clínico-Malvarrosa Health Department Esther Carrión Albert. Hospital Eugenio Avelino Hidalgo. Hospital Idoia Aramburu Aizpiri. Clínico-Malvarrosa Health Department Ignacio Ramos Manuel. Hospital Irene Marco Moreno. Clínico-Malvarrosa Health Department Isabel Gabaldón Sánchez. University. Clínico-Malvarrosa Health Department	

Strategic aims	Main lines of research
<ul style="list-style-type: none"> <li>• Consolidation of various lines of cardiometabolic research</li> <li>• Consolidation of a network of partners in the area of primary care</li> </ul>	<ul style="list-style-type: none"> <li>• Cardiovascular population studies (ESCARVAL, Big data studies)</li> <li>• Studies monitoring cardiovascular risk factors (ADAMPA)</li> </ul>

# scientific activity

4

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Torres I, Gimenez E, Albert E, Zulaica J, Alvarez-Rodriguez B, Burgos J, Peiro S, Limon R, Vanaclocha H, Rodado C, Botija P, Sifre A, Tur B, Lozano R, Orosa I, Vicente-Ruiz M, Carrion R, Clari M, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzalez-Candelas F, Geller R, Navarro D. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty (R) COVID-19 vaccine: looking for correlates of protection. *Journal of Medical Virology*. 2022 Sep;94(9):4216-4223. doi: 10.1002/jmv.27867. PMID: 35585782. IF: 20,693
2. De la Espriella R, Amiguet M, Minana G, Rodriguez JC, Moyano P, Segarra D, Fernandez J, Santas E, Nunez G, Lorenzo M, Bonanad C, Alania E, Valle A, Sanchis J, Bodi V, Gorrioz JL, Navarro J, Codina P, Voors AA, Bayes-Genis A, Nunez J. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure. *European Journal of Heart Failure*. 2022 Nov;24(11):2108-2117. doi: 10.1002/ejhf.2651. PMID: 36054502. IF: 17,349
3. Calderon J, Martinez F, Diaz J, Fernandez A, Sauri I, Uso R, Trillo J, Vela S, Bea C, Redon J, Forner M. Real-world data of anticoagulant treatment in non-valvular atrial fibrillation. *Frontiers In Cardiovascular Medicine*. 2022 Jan 21;8:733300. doi: 10.3389/fcvm.2021.733300. PMID: 35127843. IF: 5,846
4. Pallares Carratala V, Carratala Munuera C, Lopez Pineda A, Quesada J, Gil Guillen V, Orozco Beltran D, Alfonso Sanchez J, Navarro Perez J, Martin Moreno J. Characterizing diagnostic inertia in arterial hypertension with a gender perspective in primary care. *Frontiers in Cardiovascular Medicine*. 2022 Jun 16;9:874764. doi: 10.3389/fcvm.2022.874764. PMID: 35783866. IF: 5,846
5. Sánchez-Sendra B, Albert E, Zulaica J, Torres I, Giménez E, Botija P, Beltrán MJ, Rodado C, Geller R, Navarro D. Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. *Scientific Reports*. 2022 Mar 8;12(1):3788. doi: 10.1038/s41598-022-07849-2. PMID: 35260713. IF: 4,996

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI21/01417

**Title:** *Cribado sistemático de insuficiencia cardíaca en pacientes con diabetes mellitus tipo 2. Estudio piloto*

**Principal Investigator:** Enrique Santas Olmeda and Jorge Navarro Pérez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total Budget:** €90.871

## THESIS

**Thesis title:** *Análisis de las prescripciones potencialmente inadecuadas según los criterios STOPP/START en los residentes de los centros sociosanitarios del Departamento de Salud Clínico-Malvarrosa de Valencia desde 2016 hasta 2018*

**Doctoral candidate:** Isabel Díaz Planelles

**Director(s):** Jorge Navarro Pérez, José Luis Trillo Mata

**Date of the defense:** 30/03/2022

**Grade:** *Sobresaliente "cum laude"*

# scientific activity


## Research Group on the Study of Cardiometabolic and Renal Risk Consolidated group



### Emerging Researcher

Raquel Cortés Vergaz


The main objective of the new field of research is to study the molecular mechanisms associated with the development of early kidney damage due to hypertension and diabetes, focusing on the characterization of extracellular vesicles and their roles as intercellular mediators. In addition, a new line of research has been opened in kidney damage associated with systemic lupus erythematosus, autoimmune disease, and the role of extracellular vesicles as diagnostic, prognostic and monitoring biomarkers of disease activity.



## Main lines of research

- Analysis of podocytes-renal proximal tubular epithelial cell communication as key player in kidney damage progression [miRNAs and exosomes]
- Impact of cardiovascular risk factors and renal function in absolute morbidity and mortality in high-risk population and in the general population
- Inflammation and oxidative stress in the development of cardiovascular disease
- Genomics, proteomics and metabolomics of early cardiometabolic and renal disorders
- Impact of environmental toxins (metals) in cardiometabolic risk
- Identification of polymorphisms and related to the control of BMI and waist circumference and the risk of obesity genes
- Venous thrombosis in young patients: factors associated with its development
- The relationship between risk of venous thromboembolic disease and arteriosclerosis
- Molecular mechanisms associated with activity changes and renal damage development in systemic lupus erythematosus

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. PMID: 36356632. IF: 202,731
2. Linschoten M, Uijl A, Schut A, et al. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. European Heart Journal. 2022 Mar 14;43(11):1104-1120. doi: 10.1093/eurheartj/ehab656. PMID: 34734634. IF: 35,855
3. Martí-Aguado D, Clemente-Sánchez A, Bataller R. Cigarette smoking and liver diseases. Journal of Hepatology. 2022 Jul;77(1):191-205. doi: 10.1016/j.jhep.2022.01.016. PMID: 35131406. IF: 30,083
4. Martí-Aguado D, Jiménez-Pastor A, Alberich-Bayarri A, Rodríguez-Ortega A, Alfaro-Cervello C, Mestre-Alagarda C, Bauza M, Gallen-Peris A, Valero-Perez E, Ballester MP, Gimeno-Torres M, Pérez-Girbes A, Benlloch S, Pérez-Rojas J, Puglia V, Ferrández A, Aguilera V, Escudero-García D, Serra MA, Martí-Bonmatí L. Automated whole-liver MRI segmentation to assess steatosis and iron quantification in chronic liver disease. Radiology. 2022 Feb;302(2):345-354. doi: 10.1148/radiol.2021211027. PMID: 34783592. IF: 29,146
5. Galvez-Fernandez M, Powers M, Grau-Perez M, Domingo-Rellosa A, Lolacono N, Goessler W, Zhang Y, Fretts A, Umans JG, Maruthur N, Navas-Acien A. Urinary zinc and incident type 2 Diabetes: prospective evidence from the Strong Heart Study. Diabetes care. 2022 Nov 1;45(11):2561-2569. doi: 10.2337/dc22-1152. PMID: 36134919. IF: 17,152

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** EHDEN - OMOP

**Title:** EHDEN. Harmonization Fund Holder

**Principal Investigator:** Josep Redón i Mas

**Funding body:** European Commission

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2023

**Total budget:** €50.000

# scientific activity

**Reference:** 945097-WELBASED

**Title:** WELLBASED. Improving health, wellbeing and equality by evidenced-based urban policies for tackling energy poverty

**Principal Investigator:** Josep Redón i Mas

**Funding body:** European Commission

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2025

**Total budget:** €395.250

**Reference:** 785815 - BigData@Heart

**Title:** Big Data for Better Hearts

**Principal Investigator:** Josep Redón i Mas

**Funding body:** European Commission

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2017-2022

**Total budget:** €386.250 (Contribution EC: 100%)

**Reference:** PI21/00249

**Title:** Identificación de ARN no codificantes en biopsia líquida con énfasis en exosomas como biomarcadores pronóstico de actividad en el lupus eritematoso sistémico. Implicación fisiopatológica en el daño renal

**Principal Investigator:** Raquel Cortés Vergaz and M<sup>a</sup> José Forner Giner

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €135.520

**Reference:** PI19/01796

**Title:** Implicaciones experimentales y clínicas del complejo proteico rabphilin-rab en daño renal en la Diabetes Mellitus tipo 2

**Principal Investigator:** Josep Redón i Mas

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2023

**Total budget:** €196.020

**Title:** Cuantificación de la hemoglobina fecal para la estadificación del riesgo de neoplasia en pacientes incluidos en el programa de cribado de cáncer colorrectal

**Principal Investigator:** David Martín Aguado

**Funding body:** Fundación SEED Investigación en Endoscopia Digestiva

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total budget:** €15.000

**Title:** Estudio multicéntrico de precisión diagnóstica para cuantificar y caracterizar la fibrosis de la enfermedad hepática metabólica mediante patología digital avanzada

**Principal Investigator:** David Martín Aguado

**Funding body:** Sociedad Valenciana de Patología Digestiva

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2022

**Total budget:** €5.000

**Title:** Cohorte Española de pacientes con infección por VIH mayores de 50 años para el estudio de la fragilidad y la función física

**Principal Investigator:** M<sup>a</sup> José Galindo Puerto

**Funding body:** Janssen - Cilag S.A.

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022

**Total budget:** €27.295,83

## THESIS

**Thesis title:** Monitorización del manejo de sepsis para la identificación de flujos asistenciales y su impacto en la evolución de los pacientes. El diagnóstico precoz de sepsis en urgencias

**Doctoral candidate:** Jorge Clar Bononad

**Director(s):** M<sup>a</sup> Rosa Oltra Sempere, Josep Redón i Mas

**Date of the defense:** 10/02/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** Evaluación cardiometabólica y adrenérgica en el sujeto obeso sano joven

**Doctoral candidate:** Adrián Ruiz Hernández



**Director(s):** M<sup>a</sup> José Forner Giner, Josep Redón i Mas

**Date of the defense:** 28/04/2022


**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group on Vascular Function Consolidated group



## PUBLICATIONS



# scientific activity

## SELECTED PUBLICATIONS

1. De Maranon A, Diaz-Pozo P, Canet F, Diaz-Morales N, Abad-Jimenez Z, Lopez-Domenech S, Vezza T, Apostolova N, Morillas C, Rocha M, Victor V. Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients. *Redox Biology.* 2022 Jul;53:102342. doi: 10.1016/j.redox.2022.102342. PMID: 35605453. IF: 10,787
2. Canet F, Diaz-Pozo P, Luna-Marco C, Fernandez-Reyes M, Vezza T, Marti M, Salazar J, Roldan I, Morillas C, Rovira-Llopis S, Rocha M, Victor V. Mitochondrial redox impairment and enhanced autophagy in peripheral blood mononuclear cells from type 1 diabetic patients. *Redox Biology.* 2022 Dec;58:102551. doi: 10.1016/j.redox.2022.102551. PMID: 36455476. IF: 10,787
3. Diaz-Pozo P, Canet F, Grirrane A, Lopez-Domenech S, Herance J, Apostolova N, Luna-Marco C, Rovira-Llopis S, Marti M, Morillas C, Rocha M, Garcia H, Victor V. Gold nanoparticles supported on ceria nanoparticles modulate leukocyte-endothelium cell interactions and inflammation in Type 2 Diabetes. *Antioxidants.* 2022 Nov 20;11(11):2297. doi: 10.3390/antiox11112297. PMID: 36421483. IF: 7,675
4. Guerra-Ojeda S, Marchio P, Rueda C, Suarez A, Garcia H, Victor V, Juez M, Martin-Gonzalez I, Vila J, Mauricio M. Cerium dioxide nanoparticles modulate antioxidant defences and change vascular response in the human saphenous vein. *Free Radical Biology & Medicine.* 2022 Nov 17;193(Pt 2):694-701. doi: 10.1016/j.freeradbiomed.2022.11.012. PMID: 36402438. IF: 8,101
5. Guerra-Ojeda S, Marchio P, Aldasoro M, Valles S, Genoves P, Mauricio M, Vila J. deleterious effects of levamisole, a cocaine adulterant, in rabbit aorta. *Vascular Pharmacology.* 2022 Jun;144:106992. doi: 10.1016/j.vph.2022.106992. PMID: 35358704. IF: 5,738

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI19/0838

**Title:** Estudio de la función mitocondrial, la autofagia y la mitofagia en la diabetes tipo 2: relación con las complicaciones cardiovasculares e implicaciones clínicas

**Principal Investigator:** Víctor Manuel Víctor González

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2022

Total budget: €183.920

**Reference:** PROMETEO/2019/027

**Title:** Patofisiología de las enfermedades cardiometabólicas

**Principal Investigator:** Víctor Manuel Víctor González

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2023

Total budget: €207.157

## THESIS

**Thesis title:** Efectos vasculares de las nanopartículas de óxido de cerio en la vena safena

**Doctoral candidate:** Cristina Rueda Muñoz

**Director(s):** Mª Dolores Mauricio Aviñó, Marina Juez López, Solanye Guerra Ojeda

**Date of the defense:** 28/10/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** Interacciones de la ranolazina con agentes vasoactivos endógenos y exógenos

**Doctoral candidate:** Elena Campos Carot

**Director(s):** José Mª Vila Salinas, Mª Dolores Aviñó, Juan B. Martínez León

**Date of the defense:** 19/12/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** Estudio del efecto de la cirugía de bypass gástrico en Y de Roux sobre los mecanismos moleculares asociados a la fisiopatología de la obesidad

**Doctoral candidate:** Zaida María Abad Jiménez

**Director(s):** Víctor Manuel Víctor González

**Date of the defense:** 22/12/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

4

## Research Group on Pediatric Nutrition Consolidated group

### Group members

#### Leading Researchers, R4

Cecilia Martínez Costa

Hospital. University

Javier Buesa Gómez

Hospital. University



#### Established Researchers, R3

Elena Crehuá Gaudiza. Hospital. University

Francisco Núñez Gómez. Hospital. University

Javier Estañ Capell. Hospital. University

Laura Martínez Rodríguez. Hospital

#### Recognised Researcher, R2

Ana Paula Grattarola. INCLIVA

#### First Stage Researchers, R1

Alba Peretó Moll. Hospital

Ana Barrés Fernández. Hospital

Ana Delgado Vicente. Hospital

Ángel Vicente Valls Arévalo. Hospital

Carlos Sáenz de Juano Petit. Hospital

Isidro Robredo García. INCLIVA

Laura Núñez Martínez. Hospital

#### Staff. Collaborating Researchers

Inmaculada Tarazona Casany. Hospital

José Vicente Arcos Machancoses. Hospital

### Strategic aims

Cardiovascular area:

- Study of metabolome and microbiome in obese children with/without insulin resistance before and after personalized nutritional intervention and physical exercise

Area of human milk:

- Characterization of mother-infant microbiome in term and preterm infants. Influence of perinatal variables

Area of hospital malnutrition and artificial nutrition:

- Validation of the pediatric screening tools for detecting the risk of malnutrition linked to chronic disease and pediatric hospitalization

# scientific activity

## Main lines of research

Cardiovascular area:

- Analysis of microbiota in obese children before and after intervention
- Analysis of microbiota in obese children with/without insulin resistance
- Analysis of metabolome in obese children with/without insulin resistance
- Monitoring exercise and energy consumption in obese schoolchildren and teenagers to adjust nutritional intervention


Area of human milk:

- Analysis of nutritional and bioactive components in human milk: influence of genotype FUT2 on oligosaccharides
  - Analysis of mother-fetal microbiome in term and preterm infants. Influence of delivery mode, maternal diet and development.
- Impact on host response and intestinal function

Area of hospital malnutrition and artificial nutrition:

- Validation of the pediatric screening tools for detecting the risk of malnutrition
- Multicenter study of acceptance and quality of life in children treated with home enteral nutrition

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Costa R, Olea B, Bracho M, Albert E, de Michelena P, Martinez-Costa C, Gonzalez-Candelas F, Navarro D. RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status. *Journal of Infection*. 2022 Apr;84(4):579-613. doi: 10.1016/j.jinf.2021.12.018. PMID: 34953901. IF: 38,637
2. Selma-Royo M, Bauerl C, Mena-Tudela D, Aguilar-Camprubi L, Perez-Cano FJ, Parra-Llorca A, Lerin C, Martinez-Costa C, Collado MC. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study. *Genome Medicine*. 2022 Apr 21;14(1):42. doi: 10.1186/s13073-022-01043-9. PMID: 35449030. IF: 15,266
3. Bauerl C, Randazzo W, Sanchez G, Selma-Royo M, Garcia-Verdevio E, Martinez L, Parra-Llorca A, Lerin C, Fumado V, Crovetto F, Crispi F, Perez-Cano F, Rodriguez G, Ruiz-Redondo G, Campoy C, Martinez-Costa C, Collado M, MilkCORONA study team. SARS-CoV-2 RNA and antibody detection in breast milk from a prospective multicentre study in Spain. *Archives of Disease in Childhood. Fetal and Neonatal Edition*. 2022 Mar;107(2):216-221. doi: 10.1136/archdischild-2021-322463. PMID: 34417223. IF: 6,643
4. Arias-Borrego A, Soto Cruz FJ, Selma-Royo M, Bauerl C, Garcia Verdevio E, Perez-Cano FJ, Lerin C, Velasco Lopez I, Martinez-Costa C, Collado MC, Garcia-Barrera T. Metallomic and untargeted metabolomic signatures of human milk from SARS-CoV-2 Positive mothers. *Molecular Nutrition & Food Research*. 2022 Aug;66(16):e2200071. doi: 10.1002/mnfr.202200071. PMID: 35687731. IF: 6,575
5. Calvo-Lerma J, Selma-Royo M, Hervas D, Yang B, Intonen L, Gonzalez S, Martinez-Costa C, Linderborg K, Collado M. Breast milk lipidome is associated with maternal diet and infants' growth. *Frontiers in Nutrition*. 2022 Jul 6;9:854786. doi: 10.3389/fnut.2022.854786. PMID: 35873422. IF: 6,59

## RESEARCH PROJECTS AND GRANTS FOR

# scientific activity

4

## RESEARCH

**Title:** PI19/00354

**Título:** Efectividad de la vacunación antigripal y antineumocócica para prevenir la hospitalización en personas menores de 65 años que presentan condiciones de riesgo

**Principal Investigator:** Ángela Domínguez García (Francisco Núñez as collaborating researcher)

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Universidad de Barcelona

**Duration:** 2020-2022

**Total budget:** €220.220

**Reference:** PCIN-2017-117

**Title:** Obesidad materna y disfunción cognitiva en la descendencia: papel causa-efecto de la microbiota intestinal y prevención dietética temprana

**Principal Investigator:** Consuelo Borrás Blasco (Cecilia Martínez Costa as collaborating researcher)

**Funding body:** Ministerio de Economía y Competitividad

**Beneficiary institution:** Universidad de Valencia

**Duration:** 2017-2022

**Total budget:** €143.000

**Reference:** AP-2021-004

**Título:** NEODIAG-VR: Realidad virtual para la formación multidisciplinar en neonatología

**Principal Investigator:** Jesús Gimeno Sancho and Javier Estañ Capell

**Funding body:** Universidad de Valencia - INCLIVA

**Beneficiary institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total budget:** €4.655

## THESIS

**Thesis title:** Anomalías craneofaciales y dentales en una población de escolares nacidos pretérmino

**Doctoral candidate:** María Aurora Peiró Guijarro

**Director(s):** Cecilia Martínez Costa, Montserrat Catalá Picarro, Laura Martínez Rodríguez

**Date of the defense:** 25/03/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** Estudio del desarrollo y la función renal, y de aspectos implicados en el síndrome metabólico del adulto, en gemelos con peso dispar al nacimiento. Valoración durante la edad pediátrica

**Doctoral candidate:** Juan Marín Serra


**Director(s):** Roberto Hernández Marco, Francisco Núñez Gómez, Jaime Fons Moreno

**Date of the defense:** 24/10/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Group on Translational Research in Ischemic Heart Disease Consolidated group



### Strategic aims

- From our research experience from the last years in the clinical and experimental field related to ischemic cardiopathy, our current goal is to focus into a translational approach
- In 2022 we continued elucidating the abnormalities in the coronary circulation after a myocardial infarction by using a swine model. Moreover, we have also started to evaluate *in vitro* the role of endothelial injury after coronary reperfusion and the implication of angiogenesis in the recovery of the microvasculature after a myocardial infarction in animal models and in patients
- We have also developed new tools to study patients with ST-segment elevation myocardial infarction using cardiac magnetic resonance imaging

### Main lines of research

- Prospective registry of patients with first ST-segment elevation myocardial infarction studied with cardiac magnetic resonance imaging at acute and chronic phases
- Multicenter registry of patients with chronic coronary syndrome studied with stress cardiac magnetic resonance imaging
- Porcine and mice model of experimental myocardial ischemia and myocardial infarction. To achieve a better understanding of the pathophysiology of ischemia, necrosis, fibrosis, angiogenesis, and reperfusion injury and test new novel therapeutic avenues
- Involvement in several large international multicenter clinical trials in the field of acute coronary syndromes

# scientific activity


4

## Emerging Researcher

Clara Bonanad Lozano

Her line of research aims to evaluate the impact of geriatric syndromes and residual risk, specifically dyslipidemia and inflammation, in patients with non-ST-segment elevation acute coronary syndrome.

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Gabaldón-Pérez A, Marcos-Garcés V, Gavara J, López-Lereu MP, Monmeneu JV, Pérez N, Ríos-Navarro C, De Dios E, Merenciano-González H, Cànoves J, Racugno P, Bonanad C, Minana G, Núñez J, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Ortiz-Pérez JT, Rodríguez-Palomares JF, Bodí V. Prognostic value of cardiac magnetic resonance early after ST-segment elevation myocardial infarction in older patients. *Age and Ageing*. 2022 Nov;51(11):afac248. doi: 10.1093/ageing/afac248. PMID: 36436010. IF: 12,782
2. Gavara J, Perez N, Marcos-Garcés V, Monmeneu J, Lopez-Lereu M, Ríos-Navarro C, de Dios E, Bonanad C, Canoves J, Moratal D, Palau P, Minana G, Núñez J, Chorro F, Bodí V. Combined assessment of stress cardiovascular magnetic resonance and angiography to predict the effect of revascularization in chronic coronary syndrome patients. *European Journal of Preventive Cardiology*. 2022 Mar 11;29(2):407-416. doi: 10.1093/eurjpc/zwab170. PMID: 34686874. IF: 8,526
3. Gavara J, Marcos-Garcés V, Lopez-Lereu, MP, Monmeneu JV, Ríos-Navarro C, de Dios E, Perez N, Merenciano H, Gabaldón A, Canoves J, Racugno P, Bonanad C, Minana G, Núñez J, Núñez E, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Rodriguez-Palomares JF, Ortiz-Perez JT, Bodí V. Magnetic resonance assessment of left ventricular ejection fraction at any time post-infarction for prediction of subsequent events in a large multicenter STEMI Registry. *Journal of Magnetic Resonance Imaging*. 2022 Aug;56(2):476-487. doi: 10.1002/jmri.27789. PMID: 34137478. IF: 5,119
4. de la Espriella R, Amiguet M, Minana G, Rodriguez JC, Moyano P, Segarra D, Fernandez J, Santas E, Núñez G, Lorenzo M, Bonanad C, Alania E, Valle A, Sanchis J, Bodí V, Gorrioz JL, Navarro J, Codina P, Voors AA, Bayes-Genis A, Núñez J. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure. *European Journal of Heart Failure*. 2022 Nov;24(11):2108-2117. doi: 10.1002/ejhf.2651. PMID: 36054502. IF: 17,394
5. Palau P, Amiguet M, Dominguez E, Sastre C, Mollar A, Seller J, Pinilla J, Larumbe A, Valle A, Doblas J, de la Espriella R, Minana G, Mezcua A, Santas E, Bodí V, Sanchis J, Pascual-Figal D, Gorrioz J, Bayes-Genis A, Núñez J. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial. *European Journal of Heart Failure*. 2022 Oct;24(10):1816-1826. doi: 10.1002/ejhf.2560. PMID: 35604416. IF: 17,394

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI20/00637

**Title:** *Resolución de la obstrucción microvascular tras un infarto de miocardio: evaluación de las consecuencias estructurales y clínicas y búsqueda de nuevas opciones terapéuticas*

**Principal Investigator:** Vicent Bodí Peris and Clara Bonanad Lozano

**Funding Body:** Instituto de Salud Carlos III-Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total Budget:** €129,470

**Reference:** PROMETEO/2021/008

**Title:** A multidisciplinary study to advance in the understanding of the basic mechanisms and clinical implications of microvascular

# 4 scientific activity

obstruction after acute myocardial infarction. Exploration of novel diagnostic and therapeutic opportunities

**Principal Investigator:** Vicente Bodí Peris

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2024

**Total Budget:** €435.929

**Title:** Resonancia magnética cardíaca de estrés con vasodilatadores para predecir la mortalidad a largo plazo en un amplio registro retrospectivo de pacientes con cardiopatía isquémica conocida o sospechada

**Principal Investigator:** Vicente Bodí Peris

**Funding Body:** Sociedad Española de Cardiología

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2022

**Total Budget:** €15.000

## THESIS

**Thesis title:** Avances en estratificación pronóstica mediante resonancia magnética cardíaca en pacientes con síndrome coronario crónico

**Doctoral candidate:** Víctor Marcos Garcés

**Director(s):** Vicent Bodí Peris, Amparo Ruiz Saurí

**Date of the defense:** 18/02/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** Patogenicidad de la infección invasiva por *Candida* Auris: virulencia en un modelo de infección in vivo y factores de riesgo de Candidemia

**Doctoral candidate:** Víctor García Bustos

**Director(s):** Javier Pemán García, Amparo Ruiz Saurí

**Date of the defense:** 09/05/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

4

## Research Group on Heart Failure Emerging group

### Group members

#### Leading Researcher, R4

Julio Núñez Villota

Hospital. University

#### Researchers by categories



#### Recognised Researchers, R2

Enrique Santas Olmeda. Hospital

Gema Miñana Escrivá. Hospital. University

Patricia Palau Sampio. Hospital. University

Researchers financed by competitive public calls or networks



#### First Stage Researchers, R1

Ana Belén Paes Martí. INCLIVA

Clara Sastre Arbona. University. CIBER

#### Staff. Collaborating Researchers

Laura López Bueno. University

Rafael de la Espriella Juan. Hospital

Raquel Heredia Cambra. INCLIVA

#### Staff. Technicians

Adoración Pérez Sánchez. INCLIVA

Adriana Conesa Bona. INCLIVA

Juan José Palmí Perales. INCLIVA

Sandra Villar Conejos. INCLIVA

Teresa Benito Ferrer. INCLIVA

#### Staff. Nurses

Alberto Ramírez Sáiz. INCLIVA

Ana Martínez Álvarez. INCLIVA

Carolina Martínez Botella. INCLIVA

Evelin Idaly Bejerano Sandoval. INCLIVA

José Manuel Civera Gómez. INCLIVA

### Strategic aims


- Phenotypic characterization of heart failure syndrome
- Deepen into pathophysiological mechanisms in the different phenotypes of the disease
- Development of tools to improve the diagnostic process of heart failure
- Risk stratification in patients with acute and chronic heart failure
- Evaluation of different therapeutic and monitoring strategies that allow improving the prognosis of heart failure

### Main lines of research

- Effect on functional capacity of withdrawal of beta-blockers in patients with heart failure and preserved ejection fraction and chronotropic incompetence
- Myocardial effects of iron repletion
- Prevalence and clinical implications of frailty in heart failure
- Usefulness of the carbohydrate antigen 125 marker in the evaluation of congestion and a guide to titrate diuretic treatment
- Effect of dapagliflozin on functional capacity in patients with heart failure and reduced ejection fraction
- Utility of continuous ambulatory peritoneal dialysis in the treatment of patients with heart failure and reduced ejection fraction
- Usefulness of intrarenal Doppler to evaluate intrarenal congestion and its clinical significance

# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Civera J, Minana G, de la Espriella R, Santas E, Sastre C, Mollar A, Conesa A, Martinez A, Nunez E, Bayes-Genis A, Nunez J. Venous leg compression for tissue decongestion in patients with worsening congestive heart failure. *Frontiers In Cardiovascular Medicine*. 2022 Jul;8:9847450. doi: 10.3389/fcvm.2022.847450. PMID: 35872894. IF: 5,846
- Palau P, Amiguet M, Dominguez E, Sastre C, Mollar A, Seller J, Pinilla J, Larumbe A, Valle A, Doblas J, de la Espriella R, Minana G, Mezcua A, Santas E, Bodi V, Sanchis J, Pascual-Figal D, Gorrioz J, Bayes-Genis A, Nunez J. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial. *European Journal of Heart Failure*. 2022 Oct;24(10):1816-1826. doi: 10.1002/ejhf.2560. PMID: 35604416. IF: 17,349
- Nunez J, de la Espriella R, Rossignol P, Voors AA, Mullens W, Metra M, Chioncel O, Januzzi JL, Mueller C, Richards AM, de Boer RA, Thum T, Arfsten H, Gonzalez A, Abdelhamid M, Adamopoulos S, Anker SD, Gal TB, Biegus J, Cohen-Solal A, Boehm M, Emdin M, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Jhund PS, Lopatin Y, Lund LH, Milicic D, Moura B, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Tocchetti CG, Van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Bayes-Genis A. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. *European Journal of Heart Failure*. 2022 Oct;24(10):1751-1766. doi: 10.1002/ejhf.2664. PMID: 36039656. IF: 17,349
- De la Espriella R, Amiguet M, Minana G, Rodriguez JC, Moyano P, Segarra D, Fernandez J, Santas E, Nunez G, Lorenzo M, Bonanad C, Alania E, Valle A, Sanchis J, Bodi V, Gorrioz JL, Navarro J, Codina P, Voors AA, Bayes-Genis A, Nunez J. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure. *European Journal of Heart Failure*. 2022 Nov;24(11):2108-2117. doi: 10.1002/ejhf.2651. PMID: 36054502. IF: 17,349
- De la Espriella R, Bayes-Genis A, Llacer P, Palau P, Minana G, Santas E, Pellicer M, Gonzalez M, Gorrioz JL, Bodi V, Sanchis J, Nunez J. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. *European Journal of Internal Medicine*. 2022 Jan;95:67-73. doi: 10.1016/j.ejim.2021.08.024. PMID: 34507853. IF: 7,749

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI21/01417

**Title:** *Cribado sistemático de insuficiencia cardíaca en pacientes con diabetes mellitus tipo 2. Estudio piloto*

**Principal Investigator:** Enrique Santas Olmeda and Jorge Navarro Pérez

**Funding Body:** *Instituto de Salud Carlos III - Co-financed FEDER*

**Beneficiary Institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2022-2024

**Total budget:** €90.871

**Reference:** PI20/00392

**Title:** *Congestión renal en insuficiencia cardíaca aguda y síndrome cardiorrenal: valoración no invasiva mediante doppler vascular renal*

**Principal Investigator:** Julio Núñez Villota

**Funding Body:** *Instituto de Salud Carlos III - Co-financed FEDER*

**Beneficiary Institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2021-2023

**Total budget:** €94.834

**Reference:** PI17/01736

**Title:** *Comparación aleatoria entre las estrategias invasivas y conservadoras en pacientes ancianos frágiles con infarto de*

# scientific activity

4

*miocardio sin elevación del segmento ST (MOSCA-FRAIL)*

**Principal Investigator:** Gema Miñana Escrivá

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2018-2022

**Total budget:** €70.180

**Reference:** AI00/2021/129

**Title:** Efecto del bloqueo de la rama izquierda sobre capacidad funcional, disincronía electromecánica y función cardiaca en población general con patología cardiovascular

**Principal Investigator:** Patricia Palau Sampio and Julio Núñez Villota

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €90.000

**Title:** Resonancia magnética cardíaca de estrés con vasodilatadores para predecir la mortalidad a largo plazo en un amplio registro retrospectivo de pacientes con cardiopatía isquémica conocida o sospechada

**Principal Investigator:** Vicent Bodí Peris (Julio Núñez Villota as collaborating researcher)

**Funding Body:** Sociedad Española de Cardiología

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2022

**Total budget:** €15.000

**Reference:** AP-2021-019

**Title:** HISTONATTR: Efecto de la activación de TLR por medio de sus ligandos sobre la polarización de macrófagos hacia M1 y su función citocida frente a las células madre de glioblastoma

**Principal Investigator:** Carlos Romá Mateo and Enrique Santas Olmeda

**Funding Body:** Universidad de Valencia - INCLIVA

**Beneficiary Institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total budget:** €4.750

## THESIS

**Thesis title:** Beneficios físicos y psicológicos de la danza española en personas mayores

**Doctoral candidate:** Luis Ibáñez Sanchis

**Director(s):** Celedonia Igual Camacho, Laura López Bueno

**Date of the defense:** 17/01/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** Historia clínica y niveles indetectables de troponina de alta sensibilidad en la evaluación del riesgo de pacientes con dolor torácico agudo y primera determinación de troponina normal

**Doctoral candidate:** Ernesto Valero Picher

**Director(s):** Juan Sanchis Forés, Julio Núñez Villota

**Date of the defense:** 28/01/2022


**Grade:** Sobresaliente "cum laude"

# 4 scientific activity

## 4.3.2 Oncology area

### Groups

- Research Group on Histopathology and Tissue Engineering
- Research Group on Central Nervous System Tumors
- Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST
- Research Group on Breast Cancer Biology
- Research Group on Skin Cancer
- Translational Research Group on Pediatric Solid Tumors
- Research Group on Hematopoietic Transplantation
- Research Group on Lymphoproliferative Disorders
- Research Group on Myeloid Neoplasms
- Research Group on Molecular Imaging and Metabolomics
- Research Group on Molecular Microbiology and Microbial Pathogenesis



■ original articles ■ letters ■ editorials ■ reviews ■ case reports ■ corrections

# scientific activity

4

## Research Group on Histopathology and Tissue Engineering Consolidated group

### Group members

#### Leading Researchers, R4

Carmen Carda Batalla. University

Manuel Mata Roig. University

Amando Peydró Olaya. INCLIVA

#### Researchers by categories



#### Established Researchers, R3

Antonio Fons Font. University

Carlos Tejerina Botella. Hospital. University

Francisco Forriol Brocal. Hospital

Genaro Galán Gil. Hospital. University

José Javier Martín de Llano. University

Mari Fe Mínguez Rey. Hospital. University

María Sancho-Tello Valls. University

Miguel Puche Torres. Hospital. University

#### Recognised Researchers, R2

Giovanna Foschini Martínez. INCLIVA

Lara Milián Medina. University

María Oliver Ferrández. University

Rubén Salvador Clavell. University

#### First Stage Researchers, R1

Ángel Aguilar Hernández. INCLIVA

Irene Monleón Guinot. University

Javier Alcácer Fernández-Coronado. INCLIVA

Zakaria Oguir. University

#### Staff. Collaborating Researchers

Ignacio Peregrín Nevado. INCLIVA

Teresa Sagrado Vives. University

### Strategic aims

The group obtained funding to continue working on to the line of Tissue Engineering with new projects:

- Bone regeneration in prosthetic implants. Biological processes conditioned by age and gender. Design of new biomaterials
- Biomimetic microgels for the study of the tumor microenvironment (TME) and the mesenchymal epithelial transition (EMT) in lung cancer
- Cartilage and bone regeneration techniques and their application in pathologies

### Main lines of research


Regenerative Medicine:

- Study of articular cartilage regeneration
- Study of bone regeneration. Effect of age and gender on the regeneration process

# scientific activity

- Study of the use of dental pulp cells as precursors in regenerative therapies
  - Study of regeneration of dental and periodontal tissues
  - Study of tumor microenvironment using biomimetic microgels
- Histopathology:
- Study of ciliary pathology

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Milián L, Monleón-Guinot I, Sancho-Tello M, Galbis JM, Cremades A, Almenar-Ordaz M, Peñaroja-Martínez J, Farras R, Martín de Llano JJ, Carda C, Mata M. In Vitro Effect of Δ9-Tetrahydrocannabinol and Cannabidiol on cancer-associated fibroblasts isolated from lung cancer. International Journal of Molecular Sciences. 2022 Jun 17;23(12):6766. doi: 10.3390/ijms23126766. PMID: 35743206. IF: 6,208
- Mata M, Peydro S, de Llano J, Sancho-Tello M, Carda C. Human dental pulp stem cells differentiate into cementoid-like-secreting cells on decellularized teeth scaffolds. International Journal of Molecular Sciences. 2022 Dec 9;23(24):15588. doi: 10.3390/ijms232415588. PMID: 36555228. IF: 6,208
- García-Arnaez I, Romero-Gavilán F, Cerqueira A, Elortza F, Azkargorta M, Muñoz F, Mata M, de Llano J, Suay J, Gurruchaga M, Goni I. Correlation between biological responses in vitro and in vivo to Ca-doped sol-gel coatings assessed using proteomic analysis. Colloids and Surfaces B-Biointerfaces. 2022 Oct 21;220:112962. doi: 10.1016/j.colsurfb.2022.112962. PMID: 36306698. IF: 5,999
- Martín-Iglesias S, Milian L, Sancho-Tello M, Salvador-Clavell R, de Llano J, Carda C, Mata M. BMP-2 enhances osteogenic differentiation of human adipose-derived and dental pulp stem cells in 2D and 3D in vitro models. Stem Cells International. 2022 Mar 4;2022:4910399. doi: 10.1155/2022/4910399. PMID: 35283997. IF: 5,131
- Pérez-Benavente B, Fathinajafabadi A, de la Fuente L, Gandia C, Martínez-Ferriz A, Pardo-Sánchez J, Milian L, Conesa A, Romero O, Carretero J, Matthiesen R, Jariel-Encontre I, Piechaczyk M, Farras R. New roles for AP-1/JUNB in cell cycle

control and tumorigenic cell invasion via regulation of cyclin E1 and TGF-beta2. Genome Biology. 2022 Dec 9;23(1):252. doi: 10.1186/s13059-022-02800-0. PMID: 36494864. IF: 17,906

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PDC2021-121658-C22

**Title:** *Microgeles bioactivos como soporte inyectable para la regeneración del cartílago articular*

**Principal Investigator:** María Sancho-Tello Valls and José Luis Gómez Ribelles

**Funding Body:** Ministerio de Economía y Competitividad

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2021-2023

**Total Budget:** €69.900

**Reference:** PID2019-106099RB-C42

**Title:** *Microgeles biomiméticos para el estudio del microentorno del tumor (TME) y la transición epitelio mesénquima (EMT) en cáncer de pulmón*

**Principal Investigator:** Manuel Mata Roig and José Javier Martín de Llano

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2023

**Total Budget:** €151.250

# scientific activity

4

**Reference:** PROMETEO/2020/069

**Title:** *Regeneración ósea en implantoprótesis. Procesos biológicos condicionados por la edad y el género. Diseño de nuevos biomateriales (ROMEN)*

**Principal Investigator:** Carmen Carda Batalla

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2023

**Total Budget:** €235.145

**Reference:** PI-2021-008

**Title:** *miR-OA: Inhibidores de miRNAs como terapia en osteoartritis*

**Principal Investigator:** Carmen Carda Batalla and Rubén Artero Allepuz

**Funding Body:** Universidad de Valencia - INCLIVA

**Beneficiary Institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total Budget:** €19.000

## THESIS

**Thesis title:** Evaluation of bioactive coatings for titanium surfaces: a proteomic approach

**Doctoral candidate:** Andreia Filipa Lages Cerqueira

**Director(s):** Julio José Suay Antón, José Javier Martín de Llano

**Date of the defense:** 04/04/2022

**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD

**Thesis title:** *Sustitutos traqueales generados por ingeniería tisular*

**Doctoral candidate:** Giovanna Foschini Martínez

**Director(s):** Genaro Galán Gil, Manuel Mata Roig, Carmen Carda Batalla

**Date of the defense:** 06/05/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** *Análisis del comportamiento de materiales de restauración sometidos a un ensayo de microtracción*

**Doctoral candidate:** Eva González Angulo


**Director(s):** Antonio Fons Font, Javier Casas Terrón, Juan Luis Román Rodríguez

**Date of the defense:** 08/07/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group on Central Nervous System Tumors Consolidated group



### Strategic aims

Clinical-pathological study of 40 patients affected by primary glioblastoma according to established protocol

- Short-cell cultures and their viability analysis have been performed. Analysis by FISH of EGFR status and freezing of the different passes according to established methodology
- The study of the proteomic analysis of the 40 tumors (frozen samples) by Western Blott according to established methodology has been completed

Experimental study:

- Spheres (neurospheres) have been elaborated from different cell lines and cell cultures of glioblastoma, characterizing and analyzing their behavior
- Analysis of cultures subjected to silencing and overexpression by transfection of miRNAs by the lipofection method
- Analysis of cell cultures in hypoxia situation, analyzing their characteristics and behavior before silencing and overexpression by transfection of selected miRNAs in hypoxia situation and in the different amplification status of the EGFR
- The pilot study of viability and effectiveness of xenotransplantation in nude mice has been completed with the achievement of neoplasias under study


### Main lines of research

- Primary GBM. Amplification status of EGFR and angiogenic/infiltrative phenotype. Molecular networks responsible for tumor modulation and reprogramming processes
- Role of microRNA in the regulation of EGFR-dependent signaling pathways in high-grade astrocytic gliomas
- Development of a model for analyzing the modulation of microRNA gene activity in cell cultures of primary GBM and GBM cell lines
- Development of a model of population analysis and spatial distribution of these neoplasias
- Metabolomics and microvascular environment characterization of aggressive human glioma by DCE-MRI and genetic study of biopsies

# scientific activity

4

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Megías J, San-Miguel T, Sánchez M, Navarro L, Monleón D, Calabuig-Fariñas S, Morales JM, Muñoz-Hidalgo L, Roldán P, Cerdá-Nicolás M, López-Ginés C. Desmoplastic infantile astrocytoma with atypical phenotype, PTEN homozygous deletion and BRAF V600E mutation. *Acta Neuropathologica Communications.* 2022 Jun 20;10(1):88. doi: 10.1186/s40478-022-01392-x. PMID: 35725578. IF: 7,581
2. San-Miguel T, Megias J, Monleon D, Navarro L, Munoz-Hidalgo L, Montoliu C, Meri M, Roldan P, Cerdá-Nicolas M, Lopez-Gines C. Matched paired primary and recurrent meningiomas points to cell-death program contributions to genomic and epigenomic instability along tumor progression. *Cancers.* 2022 Aug 19;14(16):4008. doi: 10.3390/cancers14164008. PMID: 36011000. IF: 6,575
3. Gallego J, Fiorillo A, Casanova-Ferrer F, Urios A, Ballester M, Durban L, Megias J, Rubio T, Cabrera-Pastor A, Escudero-Garcia D, Felipo V, Montoliu C. Plasma extracellular vesicles play a role in immune system modulation in minimal hepatic encephalopathy. *International Journal of Molecular Sciences.* 2022 Oct 15;23(20):12335. doi: 10.3390/ijms232012335. PMID: 36293192. IF: 6,208
4. Ballester M, Gallego J, Fiorillo A, Casanova-Ferrer F, Gimenez-Garzo C, Escudero-Garcia D, Tosca J, Rios M, Monton C, Durban L, Ballester J, Benlloch S, Urios A, San-Miguel T, Kosenko E, Serra M, Felipo V, Montoliu C. Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. *Scientific Reports.* 2022 Feb 14;12(1):2463. doi: 10.1038/s41598-022-06416-z. PMID: 35165326. IF: 4,996
5. Sabater-Marco V, Cerveró LN, Losada LO, López NS. A pigmented nodule on congenital melanocytic nevus: challenge. *American Journal of Dermatopathology.* 2022 Oct 1;44(10):e108-e109. doi: 10.1097/DAD.0000000000002265. PMID: 36122342. IF: 1,319

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PID2021-125485NB-C21

**Title:** *Astrofísica computacional y análisis de datos*

**Principal Investigator:** Pablo Cerdá Durán

**Funding body:** Ministerio de Ciencia e Innovación

**Beneficiary institution:** Universidad de Valencia

**Duration:** 2022-2025

**Total Budget:** €207.000

**Reference:** AP-2021-001

**Title:** *LIGAM1: Efecto de la activación de TLR por medio de sus ligandos sobre la polarización de macrófagos hacia M1 y su función citocida frente a las células madre de glioblastoma*

**Principal Investigator:** Javier Megías Vericat and Andrea Cabrera Pastor

**Funding body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total Budget:** €4.607,5

## THESIS

**Thesis title:** *Patrones de amplificación de EGFR en el glioblastoma, e identificación de biomarcadores implicados en sus principales vías de señalización*

**Doctoral candidate:** Lara Navarro Cerveró

**Director(s):** Concepción López Ginés, Miguel Cerdá Nicolás

**Date of the defense:** 28/10/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors - InDeST Consolidated group

### Group members

#### Leading Researcher, R4

Andrés Cervantes Ruipérez

Hospital. University



Researchers financed by competitive public calls or networks



#### Established Researchers, R3

Desamparados Roda Pérez. Hospital

Gerardo López Rodas. University

#### Emerging researchers, R2

Noelia Tarazona Llavero. Hospital

Tania Fleitas Kanonnikoff. Hospital

Valentina Gambardella. Hospital

#### Recognised Researchers, R2

Amelia Insa Mollá. Hospital

Federica Papaccio. ESMO

Fernanda Gutiérrez Bravo. INCLIVA

Francisco Gimeno Valiente. INCLIVA

Jose A. Pérez Fidalgo. Hospital. University

Josefa Castillo Aliaga. University

María Carolina Martínez Ciarpaglini. Hospital. University

Susana Roselló Keranen. Hospital

Team involved in

*ciberonc*

#### First Stage Researchers, R1

Gema Bruixola Campos. Hospital

Jorge Martín Aranda. INCLIVA

José Francisco González Muñoz. INCLIVA

Lorena Alarcón Molero. INCLIVA

Manuel Cabeza Segura. INCLIVA

Marisol Huerta Álvaro. Hospital

Paloma Martín Martorell. Hospital

Beatriz López Montero. INCLIVA

Belen Martínez Castedo. INCLIVA

Blanca García Micó. INCLIVA

Carlos Peris Casilda. INCLIVA

Carme M<sup>a</sup> Ortega Albiach. INCLIVA

Cristina Mongort Sanchis. INCLIVA

Eugenia Flores de la Luna. INCLIVA

Guillermo Moret Peiró. INCLIVA

Ignacio Castaño López. INCLIVA

José Francisco Catalá Senent. INCLIVA

Laura Olivares Ordóñez. INCLIVA

M<sup>a</sup> Carmen Martínez López. INCLIVA

M<sup>a</sup> Elena Duréndez Sáez. INCLIVA

M<sup>a</sup> Pilar Natividad López. INCLIVA

Paloma Campos Bañegil. INCLIVA

Sergio Romero Alcaide. INCLIVA

Victoria Lucía Doldán Martelli. INCLIVA

Zahara Garzón Lloria. INCLIVA

#### Staff. Collaborating Researcher

Clara Alfaro Cervelló. Hospital. University

#### Staff. Technicians

Alba Viala Monleón. INCLIVA

Alejandro Asturiano Pérez-Chao. INCLIVA

América Bueno Gómez. INCLIVA

Ana M<sup>a</sup> Miralles Marco. INCLIVA

Andrea Marín Alonso. INCLIVA

Arantxa Sánchez Cosmo. INCLIVA

# scientific activity

4

## Staff. Nurses

Ana Ruiz Quílez. INCLIVA  
Celia Martínez Ridaura. INCLIVA  
Cristina Jordá Guerola. INCLIVA  
Gloria Corredor Agulló. INCLIVA  
Inma Blasco Blasco. University  
Laura Martínez Lucía. INCLIVA  
Laura Vera Riera. INCLIVA  
Mª Isabel Calzadilla Luz. INCLIVA  
Silvia Moreno Magraner. INCLIVA  
Verónica Babiano Suárez. INCLIVA  
Verónica García Oliver. INCLIVA

## Staff. Administrative assistants

Ana Vercher Grau. INCLIVA  
Carla Gil Ferri. INCLIVA  
Elena Jiménez Martí. University  
Enrique Castelló Moreno. INCLIVA  
Gabriela Pérez Garrity. INCLIVA  
Laura Boix Bartual. INCLIVA  
Paranee Archavarat Sianmekan. INCLIVA  
Paula Petruskevicius Fernández. INCLIVA

## Strategic aims

Our group aims to improve the patient's life through the development of new diagnostic and therapeutic methods. In addition to this main goal, we intend to implement strategies to facilitate the development of precision medicine in solid tumors with innovative therapeutic approaches and provide knowledge on how to approach precision medicine in colorectal and gastric cancer from different points such as molecular classification, the use of predictive biomarkers and new therapeutic approaches.

## Main lines of research

- To develop first-in-human Phase I trials of antineoplastic agents with innovative designs
- To develop liquid biopsies [ctDNA, cmicroRNAs] for early diagnosis, monitoring and the prediction of therapeutic effects in patients with gastro-intestinal malignancies
- To use the latest technologies to improve our knowledge of the molecular and genetic causes of cancer
- To implement the use of organoids (3D cell cultures) from patients as functional models, in order to understand the underlying causes of tumorigenesis and to test the appropriateness of the treatments
- To expand current knowledge in gastric cancer microenvironment

## Emerging Researchers

*Noelia Tarazona Llavero*

Our scientific pursuits revolve around utilizing liquid biopsy, specifically circulating tumor DNA in plasma, for various objectives. These objectives include the detection of minimal residual disease and its correlation with survival rates, understanding the mechanisms behind disease progression and therapy resistance, and identifying potential therapeutic targets. Additionally, we are intrigued by the application of circulating tumor cells in characterizing minimal residual disease, which can aid in its effective eradication. We also focus on establishing organoids derived from primary or metastatic tumors and circulating tumor cells obtained from patients with gastrointestinal cancers. Furthermore, we prioritize the investigation of novel biomarkers, such as the lack of CDX2 expression in localized colon cancer.

*Tania Fleitas Kanonnikoff*

Our scientific interests are based on the understanding of the tumor immune microenvironment of Gastric Cancer. Moreover, we are also focused on the study of the clinical-epidemiological-molecular and the microbiome characteristics of patients with young gastric tumors under 50 years of age, the study of mechanisms of resistance of Her2-positive Gastric Cancer, to understand the differences and similarities among GC in European and Latin American population, and applying AI as a tool for gastric cancer prevention.

# scientific activity

Valentina Gambardella

Our scientific interest is improving precision medicine for cancer patients through genomic and transcriptomic analyses with the aim of identifying specific druggable alterations beyond the standard biomarkers. This could offer the opportunity of entering promising early clinical trials with both targeted agents and novel immunotherapies. The multi-omic evaluation of tumor and microenvironment features at baseline and at time of progression, will help in understanding those molecular mechanisms related to resistance to anticancer drugs. In particular, our interest is studying these mechanisms in KRAS mutant NSCLC patients.

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Italiano A, Cassier PA, Lin C, Alanko T, Peitola KJ, Gazzah A, Shah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. *Cancer Immunology Immunotherapy*. 2022 Feb;71(2):417-431. doi: 10.1007/s00262-021-02973-w. PMID: 34216247. IF: 6,63
2. Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, Huerta M, Rosello S, Madsen AH, Love US, Andersen PV, Thorlacius-Ussing O, Iversen LH, Gotschalck KA, Sethi H, Aleshin A, Cervantes A, Andersen CL. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. *Clinical Cancer Research*. 2022 Feb 1;28(3):507-517. doi: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408. IF: 13,801
3. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. *CA-A Cancer Journal for Clinicians*. 2022 Jul;72(4):372-401. doi: 10.3322/caac.21728. PMID: 35472088. IF: 286,13
4. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastroesophageal adenocarcinoma. *British Journal of Cancer*. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523. IF: 9,075
5. Kim T, Burris H, de Miguel Luken M, Pishvaian M, Bang Y, Gordon M, Awada A, Camidge D, Hodi F, McArthur G, Miller W, Cervantes A, Chow L, Lesokhin A, Rutten A, Sznol M, Rishipathak D, Chen S, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu L. First-in-human phase I Study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. *Clinical Cancer Research*. 2022 Aug 15;28(16):3452-3463. doi: 10.1158/1078-0432.CCR-21-4020. PMID: 35699599. IF: 13,801

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** 825832 – LEGACy  
**Title:** CeLac and European consortium for a personalized medicine approach to Gastric Cancer  
**Principal Investigator:** Andrés Cervantes Ruipérez  
**Funding Body:** European Commission  
**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia  
**Duration:** 2019-2023  
**Total Budget:** €3.577.431,27 (INCLIVA: €638.315)

**Reference:** 101057514 - MyPath  
**Title:** Developing and implementing innovative Patient-Centred Care Pathways for cancer patients  
**Principal Investigator:** Andrés Cervantes Ruipérez  
**Funding Body:** European Commission  
**Beneficiary Institution:** Fundación Investigación Hospital Clínico

# scientific activity

4

Universitario de Valencia

**Duration:** 2022-2027

**Total Budget:** €4.773.470 (INCLIVA: €388.125)

**Reference:** PI21/00689

**Title:** Caracterización y abordaje de la enfermedad mínima residual en cáncer de colon localizado: un paso hacia la medicina de precisión

**Principal Investigator:** Noelia Tarazona Llavero and Andrés Cervantes Ruipérez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total Budget:** €232.320

**Reference:** PI21/00693

**Title:** Perfil de biomarcadores inmunes como herramienta para la identificación de pacientes con cáncer gástricos subsidiarios de inmunoterapia

**Principal Investigator:** Tania Fleitas Kanonnikoff

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total Budget:** €208.120

**Reference:** PI21/00695

**Title:** Transición mesenquimal como mecanismo asociado a inhibición de la respuesta inmune en el carcinoma colorrectal sin inestabilidad de microsatélites

**Principal Investigator:** M<sup>a</sup> Carolina Martínez Ciarpaglini

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total Budget:** €94.380

**Reference:** ICI20/00009

**Title:** Investigación Clínica Independiente

**Principal Investigator:** Andrés Cervantes Ruipérez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2024

**Total Budget:** €1.039.970

**Reference:** PT20/00100

**Title:** Clinical Research Platform

**Principal Investigator:** Andrés Cervantes Ruipérez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total budget:** €199.650

**Reference:** CB16/12/00473

**Title:** Centro de Investigación Biomédica en Red Cáncer (CIBERonc)

**Principal Investigator:** Andrés Cervantes Ruipérez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2017-

**Reference:** CPP2021-009064

**Title:** Tratamiento innovador con ABT0812 para el cáncer pancreático metastásico: acortando los tiempos para su aprobación - INNOPANC

**Principal Investigator:** Carles Domenech García [Susana Roselló as collaborating researcher]

**Funding Body:** Ministerio de Ciencia e Innovación - Agencia Estatal de Investigación

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total Budget:** €180.599

**Reference:** GV/2021/006

**Title:** Subvención a grupos de Investigación emergentes

**Principal Investigator:** Clara Alfaro Cervelló

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2022

**Total budget:** €20.000

**Title:** Valor pronóstico y predictivo de respuesta del microambiente del cáncer gástrico en personas jóvenes. Proyecto VERO

**Principal Investigator:** Tania Fleitas Kanonnikoff

**Funding Body:** GEMCAD - Grupo Español Multidisciplinar en Cáncer Digestivo

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €20.000

# scientific activity

**Title:** Secuenciación del exoma completo del DNA tumoral circulante y DNA genómico para aumentar la sensibilidad en la detección de la enfermedad mínima residual y abrir nuevas vías para la medicina personalizada en cáncer de colon localizado

**Principal Investigator:** Noelia Tarazona Llavero

**Funding Body:** Sociedad Española de Oncología Médica (SEOM)

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total budget:** €20.000

**Title:** Tumor microenvironment-derived factors in localized colon cancer: clinical impact and therapeutic implications

**Principal Investigator:** Andrés Cervantes Ruipérez

**Funding Body:** Asociación Española Contra el Cáncer

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2023

**Total budget:** €992.996

**Title:** Organoides derivados de pacientes (PDOs) para personalizar el tratamiento en recaídas de cáncer de colon (CC) localizado mediante secuenciación del exoma completo y del DNA genómico

**Principal Investigator:** Noelia Tarazona Llavero

**Funding Body:** Digestive Tumors Treatment Group (TTD)

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €40.000

**Title:** Carcionogénesis colorrectal: la interacción entre el microambiente tumoral y las células madre. Impacto en el tratamiento personalizado

**Principal Investigator:** Noelia Tarazona Llavero

**Funding Body:** Fundación Mutua Madrileña

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2023

**Total budget:** €130.000

**Title:** Decoding GC microenvironment: a new step towards precision immunotherapy

**Principal Investigator:** Tania Fleitas Kanonnikoff

**Funding body:** Asociación Española Contra el Cáncer

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2026

**Total budget:** €53.000

**Reference:** PI-2021-007

**Title:** DIRUGEN: Diseño e investigación de nuevos compuestos de rutenio (III) basados en biomoléculas como potenciales agentes antitumorales

**Principal Investigator:** Francisco José Martínez Lillo and Tania Fleitas Kanonnikoff

**Funding Body:** Universidad de Valencia - INCLIVA

**Beneficiary Institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total budget:** €19.000

**Reference:** AP-2021-008

**Title:** PROTORGANOIDE: Medicina personalizada y de precisión a través del análisis proteómico de organoides

**Principal Investigator:** Manuel Martín Sánchez del Pino and Josefa Castillo Aliaga

**Funding Body:** Universidad de Valencia - INCLIVA

**Beneficiary Institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total budget:** €4.750

## THESIS

**Thesis title:** Establecimiento de organoides derivados de pacientes con carcinoma colorrectal como modelo para cribado de drogas con acción antitumoral

**Doctoral candidate:** M<sup>a</sup> Fernanda Gutiérrez Bravo



**Director(s):** Josefa Castillo Aliaga, Andrés Cervantes Ruipérez

**Date of the defense:** 04/02/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group on Breast Cancer Biology Consolidated group



# scientific activity

ER+ breast cancer:

- Evaluation of the outcomes of single versus double hormone receptor-positive breast cancer
- Description that the ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors
- Design of adjuvant endocrine therapy for premenopausal breast cancer

Breast cancer in very young women:

- Identification of biomarkers
- Review of breast cancer in pregnant patients


Prognostic and prediction:

- Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer
- Evaluation of the pathologic complete response rate to neoadjuvant chemotherapy in triple negative breast cancer subtypes
- Prediction of residual disease after neoadjuvant therapy in HER2-positive breast cancer
- Study of the incidence, characteristics, and prevention of the alopecia following adjuvant docetaxel
- Molecular characterization of oligometastatic breast cancer patients

## Main lines of research

- Cell resistance to anti-HER2 therapy and identification of strategies to overcome resistance
- Multidisciplinary dissection of the chemotherapy resistance mechanisms in triple negative breast cancer
- Molecular and Clinical characterization of breast tumors from very young women
- The role of AXL in trastuzumab-resistant breast cancer and modulation of tumor microenvironment
- Clinical and molecular characterization of oligometastatic breast cancer
- Study of biomarkers in liquid biopsy for early diagnosis of hereditary syndromes of predisposition to breast cancer
- Involvement of miRNAs and other epigenetic regulations in breast cancer processes
- Mesoporous silica nanoparticles as an innovative approach for breast cancer treatment

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Cortes J, Rugo H, Cescon D, Im S, Yusof M, Gallardo C, Lipatov O, Barrios C, Perez-Garcia J, Iwata H, Masuda N, Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. *New England Journal of Medicine*. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. PMID: 35857659. IF: 176,079
- Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos EM, Greil R, Semiglavazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffei I, Valagussa P, Viale G. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. *Annals of Oncology*. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. PMID: 35182721. IF: 51,769
- Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gurpide J, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. miR-99a-5p modulates doxorubicin resistance via the COX-

# scientific activity

4

- 2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies. *Cancer Communications.* 2022 Dec;42(12):1412-1416. doi: 10.1002/cac2.12352. PMID: 35997029. IF: 15,283
4. Adam-Artigues A, Arenas E, Martínez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, Hernando C, Martínez M, Carbonell-Asins J, Simon S, Poveda J, Moragon S, Zazo S, Martínez D, Rovira A, Burgues O, Rojo F, Albalen J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo J. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. *Science Advances.* 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. PMID: 35594351. IF: 14,957
5. Pérez-Núñez I, Rozalén C, Palomeque JÁ, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menéndez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Peña R, Montañés JC, Albà MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albalen J, Celià-Terrassa T. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. *Nature Cancer.* 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. PMID: 35301507. IF: 23,177

**Duration:** 2022-2024

**Total budget:** €123.420

**Reference:** NanoOncoTME

**Title:** Mesoporous silica nanoparticles targeting tumor microenvironment as an innovative approach for breast cancer treatment

**Principal Investigator:** Ana Lluch and Alba García

**Funding Body:** CIBER-BBN

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €16.250

**Title:** Papel de AXL en la modulación del microambiente tumoral e implicaciones terapéuticas en cáncer de mama HER2 positivo

**Principal Investigator:** Juan Miguel Cejalvo Andújar

**Funding Body:** Sociedad Española de Oncología Médica

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €30.000

**Title:** Estudio de biomarcadores en biopsia líquida para diagnóstico precoz en síndromes hereditarios de predisposición a cáncer de mama (SHCM)

**Principal Investigator:** Isabel Chirivella González

**Funding Body:** Sociedad Española de Oncología Médica

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €20.000

**Title:** Clinical and molecular characterization of oligometastatic breast cancer: revealing and improving the potential benefit of a local treatment on primary or metastatic sites. A multicentric study

**Principal Investigator:** Juan Miguel Cejalvo Andújar

**Funding Body:** Asociación Española de Cáncer de Mama Metastásico

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €40.000

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** 965231-REBECCA

**Title:** REsearch on BrEast Cancer induced chronic conditions supported by Causal Analysis of multi-source data

**Principal Investigator:** Aristotelio Panepistimio Thessalonikis (Cristina Hernando as collaborating researcher)

**Funding Body:** European Commission

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2025

**Total budget:** €466.125

**Reference:** PI21/01351

**Title:** Predicción de enfermedad residual después de la terapia neoadyuvante en cáncer de mama HER2 positivo e identificación de estrategias para superar la resistencia

**Principal Investigator:** Pilar Eroles Asensio

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

# scientific activity

**Title:** The role of AXL in modulating tumor microenvironment as potential therapeutic strategy for HER2-positive breast cancer

**Principal Investigator:** Juan Miguel Cejalvo Andújar

**Funding Body:** Gilead Fellowship Program

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €49.350

**Title:** The role of AXL modulating tumor microenvironment as potential therapeutic strategy for HER2-positive breast cancer

**Principal Investigator:** Juan Miguel Cejalvo Andújar

**Funding Body:** Fundación FERO

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €80.000

**Title:** The role of AXL and tumor microenvironment in determining resistance to anti-HER2 agents in HER2 amplified breast cancer models

**Principal Investigator:** Ana M<sup>a</sup> Ágreda Roca

**Funding Body:** Fundación Científica Asociación Española Contra el Cáncer

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €66.000

**Title:** Dissección multidisciplinar de los mecanismos de resistencia a quimioterapia en cáncer de mama triple negativo: un paso hacia una mejor atención clínica

**Principal Investigator:** Juan Miguel Cejalvo Andújar

**Funding Body:** Asociación Española Contra el Cáncer

**Beneficiary institution:** CIBERONC/Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total budget:** €268.500

**Title:** Multidisciplinary dissection of the chemotherapy resistance mechanisms in triple negative breast cancer: a step towards improved clinical care

**Principal Investigator:** Ángel R Nebreda [Juan Miguel Cejalvo as collaborating researcher]

**Funding Body:** Instituto de Investigación Biomédica-IRB

**Beneficiary institution:** CIBERONC/Fundación Investigación

Hospital Clínico Universitario de Valencia

**Duration:** 2021-2026

**Total budget:** €268.500

**Title:** Factores pronósticos y predictivos en cáncer de mama oligometastásico que identifiquen pacientes en las que el tratamiento local sobre la metástasis aumente su supervivencia: beneficio del estadio NED (no evidencia de enfermedad)

**Principal Investigator:** Juan Miguel Cejalvo Andújar

**Funding Body:** METAPREMIOS 1. Asociación de Cáncer de Mama Metastásico

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020- 2022

**Total budget:** €16.500

**Title:** Dimerización de AXL-HER2 como mecanismo de resistencia adquirida a la terapia anti-HER2 en cáncer de mama HER2+: un paso hacia la medicina de precisión

**Principal Investigator:** Juan Miguel Cejalvo Andújar

**Funding Body:** ADAMED

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €18.000

## THESIS

**Thesis title:** Overcoming resistance to HER2 blockade in breast cancer: AXL as a promising druggable target and prognostic biomarker

**Doctoral candidate:** Anna Adam Artigues

**Director(s):** Ana Lluch Hernández, Pilar Eroles Asensio

**Date of the defense:** 12/04/2022

**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD


# scientific activity

4


## Research Group on Skin Cancer Consolidated group



Researchers financed by  
competitive public calls or networks



## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Mosquera-Zamudio A, Launet L, Tabatabaei Z, Parra-Medina R, Colomer A, Moll J, Monteagudo C, Janssen E, Naranjo V. Deep learning for skin melanocytic tumors in whole-slide images:

a systematic review. Cancers. 2022 Dec 21;15(1):42. doi: 10.3390/cancers15010042. PMID: 36612037. IF: 6,575

# scientific activity

2. Sanchez-Sendra B, Perez-Deben S, Gonzalez-Munoz JF, Murgui A, Monteagudo C. Prognostic value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) intratumoral expression in melanoma patients at the time of diagnosis: comparative analysis of rt-qpcr versus immunohistochemistry. *Cancers.* 2022 May 7;14(9):2319. doi: 10.3390/cancers14092319. PMID: 35565448. IF: 6,575
3. Sanchez-Sendra B, Gonzalez-Munoz J, Perez-Deben S, Monteagudo C. The prognostic value of miR-125b, miR-200c and miR-205 in primary cutaneous malignant melanoma is independent of BRAF mutational status. *Cancers.* 2022 Mar 16;14(6):1532. doi: 10.3390/cancers14061532. PMID: 35326682. IF: 6,575
4. Rios-Martín J, Rodriguez-Salas N, Vazquez-Doval F, Llombart B, Rojas-Ferrer N, Gonzalez-Vela M, Zulueta T, Monteagudo C, Aneiros-Fernandez J, Beato M, Carrillo R, Silva-Carmona M, Ayala M, Gallego E, Rodriguez-Peralto J, Fraga-Fernandez J, Fernandez-Figueras M, Barranco C, Cordoba A, Sanz-Zorrilla A, Ferrer B, Funez R, Santonja C, Saus C, Idoate M, Santos-Briz A, Onrubia J, Pinedo F, de Las Penas R. Clinical and pathological features of Merkel cell carcinoma: a 4-year follow-up observational retrospective study in Spain. *Cancer Epidemiology.* 2022 Feb;76:102081. doi: 10.1016/j.canep.2021.102081. PMID: 34922051. IF: 2,89
5. Moral R, Monteagudo C, Muriel J, Moreno L, Peiro A. Fluorescent in situ hybridization (FISH): a useful diagnostic tool for childhood conjunctival melanoma. *European Journal of Ophthalmology.* 2022 Nov;32(6):NP13-NP19. doi: 10.1177/11206721211030775. PMID: 34240653. IF: 1,922

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** 860627-H2020 - Marie Skłodowska-Curie Innovative Training Networks

**Title:** Cloud Artificial Intelligence for pathology-CLARIFY

**Principal Investigator:** José Carlos Monteagudo Castro

**Funding body:** European Commission

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2023

**Total Budget:** €252.000

**Reference:** PI20/00094

**Title:** Análisis combinado por Inteligencia Artificial de marcadores

epigenéticos e imágenes microscópicas digitalizadas de tumores melanocíticos ambiguos para optimizar su clasificación diagnóstica y pronóstica

**Principal Investigator:** José Carlos Monteagudo Castro

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total Budget:** €220.220

**Title:** Sistema de visión artificial aumentada para la caracterización molecular y morfológica del cáncer de piel

**Principal Investigator:** Carlos Monteagudo Castro

**Funding body:** Agencia Valenciana de la Innovación-AV Generalitat Valenciana

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total Budget:** €192.868,53

## THESIS

**Thesis title:** Análisis comparativo de perfiles proteómicos endometriales y estudio del efecto disruptor del cobre y plomo sobre la receptividad endometrial

**Doctoral candidate:** Silvia Pérez Debén


**Director(s):** Francisco Domínguez Hernández, José Remohí Giménez

**Date of the defense:** 02/06/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Translational Research Group on Pediatric Solid Tumors Consolidated group



### Strategic aims


- Genomic heterogeneity in neuroblastoma (NB)
- 3D in vitro and xenotransplant models of NB
- Importance of extracellular matrix and stroma cells (including immune cells) in tumors
- Morphological and molecular analysis of neuroblastic and malignant infantile skeletal tumors

### Main lines of research

- Genetic analysis in neuroblastoma. At the European level, we participate in the establishment of a uniform nomenclature, and standard practices and quality validation studies, essential to obtain and maintain high quality in genetic results used for therapeutic stratification
- Identification of new genetic factors with prognostic value in neuroblastic and malignant infantile skeletal and soft tissue tumors
- Digital analysis of diagnostic, prognostic and therapeutic biomarkers in tumors
- Tumor microenvironment studies in tumors
- Preclinical models. Obtaining and characterizing cell lines in vivo and in vitro (2D and 3D) from fresh tumor material

# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Machado I, Bujeda A, Giner F, Morales M, Cruz J, Lavernia J, Navarro S, Fernandez A, Ruiz-Sauri A, Llombart-Bosch A. Evaluation of alternative risk stratification systems in a large series of solitary fibrous tumors with molecular findings and Ki-67 Index Data: do they improve risk assessment?. *International Journal of Molecular Sciences*. 2022 Dec 27;24(1):439. doi: 10.3390/ijms24010439. PMID: 36613891. IF: 6,208
- Monferrer E, Dobre O, Trujillo S, Oliva M, Trubert-Paneli A, Acevedo-Leon D, Noguera R, Salmeron-Sanchez M. Vitronectin-based hydrogels recapitulate neuroblastoma growth conditions. *Frontiers in Cell and Developmental Biology*. 2022 Oct 11;10:988699. doi: 10.3389/fcell.2022.988699. PMID: 36425532. IF: 6,081
- Sonzini G, Granados-Aparici S, Sanegre S, Diaz-Lagares A, Diaz-Martin J, de Andrea C, Eritja N, Bao-Caamano A, Costa-Fraga N, Garcia-Ros D, Salguero-Aranda C, Davidson B, Lopez-Lopez R, Melero I, Navarro S, Ramon Y Cajal S, de Alava E, Matias-Guiu X, Noguera R. Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness. *Frontiers in Cell and Developmental Biology*. 2022 Nov 18;10:1052098. doi: 10.3389/fcell.2022.1052098. PMID: 36467415. IF: 6,081
- Martinez-Monleon A, Oberg H, Gaarder J, Berbegall A, Javanmardi N, Djos A, Ussowicz M, Taschner-Mandl S, Ambros I, Ora I, Sandstedt B, Beiske K, Ladenstein R, Noguera R, Ambros P, Murkes L, Ljungman G, Kogner P, Fransson S, Martinsson T. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup. *Scientific Reports*. 2022 Jul 20;12(1):12420. doi: 10.1038/s41598-022-16455-1. PMID: 35859155. IF: 4,996
- Vieco-Marti I, Lopez-Carrasco A, de la Cruz-Merino L, Noguera R, Alvaro Naranjo T. The complexity of cancer immunotherapy illustrated through skin tumors. *International Journal of Biological Markers*. 2022 Jun;37(2):113-122. doi: 10.1177/03936155221088884. PMID: 35473449. IF: 3,248

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI20/01107

**Title:** Neuroblastoma: estrategias mecanoterapéuticas basadas en modelos 3D y tumores derivados de pacientes con microambiente rico en vitronectina

**Principal Investigator:** Rosa Noguera Salvá

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total budget:** €232.320

**Reference:** CB16/12/00484

**Title:** Centro de Investigación Biomédica en Red de Oncología (CIBERONC)

**Principal Investigator:** Rosa Noguera Salvá

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Universidad de Valencia

**Duration:** 2017-

**Total budget:** €360.000

**Reference:** CASA-DP

**Title:** Cancer Stroma Assessment through Digital Pathology

**Principal Investigator:** Núria Malats (Rosa Noguera Salvá as collaborating researcher)

**Funding body:** CIBERONC

**Beneficiary institution:** CIBERONC

**Duration:** 2021-2023

**Total budget:** €90.000

# scientific activity

4

**Reference:** PMP21/00107

**Title:** INtegrative GENomic, digital Imaging and clinical information towards Precision Oncology Optimization - INGENIO

**Principal Investigator:** Luis Paz-Ares Rodríguez (Rosa Noguera, Samuel Navarro, Amparo López and Sofía Granados as collaborating researchers)

**Funding body:** Ministerio de Ciencia e Innovación

**Beneficiary institution:** CIBERONC

**Duration:** 2021-2024

**Total budget:** €3.780.700

**Reference:** IDIFEDER/2021/067

**Title:** Implantación de una plataforma de análisis genético de última generación para la investigación en genética biomédica

**Principal Investigator:** Rosa Noguera Salvá

**Funding body:** Conselleria de Educación, Investigación, Cultura y Deporte

**Beneficiary institution:** Universidad de Valencia

**Duration:** 2021-2027

**Total budget:** €365.142,5

**Title:** Identificación de nuevas dianas terapéuticas relacionadas con la matriz extracelular de los sarcomas "Ewing-like": estudio morfo-molecular

**Principal Investigator:** Rosa Noguera Salvá and Enrique de Álava

**Funding body:** FISEVI - Fundación CRIS

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2022

**Total budget:** €60.000

**Reference:** PRV00166

**Title:** Espacio intercelular: Bioimagen microscópica, Fase II

**Principal Investigator:** Rosa Noguera Salvá

**Funding body:** Fundación Neuroblastoma


**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2024

**Total budget:** €20.000

# scientific activity

## Research Group on Hematopoietic Transplantation Consolidated group



### Strategic aims

- Translational research on biology and treatment of graft-versus-host disease after allogeneic transplantation of hematopoietic progenitor cells
- Infection and immune reconstitution after haematopoietic transplant
- Development of an Advanced Therapies- clinical and translational program in *Hospital Clínico Universitario de Valencia – INCLIVA*
- Design and implementation of an outpatient programme in hematopoietic transplant and cellular therapy

### Main lines of research

- Translational research on complications of allogeneic hematopoietic transplantation: graft-versus-host disease
- Infection and immune reconstitution after hematopoietic transplantation
- Translational research of alloreactivity in the context of new modalities of allogeneic transplantation from compatible and incompatible alternative donors (haploidentical transplant)
- Clinical application of gene and cellular therapy using CAR-T and other immune effector cells
- Scientific and logistical implications of the implementation of a transplant programme in the outpatient setting

# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Pinana JL, Lopez-Corral L, Martino R, Vazquez L, Perez A, Martin-Martin G, Gago B, Sanz-Linares G, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave MT, Corona M, Marcos-Corrales S, Tormo M, Hernandez-Rivas JA, Montoro J, Rodriguez-Fernandez A, Risco-Galvez I, Rodriguez-Belenguer P, Hernandez-Boluda JC, Garcia-Cadenas I, Ruiz-Garcia M, Munoz-Bellido JL, Solano C, Cedillo A, Sureda A, Navarro D. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. *Journal of Hematology & Oncology.* 2022 May;7:15(1):54. doi: 10.1186/s13045-022-01275-7. PMID: 35526045. IF: 23,168
- Hernani R, Benzaquen A, Solano C. Toxicities following CAR-T therapy for hematological malignancies. *Cancer Treatment Reviews.* 2022 Dec;111:102479. doi: 10.1016/j.ctrv.2022.102479. PMID: 36308910. IF: 13,608
- Pinana J, Lopez-Corral L, Martino R, Montoro J, Vazquez L, Perez A, Martin-Martin G, Facal-Malvar A, Ferrer E, Pascual M, Sanz-Linares G, Gago B, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave M, Lopez-Jimenez J, Marcos-Corrales S, Garcia-Blazquez M, Garcia-Gutierrez V, Hernandez-Rivas J, Saus A, Espigado I, Alonso C, Hernani R, Solano C, Ferrer-Lores B, Guerreiro M, Ruiz-Garcia M, Munoz-Bellido J, Navarro D, Cedillo A, Sureda A, Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). *American Journal of Hematology.* 2022 Jan;97(1):30-42. doi: 10.1002/ajh.26385. PMID: 34695229. IF: 13,265
- Bastos-Oreiro M, Gutierrez A, Reguera J, Iacoboni G, Lopez-Corral L, Terol M, Ortiz-Maldonado V, Sanz J, Guerra-Dominguez L, Bailen R, Mussetti A, Abrisqueta P, Hernani R, Luzardo H, Sancho J, Delgado-Serrano J, Salar A, Grande C, Bento L, de Villambrasia S, Garcia-Belmonte D, Sureda A, Perez-Martinez A, Barba P, Kwon M, Garcia-Sancho A. Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO/GETH Spanish Groups. *Frontiers in Immunology.* 2022 Jul 12;13:855730. doi: 10.3389/fimmu.2022.855730. PMID: 35911769. IF: 8,786
- Pinana J, Rodriguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol M, Vazquez L, Calabuig M, Sanz-Linares G, Marin-Jimenez F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual M, Rodriguez-Fernandez A, Olave M, Cascales-Hernandez A, Gago B, Hernandez-Rivas J, Villalon L, Corona M, Roldan-Perez A, Ribes-Amoros J, Gonzalez-Santillana C, Garcia-Sanz R, Navarro D, Serrano-Lopez A, Cedillo A, Soria-Olivas E, Sureda A, Solano C. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. *Annals of Hematology.* 2022 Sep;101(9):2053-2067. doi: 10.1007/s00277-022-04906-8. PMID: 35780254. IF: 4,03

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI21/01628

**Title:** Inmunobiología de células NK expandidas con criterios GMP de donantes seleccionados de banco de linfocitos para inmunoterapia adoptiva después de TPH alógénico o trasplante de órgano sólido

**Principal Investigator:** Carlos Solano Vercet

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €102.850

**Reference:** PI18/01473

**Title:** Inmunobiología de la infusión de linfocitos del donante con

# scientific activity

*depleción ex vivo de linfocitos T CD45RA+ en pacientes con alto riesgo de infección viral tras TPH alogénico*

**Principal Investigator:** Carlos Solano Vercet

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2023

**Total budget:** €123.420

**Reference:** PI17/01097

**Title:** Score integrado de factores inmunológicos y genotípicos de predicción del riesgo y evolución de la infección por CMV en pacientes con trasplante renal

**Principal Investigator:** María José Remigia Pellicer

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2018-2022

**Total budget:** €32.670

**Reference:** ICI21/00016

**Title:** Terapia celular combinada para pacientes COVID-19 de alto riesgo de mortalidad (DECODE-19)

**Principal Investigator:** Bernat Soria Escoms [Carlos Solano as collaborating researcher]

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL)

**Duration:** 2021-2024

**Total budget:** €459.800

**Title:** Inmunobiología de la infusión de linfocitos del donante con depleción ex vivo de linfocitos T CD45RA+ en pacientes con alto riesgo de infección viral tras TPH alogénico

**Principal Investigator:** Carlos Solano Vercet

**Funding body:** Janssen - Cilag S.A.

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022

**Total budget:** €42.500

**Title:** Torquetenovirus en terapia CAR-T: predicción del riesgo de síndrome de liberación de citocinas y diagnóstico diferencial con infección

**Principal Investigator:** Rafael Hernani Morales

**Funding body:** Fundación Española de Hematología y Hemoterapia-Gilead

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €60.000

**Reference:** BI021/COV/030

**Title:** Estudio de la inmunidad y Creación de un Banco Nacional de Terapia Celular Adoptiva de donantes de linfocitos que han superado COVID-19. Ensayo clínico Fase I multicéntrico para evaluar la seguridad de la infusión de células natural killer como terapia adoptiva en casos pacientes con neumonía y/o linfopenia debido al coronavirus SARS-CoV-2 (RELEASE)

**Principal Investigator:** Cristina Eguizabal [Carlos Solano as collaborating researcher]

**Funding body:** Fundación Vasca de Innovación e investigación Sanitarias (BIOEFF)

**Beneficiary institution:** Instituto de Investigación Sanitaria Biocruces

**Duration:** 2021-2022

**Total budget:** €99.935

**Title:** Immunobiology of GMP-compliant expanded NK cells from selected lymphocyte-bank-registry donors for adoptive immunotherapy after allogeneic HSC in hematological neoplasias or solid organ transplantation

**Principal Investigator:** Rut Meseguer Naturil

**Funding body:** Fundación Científica Asociación Española Contra el Cáncer

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €66.000

**Reference:** PI-2021-004

**Title:** TECO: Validación de dos sistemas biosensor para la diagnosis simultánea de COVID19 y otros patógenos aéreos

**Principal Investigator:** David Giménez Romero [José Luis Piñana as collaborating researcher]

**Funding body:** Universidad de Valencia - INCLIVA

**Beneficiary institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total budget:** €19.000

# scientific activity

4

## THESIS

**Thesis title:** *Significado pronóstico de la expresión del factor de crecimiento endotelial vascular (VEGF) y de genes implicados en las vías de señalización del VEGF en pacientes con leucemia aguda mieloblástica*

**Doctoral candidate:** Marisa Calabuig Muñoz

**Director(s):** Mar Tormo Díaz, Carlos Solano Vercet

**Date of the defense:** 04/05/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** *Impacto de la alorreactividad NK en el trasplante haploidéntico de progenitores hematopoyéticos asociado al uso de la ciclofosfamida postrasplante*

**Doctoral candidate:** M<sup>a</sup> Mar Luis Hidalgo

**Director(s):** Carlos Solano Vercet, José Luis Piñana Sánchez, Dolores Planelles Silvestre

**Date of the defense:** 21/12/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity


## Research Group on Lymphoproliferative Disorders Consolidated group

Group members	Researchers by categories
<b>Leading Researcher, R4</b> M <sup>a</sup> José Terol Casterá Hospital. University	R1 2
<b>Established Researcher, R3</b> Antonio Ferrández Izquierdo. Hospital. University	R2 3
<b>Recognised Researchers, R2</b> Ana Isabel Teruel Casasús. Hospital. University Blanca Ferrer Lores. Hospital Edelmira Martí Sáez. Hospital	R3 1
<b>First Stage Researchers, R1</b> Alicia Serrano Alcalá. INCLIVA Juan Ramón de Moya Romero. Hospital. University	R4 1
<b>Staff. Collaborating Researchers</b> Alfonso Ortiz Algarra. Hospital Ana Saus Carreres. Hospital Raimundo Cervera Vidal. INCLIVA	STAFF 5
<b>Staff. Nurses</b> Esther Lozano García. INCLIVA Mercedes Bou Moreno. INCLIVA	

Strategic aims
<ul style="list-style-type: none"> <li>During the year 2022, we were able to deepen the knowledge of the role of the NOTCH1/FBXW7/PI3K/PTEN/AKT signaling pathway in the progression of Chronic Lymphocytic Leukemia B [CLL-B] to advanced forms. Thus, in the cell lines and in the patient's primary cells, we observed a variation in the number of gene copies by both FISH and PCRq in the NOTCH1, FBXW7 and PTEN genes, with an inverse relationship between NOTCH1 and FBXW7/PTEN</li> <li>A second objective has been to analyse the clinical significance of the rearrangements of MYC, BCL-2 and BCL-6 in diffuse large cell lymphoma. We have been able to verify that patients with concomitant C-MYC and BCL-2 protein expression present a worse prognosis in terms of SLP and Sg than the rest</li> <li>Thirdly, during 2022, the study of the mutational status of IgVH in CLL and its prognostic impact in a wide series of patients has been implemented. New molecular markers (mutations TP53, BIRC3, MYD88, NOTCH1 and SF3B1) have also been studied in CLL by new generation sequencing techniques. In addition, we have continued the collaboration in the GENOMA CLL sequencing project, with a clinical-evolutionary update</li> <li>Finally, we have expanded our participation in clinical research projects in CLL, refractory lymphomas and multiple myeloma, both with the incorporation of new drugs and in the design and development of new therapeutic options</li> </ul>
Main lines of research
<ul style="list-style-type: none"> <li>Analysis of the interactions of CLL cells with their cellular microenvironment: further study of the intracellular mechanisms triggered by VEGF. Analysis of the possible correlation with CXCR4/CCR7 cytokines pathway. Transactivation mechanisms of the aforementioned receptors</li> </ul>

- Role of the NOTCH1/FBXW7/PI3K/PTEN/AKT signaling pathway in the progression of Chronic Lymphocytic Leukemia B (CLL-B) to advanced forms: pathway molecular profile analysis in 100 patients with CLL-B of primary cells obtained at diagnosis and at the time of the progression, analyzing for this, the presence of mutations and number of copies of DNA, gene expression, FISH and (RT-PCR)
- Study of the rearrangements of BCL-2, BCL-6 and MYC in diffuse large cell lymphoma: clinical significance and correlation with immunohistochemical expression using FISH and IHQ techniques
- Study of new molecular markers (mutations of IgVH, TP53, BIRC3, MYD88, NOTCH1 and SF3B1) in CLL: conventional versus NGS techniques. Implication in clonal evolution associated with tumor progression
- New therapeutic options for CLL/MM patients who are resistant to chemoimmunotherapy

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Giné E, de la Cruz F, Jiménez Ubieto A, López Jimenez J, Martín García-Sancho A, Terol MJ, González Barca E, Casanova M, de la Fuente A, Marín-Niebla A, Muntanola A, González-López TJ, Aymerich M, Setoain X, Cortés-Romera M, Rotger A, Rodríguez S, Medina Herrera A, García Sanz R, Nadeu F, Beà S, Campo E, López-Guillermo A. Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, Phase II Trial. *Journal of Clinical Oncology*. 2022 Apr 10;40(11):1196-1205. doi: 10.1200/JCO.21.02321. PMID: 35030036. IF: 50,717
- Marti-Aguado D, Jimenez-Pastor A, Alberich-Bayarri A, Rodriguez-Ortega A, Alfaro-Cervello C, Mestre-Alagarda C, Bauza M, Gallen-Peris A, Valero-Perez E, Ballester MP, Gimeno-Torres M, Perez-Girbes A, Benlloch S, Perez-Rojas J, Puglia V, Ferrandez A, Aguilera V, Escudero-Garcia D, Serra MA, Marti-Bonmati L. Automated whole-liver MRI segmentation to assess steatosis and iron quantification in chronic liver disease. *Radiology*. 2022 Feb;302(2):345-354. doi: 10.1148/radiol.2021211027. PMID: 34783592. IF: 29,146
- Burn E, Li X, Delmestri A, Jones N, Duarte-Salles T, Reyes C, Martinez-Hernandez E, Marti E, Verhamme K, Rijnbeek P, Strauss V, Prieto-Alhambra D. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom. *Nature Communications*. 2022 Nov 23;13(1):7167. doi: 10.1038/s41467-022-34668-w. PMID: 36418291. IF: 17,694
- Pinana J, Lopez-Corral L, Martino R, Montoro J, Vazquez L, Perez A, Martin-Martin G, Facal-Malvar A, Ferrer E, Pascual M, Sanz-Linares G, Gago B, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave M, Lopez-Jimenez J, Marcos-Corrales S, Garcia-Blazquez M, Garcia-Gutierrez V, Hernandez-Rivas J, Saus A, Espigado I, Alonso C, Hernani R, Solano C, Ferrer-Lores B, Guerreiro M, Ruiz-Garcia M, Munoz-Bellido J, Navarro D, Cedillo A, Sureda A, Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). *American Journal of Hematology*. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. PMID: 34695229. IF: 13,265
- Baptista MJ, Tapia G, Munoz-Marmol AM, Muncunill J, Garcia O, Montoto S, Gribben JG, Calaminici M, Martinez A, Veloza L, Martinez-Trillo A, Aldamiz T, Menarguez J, Terol MJ, Ferrandez A, Alcoceba M, Briones J, Gonzalez-Barca E, Climent F, Muntanola A, Moraleda JM, Provencio M, Abrisqueta P, Abella E, Colomo L, Garcia-Ballesteros C, Garcia-

# 4 scientific activity

Caro M, Sancho JM, Ribera JM, Mate JL, Navarro JT. Genetic and phenotypic characterization of HIV-associated aggressive B-cell non-Hodgkin lymphomas, that do not occur specifically in this population: diagnostic and prognostic implications. *Histopathology*. 2022 Dec;81(6):826-840. doi: 10.1111/his.14798. PMID: 36109172. IF: 7,778

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PMP21/00015

**Title:** *Medicina de precisión genómica en neoplasias linfoides (PREGENLINF)*

**Principal Investigator:** Elías Campo Güerri [M<sup>a</sup> José Terol as collaborating researcher]

**Funding body:** *Instituto de Salud Carlos III* - Co-financed FEDER

**Beneficiary institution:** *Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS)*

**Duration:** 2022-2025

**Total budget:** €3.063.060

**Title:** CART-AI-Radiomics in lymphomas: predictive value of artificial intelligence in Non-Hodgkin Lymphoma treated with CART-T therapy

**Principal Investigator:** María José Terol Castera

**Funding body:** Gilead Fellowship Program

**Beneficiary institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2022-2023

**Total budget:** €49.657


# scientific activity

## Research Group on Myeloid Neoplasms Consolidated group

Group members	Researchers by categories
<b>Leading Researchers, R4</b>	R1 1    R2 4    R3 1    R4 2    STAFF 2
Mar Tormo Díaz Hospital. University	
Juan Carlos Hernández Boluda Hospital. University	
<b>Established Researcher, R3</b>	
Eva Villamón Ribate. INCLIVA	
<b>Recognised Researchers, R2</b>	
Carlos Carretero Márquez. Hospital	
Iván Martín Castillo. INCLIVA	
Marisa Calabuig Muñoz. Hospital	
Montserrat Gómez Calafaz. Hospital	
<b>First Stage Researcher, R1</b>	
Irene Pastor Galán. Hospital	
<b>Staff. Nurses</b>	
Alicia Borrero Abarca. INCLIVA	
Mª Carmen Hurtado Fontelles. INCLIVA	

Strategic aims
<ul style="list-style-type: none"> <li>Analyze of the risk factors for thrombosis in myelofibrosis</li> <li>Analyze patients diagnosed with myelodysplastic syndromes with 20q deletion and del[20q]. Assess the incidence, prognostic value and impact on response to azacitidine of azacitidine</li> <li>Analyze in patients diagnosed of acute myeloid leukemias and del[7q] the incidence, prognostic value and potential as a therapeutic target of chromosomal deletions of the EZH2 gene and of genetic mutations alterations and other genetic mutations</li> </ul>
Main lines of research
<ul style="list-style-type: none"> <li>Study of mechanisms involved in leukemic transformation in myeloproliferative neoplasms</li> <li>Study of risk factors for thrombosis in myelofibrosis</li> <li>Study of acute myeloid leukemias with 7q deletion</li> <li>Study of myelodysplastic syndromes with 20q deletion</li> <li>Collaborative studies with the CETLAM group (LMA, SMD), PETHEMA (LLA, LMA), the Spanish Philadelphia-negative chronic myeloproliferative disorders group (GEMFIN), the Spanish LMC group (GELMC), the Spanish SMD group (GESMD) and Spanish Group of Advanced Systemic Mastocytosis (GEMAST)</li> </ul>

## PUBLICATIONS



# scientific activity

## SELECTED PUBLICATIONS

1. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. *Blood Advances*. 2022 Apr; 12(6):2207-2218. doi: 10.1182/bloodadvances.2021005487. PMID: 34972214. IF: 7,637
2. Bataller A, Garrido A, Guijarro F, Onate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, de Llano M, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Guinon A, Salamero O, Sampol A, Merchan B, Bargay J, Castano-Diez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, Lopez-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu J, Colomer D, Brunet S, Sierra J, Esteve J. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. *Blood Advances*. 2022 Feb; 22(6):1193-1206. doi: 10.1182/bloodadvances.2021005585. PMID: 34911079. IF: 7,637
3. Mosquera-Orgueira A, Perez-Encinas M, Hernandez-Sanchez A, Gonzalez-Martinez T, Arellano-Rodrigo E, Martinez-Elicezug J, Villaverde-Ramiro A, Raya JM, Ayala R, Ferrer-Marin F, Fox ML, Velez P, Mora E, Xicoy B, Mata-Vazquez MI, Garcia-Fortes M, Angona A, Cuevas B, Senin MA, Ramirez-Payer A, Ramirez MJ, Perez-Lopez R, Gonzalez de Villambrosia S, Martinez-Valverde C, Gomez-Casares MT, Garcia-Hernandez C, Gasior M, Bellosillo B, Steegmann JL, Alvarez-Larran A, Hernandez-Rivas JM, Hernandez-Boluda JC. Machine learning improves risk stratification in myelofibrosis: an analysis of the Spanish registry of myelofibrosis. *Hemisphere*. 2022 Dec; 20(7):e818. doi: 10.1097/HS9.0000000000000818. PMID: 36570691. IF: 8,3
4. Pastor-Galan I, Martin I, Ferrer B, Hernandez-Boluda J. Impact of molecular profiling on the management of patients with myelofibrosis. *Cancer Treatment Reviews*. 2022 Jul; 81:102435. doi: 10.1016/j.ctrv.2022.102435. PMID: 35839532. IF: 13,608
5. Hernandez-Boluda JC, Pastor-Galan I, Arellano-Rodrigo E, Raya JM, Perez-Encinas M, Ayala R, Ferrer-Marin F, Velez P, Mora E, Fox ML, Hernandez-Rivas JM, Xicoy B, Mata-Vazquez MI, Garcia-Fortes M, Perez-Lopez R, Angona A, Cuevas B, Senin A, Ramirez MJ, Ramirez-Payer A, Gomez-Casares MT, Martinez-Valverde C, Magro E, Steegmann JL, Duran MA, Garcia-Hernandez C, Gasior M, de Villambrosia S, Alvarez-Larran A, Pereira A. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis. *British Journal of Haematology*. 2022 Nov; 199(4):529-538. doi: 10.1111/bjh.18440. PMID: 36089912. IF: 8,615

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI21/00538

**Title:** Factores clinicobiológicos y genéticos asociados al riesgo de trombosis en la mielofibrosis

**Principal Investigator:** Juan Carlos Hernández Boluda

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total Budget:** €96.800

**Title:** Inmunobiología de la infusión de linfocitos del donante con depleción ex vivo de linfocitos T CD45RA+ en pacientes con alto riesgo de infección viral tras TPH alogénico

**Principal Investigator:** Carlos Solano Vercet and Eva Villamón Ribate

**Funding body:** Janssen - Cilag S.A.

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022

**Total Budget:** €42.500

## THESIS

**Thesis title:** Significado pronóstico de la expresión del factor de crecimiento endotelial vascular (VEGF) y de genes implicados en las vías de señalización del VEGF en pacientes con leucemia aguda mieloblástica

**Doctoral candidate:** Marisa Calabuig Muñoz



**Director(s):** Mar Tormo Díaz, Carlos Solano Vercet

**Date of the defense:** 04/05/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group on Molecular Imaging and Metabolomics Consolidated group



## PUBLICATIONS



# scientific activity

## SELECTED PUBLICATIONS

1. Sanz-Ros J, Romero-Garcia N, Mas-Bargues C, Monleon D, Gordevicius J, Brooke RT, Dromant M, Diaz A, Derevyanko A, Guio-Carrión A, Roman-Dominguez A, Ingles M, Blasco MA, Horvath S, Vina J, Borras C. Small extracellular vesicles from young adipose-derived stem cells prevent frailty, improve health span, and decrease epigenetic age in old mice. *Science Advances*. 2022 Oct; 21(8):eabq2226. doi: 10.1126/sciadv.abq2226. PMID: 36260670. IF: 14,957
2. Galvez-Fernandez M, Sanchez-Saez F, Domingo-Rellosa A, Rodriguez-Hernandez Z, Tarazona S, Gonzalez-Marrachelli V, Grau-Perez M, Morales-Tatay J, Amigo N, Garcia-Barrera T, Gomez-Ariza J, Chaves F, Garcia-Garcia A, Melero R, Tellez-Plaza M, Martin-Escudero J, Redon J, Monleon D. Gene-environment interaction analysis of redox-related metals and genetic variants with plasma metabolic patterns in a general population from Spain: the Hortega Study. *Redox Biology*. 2022 Jun;52:102314. doi: 10.1016/j.redox.2022.102314. PMID: 35460952. IF: 10,787
3. Delgado-Velandia M, Gonzalez-Marrachelli V, Domingo-Rellosa A, Galvez-Fernandez M, Grau-Perez M, Olmedo P, Galan I, Rodriguez-Artalejo F, Amigo N, Briongos-Figuero L, Redon J, Martin-Escudero J, Monleon-Salvado D, Tellez-Plaza M, Sotos-Prieto M. Healthy lifestyle, metabolomics and incident type 2 diabetes in a population-based cohort from Spain. *International Journal of Behavioral Nutrition and Physical Activity*. 2022 Jan;27(1):8. doi: 10.1186/s12966-021-01219-3. PMID: 35086546. IF: 8,915
4. Megias J, San-Miguel T, Sanchez M, Navarro L, Monleon D, Calabuig-Farinés S, Morales J, Munoz-Hidalgo L, Roldan P, Cerda-Nicolas M, Lopez-Gines C. Desmoplastic infantile astrocytoma with atypical phenotype, PTEN homozygous deletion and BRAF V600E mutation. *Acta Neuropathologica Communications*. 2022 Jun; 20(10):88. doi: 10.1186/s40478-022-01392-x. PMID: 35725578. IF: 7,578
5. Wei D, Marrachelli V, Melgarejo J, Liao C, Janssens S, Verhamme P, Vanassche T, Van Aelst L, Monleon D, Redon J, Zhang Z. Lipoprotein profiles of fat distribution and its association with insulin sensitivity. *Frontiers in Endocrinology*. 2022 Oct; 25:13978745. doi: 10.3389/fendo.2022.978745. PMID: 36387872. IF: 6,055

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** AP-2021-016

**Title:** BREIC: Identificación de biomarcadores del eje corazón-microbiota-sistema inmune por RMN para la estratificación de pacientes con insuficiencia cardiaca

**Principal Investigator:** Vannina González Marrachelli and Anna Mollar Fernández

**Funding Body:** Universidad de Valencia - INCLIVA

**Beneficiary Institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total Budget:** €4.750

**Reference:** PCIN-2017-117

**Title:** Obesidad materna y disfunción cognitiva en la descendencia: papel causa-efecto de la microbiota intestinal y prevención dietética temprana

**Principal Investigator:** Consuelo Borrás Blasco (Daniel Monleón Salvadó, Vannina González Marrachelli, José Manuel Morales Tatay as collaborating researchers)

**Funding Body:** Ministerio de Economía, Industria y Competitividad

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2017-2022

**Total Budget:** €143.000

**Reference:** PID2020-113839RB-I00

**Title:** Efecto del tratamiento con vesículas extracelulares de células madre de grasa de ratones jóvenes sobre parámetros de envejecimiento y fragilidad en ratones de edad avanzada

**Principal Investigator:** Consuelo Borrás Blasco (Vannina González Marrachelli as collaborating researcher)

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2021-2024

**Total Budget:** €181.500

**Reference:** PID2019-108973RB-C22

**Title:** Metabolomic study of mechanisms for Se-related diabetes and insulin resistance

**Principal Investigator:** Daniel Monleón Salvadó

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2023

**Total Budget:** €140.000

# scientific activity

4

**Reference:** IDIFEDER/2021/072

**Title:** *Metabolómica automatizada de alto rendimiento para estudios epidemiológicos, búsqueda de biomarcadores y 'big data'*

**Principal Investigator:** Daniel Monleón Salvadó

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2021-2023

**Total Budget:** €148.571,52

## THESIS

**Thesis title:** *Estudio metabolómico en tejido prostático y orina para el diagnóstico y pronóstico del cáncer de próstata*

**Doctoral candidate:** Jorge Panach Navarrete

**Director(s):** José María Martínez Jabaloyas, José Manuel Morales Tatay, Vannina González Marrachelli

**Date of the defense:** 08/04/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** *Detección de nuevos marcadores asociados a daño por reperfusión y fibrosis infarto de miocardio validados histopatológicamente mediante análisis multivariante de resonancia magnética multimodal*

**Doctoral candidate:** Itziar Pérez Terol

**Director(s):** Daniel Monleón Salvadó, José Manuel Morales Tatay

**Date of the defense:** 21/07/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group on Molecular Microbiology and Microbial Pathogenesis Consolidated group

Group members	Researchers by categories
<b>Leading Researcher, R4</b> David Navarro Ortega Hospital. University	R2 3
<b>Emerging Researchers, R2</b> Eliseo Alejandro Albert Vicent. Hospital Estela Giménez Quiles. Hospital	R4 1
<b>Recognised Researcher, R2</b> Ignacio Torres Fink. Hospital	STAFF 4
<b>Staff. Collaborating Researchers</b> Ester Colomer Roig. INCLIVA Javier Colomina Rodriguez. Hospital Mª Ángeles Clarí Pons. Hospital Patricia Navarro Domínguez. INCLIVA	R2 3

**Researchers financed by competitive public calls or networks**

### Strategic aims

- Study of the basic aspects of infectious diseases
- Study of the microorganisms that cause human pathology, characterization, biology and physiopathogenesis
- The implementation and optimization of the use of new diagnostic technologies in the clinical management of infectious patients, particularly in the context of a basic onco-haematological pathology
- Creation of multidisciplinary “diagnostic stewardship” Units (Programs for optimization of the use of diagnostic techniques -PRODIM-) with other services (Oncology/Hematology/ICU/Resuscitation, Primary Care)
- Study of the immunobiology of patients with infectious diseases, characterization and study of their clinical impact on individuals and society

### Main lines of research

- Immunobiology of cytomegalovirus infection in patients undergoing allogeneic transplantation of hematopoietic precursors and hematological neoplasms
- Viroma study, in particular the usefulness of monitoring anelloviruses, their quantity and distribution, as a tool to quantify the degree of immunosuppression or immunoreconstitution in allogeneic hematopoietic precursor transplantation (Alo-HSCT), in solid organ transplantation (SOT) and in autoimmune diseases treated with immunosuppressants
- Immunobiology of SARS-CoV-2 infection
- Design and evaluation of diagnostic algorithms, applicability and actions associated with the result of analytical techniques and development of new diagnostic strategies
- Molecular characterization of *Neisseria gonorrhoeae*
- Analytical validation of diagnostic techniques
- Clinical validation of diagnostic techniques

## Emerging Researchers


Estela Giménez Quiles

The main objective is the study of the dynamics of the composition and of the viral load of the main components of the human plasma virome as a predictor of functional immunity in the context of allogeneic transplantation of hematopoietic progenitors

Eliseo Alejandro Albert Vicent

The main objective is the study of infection in immunosuppressed patients, particularly in Cytomegalovirus and Alphaherpesvirus infection in patients undergoing allogeneic hematopoietic stem cell transplantation

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Gimenez E, Alberola J, Torres I, Albert E, Alcaraz MJ, Botija P, Amat P, Remigia MJ, Beltran MJ, Rodado C, Huntley D, Olea B, Navarro D. Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty COVID-19 vaccine. *Journal of Infection*. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.10.026. PMID: 34740744. IF: 38,637
2. Torres I, Gimenez E, Albert E, Zulaica J, Alvarez-Rodriguez B, Burgos J, Peiro S, Limon R, Vanaclocha H, Rodado C, Botija P, Sifre A, Tur B, Lozano R, Orosa I, Vicente-Ruiz M, Carrion R, Clari M, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzalez-Candelas F, Geller R, Navarro D. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty (R) COVID-19 vaccine: looking for correlates of protection. *Journal of Medical Virology*. 2022 Sep;94(9):4216-4223. doi: 10.1002/jmv.27867. PMID: 35585782. IF: 20,693
3. Torres I, Bellido-Blasco JB, Gimeno C, Burgos JS, Albert E, Moya-Malo R, Gasco-Laborda JC, Tornero A, Soriano J, Meseguer-Ferrer N, Martinez-Serrano M, Ortiz-Rambla J, Buj H, Hernandez N, Peiro S, Salas D, Limon R, Vanaclocha H, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzalez-Candelas F, Navarro D. SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty (R) COVID-19 vaccination. *Journal of Medical Virology*. 2022 Aug;94(8):3776-3782. doi: 10.1002/jmv.27799. PMID: 35445415. IF: 20,693
4. Albert E, Burgos JS, Peiro S, Salas D, Vanaclocha H, Gimenez E, Limon R, Alcaraz MJ, Sanchez-Paya J, Diez-Domingo J, Cervantes A, Navarro D. Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty COVID-19 vaccine in nursing home residents. *Clinical Microbiology and Infection*. 2022 Feb;28(2):279-284. doi: 10.1016/j.cmi.2021.09.031. PMID: 34619398. IF: 13,31
5. Pinana J, Lopez-Corral L, Martino R, Montoro J, Vazquez L, Perez A, Martin-Martin G, Facal-Malvar A, Ferrer E, Pascual M, Sanz-Linares G, Gago B, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave M, Lopez-Jimenez J, Marcos-Corrales S, Garcia-Blazquez M, Garcia-Gutierrez V, Hernandez-Rivas J, Saus A, Espigado I, Alonso C, Hernani R, Solano C, Ferrer-Lores B, Guerreiro M, Ruiz-Garcia M, Munoz-Bellido J, Navarro D, Cedillo A, Sureda A, Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). *American Journal of Hematology*. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. PMID: 34695229. IF: 13,265

# scientific activity

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH      THESIS

**Reference:** TTVGuideTX

**Title:** Personalisation of immunosuppression by monitoring viral load post kidney transplantation - a randomised controlled phase II trial

**Principal Investigator:** David Navarro Ortega

**Funding body:** European Commission

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2026

**Total budget:** €85.625

**Reference:** PI21/00563

**Title:** Inmunidad adaptativa de linfocitos B y T frente a SARS-CoV-2 tras la vacunación de pacientes en riesgo de sufrir COVID-19 severa

**Principal Investigator:** David Giménez Romero (Estela Giménez as collaborating researcher)

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €169.400

**Reference:** PI18/00127

**Title:** Virología e inmunología de la infección por el citomegalovirus (CMV) en el paciente con neoplasia hematológicas en la era de las nuevas bioterapias

**Principal Investigator:** David Navarro Ortega

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2022

**Total budget:** €111.320

**Reference:** PI-2021-004

**Title:** TECO: Validación de dos sistemas biosensor para la diagnosis simultánea de COVID19 y otros patógenos aéreos

**Principal Investigator:** David Giménez Romero (Estela Giménez as collaborating researcher)

**Funding body:** Universidad de Valencia - INCLIVA

**Beneficiary institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total budget:** €19.000

**Thesis title:** Valor predictivo de la carga viral de citomegalovirus y torquetenovirus en heces y plasma del desarrollo de la enfermedad inerto contra huésped intestinal en pacientes sometidos a trasplante alogénico de precursores hematopoyéticos

**Doctoral candidate:** Felipe Bueno Ferrando

**Director(s):** David Navarro Ortega

**Date of the defense:** 15/06/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** Nuevas aplicaciones del Sistema MALDI-TOF MS en la microbiología clínica

**Doctoral candidate:** Ignacio Torres Fink

**Director(s):** David Navarro Ortega

**Date of the defense:** 14/07/2022

**Grade:** Sobresaliente "cum laude"


# scientific activity

4

## 4.3.3 Metabolism and Organ Damage Area

### Groups

- Research Group on Genetics of Osteoporosis
- Research Group on Neurological Impairment
- Research Group on Inflammation
- Research Group on Psychiatry and Neurodegenerative Diseases
- Research Group on Respiratory Diseases
- Research Group on Tissular Biochemistry
- Research Group on Aging and Physical Activity
- Research Group on Anesthesiology and Reanimation
- Research Group on Human Translational Genomics
- Research Group on General and Digestive Surgery
- Research Group on Personal Autonomy, Dependence and Severe Mental Disorders (TMAP)
- Research Group on Cellular and Organic Physiopathology of Oxidative Stress
- Research Group on Nuclear Receptors in Cardiometabolic Pathology
- Research group on Metabolic Diseases
- Research Group on Rare Respiratory Diseases (RRD)
- Research Group on Healthy Aging (MiniAging)
- Research Group on Exercise, Nutrition and Healthy Lifestyle
- Research Group on Epigenomics and Translational Epigenetics
- Research Group in Medical Chemistry for Drug Development
- Research Group on Neurobiology and Molecular Physiopathology in Rare Diseases – NeuroFisER



# scientific activity

## Research Group on Genetics of Osteoporosis Consolidated group

### Group members

#### Leading Researcher, R4

Miguel Ángel García Pérez. University

### Researchers by categories



#### Established Researcher, R3

Damián Mifsut Miedes. University

#### Staff. Collaborating Researcher

Rosa María Aliaga Corachán. University

### Strategic aims

- Identification of genes and polymorphisms associated with bone phenotypes such as bone mineral density and fragility fracture
- Identification of miRNAs as biomarkers of fragility fracture and osteoarthritis
- Study of the metabolome in fragility fracture and severe osteoarthritis
- Development of animal models of accelerated bone loss as a source of candidate genes for study in humans
- Functional characterization of genetic variants associated with quantitative phenotypes
- Characterization of the type of chromosome duplication, its paternal/maternal origin, global gene expression, and miRNA expression profile in patients with Idic-15 syndrome

### Main lines of research

- Genetics of postmenopausal osteoporosis
- Genetic and epigenetic biomarkers of prevalent bone phenotypes
- Functional analysis of genetic variants
- Development of animal models of accelerated bone loss and cellular models of osteogenesis
- Genetic study of patients with chromosome 15 duplication inversion syndrome (Idic-15)

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Pertusa C, Mifsut D, Morales J, Tarin J, Cano A, Monleon D, Garcia-Perez M. Metabolomic analysis of severe osteoarthritis in a Spanish population of women compared to healthy and osteoporotic subjects. *Metabolites*. 2022 Jul 24;12(8):677. doi: 10.3390/metabo12080677. PMID: 35893245. IF: 5,581
- Tarin J, Garcia-Perez M, Cano A. It is premature to use postmortem sperm for reproductive purposes: a data-driven opinion. *Reproductive Sciences*. 2022 Dec;29(12):3387-3393. doi: 10.1007/s43032-022-00874-6. PMID: 35146695. IF: 2,924

# scientific activity

## Research Group on Neurological Impairment Consolidated group

### Group members

#### Leading Researcher, R4

Carmina Montoliu Félix. University

#### Established Researchers, R3

Amparo Escudero García. Hospital. University

José Ballester Fayos. Hospital

José Luis León Guijarro. Hospital

Roberto Aliaga Méndez. Hospital

#### Recognised Researcher, R2

Andrea Cabrera Pastor. University. INCLIVA

#### Recognised Researchers, R2

Amparo Uriós Lluch. INCLIVA

Cristina Ipiens Escuer. INCLIVA

Cristina Montón Rodríguez. Hospital

Maria Pilar Ballester Ferrer. Hospital. INCLIVA

Nicolás Peñaranda Sarmiento. Hospital

Paula Cases Bergón. Hospital

Rut Víctorio Muñoz. Hospital

#### First Stage Researchers, R1

Alessandra Fiorillo. INCLIVA

Dalia Rega Caballero. INCLIVA

Franc Casanova Ferrer. INCLIVA

Juan José Gallego Roig. INCLIVA



Researchers financed by competitive public calls or networks



### Staff. Collaborating Researcher

Mika Aiko. Hospital

### Staff. Nurses

Clara Barberá Fuset. Hospital

María Jesús Campa Santiago. Hospital

Pilar Aguilar Santaisabel. Hospital

### Staff. Technicians

Alberto Sabio Palomares. INCLIVA

Alejandra Hernández Hernández. University. INCLIVA

Christian Torregrosa Sanchis. INCLIVA

Consuelo Miguel Moreno. Hospital

Laura García Gálvez. INCLIVA

Laura Puchades Lanza. INCLIVA

### Strategic aims

- Evaluation of cognitive and motor alterations in patients with liver cirrhosis and minimal hepatic encephalopathy (MHE)
- To characterize the inflammatory processes and create a bioinformatic model of the molecular and cellular events of the immune system associated to the onset of MHE. Assess its utility to predict or diagnose MHE
- To analyze cerebral alterations: visual evoked potentials; neuronal connectivity using functional magnetic resonance
- Analysis of alterations in thermal and mechanical sensitivity and in peripheral nerve conduction velocity
- Assess the utility of the analysis of eye movements for early diagnosis of MHE
- Assess the effects of rifaximin treatment on the alterations analyzed in the above objectives
- To identify procedures based on above results, which improve diagnosis of MHE

### Main lines of research

Main Line of research: Characterization of neurological and cerebral alterations in patients with minimal hepatic encephalopathy (MHE). Mechanisms: Contribution of inflammation. Diagnostic and therapeutic implications. Sublines:

- Characterization of cognitive, functional and cerebral alterations in patients with minimal hepatic encephalopathy

# scientific activity


- Characterize alterations in inflammation, neuroinflammation, brain function and structure associated with the onset of MHE
- Identify biomarkers for the early detection of mild cognitive impairment in MHE
- To assess the effects of rifaximin treatment and new treatments: mechanisms involved
- Identification and modelling of molecular and cellular events of the immune response associated to the appearance of minimal hepatic encephalopathy in cirrhotic patients
- To assess the usefulness of eye movement analysis for the early diagnosis of MHE
- Research on cognitive and motor alterations in patients with non-alcoholic fatty liver disease showing mild cognitive impairment (MCI)

## Emerging Researcher

*Andrea Cabrera Pastor*

The main focus of the research is to understand the role of extracellular vesicles in comorbidities associated with obesity, including molecular mechanisms, diagnostic and therapeutic implications

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Tranah T, Ballester M, Carbonell-Asins J, Ampuero J, Alexandrino G, Caracostea A, Sanchez-Torrijos Y, Thomsen K, Kerbert A, Capilla-Lozano M, Romero-Gomez M, Escudero-Garcia D, Montoliu C, Jalan R, Shawcross D. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. *Journal of Hepatology*. 2022 Dec;77(6):1554-1563. doi: 10.1016/j.jhep.2022.07.014. PMID: 35872326. IF: 30,083
2. Martí-Aguado D, Jiménez-Pastor A, Alberich-Bayarri A, Rodríguez-Ortega A, Alfaro-Cervello C, Mestre-Alagarda C, Bauza M, Gallen-Peris A, Valero-Perez E, Ballester MP, Gimeno-Torres M, Pérez-Girbes A, Benlloch S, Pérez-Rojas J, Puglia V, Ferrández A, Aguilera V, Escudero-García D, Serra MA, Martí-Bonmatí L. Automated whole-liver MRI segmentation to assess steatosis and iron quantification in chronic liver disease. *Radiology*. 2022 Feb;302(2):345-354. doi: 10.1148/radiol.2021211027. PMID: 34783592. IF: 29,146
3. Gallego J, Fiorillo A, Casanova-Ferrer F, Urios A, Ballester M, Durban L, Megias J, Rubio T, Cabrera-Pastor A, Escudero-García D, Montoliu C, Serra M, Felipo V, Montoliu C. Plasma extracellular vesicles play a role in immune system modulation in minimal hepatic encephalopathy. *International Journal of Molecular Sciences*. 2022 Oct 15;23(20):12335. doi: 10.3390/ijms232012335. PMID: 36293192. IF: 6,208
4. Ballester M, Gallego J, Fiorillo A, Casanova-Ferrer F, Giménez-Garzo C, Escudero-García D, Tosca J, Ríos M, Montón C, Durban L, Ballester J, Benlloch S, Urios A, San-Miguel T, Kosenko E, Serra M, Felipo V, Montoliu C. Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. *Scientific Reports*. 2022 Feb 14;12(1):2463. doi: 10.1038/s41598-022-06416-z. PMID: 35165326. IF: 4,996
5. Casanova-Ferrer F, García-Cena CE, Gallego JJ, Fiorillo A, Urios A, Calvo-Cordoba A, Ballester MP, Ríos MP, Durban L, Hidalgo MR, García F, Felipo V, Montoliu C. Minimal hepatic encephalopathy is associated to alterations in eye movements. *Scientific Reports*. 2022 Oct 7;12(1):16837. doi: 10.1038/s41598-022-21230-3. PMID: 36207472. IF: 4,996

# scientific activity

4

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** CP20/00009

**Title:** Role of extracellular vesicles, metabolome and altered intercellular communication in the induction of minimal hepatic encephalopathy: mechanisms, therapeutic and diagnostic implications

**Principal Investigator:** Andrea Cabrera Pastor

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2024

**Total budget:** €40.000

**Title:** Identification and modelling of molecular and cellular events of the immune response associated to the appearance of minimal hepatic encephalopathy in cirrhotic patients

**Principal Investigator:** Carmina Montoliu Félix

**Funding body:** Fundación Ramón Areces

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2022

**Total budget:** €129.600

**Reference:** AP-2021-001

**Title:** LIGAM1: Efecto de la activación de TLR por medio de sus ligandos sobre la polarización de macrófagos hacia M1 y su función citocida frente a las células madre de glioblastoma

**Principal Investigator:** Javier Megías Vericat and Andrea Cabrera Pastor

**Funding body:** Universidad de Valencia - INCLIVA

**Beneficiary institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total budget:** €4.067,5

**Title:** Estudio multicéntrico de precisión diagnóstica para cuantificar y caracterizar la fibrosis de la Enfermedad Hepática Metabólica mediante patología digital avanzada

**Principal Investigator:** David Martín Aguado (Amparo Escudero García as collaborating researcher)

**Funding body:** Sociedad Valenciana de Patología Digestiva

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2022

**Total budget:** €5.000

**Reference:** CIGE/2021/083

**Title:** Estudio de las vesículas extracelulares en plasma de pacientes con obesidad mórbida antes y tras cirugía bariátrica. Subvenciones concedidas a grupos de investigación emergentes

**Principal Investigator:** Andrea Cabrera Pastor

**Funding body:** Conselleria de Educación

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2023

**Total budget:** €20.000

## THESIS

**Thesis title:** Mecanismos moleculares por los que la hiperamonemia crónica induce neuroinflamación y alteraciones en la neurotransmisión en cerebelo de ratas hiperamonémicas

**Doctoral candidate:** Yaiza María Arenas Ortiz

**Director(s):** Andrea Cabrera Pastor, Tiziano Balzano, Vicente Felipo Orts

**Date of the defense:** 12/04/2022

**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD

**Thesis title:** Papel de las vesículas extracelulares en el deterioro cognitivo y motor en hiperamonemia y encefalopatía hepática. Mecanismos moleculares e implicaciones terapéuticas

**Doctoral candidate:** Paula Izquierdo Altarejos

**Director(s):** Vicente Felipo Orts, Andrea Cabrera Pastor

**Date of the defense:** 20/05/2022

**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD

**Thesis title:** Characterization and evaluation of alterations in sensitivity and autonomic function in patients with minimal hepatic encephalopathy

**Doctoral candidate:** Dalia Rega Caballero

**Director(s):** Carmina Montoliu Félix, Amparo Uriós Lluch, Paula Cases Bergón

**Date of the defense:** 05/12/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group on Inflammation Consolidated group

### Group members

#### Leading Researchers, R4

Esteban Morcillo Sánchez  
Hospital. University  
María Jesús Sanz Ferrando  
University



Researchers financed by  
competitive public calls or networks



#### Recognised Researcher, R2

Patrice Gomes Marques. INCLIVA

Team involved in



#### First Stage Researcher, R1

Elena Domingo Pérez. INCLIVA

#### Staff. Technicians

Inés Descalzo Arenas. INCLIVA  
José Aparicio Collado. INCLIVA

### Strategic aims

- Study of the systemic inflammation associated to Primary and Familial Hypercholesterolemia as well as Metabolic Syndrome
- Study of the CCL11/CCR3 axis in Primary Hypercholesterolemia and atherosclerosis development
- Study of the impact of PCSK9 blockade in the systemic inflammation and endothelial dysfunction associated to Familial Hypercholesterolemia
- Synthesis of new dual PPAR $\alpha/\gamma$  and pan PPAR agonists. Pharmacological in vitro and in vivo studies in ob/ob mice
- Synthesis of new dual LXR/PPAR $\alpha/\gamma$  agonists and pharmacology study

### Main lines of research

- Study of the vascular inflammation induced by different risk factors of atherosclerosis: metabolic syndrome, primary and familial hypercholesterolemia
- Study of novel immune players in the atherosclerotic lesion formation
- Study of the impact of recent therapeutic approaches in the systemic inflammation and endothelial dysfunction associated to Familial Hypercholesterolemia
- Synthesis of new dual PPAR $\alpha/\gamma$  and pan PPAR agonists to be used in the control of cardiometabolic disorders
- Synthesis of new dual LXR/PPAR $\alpha/\gamma$  agonists to be used in the control of cardiometabolic disorders

### PUBLICATIONS



# scientific activity

4

## SELECTED PUBLICATIONS

1. Marques P, Domingo E, Rubio A, Martínez-Hervas S, Ascaso JF, Piqueras L, Real JT, Sanz MJ. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. *Biomedicine & Pharmacotherapy*. 2022 Jan;145:112460. doi: 10.1016/j.biopha.2021.112460. PMID: 34864314. IF: 7,419
2. Corro Morón M, Granell A, Ivanova V, Domingo E, Beltran Debon R, Barril X, Sanz MJ, Matheu MI, Castillon S, Diaz Y. Revealing 2-dimethylhydrazino-2-alkyl alkynyl sphingosine derivatives as sphingosine kinase 2 inhibitors: some hints on the structural basis for selective inhibition. *Bioorganic Chemistry*. 2022 Apr;121:105668. doi: 10.1016/j.bioorg.2022.105668. PMID: 35219046. IF: 5,307
3. Francisco V, Sanz M, Real J, Marques P, Capuozzo M, Ait El Djoudi D, Gualillo O. Adipokines in non-alcoholic fatty liver disease: are we on the road toward new biomarkers and therapeutic targets?. *Biology*. 2022 Aug 19;11(8):1237. doi: 10.3390/biology11081237. PMID: 36009862. IF: 5,168
4. Marques P, Fernandez-Presa L, Carretero A, Gómez-Cabrera MC, Viña J, Signes-Costa J, Sanz MJ. The radiographic assessment of lung edema score of lung edema severity correlates with inflammatory parameters in patients with coronavirus disease 2019-Potential new admission biomarkers to predict coronavirus disease 2019 worsening. *Frontiers in Medicine*. 2022 Aug 11;9:871714. doi: 10.3389/fmed.2022.871714. PMID: 36035415. IF: 5,058
5. Vila L, Cabedo N, Villaruel-Vicente C, García A, Bernabeu A, Hennuyer N, Staels B, Franck X, Figadere B, Sanz MJ, Cortes D. Synthesis and biological studies of polycerasoidol and trans-delta-tocotrienolic acid derivatives as PPARalpha and/or PPARgamma agonists. *Bioorganic & Medicinal Chemistry*. 2022 Jan 1;53:116532. doi: 10.1016/j.bmc.2021.116532. PMID: 34863066. IF: 3,641

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Título:** The William Harvey International Translational Research Academy (WHRI-ACADEMY)

**Investigadora principal:** Márta Korbonits (María Jesús Sanz Ferrando as collaborating researcher)

**Entidad financiadora:** FP7 Marie Curie Actions

**Institución beneficiaria:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duración:** 2015-

**Presupuesto total:** €6.500.000

**Reference:** CB06/06/0027

**Title:** Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERes)

**Principal Investigator:** Esteban Morcillo Sánchez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Universidad de Valencia

**Duration:** 2007-

**Reference:** PID2020-120336RB-I00

**Title:** Modulación de la inflamación metabólica en la prevención de la patología cardiovascular: Identificación de nuevas dianas terapéuticas y desarrollo de fármacos novedosos

**Principal Investigator:** María Jesús Sanz Ferrando

**Funding Body:** Ministerio de Ciencia, Innovación y Universidades

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2024

**Total Budget:** €290.400

**Reference:** PROMETEO/2019/032

**Title:** Una aproximación traslacional desde la clínica a la experimentación animal: estudio del papel del eje CCL11/CCR3 y la inflamación eosinofílica en la patología cardiovascular asociada a desórdenes metabólicos

**Principal Investigator:** María Jesús Sanz Ferrando

**Funding body:** Consellería de Educación Cultura y Deporte

**Beneficiary institution:** Universidad de Valencia

**Duration:** 2020-2023

**Total budget:** €211.736

## THESIS

**Thesis title:** Effect of SGLT-2 inhibition in abdominal aortic aneurysm development. Role of rora in adipose tissue inflammation associated to obesity

**Doctoral candidate:** Rebeca Ortega Herráiz

**Director(s):** Laura Piqueras Ruiz, María Jesús Sanz Ferrando, José Tomás Real Collado

**Date of the defense:** 21/02/2022

**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD

# scientific activity

## Research Group on Psychiatry and Neurodegenerative Diseases Consolidated group

### Group members

#### Leading Researcher, R4

Julio Sanjuán Arias

Hospital. University

#### Established Researchers, R3

Eduardo Jesús Aguilar García-Iturrospe. Hospital. University

Juan Nacher Roselló. University

María Dolores Moltó Ruiz. University

#### Emerging Researcher, R2

Olga María Rivero Martín. INCLIVA

#### Recognised Researchers, R2

Carlos Cañete Nicolás. Hospital. University

Esther Lorente Rovira. Hospital. University

Francisco Olucha Bordonau. University

Gracián García Martí. CIBER

Héctor Carceller Cerdá. University

José Carlos González Piqueras. Hospital. University

Lucía Bonet Mora. University

María José Escartí Fabra. Hospital

Marien Gadea Domenech. University

Marta Pérez Rando. University

Miguel Hernández Viadel. Hospital

#### First Stage Researchers, R1

Javier David Lluesma. University

Jon Iñaki Etxeandia Pradera. Hospital

Julia Alcaide Pozo. University

Marc Beltrán Martínez. University

Patrycja Klimczak. University

Yaiza Gramuntell Roch. University

### Researchers by categories



Researchers financed by competitive public calls or networks



### Team involved in

*cibersam*

### Staff. Collaborating Researcher

Alba Postiguillo Giraldos. INCLIVA

### Staff. Nurse

Blanca Llàcer Iborra. CIBER

### Staff. Technician

Joan Blasco Palanca. INCLIVA

### Staff. Administrative assistants

Julen Santiago Agrediano. INCLIVA

Virginia Gómez Soriano. INCLIVA

### Strategic aims

- Elaboration of a mobile application associated to the Clinical Records to improve adherence to the treatment of patients with first episode psychosis
  - Publication of Results of Gene Environmental interaction First Episode Psychosis projects
  - Development of new techniques to diagnosis psychosis by fMRI and machine learning approach
  - Development of animal models in severe mental disorder
  - Models of Prediction of Response in First Psychotic Episodes
- Identifying genetic risk factors and biomarkers of response to medication in schizophrenia
- Identification of modifying genes, new targets and molecules with therapeutic potential in Friedreich's Ataxia

## Main lines of research

- Blood Gene Expression Profiles in First-Episode Psychosis Patients
- Development and characterization of new cellular preclinical models of personalized medicine in psychosis
- Study on animal models in serious mental illness
- Study of neurodegenerative diseases (Friedreich's Ataxia) in Drosophila models
- Study of genetic and environmental risk factors in affective and psychotic disorders
- Identifying abnormal patterns in neuroimaging (morphometry, functional, spectroscopy) in psychotic patients
- Design and coordination of clinical, genetic and neuroimaging data bases oriented to performing multicenter projects
- Development of interactive systems for improving therapeutic adherence
- Study on the efficiency of psycho-social intervention techniques in serious mental illness

## Emerging Researcher, R2

*Olga María Rivero Martín*

The main line of research is the identification of biomarkers associated with the appearance of the first psychotic episode and response to antipsychotic medication. These biomarkers will be studied in neuronal cultures of first-episode psychotic patients and healthy subjects.

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Trubetskoy V, Pardinas A, Qi T, Panagiotaropoulou G, Indonesia Schizophrenia Consortium, PsychENCODE, Psychosis Endophenotypes International Consortium, SynGO Consortium, Schizophrenia Working Group of the Psychiatric Genomics Consortium. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*. 2022 Apr;604(7906):502-508. doi: 10.1038/s41586-022-04434-5. PMID: 35396580. IF: 69,504
2. Soldevila-Matias P, Garcia-Martí G, Fuentes-Dura I, Ruiz JC, Gonzalez-Navarro L, Gonzalez-Vivas C, Radua J, Sanjuan J. Brain activity changes with emotional words in different stages of psychosis. *European Psychiatry*. 2022 Oct 4;1-27. doi: 10.1192/j.eurpsy.2022.2321. PMID: 36193735. IF: 7,156
3. Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pence AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altinayazar V, Yalincetin B, Gumus-Akay G, Cihan B, Soygur H, Ulas H, Cankurtaran ES, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, Garcia-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jimenez-Lopez E, Arrojo M, Carracedo A, Lopez G, Gonzalez-Penas J, Parellada M, Maric NP, Atbasoglu C, Ucok A, Alptekin K, Saka MC, Aguglia E, Arango C, Rutten BP, Guloksuz S. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: results from the EUGEI study. *European Neuropsychopharmacology*. 2022 Aug 30;63:47-59. doi: 10.1016/j.euroneuro.2022.08.003. PMID: 36055075. IF: 5,415
4. Perez-Rando M, Elvira U, Garcia-Martí G, Gadea M, Aguilar E, Escartí M, Ahullo-Fuster M, Grasa E, Corripio I, Sanjuan J, Nacher J. Alterations in the volume of thalamic nuclei in patients with schizophrenia and persistent auditory hallucinations. *NeuroImage Clinical*. 2022 Jun 1;35:103070. doi: 10.1016/j.nicl.2022.103070. PMID: 35667173. IF: 4,891
5. Etxeandia-Pradera J, Landeta J, Gonzalez-Such J, Aguilar E. How to improve training in descriptive psychopathology for psychiatry residents: a Delphi study. *Psychopathology*. 2022 Jul 29;1-14. doi: 10.1159/000525691. PMID: 35908537. IF: 3,849

# scientific activity

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI20/00473

**Title:** *Estudio longitudinal de una cohorte representativa: superando la heterogeneidad clínica y biológica en primeros episodios psicóticos*

**Principal Investigator:** Julio Sanjuán Arias

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total budget:** €68.970

**Reference:** CB07/09/0006

**Title:** *Centro de Investigación Biomédica en Red en Salud Mental (CIBERsam)*

**Principal Investigator:** Juan Nacher Roselló

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Universidad de Valencia

**Duration:** 2008-

**Reference:** INVEST/2022/141

**Title:** *Programa de formación y ocupabilidad de psicólogo/a en evaluaciones clínicas y uso seguimiento del aplicativo Remindcare en proyectos de investigación*

**Principal Investigator:** Julio Sanjuan Arias

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €66.217,84

**Reference:** INVEST/2022/49

**Title:** *Programa de formación y ocupabilidad de especialista en análisis de imagen de sistema nervioso*

**Principal Investigator:** Juan Nácher Roselló

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €66.217,84

**Reference:** PROMETEO/2020/024

**Title:** *Estudio longitudinal de una cohorte representativa: superando la heterogeneidad clínica y biológica en primeros episodios psicóticos*

**Principal Investigator:** Julio Sanjuán Arias

**Funding Body:** Conselleria de Educación, Cultura y Deporte

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2023

**Total budget:** €174.588

**Reference:** 2021095290

**Title:** *Intracellular iron deposits in a Drosophila Model of Friedreich´s Ataxia*

**Principal Investigator:** Juan Antonio Navarro (Mª Dolores Moltó as collaborating researcher)

**Funding Body:** Center of Excellence ALBA synchrotron

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022

**Total budget:** €51.471,36

# scientific activity

4

## Research Group on Respiratory Diseases Consolidated group

### Group members

#### Leading Researcher, R4

Jaime Signes-Costa Miñana

Hospital

### Researchers by categories



#### Established Researchers, R3

Jesús Sancho Chinesta. Hospital

José Franco Serrano. Hospital. University

Mª Cruz González Villaescusa. Hospital

Mª Luisa Briones Urtiaga. Hospital

#### Recognised Researchers, R2

Carmen Muñoz Esteban. Hospital

Francisco Carrión Valero. Hospital. University

José Luis Díaz Cordobés. Hospital

Mª Belén Safont Muñoz. Hospital

Pilar Bañuls Polo. Hospital

Antonio Herrera Cuadros. INCLIVA

Antonio Quezada Reynosa. Hospital

Carlos Alonso Ruzo. Hospital

Cristina Rosario Martín. Hospital

Elena Giménez Civera. INCLIVA

Elia Giménez Samblas. Hospital

Elvira Bondía Real. Hospital

Enric Burés Sales. Hospital

Erick Monclou Garzón. Hospital

Heidi Mora Bastida. Hospital

Julia Tarrasó Castillo. INCLIVA

Lucía Fernández Presa. Hospital

Manuela Marín González. Hospital

Mariam García Alfaro. Hospital

Natividad Blasco Angulo. INCLIVA

Pablo Royo Simó. University

#### First Stage Researchers, R1

Alba Mulet Arabi. Hospital

Irene Bocigas Huéscar. Hospital

Nieves Navarro Soriano. Hospital

Paola Lisseth Ordóñez Gómez. Hospital

Santos Ferrer Espinosa. Hospital

#### Staff. Collaborating Researchers

Ana Ferrer Pons. Hospital

Ana María Ferrer Martí. Hospital

Andrea Ballester Férriz. Hospital

Andrés Vales Veiga. Hospital

### Strategic aims

- Study of respiratory complications in patients with neuromuscular diseases. Utility of mechanical ventilation and other respiratory supports
- Implication of early diagnosis of obstructive airway diseases in the prognosis and follow-up of patients. Emphysema early detection program. Program for early detection of Alpha 1 Antitrypsin Deficiency
- Early follow-up program for COPD with exacerbator phenotype
- Severe Asthma control program
- Control of respiratory disorders during sleep as prevention of cardiovascular risk factors
- Early diagnosis of idiopathic interstitial respiratory diseases (IPF) and secondary diseases (drug toxicity and post-BMT)

# scientific activity

## Main lines of research

- Usefulness of non-invasive ventilation in the weaning process of patients with prolonged mechanical ventilation
- Improve the effectiveness of mechanically assisted cough procedures in patients with ALS, as well as the precision of the clinical tools available to evaluate frontotemporal dementia in them
- Study in smokers of the early stages of COPD. GOLD classification paradigm O
- Identify cardiac morphological changes in patients with sleep-disordered breathing and ischemic heart disease treated with CPAP
- Follow-up of patients admitted for bilateral COVID19 pneumonia: changes in pulmonary function tests for the early diagnosis of pulmonary fibrotic sequelae
- Study of oxidative stress and inflammatory mechanisms underlying acute lung damage caused by SARS-CoV-2

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Zhang Q, Pizzorno A, Miorin L, Bastard P, Gervais A, Le Voyer T, Bizien L, Manry J, Rosain J, Philippot Q, Goavec K, Padey B, Cupic A, Laurent E, Saker K, Vanker M, Sarekannu K, Garcia-Salum T, Ferres M, Le Corre N, Sanchez-Cespedes J, Balsera-Manzanero M, Carratala J, Retamar-Gentil P, Abelenda-Alonso G, Valiente A, Tiberghien P, Zins M, Debette S, Meyts I, Haerynck F, Castagnoli R, Notarangelo LD, Gonzalez-Granado LI, Dominguez-Pinilla N, Andreakos E, Triantafyllia V, Rodriguez-Gallego C, Sole-Violan J, Ruiz-Hernandez JJ, Rodriguez de Castro F, Ferreres J, Briones M, Wauters J, Vanderbeke L, Feys S, Kuo CY, Lei WT, Ku CL, Tal G, Etzioni A, Hanna S, Fournet T, Casalegno JS, Queromes G, Argaud L, Javouhey E, Rosa-Calatrava M, Cordero E, Aydillo T, Medina RA, Kisand K, Puel A, Jouanguy E, Abel L, Cobat A, Trouillet-Assant S, Garcia-Sastre A, Casanova JL. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. *Journal of Experimental Medicine*. 2022 Nov 7;219(11):e20220514. doi: 10.1084/jem.20220514. PMID: 36112363. IF: 17,579
- Tarraso J, Safont B, Carbonell-Asins JA, Fernandez-Fabrellas E, Sancho-Chust JN, Naval E, Amat B, Herrera S, Ros JA, Soler-Cataluna JJ, Rodriguez-Portal JA, Andreu AL, Marin M, Rodriguez-Hermosa JL, Gonzalez-Villaescusa C, Soriano JB, Signes-Costa J. Lung function and radiological findings 1 year after COVID-19: a prospective follow-up. *Respiratory Research*. 2022 Sep 12;23(1):242. doi: 10.1186/s12931-022-02166-8. PMID: 36096801. IF: 7,162
- Miravitles M, Turner AM, Torres-Duran M, Tanash H, Rodriguez-García C, López-Campos JL, Chlumsky J, Guimaraes C, Rodriguez-Hermosa JL, Corsico A, Martinez-González C, Hernández-Pérez JM, Bustamante A, Parr DG, Casas-Maldonado F, Hecimovic A, Janssens W, Lara B, Barrecheguren M, González C, Stolk J, Esquinas C, Clarenbach CF. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry. *Respiratory Research*. 2022 Dec 16;23(1):352. doi: 10.1186/s12931-022-02275-4. PMID: 36527073. IF: 7,162
- Safont B, Tarraso J, Rodriguez-Borja E, Fernandez-Fabrellas E, Sancho-Chust JN, Molina V, Lopez-Ramirez C, Lope-Martinez A, Cabanes L, Andreu A, Herrera S, Lahosa C, Ros JA, Rodriguez-Hermosa JL, Soriano JB, Moret-Tatay I, Carbonell-Asins JA, Mulet A, Signes-Costa J. Lung function, radiological findings and biomarkers of fibrogenesis in a cohort of COVID-19 patients six months after hospital discharge. *Archivos de Bronconeumología*. 2022 Feb;58(2):142-149. doi: 10.1016/j.arbres.2021.08.014. PMID: 34497426. IF: 6,333

# scientific activity

4

5. Panizo N, Albert E, Gimenez-Civera E, Puchades M, D'Marco L, Gandia-Salmeron L, Gimenez E, Torre I, Sancho A, Gavela E, Gonzalez-Rico M, Montomoli M, Perez-Baylach C, Bonilla B, Solano C, Alvarado M, Torregrosa I, Alcaraz M, Gorri J, Navarro D. Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within 3 months after COVID-19 full vaccination. *Clinical Kidney Journal.* 2022 Apr 9;15(8):1562-1573. doi: 10.1093/ckj/sfac093. PMID: 35880064. IF: 5,86

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Title:** GOLD O-DLCO 1. Una mirada más allá de la obstrucción. ¿Es suficiente la espirometría en el screening de EPOC?

**Principal Investigator:** Cruz González Villaescusa

**Funding body:** Sociedad Valenciana de Neumología (SVN)

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total Budget:** €12.000

**Title:** Estudio de los microRNAs circulantes como biomarcadores pronósticos en pacientes con déficit de alfa-1 antitripsina. Un enfoque funcional

**Principal Investigator:** Francisco Dasi Fernández (Jaime Signes-Costa as collaborating researcher)

**Funding body:** Sociedad Valenciana de Neumología (SVN)

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €6.000

**Title:** Impacto clínico asistencial de la creación de circuitos de derivación precoz en fibrosis pulmonar idiopática

**Principal Investigator:** Belén Safont Muñoz

**Funding body:** Sociedad Valenciana de Neumología (SVN)

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2025

**Total Budget:** €12.000

**Title:** Estudio de la aparición de cambios fibróticos pulmonares asociados a la infección por SARS-CoV-2

**Principal Investigator:** Jaime Signes-Costa Miñana and Julia Tarrasó Castillo

**Funding body:** Janssen-Cilag

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022

**Total Budget:** €8.500

**Reference:** ICI21/00016

**Title:** Terapia celular combinada para pacientes COVID-19 de alto riesgo de mortalidad (DECODE-19)

**Principal Investigator:** Bernat Soria Escoms (Mª Luisa Briones as collaborating researcher)

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2024

**Total budget:** €459.800

**Reference:** GVA-COVID19/2021/028

**Title:** Efecto de la infección por COVID-19 sobre la longitud del telómero y parámetros de función mitocondrial y su relación con la evolución a fibrosis pulmonar de tipo idiopático

**Principal Investigator:** Federico V. Pallardó Calatayud (Jaime Signes-Costa as collaborating researcher)

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital



**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2022


**Total budget:** €62.280

# scientific activity

## Research Group on Tissular Biochemistry Consolidated group



## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Garcia-Gimenez JL, Garcia-Trevijano ER, Aviles-Alia AI, Ibanez-Cabellos JS, Bovea-Marco M, Bas T, Pallardo FV, Vina JR, Zaragoza R. Identification of circulating miRNAs differentially expressed in patients with Limb-girdle, Duchenne or facioscapulohumeral muscular dystrophies. *Orphanet Journal of Rare Diseases.* 2022 Dec 27;17(1):450. doi: 10.1186/s13023-022-02603-3. PMID: 36575500. IF: 4,303
2. Ortiz-Zapater E, Signes-Costa J, Montero P, Roger I. Lung fibrosis and fibrosis in the lungs: is it all about myofibroblasts?. *Biomedicines.* 2022 Jun 15;10(6):1423. doi: 10.3390/biomedicines10061423. PMID: 35740444. IF: 4,757
3. Owczarek C, Ortiz-Zapater E, Kim J, Papaevangelou E, Santis G, Parsons M. CAR co-operates with integrins to promote lung cancer cell adhesion and invasion. *Frontiers in Oncology.* 2022 Feb 14;12:829313. doi: 10.3389/fonc.2022.829313. PMID: 35252000. IF: 5,738
4. Ortiz-Zapater E, Bagley DC, Hernandez VL, Roberts LB, Maguire TJA, Voss F, Mertins P, Kirchner M, Peset-Martin I, Woszczeck G, Rosenblatt J, Gotthardt M, Santis G, Parsons M. Epithelial coxsackievirus adenovirus receptor promotes house dust mite-induced lung inflammation. *Nature Communications.* 2022 Oct 27;13(1):6407. doi: 10.1038/s41467-022-33882-w. PMID: 36302767. IF: 17,694

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** CIPROM/2021/051

**Title:** Subvenciones concedidas del Programa Prometeo para grupos de investigación de excelencia

**Principal Investigator:** Elena Ruiz García-Trevijano and Juan Viña Ribes

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital



**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2022-2025

**Total Budget:** €240.238

# scientific activity

## Research Group on Aging and Physical Activity Consolidated group



## PUBLICATIONS



# scientific activity

4

## SELECTED PUBLICATIONS

1. Sanz-Ros J, Romero-Garcia N, Mas-Bargues C, Monleon D, Gordevicius J, Brooke RT, Dromant M, Diaz A, Derevyanko A, Guió-Carrion A, Roman-Dominguez A, Ingles M, Blasco MA, Horvath S, Vina J, Borras C. Small extracellular vesicles from young adipose-derived stem cells prevent frailty, improve health span, and decrease epigenetic age in old mice. *Science Advances*. 2022 Oct 21;8(42):eabq2226. doi: 10.1126/sciadv.abq2226. PMID: 36260670. IF: 14,957
2. Vina J, Escudero J, Baquero M, Cebrian M, Carbonell-Asins J, Munoz J, Satorres E, Melendez J, Ferrer-Rebolleda J, Cozar-Santiago M, Santabarbara-Gomez J, Jove M, Pamplona R, Tarazona-Santabalbina F, Borras C. Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial. *Alzheimers Research & Therapy*. 2022 Nov 4;14(1):164. doi: 10.1186/s13195-022-01097-2. PMID: 36329553. IF: 8,823
3. Mas-Bargues C, Borras C, Vina J. The multimodal action of genistein in Alzheimer's and other age-related diseases. *Free Radical Biology & Medicine*. 2022 Apr;183:127-137. doi: 10.1016/j.freeradbiomed.2022.03.021. PMID: 35346775. IF: 8,101
4. De la Rosa A, Olaso-Gonzalez G, Garcia-Dominguez E, Mastaloudis A, Hester S, Wood S, Gomez-Cabrera M, Vina J. Glucosamine supplementation improves physical performance in trained mice. *Medicine and Science in Sports and Exercise*. 2022 Mar 1;54(3):466-474. doi: 10.1249/MSS.0000000000002821. PMID: 34711707. IF: 6,289
5. Esteve D, Molina-Navarro MM, Giraldo E, Martínez-Varea N, Blanco-Gandia MC, Rodríguez-Arias M, García-Verdugo JM, Viña J, Lloret A. Adult neural stem cell migration is impaired in a mouse model of Alzheimer's disease. *Molecular Neurobiology*. 2022 Feb;59(2):1168-1182. doi: 10.1007/s12035-021-02620-6. PMID: 34894324. IF: 5,682

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** DIABFRAIL-LATAM-825546

**Title:** Scaling-up of and evidence-based intervention programme in older people with Diabetes and Frailty in LatinAmerica

**Principal Investigator:** José Viña Ribes and Leocadio Rodríguez Mañas

**Funding Body:** European Commission

**Beneficiary Institution:** CIBER (Fundación Investigación Hospital Clínico Universitario de Valencia as Third Party)

**Duration:** 2019-2024

**Total Budget:** €273.720

**Reference:** AC20/00026

**Title:** Combining vitamin E-functionalized CHOcolate with physical exercise to reduce the risk of protein energy malnutrition in pre-dementia AGEd people. ERA-HDHL Call for Joint Transnational Research Proposals on Development of targeted nutrition for prevention of undernutrition for older adults (PREVNUT)

**Principal Investigator:** José Viña Ribes

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2021-2023

**Total budget:** €169.098

**Reference:** CB16/10/00435

**Title:** Centro de Investigación Biomédica en Red en Fragilidad y Envejecimiento (CIBERfes)

**Principal Investigator:** José Viña Ribes

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2017-

**Reference:** PID2019-110906RB-100

**Title:** Nuevas intervenciones terapéuticas multidominio para retrasar la fragilidad y la discapacidad. Identificación de mecanismos moleculares con relevancia traslacional

**Principal Investigator:** José Viña Ribes and Consuelo Gómez Cabrera

**Funding Body:** Ministerio de Economía y Competitividad

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2023

**Total budget:** €270.000

**Reference:** PROMETEO/2019/097

**Title:** Diferencias de fragilidad entre géneros: evaluación de biomarcadores y estrategias de intervención

**Principal Investigator:** José Viña Ribes

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2023

**Total budget:** €189.391

# 4 scientific activity

## THESIS

**Thesis title:** *Papel de la xantina oxidasa en la pérdida de masa muscular por inmovilización en humanos. Importancia del protocolo de obtención de biopsias musculares en los estudios de atrofia muscular*

**Doctoral candidate:** Vicente Sebastiá Alcàcer

**Director(s):** M<sup>a</sup> Carmen Gómez Cabrera, José Viña Ribes, Enrique Viosca Herrero

**Date of the defense:** 28/06/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** *Intervención con ejercicio físico multicomponente sobre el adulto mayor frágil en la vida real* (Real Life Intervention)

**Doctoral candidate:** Fernando Millán Domingo

**Director(s):** José Viña Ribes, María Carmen Gómez Cabrera, Francisco José Tarazona Santabalbina

**Date of the defense:** 01/07/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group on Anesthesiology and Reanimation Consolidated group


Group members	Researchers by categories
<b>Leading Researcher, R4</b> Rafael Badenes Quiles Hospital. University	<b>R1</b> 1 <b>R2</b> 7 <b>R3</b> 4 <b>R4</b> 1 <b>STAFF</b> 15
<b>Established Researchers, R3</b> Armando Maruenda Paulino. Hospital Carlos Tornero Tornero. Hospital. University Gerardo Aguilar Aguilar. Hospital. University Marina Soro Domingo. University	Cristina Crisán Ovidiu. Hospital Ernesto Pastor Martínez. Hospital Estefanía Gracia Ferrández. Hospital José Antonio Carbonell López. Hospital Laura Reviriego Agudo. Hospital Liliana Patricia Henao Guerrero. Hospital Luis Robert Sánchez. Hospital María José Parra González. Hospital María Luisa Laredo Alcázar. Hospital Mario de Fez Barberá. Hospital Paola Valls Montero. Hospital
<b>Recognised Researchers, R2</b> Ana Mugarra Llopis. Hospital Andrea Gutiérrez Valcárcel. Hospital. University Benigno Escamilla Cañete. Hospital Jorge Orduña Valls. Hospital Mar Garzando Civera. Hospital María Luisa García Pérez. Hospital. University Rosa Herrera Castro. Hospital	<b>Staff. Nurse</b> Alicia García Vigara. INCLIVA <b>Staff. Administrative assistants</b> Laura Verdini Martínez. INCLIVA Nuria Bargues Martín. INCLIVA
<b>First Stage Researcher, R1</b> Blanca Arocas Chicote. Hospital	
<b>Staff. Collaborating Researchers</b> Antonio Guillén Bañuelos. Hospital	

<b>Strategic aims</b>
<ul style="list-style-type: none"> <li>• Open lung approach for respiratory management</li> <li>• Management of chronic pain</li> <li>• Performance analysis of homecare and ICU ventilators [bench model]</li> <li>• Respiratory management in ARDS COVID19 patients</li> <li>• Controlled donation after circulatory determination of death with the use of normothermic regional perfusion</li> <li>• Determination of death by neurological criteria</li> <li>• Prevalence and risk factors for delirium</li> <li>• Advance neuromonitoring neurocritical care patients</li> <li>• COVID 19 (SARS-CoV-2) ICU management</li> </ul>
<b>Main lines of research</b>
<ul style="list-style-type: none"> <li>• Development of new strategies and drugs for pain treatment</li> <li>• Organ donation and transplantation</li> <li>• Delirium critically ill patients</li> <li>• Severe Traumatic Brain Injury</li> </ul>

# scientific activity

- COVID 19 (SARS-CoV-2) critically ill patients
- Retrospective analysis of COVID19 patients management

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. NIHR Global Health Unit on Global Surgery; COVIDSurg Collaborative. Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries. *Lancet.* 2022 Nov 5;400(10363):1607-1617. doi: 10.1016/S0140-6736(22)01846-3. PMID: 36328042. IF: 202,731
2. Cinotti R, Mijangos JC, Pelosi P, Haenggi M, Gurjar M, Schultz MJ, Kaye C, Godoy DA, Alvarez P, Ioakeimidou A, Ueno Y, Badenes R, Elbuzidi AAS, Piagnerelli M, Elhadi M, Reza ST, Azab MA, McCredie V, Stevens RD, Digitale JC, Fong N, Asehnoune K. Extubation in neurocritical care patients: the ENIO international prospective study. *Intensive Care Medicine.* 2022 Nov;48(11):1539-1550. doi: 10.1007/s00134-022-06825-8. PMID: 36038713. IF: 41,787
3. Young PJ, Eastwood G, Chew MS, Unden J, Thomas M, Joannidis M, Nichol A, Lundin A, Hollenberg J, Hammond N, Saxena M, Annborn M, Solar M, Taccone FS, Dankiewicz J, Nielsen N, Pelosi P, TTM2 Trial Collaborators. Ventilatory settings in the initial 72 h and their association with outcome in out-of-hospital cardiac arrest patients: a preplanned secondary analysis of the targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest (TTM2) trial. *Intensive Care Medicine.* 2022 Aug;48(8):1024-1038. doi: 10.1007/s00134-022-06756-4. PMID: 35780195. IF: 41,787
4. Rasulo F, Calza S, Robba C, Taccone F, Biasucci D, Badenes R, Piva S, Savo D, Citerio G, Dibu J, Curto F, Merciadri M, Gritti P, Fassini P, Park S, Lamperti M, Bouzat P, Malacarne P, Chieregato A, Bertuetti R, Aspide R, Cantoni A, McCredie V, Quadrini L, Latronico N. Transcranial Doppler as a screening test to exclude intracranial hypertension in brain-injured patients: the IMPRESSIT-2 prospective multicenter international study. *Critical Care.* 2022 Apr 15;26(1):110. doi: 10.1186/s13054-022-03978-2. PMID: 35428353. IF: 19,334
5. Robba C, Badenes R, Battaglini D, Ball L, Sanfilippo F, Brunetti I, Jakobsen JC, Lilja G, Friberg H, Wendel-Garcia PD, Young

PJ, Eastwood G, Chew MS, Unden J, Thomas M, Joannidis M, Nichol A, Lundin A, Hollenberg J, Hammond N, Saxena M, Martin A, Solar M, Taccone FS, Dankiewicz J, Nielsen N, Grejs AM, Ebner F, Pelosi P; TTM2 Trial collaborators. Oxygen targets and 6-month outcome after out of hospital cardiac arrest: a pre-planned sub-analysis of the targeted hypothermia versus targeted normothermia after Out-of-Hospital Cardiac Arrest [TTM2] trial. *Critical Care.* 2022 Oct 21;26(1):323. doi: 10.1186/s13054-022-04186-8. PMID: 36271410. IF: 19,334

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI19/00141

**Title:** Modelos de estratificación y predicción en pacientes con insuficiencia respiratoria aguda hipoxémica con técnicas de inteligencia artificial y aprendizaje automático

**Principal Investigator:** Jesús Villar Hernández (Marina Soro as collaborating researcher)

**Funding body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Doctor Negrín

**Duration:** 2020-2022

**Total budget:** €62.920

**Title:** Ensayo clínico randomizado: hemoabsorción con cytosorb vs práctica clínica habitual para analizar su efecto sobre biomarcadores de daño renal en la donación en asistolia controlada con ECMO

**Principal Investigator:** Rafael Badenes Quiles

**Entidad financiadora:** Fundación Mutua Madrileña



**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €65.000


# scientific activity

## Research Group on Translational Genomics Consolidated group



# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Januel C, Menduti G, Mamchaoui K, Martinat C, Artero R, Konieczny P, Boido M. Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model. *Cellular and Molecular Life Sciences*. 2022 Jul 22;79(8):441. doi: 10.1007/s00018-022-04450-8. PMID: 35864358. IF: 9,207
- Espinosa-Espinosa J, Gonzalez-Barriga A, Lopez-Castel A, Artero R. Deciphering the complex molecular pathogenesis of myotonic dystrophy type 1 through omics studies. *International Journal of Molecular Sciences*. 2022 Jan 27;23(3):1441. doi: 10.3390/ijms23031441. PMID: 35163365. IF: 6,208
- Overby SJ, Cerro Herreros E, Gonzalez Martinez I, Varela MA, Seoane Miraz D, Jad Y, Raz R, Moller T, Perez Alonso M, Wood MJ, Llamusi B, Artero R. Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model. *Molecular Therapy. Nucleic Acids*. 2022 Feb 10;27:1146-1155. doi: 10.1016/j.omtn.2022.02.003. PMID: 35282418. IF: 10,183

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €141.570

**Reference:** PI19/01796

**Title:** Implicaciones experimentales y clínicas del complejo proteico Rabphilin-Rab en daño renal en la diabetes mellitus tipo 2

**Principal Investigator:** Josep Redón i Mas [Arturo López Castel as collaborating researcher]

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2023

**Total budget:** €196.020

**Reference:** DTS21/00081

**Title:** Desarrollo preclínico de Gapmers contra una nueva diana terapéutica en Distrofia Miotónica

**Principal Investigator:** Manuel Pérez Alonso

**Funding Body:** Instituto de Salud Carlos III - Cofinanced FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2023

**Total budget:** €127.600

**Reference:** DTS19/00128

**Title:** Desarrollo preclínico de un fármaco innovador para Distrofia Miotónica

**Principal Investigator:** Rubén Artero Allepuz

**Funding Body:** Instituto de Salud Carlos III - Cofinanced FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €111.100

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** CA17103 COST-DARTER

**Title:** COST: European Cooperation in Science and Technology, Delivery of Antisense RNA Therapeutics (DARTER)

**Principal Investigator:** Virginia Arechavala [Rubén Artero Allepuz as Co-IP]

**Funding Body:** European Commission

**Beneficiary Institution:** Instituto de Investigación Sanitaria Biocruces

**Duration:** 2018-2022

**Total Budget:** €500.000

**Reference:** PI21/00311

**Title:** Caracterización de una nueva diana terapéutica en disfunción muscular en la distrofia miotónica de tipo 1

**Principal Investigator:** Manuel Pérez Alonso

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

# scientific activity

4

**Reference:** MRR/PDC2022-133103-100

**Title:** Desarrollo preclínico de un fármaco Gapmer para tratar distrofia miotónica y otras atrofias musculares

**Principal Investigator:** Rubén Artero Allepuz

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2022-2024

**Total budget:** €149.500

**Reference:** PID2021-1259780B-C22

**Title:** Comprensión de la atrofia muscular inducida por TNPO3 mutante: modelos preclínicos y aproximaciones terapéuticas en LGMDD2

**Principal Investigator:** Rubén Artero Allepuz

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2022-2025

**Total budget:** €242.000

**Reference:** PLEC2022-009367

**Title:** Nuevas herramientas en moscas y cultivos en 3D para el desarrollo de oligonucleótidos terapéuticos

**Principal Investigator:** Arturo López Castel

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2022-2024

**Total budget:** €46.000

**Reference:** EIN2020-112137

**Title:** Del RNA tóxico a la medicina traslacional en Distrofia Miotónica (para la captación de recursos UE)

**Principal Investigator:** Rubén Artero Allepuz

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2022-2022

**Total budget:** €15.000

**Reference:** INNVA1/2021/44

**Title:** Reposicionamiento de un fármaco para atrofia muscular espinal

**Principal Investigator:** Rubén Artero Allepuz

**Funding Body:** Agencia Valenciana de la Innovación-AVI Generalitat Valenciana

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2021-2023

**Total budget:** €487.727

**Reference:** INVEST/2022/63

**Title:** Especialización en fenotipado y caracterización molecular de modelos biomédicos murinos

**Principal Investigator:** Rubén Artero Allepuz

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €44.812

**Reference:** INVEST/2022/81

**Title:** Utilización de *Drosophila melanogaster* en el desarrollo de oligonucleótidos antisentido como medicamentos

**Principal Investigator:** Arturo López Castell

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €66.217,84

**Reference:** PROMETEO/2020/081

**Title:** Uso de moduladores de microRNAs como terapias experimentales en distrofia miotónica de tipo 1

**Principal Investigator:** Rubén Artero Allepuz

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020 - 2023

**Total budget:** €193.051

**Reference:** CI21-00135

**Title:** Valorization of the repurposing of two drug candidates for spinal muscular atrophy

**Principal Investigator:** Rubén Artero Allepuz

**Funding Body:** Fundació Bancària La Caixa

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2021-2023

**Total budget:** €100.000

**Reference:** PI-2021-008

**Title:** miR-OA: Inhibidores de miRNAs como terapia en osteoartritis

**Principal Investigator:** Rubén Artero Allepuz

**Funding Body:** Universidad de Valencia - INCLIVA

**Beneficiary Institution:** Universidad de Valencia - INCLIVA

# 4 scientific activity

**Duration:** 2021-2022

**Total budget:** €19.000

## THESIS

**Thesis title:** Proof of concept of therapeutic gene modulation of MBNL1/2 in myotonic dystrophy

**Doctoral candidate:** Sarah Overby

**Director(s):** Rubén Artero Allepuz

**Date of the defense:** 21/01/2022

**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD

**Thesis title:** Ruta de la autofagia, MSI2 Y MIR-7 como nuevas dianas terapéuticas para la disfunción muscular en distrofia miotónica de tipo 1

**Doctoral candidate:** María Sabater Arcís

**Director(s):** Rubén Artero Allepuz, Ariadna Bargiela Schönbrunn

**Date of the defense:** 01/04/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity


## Research Group on General and Digestive Surgery Consolidated group

Group members	Researchers by categories
<b>Leading Researcher, R4</b> Joaquín Ortega Serrano Hospital. University	R1 5
<b>Established Researchers, R3</b> Alejandro Espí Macías. Hospital. University Luis Sabater Ortí. Hospital. University	R2 12
<b>Recognised Researchers, R2</b> David Casado Rodrigo. Hospital David Moro Valdezate. Hospital Dimitri Dorcaratto. Hospital. University Elena Muñoz Forner. Hospital. University Estefanía García Botello. Hospital. University Fernando López Mozos. Hospital. University José Martín Arévalo. Hospital. University Marina Garcés Albir. Hospital. University Norberto Cassinello Fernández. Hospital. University Raquel Alfonso Ballester. Hospital Roberto Martí Obiol. Hospital Vicente Pla Martín. Hospital	R3 2
	R4 1
	STAFF 6
	<b>First Stage Researchers, R1</b> Carlos León Espinoza. Hospital Isabel Mora Oliver. Hospital María Lapeña Rodríguez. Hospital Leticia Pérez Santiago. INCLIVA Mª Carmen Fernández Moreno. Hospital
	<b>Staff. Collaborating Researchers</b> Elena Martí Cuñat. Hospital Guillermo Pou Santonja. Hospital Marcos Adriánzén Vargas. Hospital María Eugenia Barrios Carvajal. Hospital Rosa Martí Fernández. Hospital Vicente López Flor. Hospital

<b>Strategic aims</b>
<ul style="list-style-type: none"> <li>• Development of a diagnostic algorithm with endoscopy in endocrine and metabolic surgery</li> <li>• Development of 3D modelling for hepatic, pancreatic and colorectal tumours</li> <li>• Research about the influence of postoperative complications on the oncologic outcome of metastatic disease</li> <li>• Development of a new efficient protocol for the diagnosis of hyperparathyroidism</li> <li>• Treatment of perianal fistulae with stem cells</li> <li>• Development of a new organ preservation system for transplantation</li> </ul>
<b>Main lines of research</b>
<ul style="list-style-type: none"> <li>• Coloproctology: quality standards for coloproctology, 3D endorectal ultrasound, perianal fistula surgery, stem cells in proctology</li> <li>• Hepato-bilio-pancreatic surgery: sarcopenia in postoperative outcomes, 3D imaging in HBP surgery, organ preservation for hepatic transplantation</li> <li>• Endocrine surgery: PET-Coline in HPT, ambulatory surgery in HPT, digestive endoscopy in the Surgery office</li> <li>• Bariatric surgery: biliary reflux after BAGUA</li> <li>• Breast surgery: breast endoscopic surgery. Selective sentinel node biopsy. Axilla assessment in DCIS</li> <li>• Gastroesophageal surgery: perioperative QT in advanced gastric cancer, PIPAC technique in advanced carcinomatosis surgery</li> </ul>

# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Garcia-Botello S, Fernandez R, Lozano C, Salher S, Martin-Arevalo J, Moro-Valdezate D, Pla-Martí V, Espí-Macías A. Concordance and survival implications of preoperative subclassification of T3 rectal cancers by depth of mesorectal invasion using a 5-mm cut-off point with endorectal ultrasound and magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery. 2022 Apr;12(4):2356-2367. doi: 10.21037/qims-21-880. PMID: 35371947. IF: 4,63
2. Di Martino M, Primavesi F, Syn N, Dorcaratto D, de la Hoz Rodriguez A, Dupre A, Piardi T, Rhaiem R, Blanco Fernandez G, de Armas Conde N, Rodriguez Sanjuan J, Fernandez Santiago R, Fernandez-Moreno M, Ferret G, Lopez Ben S, Suarez Munoz M, Perez-Alonso A, Koh Y, Jones R, Martin-Perez E. Long-term outcomes of perioperative versus neoadjuvant chemotherapy for resectable colorectal liver metastases: an international multicentre propensity-score matched analysis with stratification by contemporary risk-scoring. Annals of Surgical Oncology. 2022 Oct;29(11):6829-6842. doi: 10.1245/s10434-022-12027-9. PMID: 35849284. IF: 4,339
3. Garcia-Fadrique A, Estevan Estevan R, Sabater Ortí L. Quality standards for surgery of colorectal peritoneal metastasis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Annals of Surgical Oncology. 2022 Jan;29(1):188-202. doi: 10.1245/s10434-021-10642-6. PMID: 34435297. IF: 4,339
4. Garcia-Botello S, Martín-Arévalo J, Martí-Fernández R, Moro-Valdezate D, Pla-Martí V, Espí-Macías A. Three-dimensional endoanal ultrasound to assess the validity of Goodsall's Rule and the Midline Rule in predicting the path of perianal fistula-in-ano and the location of the internal opening. Techniques in Coloproctology. 2022 May;26(5):351-361. doi: 10.1007/s10151-022-02592-2. PMID: 35217938. IF: 3,699
5. Castro A, Cassinello N, Alfonso R, Ortega J. Preoperative risk factors for early hemorrhagic complications in bariatric surgery: a case-control study. Surgical Endoscopy. 2022 Jan;36(1):430-434. doi: 10.1007/s00464-021-08302-7. PMID: 33523271. IF: 3,453

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI19/00250

**Title:** *Anastomosis pancreática tras duodenopancreatectomía cefálica: pancreatogastrostomía versus anastomosis de Blumgart. Estudio prospectivo, aleatorizado y multicéntrico*

**Principal Investigator:** Luis Sabater Ortí

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total Budget:** €85.910

**Reference:** PI20/00008

**Title:** *Transección pancreática asistida por radiofrecuencia vs endograpadora. TRANSPAIRe. Ensayo clínico en fase III*

**Principal Investigator:** Patricia Sánchez Velázquez [Dimitri Dorcaratto, Marina Garcés, Elena Muñoz and Luis Sabater as collaborating researchers]

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Instituto Hospital del Mar de Investigaciones Médicas. IMIM

**Duration:** 2021-2023

**Total Budget:** €75.020

**Title:** Proyecto RENACI

**Principal Investigator:** Mario Serradilla Martín [Luis Sabater Ortí as collaborating researcher]



**Funding Body:** Asociación Española de Cirujanos

**Beneficiary institution:** Hospital Universitario Miguel Servet de Zaragoza

**Duration:** 2020-2022


# scientific activity

## Research Group on Personal Autonomy, Dependence and Severe Mental Disorders (TMAP) Consolidated group



# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Sanchez-Orti J, Balanza-Martinez V, Correa-Ghisays P, Selva-Vera G, Vila-Frances J, Magdalena-Benedito R, San-Martin C, Victor V, Escribano-Lopez I, Hernandez-Mijares A, Vivas-Lalinde J, Crespo-Facorro B, Tabares-Seisdedos R. Specific metabolic syndrome components predict cognition and social functioning in people with type 2 diabetes mellitus and severe mental disorders. *Acta Psychiatrica Scandinavica*. 2022 Sep;146(3):215-226. doi: 10.1111/acps.13433. PMID: 35359023. IF: 7,734
2. Correa-Ghisays P, Vicent Sanchez-Orti J, Balanza-Martinez V, Fuentes-Dura I, Martinez-Aran A, Ruiz-Bolo L, Correa-Estrada P, Ruiz-Ruiz J, Selva-Vera G, Vila-Frances J, Macias Saint-Gerons D, San-Martin C, Ayesa-Arriola R, Tabares-Seisdedos R. MICEmi: a method to identify cognitive endophenotypes of mental illnesses. *European Psychiatry*. 2022 Nov 28;65(1):e85. doi: 10.1192/j.eurpsy.2022.2348. PMID: 36440538. IF: 7,156
3. Correa-Ghisays P, Sanchez-Orti JV, Balanza-Martinez V, Selva-Vera G, Vila-Frances J, Magdalena-Benedito R, Victor VM, Escribano-Lopez I, Hernandez-Mijares A, Vivas-Lalinde J, San-Martin C, Crespo-Facorro B, Tabares-Seisdedos R. Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: a 1-year follow-up study. *Journal of Affective Disorders*. 2022 Mar 1;300:99-108. doi: 10.1016/j.jad.2021.12.074. PMID: 34965401. IF: 6,533
4. San Martin Valenzuela C, Duenas L, Tomas J, Correa-Ghisays P, Serra-Ano P. Relevance of sociodemographics and clinical tests in single- and dual-task conditions as gait speed predictors of Parkinson's disease. *Journal of Clinical Medicine*. 2022 Jan 30;11(3):757. doi: 10.3390/jcm11030757. PMID: 35160208. IF: 4,964
5. Gares-Caballer M, Sanchez-Orti J, Correa-Ghisays P, Balanza-Martinez V, Selva-Vera G, Vila-Frances J, Magdalena-Benedito R, San-Martin C, Victor V, Escribano-Lopez I, Hernandez-Mijares A, Vivas-Lalinde J, Vieta E, Leza J, Tabares-Seisdedos R. Immune-inflammatory biomarkers predict cognition and social functioning in patients with Type 2 Diabetes Mellitus, major depressive disorder, bipolar disorder, and schizophrenia: a 1-year follow-up study. *Frontiers in Neurology*. 2022 Jun 2;13:883927. doi: 10.3389/fneur.2022.883927. PMID: 35720107. IF: 4,086

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PID2021-1290990B-100

**Title:** *MULTImorbilidad en personas con trastornos del Sistema Nervioso Central: una prioridad para la salud global desde los registros médicos*

**Principal Investigator:** Rafael Tabarés Seisdedos

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €104.060

**Reference:** PI20/00066

**Title:** *Adaptación y validación de la batería cognitiva Brief Assessment of Cognition App (BAC App) y del Virtual Reality Assessment of Functional Capacity Tool (VRFCAT) para su uso en España*

**Principal Investigator:** Rosa Ayesa Arriola [Patricia Correa as collaborating researcher]

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL)

**Duration:** 2021-2023

**Total budget:** €87.120

**Reference:** CB07/09/0021

**Title:** *Centro de Investigación Biomédica en Enfermedades Mentales (CIBERSam)*

**Principal Investigator:** Rafael Tabarés Seisdedos

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** CIBERSAM

**Duration:** 2015-

# scientific activity

4

**Reference:** UV-INV-AE-1554362

**Title:** *Estigma social hacia personas con diagnóstico de esquizofrenia en estudiantes universitarios: PREVAL*

**Principal Investigator:** Rafael Tabarés Seisdedos

**Funding Body:** Universidad de Valencia

**Beneficiary institution:** Universidad de Valencia

**Duration:** 2021-2022

**Total budget:** €7.510

**Title:** Drug safety and effectiveness network methods and applications group in indirect comparisons (DSEN MAGIC) Team

**Principal Investigator:** Hutton B, Moher D, Straus SE, Wells G  
(Ferrán Catalá as collaborating researcher)

**Funding Body:** Canadian Institutes of Health Research/Drug Safety and Effectiveness Network

**Beneficiary institution:** CIBERSAM

**Duration:** 2019-2023

**Total budget:** €2.875.010,8

**Title:** Methods and Applications Group for Indirect Comparisons Collaborating Centre

**Principal Investigator:** Hutton B, Moher D, Straus SE, Wells G  
(Ferrán Catalá as collaborating researcher)

**Funding Body:** Canadian Institutes of Health Research/Drug Safety and Effectiveness Network



**Beneficiary institution:** Universidad de Valencia

**Duration:** 2019-2023

**Total budget:** €2.875.010,8

# scientific activity

## Research Group on Cellular and Organic Physiopathology of Oxidative Stress Consolidated group



# scientific activity

4

## Emerging Researcher

Juan Antonio Navarro Langa

Our scientific interests are focused on deciphering the programmed death mechanism followed by cells in Friedreich´s Ataxia patients using *Drosophila melanogaster* models. With Filippo Santorelli (University of Pisa), he is establishing a translational platform using *Drosophila* to model hereditary spastic paraplegia

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Rodríguez LR, Lapeña-Luzón T, Benetó N, Beltran-Beltran V, Pallardó FV, Gonzalez-Cabo P, Navarro JA. Therapeutic strategies targeting mitochondrial calcium signaling: a new hope for neurological diseases?. *Antioxidants*. 2022 Jan 15;11(1):165. doi: 10.3390/antiox11010165. PMID: 35052668. IF: 7,675
2. Osca-Verdegal R, Beltran-Garcia J, Paes A, Nacher-Sendra E, Novella S, Hermenegildo C, Carbonell N, Garcia-Gimenez J, Pallardo F. Histone citrullination mediates a protective role in endothelium and modulates inflammation. *Cells*. 2022 Dec 15;11(24):4070. doi: 10.3390/cells11244070. PMID: 36552833. IF: 7,666
3. Fatmi A, Chabni N, Cernada M, Vento M, González-López M, Aribi M, Pallardó FV, García-Giménez JL. Clinical and immunological aspects of microRNAs in neonatal sepsis. *Biomedicine & Pharmacotherapy*. 2022 Jan;145:112444. doi: 10.1016/j.bioph.2021.112444. PMID: 34808550. IF: 7,419
4. Saadi W, Fatmi A, Pallardo FV, García-Giménez JL, Mena-Molla S. Long non-coding RNAs as epigenetic regulators of immune checkpoints in cancer immunity. *Cancers*. 2022 Dec 28;15(1):184. doi: 10.3390/cancers15010184. PMID: 36612180. IF: 6,575
5. Muñoz-Lasso DC, Mollá B, Sáenz-Gamboa JJ, Insuasty E, de la Iglesia-Vaya M, Pook MA, Pallardó FV, Palau F, Gonzalez-Cabo P. Frataxin deficit leads to reduced dynamics of growth cones in dorsal root ganglia neurons of Friedreich's Ataxia YG8sR model: a multilinear algebra approach. *Frontiers in Molecular Neuroscience*. 2022 Jun 13;15:912780. doi: 10.3389/fnmol.2022.912780. PMID: 35769335. IF: 6,261

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** IFEQ22/00178

**Title:** Sistema de espectrometría de masas acoplado a un sistema de cromatografía líquida de alta precisión

**Principal Investigator:** Federico V. Pallardó Calatayud

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022

**Total budget:** €300.000

**Reference:** DTS21/00193

**Title:** Test basados en péptidos spike-in y espectrometría de masas para la cuantificación de histonas circulantes y proteína APC, para el manejo clínico del paciente crítico

**Principal Investigator:** Jose Luis García Giménez (Federico V. Pallardó Calatayud as collaborating researcher)

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2023

**Total budget:** €122.100

**Reference:** PI19/01084

**Title:** Nuevas terapias en Ataxia de Friedreich

**Principal Investigator:** Federico V. Pallardó Calatayud

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

# scientific activity

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia  
**Duration:** 2020-2022  
**Total budget:** €93.170

**Reference:** CB06/07/0073  
**Title:** Centro de Investigación Biomédica en Enfermedades Raras [CIBERer]  
**Principal Investigator:** Federico V. Pallardó Calatayud  
**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER  
**Beneficiary institution:** Universidad de Valencia  
**Duration:** 2007-

**Reference:** PID2020-119127RA-I00  
**Title:** Citotoxicidad mediada por macromoléculas nucleares: mecanismos moleculares y potencial para el desarrollo de biomarcadores de sepsis y choque séptico  
**Principal Investigator:** Carlos Romá Mateo  
**Funding Body:** Ministerio de Ciencia e Innovación  
**Beneficiary Institution:** Universidad de Valencia  
**Duration:** 2021-2024  
**Total budget:** €121.000

**Reference:** RTC2019-006825-1  
**Title:** Potencial de la leriglitazona para el tratamiento de enfermedades asociadas a la acumulación de hierro, distrofias y enfermedades neuromusculares  
**Principal Investigator:** Pilar González Cabo (Federico V. Pallardó Calatayud as collaborating researcher)  
**Funding Body:** Ministerio de Ciencia e Innovación  
**Beneficiary institution:** Minoryx Therapeutic SL  
**Duration:** 2020-2023  
**Total budget:** €90.000

**Title:** GVA-COVID19/2021/028  
**Title:** Efecto de la infección por COVID-19 sobre la longitud del telómero y parámetros de función mitocondrial y su relación con la evolución a fibrosis pulmonar de tipo idiopático  
**Principal Investigator:** Federico V. Pallardó Calatayud  
**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital  
**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia  
**Duration:** 2021-2022  
**Total budget:** €62.280

**Title:** CDEI-04/20-C  
**Title:** Drosophila melanogaster as model to study the impact of ferroptosis in Friedreich's Ataxia

**Principal Investigator:** Juan Antonio Navarro  
**Funding Body:** Conselleria de Sanidad Universal y Salud Pública  
**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia  
**Duration:** 2020-2023  
**Total budget:** €246.500

**Reference:** 90/C/2020  
**Title:** Therapeutical strategies for cystinuria  
**Principal Investigator:** Federico V. Pallardó Calatayud  
**Funding Body:** Marató TV3  
**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia  
**Duration:** 2021-2023  
**Total budget:** €35.580

**Reference:** AP-2021-009  
**Title:** NATAX: Nanozimas como aproximación terapéutica para el tratamiento del estrés oxidativo en la Ataxia de Friedreich  
**Principal Investigator:** José Vicente Ros Lis and Federico V. Pallardó Calatayud  
**Funding Body:** Universidad de Valencia - INCLIVA  
**Beneficiary Institution:** Universidad de Valencia - INCLIVA  
**Duration:** 2021-2022  
**Total budget:** €4.750

**Reference:** AP-2021-014  
**Title:** FlyAvatar: Drosophila melanogaster como herramienta de diagnóstico molecular para la Paraparesia Espástica Hereditaria 7 [HSP7]  
**Principal Investigator:** Mª José Martínez Sebastián and Juan Antonio Navarro Langa

**Funding Body:** Universidad de Valencia - INCLIVA  
**Beneficiary Institution:** Universidad de Valencia - INCLIVA  
**Duration:** 2021-2022  
**Total budget:** €4.750

**Reference:** AP-2021-019  
**Title:** HISTONATTR: Efecto de la activación de TLR por medio de sus ligandos sobre la polarización de macrófagos hacia M1 y su función citocida frente a las células madre de glioblastoma  
**Principal Investigator:** Carlos Romá Mateo and Enrique Santas Olmeda

# scientific activity

4

**Funding Body:** Universidad de Valencia - INCLIVA  
**Beneficiary Institution:** Universidad de Valencia - INCLIVA  
**Duration:** 2021-2022  
**Total budget:** €4.750

**Reference:** 2021095290  
**Title:** Intracellular iron deposits in a Drosophila Model of Friedreich´s Ataxia  
**Principal Investigator:** Juan Antonio Navarro  
**Funding Body:** Center of Excellence ALBA Synchrotron  
**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia  
**Duration:** 2022  
**Total budget:** €51.471,36

## THESIS

**Thesis title:** *Uso de las histonas circulantes y sus modificaciones post-traduccionales como biomarcadores en sepsis y shock séptico*  
**Doctoral candidate:** Jesús Beltrán García  
**Director(s):** José Luis García Giménez, Federico Pallardó Calatayud  
**Date of the defense:** 20/01/2022  
**Grade:** Sobresaliente “cum laude”  
**Quality recognition/Award:** European PhD

# scientific activity

## Research Group on Nuclear Receptors in Cardiometabolic Pathology Emerging group



### Strategic aims

- Identification of new mechanisms involved in angiogenesis and inflammation in obese patients:
  - Study and characterization of the role of the CCR4 receptor and its ligands CCL17/TARCE, CCL22/MDC and CKLF1 in angiogenesis and inflammation associated with obesity and in response to bariatric surgery
  - Characterization of the role of constitutive nuclear receptors for androstane (CAR) in endothelial dysfunction and angiogenesis associated with obesity and in response to bariatric surgery
- Identification of new mechanisms involved in angiogenesis and inflammation in acute myocardial infarction. Role of the antiangiogenic isoform VEGF165b:
  - Determination of VEGF-A165b levels in patients with STEMI and its relationship with microvascular obstruction
  - To study the effects of the neutralization of the VEGF-165b isoform in a mouse model with acute myocardial infarction
- Study of the role of the SGLT2 transporter in the development of abdominal aortic aneurysm:
  - To evaluate the effect of empagliflozin, an SGLT2 inhibitor, in an animal model of abdominal aortic aneurysm and to investigate the possible anti-inflammatory effect of empagliflozin on endothelial dysfunction

### Main lines of research

- Identification of new mechanisms involved in angiogenesis and inflammation in obese patients. Role of CCR4 chemokine receptor ligands and constitutive nuclear androstane receptors
- Identification of new mechanisms involved in angiogenesis and inflammation in acute myocardial infarction. Role of the antiangiogenic isoform VEGF165b
- Study of the SGLT2 transporter in the development of abdominal aortic aneurysm

### PUBLICATIONS



# scientific activity

## SELECTED PUBLICATIONS

1. Marques P, Domingo E, Rubio A, Martínez-Hervás S, Ascaso JF, Piqueras L, Real JT, Sanz MJ. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. *Biomedicine & Pharmacotherapy*. 2022 Jan;145:112460. doi: 10.1016/j.biopha.2021.112460. PMID: 34864314. IF: 7,419
2. Moreno B, Hueso L, Ortega R, Benito E, Martínez Hervás S, Peiro M, Civera M, Sanz MJ, Piqueras L, Real JT. Association of chemokines IP-10/CXCL10 and ILTAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity. *Microvascular Research*. 2022 Jan;139:104254. doi: 10.1016/j.mvr.2021.104254. PMID: 34534571. IF: 3,75

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI21/00220

**Title:** Estudio de nuevos ejes de quimiocinas como potenciales dianas de intervención en la obesidad y la resistencia a la insulina

**Principal Investigator:** Laura Piqueras Ruiz and José Tomás Real Collado

**Funding body:** Instituto de Salud Carlos III - Cofinanciado FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duración:** 2022-2024

**Presupuesto total:** €204.490

**Reference:** PI18/00209

**Title:** Identificación de nuevos mecanismos implicados en la angiogénesis e inflamación en pacientes obesos. Modulación por ligandos de receptores nucleares constitutivos de androstano

**Principal Investigator:** Laura Piqueras Ruiz and José Tomás Real Collado

**Funding body:** Instituto de Salud Carlos III - Cofinanciado FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duración:** 2019-2022

**Presupuesto total:** €173.332,5

**Reference:** CDEI-04/20-A

**Title:** Plan GenT

**Principal Investigator:** Laura Piqueras Ruiz

**Funding body:** Conselleria de Sanitat

**Beneficiary institution:** Fundación Investigación Hospital Clínico

Universitario de Valencia

**Duración:** 2020-2023

**Presupuesto total:** €253.000

## THESIS

**Thesis title:** Effect of SGLT-2 inhibition in abdominal aortic aneurysm development. Role of rora in adipose tissue inflammation associated to obesity

**Doctoral candidate:** Rebeca Ortega Herráiz

**Director(s):** Laura Piqueras Ruiz, María Jesús Sanz Ferrando, José Tomás Real Collado

**Date of the defense:** 21/02/2022

**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD

# scientific activity

## Research Group on Metabolic Diseases Emerging group

### Group members

#### Leading Researcher, R4

Herminia González Navarro

INCLIVA. University

#### Recognised Researchers, R2

Alida Taberner Cortés. INCLIVA

Elena Jiménez Martí. University

#### First Stage Researchers, R1

Gema Hurtado Genovés. INCLIVA

María Aguilar Ballester. INCLIVA

Susana Martín Vañó. INCLIVA

#### Staff. Technicians

Andrea Herrero Cervera. INCLIVA

Marta Ruiz Piquer. INCLIVA

Pablo Arjona Fernández-Sanabria. INCLIVA

### Researchers by categories



Researchers financed by competitive public calls or networks



### Strategic aims

- Study of the effect of inflammatory mediators of the lymphotoxin family and their receptors on the development of metabolic associated fatty liver disease
- Study of the cytokine LIGHT in the stability of the plaque during the progression of atherosclerosis
- Characterization of immune populations in human metabolic diseases

### Main lines of research

- Identification of novel cellular plasticity mechanisms involved in atheroma plaque stability
- Identification and characterization of tissular immune populations associated with metabolic diseases
- Novel biomarkers for the stratification of patients with diabetes and atherosclerosis

### PUBLICATIONS



# scientific activity

4

## SELECTED PUBLICATIONS

1. Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. *Cellular & Molecular Immunology*. 2022 Feb;19(2):177-191. doi: 10.1038/s41423-021-00832-3. PMID: 35039631. IF: 22,096
2. Jimenez-Martí E, Hurtado-Genoves G, Aguilar-Ballester M, Martínez-Hervás S, González-Navarro H. Novel therapies for cardiometabolic disease: recent findings in studies with hormone peptide-derived G protein coupled receptor agonists. *Nutrients*. 2022 Sep 13;14(18):3775. doi: 10.3390/nu14183775. PMID: 36145148. IF: 6,706
3. Albanell-Fernandez M, Oltra S, Orts-Arroyo M, Ibarrola-Villava M, Carrasco F, Jimenez-Martí E, Cervantes A, Castro I, Martínez-Lillo J, Ribas G. RUNAT-BI: a Ruthenium(III) complex as a selective anti-tumor drug candidate against highly aggressive cancer cell lines. *Cancers*. 2022 Dec 22;15(1):69. doi: 10.3390/cancers15010069. PMID: 36612065. IF: 6,575

**Beneficiary institution:** Fundación Investigación Hospital Clínico

*Universitario de Valencia*

**Duration:** 2020-2022

**Total Budget:** €12.000

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI19/00169

**Title:** Papel de los procesos inflamatorios en las enfermedades metabólicas y en las complicaciones asociadas

**Principal Investigator:** Herminia González Navarro and Sergio Martínez Hervás

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary institution:** Fundación Investigación Hospital Clínico  
*Universitario de Valencia*

**Duration:** 2020-2022

**Total Budget:** €159.720

**Reference:** CDEI0420B

**Title:** Plan GenT

**Principal Investigator:** Herminia González Navarro

**Funding Body:** Conselleria de Sanitat

**Beneficiary institution:** Fundación Investigación Hospital Clínico  
*Universitario de Valencia*

**Duration:** 2020-2023

**Total Budget:** €253.000

**Title:** Papel de la vía de señalización mediada por LIGHT en el fenotipo y la reprogramación celular en la placa de ateroma

**Principal Investigator:** Herminia González Navarro

**Funding Body:** Sociedad Española de arteriosclerosis/Fundación Española de arteriosclerosis

# scientific activity

## Research Group on Rare Respiratory Diseases (RRD) Emerging group



### Strategic aims


- We have shown that NK and lymphocytes B express and secrete alpha-1 antitrypsin
- We have discovered a group of miRNAs that could be used for the diagnosis and prognosis of alpha-1 antitrypsin deficiency.  
We are currently validating these results using an external cohort
- A new method based on oxidative stress markers to identify patients with Primary Ciliary Dyskinesia has been set up
- We have set up the high-speed video method to identify patients with Primary Ciliary Dyskinesia
- We have shown that hypoxia modifies neutrophil degranulation and enhances oxidative damage in alpha-1 antitrypsin deficiency patients

### Main lines of research

- The group is currently conducting active basic research on two rare respiratory diseases (RRDs); Alpha-1 Antitrypsin Deficiency (AATD) and primary ciliary dyskinesia (PCD)
- The specific lines of action of the group are:
  - To characterize the molecular mechanisms (especially those aspects related to REDOX regulation) involved in the development of disease in AATD and PCD
  - To evaluate the diagnostic and/or prognostic value of circulating nucleic acids in plasma/serum
  - Development of cellular models from cells of patients with RRD, which allow research in these diseases
  - To develop new therapeutic strategies based on gene therapy
  - To generate social awareness of RRD, through the scientific dissemination of biomedical advances and social and health policies aimed at improving the quality of life of patients

# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Dasi F. Alpha-1 antitrypsin deficiency. *Medicina Clinica*. 2022 Oct 14;50025-7753[22]00458-4. doi: 10.1016/j.medcli.2022.09.001. PMID: 36253208. IF: 3,2
- Torrent-Vernetta A, Gaboli M, Castillo-Corullon S, Mondejar-Lopez P, Santiago V, Costa-Colomer J, Osuna B, Torres-Borrego J, De la Serna-Blazquez O, Alonso S, Aguilera P, De Atauri A, Soria A, Ayats R, de Vicente C, Gonzalez V, Gonzalez J, Calderin E, Pastor-Vivero M, Alvarez M, Rovira-Amigo S, Serrano I, Izquierdo A, Messa I, Gartner S, Navarro A, Baz-Redon N, Carmona R, Camats-Tarruella N, Fernandez-Cancio M, Rapp C, Dopazo J, Griesse M, Moreno-Galdo A. Incidence and prevalence of children's diffuse lung disease in Spain. *Archivos de Bronconeumología*. 2022 Jan;58(1):22-29. doi: 10.1016/j.arbres.2021.06.001. PMID: 35249699. IF: 6,333
- Mondejar-Lopez P, Zolin A, Garcia-Marcos P, Pastor-Vivero M, Rosa-Silvestre M, Sanchez-Martinez F, Salvatore D, Cimino G, Majo F, Sole-Jover A, de la Cruz O, Calderazzo M, Pizzamiglio G, Castillo-Corullon S, Alvarez-Fernandez A, Gartner S, Padoan R, Carnovale V, Salvatore M, Moya-Quiles M, Orenti A, Glover G, Sanchez-Solis M. Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation. *Respiratory Medicine*. 2022 Feb;192:106736. doi: 10.1016/j.rmed.2022.106736. PMID: 35032736. IF: 4,582
- Raidt J, Maitre B, Pennekamp P, Altenburg J, Anagnostopoulou P, Armengot M, Bloemsma L, Boon M, Borrelli M, Brinkmann F, Carr S, Carroll M, Castillo-Corullon S, Coste A, Cutrera R, Dehlink E, Destouches D, Di Cicco M, Dixon L, Emiralioglu N, Eralp E, Haarman E, Hogg C, Karadag B, Kobbernagel H, Lorent N, Mall M, Marthin J, Martinu V, Narayanan M, Ozcelik U, Peckham D, Pifferi M, Pohunek P, Polverino E, Range S, Ringshausen F, Robson E, Roehmel J, Rovira-Amigo S, Santamaría F, Schlegtenthal A, Szepfalusi Z, Tempels P, Thouvenin G, Ullmann N, Walker W, Wetzké M, Yiallouras P, Omran H, Nielsen K. The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN. *ERJ Open Research*. 2022 Aug 15;8(3):00139-2022. doi: 10.1183/23120541.00139-2022. PMID: 35983540. IF: 4,239
- Martinez-Redondo M, Prados Sanchez C, Garcia-Rio F, Quintana Gallego E, Castillo Corullon S, Salcedo Posadas A, Giron Moreno

R, Martinez Martinez M, Maiz Carro L, de Vicente C, Costa Colomer J, Alvarez-Sala Walther R. The relation of CFTR genotype and associated comorbidities to development of pulmonary atelectasis in cystic fibrosis patients. *Archivos de Bronconeumología*. 2022 Sep;58(9):666-668. doi: 10.1016/j.arbres.2022.02.009. PMID: 35644710. IF: 6,333

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Title:** *Estudio de los microRNAs circulantes como biomarcadores pronósticos en pacientes con déficit de alfa-1 antitripsina. Un enfoque funcional*

**Principal Investigator:** Francisco Dasí Fernández

**Funding body:** Sociedad Valenciana de Neumología

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €6.000

**Title:** *Estudio de la utilidad clínica de los exosomas plasmáticos en la discinesia ciliar primaria*

**Principal Investigator:** Francisco Dasí Fernández

**Funding body:** Sociedad Valenciana de Neumología

**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2023

**Total budget:** €12.000

## THESIS

**Thesis title:** *Edición génica del gen serpina1 mediante el uso de CRISPR/CAS9 en células sanguíneas de pacientes con déficit de alfa-1 antitripsina*

**Doctoral candidate:** Lucía Bañuls Soto

**Director(s):** Francisco Dasí Fernández, Amparo Escribano

# 4 scientific activity

Montaner, Salvador Martí Pérez

**Date of the defense:** 20/05/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** *Estudio de la utilidad clínica de los microARNs en suero y orina de pacientes con cáncer de vejiga*

**Doctoral candidate:** Ana María Castelló Porcar

**Director(s):** Francisco Dasí Fernández, José María Martínez Jabaloyas

**Date of the defense:** 27/10/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** *Efecto de la hipoxia en la degranulación, producción de citoquinas y perfil oxidativo de neutrófilos en pacientes con déficit de alfa-1 antitripsina*

**Doctoral candidate:** María Magallón Serrano


**Director(s):** Francisco Dasí Fernández

**Date of the defense:** 01/12/2022


**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group on Healthy Aging (MiniAging) Emerging group



## PUBLICATIONS



# scientific activity

## SELECTED PUBLICATIONS

1. Sanz-Ros J, Romero-García N, Mas-Bargues C, Monleón D, Gordevicius J, Brooke RT, Dromant M, Díaz A, Derevyanko A, Guió-Carrión A, Román-Domínguez A, Inglés M, Blasco MA, Horvath S, Viña J, Borrás C. Small extracellular vesicles from young adipose-derived stem cells prevent frailty, improve health span, and decrease epigenetic age in old mice. *Science Advances*. 2022 Oct 21;8(42):eabq2226. doi: 10.1126/sciadv.abq2226. PMID: 36260670. IF: 14,957
2. Viña J, Escudero J, Baquero M, Cebrián M, Carbonell-Asins JA, Muñoz JE, Satorres E, Meléndez JC, Ferrer-Rebolleda J, Cázar-Santiago MDP, Santabarbara-Gómez JM, Jové M, Pamplona R, Tarazona-Santabalbina FJ, Borrás C. Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial. *Alzheimer's Research & Therapy*. 2022 Nov 4;14(1):164. doi: 10.1186/s13195-022-01097-2. PMID: 36329553. IF: 8,823
3. Inglés M, Belenguer-Varea A, Serna E, Mas-Bargues C, Tarazona-Santabalbina FJ, Borrás C, Vina J. Functional transcriptomic analysis of centenarians' offspring reveals a specific genetic footprint that may explain that they are less frail than age-matched noncentenarians' offspring. *The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*. 2022 Oct 6;77(10):1931-1938. doi: 10.1093/gerona/glac119. PMID: 35640160. IF: 6,591
4. Mas-Bargues C, Borrás C, Viña J. The multimodal action of genistein in Alzheimer's and other age-related diseases. *Free Radical Biology & Medicine*. 2022 Apr;183:127-137. doi: 10.1016/j.freeradbiomed.2022.03.021. PMID: 35346775. IF: 8,101
5. Mas-Bargues C, García-Domínguez E, Borrás C. Recent approaches to determine static and dynamic redox state-related parameters. *Antioxidants*. 2022 Apr 28;11(5):864. doi: 10.3390/antiox11050864. PMID: 35624728. IF: 7,675

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** AC20/00026

**Title:** Combining vitamin E-functionalized CHOcolate with physical exercise to reduce the risk of protein energy malnutrition in pre-dementia AGEd people. ERA-HDHL Call for Joint Transnational Research Proposals on Development of targeted nutrition for prevention of undernutrition for older adults (PREVNUT)

**Principal Investigator:** José Viña Ribes (Consuelo Borrás Blasco as collaborating researcher)

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2021-2023

**Total Budget:** €169.098

**Reference:** PID2020-113839RB-I00

**Title:** Efecto del tratamiento con vesículas extracelulares de células madre de grasa de ratones jóvenes sobre parámetros de envejecimiento y fragilidad en ratones de edad avanzada

**Principal Investigator:** Consuelo Borrás Blasco

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2021-2024

**Total Budget:** €181.500

**Reference:** PCIN-2017-117

**Title:** Obesidad materna y disfunción cognitiva en la descendencia: papel causa-efecto de la microbiota intestinal y prevención dietética temprana

**Principal Investigator:** Consuelo Borrás Blasco

**Funding Body:** Ministerio de Economía, Industria y Competitividad

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2017-2022

**Total Budget:** €143.000

**Reference:** GE/2022/134

**Title:** Papel de BCL-XI en el envejecimiento saludable y la prevención de la fragilidad

**Principal Investigator:** Cristina Más Bargues

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2022-2023

**Total Budget:** €20.000

# scientific activity

4

## THESIS

**Thesis title:** *Estudio comparativo de los efectos del ejercicio físico de baja intensidad, de la estimulación magnética transcraneal y de la terapia con oxígeno hiperbárico en mujeres con fibromialgia.*

*Ensayo clínico aleatorizado*

**Doctoral candidate:** Ruth Izquierdo Alventosa

**Director(s):** Marta Inglés de la Torre, Pilar Serra Añó, Sara Cortés Amador

**Date of the defense:** 14/01/2022

**Grade:** *Sobresaliente "cum laude"*

**Thesis title:** *Efecto favorable de la comunicación intercelular a través de vesículas extracelulares derivadas de células madre del tejido adiposo en el envejecimiento*

**Doctoral candidate:** Jorge Manuel Sanz Ros


**Director(s):** Consuelo Borrás Blasco, José Viña Ribes, Cristina Más Bargues

**Date of the defense:** 16/09/2022

**Grade:** *Sobresaliente "cum laude"*

# scientific activity

## Research Group on Exercise, Nutrition and Healthy Lifestyle Emerging group



## PUBLICATIONS



# scientific activity

4

## SELECTED PUBLICATIONS

1. Rodriguez-Rovira I, Arce C, De Rycke K, Perez B, Carretero A, Arbones M, Teixido-Tura G, Gomez-Cabrera M, Campuzano V, Jimenez-Altayo F, Egea G. Allopurinol blocks aortic aneurysm in a mouse model of Marfan syndrome via reducing aortic oxidative stress. *Free Radical Biology & Medicine*. 2022 Nov 5;193(Pt 2):538-550. doi: 10.1016/j.freeradbiomed.2022.11.00. PMID: 36347404. IF: 8,101
2. Garcia-Dominguez E, Carretero A, Vina-Almunia A, Domenech-Fernandez J, Olaso-Gonzalez G, Vina J, Gomez-Cabrera MC. Glucose 6-P dehydrogenase—an antioxidant enzyme with regulatory functions in skeletal muscle during exercise. *Cells*. 2022 Sep 28;11(19):3041. doi: 10.3390/cells11193041. PMID: 36231003. IF: 7,666
3. Millan-Domingo F, Tarazona-Santabalbina F, Carretero A, Olaso-Gonzalez G, Vina J, Gomez-Cabrera M. Real-life outcomes of a multicomponent exercise intervention in community-dwelling frail older adults and its association with nutritional-related factors. *Nutrients*. 2022 Dec 3;14(23):5147. doi: 10.3390/nu14235147. PMID: 36501177. IF: 6,706
4. De la Rosa A, Olaso-Gonzalez G, Garcia-Dominguez E, Mastaloudis A, Hester S, Wood S, Gomez-Cabrera M, Vina J. Glucosamine supplementation improves physical performance in trained mice. *Medicine and Science in Sports and Exercise*. 2022 Mar 1;54(3):466-474. doi: 10.1249/MSS.0000000000002821. PMID: 34711707. IF: 6,289
5. Marques P, Fernandez-Presa L, Carretero A, Gomez-Cabrera MC, Viña J, Signes-Costa J, Sanz MJ. The radiographic assessment of lung edema score of lung edema severity correlates with inflammatory parameters in patients with coronavirus disease 2019-Potential new admission biomarkers to predict coronavirus disease 2019 worsening. *Frontiers in Medicine*. 2022 Aug 11;9:871714. doi: 10.3389/fmed.2022.871714. PMID: 36035415. IF: 5,058

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** DIABFRAIL-LATAM-825546

**Title:** Scaling-up of and evidence-based intervention programme in older people with Diabetes and Frailty in LatinAmerica

**Principal Investigator:** Leocadio Rodríguez Mañas [M<sup>a</sup> Carmen Gómez Cabrera as collaborating researcher]

**Funding Body:** European Commission

**Beneficiary Institution:** CIBER (*Fundación Investigación Hospital Clínico Universitario de Valencia* as Third Party)

**Duration:** 2019-2024

**Total Budget:** €273.720

**Reference:** PID2019-110906RB-100

**Title:** Nuevas intervenciones terapéuticas multidominio para retrasar la fragilidad y la discapacidad. Identificación de mecanismos moleculares con relevancia traslacional

**Principal Investigator:** José Viña Ribes and Consuelo Gómez Cabrera

**Funding Body:** Ministerio de Economía y Competitividad

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2023

**Total budget:** €270.000

**Reference:** 45/UPB/20

**Title:** Redes de Investigación en ciencias del deporte: EXERNET. Red de ejercicio físico y salud

**Principal Investigator:** José Antonio Casajús [M<sup>a</sup> Carmen Gómez Cabrera as collaborating researcher]

**Funding Body:** Ministerio de Cultura y Deporte

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2021-2022

**Total Budget:** €8.000

**Reference:** PROMETEO/2019/097

**Title:** Diferencias de fragilidad entre géneros: evaluación de biomarcadores y estrategias de intervención

**Principal Investigator:** José Viña Ribes [M<sup>a</sup> Carmen Gómez Cabrera as collaborating researcher]

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2023

**Total Budget:** €189.391

# 4 scientific activity

## THESIS

**Thesis title:** *Papel de la xantina oxidasa en la pérdida de masa muscular por inmovilización en humanos. Importancia del protocolo de obtención de biopsias musculares en los estudios de atrofia muscular*

**Doctoral candidate:** Vicente Sebastiá Alcàcer

**Director(s):** M<sup>a</sup> Carmen Gómez Cabrera, José Viña Ribes, Enrique Viosca Herrero

**Date of the defense:** 28/06/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** *Intervención con ejercicio físico multicomponente sobre el adulto mayor frágil en la vida real* (Real Life Intervention)

**Doctoral candidate:** Fernando Millán Domingo

**Director(s):** José Viña Ribes, María Carmen Gómez Cabrera, Francisco José Tarazona Santabalbina


**Date of the defense:** 01/07/2022

**Grade:** Sobresaliente "cum laude"


# scientific activity

4

## Research Group on Epigenomics and Translational Epigenetics Emerging group



## PUBLICATIONS



## SELECTED PUBLICATIONS

- Beltrán-García J, Osca-Verdegal R, Pérez-Cremades D, Novella S, Hermenegildo C, Pallardó FV, García-Giménez JL. Extracellular histones activate endothelial NLRP3 inflammasome and are associated with a severe sepsis phenotype. *Journal of Inflammation Research*. 2022 Jul 25;15:4217-4238. doi: 10.2147/JIR.S363693. PMID: 35915852. IF: 4,631
- Beltrán-García J, Osca-Verdegal R, Jávega B, Herrera G, O'Connor JE, García-López E, Casabó-Vallés G, Rodriguez-Gimillo M, Ferreres J, Carbonell N, Pallardó FV, García-Giménez JL. Characterization of early peripheral immune responses in patients with sepsis and septic shock. *Biomedicines*. 2022 Feb 23;10(3):525. doi: 10.3390/biomedicines10030525. PMID: 35327327. IF: 4,757
- Fatmi A, Chabni N, Cernada M, Vento M, González-López M, Aribi M, Pallardó FV, García-Giménez JL. Clinical and

# scientific activity

- immunological aspects of microRNAs in neonatal sepsis.  
*Biomedicine & Pharmacotherapy.* 2022 Jan;145:112444.  
doi: 10.1016/j.biopha.2021.112444. PMID: 34808550. IF: 7,419
4. García-Giménez JL, García-Trevijano ER, Avilés-Alía AI, Ibañez-Cabellos JS, Bovea-Marco M, Bas T, Pallardó FV, Viña JR, Zaragozá R. Identification of circulating miRNAs differentially expressed in patients with Limb-girdle, Duchenne or facioscapulohumeral muscular dystrophies. *Orphanet Journal of Rare Diseases.* 2022 Dec 27;17(1):450. doi: 10.1186/s13023-022-02603-3. PMID: 36575500. IF: 4,303
5. Osca-Verdegal R, Beltrán-García J, Górriz JL, Martínez-Jabaloyas JM, Pallardó FV, García-Giménez JL. Use of circular RNAs in diagnosis, prognosis and therapeutics of renal cell carcinoma. *Frontiers in Cell and Developmental Biology.* 2022 Jun 22;10:879814. doi: 10.3389/fcell.2022.879814 PMID: 35813211. IF: 6,081

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI19/00994

**Title:** Biomarcadores epigenéticos en sepsis y su implicación en inmunosupresión y futuras comorbilidades en supervivientes

**Principal Investigator:** José Luis García Giménez

**Funding Body:** Instituto de Salud Carlos III-Co-financed FEDER

**Beneficiary institution:** Universidad de Valencia

**Duration:** 2020-2022

**Total budget:** €111.320

**Reference:** DTS21/00193

**Title:** Test basados en péptidos spike-in y espectrometría de masas para la cuantificación de histonas circulantes y proteína APC, para el manejo clínico del paciente crítico

**Principal Investigator:** José Luis García Giménez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2023

**Total budget:** €122.100

**Title:** Identificación de biomarcadores mediante el uso de las ómicas y la Inteligencia Artificial para el diagnóstico y el pronóstico de la sepsis neonatal

**Principal Investigator:** José Luis García Giménez

**Entidad financiadora:** Fundación Mutua Madrileña

**Beneficiary Institution:** Fundación Investigación Hospital Clínico

*Universitario de Valencia*

**Duration:** 2020-2023

**Total budget:** €100.000

**Reference:** RTC2019-006825-1

**Title:** Potencial de la leriglitazona para el tratamiento de enfermedades asociadas a la acumulación de hierro, distrofias y enfermedades neuromusculares

**Principal Investigator:** Pilar González Cabo [José Luis García Giménez as collaborating researcher]

**Entidad financiadora:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Minoryx Therapeutic SL

**Duration:** 2020-2023

**Total budget:** €90.000

**Reference:** CPP2021-008643

**Title:** Identificación y validación de biomarcadores mediante el uso de las ómicas y la Inteligencia Artificial para el diagnóstico temprano y mejora del manejo clínico de la sepsis

**Principal Investigator:** Edurne Carbonell [José Luis García Giménez as collaborating researcher]

**Entidad financiadora:** Ministerio de Ciencia e Innovación

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €150.269

## THESIS

**Thesis title:** Uso de las histonas circulantes y sus modificaciones post-traduccionales como biomarcadores en sepsis y shock séptico

**Doctoral candidate:** Jesús Beltrán García

**Director(s):** José Luis García Giménez, Federico Pallardó Calatayud

**Date of the defense:** 20/01/2022

**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD

**Thesis title:** Potencial uso de la tecnología basada en microARNs para el diagnóstico y pronóstico de la escoliosis idiopática del adolescente

**Doctoral candidate:** Ester Berenguer Pascual



**Director(s):** José Luis García Giménez, Giselle Pérez Machado, Salvador Mena Mollá

**Date of the defense:** 10/02/2022


**Grade:** Sobresaliente "cum laude"

# scientific activity

## Research Group in Medical Chemistry for Drug Development Emerging group



## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Ferri J, Martínez-Ibáñez J, Terradez L, Savall E, Martínez-Hervas S, Oller M, Lorente R, Ascaso J, Real J. Corticotroph cell hyperplasia as a rare cause of ACTH-dependent Cushing syndrome. *Endocrinología, Diabetes y Nutrición.* 2022 Nov;69(9):694-701. doi: 10.1016/j.endien.2022.11.004. PMID: 36470644. IF: 1.833
2. Gu Hong W, Ferri J, Ampudia-Blasco F, Martín-Brufau R, Peiro M, Benito E, Martínez-Hervas S, Sanz M, Real J. Effect of personality on blood glucose control in patients with type 1 diabetes. *Endocrinología, Diabetes y Nutricion.* 2022

# 4 scientific activity

- Nov;69(9):677-685. doi: 10.1016/j.endien.2021.11.034.  
PMID: 36470643. IF: 1,833
3. Vila L, Cabedo N, Villarroel-Vicente C, Garcia A, Bernabeu A, Hennuyer N, Staels B, Franck X, Figadere B, Sanz MJ, Cortes D. Synthesis and biological studies of polycerasoidol and trans-delta-tocotrienolic acid derivatives as PPARalpha and/or PPARgamma agonists. *Bioorganic & Medicinal Chemistry*. 2022 Jan 1;53:116532. doi: 10.1016/j.bmc.2021.116532.  
PMID: 34863066. IF: 3,461

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI21/02045

**Title:** *Desarrollo de nuevos moduladores multidiana de receptores nucleares y biomarcadores lipídicos para el tratamiento del síndrome metabólico y las comorbilidades asociadas*

**Principal Investigator:** Nuria Cabedo Escrig

**Funding Body:** *Instituto de Salud Carlos III* - Co-financed FEDER

**Beneficiary Institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2022-2024

**Total Budget:** €174.240

**Reference:** PI18/01450

**Title:** *Desarrollo químico y farmacológico de nuevos fármacos "multidiana" en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular asociada*

**Principal Investigator:** Nuria Cabedo Escrig

**Funding Body:** *Instituto de Salud Carlos III* - Co-financed FEDER

**Beneficiary institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*



**Duración:** 2019-2022

**Presupuesto total:** €61.710


# scientific activity

4

## Research Group on Epigenomics and Translational Epigenetics Emerging group



## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Rodríguez LR, Lapeña-Luzón T, Benetó N, Beltran-Beltran V, Pallardó FV, Gonzalez-Cabo P, Navarro JA. Therapeutic strategies targeting mitochondrial calcium signaling: a new hope for neurological diseases?. *Antioxidants*. 2022 Jan 15;11(1):165. doi: 10.3390/antiox11010165. PMID: 35052668. IF: 7,675
2. Muñoz-Lasso DC, Mollá B, Sáenz-Gamboa JJ, Insuasty E, de la Iglesia-Vaya M, Pook MA, Pallardó FV, Palau F, Gonzalez-Cabo P. Frataxin deficit leads to reduced dynamics of growth cones in dorsal root ganglia neurons of Friedreich's ataxia YG8sR

# scientific activity

- model: a multilinear algebra approach. *Frontiers in Molecular Neuroscience*. 2022 Jun 13;15:912780. doi: 10.3389/fnmol.2022.912780. PMID: 35769335. IF: 6,261
3. Luque J, Mendes I, Gomez B, Morte B, de Heredia M, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch R, Fillat C, Perez-Jurado L, Montoliu L, Carracedo A, Millan J, Webb S, Palau F, Lapunzina P, Pallardo Calatayud F, CIBERER Network. CIBERER: Spanish national network for research on rare diseases: a highly productive collaborative initiative. *Clinical Genetics*. 2022 May;101(5-6):481-493. doi: 10.1111/cge.14113. PMID: 35060122. IF: 4,296

**Reference:** RTC2019-006825-1

**Title:** *Potencial de la leriglitazona para el tratamiento de enfermedades asociadas a la acumulación de hierro, distrofias y enfermedades neuromusculares*

**Principal Investigator:** Pilar González Cabo

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary institution:** Minoryx Therapeutic SL

**Duration:** 2020-2023

**Total budget:** €90.000

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** ACCI 2020

**Title:** *Síndrome de CANVAS: diagnóstico precoz y modelo fisiopatológico mediante iPSC*

**Principal Investigator:** Pilar González Cabo

**Funding Body:** Instituto de Salud Carlos III-Co-financed FEDER

**Beneficiary institution:** CIBER de Enfermedades Raras (CIBERER-ISCIII)

**Duration:** 2021-2022

**Total budget:** €75.000

**Reference:** ACCI-2019-22

**Title:** *Degradoación de la huntingtina mediante ubiquibodies de camélidos*

**Principal Investigator:** Pilar González Cabo

**Funding Body:** CIBER de Enfermedades Raras (CIBERER-ISCIII)

**Beneficiary institution:** CIBER de Enfermedades Raras (CIBERER-ISCIII)

**Duration:** 2020-2022

**Total budget:** €18.000

**Reference:** PID2020-115190RB-I00

**Title:** *Relacionando cofilina, una proteína de unión a actina, con la desregulación del calcio: un enfoque de precisión para el tratamiento de la Ataxia de Friedreich*

**Principal Investigator:** Pilar González Cabo

**Funding Body:** Ministerio de Ciencia e Innovación

**Beneficiary institution:** CIBER de Enfermedades Raras (CIBERER-ISCIII)

**Duration:** 2021-2024


**Total budget:** €196.300

# scientific activity

## 4.3.4 Reproductive medicine area

### Groups

- Research Group on Women's Health
- Research Group on Reproductive Medicine
- Research Group on Therapies Against Endometriosis and Endometrial Cancer
- Research Group on Maternal Fetal Communication



original articles   letters   editorials   reviews

# scientific activity

## Research Group on Women's Health Consolidated group

### Group members

#### Leading Researchers, R4

Antonio Cano Sánchez. Hospital. University  
Juan José Tarín Folgado. University

#### Researchers by categories



#### Recognised Researchers, R2

Ana Martínez Aspas. Hospital. University  
Celia Bauset Castelló. Hospital  
Ester Ortiz Murillo. Hospital  
Gemma Arribas Ferriol. Hospital  
Irene Zolfaroli. Hospital

#### Staff. Collaborating Researchers

Aitana Monllor Tormos. Hospital  
Laura Carbonell López. Hospital  
Rocío Belda Montesinos. Hospital

#### Staff. Nurses

Alicia García Vigara. Hospital

### Strategic aims

- The group is positioned in the field of healthy ageing, particularly in what relates women, with special interest to frailty, where it has collaborated in the support of INCLIVA in the project ADVANTAGE
- We have collaborated to position the reference site of the Valencia Region within EIPAHA, the partnership of the European Commission
- Moreover, we have participated in the application to different European projects with groups from different European countries, including an application to the Maire Curie grants

### Main lines of research

- In healthy ageing in the female we are continuing our interest on osteoporosis but also have added frailty and functional decline.  
The group is consolidating the CARMEN cohort
- There is a new area of interest on the use of ICT to promote women's health with regard to endometriosis:
  - To analyze the role of microRNA and vascularization regulators and pain mechanisms. Role of the TNF cytokine family
  - To analyze the initial atherogenesis and selective estrogen receptor modulators

### PUBLICATIONS



## SELECTED PUBLICATIONS

1. Bauset C, Martinez-Aspas A, Smith-Ballester S, Garcia-Vigara A, Monllor-Tormos A, Kadi F, Nilsson A, Cano A. Nuts and metabolic syndrome: reducing the burden of metabolic syndrome in menopause. *Nutrients*. 2022 Apr 18;14(8):1677. doi: 10.3390/nu14081677. PMID: 35458240. IF: 6,706
2. Gomez R, Tejada M, Rodriguez-Garcia V, Burgues O, Santos-Llamas A, Martinez-Massa A, Marin-Montes A, Tarin J, Cano A. Histological grade and tumor stage are correlated with expression of receptor activator of nuclear factor Kappa b (Rank) in epithelial ovarian cancers. *International Journal of Molecular Sciences*. 2022 Feb 3;23(3):1742. doi: 10.3390/ijms23031742. PMID: 35163671. IF: 6,208
3. Stute P, Cano A, Thurston R, Small M, Lee L, Scott M, Siddiqui E, Schultz N. Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States. *Maturitas*. 2022 Jun 23;164:38-45. doi: 10.1016/j.maturitas.2022.06.008. PMID: 35785563. IF: 5,11
4. Mendoza N, Ramirez I, de la Viuda E, et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. *Maturitas*. 2022 Aug 30;166:65-85. doi: 10.1016/j.maturitas.2022.08.008. PMID: 36081216. IF: 5,11
5. Tejada MA, Santos Llamas A, Escrivá L, Tarin JJ, Cano A, Fernandez Ramirez MJ, Nunez Badinez P, De Leo B, Saunders PTK, Vidal V, Bartha F, Vincent K, Sweeney PJ, Sililito RR, Armstrong JD, Nagel J, Gomez R. Identification of altered evoked and non-evoked responses in a heterologous mouse model of endometriosis-associated pain. *Biomedicines*. 2022 Feb 21;10(2):501. doi: 10.3390/biomedicines10020501. PMID: 35203710. IF: 4,757

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** AC19/00084

**Title:** Patrones dietéticos en población europea senescente: acercamiento multidisciplinar para combatir las enfermedades metabólicas ligadas a sobrepeso. Proyecto Eurodiet

**Principal Investigator:** Antonio Cano Sánchez

**Funding body:** European Commission


**Beneficiary institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €27.225

# scientific activity

## Research Group on Reproductive Medicine Consolidated group



# scientific activity

4


- The endometrial microbiome in human reproduction: our research group has described the existence of the endometrial microbiome and its clinical implications on the reproductive outcome. We investigate the impact of uterine microbiome dysbiosis and its clinical impact
- The maternal implication in the origin of pre-eclampsia: our research has provided evidence that endometrial decidualization resistance is implicated in the origin of this disease. This finding offers a new perspective based on the maternal contribution to gestation, aiming to develop a tool that will diagnose pre-eclampsia
- Molecular diagnosis of myometrial tumors: our previous work has demonstrated the genomic differential characterization of myomas and leiomyosarcomas. We aim to shift the diagnostic and therapeutic focus of uterine leiomyomas and leiomyosarcomas through genomic characterization

## Emerging Researcher

Aymara Mas Perucho

The main objective of this research is focused on understanding those factors that contribute to the pathophysiology of myometrial tumors at the molecular level.

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Moreno I, Garcia-Grau I, Perez-Villaroya D, Gonzalez-Monfort M, Bahcec M, Barrionuevo MJ, Taguchi S, Puente E, Dimattina M, Lim MW, Meneghini G, Aubuchon M, Leondires M, Izquierdo A, Perez-Olgati M, Chavez A, Seethram K, Bau D, Gomez C, Valbuena D, Vilella F, Simon C. Endometrial microbiota composition is associated with reproductive outcome in infertile patients. *Microbiome*. 2022 Jan 4;10(1):1. doi: 10.1186/s40168-021-01184-w. PMID: 34980280. IF: 16,837
2. Garrido Gomez T, Castillo Marco N, Cordero T, Simon Valles C. Decidualization resistance in the origin of preeclampsia. *American Journal of Obstetrics and Gynecology*. 2022 Feb;226(2S):S886-S894. doi: 10.1016/j.ajog.2020.09.039. PMID: 33007270. IF: 10,693
3. Capalbo A, Cimadomo D, Rienzi L, Garcia-Velasco J, Simon C, Ubaldi F. Avoid mixing apples and oranges: blastocysts diagnosed with uniform whole chromosome aneuploidies are reproductively incompetent and their transfer is harmful. *Human Reproduction*. 2022 Aug 25;37(9):2213-2214. doi: 10.1093/humrep/deac149. PMID: 35796677. IF: 6,353
4. Balaguer N, Mateu-Bruell E, Gomez-Lopez M, Simon C, Milan M. Cell-free fetal DNA testing performance and fetal fraction estimation are not affected in ART-conceived pregnancies. *Human Reproduction*. 2022 Nov 24;37(12):2743-2756. doi: 10.1093/humrep/deac217. PMID: 36223600. IF: 6,353
5. Machado Lopez A, Alonso R, Lago V, Jimenez Almazan J, Garcia M, Monleon J, Lopez S, Barcelo F, Torroba A, Ortiz S, Domingo S, Simon C, Mas A. Integrative genomic and transcriptomic profiling reveals a differential molecular signature in uterine leiomyoma versus leiomyosarcoma. *International Journal of Molecular Sciences*. 2022 Feb 16;23(4):2190. doi: 10.3390/ijms23042190. PMID: 35216305. IF: 6,208

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** 874867 - HUTER

**Title:** Human Uterus Cell Atlas

**Principal Investigator:** Carlos Simón Vallés

**Funding Body:** European Commission

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €4.118.942,50

# scientific activity

**Reference:** PI21/00235

**Title:** *Estudio del impacto del microbioma endometrial sobre el endometrio humano en condiciones fisiológicas y patológicas a nivel de célula única*

**Principal Investigator:** Inmaculada Moreno Gimeno

**Funding Body:** *Instituto de Salud Carlos III - Co-financed FEDER*

**Beneficiary Institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2022-2024

**Total budget:** €169.279

**Reference:** PI-2021-010

**Title:** *CellStats: Desarrollo de un modelo estadístico para la evaluación de cambios poblacionales en datos transcriptómicos de célula única del endometrio humano*

**Principal Investigator:** Guillermo Ayala Gallego and Beatriz Rosón Burgo

**Funding Body:** *Universidad de Valencia - INCLIVA*

**Beneficiary institution:** *Universidad de Valencia - INCLIVA*

**Duration:** 2021-2022

**Total budget:** €16.150

**Reference:** PI20/00942

**Title:** *Desarrollo de un modelo predictivo para el diagnóstico diferencial temprano de leiomiomas y leiomiosarcomas uterinos*

**Principal Investigator:** Aymara Mas Perucho

**Funding Body:** *Instituto de Salud Carlos III - Co-financed FEDER*

**Beneficiary Institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2021-2023

**Total budget:** €99.825

**Reference:** PI19/01659

**Title:** *Análisis transcriptómico a nivel de célula única y tejido endometrial completo del fallo en deciduación presente en pacientes con preeclampsia severa*

**Principal Investigator:** Tamara Garrido Gómez

**Funding Body:** *Instituto de Salud Carlos III - Co-financed FEDER*

**Beneficiary Institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2020-2022

**Total budget:** €93.170

**Reference:** RTI2018-094946-B-I00

**Title:** *Contribución maternal en la patogénesis de enfermedades gestacionales tardías como la preeclampsia*

**Principal Investigator:** Carlos Simón Vallés

**Funding Body:** *Ministerio de Ciencia, Innovación y Universidades*



**Beneficiary Institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2019-2022


**Total budget:** €254.100

# scientific activity

## Research Group on Therapies Against Endometriosis and Endometrial Cancer Emerging group



## PUBLICATIONS



# scientific activity

## SELECTED PUBLICATIONS

1. Fell C, Hagelkruys A, Cicvaric A, Horrer M, Liu L, Li J, Stadlmann J, Polyansky A, Mereiter S, Tejada M, Kokotovic T, Achuta V, Scaramuzza A, Twyman K, Morrow M, Juusola J, Yan H, Wang J, Burmeister M, Choudhury B, Andersen T, Wirnsberger G, Holmskov U, Perrimon N, Aagrovic B, Monje F, Moeller J, Penninger J, Nagy V. FIBCD1 is an endocytic GAG receptor associated with a novel neurodevelopmental disorder. *EMBO Molecular Medicine*. 2022 Sep 7;14(9):e15829. doi: 10.15252/emmm.202215829. PMID: 35916241. IF: 14,26
2. Gomez R, Tejada M, Rodriguez-Garcia V, Burgues O, Santos-Llamas A, Martinez-Massa A, Marin-Montes A, Tarin J, Cano A. Histological grade and tumor stage are correlated with expression of receptor activator of nuclear factor Kappa b (Rank) in epithelial ovarian cancers. *International Journal of Molecular Sciences*. 2022 Feb 3;23(3):1742. doi: 10.3390/ijms23031742. PMID: 35163671. IF: 6,208
3. Tejada MA, Santos Llamas A, Escrivá L, Tarin JJ, Cano A, Fernandez Ramirez MJ, Nunez Badinez P, De Leo B, Saunders PTK, Vidal V, Bartha F, Vincent K, Sweeney PJ, Sillito RR, Armstrong JD, Nagel J, Gomez R. Identification of altered evoked and non-evoked responses in a heterologous mouse model of endometriosis-associated pain. *Biomedicines*. 2022 Feb 21;10(2):501. doi: 10.3390/biomedicines10020501. PMID: 35203710. IF: 4,757

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** 777500- IMI-PainCare

**Title:** Improving the care of patients suffering from acute or chronic pain

**Principal Investigator:** Raúl Gómez Gallego

**Funding body:** European Commission

**Beneficiary institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2018-2023

**Total budget:** €257.066,25

**Reference:** PI20/01835

**Title:** *Evaluación del potencial papel terapéutico de la inhibición de RANK en modelos optimizados de dolor e infertilidad asociados a endometriosis*

**Principal Investigator:** Raúl Gómez Gallego

**Funding body:** *Instituto de Salud Carlos III* - Co-financed FEDER

**Beneficiary institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2021-2023

**Total budget:** €98.010

# scientific activity

4

## Research Group on Maternal Fetal Communication Emerging group

Group members	Researchers by categories
<b>Leading Researcher, R4</b> Felip Vilella Mitjana. INCLIVA	R1 1
<b>Established Researcher, R3</b> Francisco Raga Baixauli. Hospital. University	R2 2
<b>Recognised Researchers, R2</b> David Bolumar Recuero. INCLIVA Javier Moncayo Arlandi. Carlos Simón Foundation	R3 1
<b>First Stage Researcher, R1</b> Javier González Fernández. INCLIVA	R4 1
<b>Staff. Technicians</b> Ana Ochando Fernández. Carlos Simón Foundation Neus Puig López. INCLIVA Sofía Zaragozano Martínez. Carlos Simón Foundation	STAFF 3

Researchers financed by competitive public calls or networks



## Strategic aims


- Project origin of diseases: functional capacity of miRNAs secreted into endometrial fluid in obese and type 2 diabetic patients to determine if they are capable of modifying mouse embryos transcriptomically and/or epigenetically
- Project Transcriptomic and epigenetic modifications in human embryos: obtain the target genes of miRNA miR-30d in human embryos to have a list of regions potentially susceptible to methylation. These regions will be used to design the PCRs of the bisulfite regions by miSeq sequencing
- Project Function of DNA and RNA contained in extracellular vesicles secreted by the human endometrium on the pre-implantation embryo: it has been described that the endometrial fluid is secreted by a series of populations of extracellular vesicles (apoptotic bodies, microvesicles and exosomes) that represent a conveyance. We propose that these vesicles contain biomolecules of different natures, specifically focusing on the different types of RNAs and DNA, and that their composition in these chemical species varies throughout the menstrual cycle and depending on the subpopulation of vesicles that is analyzed

## Main lines of research

- Study of endometrial receptivity and perform the Cell Atlas of the human uterus: we discovered the transcriptomic signature of human endometrial receptivity. Now, we are part of the International Human Cell Atlas initiative to create the first human cell atlas of the uterus
- Maternal-embryonic communication. We investigated how the mother communicates with the preimplantation embryo before implantation and discovered that the maternal endometrium modifies the transcriptomics of the embryo under healthy and pathological conditions
- Progenitor cells of endometrial regeneration. Our research group analyzes gene expression in different menstrual cycle phases to identify progenitor cells responsible for endometrial regeneration throughout the distinct cell layers

# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Moreno I, Garcia-Grau I, Perez-Villaroya D, Gonzalez-Monfort M, Bahcec M, Barrionuevo MJ, Taguchi S, Puente E, Dimattina M, Lim MW, Meneghini G, Aubuchon M, Leondires M, Izquierdo A, Perez-Olgati M, Chavez A, Seethram K, Bau D, Gomez C, Valbuena D, Vilella F, Simon C. Endometrial microbiota composition is associated with reproductive outcome in infertile patients. *Microbiome*. 2022 Jan 4;10(1):1. doi: 10.1186/s40168-021-01184-w. PMID: 34980280. IF: 16,837

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2022

**Total budget:** €135.520

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** 874867 - HUTER

**Title:** Human Uterus Cell Atlas

**Principal Investigator:** Carlos Simón Vallés [Felip Vilella Mitjana as collaborating researcher]

**Funding Body:** European Commission

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €4.118.942,50

**Reference:** PI21/00528

**Title:** Caracterización transcriptómica de la implantación embrionaria humana a nivel de célula única usando un endometrio 3D en un chip de microfluídica

**Principal Investigator:** Felip Vilella Mitjana

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €90.750

**Reference:** PI18/00957

**Title:** Función del ADN y ARN contenido en vesículas extracelulares secretadas por el endometrio humano sobre el embrión pre-implantatorio

**Principal Investigator:** Felip Vilella Mitjana


**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

# scientific activity

## 4.3.5 Clinical Associated Groups

### Groups

- Research Group in Care. INVESTENF-INCLIVA
- Associated Clinical Group in Urology
- Associated Clinical Group in Digestive Medicine
- Associated Clinical Group in Traumatology and Orthopedics
- Associated Clinical Group in Neurology
- Associated Clinical Group in Pharmacy



■ original articles ■ letters ■ editorials ■ case reports ■ corrections

# scientific activity

## Research Group on Research in Care. INVESTENF-INCLIVA Clinical Associated group

Group members	Researchers by categories
<b>Leading Researcher, R4</b> M <sup>a</sup> José Gastaldo Zaragozá. Hospital	R1 1
<b>Recognised Researchers, R2</b> Antonio Martínez Sabater. Hospital. University Iván Julián Rochina. Hospital. University Montserrat Cañabate Ros. Hospital. University Pablo García Molina. University	R2 4
<b>First Stage Researcher, R1</b> Evelin Balaguer López. Hospital. University	R4 1
<b>Staff. Nurses</b> Adán Álvarez Ordiales. Hospital Ana Bela Espinosa Briones. Hospital Ana Gancedo Herrero. Hospital Concepción Mateo Orrios. Hospital Laura Pla Marzo. Hospital M <sup>a</sup> Ángeles Montal Navarro. Hospital. University M <sup>a</sup> Carmen Barberá Ventura. Hospital M <sup>a</sup> Carmen Rodríguez Dolz. Hospital. University M <sup>a</sup> Concepción Rodrigo Ruiz. Hospital M <sup>a</sup> Dolores Cantero López. Hospital M <sup>a</sup> Gabriela Chova Mallent. Hospital M <sup>a</sup> Jesús Zafra Pirés. Hospital M <sup>a</sup> Luisa Muñoz Illescas. Hospital M <sup>a</sup> Pilar Bernabéu Adrián. Hospital M <sup>a</sup> Victoria Orejón Lagunas. Hospital	STAFF 19
	Mireia Sánchez Morcillo. Hospital Nuria Garrido Zafra. University Sonia Mora Navarro. Hospital
	<b>Staff. Technician</b> David Palanca Broseta. Hospital

<b>Strategic aims</b> <ul style="list-style-type: none"> <li>• Contribute with scientific nursing evidence to improve pediatric nursing care</li> <li>• Conduct research in pediatric nursing to disseminate new knowledge</li> <li>• Work for the Quality and Safety of pediatric nursing care</li> </ul>
<b>Main lines of research</b> <ul style="list-style-type: none"> <li>• Child and adolescent health care</li> <li>• Skin care and skin integrity</li> <li>• Mental Health Care</li> <li>• Care in aging, fragility and chronicity</li> </ul>

# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Zamora-Sanchez J, Urpi-Fernandez A, Sastre-Rus M, Lumillo-Gutierrez I, Gea-Caballero V, Jodar-Fernandez L, Julian-Rochina I, Zabaleta-Del-Olmo E. The Tilburg Frailty Indicator: a psychometric systematic review. *Ageing Research Reviews.* 2022 Apr;76:101588. doi: 10.1016/j.arr.2022.101588. PMID: 35150901. IF: 11,788
2. Chover-Sierra E, Perez-Ros P, Julian-Rochina I, Long C, Cauli O. Knowledge and attitudes towards palliative care: validation of the Spanish version of questionnaire on palliative care for advanced dementia. *Healthcare.* 2022 Mar 31;10(4):656. doi: 10.3390/healthcare10040656. PMID: 35455834. IF: 3,16
3. Perez-Ros P, Cauli O, Julian-Rochina I, Long C, Chover-Sierra E. Level of knowledge and attitudes towards palliative care for people with advanced dementia in Spain: role of professional and academic factors. *Current Alzheimer Research.* 2022 Dec 21. doi: 10.2174/1567205020666221221145259. PMID: 36545733. IF: 3,04
4. Balaguer Lopez E, Garcia-Molina P, Nunez F, Crehua-Gaudiza E, Montal Navarro M, Pedron Giner C, Vitoria Minana I, Jovani Casano C, Galera Martinez R, Gomez-Lopez L, Rodriguez Martinez G, Martinez-Costa C. Cross-cultural adaptation to Spanish and content validity of three nutritional risk scales. *Anales de Pediatría.* 2022 Jul;97(1):12-21. doi: 10.1016/j.anpede.2022.06.001. PMID: 35729061. IF: 2,377

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** AP-2021-015

**Title:** VISUALSKIN: Diseño de dispositivo clínico para la evaluación del riesgo de lesión en la piel en personas encamadas o usuarias de silla de ruedas

**Principal Investigator:** Julio Martos Torres and Pablo García Molina

**Funding Body:** Universidad de Valencia - INCLIVA



**Beneficiary institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total Budget:** €4.750

# scientific activity

## Clinical Associated Group in Urology Clinical Associated group



## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Osca Verdagel R, Beltran Garcia J, Gorri J, Jabaloyas J, Pallardo F, Garcia Gimenez J. Use of circular RNAs in diagnosis, prognosis and therapeutics of renal cell carcinoma. *Frontiers in Cell and Developmental Biology*. 2022 Jun 22;10:879814. doi: 10.3389/fcell.2022.879814. PMID: 35813211. IF: 6,081
2. Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Impact of the COVID-19 pandemic on a cancer fast-track programme. *Cancer Control*. 2022 Jan-Dec;29:10732748221131000. doi: 10.1177/10732748221131000. PMID: 36355430. IF: 2,339
3. Panach-Navarrete J, Martinez-Montava E, Gil-Viana R, Valls-Gonzalez L, Martinez-Jabaloyas J. Early ultrasound after endoscopic puncture of ureterocele: signs that show surgical treatment success. *Archivos Espanoles de Urologia*. 2022 Aug;75(6):567-571. doi: 10.37554/es-j.arch.esp.urol-20210119-3532-31. PMID: 36138507. IF: 0,43
4. Negueroles-Garcia M, Pastor-Hernandez F, Martinez-Jabaloyas J. Emergency radical nephrectomy in a polytrauma patient. *Archivos Espanoles de Urologia*. 2022 Oct;75(8):736-737. doi: 10.56434/j.arch.esp.urol.20227508.107. PMID: 36330577. IF: 0,43

# scientific activity

4

5. Negueroles-Garcia M, Panach-Navarrete J, Martinez-Jabaloyas J. The use of urokinase in urinary catheter obstructed by clots. Archivos Espanoles de Urologia. 2022 Jan;75(1):82-86. doi: 10.37554/es-j.arch.esp.urol-20210317-3534-33. PMID: 35173068. IF: 0,43

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** INVEST/2022/60

**Title:** Desarrollo de un método que permita la generación de interfaces gráficas de usuario centradas en el usuario que sean usables y accesibles para cualquier usuario

**Principal Investigator:** Jorge Panach Navarrete

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €66.217,84

## THESIS

**Thesis title:** Estudio metabolómico en tejido prostático y orina para el diagnóstico y pronóstico del cáncer de próstata

**Doctoral candidate:** Jorge Panach Navarrete

**Director(s):** José María Martínez Jabaloyas, José Manuel Morales Tatay, Vannina González Marrachelli

**Date of the defense:** 08/04/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** Estudio de la utilidad clínica de los microARNs en suero y orina de pacientes con cáncer de vejiga

**Doctoral candidate:** Ana María Castelló Porcar

**Director(s):** Francisco Dasí Fernández, José María Martínez Jabaloyas

**Date of the defense:** 27/10/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Clinical Associated Group in Digestive Medicine Clinical Associated group


Group members	Researchers by categories
<b>Leading Researchers, R4</b> Isabel Pascual Moreno. Hospital. University Miguel Minguez Pérez. University	R1 3      R2 2      R3 5      R4 2      STAFF 10
<b>Established Researchers, R3</b> Andrés Peña Aldea. Hospital Joan Tosca Cuquerella. Hospital Marta Maia Boscá Watts. Hospital Paloma Lluch García. Hospital. University Vicente Sanchiz Soler. Hospital	
<b>Recognised Researchers, R2</b> Marta Ponce Romero. Hospital Pilar Más Mercader. Hospital	
<b>First Stage Researchers, R1</b> Carles Suria Bolufer. Hospital Eva Romero González. Hospital María Capilla Lozano. Hospital	
<b>Staff. Collaborating Researchers</b> Ana Sanahuja Martínez. Hospital Consuelo Gálvez Castillo. Hospital Pablo Navarro Cortés. Hospital Rosana Villagrasa Manzano. Hospital Rosario Antón Ausejo. Hospital Sherly Hernández. Hospital	
<b>Staff. Technicians</b> Desamparados Giménez Choví. INCLIVA Lorena Boronat Cifre. INCLIVA	<b>Staff. Nurses</b> Amparo Ruiz Álvarez. Hospital Nuria Casasús Moya. Hospital

Strategic aims
<ul style="list-style-type: none"> <li>• Knowledge of physiopathologic mechanisms and treatment of inflammatory bowel disease</li> <li>• Diagnosis and treatment of minimal hepatic encephalopathy and liver diseases</li> <li>• Knowledge of immune mechanisms and treatment of hepatocarcinoma</li> <li>• Investigate prognostic factors and treatment of acute and chronic pancreatitis</li> <li>• Establish a translational research team in inflammatory bowel, pancreatic and liver disease</li> <li>• Diagnosis and treatment of functional digestive disease</li> <li>• Analyze endoscopic treatment and prognostic factors of response in different digestive diseases</li> </ul>

## Main lines of research

- Stem cell treatment in fistulizing inflammatory bowel disease (IBD)
- Local biologic treatment of IBD
- Anorectal function in IBD
- Inflammatory markers and immune regulation in IBD
- Natural history of acute and chronic pancreatitis
- Evaluation of new treatment strategies in acute and chronic pancreatitis
- Caustic ingestion: risk stratification and diagnostic modalities
- Blood Immune profile in liver cancer and cirrhosis
- Liver disease: alcohol, virus and autoimmune
- Evaluation of different therapies in hepatocarcinoma
- Studies in healthy population of the physiological motor characteristics of the upper and lower digestive tract
- Endoscopic treatment in Zencker diverticulum and pancreatic disease
- Therapeutic endoscopic ultrasound: different drainages and gastro-jejunostomy with lumen apposing metal stents

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. De-Madaria E, Buxbaum JL, Maisonneuve P, Garcia Garcia de Paredes A, Zapater P, Guilabert L, Vaillo-Rocamora A, Rodriguez-Gandia MA, Donate-Ortega J, Lozada-Hernandez EE, Collazo Moreno AJR, Lira-Aguilar A, Llovet LP, Mehta R, Tandel R, Navarro P, Sanchez-Pardo AM, Sanchez-Marín C, Cobreros M, Fernandez-Cabrera I, Casals-Seoane F, Deza D, Lauret-Brana E, Martí-Marques E, Camacho-Montano LM, Ubieto V, Ganuza M, Bolado F. Aggressive or moderate fluid resuscitation in acute pancreatitis. *New England Journal of Medicine*. 2022 Sep 15;387(11):989-1000. doi: 10.1056/NEJMoa2202884. PMID: 36103415. IF: 176,079
2. Loras C, Andujar X, Gornals JB, Sanchiz V, Brullet E, Sicilia B, Martin Arranz MD, Naranjo A, Barrio J, Duenas C, Foruny JR, Busquets D, Monfort D, Pineda JR, Gonzalez Huix F, Perez Roldan F, Pons V, Gonzalez B, Reyes Moreno J, Sainz E, Guardiola J, Bosca Watts MM, Fernandez Banares F, Mayor V, Esteve M. Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial. *Lancet. Gastroenterology & Hepatology*. 2022 Apr;7(4):332-341. doi: 10.1016/S2468-1253(21)00386-1. PMID: 35065738. IF: 45,042
3. Tosca J, Sanchez A, Sanahuja A, Villagrasa R, Poyatos P, Mas P, Pascual I, Lluch P, Herreros B, Pena A, Sanchiz V, Minguez M. Caustic ingestion: a risk-based algorithm. *American Journal of Gastroenterology*. 2022 Oct 1;117(10):1593-1604. doi: 10.14309/ajg.00000000000001953. PMID: 36194047. IF: 12,045
4. Ballester MP, Mesonero F, Florez-Diez P, Gomez C, Fuentes-Valenzuela E, Martin N, Senosiain C, Vela M, Fernandez-Clotet A, Perez P, Rubin de Celis C, Calvino-Suarez C, Hermida B, Munoz R, Gonzalez-Vivo M, Brunet E, Jimenez N, Botella B, Yebra J, Suarez-Ferrer C, Bouhmidi A, Lopez-Serrano A, Ponferrada A, Duenas C, Minguez M. Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study. *Alimentary Pharmacology & Therapeutics*. 2022 Jun;55(11):1402-1413. doi: 10.1111/apt.16832. PMID: 35224758. IF: 9,524
5. González MRD, Ballester MP, Romero-González E, Sánchez-Pardo AM, Martí-Aguado D, Tosca J, Suria C, Ausejo RA, Moreno IP, Silvestre MDP, Pérez MM, Bosca-Watts MM. Biological treatment interruption in Inflammatory Bowel Disease: motivation and predictive factors. *Gastroenterología*

# 4 scientific activity

y Hepatología. 2022 Nov 11;S0210-5705(22)00267-9. doi: 10.1016/j.gastrohep.2022.10.021. PMID: 36375696. IF: 5,867

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** CIPROM2021/044

**Title:** Pharmacology of the hepato-gastrointestinal tract: analysis of cellular and molecular targets for the treatment of fibrosis

**Principal Investigator:** Juan Vicente Esplugues Mota and Mª Dolores Barrachina Sancho [Maia Boscá as collaborating researcher]

**Funding Body:** Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital

**Beneficiary Institution:** University of Valencia

**Duration:** 2022-2025

**Total Budget:** €539.240

**Title:** Estudio nacional en enfermedad inflamatoria intestinal sobre determinantes genéticos y ambientales (Estudio ENEIDA)

**Principal Investigator:** Miguel Minguez Pérez and Lorena Boronat Cifre

**Funding Body:** Janssen-Cilag

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022

**Total Budget:** €17.637

**Title:** Influencia de la actividad inflamatoria en la función anorrectal de los pacientes con Enfermedad Inflamatoria Intestinal

**Principal Investigator:** Ana Sanahuja Martínez

**Funding Body:** Sociedad Valenciana de Patología Digestiva

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total Budget:** €5.000


# scientific activity

## Clinical Associated Group in Traumatology and Orthopedics Clinical Associated group

Group members	Researchers by categories
<b>Leading Researcher, R4</b> Antonio Silvestre Muñoz. Hospital. University	R2 3
<b>Established Researcher, R3</b> Rosa María Cibrián Ortiz de Anda. University	R3 1
<b>Recognised Researchers, R2</b> José Albelda Vitoria. University Laura Pino Almero. University Rosario Salvador Palmer. University	R4 1
	STAFF 1
	<b>Staff. Collaborating Researcher</b> José Expósito Ollero. INCLIVA

Strategic aims
<ul style="list-style-type: none"> <li>Non-invasive imaging in orthopedics</li> <li>New prosthesis fixation systems applied to Traumatology</li> <li>Mechanisms of inflammation and oxidative stress in bone pathologies</li> </ul>
Main lines of research
<ul style="list-style-type: none"> <li>Cellular oxidative stress and its relationship with idiopathic femoral osteonecrosis</li> <li>Diagnosis and monitoring of the diabetic foot using infrared thermography</li> <li>Protection strategies against osteoarticular deterioration</li> <li>Sequentiality of muscle contraction: importance in the early detection of lumbopelvic dysfunction, cervical and shoulder girdle</li> <li>Cellular mechanisms to regulate the inflammatory response in chronic inflammatory diseases</li> <li>Robotics for precision in orthopedic reconstructive surgery</li> <li>Rehabilitation to improve results after a randomized prospective study of total knee arthroplasty</li> <li>Local mechanical stimulation of mesenchymal cells for osteogenic and chondrogenic differentiation in regenerative medicine</li> </ul>

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Blasco J, Perez-Maletzki J, Diaz-Diaz B, Silvestre-Munoz A, Martinez-Garrido I, Roig-Casasus S. Fall classification, incidence and circumstances in patients undergoing total knee replacement. *Scientific Reports*. 2022 Nov 18;12(1):19839. doi: 10.1038/s41598-022-23258-x. PMID: 36400816. IF: 4,996
- Gene-Morales J, Gene-Sampedro A, Salvador-Palmer R, Colado JC. Effects of squatting with elastic bands or conventional resistance-training equipment at different effort levels in post-exercise intraocular pressure of healthy men. *Biology of Sport*. 2022 Oct;39(4):895-903. doi: 10.5114/biolsport.2022.109955. PMID: 36247937. IF: 4,606

# scientific activity

3. Priego-Quesada J, Catala-Vilaplana I, Bermejo-Ruiz J, Gandia-Soriano A, Pellicer-Chenoll M, Encarnacion-Martinez A, Cibrian Ortiz de Anda R, Salvador-Palmer R. Effect of 10 km run on lower limb skin temperature and thermal response after a cold-stress test over the following 24 h. *Journal of Thermal Biology.* 2022 Apr;105:103225. doi: 10.1016/j.jtherbio.2022.103225. PMID: 35393059. IF: 3,189
4. Sanchez-Jimenez JL, Aparicio I, Romero-Avila JL, Bellot-Arcis C, Cibrián Ortiz de Anda RM, Priego-Quesada Jl. Skin temperature measurement in individuals with spinal cord injury during and after exercise: Systematic review. *Journal of Thermal Biology.* 2022 Apr;105:103146. doi: 10.1016/j.jtherbio.2021.103146. PMID: 35393040. IF: 3,189
5. Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Impact of the COVID-19 pandemic on a cancer fast-track programme. *Cancer Control.* 2022 Jan-Dec;29:10732748221131000. doi: 10.1177/10732748221131000. PMID: 36355430. IF: 2,339

## THESIS

**Thesis title:** The potential of elastic bands to optimize ocular and cardiovascular responses, subjective effort, and performance in squats

**Doctoral candidate:** Javier Gené Morales

**Director(s):** María Rosario Salvador Palmer, Andrés Gené Sampedro, Juan Carlos Colado Sánchez

**Date of the defense:** 07/04/2022

**Grade:** Sobresaliente "cum laude"

**Thesis title:** Utilización de cótilos de doble movilidad en cirugía protésica de cadera ¿pueden mejorar los óptimos resultados?

**Doctoral candidate:** Lorenzo José Hernández Ferrando

**Director(s):** Antonio Silvestre Muñoz

**Date of the defense:** 25/11/2022

**Grade:** Sobresaliente "cum laude"

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Title:** Evaluación de la eficiencia de la metodología para el seguimiento de pacientes con prótesis de rodilla

**Principal Investigator:** Antonio Silvestre Muñoz

**Funding Body:** Fundación Mutua Madrileña

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €65.000


# scientific activity

## Clinical Associated Group in Neurorology Clinical Associated group

Group members	Researchers by categories
<b>Leading Researcher, R4</b> José Miguel Láinez Andrés Hospital. University	R2 4
<b>Recognised Researchers, R2</b> Alejandro Ponz de Tienda. Hospital. University Anna Piera Balbastre. Hospital Raquel Chamarro Lázaro. Hospital Rosario Gil Gimeno. Hospital	R4 1
<b>Staff. Collaborating Researchers</b> Ana Isabel Pareja Martínez. Hospital Antonio Salvador Aliaga. Hospital Begoña López Pesquera. Hospital David García López. Hospital Francisco Gascón Giménez. Hospital Jésica García Ull. Hospital	STAFF 10
	José Andrés Domínguez Morán. Hospital José María Salom Juan. Hospital José Miguel Santonja Llabata. Hospital
	<b>Staff. Nurse</b> Míriam Iborra Perales. Hospital

Main lines of research
<ul style="list-style-type: none"> <li>Cognitive impairment and dementia</li> <li>Cerebrovascular diseases</li> <li>Demyelinating diseases</li> <li>Epilepsy</li> <li>Extrapyramidal pathology</li> <li>Pain/headaches</li> </ul>

## PUBLICATIONS



## SELECTED PUBLICATIONS

- Fernández-Velasco JL, Monreal E, Kuhle J, Meca-Lallana V, Meca-Lallana J, Izquierdo G, Oreja-Guevara C, Gascón-Giménez F, Sainz de la Maza S, Walo-Delgado PE, Lapuente-Suanzes P, Maceski A, Rodríguez-Martín E, Roldán E, Villarrubia N, Saiz A, Blanco Y, Diaz-Pérez C, Valero-López G, Diaz-Díaz J,

Aladro Y, Brieva L, Íñiguez C, González-Suárez I, Rodríguez de Antonio LA, García-Domínguez JM, Sabin J, Llufriu S, Masjuan J, Costa-Frossard L, Villar LM. Baseline inflammatory status reveals dichotomic immune mechanisms involved in primary-progressive multiple sclerosis pathology. *Frontiers in Immunology*.

# 4 scientific activity

- in Immunology. 2022 Mar 21;13:842354. doi: 10.3389/fimmu.2022.842354. PMID: 35386690. IF: 8,786
- 2. Mendibe Bilbao M, Ezpeleta Echavarri D, Lainez Andres J. The SEN and the Spanish model of recertification promoted by the Spanish Federation of Medical and Scientific Associations and its members. Neurologia. 2022 Sep 29;S2173-5808(22)00102-X. doi: 10.1016/j.nrleng.2022.09.001. PMID: 36183954. IF: 5,486
  - 3. Santos-Lasaosa S, Belvis R, Cuadrado M, Diaz-Insa S, Gago-Veiga A, Guerrero-Peral A, Huerta M, Irimia P, Lainez J, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sanchez-Del Rio M, Viguera J, Pozo-Rosich P. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. Neurologia. 2022 Jun;37(5):390-402. doi: 10.1016/j.nrleng.2019.03.025. PMID: 35672126. IF: 5,486
  - 4. Quintanilla-Bordas C, Gascon-Gimenez F, Alcala C, Paya M, Mallada J, Silla R, Carratala-Bosca S, Gasque-Rubio R, Castillo J, Casanova B. Case Report: exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis: a case series. Frontiers in Neurology. 2022 Apr 27;13:897275. doi: 10.3389/fneur.2022.897275. PMID: 35572939. IF: 4,086
  - 5. Vicente C, Lacruz L, Gascon F, Carratala S, Quintanilla-Bordas C, Sanz M, Carcelen-Gadea M, Mallada J, Carreres J, Torres L, Dominguez J, Canizares E, Gil-Perotin S, Cubas L, Rubio R, Castillo-Villalba J, Perez-Miralles F, Casanova B. Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis. Frontiers in Neurology. 2022 Oct 28;13:991596. doi: 10.3389/fneur.2022.991596. PMID: 36388220. IF: 4,086

## THESIS

**Thesis title:** *Vagus nerve stimulator en epilepsia fármaco-resistente*

**Doctoral candidate:** Ana Suller Martí

**Director(s):** Jose Miguel Láinez Andres

**Date of the defense:** 21/03/2022

**Grade:** Sobresaliente "cum laude"

**Quality recognition/Award:** European PhD

# scientific activity


## Clinical Associated Group in Pharmacy Clinical Associated group

Group members	Researchers by categories
<b>Leading Researcher, R4</b> Manuel Alós Almiñana Hospital. University	R2 3
<b>Established Researcher, R3</b> Teresa Torrecilla Junyent. Hospital	R3 1
<b>Recognised Researchers, R2</b> Carmen Carrión Carrión. Hospital. University Francisco Ferriols Lisart. Hospital. University Rafael Ferriols Lisart. Hospital. University	R4 1
<b>Staff. Collaborating Researchers</b> Carlos Ezquer Garín. INCLIVA Diego Cano Blanquer. Hospital Mercedes Jiménez Heredia. Hospital Raquel Pardillo Armuña. INCLIVA	STAFF 4

Strategic aims
<ul style="list-style-type: none"> <li>Implementation of a new therapeutical drug monitoring system in a clinical analytical laboratory for pharmacokinetic control of antibiotic, antifungal and antineoplastic agents in the hospitalized patient, with the aim of optimal and rational use of pharmacological treatment</li> <li>Observational Study of population pharmacokinetic model of voriconazole in allogeneic stem cell transplantation. Study approved by the <i>Agencia Española del medicamento y Productos Sanitarios</i> with code CSV-VOR-2014-01</li> <li>Study of Physico-chemical stability of a new mycophenolate mofetil intravenous solution in polypropylene infusion bag at different storage conditions</li> <li>Study of pharmacokinetics of caspofungin in patients under hemodiafiltration. Study approved by the <i>Agencia Española del Medicamento y Productos Sanitarios</i> with code MER-CAS-2013-01</li> <li>Study of pharmacokinetics of Ceftolozane in critical patients. Study pending of approval by the <i>Agencia Española del Medicamento y Productos Sanitarios</i> with code CEFT-TCRR-2017</li> <li>Study of Physico-chemical stability of a new ophthalmic eyedrop formulation at different storage conditions</li> </ul>
Main lines of research
<ul style="list-style-type: none"> <li>Pharmacokinetics and Biopharmacy</li> <li>Economic evaluation of medicines and health technologies</li> <li>Anti-infective optimization program</li> </ul>

# scientific activity

## PUBLICATIONS



## SELECTED PUBLICATIONS

1. Usach I, Di Marco S, Díez O, Alós M, Peris JE. The usefulness of in vitro percutaneous absorption experiments applying the infinite dose technique to predict in vivo plasma levels: comparison of model-predicted and observed plasma concentrations of nortriptyline in rats. *Pharmaceutics*. 2022 Jul 12;14(7):1457.doi:10.3390/pharmaceutics14071457. PMID: 35890351. IF: 6,525

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Title:** *Evaluación económica en la práctica asistencial del tratamiento del virus de la hepatitis C basado en antivirales de acción directa*

**Principal Investigator:** Manuel Alós Almiñana and Raquel Pardillo Armuña

**Funding Body:** Janssen-Cilag

**Beneficiary Institution:** *Fundación Investigación Hospital Clínico Universitario de Valencia*

**Duration:** 2022

**Total Budget:** €27.580,69

## THESIS

**Thesis title:** *Evaluación económica en la práctica asistencial del tratamiento del virus de la hepatitis C basado en antivirales de acción directa*

**Doctoral candidate:** Raquel Pardillo Armuña

**Director(s):** Manuel Alós Almiñana, Pilar D'ocón Navaza, Rafael Ferriols Lisart

**Date of the defense:** 21/11/2022

**Grade:** *Sobresaliente "cum laude"*


# scientific activity

4

## 4.4 Hospital division research area

### Groups

- Department of Anesthesiology
- Department of Angiology and Vascular Surgery
- Department of Biochemistry and Clinical Analysis
- Arrhythmia and Cardiac Pacing Unit
- Department of Cardiology
- Department of Cardiovascular Surgery
- Department of Dermatology
- Department of Digestive Medicine
- Department of Endocrinology
- Department of Family and Community Medicine
- Department of Gynecology and Obstetrics
- Department of Hematology and Hemotherapy
- Department of Intensive Medicine
- Department of Internal Medicine
- Department of Maxillofacial Surgery
- Department of Medical Emergency
- Department of Microbiology
- Department of Nephrology
- Department of Neurology
- Department of Neurophysiology
- Department of Neurosurgery
- Department of Nuclear Medicine
- Department of Ophthalmology
- Department of Otorhinolaryngology
- Department of Pathological Anatomy
- Department of Pediatrics
- Department of Pharmacy
- Department of Preventive Medicine and Quality of Care
- Department of Psychiatry
- Department of Radiologic Diagnosis
- Department of Thoracic Surgery
- Department of Traumatology and Orthopedic Surgery
- Department of Urology
- Teaching and Dissemination of Knowledge Unit




■ original articles ■ letters ■ editorials ■ reviews ■ case reports ■ corrections

# scientific activity

## Department of Anesthesiology

### PUBLICATIONS




### SELECTED PUBLICATIONS

1. Sanz-Ros J, Mas-Bargues C, Romero-Garcia N, Huete-Acevedo J, Dromant M, Borras C. Therapeutic potential of extracellular vesicles in aging and age-related diseases. International Journal of Molecular Sciences. 2022 Nov 23;23(23):14632. doi: 10.3390/ijms232314632. PMID: 36498960. IF: 6,208
2. Garcia-Llana H, Panizo N, Gandia L, Ortí M, Giménez-Civera E, Forquet C, D'Marco L, Puchades M, Sargsyan M, Sanchis I, Ribera C, Marco M, Ferra C, Pérez-Baylach C, Bonilla B, Frances F, Pérez-Bernat E, Sancho A, Gorri J. COVID-19 vaccination improved psychological distress (anxiety and depression scores) in chronic kidney disease patients: a prospective study. Vaccines. 2022 Feb 16;10(2):299. doi: 10.3390/vaccines10020299. PMID: 35214757. IF: 4,961

## Department of Angiology and Vascular Surgery

### PUBLICATIONS




### SELECTED PUBLICATIONS

1. Torres-Blanco A, Altable-García M, Miralles-Hernández M. Conservative surgical management of late carotid patch infection in a patient with subsequent stenting for restenosis. Vascular and Endovascular Surgery. 2022 Jan;56(1):112-116. doi: 10.1177/15385744211043329. PMID: 34601983. IF: 1,046

## Department of Biochemistry and Clinical Analysis

### PUBLICATIONS




# scientific activity

## SELECTED PUBLICATIONS

1. Garcia de Guadiana-Romualdo L, Rodriguez Rojas C, Morell-Garcia D, Andaluz-Ojeda D, Rodriguez Mulero M, Rodriguez-Borja E, Ballesteros-Vizoso A, Calvo M, Albert-Botella L, Pozo Giraldez A, Llompart-Alabern I, Bolado Jimenez C, Hernandez Olivo M, Fernandez Presa L, Ortega-Perez J, Fora Romero M, Campos-Rodriguez V, Ballester Ferriz A, Guiu-Marti A, Pinilla Arribas L, Galindo Martinez M, Puerto-Lara E, Lopez Tarazaga A, Ros Braquehais M, Nogales Martin L, Juez Santamaria C, Trapiello Fernandez W, Espinilla Fernandez V, Havelka A, Albaladejo-Oton M. Circulating levels of calprotectin, a signature of neutrophil activation in prediction of severe respiratory failure in COVID-19 patients: a multicenter, prospective study [CalCov study]. *Inflammation Research.* 2022 Jan;71(1):57-67. doi: 10.1007/s00011-021-01516-4. PMID: 34718856. IF: 6,986
2. Safont B, Tarraso J, Rodriguez-Borja E, Fernandez-Fabrellas E, Sancho-Chust JN, Molina V, Lopez-Ramirez C, Lope-Martinez A, Cabanes L, Andreu A, Herrera S, Lahosa C, Ros JA, Rodriguez-Hermosa JL, Soriano JB, Moret-Tatay I, Carbonell-Asins JA, Mulet A, Signes-Costa J. Lung function, radiological findings and biomarkers of fibrogenesis in a cohort of COVID-19 patients six months after hospital discharge. *Archivos de Bronconeumología.* 2022 Feb;58(2):142-149.
3. Palanca A, Quinones Torrelo C, Girbes J, Real JT, Ampudia Blasco FJ. Impact of COVID-19 lockdown on diabetes management and follow-up in a broad population in Spain. *European Journal of Clinical Investigation.* 2022 Jun;52(6):e13771. doi: 10.1111/eci.13771. PMID: 35313009. IF: 5,722
4. Cuellar C, Rodero M, Perez-Griera J, Galindo-Regal L, Lopez-Chulia F, Garcia-Ballesteros C, Andreu-Ballester J. Association between anti-Anisakis simplex antibodies and interleukin-7 levels. *International Immunopharmacology.* 2022 Oct;111:109134. doi: 10.1016/j.intimp.2022.109134. PMID: 35964412. IF: 5,714
5. Garcia-de-la-Asuncion J, Moreno T, Duca A, Garcia-del-Olmo N, Perez-Griera J, Belda J, Soro M, Garcia-del-Olmo E. Effects of remote ischemic postconditioning on HIF-1 alpha and other markers in on-pump cardiac surgery. *General Thoracic and Cardiovascular Surgery.* 2022 Mar;70(3):239-247. doi: 10.1007/s11748-021-01690-6. PMID: 34378159. IF: 1,227

## Arrhythmia and Cardiac Pacing Unit

### PUBLICATIONS



## SELECTED PUBLICATIONS

1. Palau P, Amiguet M, Domínguez E, Sastre C, Mollar A, Seller J, Garcia Pinilla JM, Larumbe A, Valle A, Gómez Doblas JJ, de la Espriella R, Miñana G, Mezcua AR, Santas E, Bodí V, Sanchis J, Pascual-Figal D, Górriz JL, Bayés-Genís A, Núñez J; DAPA-VO2 Investigators. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction [DAPA-VO2]: a randomized clinical trial. *European Journal of Heart Failure.* 2022 Oct;24(10):1816-1826. doi: 10.1002/ejhf.2560. PMID: 35604416. IF: 18,174
2. Gabaldón-Pérez A, Marcos-Garcés V, Gavara J, López-Lereu MP, Monmeneu JV, Pérez N, Ríos-Navarro C, de Dios E, Merenciano-González H, Cànoves J, Racugno P, Bonanad C, Minana G, Núñez J, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Ortiz-Pérez JT, Rodríguez-Palomares JF, Bodí V. Prognostic value of cardiac magnetic resonance early after ST-segment elevation myocardial infarction in older patients. *Age Ageing.* 2022 Nov 2;51(11):afac248. doi: 10.1093/ageing/afac248. PMID: 36436010. IF: 12,782
3. Palau P, Domínguez E, Gonzalez C, Bondía E, Albiach C, Sastre C, Martínez ML, Núñez J, López L. Effect of a home-based

# scientific activity

- inspiratory muscle training programme on functional capacity in postdischarged patients with long COVID: the InsCOVID trial. *BMJ Open Respiratory Research.* 2022 Dec;9(1):e001439. doi: 10.1136/bmjresp-2022-001439. PMID: 36549786. IF: 5,054
4. Palau P, Domínguez E, Sastre C, Martínez ML, González C, Bondía E, Albiach C, Núñez J, López L. Effect of a home-based inspiratory muscular training programme on functional capacity in patients with chronic COVID-19 after a hospital discharge: protocol for a randomised control trial [InsCOVID trial]. *BMJ Open Respiratory Research.* 2022 Jul;9(1):e001255. doi: 10.1136/bmjresp-2022-001255. PMID: 35790316. IF: 5,054
5. Valles E, Jimenez J, Martí-Almor J, Toquero J, Ormaetxe JM, Barrera A, Garcia Alberola A, Rubio JM, Morina P, Grande C, Fe Arcocha M, Peinado R, Cozar R, Hernandez J, Perez Alvarez L, Gatzanaga L, Ferrero De Loma Osorio A, Ruiz Granell R, Villuendas R, Martinez-Alday JD. Cryoballoon ablation
- for persistent and paroxysmal atrial fibrillation: procedural differences and results from the Spanish Registry (RECABA). *Journal of Clinical Medicine.* 2022 Feb 22;11(5):1166. doi: 10.3390/jcm11051166. PMID: 35268259. IF: 4,964

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI-2021-015

**Title:** RECONST\_ECG: *Evaluación del proceso de reconstrucción de un electrocardiograma de 12 derivaciones a partir de 3 en condiciones ambulatorias*

**Principal Investigator:** Javier Calpe Maravillas and Ricardo Ruiz Granell

**Funding Body:** Universidad de Valencia - INCLIVA


**Beneficiary Institution:** Universidad de Valencia - INCLIVA

**Duration:** 2021-2022

**Total Budget:** €8.712

## Department of Cardiology

### PUBLICATIONS



### SELECTED PUBLICATIONS

- De la Espriella R, Amiguet M, Minana G, Rodriguez JC, Moyano P, Segarra D, Fernandez J, Santas E, Nunez G, Lorenzo M, Bonanad C, Alania E, Valle A, Sanchis J, Bodi V, Gorriz JL, Navarro J, Codina P, Voors AA, Bayes-Genis A, Nunez J. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure. *European Journal of Heart Failure.* 2022 Nov;24(11):2108-2117. doi: 10.1002/ejhf.2651. PMID: 36054502. IF: 17,349
- Lorenzo Hernandez M, Sanchis J. Management of acute decompensated heart failure in Spain: where are we now?. *Emergencias.* 2022 Apr;34(2):81-82. PMID: 35275457. IF: 5,345
- Gavara J, Marcos-Garcés V, Lopez-Lereu, MP, Monmeneu JV, Rios-Navarro C, de Dios E, Perez N, Merenciano H, Gabaldon A, Canoves J, Racugno P, Bonanad C, Minana G, Nunez J, Nunez E, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Rodriguez- Nunez J, Nunez E, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Rodriguez-
- Nunez J, Nunez E, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Rodriguez-Palomares JF, Ortiz-Perez JT, Bodi V. Magnetic resonance assessment of left ventricular ejection fraction at any time post-infarction for prediction of subsequent events in a large multicenter STEMI Registry. *Journal of Magnetic Resonance Imaging.* 2022 Aug;56(2):476-487. doi: 10.1002/jmri.27789. PMID: 34137478. IF: 5,119
- Lorenzo Hernandez M, Sanchis J. Management of acute decompensated heart failure in Spain: where are we now?. *Emergencias.* 2022 Apr;34(2):81-82. PMID: 35275457. IF: 4,964
- Gavara J, Marcos-Garcés V, Lopez-Lereu, MP, Monmeneu JV, Rios-Navarro C, de Dios E, Perez N, Merenciano H, Gabaldon A, Canoves J, Racugno P, Bonanad C, Minana G, Nunez J, Nunez E, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Rodriguez-


# scientific activity

Palomares JF, Ortiz-Perez JT, Bodi V. Magnetic resonance assessment of left ventricular ejection fraction at any time post-infarction for prediction of subsequent events in a large

multicenter STEMI Registry. *Journal of Magnetic Resonance Imaging.* 2022 Aug;56(2):476-487. doi: 10.1002/jmri.27789. PMID: 34137478. IF: 4,996

## Department of Cardiovascular Surgery

### PUBLICATIONS




### SELECTED PUBLICATIONS

- Cano J, Facila L, Gracia-Baena J, Zangroniz R, Alcaraz R, Rieta J. The relevance of calibration in machine learning-based hypertension risk assessment combining

photoplethysmography and electrocardiography. *Biosensors-Basel.* 2022 May 1;12(5):289. doi: 10.3390/bios12050289. PMID: 35624590. IF: 5,743

## Department of Dermatology

### PUBLICATIONS



### SELECTED PUBLICATIONS

- Rocamora V, Crespi L, Ferran M, Llamas-Velasco M, del Alcazar E, Carrascosa J, Beltran E, Urruticoechea-Arana A, Estebaranz J, Vidal D, Riera J, Rodriguez L, Armesto S, Fernandez J, Aparicio G, Perez S, Porcar S, Montesinos E, Gallardo F. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. *Dermatologic Therapy.* 2022 Nov;35(11):e15865. doi: 10.1111/dth.15865. PMID: 36175141. IF: 3,858
- Saura S, Benavent M. Pachydermodactyly. *Journal of Cutaneous Medicine and Surgery.* 2022;26(3):310. doi: 10.1177/12034754211003523. doi: 10.1177/12034754211003523. PMID: 33779338. IF: 2,854
- Benavent M, Saura S. Visual dermatology: annular elastolytic giant cell granuloma. *Journal of Cutaneous Medicine and Surgery.* 2022;26(1):98. doi: 10.1177/1203475420962047. PMID: 32988233. IF: 2,854
- Agud-Dios M, Perandones-Gonzalez H, Fernández-Domper L, Dominguez Santas M, Boixeda de Miquel P. Picosecond 755-nm alexandrite laser treatment for oral lentiginosis in Peutz-Jeghers disease. *Lasers in Surgery and Medicine.* 2022 Aug;54(6):823-824. doi: 10.1002/lsm.23553. PMID: 35485783. IF: 2,703
- Fernandez-Domper L, Redondo M, De Dios M, Gonzalez H, Boixeda P. Erythema Ab Igne successfully treated with a 755-nm alexandrite picosecond laser. *Lasers in Medical Science.*

# scientific activity

2022 Jun;37(4):2321-2322. doi: 10.1007/s10103-021-03459-y. PMID: 34750732. IF: 2,555

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Title:** Estudio del MP-3 como potencial biomarcador plasmático de progresión de melanoma

**Principal Investigator:** Ángeles Revert Fernández and Raúl Ballestín Hinojosa

**Funding Body:** Janssen-Cilag


**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022

**Total budget:** €8.236,03

## Department of Digestive Medicine

### PUBLICATIONS




### SELECTED PUBLICATIONS

- Tranah T, Ballester M, Carbonell-Asins J, Ampuero J, Alexandrino G, Caracostea A, Sanchez-Torrijos Y, Thomsen K, Kerbert A, Capilla-Lozano M, Romero-Gomez M, Escudero-Garcia D, Montoliu C, Jalan R, Shawcross D. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. *Journal of Hepatology*. 2022 Dec;77(6):1554-1563. doi: 10.1016/j.jhep.2022.07.014. PMID: 35872326. IF: 30,083
- Tosca J, Sanchez A, Sanahuja A, Villagrasa R, Poyatos P, Mas P, Pascual I, Lluch P, Herreros B, Pena A, Sanchiz V, Minguez M. Caustic ingestion: a risk-based algorithm. *American Journal of Gastroenterology*. 2022 Oct 1;117(10):1593-1604. doi: 10.14309/ajg.00000000000001953. PMID: 36194047. IF: 12,045
- Ballester MP, Mesonero F, Florez-Diez P, Gomez C, Fuentes-Valenzuela E, Martin N, Senosiain C, Vela M, Fernandez-Clotet A, Perez P, Rubin de Celis C, Calvino-Suarez C, Hermida B, Munoz R, Gonzalez-Vivo M, Brunet E, Jimenez N, Botella B, Yebra J, Suarez-Ferrer C, Bouhmidi A, Lopez-Serrano A, Ponferrada A, Duenas C, Minguez M. Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study. *Alimentary Pharmacology & Therapeutics*. 2022 Jun;55(11):1402-1413. doi: 10.1111/apt.16832. PMID: 35224758. IF: 9,524
- González MRD, Ballester MP, Romero-González E, Sánchez-Pardo AM, Martí-Aguado D, Tosca J, Suria C, Ausejo RA, Moreno IP, Silvestre MDP, Pérez MM, Bosca-Watts MM. Biological treatment interruption in Inflammatory Bowel Disease: motivation and predictive factors. *Gastroenterología y Hepatología*. 2022 Nov 11;S0210-5705(22)00267-9. doi: 10.1016/j.gastrohep.2022.10.021. PMID: 36375696. IF: 5,867

# scientific activity

## Department of Endocrinology

### PUBLICATIONS




### SELECTED PUBLICATIONS

1. Casany-Fernandez R, Gascon-Gimenez F, Matarredona Solaz E, Pardo Lozano F, Dominguez-Moran J, Ferri Ciscar J, Real J. Remission of graves disease after initiation of ocrelizumab in patients with multiple sclerosis. *Thyroid*. 2022 Nov 23. doi: 10.1089/thy.2022.0398. PMID: 36416241. IF: 6,506
2. Alarcon Chulilla M, Avila Fuentes M, Casan Fernandez R, Muelas N, Real Collado J. Immune-mediated necrotising inflammatory myopathy. A rare side effect of statins. *Endocrinologia, Diabetes y Nutricion*. 2022 Oct;69(8):648-649. doi: 10.1016/j.endien.2022.10.001. PMID: 36347793. IF: 1,833

## Department of Family and Community Medicine

### PUBLICATIONS




### SELECTED PUBLICATIONS

1. Menendez Rodriguez M, Garau Ramirez J, Traver Salvador A, Hervas Jimenez Y, Garcia Morales N, Seoane Pillado T, Pin Vieito N, Vega Villaamil P, Montes Martinez A, Cubilla J. Rawl's questionnaire Spanish validation for colorectal cancer screening with faecal occult blood testing. *Gastroenterologia y Hepatologia*. 2022 Feb;45(2):106-113. doi: 10.1016/j.gastrohep.2021.04.001. PMID: 34023478. IF: 5,867

## Department of Gynecology and Obstetrics

### PUBLICATIONS



### SELECTED PUBLICATIONS


1. Moccia P, Belda-Montesinos R, Monllor-Tormos A, Chedraui P, Cano A. Body weight and fat mass across

# scientific activity

- the menopausal transition: hormonal modulators. *Gynecological Endocrinology*. 2022 Feb;38(2):99-104. doi: 10.1080/09513590.2021.2004395. PMID: 34898344. IF: 2,277
2. Tejada MA, Santos Llamas A, Escrivá L, Tarin JJ, Cano A, Fernandez Ramirez MJ, Nunez Badinez P, De Leo B, Saunders PTK, Vidal V, Barthas F, Vincent K, Sweeney PJ, Sillito RR, Armstrong JD, Nagel J, Gomez R. Identification of altered evoked and non-evoked responses in a heterologous mouse model of endometriosis-associated pain. *Biomedicines*. 2022 Feb 21;10(2):501. doi: 10.3390/biomedicines10020501. PMID: 35203710. IF: 4,757
  3. Bauset C, Martinez-Aspas A, Smith-Ballester S, Garcia-Vigara A, Monllor-Tormos A, Kadi F, Nilsson A, Cano A. Nuts and metabolic syndrome: reducing the burden of metabolic syndrome in menopause. *Nutrients*. 2022 Apr 18;14(8):1677. doi: 10.3390/nu14081677. PMID: 35458240. IF: 6,706

## Department of Hematology and Hemotherapy

### PUBLICATIONS




### SELECTED PUBLICATIONS

1. Pinana J, Lopez-Corral L, Martino R, Montoro J, Vazquez L, Perez A, Martin-Martin G, Facal-Malvar A, Ferrer E, Pascual M, Sanz-Linares G, Gago B, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave M, Lopez-Jimenez J, Marcos-Corrales S, Garcia-Blazquez M, Garcia-Gutierrez V, Hernandez-Rivas J, Saus A, Espigado I, Alonso C, Hernani R, Solano C, Ferrer-Lores B, Guerreiro M, Ruiz-Garcia M, Munoz-Bellido J, Navarro D, Cedillo A, Sureda A, Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). *American Journal of Hematology*. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. PMID: 34695229. IF: 13,265

of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). *American Journal of Hematology*. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. PMID: 34695229. IF: 13,265

## Department of Intensive Medicine

### PUBLICATIONS



### SELECTED PUBLICATIONS

1. Olea B, Albert E, Torres I, Gozalbo-Rovira R, Carbonell N, Ferreres J, Poujois S, Costa R, Colomina J, Rodriguez J, Blasco M, Navarro D. SARS-CoV-2 N-antigenemia in critically ill adult COVID-19 patients: frequency and association with

inflammatory and tissue-damage biomarkers. *Journal of Medical Virology*. 2022 Jan;94(1):222-228. doi: 10.1002/jmv.27300. PMID: 34449894. IF: 20,693

# scientific activity

4

2. Forque L, Albert E, Gimenez E, Torres I, Carbonell N, Ferreres J, Blasco M, Navarro D. Monitoring of Torque Teno virus DNAemia in critically ill COVID-19 patients: may it help to predict clinical outcomes?. *Journal of Clinical Virology*. 2022 Jan 23;148:105082. doi: 10.1016/j.jcv.2022.105082. PMID: 35091226. IF: 14,481
3. Juarez-Vela R, Andres-Esteban E, Gea-Caballero V, Sanchez-Gonzalez J, Marcos-Neira P, Serrano-Lazaro A, Tirado-Angles G, Ruiz-Rodriguez J, Durante A, Santolalla-Arnedo I, Garcia-Erce J, Quintana-Diaz M. Related factors of anemia in critically ill patients: a prospective multicenter study. *Journal of Clinical Medicine*. 2022 Feb 16;11(4):1031. doi: 10.3390/jcm11041031. PMID: 35207301. IF: 4,964
4. Juarez-Vela R, Garcia-Erce J, Gea-Caballero V, de Vinaspre-Hernandez R, Santos-Sánchez J, Sanchez-Gonzalez J, Andres-Esteban E, Czapla M, Tejada C, Nanwani-Nanwani K, Serrano-Lazaro A, Quintana-Diaz M. A Cohort Study in Intensive Care Units: health decisions related to blood transfusion during the COVID-19 Pandemic. *Journal of Clinical Medicine*. 2022 Jul 28;11(15):4396. doi: 10.3390/jcm11154396. PMID: 35956012. IF: 4,964
5. Costa R, Alberola J, Olea B, Gozalbo-Rovira R, Gimenez E, Cuevas-Ferrando E, Torres I, Albert E, Carbonell N, Ferreres J, Sanchez G, Rodriguez-Diaz J, Blasco M, Navarro D. Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients. *Scientific Reports*. 2022 May 18;12(1):8273. doi: 10.1038/s41598-022-12461-5. PMID: 35585163. IF: 4,996

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI19/00994

**Title:** Biomarcadores epigenéticos en sepsis y su implicación en inmunosupresión y futuras comorbilidades en supervivientes

**Principal Investigator:** José Luis García Giménez (José Ferreres and Ainhoa Lázaro as collaborating researchers)

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER


**Beneficiary Institution:** Universidad de Valencia

**Duration:** 2020-2022

**Total budget:** €111.320

## Department of Internal Medicine

### PUBLICATIONS




### SELECTED PUBLICATIONS

1. Calderon J, Martinez F, Diaz J, Fernandez A, Sauri I, Uso R, Trillo J, Vela S, Bea C, Redon J, Forner M. Real-world data of anticoagulant treatment in non-valvular atrial fibrillation. *Frontiers in Cardiovascular Medicine*. 2022 Jan 21;8:733300. doi: 10.3389/fcvm.2021.733300. PMID: 35127843. IF: 5,846
2. Alvarez H, Rava M, Martinez C, Portilla J, Peraire J, Rivero A, Cervero M, Marino A, Poveda E, Llibre J, CoRIS Study Group, Ferrer Ribera A, CoRIS Study Group. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: a Spanish nationwide cohort. *HIV. Medicine*. 2022 Sep;23(8):825-836. doi: 10.1111/hiv.13265. PMID: 35234328. IF: 3,094
3. Ruiz-Alguero M, Alejos B, Yubero C, Jaume M, Iribarren J, Asensi V, Pasquau F, Galera C, Pascual-Carrasco M, Munoz A, Jarrin I, Ferrer Ribera A, Galindo Puerto M, Suarez-Garcia I. Use of generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection in Spain. *AIDS Research and Human Retroviruses*. 2022 Jun;38(6):433-440. doi: 10.1089/AID.2021.0122. PMID: 35357907. IF: 1,723

# scientific activity

## Department of Maxillofacial Surgery

### PUBLICATIONS



### SELECTED PUBLICATIONS

1. Botella Casas G, Cassinello Fernandez N, Perez Santiago L, Alfonso Ballester R, Ortega Serrano J. Influence of carotid anatomy anomaly in rescue surgery due to relapse of papillary thyroid cancer. Cirugia Espanola. 2022 Oct;100(10):657-659. doi: 10.1016/j.cireng.2022.06.035. PMID: 35753572. IF: 2,242

## Department of Medical Emergency

### PUBLICATIONS



### SELECTED PUBLICATIONS

1. Miró Ò, Jiménez S, Llorens P, Roussel M, Gorlicki J, García-Lamberechts EJ, Le Borgne P, Jacob J, Chauvin A, Lucidarme O, Burillo-Putze G, Aguirre A, Brigant F, Lozano L, González Del Castillo J, Freund Y; SIESTA and PEPCOV research teams. Pulmonary embolism severity and in-hospital mortality: an international comparative study between COVID-19 and non-COVID patients. European Journal of Internal Medicine. 2022 Apr;98:69-76. doi: 10.1016/j.ejim.2022.01.035. PMID: 35115232. IF: 7,749
2. Miró Ò, Sabaté M, Jiménez S, Mebazaa A, Martínez-Nadal G, Piñera P, Burillo-Putze G, Martín A, Martín-Sánchez FJ, Jacob J, Alquézar-Arbé A, García-Lamberechts EJ, Llorens P, González Del Castillo J; Spanish Investigators on Emergency Situations TeAm (SIESTA) network; SIESTA network. A case-control, multicentre study of consecutive patients with COVID-19 and acute [myo]pericarditis: incidence, risk factors, clinical characteristics and outcomes. Emergency Medicine Journal. 2022 May;39(5):402-410. doi: 10.1136/emermed-2020-210977. PMID: 35304388. IF: 3,814
3. Jacob J, Albert-Casado A, Del-Castillo J, Llorens-Soriano P, Jimenez-Hernandez S, Burillo-Putze G, Martin-Martinez A, Martin-Sanchez F, Garcia-Lamberechts E, Pinera-Salmeron P, Alquezar-Arbe A, Ferre-Losa C, Juan-Gomez M, Serrano-Lazaro L, Noceda-Bermejo J, Salido-Mota M, Fortuny-Bayarri M, Gonzalez-Tejera M, Ferreras-Amez J, Diaz-Fernandez E, Quero-Motto E, Peiro-Gomez A, Martin-Mojarro E, Llopis-Roca F, Huerta-Garcia A, Pedraza-Garcia J, Melendez-Calix N, Brazo-Aznar J, Cano-Cano M, Miro O. Safety and revisit related to discharge the sixty-one Spanish emergency department medical centers without hospitalization in patients with COVID-19 pneumonia. A prospective cohort study UMC-Pneumonia COVID-19. Revista de Investigacion Clinica. 2022 May 2;74(3):135-146. doi: 10.24875/RIC.22000021. PMID: 35240755. IF: 2,667
4. Alquézar-Arbé A, Miró Ò, Castillo JGD, Jiménez S, Llorens P, Martín A, Martín-Sánchez FJ, García-Lamberechts EJ, Piñera P, Jacob J, Porrino JMM, Jiménez B, Río RD, García CP, Aznar JVB, Ponce MC, Fernández ED, Tost J, Mojarrero EM, García AH, Quirós AM, Noceda J, Cano MJC, Almela AFS, Bayarri MJF, Tejera MG, Rodriguez AD, Burillo-Putze G; Spanish Investigators on Emergency Situations TeAm

# scientific activity

(SIESTA) Network. Incidence, clinical characteristics, risk factors and outcomes of acute coronary syndrome in patients with COVID-19: results of the UMC-19-S1010.

Journal of Emergency Medicine. 2022 Apr;62(4):443-454. doi: 10.1016/j.jemermed.2021.10.046. PMID: 35065863. IF: 2,667

## Department of Microbiology

### PUBLICATIONS




### SELECTED PUBLICATIONS

1. Gimenez E, Albert E, Zulaica J, Torres I, Rusu L, Rodriguez Moreno A, Burgos JS, Peiro S, Salas D, Vanaclocha H, Limon R, Alcaraz MJ, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzales Candelas F, Geller R, Navarro D. SARS-CoV-2 adaptive immunity in nursing home residents following a third dose of the Comirnaty COVID-19 vaccine. *Clinical Infectious Diseases*. 2022 Aug 24;75(1):e865-e868. doi: 10.1093/cid/ciac223. PMID: 35314856. IF: 20,999
2. de Michelena P, Olea B, Torres I, Gonzalez-Candelas F, Navarro D. SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2. *Journal of Medical Virology*. 2022 Dec;94(12):5836-5840. doi: 10.1002/jmv.28079. PMID: 35986484. IF: 20,693
3. Olea B, Albert E, Torres I, Gozalbo-Rovira R, Carbonell N, Ferreres J, Poujois S, Costa R, Colomina J, Rodriguez J, Blasco M, Navarro D. SARS-CoV-2 N-antigenemia in critically ill adult COVID-19 patients: frequency and association with inflammatory and tissue-damage biomarkers. *Journal of Medical Virology*. 2022 Jan;94(1):222-228. doi: 10.1002/jmv.28079. PMID: 35986484. IF: 20,693
4. Albert E, Burgos JS, Peiro S, Salas D, Vanaclocha H, Gimenez E, Limon R, Alcaraz MJ, Sanchez-Paya J, Diez-Domingo J, Cervantes A, Navarro D. Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty COVID-19 vaccine in nursing home residents. *Clinical Microbiology and Infection*. 2022 Feb;28(2):279-284. doi: 10.1016/j.cmi.2021.09.031. PMID: 34619398. IF: 13,31
5. Cancino-Munoz I, Lopez M, Torres-Puente M, Villamayor L, Borras R, Borras-Manez M, Bosque M, Camarena J, Colijn C, Colomer-Roig E, Colomina J, Escribano I, Esparcia-Rodriguez O, Garcia-Garcia F, Gil-Brusola A, Gimeno C, Gimeno-Gascon A, Gomila-Sard B, Gonzales-Granda D, Gonzalo-Jimenez N, Guna-Serrano M, Lopez-Hontangas J, Martin-Gonzalez C, Moreno-Munoz R, Navarro D, Navarro M, Orta N, Perez E, Prat J, Rodriguez J, Ruiz-Garcia M, Vanaclocha H, Comas I. Population-based sequencing of Mycobacterium tuberculosis reveals how current population dynamics are shaped by past epidemics. *eLife*. 2022 Jul 26;11:e76605. doi: 10.7554/eLife.76605. PMID: 35880398. IF: 8,713

## Department of Nephrology

### PUBLICATIONS




# scientific activity

## SELECTED PUBLICATIONS

1. Heerspink H, Cherney D, Postmus D, Stefansson B, Chertow G, Dwyer J, Greene T, Kosiborod M, Langkilde A, McMurray J, Correa-Rotter R, Rossing P, Sjostrom C, Toto R, Wheeler D. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. *Kidney International*. 2022 Jan;101(1):174-184. doi: 10.1016/j.kint.2021.09.005. PMID: 34560136. IF: 18,998
2. De la Espriella R, Amiguet M, Minana G, Rodriguez JC, Moyano P, Segarra D, Fernandez J, Santas E, Nunez G, Lorenzo M, Bonanad C, Alania E, Valle A, Sanchis J, Bodi V, Gorri J, Navarro J, Codina P, Voors AA, Bayes-Genis A, Nunez J. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure. *European Journal of Heart Failure*. 2022 Nov;24(11):2108-2117. doi: 10.1002/ejhf.2651. PMID: 36054502. IF: 17,349
3. Palau P, Amiguet M, Dominguez E, Sastre C, Mollar A, Seller J, Pinilla J, Larumbe A, Valle A, Doblas J, de la Espriella R, Minana G, Mezcua A, Santas E, Bodi V, Sanchis J, Pascual-Figal D, Gorri J, Bayes-Genis A, Nunez J. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial. *European Journal of Heart Failure*. 2022
4. Provenzano M, Puchades M, Garofalo C, Jongs N, D'Marco L, Andreucci M, De Nicola L, Gorri J, Heerspink H. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial. *Journal of the American Society of Nephrology*. 2022 Aug;33(8):1569-1580. doi: 10.1681/ASN.2022020207. PMID: 35440501. IF: 14,978
5. De la Espriella R, Bayes-Genis A, Llacer P, Palau P, Minana G, Santas E, Pellicer M, Gonzalez M, Gorri J, Bodi V, Sanchis J, Nunez J. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. *European Journal of Internal Medicine*. 2022 Jan;95:67-73. doi: 10.1016/j.ejim.2021.08.024. PMID: 34507853. IF: 7,749

## Department of Neurology

### PUBLICATIONS



## SELECTED PUBLICATIONS


1. Amarenco P, Kim J, Labreuche J, Charles H, Giroud M, Lavallée P, Lee B, Mahagne M, Meseguer E, Nighoghossian N, Steg P, Vicaut E, Bruckert E. Intracranial hemorrhage in the TST Trial. *Stroke*. 2022 Feb;53(2):457-462. doi: 10.1161/STROKEAHA.121.035846. PMID: 34963300. IF: 10,17
2. Quintanilla-Bordas C, Gascon-Gimenez F, Alcala C, Paya M, Mallada J, Silla R, Carratala-Bosca S, Gasque-Rubio R, Castillo J, Casanova B. Case Report: exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis: a case series. *Frontiers in Neurology*. 2022 Apr 27;13:897275. doi: 10.3389/fneur.2022.897275. PMID: 35572939. IF: 4,086

# scientific activity

4

## Department of Neurophysiology

### PUBLICATIONS




### SELECTED PUBLICATIONS

- Terres-Jimenez B, Dominguez-Cabanero EM, Gonzalez-Vivas C, Garcia-Parreno B, Diego-Castano S, Aiko Gesler M, De Entrambasaguas M, Lorente-Rovira E. Variables associated with the success of group cognitive behavioral therapy for insomnia: preliminary results. *Actas Espanolas de Psiquiatria*. 2022 Sep;50(5):233-240. PMID: 36273383. IF: 1,667

## Department of Neurosurgery

### PUBLICATIONS




### SELECTED PUBLICATIONS

- Martorell-Llobregat C, Gonzalez-Lopez P, Luna E, Asensio-Asensio M, Jadraque-Rodriguez R, Garcia-March G, Moreno-Lopez P. The role of vagus nerve stimulation in the treatment of refractory epilepsy: clinical outcomes and impact on quality of life. *Neurologia*. 2022 Jul-Aug;37(6):450-458. doi: 10.1016/j.nrleng.2019.04.004. PMID: 34088638. IF: 5,486
- Gonzalez-Darder J, Capilla-Guasch P. The temporary resection of the cranial vault by Wilhelm Wagner (1848-1900) instead of trepanation: the cornerstone of the modern craniotomy. *Journal of Neurosurgery*. 2022 Dec 9;1-6. doi: 10.3171/2022.11. JNS221680. PMID: 36681976. IF: 5,408
- Garcia-Oriola G, Tomasi S, Gallardo F, Umana G, Lawton M, Winkler P. Optic tract as an upper limit in amygdalectomy: microsurgical study. *Operative Neurosurgery*. 2022 Jul 1;23(1):e42-e48. doi: 10.1227/ons.0000000000000208. PMID: 35486869. IF: 2,817
- Sanchez-Ramos D, Vega-Torres E, Irles-Vidal C, Colomina-Rodriguez J. Cerebellious abscesses caused by Nocardia farcinica in an immunocompromised patient. *Revista Espanola de Quimioterapia*. 2022 Aug;35(4):418-420. doi: 10.37201/req/034.2022. PMID: 35711122. IF: 2,515

# scientific activity

## Department of Nuclear Medicine PUBLICATIONS




### SELECTED PUBLICATIONS

- Einstein AJ, Hirschfeld C, Williams MC, Vitola JV, Better N, Villines TC, Cerci R, Shaw LJ, Choi AD, Dorbala S, Karthikeyan G, Lu B, Sinitsyn V, Ansheles AA, Kudo T, Bucciarelli-Ducci C, Nørgaard BL, Maurovich-Horvat P, Campisi R, Milan E, Louw L, Allam AH, Bhatia M, Sewanan L, Malkovský E, Cohen Y, Randazzo M, Narula J, Morozova O, Pascual TNB, Pynda Y, Dondi M, Paez D. Worldwide disparities in recovery of cardiac testing 1 year into COVID-19. *Journal of the American College of Cardiology.* 2022 May 24;79(20):2001-2017. doi: 10.1016/j.jacc.2022.03.348. PMID: 35589162. IF: 27,203
- Alonso JC, Casans I, González FM, Fuster D, Rodríguez A, Sánchez N, Oyagüez I, Burgos R, Williams AO, Espinoza N. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review. *BMC Gastroenterology.* 2022 Jul 2;22(1):326. doi: 10.1186/s12876-022-02396-6. PMID: 35780112. IF: 2,847
- Carrero-Vasquez V, Prado-Wohlwend S. [68Ga] Ga-DOTA-TOC PET/CT uptake by parathyroid adenoma in the context of multiple endocrine neoplasia type 1 [MEN1]. *Revista Española de Medicina Nuclear e Imagen Molecular.* 2022;41 Suppl 1:S66-S68. doi: 10.1016/j.remmie.2022.04.004. PMID: 35550366. IF: 1,247

## Department of Ophthalmology

### PUBLICATIONS



### SELECTED PUBLICATIONS

- Oliver L, Barron A, Montero A, Gil-Hernandez I, Samper A. A case of sterile corneal stromal infiltration with hypotonic maculopathy under brimonidine treatment. *Ocular Immunology and Inflammation.* 2022 Jun 16;1-4. doi: 10.1080/09273948.2022.2087687. PMID: 35708458. IF: 3,728
- Vidal Oliver L, Bayo Calduch P, Forque Rodriguez L, Navarro Ortega D, Duch Samper AM, Colomina Rodriguez J. Methicillin-resistant *Staphylococcus epidermidis* infectious keratitis: clinical and microbiological profile. *Revista Española de Quimioterapia.* 2022 Apr;35(2):171-177. doi: 10.37201/req/128.2021. PMID: 35067009. IF: 2,515

### THESIS

**Thesis title:** Study of conjunctival bullae after filtering surgery with express valve using optical coherence tomography of the anterior segment

**Doctoral candidate:** Rosario Inés De la Cruz Aguiló

**Director(s):** Vicente-Tomás Pérez Torregrosa, Antonio Miguel Duch Samper


**Date of the defense:** 06/04/2022

**Grade:** Sobresaliente "cum laude"

# scientific activity

## Department of Otorhinolaryngology

### PUBLICATIONS



### SELECTED PUBLICATIONS

- Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Impact of the COVID-19 pandemic on a cancer fast-track programme. *Cancer Control.* 2022 Jan-Dec;29:10732748221131000. doi: 10.1177/10732748221131000. PMID: 36355430. IF: 2,339
- Perez-Carbonell T, Orts-Alborch M, Perez-Guillen V, Pla-Gil I, Tenias-Burillo JM, Marco-Algarra J, Perez-Garrigues H. Bilateral Meniere's disease according to its form of debut: synchronous and metachronous disease. *Journal of Laryngology and Otology.* 2022 Oct 6;1-19. doi: 10.1017/S0022215122002262. PMID: 36200516. IF: 2,187
- Perez-Carbonell T, Orts-Alborch M, Perez-Guillen V, Tenias-Burillo J, Pla-Gil I, Marco-Algarra J, Perez-Garrigues H. A longitudinal study of unilateral Meniere's disease and clinical evolutionary models. *Journal of Laryngology and Otology.* 2022 Aug 4;1-27. doi: 10.1017/S0022215122001773. PMID: 35924453. IF: 2,187

### THESIS

**Thesis title:** *Análisis del rendimiento auditivo y de la potencia de salida de los dispositivos osteointegrados percutáneos*

**Doctoral candidate:** Jordi Calvo Gómez

**Director(s):** Ignacio Pla Gil, Jaime Marco Algarra

**Date of the defense:** 11/02/2022

**Grade:** *Sobresaliente "cum laude"*

**Thesis title:** *El tratamiento personalizado de la insuficiencia velofaríngea mediante injerto adiposo autólogo de la faringe*

**Doctoral candidate:** Chiara Suzzi


**Director(s):** Jaime Marco Algarra, Luis Miragall Alba, Guillaume Captier

**Date of the defense:** 12/12/2022

**Grade:** *Sobresaliente "cum laude"*

## Department of Pathological Anatomy

### PUBLICATIONS



### SELECTED PUBLICATIONS

- Silva-Rodriguez J, Schmidt A, Sales M, Molina R, Naranjo V. Proportion constrained weakly supervised histopathology image classification. *Computers in Biology and Medicine.* 2022 Aug;147:105714. doi: 10.1016/j.combiomed.2022.105714. PMID: 35753089. IF: 6,698
- Benavent M, Delgado V, Adrian J, Felix F, Ciarpaglini C. A fast-growing tumor on the head of an elderly woman:

# scientific activity

- challenge. American Journal of Dermatopathology. 2022 Jul 1;44(7):e71-e74. doi: 10.1097/DAD.0000000000002154. PMID: 35704916. IF: 1,319
- American Journal of Dermatopathology. 2022 Jul 1;44(7):535-536. doi: 10.1097/DAD.0000000000002153. PMID: 35704913. IF: 1,319
3. Benavent M, Delgado V, Adrian J, Felix F, Ciarpaglini C. A fast-growing tumor on the head of an elderly woman: answer.

## Department of Pediatrics

### PUBLICATIONS



### SELECTED PUBLICATIONS

1. Aguinik A, Kizyma R, Salek M, Włodarski M, Pogorelyy M, Oszer A, Yakimkova T, Nogovitsyna Y, Dutkiewicz M, Dalle J, Dirksen U, Eggert A, Fernandez-Teijeiro A, Greiner J, Kraal K, Mueller A, Sramkova L, Zecca M, Wise P, Mlynarski W, SAFER Ukraine Collaborative, SAFER Ukraine Collaborative. Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war. Lancet Haematology. 2022 Sep;9(9):e645-e647. doi: 10.1016/S2352-3026(22)00259-9. PMID: 36055331. IF: 30,153
2. Kroese E, Padilla L, Bakker M, Boer J, Hagleitner M, Burkhardt B, Mori T, Attarbaschi A, Verdu-Amorós J, Pillon M, Anderzhanova L, Kabickova E, Chiang A, Kebudi R, Mellgren K, Lazic J, Jazbec J, Meijerink J, Beishuizen A, Loeffen J. Pediatric precursor B-Cell lymphoblastic malignancies: from extramedullary to medullary involvement. Cancers. 2022 Aug 12;14(16):3895. doi: 10.3390/cancers14163895. PMID: 36010889. IF: 6,575
3. Salmeron-Villalobos J, Ramis-Zaldivar J, Balague O, Verdu-Amorós J, Celis V, Sabado C, Garrido M, Mato S, Uriz J, Ortega M, Gutierrez-Camino A, Sinnett D, Illarregi U, Carron M, Regueiro A, Galera A, Gonzalez-Farre B, Campo E, Garcia N, Colomer D, Astigarraga I, Andres M, Llavor M, Martin-Guerrero I, Salaverria I. Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma. Pediatric Blood & Cancer. 2022 Nov;69(11):e29926. doi: 10.1002/pbc.29926. PMID: 36000950. IF: 3,838
4. Parra Cotanda C, Munoz Lozon A, Botifoll Garcia E. Role of the pediatric emergency department during SARS-CoV-2 pandemic. Anales de Pediatría. 2022 Jan;96(1):64-65. doi: 10.1016/j.anpede.2020.11.011. PMID: 34872882. IF: 2,377
5. Guzmán Morais B, Ordóñez Álvarez FÁ, Santos Rodríguez F, Martín Ramos S, Fernández Novo G. Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: a tertiary hospital. Anales de Pediatría. 2022 Feb;96(2):83-90. doi: 10.1016/j.anpede.2020.12.019. PMID: 35144901. IF: 2,377

### RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Title:** Sistema inteligente de apoyo a la toma de decisiones clínicas en medicina de precisión

**Principal Investigator:** Jaime Verdú Amorós

**Funding Body:** Agencia Valenciana de la Innovación-AVI Generalitat Valenciana

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total Budget:** €107.904,85

### THESIS

**Thesis title:** Efficacy and safety of mini-extracorporeal photopheresis for the treatment of refractory graft-versus-host disease in children and adolescents

**Doctoral candidate:** José Jaime Verdú Amorós

**Director(s):** Wilhelm Wössmann

**Date of the defense:** 17/10/2022

**Grade:** Sobresaliente "cum laude"


**Quality recognition/Award:** European PhD

# scientific activity

4

## Department of Pharmacy

### PUBLICATIONS



### SELECTED PUBLICATIONS

- Roger I, Montero P, Garcia A, Milara J, Ribera P, Perez-Fidalgo JA, Cortijo J. Evaluation of antineoplastic delayed-type hypersensitivity skin reactions in vitro. *Pharmaceuticals*. 2022 Sep 6;15(9):1111. doi: 10.3390/ph15091111. PMID: 36145332. IF: 5,215

## Department of Preventive Medicine

### PUBLICATIONS




### SELECTED PUBLICATIONS

- Mortier P, Vilagut G, Alayo I, Ferrer M, Amigo F, Aragonès E, Aragón-Peña A, Asúnsolo Del Barco A, Campos M, Espuga M, González-Pinto A, Haro JM, López Fresneña N, Martínez de Salázar A, Molina JD, Ortí-Lucas RM, Parellada M, Pelayo-Terán JM, Pérez-Gómez B, Pérez-Zapata A, Pijoan JL, Plana N, Polentinos-Castro E, Portillo-Van Diest A, Puig MT, Rius C, Sanz F, Serra C, Urreta-Barallobre I, Kessler RC, Bruffaerts R, Vieta E, Pérez-Solá V, Alonso J. Four-month incidence of suicidal thoughts and behaviors among healthcare workers after the first wave of the Spain COVID-19 pandemic. *Journal of Psychiatric Research*. 2022 May;149:10-17. doi: 10.1016/j.jpsychires.2022.02.009. PMID: 35217315. IF: 5,25
- Abiétar DG, Beltrán Aguirre JL, García AM, García-Armesto S, Gutiérrez-Ibarluzea I, Segura-Benedicto A, Franco M, Hernández-Aguado I, en nombre del Grupo de Trabajo de SESPAS sobre la Agencia Estatal de Salud Pública. Future National Public Health Agency: an opportunity for the public health system in Spain. *Gaceta Sanitaria*. 2022; 36(3): 265-269. doi: 10.1016/j.gaceta.2021.12.001. PMID: 35120795. IF: 2,479
- Alonso J, Vilagut G, Alayo I, Ferrer M, Amigo F, Aragon-Peña A, Aragones E, Campos M, Del Cura-Gonzalez I, Urreta I, Espuga M, Pinto A, Haro J, Fresnena N, de Salazar A, Molina J, Lucas R, Parellada M, Pelayo-Teran J, Zapata A, Pijoan J, Plana N, Puig M, Rius C, Rodriguez-Blazquez C, Sanz F, Serra C, Kessler R, Bruffaerts R, Vieta E, Perez-Sola V, Mortier P. Mental impact of COVID-19 among Spanish healthcare workers. A large longitudinal survey. *Epidemiology and Psychiatric Sciences*. 2022 Apr 29;31:e28. doi: 10.1017/S2045796022000130. PMID: 35485802. IF: 7,818
- Orti Lucas R, Luciano E. New immunomagnetic separation method to analyze risk factors for Legionella colonization in health care centres. *Journal of Exposure Science and Environmental Epidemiology*. 2022 Sep;32(5):744-750. doi: 10.1038/s41370-022-00421-0. PMID: 35264765. IF: 6,371
- Sosa-Palanca E, Saus-Ortega C, Gea-Caballero V, Andani-Cervera J, Garcia-Martinez P, Ortí-Lucas R. Nurses' perception of patient safety culture in a referral hospital: a cross-sectional study. *International Journal of Environmental Research and Public Health*. 2022 Aug 16;19(16):10131. doi: 10.3390/ijerph191610131. PMID: 36011763. IF: 4,614

# scientific activity

## Department of Psychiatry

### PUBLICATIONS




### SELECTED PUBLICATIONS

1. Rodriguez Ruzafa M, Carrasco Picazo JP, Junquera Fernandez G, Aguilar Garcia-Iturrospe EJ. EUROLD: preliminary results of the ecological study on suicide and its associated socioeconomic variables in people over 85 in Europe. *International Psychogeriatrics*. 2022 Feb 28;1-3. doi: 10.1017/S1041610222000072. PMID: 35225213. IF: 7,191
2. Ferrer-Quintero M, Fernandez D, Lopez-Carrilero R, Birules I, Barajas A, Lorente-Rovira E, Luengo A, Diaz-Cutraro L, Verdaguer M, Garcia-Mieres H, Gutierrez-Zotes A, Grasa E, Pousa E, Huerta-Ramos E, Pelaez T, Barrigon M, Gomez-Benito J, Gonzalez-Higueras F, Ruiz-Delgado I, Cid J, Moritz S, Sevilla-Llewellyn-Jones J, Ochoa S. Males and females with first episode psychosis present distinct profiles of social cognition and metacognition. *European Archives of Psychiatry and Clinical Neuroscience*. 2022 Oct;272(7):1169-1181. doi: 10.1007/s00406-022-01438-0. PMID: 35802165. IF: 5,76
3. Cabedo E, Prieto J, Quiles L, Arnaez S, Rivas M, Riveiro Y, Aguilar E, Renovell M. Factores asociados a impacto emocional de la pandemia por COVID-19 en profesionales sanitarios. *Behavioral Psychology*. 2022; 30(1): 69-91. doi: 10.51668/bp.8322104s. IF: 1,111

## Department of Radiologic Diagnosis

### PUBLICATIONS



### SELECTED PUBLICATIONS


1. Scurt M, Balint L, Mijaica R. Improving body mass index in students with excess weight through a physical activity programme. *Children*. 2022 Oct 27;9(11):1638. doi: 10.3390/children9111638. PMID: 36360366. IF: 2,835
2. Panach-Navarrete J, Valls-Gonzalez L, Gil-Viana R, Martinez-Jabaloyas J. Renal cyst after heminephrectomy in a pediatric patient: complication or normality?. *Archivos Espanoles de Urologia*. 2022 Nov;75(9):803-806. doi: 10.56434/j.arch.esp.urol.20227509.1117. PMID: 36472064. IF: 0,43
3. Panach-Navarrete J, Martinez-Montava E, Gil-Viana R, Valls-Gonzalez L, Martinez-Jabaloyas J. Early ultrasound after endoscopic puncture of ureterocele: signs that show surgical treatment success. *Archivos Espanoles de Urologia*. 2022 Aug;75(6):567-571. doi: 10.37554/es-j.arch.esp.urol-20210119-3532-31. PMID: 36138507. IF: 0,43

# scientific activity

4

## Department of Thoracic Surgery

### PUBLICATIONS




### SELECTED PUBLICATIONS

1. Recuero Diaz JL, Almanzar S, Munoz C, Sierra J, Porras M, Medina D, Vicuna M, Moreno L, Cantalejo M, Porcel J. Recommendations of the Spanish Society of Thoracic Surgery for the management of malignant pleural effusion. *Cirugia Espanola*. 2022 Nov;100(11):673-683. doi: 10.1016/j.cireng.2022.06.009. PMID: 35667609. IF: 2,242
2. Cilleruelo Ramos Á, Figueroa Almánzar S, López Castro R, Martínez Hernández NJ, Mezquita Pérez L, Moreno Casado P, Zabaleta Jiménez J. Spanish Society of Thoracic Surgery (SECT) consensus document. Long-term follow-up for operated patients with lung cancer. *Cirugia Espanola*. 2022 Jun;100(6):320-328. doi: 10.1016/j.cireng.2022.05.024. PMID: 35643357. IF: 2,242
3. Rodriguez-Perez M, Tung-Chen Y, Herrera-Cubas R. Detection and semiquantification of pneumothorax through lung ultrasound: case report of a COVID-19 patient. *Enfermedades Infecciosas y Microbiologia Clinica* (English ed.). 2022 Nov;40(9):524-525. doi: 10.1016/j.eimce.2022.06.004. PMID: 35750584. IF: 1,994
4. Rodriguez-Perez M, Tung-Chen Y, Herrera-Cubas R. Detección y semicuantificación del neumotórax mediante la ultrasonido pulmonar: caso de paciente con COVID-19. *Enfermedades Infecciosas y Microbiología Clínica*. 2022 Nov;40(9):524-525. doi: 10.1016/j.eimc.2021.12.004. PMID: 35017770. IF: 1,994

## Department of Traumatology and Orthopedic Surgery

### PUBLICATIONS



### SELECTED PUBLICATIONS

1. Henn M, Martin-Gorgojo V, Martin-Moreno J. Vitamin D in cancer prevention: gaps in current knowledge and room for hope. *Nutrients*. 2022 Oct 27;14(21):4512. doi: 10.3390/nu14214512. PMID: 36364774. IF: 6,706
2. Martin-Moreno JM, Alegre-Martinez A, Martin-Gorgojo V, Alfonso-Sanchez JL, Torres F, Pallares-Carratala V. Predictive models for forecasting public health scenarios: practical experiences applied during the first wave of the COVID-19 Pandemic. *International Journal of Environmental Research and Public Health*. 2022 May 3;19(9):5546. doi: 10.3390/ijerph19095546. PMID: 35564940. IF: 4,614

# scientific activity

## Department of Urology

### PUBLICATIONS




### SELECTED PUBLICATIONS

- Panach-Navarrete J, Martinez-Montava E, Gil-Viana R, Valls-Gonzalez L, Martinez-Jabaloyas J. Early ultrasound after endoscopic puncture of ureterocele: signs that show surgical treatment success. *Archivos Espanoles de Urologia*. 2022 Aug;75(6):567-571. doi: 10.37554/es-j.arch.esp.urol-20210119-3532-31. PMID: 36138507. IF: 0,43
- Negueruela-Garcia M, Pastor-Hernandez F, Martinez-Jabaloyas J. Emergency radical nephrectomy in a polytrauma patient. *Archivos Espanoles de Urologia*. 2022 Oct;75(8):736-737. doi: 10.56434/j.arch.esp.urol.20227508.107. PMID: 36330577. IF: 0,43
- Panach-Navarrete J, Valls-Gonzalez L, Gil-Viana R, Martinez-Jabaloyas J. Renal cyst after heminephrectomy in a pediatric patient: complication or normality?. *Archivos Espanoles de Urologia*. 2022 Nov;75(9):803-806. doi: 10.56434/j.arch.esp.urol.20227509.117. PMID: 36472064. IF: 0,43
- Negueruela-Garcia M, Panach-Navarrete J, Martinez-Jabaloyas J. The use of urokinase in urinary catheter obstructed by clots. *Archivos Espanoles de Urologia*. 2022 Jan;75(1):82-86. doi: 10.37554/es-j.arch.esp.urol-20210317-3534-33. PMID: 35173068. IF: 0,43

## Teaching and Dissemination of Knowledge Unit

### PUBLICATIONS



### SELECTED PUBLICATIONS

- Henn M, Martin-Gorgojo V, Martin-Moreno JM. Vitamin D in cancer prevention: gaps in current knowledge and room for hope. *Nutrients*. 2022 Oct 27;14(21):4512. doi: 10.3390/nu14214512. PMID: 36364774. IF: 6,706
- Cantarero-Prieto D, Lera J, Lanza-Leon P, Barreda-Gutierrez M, Guillem-Porta V, Castelo-Branco L, Martin-Moreno JM. The economic burden of localized prostate cancer and insights derived from cost-effectiveness studies of the different treatments. *Cancers*. 2022 Aug 24;14(17):4088. doi: 10.3390/cancers14174088. PMID: 36077625. IF: 6,575
- Lopes H, Baptista-Leite R, Franco D, Serra MA, Escudero A, Martín-Moreno JM. Let's end HepC: modelling public health epidemiological policies applied to Hepatitis C in Spain. *Frontiers in Public Health*. 2022 Jan 7;9:735572. doi: 10.3389/fpubh.2021.735572. PMID: 35071151. IF: 6,461
- Pallares-Carratala V, Carratala-Munuera C, Lopez-Pineda A, Quesada JA, Gil-Guillem V, Orozco-Beltran D, Alfonso-Sanchez JL, Navarro-Perez J, Martin-Moreno JM. Characterizing diagnostic inertia in arterial hypertension with a gender perspective in primary care. *Frontiers in Cardiovascular Medicine*. 2022 Jun 16;9:874764. doi: 10.3389/fcvm.2022.874764. PMID: 35783866. IF: 5,848
- Pardavila-Belio MI, de la O V, Hershey MS, Barbería-Latasa M, Toledo E, Martin-Moreno JM, Martínez-González MÁ,

# scientific activity

4

Ruiz-Canela M. Joint association of the Mediterranean diet and smoking with all-cause mortality in the Seguimiento Universidad de Navarra (SUN) cohort. *Nutrition*. 2022 Nov-Dec;103-104:111761. doi: 10.1016/j.nut.2022.111761. PMID: 35843044. IF: 4,893

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PI18/01937

**Title:** *Desigualdades por género derivadas de la inercia diagnóstica en los factores más prevalentes de riesgo cardiovascular: un estudio de cohortes de base poblacional (ESCAARVAL GENERO)*

**Principal Investigator:** José María Martín Moreno

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2022

**Total budget:** €33.880

# scientific activity

## 4.5 Other scientific contributions from scientific platforms

### 4.5.1 Biobank

#### Team

##### PI:

Antonio Ferrández Izquierdo. Hospital. University.

##### Collaborating researcher:

Lorena Peiró Chova. INCLIVA

*biobanco@incliva.es*

#### Technicians

Olga Bahamonde Ponce. INCLIVA

Àngela Bañuls Alemany. INCLIVA

Laura Blasco Maza. INCLIVA

Marta Belda Moscardó. INCLIVA

### ACTIVITIES DEVELOPED

#### Incorporation of samples in pre-existing collections within the biobank regime in 2022:

##### Oncological Node:

- Collection of solid tumors: 71 new sample donations
- Collection of peripheral blood and derivative products in patients suffering from breast cancer (including cases of AURK-Seom project): 535 new sample donations
- Collections of peripheral blood and derivative products in patients suffering from lung cancer: 213 new sample donations
- Collection of peripheral blood and derivative products in patients suffering from melanoma: no new sample donations
- Collection of peripheral blood and derivative products in patients suffering from gastrointestinal cancer (including colorectal, pancreatic and gastric cancer, and cases of TFK project): 1271 new sample donations
- Collection of peripheral blood and derivative products in patients suffering from head and neck tumors: 252 new sample donations
- Collections of peripheral blood and derivative products in patients suffering from brain tumors: no new sample donations
- Collections of peripheral blood and derivative products in patients suffering from gynecological tumors (including cases of AURK-Seom project): 17 new sample donations
- Collections of peripheral blood and derivative products in patients suffering from sarcoma: no new sample donations
- Collections of peripheral blood, derivative products and urine in patients suffering from bladder cancer: no new sample donations
- Hereditary Cancer Collection: peripheral blood and derivative products in patients suffering from this pathology: 3 new sample donations

##### Immunological Diseases Node:

- Collection of peripheral blood and derivative products in patients suffering from Systemic Lupus Erythematosus or other autoimmune diseases: 13 new sample donations

##### Cardiovascular Node:

- Collection of peripheral blood and derivative products and urine in patients suffering from Hyperaldosteronism: no new sample donations
- Collection of peripheral blood and derivative products in patients suffering from Hypertension: no new sample donations
- Collection of peripheral blood and derivative products and urine in patients suffering from Acute heart failure: 5 new sample donations
- Collection of peripheral blood and derivative products in patients suffering from ST-segment elevation myocardial infarction: 58 new sample donations

##### Endocrinology Node:

- Collection of peripheral blood and derivative products and urine in patients suffering from endocrine diseases (DM1, DM2 and controls): 135 new sample donations

##### Reproductive Medicine Node:

- Single Cell Cryopreserved Human Endometrial Sample Collection; viable cells from endometrial biopsy or from endometrial fluid taken from women at different phases of their menstrual cycle: no new sample donations

##### Other collections:

- Collection of peripheral blood and derivative products in patients suffering from sepsis gravis, septic shock and non-septic patients from ICU: 22 new sample donations
- Collection of peripheral blood and derivative products in patients suffering from Multiple Sclerosis: no new cases
- Collection of peripheral blood and derivative products and urine in standard population (including cases of Obenoutec subcollection): no new sample donations
- Collection of peripheral blood and derivative products in patients suffering from COVID-19 disease and follow-up: no new cases

# scientific activity

- Collection of peripheral blood and derivative products in patients suffering from Pulmonary Emphysema disease: 52 new sample donations
- COVID-19 Vaccinated Collection; peripheral blood mononuclear cells from standard population vaccinated against COVID-19 disease: 97 new sample donations

## **Incorporation of new collections within the biobank regime in 2022:**

- Collection of peripheral blood and derivative products in patients suffering from acute coronary syndrome: 47 sample donations
- Collection of peripheral blood and derivative products in patients suffering from atrial fibrillation: 12 sample donations

In summary, 2803 new sample donations have been received, 13709 samples have been processed and 61203 aliquots have been stored in 2022 at INCLIVA Biobank facilities from collections within biobank regime.

In addition, the Biobank has surplus diagnostic samples from the HCUV Pathology and Hematology services that may be used in research provided they have the corresponding Biobank Informed Consent.

**Incorporation of samples in pre-existing collections outside the biobank regime in 2022.** The collections are outside the organizational structure of the biobank and they are generated in the scope of projects and/or private clinical trials. The biobank manages the storage and custody of the samples, as well as the processing of the same in some cases.

- Amadix Study: processing, conservation and shipment of processed samples for the "PancreaDIX study: study for the development and validation of a genetic fingerprint for the diagnosis of pancreatic cancer and precursor lesions". AMD-CPA-2016-01: 6 new sample donations
- Renas Study: processing, conservation and shipment of processed samples for the study "Effect of CPAP on the deterioration of renal function in early stages of chronic kidney disease". 195/2015: custody of 2 cryoboxes
- Rolando Study: processing, conservation and shipment of processed samples for translational study within the framework of the ROLANDO trial "Multicenter and uncontrolled phase II clinical trial to evaluate the safety and efficacy of the combination of Olaparib and Pegylated Liposomal Doxorubicin (DLP) in patients with peritoneal carcinoma primary ovarian and resistant platinum fallopian tubes". GEICO-1601 ROLANDO: custody of 8 cryoboxes
- European LEGACy Project: processing, conservation and shipment of processed samples for this project: 95 new sample donations

- ALFAQMEGA/PEGASUS Study: processing, conservation and shipment of processed samples for this clinical trial: 181 sample donations
- Diabetic Nephropathy study: processing, conservation and shipment of processed samples for the study "Early detection of histological lesions in nephrectomy pieces of diabetic patients. Anatomoclinical correlation. Analysis of the expression of Klotho in healthy kidney tissue vs tumor tissue": 5 new sample donations
- NIKOLE Study (GEICAM/2018-03): processing, conservation and shipment of processed samples for the clinical trial "Characterization of innate immune system in patients with luminal advanced breast cancer": 36 new sample donations
- VERONA Study (RPL554-CO-302): processing, conservation and shipment of processed samples for the clinical trial "A Phase III randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ensifentript over 24 weeks in patients with moderate to Severe Chronic Obstructive Pulmonary Disease": 9 new sample donations [Finished study]
- HIPRA HH-2 Study: processing, conservation and shipment of processed samples for the clinical trial "A phase IIb, double-blind, randomised, active-controlled, multicentre, non-inferiority trial followed by a phase III, single-arm, open-label trial to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-CoV-2 in adults fully vaccinated against COVID-19": 198 new sample donations
- TRANSPAIRE Study: processing, conservation and shipment of processed samples for the study "Radiofrequency-assisted pancreatic transection vs endostapler": 2 new sample donations
- Cytosorb Study: processing, conservation and shipment of processed samples for the study "Hemoabsorption with Cytosorb vs usual clinical practice to analyze its effect on kidney damage biomarkers in asystole donation controlled with ECMO": 11 sample donations

## **Incorporation of new collections outside the biobank regime in 2022:**

- CONREN study: processing, conservation and shipment of processed samples for the study "Congestion as a catalyst for the progression of chronic kidney disease": 89 sample donations
- GSK3511294 Study: processing, conservation and shipment of processed samples for the clinical trial "A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled

# scientific activity

- asthma with an eosinophilic phenotyper": 36 sample donations
- WA42293 Study: processing, conservation and shipment of processed samples for the clinical trial "A Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis (IPF)": 26 sample donations
  - OBERON Study: processing, conservation and shipment of processed samples for the clinical trial "A Phase III, multicentre, randomised, double-blind, chronic-dosing, parallel-group, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of MEDI3506 in participants with symptomatic Chronic Obstructive Pulmonary Disease [COPD] with a history of COPD Exacerbations (OBERON)": 6 sample donations
  - HIPRA-HH-2 phase IIb Study: processing, conservation and shipment of processed samples for the clinical trial "A phase IIb, double-blind, randomised, active-controlled, multicentre, non-inferiority trial followed by a phase III, single-arm, open-label trial to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-CoV-2 in adults fully vaccinated against COVID-19 followed by an extension period to study a fourth dose administration of PHH-1V": 72 sample donations
  - HIPRA-HH-5 Study: processing, conservation and shipment of processed samples for the clinical trial "A phase III, open label, single arm, multi-centre, trial to assess the safety and immunogenicity of a booster vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in adults vaccinated against COVID-19": 504 sample donations
  - CIRCULATE-SPAIN-01 Study: processing, conservation and shipment of processed samples for the clinical trial "Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localized colon cancer with circulating tumor DNA": 110 sample donations
  - AFM-24-101 Study: processing, conservation and shipment of processed samples for the clinical trial "A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of AFM24 in patients with advanced solid cancers": 27 sample donations
  - AFM-24-102 Study: processing, conservation and shipment of processed samples for the clinical trial "A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in combination with atezolizumab in patients with selected advanced/metastatic EGFR-expression cancers": 13 sample donations
  - HFB-200301-01 Study: processing, conservation and shipment of processed samples for the clinical trial "A phase I, open-label, multi-center, dose escalation and expansion study of HFB200301 [TNFR2 agonist antibody] in adult patients with advanced solid tumors": 5 sample donations.

In summary, 1432 new sample donations have been received, 4106 samples have been processed and 9651 aliquots have been stored in 2022 at INCLIVA Biobank facilities from studies outside biobank regime. In addition, 7034 aliquots have been supplied to these studies in 2022.

## Transfer of samples

Project	Ref./Agency	Principal Researcher, Institution	Samples
BBI_12/2018 and BBI_10/2020 Identification and analysis of image and circulating biomarkers with prognostic value and response predictor in patients with head and neck squamous cell carcinoma	NA / INCLIVA	Gema Bruixola, HCUV/INCLIVA	Head and neck tumors: 529 plasma aliquots and 28 DNA aliquots
BBI_06/2019 and BBI_03/2020 Usefulness of liquid biopsy and organoids in the management and treatment of pancreatic adenocarcinoma: towards precision medicine	NA, Fundación Mutua Madrileña	Andrés Cervantes, HCUV/INCLIVA	Pancreatic cancer: 256 plasma aliquots and 36 DNA aliquots

# scientific activity

4

BBI_09/2019 Personalized Medicine in patients with localized colorectal cancer: multiomic approach to minimal residual disease in liquid biopsy and organoid models	PI18/01909 / ISCIII	Andrés Cervantes, HCUV/ INCLIVA	Gastrointestinal tumors: 40 plasma aliquots
BBI_11/2020 and BBI_08/2021 Epigenetic biomarkers for sepsis. Focus on long-term immunosuppression and future comorbidities in survivors	PI19/00994 / ISCIII	José Luis García Giménez, CIBERER, INCLIVA/UV	Sepsis and Septic Shock: 100 plasma aliquots, 9 serum aliquots and 70 DNA aliquots
BBI_07/2021 and BBI_13_2021 Study of the appearance of pulmonary fibrotic changes associated with SARS-CoV-2 infection	COV20/01209 / ISCIII	Jaime Signes-Costa, HCUV	COVID-19 Collection: 69 DNA aliquots and 138 serum aliquots
BBI_16/2021 Linking cofilin, an actin-binding protein, to calcium dysregulation: a precision approach to the treatment of Friedreich's Ataxia	PID2020-115190RB-I00, Ministerio de Ciencia e Innovación	Pilar González Cabo, CIBER, INCLIVA/UV	Standard population: 34 plasma aliquots
BBI_01/2022 Evaluation of the involvement of MIR-99A in the resistance to treatment in breast cancer. Addendum v3: relationship of miR-30b-5p expression with plasma estradiol concentrations	NA / INCLIVA	Pilar Eroles Asensio, INCLIVA	Breast cancer: 67 plasma aliquots; Standard population: 32 plasma aliquots
BBI_02/2022 Characterization and approach of minimal residual disease in localized colon cancer: a step towards precision medicine	PI21/00689 / ISCIII	Noelia Tarazona Llavero, INCLIVA	Gastrointestinal tumors: 11 FFPE samples (slides) and 457 plasma aliquots
BBI_03/2022 Role of P53 ferroptosis and redox signaling via NOX/TRP14 in acute pancreatitis and pancreatic regeneration	PID2019-108615RB-I00, Ministerio de Ciencia, Innovación y Universidades	Juan José Sastre Belloch, UV	Pancreatic cancer: 14 FFPE samples (slides)
BBI_04/2022 Molecular characterization of lymphoid neoplasms B. Development of useful biomarkers in the diagnosis and monitoring of the disease	NA / INCLIVA	Javier Chaves, INCLIVA	Chronic lymphoproliferative syndromes: 311 DNA aliquots
BBI_05/2022 Tests based on spike-in peptides and mass spectrometry for the quantification of histones circulating cells and APC protein, for the clinical management of critically ill patients	DTS21/00193 / ISCIII	José Luis García Giménez, CIBER, INCLIVA/UV	Transplantation and lymphoproliferative syndromes: 284 plasma aliquots

# 4 scientific activity

BI_06/2022 Effect of COVID-19 infection on telomer length and mitochondrial function parameters and its relationship with the evolution to idiopathic pulmonary fibrosis	GVA-COVID19/2021/028, <i>Generalitat Valenciana</i>	Federico V. Pallardó Calatayud, INCLIVA	COVID-19 Collection: 130 plasma aliquots
BBI_07/2022 Study of IMP-3 as a potential plasmatic biomarker of melanoma progression	NA / INCLIVA	M <sup>a</sup> Isabel Pinazo Canales, HCUV	Melanoma: 82 plasma aliquots
BBI_08/2022 Identification of non-coding RNAs in liquid biopsy with emphasis on exosomes as activity prognosis biomarkers in systemic lupus erythematosus. Physiopathological role in renal damage	PI21/00249, ISCIII	Raquel Cortés Vergaz / María José Forner, INCLIVA / HCUV	Systemic Lupus Erythematosus: 61 plasma aliquots and 30 serum aliquots
BBI_09/2022 Renal congestion in acute heart failure and cardiorenal syndrome: non-invasive assessment using renal vascular Doppler	PI20/00392, ISCIII	Julio Núñez, INCLIVA	Acute heart failure: 126 urine aliquots
BBI_10/2022 GEICAM's participation in Confluence Project with the male breast cancer registry [GEICAM/2016-04]. Analysis of CMV genetic risk factors using genetic sequencing	NA / GEICAM, NCI	Marina Pollán Santamaría, ISCIII	No samples delivered
BBI_11/2022 Role of somatic mutations and clonal hematopoiesis in the progression of heart failure	PI20/00677, ISCIII	Domingo Pascual Figal, IMIB-Arrixaeca	No samples delivered

In summary, 2914 aliquots were transferred in 2022.

In addition, 249 aliquots have been processed and delivered to provide specialized technical services to the following research projects:

SERVO1/2022 "Study of the appearance of pulmonary fibrotic changes associated with SARS-CoV-2 infection": management of external samples from collaborating centers, 89 serum aliquots delivered.

SERVO2/2022 "Identification and validation of biomarkers using omics and artificial intelligence for sepsis prognosis neonatal": 48 DNA isolations.

SERVO3/2022 "Effect of COVID-19 infection on telomer length and mitochondrial function parameters and its relationship with the evolution to idiopathic pulmonary fibrosis": 71 DNA isolations and 47 PBMCs/buffy aliquots delivered.

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PT20/00029

**Title:** Biobanks and Biomodels Platform

**Principal Investigator:** Antonio Ferrández Izquierdo

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total Budget:** €265.650

## PUBLICATIONS

Note that these are 2022 scientific publications derived from the use of samples or services provided by the biobank.

1. Safont B, Tarraso J, Rodriguez-Borja E, Fernández-Fabrellas E, Sancho-Chust JN, Molina V, Lopez-Ramirez C, Lope-Martinez A, Cabanes L, Andreu AL, Herrera S, Lahosa C, Ros JA, Rodriguez-Hermosa JL, Soriano JB, Moret-Tatay I, Carbonell-Asins JA, Mulet A, Signes-Costa J. Lung function, radiological findings and biomarkers of fibrogenesis in a cohort of COVID-19 patients six months after hospital discharge. *Archivos de Bronconeumología [Engl Ed]*. 2022 Feb;58(2):142-149. doi: 10.1016/j.arbres.2021.08.014. PMID: 34497426
2. Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, Huerta M, Roselló S, Madsen AH, Løve US, Andersen PV, Thorlacius-Ussing O, Iversen LH, Gotschalck KA, Sethi H, Aleshin A, Cervantes A, Andersen CL. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. *Clinical Cancer Research*. 2022 Feb 1;28(3):507-517. doi: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408
3. García de Guadiana-Romualdo L, Rodriguez Rojas C, Morell-García D, Andaluz-Ojeda D, Rodríguez Mulero MD, Rodríguez-Borja E, Ballesteros-Vizoso A, Calvo MD, Albert-Botella L, Pozo Giráldez A, Llompart-Alabern I, Bolado Jiménez C, Hernández Olivo M, Fernández Presa L, Ortega-Pérez J, Fora Romero MJ, Campos-Rodríguez V, Ballester Férriz A, Guiu-Martí AM, Pinilla Arribas L, Galindo Martínez M, Puerto-Lara ER, López Tarazaga AB, Ros Braquehais MS, Nogales Martín L, Juez Santamaría C, Trapiello Fernández W, Espinilla Fernández V, Havelka A, Albaladejo-Otón MD. Circulating levels of calprotectin, a signature of neutrophil activation in prediction of severe respiratory failure in COVID-19 patients: a multicenter, prospective study [CalCov study]. *Inflammation Research*. 2022 Jan;71(1):57-67. doi: 10.1007/s00011-021-01516-4. PMID: 34718856
4. Beltrán-García J, Osca-Verdegal R, Jávega B, Herrera G, O'Connor JE, García-López E, Casabó-Vallés G, Rodriguez-Gimillo M, Ferreres J, Carbonell N, Pallardó FV, García-Giménez JL. Characterization of early peripheral immune responses in patients with sepsis and septic shock. *Biomedicines*. 2022 Feb 23;10(3):525. doi: 10.3390/biomedicines10030525. PMID: 35327327
5. Sánchez-Sendra B, González-Muñoz JF, Pérez-Debén S, Monteagudo C. The prognostic value of miR-125b, miR-200c and miR-205 in primary cutaneous malignant melanoma is independent of BRAF Mutational Status. *Cancers*. 2022 Mar 16;14(6):1532. doi: 10.3390/cancers14061532. PMID: 35326682
6. López-Guerrero JA, Mendiola M, Pérez-Fidalgo JA, Romero I, Torres A, Recalde D, Molina E, Gómez-Raposo C, Levin AM, Herrero A, Alarcón J, Esteban C, Marquina G, Rubio MJ, Guerra E, Sánchez-Lorenzo L, Gálvez-Montosa F, de Juan A, Churruca C, Gallego A, González-Martín A. Prospective real-world gynaecological cancer clinical registry with associated biospecimens: a collaborative model to promote translational research between GEICO and the Spanish Biobank Network. *Cancers*. 2022 Apr 13;14(8):1965. doi: 10.3390/cancers14081965. PMID: 35454870
7. Gargallo P, Molero M, Bilbao C, Stuckey R, Carrillo-Cruz E, Hermosín L, Pérez-López O, Jiménez-Velasco A, Soria E, Lázaro M, Carbonell P, Yáñez Y, Gómez I, Izquierdo-García M, Valero-García J, Ruiz C, Such E, Calabria I. Next-generation DNA sequencing-based gene panel for diagnosis and genetic risk stratification in onco-hematology. *Cancers*. 2022 Apr 14;14(8):1986. doi: 10.3390/cancers14081986. PMID: 35454892
8. Luque M, Cristóbal I, Sanz-Álvarez M, Santos A, Zazo S, Eroles P, Arpí O, Rovira A, Albanell J, Madoz-Gúrpide J, García-Foncillas J, Rojo F. CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer. *Journal of Clinical Medicine*. 2022 Mar 14;11(6):1610. doi: 10.3390/jcm11061610. PMID: 35329936
9. Pérez-Núñez I, Rozalén C, Palomeque JÁ, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Peña R, Montañés JC, Albà MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. *Nature Cancer*. 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. PMID: 35301507
10. Provenzano M, Puchades MJ, Garofalo C, Jongs N, D'Marco L, Andreucci M, De Nicola L, Gorrioz JL, Heerspink HJL; ROTATE-3 study group. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial. *Journal of the American Society of Nephrology*. 2022 Aug;33(8):1569-1580. doi: 10.1681/ASN.2022020207. PMID: 35440501

# scientific activity

11. Sánchez-Sendra B, Pérez-Debén S, González-Muñoz JF, Murgui A, Monteagudo C. Prognostic value of IGF2 mRNA-binding protein 3 (IGF2BP3) intratumoral expression in melanoma patients at the time of diagnosis: comparative analysis of RT-qPCR versus immunohistochemistry. *Cancers.* 2022 May 7;14(9):2319. doi: 10.3390/cancers14092319. PMID: 35565448
12. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcón-Molero L, González-Vilanova A, Zuñiga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Durá A, Richart P, Alonso N, Huerta M, Roselló S, Roda D, Tarazona N, Martínez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. *British Journal of Cancer.* 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523
13. Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, Hernando C, Martínez MT, Carbonell-Asins J, Simón S, Poveda J, Moragón S, Zazo S, Martínez D, Rovira A, Burgués O, Rojo F, Albanej J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo JM. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. *Science Advances.* 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. PMID: 35594351
14. Beltrán-García J, Osca-Verdegal R, Pérez-Cremades D, Novella S, Hermenegildo C, Pallardó FV, García-Giménez JL. Extracellular histones activate endothelial NLRP3 inflammasome and are associated with a severe sepsis phenotype. *Journal of Inflammation Research.* 2022 Jul 25;15:4217-4238. doi: 10.2147/JIR.S363693. PMID: 35915852
15. Osca-Verdegal R, Beltrán-García J, Paes AB, Nacher-Sendra E, Novella S, Hermenegildo C, Carbonell N, García-Giménez JL, Pallardó FV. Histone citrullination mediates a protective role in endothelium and modulates inflammation. *Cells.* 2022 Dec 15;11(24):4070. doi: 10.3390/cells11244070. PMID: 36552833
16. Pattanayak B, Lameirinhos A, Torres-Ruiz S, Burgués O, Rovira A, Martínez MT, Tapia M, Zazo S, Albanej J, Rojo F, Bermejo B, Eroles P. Role of SALL4 in HER2+ breast cancer progression: regulating PI3K/AKT Pathway. *International Journal of Molecular Sciences.* 2022 Oct 31;23(21):13292. doi: 10.3390/ijms232113292. PMID: 36362083
17. Beltrán-García J, Osca-Verdegal R, García-Giménez JL, Pallardó FV. Oxidative stress leads to severe phenotypes in sepsis through activation of NLRP3-pyroptosis. *Redox Experimental Medicine.* 2022; 1: R84-R95. doi.org/10.1530/REM-22-0006.
- Book Chapter:** Jesús Beltrán-García, Rebeca Osca-Verdegal, Salvador Mena-Mollá, Marta Seco-Cervera, Lorena Peiró-Chova, José Luis García-Giménez, Pierre Laurent-Puig, Andrés Cervantes. Chapter 2: Translational epigenetics in precision medicine of colorectal cancer. *Epigenetics in Precision Medicine, Volume 30 in Translational Epigenetics 2022*, Pages 19-41.

## THESIS

Note that these are 2022 thesis derived from the use of samples or services provided by the biobank.

**Thesis title:** *Establecimiento de organoides derivados de pacientes con carcinoma colorrectal como modelo para cribado de drogas con acción antitumoral*

**Doctoral candidate:** M<sup>a</sup> Fernanda Gutiérrez Bravo

**Director(s):** Josefa Castillo Aliaga, Andrés Cervantes Ruipérez

**Date of the defense:** 04/02/2022

**Grade:** *Sobresaliente “cum laude”*

**Thesis title:** *Significado pronóstico de la expresión del factor de crecimiento endotelial vascular (VEGF) y de genes implicados en las vías de señalización del VEGF en pacientes con leucemia aguda mieloblástica*

**Doctoral candidate:** Marisa Calabuig Muñoz

**Director(s):** Mar Tormo Díaz, Carlos Solano Vercet

**Date of the defense:** 04/05/2022

**Grade:** *Sobresaliente “cum laude”*

# scientific activity

4

## 4.5.2 Oncology Phase I Oncology Clinical Trials unit

### Team

#### PI:

Andres Cervantes Ruipérez. Hospital. University

#### Medical doctors

Alba Viala Monleón. Hospital  
Amelia Insa Mollá. Hospital  
Begoña Bermejo de las Heras. Hospital. University  
Cristina Hernando Meliá. Hospital  
Desamparados Roda Pérez. Hospital  
Gema Bruixola Campos. Hospital  
Inés González Barrallo. Hospital.  
Isabel Chirivella González. Hospital. University  
José Vicente Montón Bueno. Hospital  
Jose A. Pérez Fidalgo. Hospital. University  
Juan Miguel Cejalvo Andújar. Hospital  
Marisol Huerta Álvaro. Hospital  
Paloma Martín Martorell. Hospital  
Susana Roselló Keranen. Hospital  
Tania Fleitas Kanonnikoff. Hospital  
Valentina Gambardella. Hospital

#### Nurses

Arantxa Sánchez Cosmo. INCLIVA  
Cecilia Ramón Mascarell. INCLIVA  
Gloria Corredor Agulló. INCLIVA  
Guillermo Morín Pedrosa. INCLIVA  
Imma Blasco Blasco INCLIVA  
Laura Ávila Fernández. INCLIVA  
Laura Martínez Lucía. INCLIVA  
María Isabel Calzadilla Luz. INCLIVA  
Nuria Aguado Machancoses. INCLIVA  
Paula Martínez Lucas. INCLIVA  
Silvia Moreno Magraner. INCLIVA

#### Data Managers

Alejandro Asturiano. INCLIVA  
Ana Vercher Grau. INCLIVA  
Andrea Pascual Herrero. INCLIVA  
Beatriz López Montero. INCLIVA.  
Guillermo Moret Peiró. INCLIVA  
Ignacio Castaño López. INCLIVA  
Júlia Soler Flores. INCLIVA.  
Mª Carmen Martínez López. INCLIVA  
Sergio Romero Alcaide. INCLIVA

#### Administrative assistants

Paloma Campos. INCLIVA  
Paula Petruskevicius Fernández. INCLIVA

INCLIVA is the only hospital in Valencia performing Phase I cancer clinical trials, and one of the few in Spain. Phase I trials are those in which a substance or product is tested in humans for the first time.

INCLIVA is conducting, through the Oncology Department, 234 clinical trials, 151 of them related to treatment in the early stages of testing (69 phase I or "first in human" and 82 phase II). INCLIVA's new facilities provide a full floor and a half specifically dedicated to host the unit.

The unit aims to develop and select new drugs through clinical trials and to perform studies related to the pathogenesis, prognosis and new experimental therapies in solid tumors.

# 4 scientific activity

## FUNCTIONS

The unit implements early clinical trials with experimental agents in the field of Oncology.

## EQUIPMENTS

- -80° C Freezer
- -20° C Freezer
- 2 Refrigerated desktop centrifuge
- Scientific refrigerator
- Conventional fridge
- Defibrillator
- Electrocardiographic equipment
- 7 monitors (blood pressure, heart rate and O2 saturation)
- 7 double medication infusion pumps
- 7 heads gases (oxygen and vacuum)

## LOCATION

The following facilities are located on the second floor:

- Reception and waiting room
- 2 Consulting rooms
- Staff room
- Meeting room
- Therapy room

The third floor hosts the following facilities:

- Clinical trials office
- Monitoring room
- Clinical trials archives

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** CIRCULATE-SPAIN-01

**Title:** Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA

**Principal Investigator:** Andrés Cervantes Ruipérez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2026

**Total budget:** €1.039.967,68

# scientific activity

## 4.5.3. Spanish Clinical Research Network (SCReN), Clinical Research and Clinical Trials of the Clinical Trials Platform (UICEC INCLIVA)

Team
<b>PI:</b>
Andrés Cervantes Ruipérez. Hospital. University
<b>Associated Members:</b>
Esteban Jesús Morcillo Sánchez. Hospital. INCLIVA
José Enrique Muñoz Cebriá. INCLIVA
Juan Antonio Carbonell Asins. Hospital. INCLIVA
Julio Núñez Villota. Hospital. INCLIVA
Luis Sabater Ortí. Hospital. INCLIVA
Marta Peiró Signes. INCLIVA
Patricia Caunedo Almagro. INCLIVA
Verónica Guillot Yacyszyn. INCLIVA
<b>Hired Members:</b>
Ana Portolés Monzón. INCLIVA
Mercedes Peris Costá. INCLIVA
Mireya Ferrandis Martínez. INCLIVA

UICEC participates in all activities related with the correct development of observational studies and clinical trials, in accordance with the applicable legal regulations and the standards of good clinical practice.

Currently, the portfolio of services includes, among others, the following activities:

1. Methodological and regulatory advice: collaboration tasks in the drafting of the protocol, CRF, Patient Information Sheet and Informed Consent and all documentation necessary for the correct development of the study in accordance with applicable regulations.
2. Start-up activities: in this phase the Unit collaborate with economic viability evaluation; identification and selection of participating sites; submission to national and local Authorities and Ethics Committee; contract management with the participating sites; monitoring plan; master file creation.
3. Development activities: project management activities, notifications; processing of amendments, interim analysis and reports; home visits; maintenance of file and monitoring visits.
4. Completion and closure activities: close-out visits; resolution of queries, elaboration of final reports, closure notifications to national and local Authorities and Ethics Committees.

## ACTIVITIES DEVELOPED

During 2022, UICEC has collaborated with the development of the following clinical trials, interventional and observational studies:

### Clinical trials /Interventional Studies

#### Study: SEVO-COVID19

**Title:** Sevoflurane versus propofol sedation in patients with acute respiratory distress syndrome caused by COVID19 infection

**EUDRACT:** 2020-001379-34

**Sponsor:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Phase:** IV (Low intervention clinical trial)

#### Study: SOLIDARITY

**Title:** An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care

**EUDRACT:** 2020-001366-11

**Sponsor:** Ministerio de Sanidad, Consumo y Bienestar Social

**Phase:** IV

# scientific activity

**Study:** ESR-17-13447[DAPA-HF]

**Title:** Short-term effects of Dapagliflozin on Peak VO<sub>2</sub> in patients with heart failure with reduced ejection fraction

**EUCRACT:** 2018-002614-12

**Sponsor:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Phase:** IV

**Study:** ELECLA

**Title:** Analysis of the effectiveness of neoadjuvant chemotherapy in treating colon cancer locally advanced

**EUCRACT:** 2016-002970-10

**Sponsor:** Jorge Arredondo Chávez, Complejo Asistencial Universitario de León

**Phase:** IV [Low interventional clinical trial]

**Study:** LINES

**Title:** European Low and Intermediate Risk Neuroblastoma

**EUCRACT:** 2010-021396-81

**Sponsor:** Fundación para la Investigación Hospital Universitario y Politécnico La Fe

**Phase:** III

**Study:** RAPIDO

**Title:** Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemoradiotherapy and surgery and optional adjuvant chemotherapy

**EUCRACT:** 2010-023957-12

**Sponsor:** UMCG, Groningen, The Netherlands

**Phase:** III

**Study:** HaploMUDStudy

**Title:** Matched unrelated vs. haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GVHD prophylaxis – a randomized prospective European trial

**Sponsor:** University Medical Center Hamburg-Eppendorf Investigator Initiated Trial (IIT) [financial support by DKMS]

**Phase:** Non Observational with no drugs study

**Study:** PANGASBLUM

**Title:** Pancreatic anastomosis following pancreateoduodenectomy: pancreatogastrostomy versus bLumgart's anastomosis. A randomized, prospective, multicenter study

**Sponsor:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Phase:** Non Observational with no drugs study

**Study:** MOSCA FRAIL

**Title:** Randomized comparison between the invasive and conservative strategies in elderly frail patients with non-ST elevation myocardial infarction: the MOSCA-FRAIL Clinical Trial

**Sponsor:** Sociedad Española de Cardiología

**Phase:** Intervention clinical trial

**Study:** CETUPANC

**Title:** Impact of the dissemination of the circulating tumor cells (CTCs) during the cephal duodenopancreatology at the appearance of metastasis and survival in patients with tumors of pancreas and periamplulars (CETUPANC Study)

**Sponsor:** Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)

**Phase:** Interventional study

**Study:** FAIR

**Title:** Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality (FAIR-HF2)

**EUCRACT:** 2016-000068-40

**Sponsor:** University Medical Center Hamburg-Eppendorf Investigator Initiated Trial (IIT) [financial support by DKMS]

**Phase:** IV

**Study:** COLICA

**Title:** Randomized double-blind trial to study the benefit of Colchicine in Patients with Acutely Decompensated Heart Failure (IMIB-CO-2020-01)

**EUCRACT:** 2020-000941-15

**Sponsor:** Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS)

**Phase:** III

**Study:** ECACIKAGEL

**Title:** Ensayo Clínico Aleatorizado triple ciego para la evaluación de la seguridad y eficacia de CikaGel® en el tratamiento de las úlceras de pierna en pacientes sin Enfermedad Arterial Periférica

**Sponsor:** Georges Klein

**Phase:** Clinical trial with Medical Device

**Study:** ASTARTE

**Title:** Temociclina vs Meropenem para el tratamiento de la bacteriemia por enterobacteriales resistentes a cefalosporinas de tercera generación: ensayo aleatorizado y pragmático

**EUCRACT:** 2020-000064-39

**Sponsor:** Fundación Pública para la Gestión de la Investigación en Salud de Sevilla (FISEVI)

**Phase:** III

# scientific activity

4

## Study: CIRCULATE-SPAIN-01

**Title:** Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA

**EUDRACT:** 2021-000507-20

**Sponsor:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Phase:** II

## Study: KEEP ON [ESR-19-20217]

**Title:** Phase III, multicenter, open-label, randomized clinical trial to evaluate efficacy of Sodium Zirconium Cyclosilicate (Lokelma) compared to standard of care to manage hyperkalemia in patients with chronic kidney disease (CKD) and heart failure history

**EUDRACT:** 2020-003229-47

**Sponsor:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Phase:** III (Low intervention clinical trial)

## Study: ROTATE

**Title:** Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-3)

**EUCRACT:** 2017-004641-25

**Sponsor:** University Medical Center Groningen

**Phase:** III

## Study: FOVOCIP

**Title:** Un ensayo aleatorizado multicéntrico de fosfomicina frente a ciprofloxacino para la neutropenia febril en pacientes hematológicos: eficacia y seguridad microbiológica

**EUCRACT:** 2021-000354-25

**Sponsor:** Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturias (FINBA)

**Phase:** III

## Observational studies

### Study: INC-CVD-2020-01

**Title:** Study of the occurrence of fibrotic pulmonary changes associated with SARS-CoV-2 infection

**Sponsor:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Phase:** NO-EPA

### Study: DNO-IBR-2018-01

**Title:** Virology and immunology of cytomegalovirus (CMV) infection in patients with haematological malignancies in the time of new biotherapies

## Sponsor: Fundación Investigación Hospital Clínico Universitario de Valencia

**Phase:** EPA-AS

## Study: TFK-RAM-2018-01

**Title:** Macrophages associated with tumor, tumor angiogenesis and resistance to therapies in diffuse gastric cancer mesenchymal phenotype

**Sponsor:** Tania Fleitas Kanonnikoff

**Phase:** EPA-AS

## Study: OPTIM- BIOMA FIS-ANT-2017-01

**Title:** Optimization of antibiotic treatment in recipients of allogeneic LIN transplantation: impact on the intestinal microbiota and on clinical results

**Sponsor:** Fundación Pública Andaluza para la gestión de la Investigación en Salud de Sevilla (FISEVI)

**Phase:** EPA-SP

## Study: GOLD 0 -DLCO 1

**Title:** GOLD 0 - DLCO 1: A look beyond obstruction. Is spirometry sufficient in COPD screening?

**Sponsor:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Phase:** No-EPA

## Study: JGT-FER-2020-01 (COCOON)

**Title:** Efecto de la administración intravenosa de hierro carboximaltosa sobre el rendimiento físico, la fatiga y la calidad de vida en pacientes con enfermedad renal crónica no en diálisis y déficit de hierro

**Sponsor:** José Luis Górriz Teruel

**Phase:** EPA-SP

## Study: HK-01-21

**Title:** Evidencia en la vida real del uso de patiromer para el tratamiento de pacientes con hiperpotasemia crónica en una región de España

**Sponsor:** Fundación Investigación Hospital Clínico Universitario de Valencia


**Phase:** EPA-OD

# 4 scientific activity

## UNIT ACTIVITY DURING LAST 4 YEARS

During the last four years, the unit has initiated 28 studies (16 clinical trials and 12 observational studies). The following table shows its distribution by year.

	Clinical trials	Observational Studies	Total
2019	4	4	<b>8</b>
2020	5	4	<b>9</b>
2021	4	2	<b>6</b>
2022	3	2	<b>5</b>




Despite the total number of studies is decreased in 2022, it is important to notice that from 2020 on, it is shown a clear tendency in increasing the number of clinical trials comparing to observational studies, which is very positive due to the complexity of this type of clinical studies.

As accumulative activity, new and ongoing studies, the Unit maintains an average of 27 active studies, per year. Their distribution by type of study and year is detailed in the following table.

	2019	2020	2021	2022
Phase I	1	1	1	0
Phase II	0	0	0	1
Phase III	5	3	6	6
Phase IV	8	9	10	6
Clinical Trials Other Designs	4	6	6	5
Observational	8	8	9	8
<b>Total</b>	<b>26</b>	<b>27</b>	<b>32</b>	<b>26</b>

# scientific activity

4



## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** PT20/0100

**Title:** Spanish Clinical Research Network (SCReN)

**Principal Investigator:** Andrés Cervantes Ruipérez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

# scientific activity

## 4.5.4. Precision medicine unit

### Team

*ump@incliva.es*

#### PI:

Andrés Cervantes Ruipérez. Hospital. University

#### Coordinator:

Pilar Rentero Garrido. INCLIVA

#### Collaborating researchers:

Desamparados Roda Pérez. Hospital

Valentina Gambardella. INCLIVA

#### Technicians:

Enrique Seda García. INCLIVA

Laura González Castillo. INCLIVA

Laura Olivares Ordóñez. INCLIVA

Sebastián Blesa Luján. INCLIVA

The Precision Medicine Unit was established in March 2018. Since then, the group have developed a robust and wide portfolio of services to support research at INCLIVA.

To date, the unit closely collaborates with the Oncology Phase I Clinical Trial Unit. Together we have developed an integrated screening system to support personalized patient care and hence implementing the latest techniques into the clinical practice. In addition, the unit currently collaborates in several research projects from different groups at INCLIVA.

The group integrates professional profiles from multiple disciplines (Medical Oncology, Molecular Biology, Bioinformatics and Biochemistry) with large professional experience in Human Genetics and Genomics.

## FUNCTIONS

Our mission is to impulse, promote and execute quality translational research offering support in Molecular Biology as well as in Data Analysis techniques to the scientific community.

## LABORATORY EQUIPMENT

- Two massive sequencers with Illumina chemistry: MiSeq and NextSeq550
- iScan System to scan Illumina microarrays
- nanoString n-Counter platform
- Biorad ddPCR
- Chromium Single Cell System (10X Genomics)
- Glomax Discovery System (Promega)
- Maxwell RSC (Promega)
- Quantitative thermalcycler
- Standard thermalcyclers
- TapeStation system to visualize DNA and RNA
- Laminar cabins, centrifuges, heat blocks, ovens, etc.

## LOCATION

- Laboratories: *Facultad de Medicina. Avenida Blasco Ibáñez 15, Building 2, 2nd floor, UCIM Corridor, Laboratory 1*

## SERVICES

1. Next-Generation Sequencing (NGS):
  - Design, development, validation and sequencing of custom gene panels
  - Exome sequencing and analysis
  - Whole-genome sequencing
  - Sequencing small genomes “de novo”
  - RNA-sequencing (total RNA, poly(A) fraction, rRNA depleted...)
  - Microtranscriptome sequencing (smallRNA/miRNA...)
2. Microarrays:
  - Genotyping arrays
  - Methylation arrays
3. Digital PCR
4. nanoString platform
5. Chromium Single Cell System (10X genomics)
6. Other molecular biology techniques:
  - Nucleic acid isolation
  - Nucleic acid quantification (absorbance and fluorescence)
  - Luminiscence analysis
  - Uniplex and Multiplex PCR
  - Quantitative PCR

## 7. Additional services:

- Advice and methodological support in writing protocols, research project proposals, scientific papers
- Mentoring of bachelor, master and doctorate students
- On demand training
- Consulting services

## DEVELOPED ACTIVITIES

2500 oncologic patients have been molecularly tested to select the best treatment

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** ICI20/000009

**Title:** Circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II-III (CIRCULANTE-SPAIN)

**Principal Investigator:** Andrés Cervantes Ruipérez

**Funding Body:** Instituto de Salud Carlos III - Co-financed FEDER

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2024

**Total budget:** €1.039.970

**Title:** Precision medicine in oncology: development of new technological approaches for personalized treatments in Immunotherapy

**Principal Investigator:** Desamparados Roda and Sheila Zúñiga

**Funding Body:** Fundación FERO

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €300.000

**Title:** Factores derivados del microambiente tumoral en cáncer de colon localizado: impacto clínico e implicaciones terapéuticas

**Principal Investigator:** Andrés Cervantes Ruipérez

**Funding Body:** Fundación AECC

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €1.000.000

**Title:** Valor pronóstico y predictivo de respuesta del microambiente del cáncer gástrico en personas jóvenes. Proyecto VERO

**Principal Investigator:** Tania Fleitas Kanonnikoff

**Funding Body:** GEMCAD

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2022-2024

**Total budget:** €20.000

**Title:** Tumor microenvironment-derived factors in localized colon cancer: clinical impact and therapeutic implications (TUMMIC)

**Principal Investigator:** Andrés Cervantes Ruipérez

**Funding Body:** Fundación AECC

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2025

**Total budget:** €992.996

**Title:** Colorectal carcinogenesis: the interaction of the tumor microenvironment and stem cells. Impact on personalized treatment

**Principal Investigator:** Noelia Tarazona Llavero

**Funding Body:** Fundación Mutua Madrileña

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2023

**Total budget:** €130.000

**Title:** Whole exome sequencing of circulating tumor DNA and genomic DNA to increase sensitivity in the detection of minimal residual disease and open new mechanisms for personalized medicine in localized colon cancer

**Principal Investigator:** Noelia Tarazona Llavero

**Funding Body:** SEOM

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €20.000

**Title:** Patient derived organoids (PDOs) to personalize the treatment of relapsed localized colon cancer (CC) by sequencing the whole exome and genomic DNA

**Principal Investigator:** Noelia Tarazona Llavero

**Funding Body:** TTD

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €40.000

# 4 scientific activity

## PUBLICATIONS

1. Álvarez L, Marín-García PJ, Rentero-Garrido P, Llobat L. Immune and genomic analysis of boxer dog breed and its relationship with *Leishmania infantum* infection. *Veterinary Science*. 2022 Nov 2;9(11):608. doi: 10.3390/vetsci9110608. PMID: 36356085
2. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcón-Molero L, González-Vilanova A, Zuñiga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Durá A, Ríchart P, Alonso N, Huerta M, Roselló S, Roda D, Tarazona N, Martínez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. *British Journal of Cancer*. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523
3. Domingo-Rellosa A, Bozack A, Kiihl S, Rodriguez-Hernandez Z, Rentero-Garrido P, Casasnovas JA, Leon-Latre M, Garcia-Barrera T, Gomez-Ariza JL, Moreno B, Cenarro A, de Marco G, Parvez F, Siddique AB, Shahriar H, Uddin MN, Islam T, Navas-Acien A, Gamble M, Tellez-Plaza M. Arsenic exposure and human blood DNA methylation and hydroxymethylation profiles in two diverse populations from Bangladesh and Spain. *Environmental Research*. 2022 Mar;204(Pt B):112021. doi: 10.1016/j.envres.2021.112021. PMID: 34516978

# scientific activity

## 4.5.5. Bioinformatics Unit

<b>Team</b>
<b>Coordinator</b>
Sheila Zúñiga Trejos. INCLIVA
<b>Technicians</b>
Fabián Robledo Yagüe. INCLIVA
Francisco Martínez Picó. INCLIVA
José Francisco Català Senent. INCLIVA
Pilar Natividad López. INCLIVA

The unit is mainly dedicated to collaborating on various research projects, providing advice and support to researchers in the design, implementation of workflows, development of computational strategies and data analysis.

## EQUIPMENT

INCLIVA has its own Data Processing Center (DPC) which houses different servers with a total capacity of 350 CPUs, 700 execution threads, 6.5 TB of ECC RAM, ~350 TB of redundant HDD storage, 20 TB of solid-state storage (SSD) and more than 600 TB of secondary storage for backups. In addition, the DPC has servers with CUDA parallelized computing capabilities supported by two Nvidia A40 GPUs.

In addition, and as part of the Valencian biomedical research community, we also had access to a large computing facility hosted at the *Centro de Investigación Príncipe Felipe* to cope with large projects.

## ACTIVITY

In 2022, 1151 samples were analyzed for diagnostic purposes for the Phase I Clinical Trial Unit and the Haematology Department in 114 different services. In addition, we analyzed 531 samples in 80 different services related to multiple projects.

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Title:** Precision medicine in oncology: development of new technological approaches for personalized treatments in Immunotherapy

**Principal Investigator:** Sheila Zúñiga and Desamparados Roda

**Funding Body:** Fundación FERO

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2024

**Total budget:** €540.000

## THE UNIT HAS SUPPORTED THE FOLLOWING PROJECTS

Project	Funding Body	Principal Researcher	Supporting Activities
Precision medicine in oncology: development of new technological approaches for personalized treatments in Immunotherapy	Fundación FERO	Sheila Zúñiga and Desamparados Roda	Analysis of 555 samples with a custom gene panel
IC120/00009. Circulating Tumor DNA based decision for adjuvant treatment in colon cancer stage II-III (CIRCULANTE-SPAIN)	Instituto de Salud Carlos III - Co-financed FEDER	Andrés Cervantes	Analysis of 121 samples with custom gene panel to identify SNVs and small indels in FFPE tumor samples

# 4 scientific activity

PI20/1107. Neuroblastoma: mechanotherapeutic strategies based on 3D model and patient derived tumor with vitronectin rich microenvironment	<i>Instituto de Salud Carlos III - Co-financed FEDER</i>	Rosa Noguera	Analysis of 51 samples with a custom gene panel to identify SNVs, small indels and CNVs in FFPE tumor samples
PRV00097. RED53	Janssen	María José Terol Casterá	Analysis of 552 samples with three different custom gene panel to identify SNVs and small indels in blood samples to study haematologic malignancies
2021/049. Factores clínico-biológicos y genéticos asociados al riesgo de trombosis en la Mielofibrosis	<i>Instituto de Salud Carlos III - Co-financed FEDER</i>	Juan Carlos Hernández Boluda	Development and validation of a panel for cDNA capture in a customized panel and analysis of 8 samples
2020/184. Carcinogénesis colorrectal: la interacción del microambiente tumoral y las células madre. Impacto en el tratamiento personalizado	<i>Fundación Mutua Madrileña</i>	Noelia Tarazona	Development and validation of a gene panel for methylation analysis and analysis of 20 samples. Analysis of 5 samples with a custom gene pane
PI19/00169. Papel de los procesos inflamatorios en las enfermedades metabólicas y en las complicaciones asociadas	<i>Instituto de Salud Carlos III - Co-financed FEDER</i>	Herminia González	RNASeq data analysis for 12 samples
IMP/00019. Infraestructura de Medicina de Precisión asociada a la Ciencia y la Tecnología. IMPaCT - Data	<i>Instituto de Salud Carlos III - Co-financed FEDER</i>	Alfonso Valencia (BSC). Coordinator INCLIVA - Sheila Zúñiga	To develop a common, interoperable and integrated system for data collection and analysis
PI18/01909. Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en biopsia líquida y modelos de organoides	<i>Instituto de Salud Carlos III - Co-financed FEDER</i>	Andrés Cervantes	Integration of proteomics and transcriptomics data
EDGJID/2021/053. Consolidación de las plataformas centrales vinculadas a la Medicina de Precisión	<i>Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital</i>	Sheila Zúñiga	Development of new core services in the field of Precision Medicine

## PUBLICATIONS

- Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcón-Molero L, González-Vilanova A, Zúñiga-Trejos S, Rentero-Garrido P, Villagrassa R, Gil M, Durá A, Richart P, Alonso N, Huerta M, Roselló S, Roda D, Tarazona N, Martínez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. *British Journal of Cancer*. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523

# scientific activity

## 4.5.6. Biostatistics Unit

### Team

#### **Coordinator:**

Juan Antonio Carbonell Asins. INCLIVA

#### **Technician:**

Carlos Peña de los Santos. INCLIVA

The Biostatistics Unit is a core facility created in 2022. The unit is mainly dedicated to collaborate in different research projects, providing statistical advice and support to researchers in the design, workflow implementation, development of their research projects.

## FUNCTIONS

Our mission is to drive, promote and execute quality clinical and translational research through methodological and analytical support.

## EQUIPMENT

INCLIVA has a computing facility with 100 cores, 400GB of RAM memory 80TB of redundant network storage and 20TB of fast non-redundant local storage to the nodes for high I/O processes such as those applied to omics data analysis.

## SERVICES

- Design of clinical and epidemiological studies
- Sample size estimation
- Simulation techniques
- Supervised and unsupervised analysis techniques
- Predictive modelling
- Advice and methodological support to write protocols, research project proposals, articles, doctoral/MSc/BSc thesis
- Data mining and exploratory analysis of databases
- Graphical representation of research results
- Curation and analysis of databases
- Consulting

## RESEARCH PROJECTS AND GRANTS FOR RESEARCH

**Reference:** 825832 – LEGACy

**Title:** CELAC and European consortium for a personalized medicine approach to Gastric Cancer

**Principal investigator:** Andrés Cervantes Ruipérez

**Funding Body:** European Commission

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2019-2023

**Total Budget:** €3.577.431,27 (INCLIVA: €638.315)

**Title:** Secuenciación del exoma completo del DNA tumoral circulante y DNA genómico para aumentar la sensibilidad en la detección de la enfermedad mínima residual y abrir nuevas vías para la medicina personalizada en cáncer de colon localizado

**Principal Investigator:** Noelia Tarazona Llavero

**Funding Body:** Sociedad Española de Oncología Médica (SEOM)

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2021-2023

**Total budget:** €20.000

# scientific activity

**Title:** Organoides derivados de pacientes (PDOs) para personalizar el tratamiento en recaídas de cáncer de colon (CC) localizado mediante secuenciación del exoma completo y del DNA genómico

**Principal Investigator:** Noelia Tarazona Llavero

**Funding Body:** TTD Grupo de Tumores Digestivos

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2022

**Total budget:** €40.000

**Title:** Carcionogénesis colorrectal: la interacción entre el microambiente tumoral y las células madre. Impacto en el tratamiento personalizado

**Principal Investigator:** Noelia Tarazona Llavero

**Funding Body:** Fundación Mutua Madrileña

**Beneficiary Institution:** Fundación Investigación Hospital Clínico Universitario de Valencia

**Duration:** 2020-2023

**Total budget:** €130.000

## PUBLICATIONS

1. D'Marco L, Puchades M, Escudero-Saiz V, Gimenez-Civera E, Terradez L, Moscardo A, Carbonell-Asins J, Perez-Bernat E, Torregrosa I, Moncho F, Navarro J, Gorri J. Renal histologic findings in necropsies of Type 2 Diabetes Mellitus patients. *Journal of Diabetes Research.* 2022 Sep 6;2022:3893853. doi: 10.1155/2022/3893853. PMID: 36110834
2. Tarraso J, Safont B, Carbonell-Asins JA, Fernandez-Fabrellas E, Sancho-Chust JN, Naval E, Amat B, Herrera S, Ros JA, Soler-Cataluna JJ, Rodriguez-Portal JA, Andreu AL, Marin M, Rodriguez-Hermosa JL, Gonzalez-Villaescusa C, Soriano JB, Signes-Costa J. Lung function and radiological findings 1 year after COVID-19: a prospective follow-up. *Respiratory Research.* 2022 Sep 12;23(1):242. doi: 10.1186/s12931-022-02166-8. PMID: 36096801
3. Vina J, Escudero J, Baquero M, Cebrian M, Carbonell-Asins J, Munoz J, Satorres E, Melendez J, Ferrer-Rebolleda J, Cozar-Santiago M, Santabarbara-Gomez J, Jove M, Pamplona R, Tarazona-Santabalbina F, Borras C. Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial. *Alzheimer's Research & Therapy.* 2022 Nov 4;14(1):164. doi: 10.1186/s13195-022-01097-2. PMID: 36329553
4. Adam-Artigues A, Arenas E, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, Hernando C, Martinez M, Carbonell-Asins J, Simon S, Poveda J, Moragon S, Zazo S, Martinez D, Rovira A, Burgues O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo J. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. *Science Advances.* 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. PMID: 35594351
5. Safont B, Tarraso J, Rodriguez-Borja E, Fernandez-Fabrellas E, Sancho-Chust JN, Molina V, Lopez-Ramirez C, Lope-Martinez A, Cabanes L, Andreu A, Herrera S, Lahosa C, Ros JA, Rodriguez-Hermosa JL, Soriano JB, Moret-Tatay I, Carbonell-Asins JA, Mulet A, Signes-Costa J. Lung function, radiological findings and biomarkers of fibrogenesis in a cohort of COVID-19 patients six months after hospital discharge. *Archivos de Bronconeumología.* 2022 Feb;58(2):142-149. doi: 10.1016/j.arbres.2021.08.014. PMID: 34497426
6. Garcia-Vigara A, Cano A, Fernandez-Garrido J, Carbonell-Asins J, Tarin J, Sanchez-Sanchez M. Non-use of information and communication technology as a predictor of frailty in postmenopausal midlife and older women. *Maturitas.* 2022 Feb;156:60-64. doi: 10.1016/j.maturitas.2021.05.010. PMID: 34275701
7. Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, Huerta M, Rosello S, Madsen AH, Love US, Andersen PV, Thorlacius-Ussing O, Iversen LH, Gotschalck KA, Sethi H, Aleshin A, Cervantes A, Andersen CL. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. *Clinical Cancer Research.* 2022 Feb 1;28(3):507-517. doi: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408
8. Tranah T, Ballester M, Carbonell-Asins J, Ampuero J, Alexandrino G, Caracostea A, Sanchez-Torrijos Y, Thomsen K, Kerkert A, Capilla-Lozano M, Romero-Gomez M, Escudero-Garcia D, Montoliu C, Jalan R, Shawcross D. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. *Journal of Hepatology.* 2022 Dec;77(6):1554-1563. doi: 10.1016/j.jhep.2022.07.014. PMID: 35872326
9. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-

# scientific activity

4

Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Ríchart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martínez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. *British Journal of Cancer*. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523



# cli- cal trials

INCLIVA SCIENTIFIC REPORT 2022

## **5. Clinical trials and other studies**

**5.1 Activity of the Ethical Committee for  
investigation with medicinal products (CEIm)**

**5.2 Clinical research activity performed by  
Valencia Clínico-Malvarrosa Health Department**

## 5.1. Activity of the Ethical Committee for investigation with medicinal products (CElm)

The Ethical Committee for Investigation with Medicinal Products are an independent board with a multidisciplinary composition whose main purpose is to oversee the protection of the rights, safety and well-being of subjects participating in clinical studies and biomedical research projects.


As a result of its activity along 2022, the CElm has processed a total of 28 studies (clinical trials and observational studies): 27 were positively valued, and 1 was negatively valued.

Of the 27 approved studies, 15 were approved in the first evaluation and 12 after requesting clarification to the promoter.

Of the 13 clinical trials with drugs evaluated, anyone has been evaluated through the Voluntary Harmonisation Procedure (VHP) process.

The following table shows the number of clinical trials and other studies according to their typology.

TYPES OF EVALUATED STUDIES	2022
CLINICAL TRIALS WITH MEDICINAL PRODUCTS	17
Phase 0	0
Phase I	3
Phase II	10
Phase III	4
Phase IV	0
CLINICAL TRIALS WITH MEDICAL DEVICES	3
CLINICAL TRIALS WITH SUPPLEMENT	1
OBSERVATIONAL STUDIES WITH MEDICINAL PRODUCTS	6
OBSERVATIONAL STUDIES WITH MEDICAL DEVICES	1
RESEARCH PROJECTS	212
<b>TOTAL</b>	<b>240</b>



# 5 clinical trials

Distribution of the clinical studies depending on the department where they are performed is the following:

CLINICAL TRIALS BY DEPARTMENT	Nº
Anesthesiology and Reanimation	2
Cardiology	1
Dermatology	1
Endocrinology	2
General Surgery	1
Hematology	2
Nephrology	2
Neurology	1
Oncology	10
Pediatrics	2
Physical Medicine and Rehabilitation	1
Psychiatry	1
Tutelage	2
<b>TOTAL</b>	<b>28</b>

Distribution of the research projects depending on the department where they are performed is the following:

RESEARCH PROJECTS BY DEPARTMENT	Nº
Anesthesiology and Reanimation	13
Cardiology	29
Clinical Analysis and Clinical Biochemistry	2
Digestive Medicine	11
Emergencies	3
Endocrinology and Nutrition	6
External	3
General Surgery	15
Gynecology	3
Hematology	7
Incliva Research Groups	9
Infectious Diseases	3
Intensive Medicine	2
Internal Medicine	7
Microbiology	5
Nephrology	5
Neumology	5
Neurology	3
Nursery	6
Oncology	21
Ophthalmology	7
Oral and Maxillofacial Surgery	1
Orthopedic and Traumatology Surgery	5
Otorhinolaryngology	1

RESEARCH PROJECTS BY DEPARTMENT		Nº
Pathological Anatomy		3
Pediatrics		10
Primary Care		7
Phychiatry		4
Physiotherapy		3
Radiology		1
Traumatology		3
Urology		2
Others		7
<b>TOTAL</b>		<b>212</b>

## 5.2. Clinical research activity performed by Valencia Clínico-Malvarrosa Health Department

### 5.2.1. Activity during 2022


INCLIVA Biomedical Research Institute manages the clinical studies (trials, observational studies, and research projects) carried out by the *Hospital Clínico Universitario de Valencia* and the Valencia Clínico-Malvarrosa Health Department researchers.

As a result of its activity along 2022, the INCLIVA has managed a total of 105 studies (clinical trials and observational studies).


The distribution of these trials by phase is: Phase I: 15, Phase II: 41; Phase III: 31, Phase IV: 2, Observational studies: 12, others: 4. The following table shows the number of clinical trials and other studies according to their phase and department.

	Phase I	Phase II	Phase III	Phase IV	Others	Observational	TOTAL
Cardiology	0	1	3	0	3	1	<b>8</b>
Digestive Medicine	0	0	0	0	0	0	<b>0</b>
Haematology	3	4	5	0	0	1	<b>13</b>
Internal Medicine	0	1	2	0	0	0	<b>3</b>
Nephrology	0	2	2	0	0	0	<b>4</b>
Neurology	0	0	0	0	0	1	<b>1</b>
Oncology	12	33	14	0	0	1	<b>60</b>
Others	0	0	5	2	1	8	<b>16</b>
<b>TOTAL</b>	<b>15</b>	<b>41</b>	<b>31</b>	<b>2</b>	<b>4</b>	<b>12</b>	<b>105</b>

# 5 clinical trials



The Department of Medical Oncology leads the number of trials assessed to INCLIVA. It is followed by the departments of Hematology, Cardiology. These three services make over 77 % of the total processed trials.



Regarding the distribution of studies per promoter, 11 trials are considered as Independent Clinical Research (trials from associations, groups, foundations, and private individuals), 1 of which has been promoted by researchers from the *Hospital Clínico Universitario de Valencia* and INCLIVA and the rest of them have been promoted by the pharmaceutical industry.

PROMOTOR	Nº
HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA RESEARCHERS AND INCLIVA	1
INDEPENDENT CLINICAL RESEARCH	11
COMERCIAL RESEARCH	93

# clinical trials

5

## 5.2.2 Assessment activity during last 5 years


The table below shows the number of studies processed yearly.

Year	Processed studies
2018	172
2019	159
2020	206
2021	211
2022	105

One of INCLIVA's main goals is to develop clinical research at its early stages, thus contributing to translational research that moves scientific knowledge from bench to bedside. With this regard, during the period 2018-2022, Phase I and Phase II trials are prioritized and its number remains stable as shown in the table and graph below.

PHASE	2018	2019	2020	2021	2022
Phase I	22	17	33	24	15
Phase II	25	43	43	56	41
Phase III	67	43	64	67	31
Phase IV	5	7	8	3	2
Observational	51	42	50	57	4
Others	2	7	8	4	12

Evolution of clinical trial distribution by phase



# clinical trials


## 5.2.3. Ongoing studies

During 2022, 687 studies have been active. The distribution of clinical trials per department analyzed below uses a semilogarithmic scale due to the great difference between the Department of Medical Oncology and the rest of the Departments.

DEPARTMENT	Nº
Allergy	2
Anesthesia and Reanimation	14
Cardiology	50
Dermatology	3
Digestive Medicine	28
Endocrinology	10
General Surgery	4
Gynecology and Obstetrics	4
Hematology	70
Infectious Diseases Unit	12
Intensive Medicine	1
Internal Medicine	14
Medical Oncology	318
Microbiology Laboratory	2
Nephrology	27
Neurology	43
Nursing	1
Ophthalmology	3
Otorhinolaryngology	3
Pathology	1
Pediatrics	11
Pharmacy	5
Pneumology	16
Primary Care	13
Psychiatry	7
Radiotherapy	4
Rheumatology	13
Traumatology and Orthopedic Surgery	1
Urology	7
<b>TOTAL</b>	<b>687</b>


# clinical trials




5



The distribution of ongoing trials and other studies according to their typology are the following:

PHASE	Nº
Phase I	89
Phase II	161
Phase III	270
Phase IV	27
Observational	13
Other	127





# initia- tives

INCLIVA SCIENTIFIC REPORT 2022



## 6.1. Grants for external fellowships, Trainee students, Outgoing and Incoming Internships and new initiatives

To allow researchers to acquire new knowledge for clinical and research techniques, every year INCLIVA sponsors its Grants for research internships in centers of excellence. In 2022 the number of grants funded was 19.

List of beneficiaries and destination centers of the IIS INCLIVA Training Stays Grants during 2022:

<b>José Vicente Arcos Machancoses</b>	<b>José Francisco González Muñoz</b>
Sheffield's Children Hospital. Sheffield, United Kingdom	Hospital del Mar. Barcelona, Spain
<b>Manuel Cabeza Segura</b>	<b>Alba Machado López</b>
Fox Chase Center. Philadelphia, USA	Technical University of Denmark. Lyngby, Denmark
<b>Juan Pablo Carrasco Picazo</b>	<b>Gonzalo Núñez Marín</b>
Douglas Mental Health University Institute. McGill University. Montreal, Canada	<i>Instituto de Cardiología de Montreal</i> . Montreal, Canada
<b>Raquel Casabán Barberan</b>	<b>Rebeca Osca Verdegal</b>
Centro Ditem. Buenos Aires, Argentina	Salk Institute. California, USA
<b>Elena Domingo Pérez</b>	<b>Ana Belén Paes Martí</b>
Karolinska Institutet. Solna, Sweden	Inserm U1046, Université de Montpellier. Montpellier, France
<b>Esther García Domínguez</b>	<b>Irene Pastor Escartín</b>
Institute for Health & Sport. Victoria University. Wellington, Australia	Charité - Universitätsmedizin, Berlin. Germany
<b>Ainhoa Natividad García Martín</b>	<b>Sonia Puchades Latorre</b>
Instituto Pasteur de Lille. Paris, France	<i>Consulta Medicina General Dr. Biosca</i> . Toulouse, France
<b>Guillermo García Oriola</b>	<b>Laura Quiles Higuero</b>
UW Health Neurosurgery Clinic. Wisconsin, USA	<i>Hospital Príncipe de Asturias</i> . Alcalá de Henares, Spain
<b>Soraya García Sorribes</b>	<b>Isabel Trapero Gimeno</b>
<i>Fundación Pública Galega de Medicina Xenómica</i> . Santiago Compostela, Spain	Karolinska Institutet. Solna, Sweden
<b>Mª Carmen Gómez Cabrera</b>	
National Institute of Aging. Bethesda, USA	

### OUTGOING INTERNSHIPS

Researchers from our IIS INCLIVA that during 2022 carried out external fellowships in foreign centers are shown in the following table:

<b>Júlia Alcaide Pozo</b>	<b>Olga Martínez Arroyo</b>
The Douglas Research Centre. Montreal, Canada	Universidad de Turin. Italy
<b>Franc Casanova Ferrer</b>	<b>Marta Pérez Rando</b>
<i>Universidad Complutense de Madrid</i> . Madrid, Spain	<i>Fundación FIDMAG Hermanas Hospitalarias</i> . Sant Boi de Llobregat, Spain

# initiatives

## INCOMING INTERNSHIPS

The incoming researchers in 2022 are shown in the following table:

<b>Jonathan Hermenejildo</b> University of Valencia (Spain) - Genomics and Diabetes Unit	<b>Jose M<sup>a</sup> Guijarro Nuez</b> Imperial College of London (United Kingdom) - Research Group on Heart Failure
<b>Emir Sokolovid</b> Clinical Centre University of Sarajevo (Bosnia and Herzegovina) - Research Group of Innovative Diagnostic and Therapeutical Developments in solid tumors - InDeST	<b>Paola Mejía</b> <i>Instituto Nacional de Enfermedades Neoplásicas</i> (Peru) - Research Group of Innovative Diagnostic and Therapeutical Developments in solid tumors-InDeST
<b>Michael Luci</b> University of Masaryk (Czech Republic) - Research Group on Epigenomics and Translational Epigenetics	

## TRAINEE STUDENTS

There is a table attached that includes the number of students of Vocational Qualification, Degree or Master accepted during 2022 in INCLIVA. They have carried out training practices in different research groups:

31 Bachelor Degree students at the University of Valencia (including TFD students)
21 Bachelor Degree students at the Polytechnic University of Valencia (including TFD students)
16 Master's Degree students at the University of Valencia (including TFM students)
6 Master's Degree students at the Polytechnic University of Valencia (including TFM students)
12 Bachelor Degree students from other universities (including TFD students)
9 Master's Degree students from other universities (including TFM students)
27 Higher Vocational Qualification students of public and/or private centers of the Valencian Community (including dual professional education students)
1 ESO students Program for acquiring knowledge about the world of work

## TFD and TFM

The third call for applications for TFD and TFM Tutorials was opened in 2022. The call is aimed at university students enrolled in University Degrees and Masters in the Area of Health and Allied Sciences.

The following list shows the students who are going to do their TFD or TFM:

### TFD

<b>Míriam Millán Castillo</b> - Genomics and Diabetes Unit - Mr. Javier Chaves and Mrs. Ana Bárbara García García
<b>Mar Navarro Montes</b> - Research Group on Breast Cancer Biology - Mrs. Pilar Eroles Asensio
<b>Àngela Natividad i Mateu</b> - Research Group on Psychiatry and Neurodegenerative Diseases - Mrs. Olga Rivero Martín
<b>Javier Palou Queiro</b> - Research Group on Cardiometabolic Risk and Diabetes and Research Group on Inflammation - Mrs. Vera Gomes Francisco and Mrs. M <sup>a</sup> Jesús Sanz Ferrando
<b>Paula Espinosa Molina</b> - Research Group on Neurological Impairment - Mrs. Andrea Cabrera Pastor

**Adrián Abellán Soriano** - Research Group on Cellular and Organic Physiopathology of Oxidative Stress - Mr. Juan Antonio Navarro Langa

**Sofía Sánchez Valle** - Translational Research Group on Pediatric Solid Tumors - Mrs. Rosa Noguera Salvá

**Raquel Rubio Soria** - Translational Research Group on Pediatric Solid Tumors - Mrs. Rosa Noguera Salvá

#### TFM

**Eva Albuixech Lluch** - Genomics and Diabetes Unit - Mrs. Ana Bárbara García García and Mr. Javier Chaves

**Carlos Javier Peña de los Santos** - Bioinformatics Unit - Mrs. Sheila Zúñiga Trejos

**Daniel González Cambor** - Bioinformatics Unit - Mrs. Sheila Zúñiga Trejos

## 6.2 Training and teaching activities

### Courses (27)

- *Curso online Gestión de la Cronicidad*
- *XII Curso COT: la cadera en el PostCOVID*
- *Sesiones de Formación Personal de Enfermería: complicaciones Post-Trasplante*
- *Curso online Cultivos Celulares*
- *Curso Protección de Datos*
- *Programa de Formación en Hemopatología 2022*
- *Sesiones de Formación Personal de Enfermería: acreditación JACIE del Programa de Trasplantes*
- *Sesiones de Innovación y Transferencia*
- *Sesiones de Formación Personal de Enfermería: procedimientos del banco de sangre*
- *Curso de Hepatología y Enfermedad Inflamatoria Intestinal*
- *Programa Formativo en Asma 2022*
- *Curso online Puesta al día en Terapia Anticoagulante*
- *Curso LLC 2022*
- *Preceptorship sobre Nefropatía Diabética*
- *Curso Fabricación Aditiva en el sector sanitario: presentación y objetivos generales. Mr. Pérez*
- *Curso Beart*
- *Programa de Excelencia y Actualización en Diabetes y Enfermedad Cardiovascular*
- *VIII Workshop Internacional de Ecografía y Resonancia*
- *II Curso de Laparoscopia Experimental para Residentes de Urología*
- *Curso de Formación online en modelado e impresión 3D: Fabricación aditiva en el sector sanitario. Mrs. Coloma*
- *Curso Scientific Skills Expert*
- *Curso de Formación online en modelado e impresión 3D: Fabricación aditiva en el sector sanitario. Mr. Redondo*
- *Programa Formativo Insuficiencia Cardiaca para médicos de Atención Primaria*
- *Curso de Formación online en modelado e impresión 3D: Fabricación aditiva en el sector sanitario. Mr. Diego*

- *Curso de Inteligencia Artificial y Big Data en salud*
- *Curso de Anatomía Quirúrgica Aplicada HBP*
- *VIII Workshop Cirugía Laparoscópica*

### Scientific Conferences (28)

- *Jornada Ruta Asma*
- *Jornada Formativa Leucemia Linfocítica Crónica*
- *Jornada Ortopedia Infantil*
- *Jornada Hablando de COVID-19. Seis olas después, ¿nos preocupa lo mismo?*
- *Escisión Mesorrectal Total Transanal Laparoscopia (TaTME)*
- *Jornadas de Abordaje Diabetes AP*
- *Sesión Multidisciplinar Inflammageing*
- *Jornada MAIC Valencia*
- *Sesión Multidisciplinar FA y Cáncer más allá de la heparina*
- *10x Genomics new developments for single cell and spatial multiomics. Biology Insights for 2022 and beyond*
- *Jornadas-Taller: Reimagina el día a día de un ensayo clínico*
- *II Jornada sobre la utilidad del Antígeno Carbohidrato 125*
- *II Encuentro: Innovación Hospitalaria*
- *V Edición Post ESMO 2022*
- *Jornada de Cirugía Laringo-Traqueal en el Hospital Clínico*
- *Encuentro Asociaciones Cáncer de Mama*
- *Proyecto Riscap8*
- *Jornada Multidisciplinar Amiloidosis INCLIVA-HCUV*
- *Jornada Updating Diabetes*
- *Rotación en el Servicio de Nefrología*
- *[STUI] y detección de Cáncer de Próstata*
- *Actualización Teórico-Práctica de LLC*
- *Taller Teórico-Práctico Autoadministración en DAAT*
- *Jornada de Envejecimiento Activo*
- *Investigación en Cáncer de Cabeza y Cuello: encuentro con pacientes*

- *Jornada Formativa en Técnicas de Abordaje del paciente con Espasticidad Postictus*
- *Jornada: El Segmento Pulmonar: la próxima frontera*
- *I Reunión de Investigación Cardiovascular en Enfermería*

#### **INCLIVA Seminars / Meet the Expert [18]**

- *Seminario INCLIVA Mr. Prat Enero 2022*
- *Seminario Deterioro Neurológico:* Neural migration is impaired in the APP/PS1 Alzheimer's mice model due to increase senescence in migrating precursors cells. Mr. Esteve
- *Seminario Deterioro Neurológico: Caracterización de los procesos inflamatorios y alteraciones del sistema inmune asociados a la aparición de encefalopatía hepática mínima en pacientes cirróticos.* Mr. Gallego
- *Seminario INCLIVA Día de la Mujer: Importancia de las diferencias de género en la investigación.* Mrs. Borrás
- *Seminario INCLIVA Mr. Pla*
- *Seminario INCLIVA Mr. Plachta*
- *Seminario INCLIVA Mrs. Mayo-Ruiz*
- *Seminario: Sección de Imagen Biomédica y Metabolómica*
- *Seminario INCLIVA Mrs. Soucek*
- *Seminario Deterioro Neurológico: Neuroinflamación y neuropatía diabética.* Mrs. Palanca
- *Seminario INCLIVA Oncología Traslacional.* Mrs. Marsoni
- *Seminario INCLIVA Mrs. Figueiredo*
- *Seminario Deterioro Neurológico:* characterization and evaluation of alterations in sensitivity and autonomic function in patients with minimal hepatic encephalopathy. Mrs. Rega
- *Seminario:* Dreamlab: Harnessing artificial intelligence, mobile supercomputing and large omics data in the fight against cancer and COVID-19
- *Seminario Deterioro Neurológico: Neuroinflamación y neuropatía diabética.* Mrs. Palanca.
- *Seminario Deterioro Neurológico: Apolipoprotein E4 and oxidative stress: a prospective study.* Mrs. Nepomudeno
- *Seminario Deterioro Neurológico: Papel de las vesículas extracelulares en el deterioro cognitivo y motor en hiperamonemia y encefalopatía hepática.* Mrs. Izquierdo
- *Seminario:* Targeting cytosolic nucleic acid-sensing pathways in small C

#### **Social Dissemination Days [6]**

- *Hit Hospital Innovador*
- *Presentación Grupo Investigación en Atención Primaria*
- *Conecta INCLIVA*
- *I Encuentro Red de Mujeres por la Investigación Sanitaria*
- *Encuentro Direcciones Médicas de Hospitales CV*
- *Shadow Visit 2022*

# com- muni- cation

INCLIVA SCIENTIFIC REPORT 2022

## 7. Communication

### 7.1 Highlights

### 7.2 Communication Indicators 2022

## 7.1. Highlights

### January

- INCLIVA participates in the ALPHABET trial, promoted by GEICAM to delay the use of chemotherapy in patients with HER2+ metastatic breast cancer and PIK3CA mutation
- An INCLIVA study analyzes the development of pulmonary fibrosis in patients with COVID-19 pneumonia after hospital discharge
- An INCLIVA study analyzes cardiovascular risk in patients with familial hypercholesterolemia

### February

- INCLIVA participates in a project led by IRB Barcelona to combat resistance to chemotherapy in triple negative breast cancer
- An INCLIVA project opens the door to new therapeutic approaches in patients with Friedreich's Ataxia (AF)

### March

- The international study SIENDO shows the efficacy of the incorporation of the drug selinexor to the treatment in patients with endometrial cancer
- INCLIVA and Quibim sign a collaboration agreement to promote cancer research thanks to Artificial Intelligence
- The TuMiCC project, which investigates the tumor microenvironment in colon cancer, coordinated by INCLIVA, celebrates 16 months with the recruitment of patients and advances in the molecular characterization of tumors and their environment

### April

- An INCLIVA study analyzes the importance of muscular strength exercise to prevent frailty in the elderly and promote healthy aging
- INCLIVA and the UV participate in an international study that has identified 120 genes related to schizophrenia
- The INCLIVA Precision Medicine Unit, key in the advancement of personalized medicine thanks to data analysis and the sequencing of DNA samples
- INCLIVA shows its research in the cardiovascular area in an open day

### May

- INCLIVA organizes a meeting to report on the advances in research in organ donation for transplantation, neonatal sepsis, traumatology and orthopedic surgery and colorectal cancer
- An INCLIVA study tries to establish a molecular profile in liquid biopsy to anticipate outbreaks of activity in systemic lupus erythematosus (SLE) and risk of kidney damage
- INCLIVA participated in more than 170 clinical trials in 2021 that will advance early diagnosis and personalized treatment in multiple pathologies
- INCLIVA investigates the contribution of the endometrium in the origin of preeclampsia
- INCLIVA and UV undertake a line of research with the Dravet Syndrome Foundation to promote the development of advanced therapies
- INCLIVA analyzes the nutritional risk in hematopoietic stem cell transplantation (HSCT), a potentially curative treatment for different hematological diseases

### June

- INCLIVA joins the European structure for the harmonization of health databases to improve the treatment of chronic diseases
- INCLIVA identifies the AXL protein as a specific biomarker and therapeutic target in HER2+ breast cancer
- INCLIVA researchers participate in international conferences in which the latest advances in hyperkalemia will be presented
- A pioneering work by INCLIVA, CIBERFES and UV studies the functional and genetic profiles of descendants of centenarians and non-centenarians of the same age
- The European project HUTER, led by INCLIVA, concludes to create the cellular map of the human uterus

# 7 communication

## July

- INCLIVA and Smarthealth sign an agreement to advance in the control of chronic diseases through Artificial Intelligence techniques
- INCLIVA and INSVACOR promote research to improve the quality of life of patients after a serious cardiovascular event
- INCLIVA promotes a study for the differential diagnosis of benign uterine tumors and cancers
- INCLIVA trial shows improved maximal functional capacity in patients with heart failure and reduced ejection fraction attributable to dapagliflozin

## August

- INCLIVA thanks the VCF Foundation for promoting the study 'Personalized physical exercise. Keys to aging better'
- A new test that allows the detection of different respiratory infections quickly and at low cost

## September

- Nearly 30 Mediterranean faces of science are exhibited at Viveros to highlight the role of women in an exhibition organized by INCLIVA within the European project Mednight
- An INCLIVA clinical trial evaluates the efficacy of PRM-151 in patients with idiopathic pulmonary fibrosis (IPF)
- INCLIVA promotes sepsis research to improve prevention and early detection methods
- The ESMO 2022 Congress highlights the incidence in routine clinical practice of advances in immunotherapy and cell therapy
- INCLIVA investigates new molecular (liquid biopsy) and imaging biomarkers and new immunotherapy treatments in lymphomas
- INCLIVA shows the advances in breast cancer research in a meeting with patient associations

## October

- Choko -Age project, which analyzes the possible favorable effects of chocolate enriched with vitamin E in the elderly with mild cognitive impairment
- INCLIVA carries out a study to create a model for predicting the development of Type 2 Diabetes Mellitus (DM2) from routine blood tests and simple patient parameters
- INCLIVA consolidates its position as a Biomedical Research Institute and its international prestige
- Valencia renews its recognition as a European site of reference in active and healthy aging with 4 stars, the highest rating
- The European MyPath project will develop an innovative digital tool to integrate the cancer patient's perspective in real time into daily clinical practice
- INCLIVA highlights the importance of supporting research on International Breast Cancer Day
- The INCLIVA Innovation Unit and the *Hospital Clínico Universitario de Valencia* will launch the Advanced Diagnostic Unit, based on printing and 3D Medical imaging (i3DM)

## November

- INCLIVA seeks new biomarkers to develop personalized treatments in patients with localized colorectal cancer
- INCLIVA obtains three SEOM grants for breast cancer research
- INCLIVA receives a FERO Grant to study the role of the AXL protein in the modulation of the tumor microenvironment and in the immune system, which generates resistance to treatment in HER2+ breast cancer
- INCLIVA begins a study to identify NK [Natural Killer] lymphocytes that facilitate the recovery of immunity in patients with bone marrow transplants
- INCLIVA obtains three Gilead Grants for the investigation of new AI techniques applied to the treatment of non-Hodgkin lymphoma, the microbiome of young patients with gastric cancer and the inhibition of the AXL protein in the treatment of HER2+ breast cancer
- INCLIVA and the *Hospital Clínico Universitario de Valencia* show the advances in research in head and neck cancer in a meeting with patient associations

# communication


## December

- INCLIVA invites people to give away health research at Christmas through a campaign that offers citizens the opportunity to contribute to promoting health advances that save more lives
- INCLIVA participates in ABIGAIL, an international clinical trial that will compare the efficacy of abemaciclib and endocrine therapy versus chemotherapy in advanced breast cancer
- INCLIVA participates in an international investigation for the development of new drugs for the treatment of hot flashes during menopause and in women survivors of breast cancer
- INCLIVA researchers, in collaboration with *Hospital General Universitario de Valencia* and *Hospital Universitario y Politécnico La Fe*, show, in the GENIAL clinical trial, that treatment with genistein could delay the onset of dementia in patients with Alzheimer's
- INCLIVA and EpiDisease SL organize the first International Meeting of the EIA Patient Journey [Adolescent Idiopathic Scoliosis]
- INCLIVA researchers develop artificial tumor models to discover therapeutic alternatives for neuroblastoma, the most common extracranial solid tumor in childhood
- INCLIVA rewards, for the third year, the care innovation of the Department of Clinical Health -Malvarrosa
- INCLIVA researchers identify a mutation in the SREBF2 gene as a possible cause of high cholesterol and glucose levels, cardiovascular risk factors

## 7.2. Communication Indicators 2022

### Press office

During 2022, INCLIVA issued a total of 98 press releases on the Web.



### Social Media users 2022



7.030



5.848



13.681



1.636

# communication

## INCLIVA Website 2022



Website users  
90.688

Website sessions  
169.512

Website new sessions  
89.917

## Outreach 2022

98 Issued press releases

84 Newspieces on INCLIVA's website


26 News on Radio

20 News on TV

In May was held *MedNight 2022: Nit Mediterrànea de les investigadores*. The project, which started in 2020 and is celebrating its third edition this year, has received funding from the European Union thanks to the European Researchers' Night call, within the Marie Curie actions of the Horizon Europe programme. The Mednight was valued with 14 points out of 15 possible, obtaining 600,000 euros for the 2022 and 2023 editions.

In order to show the attractiveness and importance of the work and the profession of researchers to the general public, this year a series of activities have been carried out under the common umbrella of what Mednight calls Mediterranean Science.

Mednight brings together the participation of 10 institutions in a consortium: INCLIVA, FISABIO, CSIC, MUDIC, El Caleidoscopio, SciCo Cyprus, the University of Messina, the Kadir Has University of Istanbul and the European Association of Women Rectors (EWORA), under the coordination of SciCo Greece.



# **social initia- tives**

**INCLIVA SCIENTIFIC REPORT 2022**

## **8. INCLIVA social initiatives**

### **8.1 Philanthropic projects**

### **8.2 Private philanthropic donations and acknowledgments**

## 8. INCLIVA social initiatives

In 2022, the Institute of Health Research at the *Hospital Clínico Universitario de Valencia*, INCLIVA, launched an awareness campaign on the importance of health research to guarantee first-rate assistance in the field of public health, and thus save more lives every year.

Under the slogan *I support research*, which is part of its Patronage Plan, INCLIVA underlines the essential nature of research to achieve medical advances that translate into improved quality of life for all citizens.

These are the main highlights:

### CAMPAIGNS

#### **INCLIVA, AVA-ASAJA and VCF Foundation present the "Give research as a gift this Christmas" campaign awards**

INCLIVA Biomedical Research Institute, attached to the *Hospital Clínico de Valencia*, has held a charity campaign in collaboration with the Valencian Association of Farmers (AVA-ASAJA) and the València Club de Fútbol (VCF) Foundation with the motto "Give research as a gift this Christmas", which has seen widespread public response.

Running until January 6, the campaign was aimed at raising awareness of the importance of health research and encouraging individual donations of any amount, big or small, and included a prize raffle supported by the Fundació VCF and the Valencian Association of Farmers (AVA-ASAJA), who collaborated by donating prizes to encourage participation.



### OUTREACH ACTIVITY

#### **The Mediterranean Researchers' Night (Mednight) begins its third edition on the Greek island of Lesbos**

A group of institutions from Spain, Italy, Greece, Turkey, Cyprus and Belgium met on the Greek island of Lesbos on 7 and 8 of April to kick off the Mediterranean Researchers' Night (Mednight). Launched in 2020 and celebrating its third year in 2022, the project has received funding from the European Union via the European Researchers' Night call, one of the Marie Curie actions of the Horizon Europe programme. Mednight achieved a score of 14 out of 15 points, securing 600,000 euros in funding for the 2022 and 2023 editions.

INCLIVA has participated actively in Mednight, coordinating and organizing the different exhibitions that shine light on women scientists from the Mediterranean regions featured in the project.



### DONATIONS

#### **The Iralia National Association makes a new donation to INCLIVA for research in childhood cancer**

Iralia, a national association for initiatives to fund childhood cancer research, has donated 10,000 euros to health research into childhood cancer, specifically to the research line on childhood tumours carried out by Mrs. Noguera.

Mrs. Noguera expressed her deep gratitude to the Iralia National Association for its generous financial support of the project and commendable work raising awareness of the importance of health research with a specific focus paediatric oncology. She has also highlighted the tireless work of its president, Juan Latorre, a 'Vilomah' parent who lost his daughter Iralia to neuroblastoma in 2014 when



# social initiatives

she was 11 years old. Ever since his powerful appearance on the talent show "La Voz Kids", Juan Latorre has been promoting childhood cancer research fundraising activities, to keep his daughter's memory alive and out of the firm conviction that "the worldwide battle against cancer will not be won with new treatments alone, but will definitely be lost without research".

## **14/03/2022: The Valencia Endometriosis Association of (AAEV) joins INCLIVA in research into this disease**

The Valencia Endometriosis Association [AAEV] has donated 1,000 euros to INCLIVA Biomedical Research Institute to contribute to research on this disease, the start of a collaboration between the two entities aimed at advancing diagnosis and treatment.

The AAEV, which brings together endometriosis sufferers and their family and friends, aims to raise awareness of the impact of this chronic disease, which impacts on the everyday life of women who experience this condition, affects their fertility, and is aggravated by detection difficulties, with an average diagnosis time of over nine years.



## **INCLIVA and Corazón Solidario contra el Cáncer show appreciation for the Fallas collectives' commitment to childhood cancer research**

INCLIVA Biomedical Research Institute and *Corazón Solidario contra el Cáncer* have shown their gratitude to the Fallas Collectives for their extraordinary response and extensive involvement in the first Charity Piggy Bank Campaign launched by this association to support research into childhood cancer, which has raised 5,600 euros.

Accompanied by the Fallas Central Board Solidarity and Inclusion delegate Cristina Peris, representatives of the participating Fallas commissions handed over the donation at the INCLIVA headquarters. Participating in the event on behalf of INCLIVA were managing director Vicente de Juan, general secretary Maite Sáenz, and Mrs. Rosa Noguera, coordinator of the Paediatric Solid Tumor Translational Research Group. Representing *Corazón Solidario* were Josefa Jiménez Sacie, a volunteer whose business is also the association's point of sale, and Carmen Caballero from public relations.



## **INCLIVA thanks the VCF Foundation for supporting biomedical research**

The INCLIVA Biomedical Research Institute has expressed its gratitude for the donation received from the VCF Foundation as part of the 50th Trofeo Taronja to fund the 'Personalized physical exercise: keys to aging better' study of the INCLIVA Aging and Physical Exercise Research Group directed by Mr. José Viña. This study aims to demonstrate the scientific-technical feasibility of defining a personalized, multicomponent, social and physical activity program for the over 70s, addressed at reversing frailty and preventing the risk of falls.

A gift symbolic of the donation of 10,000 euros was handed over to INCLIVA managing director Vicente de Juan in the Mestalla football grounds.



## **Las Triples Association collaborates with INCLIVA's research on triple negative breast cancer**

The Las Triples Association [triple negative breast cancer association] will contribute funds for oncological research into triple negative breast

cancer through the INCLIVA Breast Cancer Biology Research Group. The specific project is 'Multidisciplinary dissection of the mechanisms of resistance in triple negative breast cancer: a step towards personalized medicine' led by doctors Juan Miguel Cejalvo and Pilar Eroles.

Both entities have this week signed a collaboration agreement to contribute to improving treatment efficacy for this tumour subtype, for which there is no specific therapeutic target. With an expected term of twelve months, the agreement may be extended up to a maximum of four years by express agreement of both parties.



**The Vestidor Fallera tailors present their third annual Charity Raffle (in collaboration with the Corazón Solidario Association) in support of breast cancer research**

The Vestidor Fallera have held a Charity Raffle for the third year running in collaboration with the Solidarity Heart Association against Cancer, which will be carried out to support INCLIVA breast cancer research. Running until the end of October, the campaign will conclude with the raffle prizegiving and donation of the money raised to INCLIVA.

The opening ceremony held in the INCLIVA auditorium was attended by Fallera Mayor of 2020 Consuelo Llobet representing the Fallas commissions, and Mr. Juan Miguel Cejalvo from the Breast Cancer Biology Research Group, who highlighted the need to advance research into increasingly effective treatments for different of breast cancer types.



**INCLIVA receives 12,500 euros from the Le Cadó Foundation for breast cancer research**

Le Cadó Foundation has donated 12,500 euros to INCLIVA for breast cancer research obtained from the 8th annual 'Walk for Life Castelló 2022' March Against Breast Cancer organized jointly with the Official College of Nurses to mark International Breast Cancer Day. The march raised a total of 25,000 euros for research into this disease.

More than 4,000 people participated in the march, which began at 10:30 a.m. in Plaça del Segon Molí to the rhythm of Ravatukem Batukada and passed along the streets of the city until reaching Ribalta Park, where the organization handed out two checks of 12,500 euros each to INCLIVA and the Universitat Jaume I.

The check for INCLIVA was collected by Mrs. Maite Martínez from the INCLIVA Breast Cancer Biology Research Group, director of breast cancer study in young women for the last three years, accompanied by Mrs. Cristina Hernando from the same research group.



**AMUHCANMA donates 3,000 euros to INCLIVA for research into triple negative breast cancer**

The Breast Cancer Association for Women and Men (AMUHCANMA) made a new donation of 3,000 euros to INCLIVA for triple negative breast cancer research. They have donated 14,800 euros to INCLIVA to different breast cancer projects since 2016.

AMUHCANMA, which celebrates its tenth anniversary next year, works to support and accompany people with breast cancer and their families, as well as raising public awareness of the need to continue research. This association located in the Port of Sagunto organizes fundraising workshops and activities such as the annual charity race held to mark International Breast Cancer Day, in which 1,340 runners took part this year.



# social initiatives

The donation was presented by AMUHCANMA president Chelo Díaz Montserrat to Mrs. Pilar Eroles, co-coordinator of the INCLIVA Breast Cancer Biology Research Group.

## Bancaja Foundation helps promote INCLIVA Precision Medicine Unit

In line with its aim to promote biotechnological research in the Valencian Community through a grants programme for social action, Bancaja Foundation has organised collaborations with three internationally renowned Valencian research centres: the INCLIVA Biomedical Research Institute, La Fe Health Research Institute (IIS La Fe) and the Foundation for promoting Health and Biomedical Research in the Valencian Community (Fundació Fisabio).

Supported by INCLIVA, the project will further promote the Oncology Precision Medicine Unit, which puts this institute at the forefront of cancer research in Spain, by transferring this type of novel approach to clinical practice in cancer patients referred from the *Hospital Clínico Universitario de València*. The Precision Medicine in Oncology project arose with the aim of identifying and characterizing new molecular targets in cancer patients to optimize and personalize treatment to each patient.



## INCLIVA invites the public to give health research as a present at Christmas

INCLIVA Biomedical Research Institute has launched the “Give research as a gift this Christmas” campaign, which runs until January 6.

Aimed at raising awareness of the importance of health research, his campaign invites individual donations of any amount, big or small, offering the public the opportunity to contribute directly to scientific progress and to finding solutions to unresolved medical problems.

The “Give research as a gift this Christmas” campaign offers an opportunity for the public to select the project they wish to contribute to and help promote health advances to save more lives.

The Fundació VCF Valencia Football Club Foundation and AVA-ASAJA [honorary INCLIVA Ambassadors] will donate prizes to encourage participation.



# social initiatives

## 8.1 Philanthropic projects

### FUNDACIÓN LE CADÓ

Fundación Le Cadó was created in 2010 under the leadership of its president Elvira Monferrer Daudi. This initiative seeks to unite efforts and resources in supporting this kind of tumor research, which is currently the fourth leading cause of death in women.

Fundación Le Cadó collaborates with INCLIVA in funding the research project "Study of breast cancer in young women under 35 years", conducted by Mrs. M<sup>a</sup> Teresa Martínez Martínez. It also involves other researchers such as Mrs. Isabel Chirivella (a genetic diagnosis specialist physician) and the entire team led by the oncologists Mrs. Ana Lluch and Mrs. Pilar Eroles.



### FUNDACIÓN NEOBLASTOMA

The Neuroblastoma Foundation, created in 2017, funds research on neuroblastoma, a particularly aggressive type of childhood cancer that affects the nervous system. Survival figures have not improved in recent years. The Neuroblastoma foundation informs families about existing treatments, and brings together families of sick children, motivating them to raise funds for research through numerous campaigns. The funds are destined to research projects and clinical trials in Spanish laboratories and hospitals, this year this year the donation received has been 10.000 euros.



### AMUNT CONTRA EL CÁNCER

Amunt Contra el Cáncer is an association based in Denia, province of Alicante, that carries out different services and actions aimed at improving the quality of life of cancer patients and their families. Organizes informative talks, offers psychological support to patients and promotes various activities to raise funds for research. This year this year the donation received has been 49.500 euros.



### CORAZÓN SOLIDARIO (SOLIDARITY HEART) ASSOCIATION

*Corazón Solidario* is an Association born out of the joint project of five colleagues, who having collaborated in various NGOs decided to pool their work to fundraise for the fight against cancer. All profits of this association go to INCLIVA.



### PROYECTO PAULA

*Proyecto Paula* is a personal initiative to raise funds for diabetes research. The initiative has collaborated with INCLIVA since 2012, is financed with public funds and private donations from companies or individuals and supports the research of Mrs. Herminia Gonzalez at INCLIVA.



### ASOCIACIÓN LAS TRIPLES

*Asociación Las Triples* is an association working to support triple negative breast cancer research, raise awareness of this cancer type, and disseminate updated information. It has collaborated with INCLIVA since 2022, supporting the research of Mr. Juan Miguel Cejalvo and Mrs. Pilar Eroles.



# 8 social initiatives

## 8.2 Private philanthropic donations and acknowledgments

On behalf of INCLIVA, we want to thank all the people who have helped our research through their donations, for their support and solidarity. For us, this collaboration means much more than an economic contribution: it is the encouragement we need to keep investigating and working in research.

### Private donations

Abarca Briones, Isabel  
Ahis Maneus, Francisco Joaquín  
Alberola Casanova, Júlia  
Albert Sorribes, Silvia  
Alfonso Pastor, Yolanda  
Alonso Sala, María Concepción  
Anaya Paniagua, Ana  
Aparicio Montell, Elena  
Bayarri Esteve, Gonzalo  
Bellver Alcaina, Miguel Ángel  
Berenguer Pérez, Raquel  
Blasco Molla, Sara  
Blasco Navarro, María José  
Borreda Bolinches, Esteban  
Borreda Bolinches, Francisco  
Bosch Sánchez, Susana  
Botella Aparicio, Francisco  
Burgos Armero, Mercedes  
Caballer Molina, Rafael Pascual  
Caballero de Luján, Guillermo  
Caballero Turiño, Antonio  
Caballero Turiño, José Carlos  
Caballero Turiño, Ramón Ginés  
Calvo Alfaro, María Pilar  
Camacho Campos, Francisca  
Camacho Gavilán, Miguel Ángel  
Carrillo Sáez, Cristina  
Casany Molero, María Consuelo  
Cava Ferreruela, Inmaculada  
Celma Olivares, Lorena  
Confuorti Confuorti, Francesco  
Cordero González, Pilar  
Cuñat Natividad, Inmaculada  
De Juan Martín, Vicente  
De La Cruz Torres, María Isabel  
De Vargas Montesinos, María Luisa  
Dinnbier Escuder, Enriqueta  
Domènec Villanueva, Ana María  
Ebri Méndez, María Luisa  
Esteve Garrido, Federico  
Femenia Cabrera, Francisca  
Fernández Aguilera, Ángel  
Fernández López, Elisa  
Ferrando Jódar, Néstor  
Font Ferrando, Natalia  
Frau Mengual, María Francisca  
Gallart Navarro, Antonia  
Gallart Navarro, Luis Miguel  
García Trujillo, Jesús  
Giménez Beltrán, María José  
Gimeno Collado, Adelina  
Gómez Dorado, Míriam  
Gómez-Cano Gutiérrez, María José  
Gómez-Ferrer Bolinches, Rocío  
González Cavero, Jesús  
González Molina, María  
González Navarro, Herminia  
Gras Martínez, María  
Hernández Merino, Natividad  
Herreras Monzó, Enrique  
Horrillo Bosch, Laura Desamparados  
Hurtado Ferrer, María  
Lacruz García, Almudena  
Llácer Llorca, María Francisca  
Llorens Dasí, María Mercedes  
Lodeiro Carpe, Patricia  
López Serrano, Carmen  
Luján Folgado, Mercedes

Manzanera Pastor, Ester  
Marín Borrás, María Vera  
Márquez Castelló, José María  
Martí Pavía, Vicente  
Martínez Álvarez, José Antonio  
Martínez Espinosa, Alicia  
Martínez González, Eva  
Martínez Ruiz, Manuel  
Martínez Villar, Míriam  
Mendoza Hernández, Patricia  
Miguel López, Rosa  
Mocholí Martín, María Teresa  
Molina García, Cristina  
Morcillo Mañas, Manoli  
Muñoz González, Amparo  
Navarro Andrés, Miguel  
Navío Ruiz, Noelia  
Nicolás Garrido, Francisco  
Ortí Campos, Leyre  
Pardo Martí, José Manuel  
Parras Ruiz, Vicky  
Pereira Lepe, Julio César  
Pérez González, José Luis  
Pérez López, Laura  
Peris Tatay, Joaquín  
Pi Ramiro, María Jesús  
Piquereres Mateu, Mónica  
Pulido Carrillo, Antonio  
Queralt Pesudo, Zaida  
Quiles Agustí, Rafael  
Quixal Alejos, María Trini  
Ramírez Lomas, Gloria  
Ramírez Serrano, Rubén  
Regaño Dionis, Félix  
Rodríguez, Mayuli  
Rodríguez Deval, María Dolores  
Ruix Barba, Esther  
Ruix Vázquez, Susana  
Sampere Vilar, Francisco Vicente  
Sanabria Codesal, Esteban

Sánchez González, María José  
Sánchez Muñoz, Vicenta  
Sánchez Pérez, Sara  
Santiago Pinazo, Sonia  
Sanz Moliner, Ana  
Schulze Steinen, Otto Heinrich  
Serrano Monedero, María Julia  
Solera Humada, Nuria  
Téllez Plaza, Juan Manuel  
Torres Ferrando, Vicente  
Torres Hernández, María de les Neus  
Tortajada Trenco, Elisa  
Vila Eres, Pilar

## Corporative donations

ACC Falla Gayano Lluch  
Amunt Contra El Cáncer  
Asociación ALFA-1 de España  
Asociación Alumnos EPA de Alaçàs  
Asociación Corazón Solidario Contra El Cáncer  
Asociación de Afectadas de Endometriosis de Valencia (AAEV)  
Asociación de Afectados de Cáncer ASAC de Segorbe  
Asociación de Mujeres y Hombres Afectados de Cáncer de Mama  
Asociación de Padres de Alumnos del Instituto de Bachillerato Misericordia  
Asociación La Virgen de los Dolores  
Asociación Las Triples  
Asociación Mujeres de La Cañada  
Associació Contra el Càncer de Pego [Associaciò Esperança]  
Associació Contra el Càncer La Vall [ACCLAVALL]  
Associació Pel Teu Somriure  
Ayuntamiento de Real de Gandía

# 8 social initiatives

Biomed Central Limited  
Boston Scientific Iberica SA  
Canals Contra el Cáncer  
Club d' Atletisme Llebeig Xabia  
Club Náutico Jávea  
Doctaforum Servicios  
European Cystic Fibrosis Society ECFS  
Ezedichi SL  
Falla Els Albalatans  
Frío Hermanos Portero, SL  
Fundación Bancaria La Caixa  
Fundación de la Comunidad Valenciana Marqués de Dos Aguas  
Fundación Javerianas Escuela Profesional Xavier  
Fundación Lecadó  
Fundación Neuroblastoma  
Glaxosmithkline SA  
Grupo Empresarial United Caro SLU  
Iraila, Iniciativas para la Financiación de la Investigación del Cáncer Infantil  
JBZ Diseño Técnico, SLU  
Pfizer SLU  
Postal Kids SC  
Queserías Romero Gozálbez, SL  
Theramex Healthcare Spain SLU  
Torse SA  
Trevoly Serv S.C. Andaluza

# publications list

INCLIVA SCIENTIFIC REPORT 2022

# publication list

## List of 786 scientific publications derived from the activity of the IIS

1. Carrero-Vasquez V, Prado-Wohlwend S. [68Ga] Ga-DOTA-TOC PET/CT uptake by parathyroid adenoma in the context of multiple endocrine neoplasia type 1 [MEN1]. *Revista Espanola de Medicina Nuclear e Imagen Molecular.* 2022;41 Suppl 1:S66-S68. doi: 10.1016/j.remmie.2022.04.004. PMID: 35550366
2. Rodriguez-Rubio P, Lacomba-Trejo L, Valero-Moreno S, Montoya-Castilla I, Perez-Marin M. 10Vida: a mental and physical health intervention for chronically ill adolescents and their caregivers in the hospital setting: an open study. *International Journal of Environmental Research and Public Health.* 2022 Mar 8;19(6):3162. doi: 10.3390/ijerph19063162. PMID: 35328851
3. Diaz-Santa J, Rodriguez-Romanos R, Coll R, Osca G, Pratcorona M, Gonzalez-Bartulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Diez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D. 5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics. *European Journal of Haematology.* 2022 Dec;109(6):755-764. doi: 10.1111/ejh.13862. PMID: 36063368
4. Oliver L, Barron A, Montero A, Gil-Hernandez I, Samper A. A case of sterile corneal stromal infiltration with hypotonic maculopathy under brimonidine treatment. *Ocular Immunology and Inflammation.* 2022 Jun 16;1-4. doi: 10.1080/09273948.2022.2087687. PMID: 35708458
5. Mirò Ò, Sabaté M, Jiménez S, Mebazaa A, Martínez-Nadal G, Piñera P, Burillo-Putze G, Martín A, Martín-Sánchez FJ, Jacob J, Alquézar-Arbé A, García-Lamberechts EJ, Llorens P, González Del Castillo J; Spanish Investigators on Emergency Situations TeAm (SIESTA) network; SIESTA network. A case-control, multicentre study of consecutive patients with COVID-19 and acute (myo) pericarditis: incidence, risk factors, clinical characteristics and outcomes. *Emergency Medicine Journal.* 2022 May;39(5):402-410. doi: 10.1136/emermed-2020-210977. PMID: 35304388
6. Martinez Gimenez J, Tabares Seisdedos R. A cofactor-based mechanism for the origin of the genetic code. *Origins of Life and Evolution of Biospheres.* 2022 Sep;52(1-3):149-163. doi: 10.1007/s11084-022-09628-5. PMID: 36071304
7. Juarez-Vela R, Garcia-Erce J, Gea-Caballero V, de Vinaspre-Hernandez R, Santos-Sanchez J, Sanchez-Gonzalez J, Andres-Esteban E, Czapla M, Tejada C, Nanwani-Nanwani K, Serrano-Lazaro A, Quintana-Diaz M. A Cohort Study in Intensive Care Units: health decisions related to blood transfusion during the COVID-19 Pandemic. *Journal of Clinical Medicine.* 2022 Jul 28;11(15):4396. doi: 10.3390/jcm11154396. PMID: 35956012
8. Stevens M, Raat H, Ferrando M, Vallina B, Lucas R, Middlemiss L, Redon J, Rocher E, van Grieken A. A comprehensive urban programme to reduce energy poverty and its effects on health and well-being of citizens in six European countries: study protocol of a controlled trial. *BMC Public Health.* 2022 Aug 19;22(1):1578. doi: 10.1186/s12889-022-13968-2. PMID: 35986259
9. Benavent M, Delgado V, Adrian J, Felix F, Ciarpaglini C. A fast-growing tumor on the head of an elderly woman: answer. *American Journal of Dermatopathology.* 2022 Jul 1;44(7):535-536. doi: 10.1097/DAD.0000000000002153. PMID: 35704913
10. Benavent M, Delgado V, Adrian J, Felix F, Ciarpaglini C. A fast-growing tumor on the head of an elderly woman: challenge. *American Journal of Dermatopathology.* 2022 Jul 1;44(7):e71-e74. doi: 10.1097/DAD.0000000000002154. PMID: 35704916
11. Lazarus J, Ortiz A, Tyrovolas S, Fernandez E, Guy D, White T, Ma R, Hay S, Naghavi M, Soriano J. A GBD 2019 study of health and sustainable development goal gains and forecasts to 2030 in Spain. *Scientific Reports.* 2022 Dec 7;12(1):21154. doi: 10.1038/s41598-022-24719-z. PMID: 36477107
12. Hernandez-Beeftink T, Guillen-Guio B, Lorenzo-Salazar J, Corrales A, Suarez-Pajes E, Feng R, Rubio-Rodriguez L, Paynton M, Cruz R, Garcia-Laorden M, Prieto-Gonzalez M, Rodriguez-Perez A, Carrié-

# publication list

- do D, Blanco J, Ambros A, Gonzalez-Higuera E, Espinosa E, Muriel A, Tamayo E, Martin M, Lorente L, Dominguez D, de Lorenzo A, Giannini H, Reilly J, Jones T, Anon J, Soro M, Carracedo A, Wain L, Meyer N, Villar J, Flores C. A genome-wide association study of survival in patients with sepsis. *Critical Care.* 2022 Nov 5;26(1):341. doi: 10.1186/s13054-022-04208-5. PMID: 36335405
13. Perez-Carbonell T, Orts-Alborch M, Perez-Guillen V, Tenias-Burillo J, Pla-Gil I, Marco-Algarra J, Perez-Garrigues H. A longitudinal study of unilateral Meniere's disease and clinical evolutionary models. *Journal of Laryngology and Otology.* 2022 Aug 4;1-27. doi: 10.1017/S0022215122001773. PMID: 35924453
14. McCoy MG, Perez Cremades D, Belkin N, Peng W, Zhang B, Chen J, Sachan M, Wara AKMK, Zhuang R, Cheng HS, Feinberg MW. A miRNA cassette reprograms smooth muscle cells into endothelial cells. *FASEB Journal.* 2022 Apr;36(4):e22239. doi: 10.1096/fj.202101872R. PMID: 35235229
15. Lazarus J, Romero D, Kopka C, Karim S, Abu-Raddad L, Almeida G, Baptista-Leite R, Barocas J, Barreto M, Bar-Yam Y, Bassat Q, Batista C, Bazilian M, Chiou S, del Rio C, Dore G, Gao G, Gostin L, Hellard M, Jimenez J, Kang G, Lee N, Maticic M, McKee M, Nsanzimana S, Oliu-Barton M, Pradelski B, Pyzik O, Rabin K, Raina S, Rashid S, Rathe M, Saenz R, Singh S, Trock-Hempler M, Villapol S, Yap P, Binagwaho A, Kamarulzaman A, El-Mohandes A. A multinational Delphi consensus to end the COVID-19 public health threat. *Nature.* 2022 Nov;611(7935):332-345. doi: 10.1038/s41586-022-05398-2. PMID: 36329272
16. Orts-Arroyo M, Gutierrez F, Gil-Tebar A, Ibarrola-Villava M, Jimenez-Marti E, Silvestre-Llora A, Castro I, Ribas G, Martinez-Lillo J. A novel adenine-based diruthenium(III) complex: synthesis, crystal structure, electrochemical properties and evaluation of the anticancer activity. *Journal of Inorganic Biochemistry.* 2022 Apr 6;232:111812. doi: 10.1016/j.jinorgbio.2022.111812. PMID: 35421769
17. Perez-Fidalgo J, Criscitiello C, Carrasco E, Regan M, Di Leo A, Ribi K, Adam V, Bedard P. A phase III trial of alpelisib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in HER2+PIK3CA-mutated breast cancer. *Future Oncology.* 2022 Jun;18(19):2339-2349. doi: 10.2217/fon-2022-0045. PMID: 35465733
18. Sabater Marco V, Cervero L, Losada L, Lopez N. A pigmented nodule on congenital melanocytic nevus: challenge. *American Journal of Dermatopathology.* 2022 Oct 1;44(10):e108-e109. doi: 10.1097/DAD.0000000000002265. PMID: 36122342
19. Al-Soufi L, Martorell L, Molto MD, Gonzalez-Penas J, Garcia-Portilla MP, Arrojo M, Rivero O, Gutierrez-Zotes A, Nacher J, Muntane G, Paz E, Paramo M, Bobes J, Arango C, Sanjuan J, Vilella E, Costas J. A polygenic approach to the association between smoking and schizophrenia. *Addiction Biology.* 2022 Jan;27(1):e13104. doi: 10.1111/adb.13104. PMID: 34779080
20. Heerspink H, Cherney D, Postmus D, Stefansson B, Chertow G, Dwyer J, Greene T, Kosiborod M, Langkilde A, McMurray J, Correa-Rotter R, Rossing P, Sjostrom C, Toto R, Wheeler D. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. *Kidney International.* 2022 Jan;101(1):174-184. doi: 10.1016/j.kint.2021.09.005. PMID: 34560136
21. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. *Blood Advances.* 2022 Apr 12;6(7):2207-2218. doi: 10.1182/bloodadvances.2021005487. PMID: 34972214
22. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Tausig DC, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. *Blood Advances.* 2022 Apr 12;6(7):2219-2229. doi: 10.1182/bloodadvances.2021006138. PMID: 34933333

# publication list

23. Lopez-Guillermo A, Canales M, Dlouhy I, Mercadal S, Briones J, Garcia-Sancho A, Sancho J, Moreda J, Terol M, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S, Bargay J, Lopez A, Panizo C, Muntanola A, Montalban C, Conde E, Hernandez M, Soler A, Marco J, Deben G, Marin J, Tomas J, PETHEMA GELTAMO GELCAB Spanish. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. *Leukemia & Lymphoma*. 2022 Jan;63(1):93-100. doi: 10.1080/10428194.2021.1971216. PMID: 34459702
24. Earl J, Calabuig-Farinés S, Sarasquete M, Romay L, Lopez-Tarruella S, Paricio B, Rodriguez M, Leoz K, Porto M, Tarazona N, Losa J, Toledo R. A standardized liquid biopsy preanalytical protocol for downstream circulating-free DNA applications. *Jove-Journal of Visualized Experiments*. 2022 Sep 16;(187). doi: 10.3791/64123. PMID: 36190291
25. Garcia-Garcia A, Martinez-Hervas S, Vernia S, Ivorra C, Pulido I, Martin-Escudero J, Casado M, Carretero J, Real J, Chaves F. A very rare variant in SREBF2, a possible cause of hypercholesterolemia and increased glycemic levels. *Biomedicines*. 2022 May 19;10(5):1178. doi: 10.3390/biomedicines10051178. PMID: 35625914
26. Hernandez Boluda JC, Martinez Cuadron D, Pereira A, Rodriguez Veiga R, Boluda B, Gil C, Casal-Marini S, Serrano J, Martinez Lopez J, Bergua J, Algarra L, Bernal T, Lopez Lorenzo JL, Colorado M, Lopez A, Tormo M, Sayas MJ, Trigo F, Lopez Pavia M, Perez Simon JA, Lavilla Rubira E, Rodriguez Medina C, Rodriguez Gutierrez JI, Sanz Caballer MA, Montesinos P. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: a series of 372 patients from the PETHEMA AML registry. *Leukemia Research*. 2022 Mar 6;115:106821. doi: 10.1016/j.leukres.2022.106821. PMID: 35286939
27. Escudero Acha P, Leizaola O, Lazaro N, Cordero M, Cossio AM, Ballesteros D, Recena P, Tizon AI, Palomo M, Del Campo MM, Freita S, Duerto J, Bilbao NM, Vidal B, Gonzalez Romero D, Diaz Dominguez F, Revuelto J, Blasco ML, Domezain M, de la Concepcion Pavia Pesquera M, Rubio O, Estella A, Pobo A, Gomez Acebo I, Gonzalez Castro A. ADENI-UCI study: analysis of non-income decisions in ICU as a measure of limitation of life support treatments. *Medicina Intensiva*. 2022 Apr;46(4):192-200. doi: 10.1016/j.medine.2022.02.008. PMID: 35227639
28. Pilar Ballester M, Mesonero F, Florez-Diez P, Gomez C, Fuentes-Valenzuela E, Martin N, Senosiain C, Vela M, Fernandez-Clotet A, Perez P, Rubin de Celis C, Calvino-Suarez C, Hermida B, Munoz R, Gonzalez-Vivo M, Brunet E, Jimenez N, Botella B, Yebra J, Suarez-Ferrer C, Bouhmidi A, Lopez-Serrano A, Ponferrada A, Duenas C, Minguez M. Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study. *Alimentary Pharmacology & Therapeutics*. 2022 Jun;55(11):1402-1413. doi: 10.1111/apt.16832. PMID: 35224758
29. Francisco V, Sanz M, Real J, Marques P, Capuozzo M, Ait Eldjoudi D, Gualillo O. Adipokines in non-alcoholic fatty liver disease: are we on the road toward new biomarkers and therapeutic targets?. *Biology*. 2022 Aug 19;11(8):1237. doi: 10.3390/biology11081237. PMID: 36009862
30. Peden A, Cullen P, Francis K, et al. Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019. *Lancet Public Health*. 2022 Aug;7(8):e657-e669. doi: 10.1016/S2468-2667(22)00134-7. PMID: 35779567
31. Esteve D, Molina-Navarro MM, Giraldo E, Martínez-Varea N, Blanco-Gandia MC, Rodríguez-Arias M, García-Verdugo JM, Viña J, Lloret A. Adult neural stem cell migration is impaired in a mouse model of Alzheimer's disease. *Molecular Neurobiology*. 2022 Feb;59(2):1168-1182. doi: 10.1007/s12035-021-02620-6. PMID: 34894324
32. Machado I, Lopez-Guerrero J, Fernandez A, Lopez R, Casado Z, Fernandez A, Llombart-Bosch A, Charville G. Adult pancreaticblastoma: report of 3 new cases with genetic diversity and autopsy findings. *International Journal of Surgical Pathology*. 2022 Dec 26;10668969221133351. doi: 10.1177/10668969221133351. PMID:

# publication list

36573045

33. Henkens M, Raafs A, Verdonschot J, Linschoten M, van Smeden M, Wang P, van der Hooft B, Tielemans R, Janssen M, ter Bekke R, Hazebroek M, van der Horst I, Asselbergs F, Magdelijns F, Heymans S. Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study. *BMC Geriatrics.* 2022 Mar 5;22(1):184. doi: 10.1186/s12877-021-02673-1. PMID: 35247983
34. De-Madaria E, Buxbaum JL, Maisonneuve P, Garcia Garcia de Paredes A, Zapater P, Guilbert L, Vaillo-Rocamora A, Rodriguez-Gandia MA, Donate-Ortega J, Lozada-Hernandez EE, Collazo Moreno AJR, Lira-Aguilar A, Llovet LP, Mehta R, Tandel R, Navarro P, Sanchez-Pardo AM, Sanchez-Marin C, Cobreros M, Fernandez-Cabrera I, Casals-Seoane F, Deza D, Lauret-Brana E, Marti-Marques E, Camacho-Montano LM, Ubieto V, Ganuza M, Bolado F. Aggressive or moderate fluid resuscitation in acute pancreatitis. *New England Journal of Medicine.* 2022 Sep 15;387(11):989-1000. doi: 10.1056/NEJMoa2202884. PMID: 36103415
35. Robba C, Battaglini D, Badenes R, Nielsen N, Pelosi P. Airway management in cardiac arrest and outcomes. Author's reply. *Intensive Care Medicine.* 2022 Dec;48(12):1829-1832. doi: 10.1007/s00134-022-06888-7. PMID: 36173414
36. Provenzano M, Puchades M, Garofalo C, Jongs N, D'Marco L, Andreucci M, De Nicola L, Gorri J, Heerspink H. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial. *Journal of the American Society of Nephrology.* 2022 Aug;33(8):1569-1580. doi: 10.1681/ASN.2022020207. PMID: 35440501
37. Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Paneesha S, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden J, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. *Bone Marrow Transplantation.* 2022 Mar;57(3):416-422. doi: 10.1038/s41409-021-01553-x. PMID: 35066569
- Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden J, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. Correction to: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. *Bone Marrow Transplantation.* 2022 Jun;57(6):1051. doi: 10.1038/s41409-022-01652-3. PMID: 35361897
38. Rey-Bua B, Cabrero M, Bento L, Montoro J, Bastos-Oreiro M, Parody R, Yanez L, Lopez-Godino O, Zanabili J, Herrera P, Gutierrez G, Perez A, Pinana J, Novelli S, Cortes M, Sureda A, Caballero D, Garcia-Sancho A. Allogeneic hematopoietic stem cell transplantation in transformed Follicular Lymphoma [tFL]: results of a retrospective multicenter study from GELTAMO/GETH-TC Spanish Groups. *Cancers.* 2022 Nov 18;14(22):5670. doi: 10.3390/cancers14225670. PMID: 36428762
39. Gutierrez A, Bento L, Novelli S, Martin A, Gutierrez G, Salas M, Bastos-Oreiro M, Perez A, Hernani R, Viguria M, Lopez-Godino O, Montoro J, Pinana J, Ferrer C, Parody R, Martin C, Espanol I, Yanez L, Rodriguez G, Zanabili J, Herrera P, Varela M, Sampol A, Solano C, Caballero D. Allogeneic stem cell transplantation in mantle cell lymphoma; insights into its potential role in the era of new immunotherapeutic and targeted therapies: the GETH/GELTAMO experience. *Cancers.* 2022 May 27;14(11):2673. doi: 10.3390/cancers14112673. PMID: 35681653
40. Rodriguez-Rovira I, Arce C, De Rycke K, Perez B, Carretero A, Arbones M, Teixido-Tura G, Gomez-Cabrera M, Campuzano V, Jimenez-Altayo F, Egea G. Allopurinol blocks aortic aneurysm in a mouse model of Marfan syndrome via reducing aortic oxidative stress. *Free Radical Biology & Medicine.* 2022 Nov 5;193(Pt 2):538-550. doi: 10.1016/j.freeradbiomed.2022.11.00. PMID: 36347404

# publication list

41. Dasi F. Alpha-1 antitrypsin deficiency. *Medicina Clinica*. 2022 Oct 14;S0025-7753(22)00458-4. doi: 10.1016/j.medcli.2022.09.001. PMID: 36253208
42. Perez-Rando M, Elvira U, Garcia-Marti G, Gadea M, Aguilar E, Escarti M, Ahullo-Fuster M, Grasa E, Corripio I, Sanjuan J, Nacher J. Alterations in the volume of thalamic nuclei in patients with schizophrenia and persistent auditory hallucinations. *NeuroImage Clinical*. 2022 Jun 1;35:103070. doi: 10.1016/j.nicl.2022.103070. PMID: 35667173
43. Bravo L, Mariscal P, Llorca-Torralba M, Lopez-Cepero J, Nacher J, Berrocoso E. Altered expression of vesicular glutamate transporter-2 and cleaved caspase-3 in the locus coeruleus of nerve-injured rats. *Frontiers in Molecular Neuroscience*. 2022 Jul 27;15:918321. doi: 10.3389/fnmol.2022.918321. PMID: 35966012
44. Gimeno-Valiente F, Lopez-Rodas G, Castillo J, Franco L. Alternative splicing, epigenetic modifications and cancer: a dangerous triangle, or a hopeful one?. *Cancers*. 2022 Jan 22;14(3):560. doi: 10.3390/cancers14030560. PMID: 35158828
45. Valdes S, Doulatram-Gamgaram V, Maldonado-Araque C, Lago-Sampedro A, Garcia-Escobar E, Garcia-Serrano S, Garcia-Vivanco M, Juan L, Theobald M, Gil V, Martin-Llorente F, Ocon P, Calle-Pascual A, Castano L, Delgado E, Menendez E, Franch-Nadal J, Gatzambide S, Girbes J, Chaves F, Galan-Garcia J, Aguilera-Venegas G, Gutierrez-Repiso C, Fernandez-Garcia J, Colomo N, Sorriquer F, Garcia-Fuentes E, Rojo-Martinez G. Ambient air pollution and thyroid function in Spanish adults. A nationwide population-based study (Di@bet.es study). *Environmental Health*. 2022 Aug 17;21(1):76. doi: 10.1186/s12940-022-00889-1. PMID: 35978396
46. de la Fuente A, Diaz Bely M, Beneit P, Fernandez Moreno A, Arnan Sangerman M, Garrido A, Vives Polo S, Fortes MG, Sampol Mayol A, Labrador J, Garcia Guinon A, Gil Cortes C, Bergua J, Olave M, Amigo ML, Ortin X, Vall-Llovera F, Estevez M, Diaz-Lopez A, Serrano J, Tormo M. AML-122 midostaurin maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: a real-life multicenter study. *Clinical Lymphoma, Myeloma & Leukemia*. 2022 Oct 1; 2: S215
47. Romaguera R, Salinas P, Gomez-Lara J, Brugaletta S, Gomez-Mencher A, Romero M, Garcia-Blas S, Ocaranza R, Bordes P, Kockar M, Salvatella N, Jimenez-Diaz V, Alameda M, Trillo R, Lee D, Martin P, Lopez-Benito M, Freites A, Pascual-Tejerina V, Hernandez-Hernandez F, Del Blanco B, Mohandes M, Bosa F, Pinar E, Roura G, Comin-Colet J, Fernandez-Ortiz A, Macaya C, Rossello X, Sabate M, Pocock S, Gomez-Hospital J, SUGAR Trial Investigators. Amphilius- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. *European Heart Journal*. 2022 Mar 31;43(13):1320-1330. doi: 10.1093/eurheartj/ehab790. PMID: 34735004
48. Martinez-Monleon A, Oberg H, Gaarder J, Berbegall A, Javanmardi N, Djos A, Ussowicz M, Taschner-Mandl S, Ambros I, Ora I, Sandstedt B, Beiske K, Ladenstein R, Noguera R, Ambros P, Murkes L, Ljungman G, Kogner P, Fransson S, Martinsson T. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup. *Scientific Reports*. 2022 Jul 20;12(1):12420. doi: 10.1038/s41598-022-16455-1. PMID: 35859155
49. Teixeira W, Pallas-Tamarit Y, Juste-Dolz A, Sena-Torralba A, Gozalbo-Rovira R, Rodriguez-Diaz J, Navarro D, Carrascosa J, Gimenez-Romero D, Maquieira A, Morais S. An all-in-one point-of-care testing device for multiplexed detection of respiratory infections. *Biosensors & Bioelectronics*. 2022 Jun 8;213:114454. doi: 10.1016/j.bios.2022.114454. PMID: 35696866
50. Garcia-Gutierrez V, Hernandez-Boluda JC. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 Tyrosine Kinase Inhibitors. *Expert Review of Hematology*. 2022 Jun;15(6):477-484. doi: 10.1080/17474086.2022.2080049. PMID: 35583386
51. Durendez-Saez E, Calabuig-Farinias S, Torres-Martinez S, Moreno-Manuel A, Herreros-Pomares A, Escorihuela E, Mosqueda M, Gallach S, Guijarro R, Serna E, Suarez-Cabrera C, Paramio J, Blasco A, Camps C, Jantus-Lewintre E. Analysis of exosomal cargo provides accurate clinical, histologic and mutational information in non-small cell lung cancer. *Cancers*. 2022 Jun 30;14(13):3216. doi: 10.3390/cancers14133216. PMID: 35804987

# publication list

52. Montero-Cabezas J, Cordoba-Soriano J, Diez-Del-hoyo F, Abellan-Huerta J, Grgis H, Rama-Merchan J, Garcia-Blas S, van Rees J, van Ramshorst J, Jurado-Roman A. Angiographic and clinical profile of patients with COVID-19 referred for coronary angiography during SARS-CoV-2 outbreak: results from a collaborative, European, multi-center registry. *Angiology*. 2022 Feb;73(2):112-119. doi: 10.1177/00033197211028760. PMID: 34318686
53. Barroso Weimar Kunz Sebba, Brandao AA, Valverde de Oliveira Vitorino P, Diogenes de Magalhaes Feitosa A, Costa Duarte Barbosa E, Dischinger Miranda R, Redon J, Camafort-Babkowski M, Coca A, Mota Gomes MA. Angiotensin receptor blockers evaluated by office and home blood pressure measurements. TeleHBPM Study. *Arquivos Brasileiros de Cardiologia*. 2022 May 9;118(6):1069-1082. doi: 10.36660/abc.20210504. PMID: 35544853
54. Belltall A, Mazzinari G, Diaz-Cambronero O, Eroles P, Navarro M. Antagonists of the Mu-opioid receptor in the cancer patient: fact or fiction? *Current Oncology Reports*. 2022 Oct;24(10):1337-1349. doi: 10.1007/s11912-022-01295-z. PMID: 35648340
55. Selma-Royo M, Bauerl C, Mena-Tudela D, Aguilar-Camprubi L, Perez-Cano FJ, Parra-Llorca A, Lerin C, Martinez-Costa C, Collado MC. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study. *Genome Medicine*. 2022 Apr 21;14(1):42. doi: 10.1186/s13073-022-01043-9. PMID: 35449030
56. Bonanad C, Esteve-Claramunt F, Garcia-Blas S, Ayesta A, Diez-Villanueva P, Perez-Rivera J, Ferreiro J, Canoves J, Lopez-Fornas F, Sole A, Raposeiras S, Vivas D, Blanco R, Berroteran D, Cordero A, Nunez J, Facila L, Nunez-Gil I, Gorriz J, Bodi V, Martinez-Selles M, Nodar J, Chorro F. Antithrombotic therapy in elderly patients with acute coronary syndromes. *Journal of Clinical Medicine*. 2022 May 26;11(11):3008. doi: 10.3390/jcm11113008. PMID: 35683397
57. Ramia J, Aparicio-Lopez D, Asencio-Pascual J, Blanco-Fernandez G, Cugat-Andorra E, Gomez-Bravo M, Lopez-Ben S, Martin-Perez E, Sabater L, Serradilla-Martin M. Applicability and reproducibility of the validated intraoperative bleeding severity scale (VIBe scale) in liver surgery: a multicenter study. *Surgery*. 2022 Oct;172(4):1141-1146. doi: 10.1016/j.surg.2022.05.022. PMID: 35871850
58. Marcos-Garces V, Gabaldon-Perez A, Merenciano-Gonzalez H, Soler M, Lorenzo-Hernandez M, Nunez-Marin G, de la Espriella R, Bonanad C, Nunez J, Chorro FJ, Bodi V, Santas E. Applicability of echocardiographic strict negative criteria for suspected infective endocarditis. *American Journal of Cardiology*. 2022 Jan 1;162:156-162. doi: 10.1016/j.amjcard.2021.09.012. PMID: 34728063
59. Pinana J, Rodriguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol M, Vazquez L, Calabuig M, Sanz-Linares G, Marin-Jimenez F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual M, Rodriguez-Fernandez A, Olave M, Cascales-Hernandez A, Gago B, Hernandez-Rivas J, Villalon L, Corona M, Roldan-Perez A, Ribes-Amoros J, Gonzalez-Santillana C, Garcia-Sanz R, Navarro D, Serrano-Lopez A, Cedillo A, Soria-Olivas E, Sureda A, Solano C. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. *Annals of Hematology*. 2022 Sep;101(9):2053-2067. doi: 10.1007/s00277-022-04906-8. PMID: 35780254
60. Desdentado L, Navarrete J, Folgado-Alufre M, de Blas A, Navarro-Siurana J, Ponce F, Molinari G, Jimeno-Martinez A, Ruperez A, Bueno-Lozano G, Cuenca-Royo A, Corbella E, Aguera Z, Banos R, Alvarez-Pitti J. Are peripheral biomarkers determinants of eating styles in childhood and adolescence obesity? A cross-sectional study. *Nutrients*. 2022 Jan 12;14(2):305. doi: 10.3390/nu14020305. PMID: 35057485
61. Cardim D, Czosnyka M, Chandrapatham K, Badenes Quiles R, Bertuccio A, Corradi F, Donnelly J, Pelosi P, Hutchinson P, Robba C. Arterial and venous cerebral blood flow velocities and their correlation in healthy volunteers and traumatic brain injury patients. *Journal of Neurosurgical Anesthesiology*. 2022 Jan 1;34(1):e24-e33. doi: 10.1097/ANA.0000000000000704. PMID: 32555064
62. Di Martino M, Primavesi F, Syn N, Dorcaratto D,

# publication list

- de la Hoz Rodriguez A, Dupre A, Piardi T, Rhaiem R, Blanco Fernandez G, de Armas Conde N, Rodriguez Sanjuan J, Fernandez Santiago R, Fernandez-Moreno M, Ferret G, Lopez Ben S, Suarez Munoz M, Perez-Alonso A, Koh Y, Jones R, Martin-Perez E. ASO visual abstract: long-term outcomes of perioperative versus neoadjuvant chemotherapy for resectable colorectal liver metastases-an international multicenter propensity-score matched analysis with stratification by contemporary risk scoring. *Annals of Surgical Oncology*. 2022 Oct;29(11):6845-6846. doi: 10.1245/s10434-022-12077-z. PMID: 35810229
63. Santoro F, Nunez-Gil I, Vitale E, Viana-Llamas M, Romero R, Eid C, Guzman G, Becerra-Munoz V, Rozas I, Uribarri A, Alfonso-Rodriguez E, Aguado M, Huang J, Mejia A, Prieto J, Elola J, Ugo F, Ce rrato E, Signes-Costa J, Roubin S, Mendez J, Pae res C, Masjuan A, Marin F, Guerra F, El-Battrawy I, Cortese B, Ramakrishna H, Perez-Villacastin J, Fernandez-Ortiz A, Brunetti N. Aspirin therapy on prophylactic anticoagulation for patients hospitalized with COVID-19: a propensity score-matched cohort analysis of the HOPE-COVID-19 Registry. *Journal of the American Heart Association*. 2022 Jul 5;11(13):e024530. doi: 10.1161/JAHA.121.024530. PMID: 35730631
64. Haakenstad A, Yearwood J, Fullman N, et al. Assessing performance of the healthcare access and quality index, overall and by select age groups, for 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. *Lancet. Global Health*. 2022 Dec;10(12):e1715-e1743. doi: 10.1016/S2214-109X(22)00429-6. PMID: 36209761
65. Cuellar C, Rodero M, Perez-Griera J, Galindo-Regal L, Lopez-Chulia F, Garcia-Ballesteros C, Andreu-Ballester J. Association between anti-Anisakis simplex antibodies and interleukin-7 levels. *International Immunopharmacology*. 2022 Oct;111:109134. doi: 10.1016/j.intimp.2022.109134. PMID: 35964412
66. Kowark A, Berger M, Rossaint R, Schmid M, Coburn M. Association between benzodiazepine premedication and 30-day mortality rate: a propensity-score weighted analysis of the Peri-interventional Outcome Study in the Elderly (POSE). *European Journal of Anaesthesiology*. 2022 Mar 1;39(3):210-218. doi: 10.1097/EJA.0000000000001638. PMID: 34817420
67. Bohm M, Schumacher H, Werner C, Teo K, Lonn E, Mahfoud F, Speer T, Mancia G, Redon J, Schmieder R, Sliwa K, Marx N, Weber M, Laufs U, Williams B, Yusuf S, Mann J. Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. *Cardiovascular Diabetology*. 2022 Jan 20;21(1):12. doi: 10.1186/s12933-021-01429-w. PMID: 35057807
68. Usategui-Martin R, Perez-Castrillon J, Mansego M, Lara-Hernandez F, Manzano I, Briongos L, Abadia-Otero J, Martin-Vallejo J, Garcia-Garcia A, Martin-Escudero J, Chaves F. Association between genetic variants in oxidative stress-related genes and osteoporotic bone fracture. *The Hortega Follow-up Study. Gene*. 2022 Jan 30;809:146036. doi: 10.1016/j.gene.2021.146036. PMID: 34688818
69. Amr-Rey O, Sanchez-Delgado P, Salvador-Palmer R, Cibrian R, Paredes-Gallardo V. Association between malocclusion and articulation of phonemes in early childhood. *The Angle Orthodontist*. 2022 Jul 1;92(4):505-511. doi: 10.2319/043021-342.1. PMID: 35275982
70. Sim M, Seet E, Khanna A, Weingarten T, Liew L, Law L, Liu K, Di Piazza F, Ti L. Association between race and opioid-induced respiratory depression: an international post hoc analysis of the prediction of opioid-induced respiratory depression in patients monitored by Capnography Trial. *Anesthesia and Analgesia*. 2022 Nov 1;135(5):1097-1105. doi: 10.1213/ANE.0000000000006006. PMID: 35350054
71. Moreno B, Hueso L, Ortega R, Benito E, Martinez Hervas S, Peiro M, Civera M, Sanz MJ, Piqueras L, Real JT. Association of chemokines IP-10/CXCL10 and ITAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity. *Microvascular Research*. 2022 Jan;139:104254. doi: 10.1016/j.mvr.2021.104254. PMID: 34534571
72. Taxonera C, Fernandez-Acenero MJ, Olivares D, Calvo M, Casis B, Bermejo F, Lopez Serrano P, Iborra M, Mesonero F, Watts Bosca M, Diaz del Arco

# publication list

- C, Vera I, Olivares S, Algaba A, Alba C. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis. *Alimentary Pharmacology & Therapeutics*. 2022 Aug;56(4):614-624. doi: 10.1111/apt.16964. PMID: 35509152
73. Alventosa R, Ingles M, Amador S, Mallench L, Rubio N, Ano P. Author response to Ilgen, U. Physical Therapy. 2022 Aug 4;102(8):pzac072. doi: 10.1093/pjz/pzac072. PMID: 35713527
74. Espi A, Herreros B, Minguez M. Authors reply to comments high recurrence rate after non-surgical treatment of chronic anal fissure: can it be prevented?. *Diseases of the Colon and Rectum*. 2022 May 1;65(5):e340. doi: 10.1097/DCR.0000000000002435. PMID: 35185136
75. Zhang Q, Pizzorno A, Miorin L, Bastard P, Gervais A, Le Voyer T, Bizien L, Manry J, Rosain J, Philippot Q, Goavec K, Padey B, Cupic A, Laurent E, Saker K, Vanker M, Sarekannu K, Garcia-Salum T, Ferres M, Le Corre N, Sanchez-Cespedes J, Balsara-Manzano M, Carratala J, Retamar-Gentil P, Abelenda-Alonso G, Valiente A, Tibergien P, Zins M, Debette S, Meyts I, Haerynck F, Castagnoli R, Notarangelo LD, Gonzalez-Granado LI, Dominguez-Pinilla N, Andreakos E, Triantafyllia V, Rodriguez-Gallego C, Sole-Violan J, Ruiz-Hernandez JJ, Rodriguez de Castro F, Ferreres J, Briones M, Wauters J, Vanderbeke L, Feys S, Kuo CY, Lei WT, Ku CL, Tal G, Etzioni A, Hanna S, Fournet T, Casalegno JS, Queromes G, Argaud L, Javouhey E, Rosa-Calatrava M, Cordero E, Aydillo T, Medina RA, Kisand K, Puel A, Jouanguy E, Abel L, Cobat A, Trouillet-Assant S, Garcia-Sastre A, Casanova JL. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. *Journal of Experimental Medicine*. 2022 Nov 7;219(11):e20220514. doi: 10.1084/jem.20220514. PMID: 36112363
76. Monton Rodriguez C, Navarro Cortes P, Lluch Garcia P, Minguez Perez M. Autoimmune hepatitis triggered by COVID-19. *Revista Espanola de Enfermedades Digestivas*. 2022 Jan;114(1):64-65. doi: 10.17235/reed.2021.8045/2021. PMID: 34015933
77. Martí-Aguado D, Jimenez-Pastor A, Alberich-Bayarri A, Rodriguez-Ortega A, Alfaro-Cervello C, Mestre-Alagarda C, Bauza M, Gallen-Peris A, Valero-Perez E, Ballester MP, Gimeno-Torres M, Perez-Girbes A, Benlloch S, Perez-Rojas J, Puglia V, Ferrandez A, Aguilera V, Escudero-Garcia D, Serra MA, Marti-Bonmati L. Automated whole-liver MRI segmentation to assess steatosis and iron quantification in chronic liver disease. *Radiology*. 2022 Feb;302(2):345-354. doi: 10.1148/radiol.2021211027. PMID: 34783592
78. Capalbo A, Cimadomo D, Rienzi L, Garcia-Velasco J, Simon C, Ubaldi F. Avoid mixing apples and oranges: blastocysts diagnosed with uniform whole chromosome aneuploidies are reproductively incompetent and their transfer is harmful. *Human Reproduction*. 2022 Aug 25;37(9):2213-2214. doi: 10.1093/humrep/deac149. PMID: 35796677
79. Labrador J, Martinez-Cuadron D, de la Fuente A, Rodriguez-Veiga R, Serrano J, Tormo M, Rodriguez-Arboli E, Ramos F, Bernal T, Lopez-Pavia M, Trigo F, Martinez-Sanchez MP, Rodriguez-Gutierrez JI, Rodriguez-Medina C, Gil C, Garcia Belmonte D, Vives S, Foncillas MA, Perez-Encinas M, Novo A, Recio I, Rodriguez-Macias G, Bergua JM, Noriega V, Lavilla E, Roldan-Perez A, Sanz MA, Montesinos P, on Behalf of Pethema Group. Azacitidine vs. Decitabine in unfit newly diagnosed acute myeloid leukemia patients: results from the PETHEMA Registry. *Cancers*. 2022 May 9;14(9):2342. doi: 10.3390/cancers14092342. PMID: 35565471
80. Fernández-Velasco JI, Monreal E, Kuhle J, Meca-Lallana V, Meca-Lallana J, Izquierdo G, Oreja-Guevara C, Gascón-Giménez F, Sainz de la Maza S, Walo-Delgado PE, Lapuente-Suanzes P, Maceski A, Rodríguez-Martín E, Roldán E, Villarrubia N, Saiz A, Blanco Y, Diaz-Pérez C, Valero-López G, Diaz-Diaz J, Aladro Y, Brieva L, Íñiguez C, González-Suárez I, Rodríguez de Antonio LA, García-Domínguez JM, Sabin J, Llufrui S, Masjuan J, Costa-Frossard L, Villar LM. Baseline inflammatory status reveals dichotomic immune mechanisms involved in primary-progressive multiple sclerosis pathology. *Frontiers in Immunology*. 2022 Mar 21;13:842354. doi: 10.3389/fimmu.2022.842354. PMID: 35386690
81. Ferrer J, Gimenez E, Carretero D, Buesa J, Morillas F, Granell R, Fuenmayor A, Navarro D, Albert E.

# publication list

- BD MAX enteric bacterial, bacterial plus, and virus panels for diagnosis of acute infectious gastroenteritis: a cost-benefit analysis. *Microbiology Spectrum*. 2022 Oct 26;10(5):e0088022. doi: 10.1128/spectrum.00880-22. PMID: 36069590
82. de la Espriella R, Bayes-Genis A, Nunez J. Bending Oxygen Saturation Index (BOSI) and risk of worsening heart failure events in chronic heart failure. *European Journal of Heart Failure*. 2022 Dec;24(12):2390-2391. doi: 10.1002/ejhf.2692. PMID: 36102193
83. De la Espriella R, Amiguet M, Minana G, Rodriguez JC, Moyano P, Segarra D, Fernandez J, Santas E, Nunez G, Lorenzo M, Bonanad C, Alania E, Valle A, Sanchis J, Bodi V, Gorrioz JL, Navarro J, Codina P, Voors AA, Bayes-Genis A, Nunez J. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure. *European Journal of Heart Failure*. 2022 Nov;24(11):2108-2117. doi: 10.1002/ejhf.2651. PMID: 36054502
84. Marques P, Domingo E, Rubio A, Martinez-Hervas S, Ascaso JF, Piqueras L, Real JT, Sanz MJ. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. *Biomedicine & Pharmacotherapy*. 2022 Jan;145:112460. doi: 10.1016/j.bioph.2021.112460. PMID: 34864314
85. Soto Rubio A, Valero Moreno S, Perez Marin M. Benefits of a support programme for family caregivers of patients at the end of life: a randomised controlled trial. *Journal of Health Psychology*. 2022 Jan;27(1):199-210. doi: 10.1177/1359105320944993. PMID: 32772853
86. Bastos-Oreiro M, Gutierrez A, Reguera J, Iacoboni G, Lopez-Corral L, Terol M, Ortiz-Maldonado V, Sanz J, Guerra-Dominguez L, Bailen R, Mussetti A, Abrisqueta P, Hernani R, Luzardo H, Sancho J, Delgado-Serrano J, Salar A, Grande C, Bento L, de Villambrrosa S, Garcia-Belmonte D, Sureda A, Perez-Martinez A, Barba P, Kwon M, Garcia-Sancho A. Best treatment option for patients with refractory aggressive b-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO/GETH Spanish Groups. *Frontiers in Immunology*. 2022 Jul 12;13:855730. doi: 10.3389/fimmu.2022.855730. PMID: 35911769
87. Formiga F, Chivite D, Nunez J, Moreno Garcia MC, Manzano L, Arevalo-Lorido JC, Cerqueiro JM, Garcia Campos A, Trullas JC, Montero-Perez-Barquiero M. Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm. *Revista Portuguesa de Cardiologia*. 2022 Oct;41(10):853-861. doi: 10.1016/j.repc.2021.06.027. PMID: 36207068
88. Perez-Carbonell T, Orts-Alborch M, Perez-Guillen V, Pla-Gil I, Tenias-Burillo JM, Marco-Algarra J, Perez-Garrigues H. Bilateral Meniere's disease according to its form of debut: synchronous and metachronous disease. *Journal of Laryngology and Otology*. 2022 Oct 6;116(10):19-23. doi: 10.1017/S0022215122002262. PMID: 36200516
89. Riffo-Campos AL, Perez-Hernandez J, Martinez-Arroyo O, Ortega A, Flores-Chova A, Redon J, Cortes R. Biofluid specificity of long non-coding RNA profile in hypertension: relevance of exosomal fraction. *International Journal of Molecular Sciences*. 2022 May 6;23(9):5199. doi: 10.3390/ijms23095199. PMID: 35563588
90. González MRD, Ballester MP, Romero-González E, Sánchez-Pardo AM, Martí-Aguado D, Tosca J, Suria C, Ausejo RA, Moreno IP, Silvestre MDP, Pérez MM, Bosca-Watts MM. Biological treatment interruption in Inflammatory Bowel Disease: motivation and predictive factors. *Gastroenterología y Hepatología*. 2022 Nov 11;SO210-5705(22)00267-9. doi: 10.1016/j.gastrohep.2022.10.021. PMID: 36375696
91. Bayes-Genis A, Aimo A, Jhund P, Richards M, de Boer RA, Arfsten H, Fabiani I, Lupon J, Anker SD, Gonzalez A, Castiglione V, Metra M, Mueller C, Nunez J, Rossignol P, Barison A, Butler J, Teerlink J, Filippatos G, Ponikowski P, Vergaro G, Zannad F, Seferovic P, Rosano G, Coats AJS, Emdin M, Januzzi JL. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*. 2022 Oct;24(10):1767-1777. doi: 10.1002/ejhf.2675. PMID: 36073112
92. Fernandez Perez R, Alba Linares JJ, Tejedor JR, Fernandez Fernandez A, Calero M, Roman Domin-

# publication list

- guez A, Borras C, Vina J, Avila J, Medina M, Fernandez Fraga M. Blood DNA methylation patterns in older adults with evolving dementia. *The journals of Gerontology. Series A, Biological Sciences and Medical Sciences*. 2022 Sep 1;77(9):1743-1749. doi: 10.1093/gerona/glac068. PMID: 35299244
93. Alvarez J, Aguilar F, Lurbe E. Blood pressure measurement in children and adolescents: key element in the evaluation of arterial hypertension. *Anales de Pediatría*. 2022 Jun;96(6):536.e1-536.e7. doi: 10.1016/j.anpede.2022.04.011. PMID: 35659490
94. Alvarez-Pitti J, Herceg-Cavrak V, Wojcik M, Radovanovic D, Brzezinski M, Grabitz C, Wuhl E, Drozdz D, Melk A. Blood pressure response to exercise in children and adolescents. *Frontiers in Cardiovascular Medicine*. 2022 Sep 30;9:1004508. doi: 10.3389/fcvm.2022.1004508. PMID: 36247478
95. Martin-Iglesias S, Milian L, Sancho-Tello M, Salvador-Clavell R, de Llano J, Carda C, Mata M. BMP-2 enhances osteogenic differentiation of human adipose-derived and dental pulp stem cells in 2D and 3D in vitro models. *Stem Cells International*. 2022 Mar 4;2022:4910399. doi: 10.1155/2022/4910399. PMID: 35283997
96. Moccia P, Belda-Montesinos R, Monllor-Tormos A, Chedraui P, Cano A. Bodyweight and fat mass across the menopausal transition: hormonal modulators. *Gynecological Endocrinology*. 2022 Feb;38(2):99-104. doi: 10.1080/09513590.2021.2004395. PMID: 34898344
97. Piñana JL, Garcia-Sanz R, Martino R, Garcia-Roa M, Martin-Martin GA, Risco-Gálvez I, Tormo M, Martinez-Barranco P, Marcos-Corrales S, Calabuig M, Conesa V, Teruel A, Ruiz-Pérez S, Solano C, Navarro D, Cedillo Á, Sureda A. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. *Blood Advances*. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326. PMID: 34905620
98. Soldevila-Matias P, Garcia-Marti G, Fuentes-Dura I, Ruiz JC, Gonzalez-Navarro L, Gonzalez-Vivas C, Rada J, Sanjuan J. Brain activity changes with emotional words in different stages of psychosis. *European Psychiatry*. 2022 Oct 4;1-27. doi: 10.1192/j.eurpsy.2022.2321. PMID: 36193735
99. Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefanis V, Sobas M, Rumi E, Elli E, Lunghi F, Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali H, Andrade-Campos M, Palandri F, Harrison C, Foncillas M, Osorio S, Koschmieder S, Mazo E, Kiladjian J, Calderon E, Heidel F, Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez A, Hernandez-Boluda J, Abadia E, Carli G, Serrano M, Kusec R, Cirici B, Guenova M, Elorza B, Angona A, Cichocka E, de Nalecz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi A. Breakthrough infections in MPN-COVID vaccinated patients. *Blood Cancer Journal*. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. PMID: 36379921
100. Calvo-Lerma J, Selma-Royo M, Hervas D, Yang B, Inttonen L, Gonzalez S, Martinez-Costa C, Linderborg K, Collado M. Breast milk lipidome is associated with maternal diet and infants' growth. *Frontiers in Nutrition*. 2022 Jul 6;9:854786. doi: 10.3389/fnut.2022.854786. PMID: 35873422
101. Armocida B, Monasta L, Sawyer S, Bustreo F, Segafredo G, Castelpietra G, Ronfani L, Pasovic M, Hay S, Perel P, Beran D. Burden of non-communicable diseases among adolescents aged 10-24 years in the EU, 1990-2019: a systematic analysis of the Global Burden of Diseases Study 2019. *Lancet Child & Adolescent Health*. 2022 Jun;6(6):367-383. doi: 10.1016/S2352-4642(22)00073-6. PMID: 35339209
102. Santos-Lasaosa S, Belvis R, Cuadrado M, Diaz-Insa S, Gago-Veiga A, Guerrero-Peral A, Huerta M, Irimia P, Lainez J, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sanchez Del Rio M, Viguera J, Pozo-Rosich P. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. *Neurologia*. 2022 Jun;37(5):390-402. doi: 10.1016/j.nrleng.2019.03.025. PMID: 35672126
103. Kocarnik J, Compton K, Dean F, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019 a systematic analysis for the Global Burden of Disease Study

# publication list

2019. JAMA Oncology. 2022 Mar 1;8(3):420-444. doi: 10.1001/jamaoncol.2021.6987. PMID: 34967848
104. Carbonell N, Alcaraz M, Serrano-Lazaro A, Rodriguez-Gimillo M, Ramos D, Ros F, Ferrer J, Blasco M, Navarro D, Clari M. CAPA in progress: a new real-life approach for the management of critically ill COVID-19 patients. *Biomedicines*. 2022 Jul 13;10(7):1683. doi: 10.3390/biomedicines10071683. PMID: 35884988
105. Owczarek C, Ortiz-Zapater E, Kim J, Papaevangelou E, Santis G, Parsons M. CAR co-operates with integrins to promote lung cancer cell adhesion and invasion. *Frontiers in Oncology*. 2022 Feb 14;12:829313. doi: 10.3389/fonc.2022.829313. PMID: 35252000
106. Llacer P, Nunez J, Manzano L, Rodrigo J, Bautista P, Garcia M, Vila J, Lopez R, Reboiro M, Montero-Perez-Barquero M. Carbohydrate antigen 125 [CA125] as a prognostic marker in the elderly with acute heart failure and preserved ejection fraction. *Medicina Clinica*. 2022 Aug 26;159(4):164-170. doi: 10.1016/j.medcli.2021.09.032. PMID: 34895749
107. Minana G, de la Espriella R, Palau P, Llacer P, Nunez E, Santas E, Valero E, Lorenzo M, Nunez G, Bodí V, Heredia R, Sanchis J, Bayes-Genis A, Chorro F, Nunez J. Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction. *Scientific Reports*. 2022 Jan 25;12(1):1344. doi: 10.1038/s41598-022-05328-2. PMID: 35079082
108. Amat-Santos I, Delgado-Arana J, Cruz-Gonzalez I, Gutierrez H, Garcia-Bolao I, Millan X, Tirado-Conte G, Ruiz-Nodar J, Mohandes M, Palazuelos J, Saura F, Valle R, Picher E, Garcia J, Gomez I, Rincon R, Arzamendi D, Nombela-Franco L, Korniiko L, Barrero A, Santos-Martinez S, Serrador A, Alberto San Roman J. Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC Study. *Revista Espanola de Cardiologia* (English ed.). 2022 Aug 4;S1885-5857(22)00208-0. doi: 10.1016/j.rec.2022.08.001. PMID: 35934294
109. Gonzalez A, Richards A, de Boer R, Thum T, Arfsten H, Hulsmann M, Falcao-Pires I, Diez J, Foo R, Chan M, Aimo A, Anene-Nzelu G, Abdelhamid M, Adamopoulos S, Anker S, Belenkov Y, Gal T, Cohen-Solal A, Bohm M, Chioncel O, Delgado V, Emdin M, Jankowska E, Gustafsson F, Hill L, Jaarsma T, Januzzi J, Jhund P, Lopatin Y, Lund L, Metra M, Milicic D, Moura B, Mueller C, Mullens W, Nunez J, Piepoli M, Rakisheva A, Ristic A, Rossignol P, Savarese G, Tocchetti C, Van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats A, Bayes-Genis A. Cardiac remodelling part 1: from cells and tissues to circulating biomarkers. *European Journal of Heart Failure*. 2022 Jun;24(6):927-943. doi: 10.1002/ejhf.24933. PMID: 35334137
110. Aimo A, Vergaro G, Gonzalez A, Barison A, Lupon J, Delgado V, Richards AM, de Boer RA, Thum T, Arfsten H, Hulsmann M, Falcao-Pires I, Diez J, Foo RSY, Chan MYY, Anene-Nzelu CG, Abdelhamid M, Adamopoulos S, Anker SD, Belenkov Y, Gal TB, Cohen-Solal A, Bohm M, Chioncel O, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Januzzi JL, Jhund P, Lopatin Y, Lund LH, Metra M, Milicic D, Moura B, Mueller C, Mullens W, Nunez J, Piepoli MF, Rakisheva A, Ristic AD, Rossignol P, Savarese G, Tocchetti CG, van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Emdin M, Bayes-Genis A. Cardiac remodelling-Part 2: clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*. 2022 Jun;24(6):944-958. doi: 10.1002/ejhf.2522. PMID: 35488811
111. Bonanad C, Fernandez-Olmo R, Garcia-Blas S, Alarcon J, Diez-Villanueva P, Mansilla C, Garcia-Pardo H, Toledo P, Ayesta A, Pereira E, Carol A, Castro-Conde A, de Pablo-Zarzoso C, Martinez-Selles M, Arrarte V, Campuzano R, Ariza-Sole A. Cardiovascular prevention in elderly patients. *Journal of Geriatric Cardiology*. 2022 May 28;19(5):377-392. doi: 10.11909/j.issn.1671-5411.2022.05.004. PMID: 35722032
112. Orozco-Beltran D, Brotons Cuixart C, Banegas J, Gil Guillen V, Cebrian Cuenca A, Martin Rioboo E, Jorda Baldo A, Vicuna J, Navarro Perez J. Cardiovascular preventive recommendations. PAPPS 2022 thematic updates. Working groups of the PAPPS. Atencion Primaria. 2022 Oct;54 Suppl 1[Suppl 1]:102444. doi: 10.1016/j.

# publication list

- aprim.2022.102444. PMID: 36435583
113. Quintanilla-Bordas C, Gascon-Gimenez F, Alcala C, Paya M, Mallada J, Silla R, Carratala-Bosca S, Gasque-Rubio R, Castillo J, Casanova B. Case Report: exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis: a case series. *Frontiers in Neurology*. 2022 Apr 27;13:897275. doi: 10.3389/fneur.2022.897275. PMID: 35572939
114. Tosca J, Sanchez A, Sanahuja A, Villagrassa R, Poyatos P, Mas P, Pascual I, Lluch P, Herreros B, Pena A, Sanchiz V, Minguez M. Caustic ingestion: a risk-based algorithm. *American Journal of Gastroenterology*. 2022 Oct 1;117(10):1593-1604. doi: 10.14309/ajg.00000000000001953. PMID: 36194047
115. Balaguer N, Mateu-Bruell E, Gomez-Lopez M, Simon C, Milan M. Cell-free fetal DNA testing performance and fetal fraction estimation are not affected in ART-conceived pregnancies. *Human Reproduction*. 2022 Nov 24;37(12):2743-2756. doi: 10.1093/humrep/deac217. PMID: 36223600
116. Sanchez-Ramos D, Vega-Torres E, Irles-Vidal C, Colomina-Rodriguez J. Cerebellious abscesses caused by Nocardia farcinica in an immunocompromised patient. *Revista Espanola de Quimioterapia*. 2022 Aug;35(4):418-420. doi: 10.37201/req/034.2022. PMID: 35711122
117. Dudek P, Andruszkiewicz P, Gelo R, Badenes R, Bi-lotta F. Cerebral diseases in liver transplant recipients: systematic review of clinical evidence. *Journal of Clinical Medicine*. 2022 Feb 13;11(4):979. doi: 10.3390/jcm11040979. PMID: 35207251
118. Siwicka-Gieroba D, Robba C, Golacki J, Badenes R, Dabrowski W. Cerebral oxygen delivery and consumption in brain-injured patients. *Journal of Personalized Medicine*. 2022 Oct 25;12(11):1763. doi: 10.3390/jpm12111763. PMID: 36573716
119. Guerra-Ojeda S, Marchio P, Rueda C, Suarez A, Garcia H, Victor V, Juez M, Martin-Gonzalez I, Vila J, Mauricio M. Cerium dioxide nanoparticles modulate antioxidant defences and change vascular response in the human saphenous vein. *Free Radical Biology & Medicine*. 2022 Nov 17;193(Pt 2):694-701. doi: 10.1016/j.freeradbiomed.2022.11.012.
- PMID: 36402438
120. Martinez-Cuadron D, Serrano J, Mariz J, Gil C, Tormo M, Martinez-Sanchez P, Rodriguez-Arboli E, Garcia-Boyero R, Rodriguez-Medina C, Martinez-Chamorro C, Polo M, Bergua J, Aguiar E, Amigo M, Herrera P, Alonso-Dominguez J, Bernal T, Espadana A, Sayas M, Algarra L, Vidriales M, Vasconcelos G, Vives S, Perez-Encinas M, Lopez A, Noriega V, Garcia-Fortes M, Chillon M, Rodriguez-Gutierrez J, Calasanz M, Labrador J, Lopez J, Boluda B, Rodriguez-Veiga R, Martinez-Lopez J, Barragan E, Sanz M, Montesinos P. Characteristics and outcomes of adult patients in the PETHEMA Registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia. *Cancers*. 2022 Jun 6;14(11):2817. doi: 10.3390/cancers14112817. PMID: 35681796
121. Garcia-Guimaraes M, Fuertes-Ferre G, Jimenez-Valero S, Lozano I, Cruz-Gonzalez I, Cortes C, Portero-Portaz J, Valero E, Bastante T, Alfonso F, Spanish Registry on SCAD investigators. Characteristics, acute results, and prognostic impact of percutaneous coronary interventions in spontaneous coronary artery dissection [from the Prospective Spanish Registry on SCAD [SR-SCAD]]. *American Journal of Cardiology*. 2022 May 15;171:177-178. doi: 10.1016/j.amjcard.2022.02.008. PMID: 35321804
122. Beltran-Garcia J, Osca-Verdegal R, Javega B, Herrera G, O'Connor J, Garcia-Lopez E, Casabó-Valles G, Rodriguez-Gimillo M, Ferreres J, Carbonell N, Pallardo F, Garcia-Gimenez J. Characterization of early peripheral immune responses in patients with sepsis and septic shock. *Biomedicines*. 2022 Feb 23;10(3):525. doi: 10.3390/biomedicines10030525. PMID: 35327327
123. Pallares Carratala V, Carratala Munuera C, Lopez Pineda A, Quesada J, Gil Guillen V, Orozco Beltran D, Alfonso Sanchez J, Navarro Perez J, Martin Moreno J. Characterizing diagnostic inertia in arterial hypertension with a gender perspective in primary care. *Frontiers in Cardiovascular Medicine*. 2022 Jun 16;9:874764. doi: 10.3389/fcvm.2022.874764. PMID: 35783866
124. D'Andrea G, Lal J, Tosato S, Gayer-Anderson C, Jongsma H, Stilo S, van der Ven E, Quattrone D,

# publication list

- Velthorst E, Berardi D, Menezes P, Arango C, Parrellada M, Lasalvia A, La Cascia C, Ferraro L, La Barbera D, Sideli L, Bobes J, Bernardo M, Sanjuan J, Santos J, Arrojo M, Del-Ben C, Tripoli G, Llorca P, de Haan L, Selten J, Tortelli A, Szoke A, Muratori R, Rutten B, van Os J, Jones P, Kirkbride J, Murray R, di Forti M, Tarricone I, Morgan C. Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study. *Psychological Medicine*. 2022 Oct;28;1-11. doi: 10.1017/S003329172200335X. PMID: 36305570
125. Sideli L, Schimmenti A, La Barbera D, La Cascia C, Ferraro L, Aas M, Alameda L, Velthorst E, Fisher H, Caretti V, Trotta G, Tripoli G, Quattrone D, Gayer-Anderson C, Seminario F, Sartorio C, Marrazzo G, Lasalvia A, Tosato S, Tarricone I, Berardi D, D'Andrea G, Arango C, Arrojo M, Bernardo M, Bobes J, Sanjuan J, Santos J, Menezes P, Del-Ben C, Jongsma H, Jones P, Kirkbride J, Llorca P, Tortelli A, Pignon B, de Haan L, Selten J, Van Os J, Rutten B, Di Forti M, Morgan C, Murray R, EU-GEI WP2 Group. Childhood maltreatment, educational attainment, and IQ: findings from a Multicentric Case-control Study of First-episode Psychosis (EU-GEI). *Schizophrenia Bulletin*. 2022 May;748(3):575-589. doi: 10.1093/schbul/sbac004. PMID: 35137235
126. Sanchez-Jimenez J, Tejero-Pastor R, Calzadillas-Villalba M, Jimenez-Perez I, de Anda R, Salvador-Palmer R, Priego-Quesada J. Chronic and acute effects on skin temperature from a sport consisting of repetitive impacts from hitting a ball with the hands. *Sensors*. 2022 Nov;7:22(21):8572. doi: 10.3390/s22218572. PMID: 36366270
127. Rivera-Caravaca J, Nunez-Gil I, Lip G, Uribarri A, Viana-Llamas M, Gonzalez A, Castro-Mejia A, Gonzalez B, Alfonso E, Prieto J, Cavallino C, Cortese B, Feltes G, Fernandez-Rozas I, Signes-Costa J, Huang J, Aguado M, Pepe M, Romero R, Cerrato E, Becerra-Munoz V, Roubin S, Santoro F, Bagur R, Sposato L, El-Batrawy I, Masjuan A, Fernandez-Ortiz A, Estrada V, Macaya C, Marin F. Chronic oral anticoagulation therapy and prognosis of patients admitted to hospital for COVID-19: insights from the HOPE COVID-19 Registry. *International Journal of Clinical Practice*. 2022 May;26:2022:7325060. doi: 10.1155/2022/7325060. PMID: 35685504
128. Palau P, Dominguez E, Seller J, Sastre C, Sanchis J, Lopez L, Bodi V, Llacer P, Minana G, Espriella R, Bayes-Genis A, Nunez J. Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction. *Revista Espanola de Cardiologia (English ed.)*. 2022 Aug 28;S1885-5857(22)00211-0. doi: 10.1016/j.rec.2022.08.003. PMID: 36038124
129. Luque J, Mendes I, Gomez B, Morte B, de Heredia M, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch R, Fillat C, Perez-Jurado L, Montoliu L, Carracedo A, Millan J, Webb S, Palau F, Lapunzina P, Pallardo Calatayud F, CIBERER Network. CIBERER: Spanish national network for research on rare diseases: a highly productive collaborative initiative. *Clinical Genetics*. 2022 May;101(5-6):481-493. doi: 10.1111/cge.14113. PMID: 35060122
130. Marti-Aguado D, Clemente-Sanchez A, Bataller R. Cigarette smoking and liver diseases. *Journal of Hepatology*. 2022 Jul;77(1):191-205. doi: 10.1016/j.jhep.2022.01.016. PMID: 35131406
131. Luque M, Cristobal I, Sanz-Alvarez M, Santos A, Zazo S, Eroles P, Arpi O, Rovira A, Albanell J, Madoz-Gurpide J, Garcia-Foncillas J, Rojo F. CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer. *Journal of Clinical Medicine*. 2022 Mar 14;11(6):1610. doi: 10.3390/jcm11061610. PMID: 35329936
132. Garcia de Guadiana-Romualdo L, Rodriguez Rojas C, Morell-Garcia D, Andaluz-Ojeda D, Rodriguez Mulero M, Rodriguez-Borja E, Ballesteros-Vizoso A, Calvo M, Albert-Botella L, Pozo Giraldez A, Llompart-Alabern I, Bolado Jimenez C, Hernandez Olivo M, Fernandez Presa L, Ortega-Perez J, Fora Romero M, Campos-Rodriguez V, Ballester Ferriz A, Guiu-Marti A, Pinilla Arribas L, Galindo Martinez M, Puerto-Lara E, Lopez Tarazaga A, Ros Braquehais M, Nogales Martin L, Juez Santamaria C, Trapiello Fernandez W, Espinilla Fernandez V, Havelka A, Albaladejo-Oton M. Circulating levels of calprotectin, a signature of neutrophil activation in prediction of severe respiratory failure in COVID-19 patients: a multicenter, prospective study (CalCov study). *Inflammation Research*. 2022 Jan;71(1):57-67. doi: 10.1007/s00011-021-01516-4. PMID: 34718856

# publication list

133. Mompeon A, Perez-Cremades D, Paes A, Sanchis J, Ortega-Paz L, Andrea R, Brugaletta S, Sabate M, Novella S, Dantas A, Hermenegildo C. Circulating miRNA fingerprint and endothelial function in myocardial infarction: comparison at acute event and one-year follow-up. *Cells.* 2022 Jun 2;11(11):1823. doi: 10.3390/cells11111823. PMID: 35681518
134. Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, Huerta M, Rosello S, Madsen AH, Love US, Andersen PV, Thorlacius-Ussing O, Iversen LH, Gotschalck KA, Sethi H, Aleshin A, Cervantes A, Andersen CL. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. *Clinical Cancer Research.* 2022 Feb 1;28(3):507-517. doi: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408
135. Garcia V, Vallejo-Aparicio L, Ismaila A, Sicras-Maiñar A, Sicras-Navarro A, Gonzalez C, Cuervo R, Shukla S, Garcia-Penuela M. Clinical and economic impact of long-term inhaled corticosteroid withdrawal in patients with chronic obstructive pulmonary disease treated with Triple Therapy in Spain. *International Journal of Chronic Obstructive Pulmonary Disease.* 2022 Sep 7;17:2161-2174. doi: 10.2147/COPD.S367708. PMID: 36101793
136. Miravitlles M, Turner AM, Torres-Duran M, Tanash H, Rodríguez-García C, López-Campos JL, Chlumsky J, Guimaraes C, Rodríguez-Hermosa JL, Corsico A, Martinez-González C, Hernández-Pérez JM, Bustamante A, Parr DG, Casas-Maldonado F, Hecimovic A, Janssens W, Lara B, Barrecheguren M, González C, Stolk J, Esquinas C, Clarenbach CF. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO International registry. *Respiratory Research.* 2022 Dec 16;23(1):352. doi: 10.1186/s12931-022-02275-4. PMID: 36527073
137. Fatmi A, Chabni N, Cernada M, Vento M, Gonzalez-Lopez M, Aribi M, Pallardo FV, Garcia-Gimenez JL. Clinical and immunological aspects of microRNAs in neonatal sepsis. *Biomedicine & Pharmacotherapy.* 2022 Jan;145:112444. doi: 10.1016/j.bioph.2021.112444. PMID: 34808550
138. Rios-Martin J, Rodriguez-Salas N, Vazquez-Doval F, Llombart B, Rojas-Ferrer N, Gonzalez-Vela M, Zulueta T, Monteagudo C, Aneiros-Fernandez J, Beato M, Carrillo R, Silva-Carmona M, Ayala M, Gallego E, Rodriguez-Peralto J, Fraga-Fernandez J, Fernandez-Figueras M, Barranco C, Cordoba A, Sanz-Zorrilla A, Ferrer B, Funez R, Santonja C, Saus C, Idoate M, Santos-Briz A, Onrubia J, Pinedo F, de Las Penas R. Clinical and pathological features of Merkel cell carcinoma: a 4-year follow-up observational retrospective study in Spain. *Cancer Epidemiology.* 2022 Feb;76:102081. doi: 10.1016/j.canep.2021.102081. PMID: 34922051
139. Lope V, Guerrero-Zotano A, Ruiz-Moreno E, Bermejo B, Antolin S, Montano A, Baena-Canada JM, Ramos Vazquez M, Fernandez de Larrea-Baz N, Chacon JI, Garcia-Saenz JA, Olier C, Munoz M, Anton A, Sanchez Rovira P, Arcusa Lanza A, Gonzalez S, Oltra A, Brunet J, Gavila Gregori J, Martinez MT, Calvo L, Rosell L, Bezares S, Pastor-Barriuso R, Perez-Gomez B, Martin M, Pollan M. Clinical and sociodemographic determinants of adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations in breast cancer survivors-health-EpiGEICAM Study. *Cancers.* 2022 Sep 27;14(19):4705. doi: 10.3390/cancers14194705. PMID: 36230628
140. Llacer Iborra P, Nunez Villota J. Clinical characteristics and risk factors for mortality on admission in patients with heart failure hospitalized due to COVID-19 in Spain. *Revista Clinica Española.* 2022 May;222(5):299-300. doi: 10.1016/j.rceng.2022.02.002. PMID: 35512909
141. Llacer P, Nunez J. Clinical characteristics and risk factors for mortality on admission in patients with heart failure hospitalized due to COVID-19 in Spain. *Revista Clinica Española.* 2022 May;222(5):299-300. doi: 10.1016/j.rce.2022.02.006. PMID: 35250040
142. Pinto A, Reig O, Iglesias C, Gallardo E, Garcia-Del Muro X, Alonso T, Anguera G, Suarez C, Munoz-Langa J, Villalobos-Leon L, Rodriguez-Sanchez A, Lainez N, Martinez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzman J, Mendez-Vidal M, Rubio G, Garcia I, Capdevila L, Lambea J,

# publication list

- Vazquez S, Fernandez O, Hernando-Polo S, Cerezo S, Santander C, Garcia-Marrero R, Zambrana F, Gonzalez-Del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, Garcia A, Sotelo M, Arevalo M, Garcia-Donas J, Hernandez C, Bolos M, Llinares J, Climent M. Clinical factors associated with long-term benefit in patients with metastatic renal cell carcinoma treated with axitinib: real-world AXILONG Study. *Clinical Genitourinary Cancer*. 2022 Feb;20(1):25-34. doi: 10.1016/j.clgc.2021.09.006. PMID: 34789409
- supportive care needs. *Supportive Care in Cancer*. 2022 Feb;30(2):1483-1491. doi: 10.1007/s00520-021-06513-1. PMID: 34529142
143. Alfonso F, Garcia-Guimaraes M, Alvarado T, Sanz-Ruiz R, Roura G, Amat-Santos I, Altisent O, Tizon-Marcos H, Flores-Rios X, Masotti M, Perez-de Prado A, Ferre G, Ruiz-Poveda F, Valero E, Portero-Portaz J, Diez-Villanueva P, Salamanca J, Bastante T, Rivero F. Clinical implications of arterial hypertension in patients with spontaneous coronary artery dissection. *Coronary Artery Disease*. 2022 Mar 1;33(2):75-80. doi: 10.1097/MCA.0000000000001043. PMID: 33878074
144. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. *CA-A Cancer Journal for Clinicians*. 2022 Jul;72(4):372-401. doi: 10.3322/caac.21728. PMID: 35472088
145. Linschoten M, Uijl A, Schut A, et al. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. *European Heart Journal*. 2022 Mar 14;43(11):1104-1120. doi: 10.1093/eurheartj/ehab656. PMID: 34734634
146. Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, Castro A, Cebrian-Cuenca A, De Torres-Sanchez A, Garcia-de-Lucas MD, Nunez J, Obaya JC, Soler MJ, Gorri JL, Rubio-Herrera MA. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. *Journal of Clinical Medicine*. 2022 Dec 24;12(1):145. doi: 10.3390/jcm12010145. PMID: 36614945
147. Andreu Y, Martinez P, Soto-Rubio A, Fernandez S, Bosch C, Cervantes A. Colorectal cancer survival: prevalence of psychosocial distress and unmet
148. Gavara J, Perez N, Marcos-Garces V, Monmeneu J, Lopez-Lereu M, Rios-Navarro C, de Dios E, Bonanad C, Canoves J, Moratal D, Palau P, Minana G, Nunez J, Chorro F, Bodi V. Combined assessment of stress cardiovascular magnetic resonance and angiography to predict the effect of revascularization in chronic coronary syndrome patients. *European Journal of Preventive Cardiology*. 2022 Mar 11;29(2):407-416. doi: 10.1093/eurjpc/zwab170. PMID: 34686874
149. Costa R, Alberola J, Olea B, Gozalbo-Rovira R, Gimenez E, Cuevas-Ferrando E, Torres I, Albert E, Carbonell N, Ferreres J, Sanchez G, Rodriguez-Diaz J, Blasco M, Navarro D. Combined kinetic analysis of SARS-CoV-2 RNAemia, N-antigenemia and virus-specific antibodies in critically ill adult COVID-19 patients. *Scientific Reports*. 2022 May 18;12(1):8273. doi: 10.1038/s41598-022-12461-5. PMID: 35585163
150. SEC Working Group for the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and SEC Guidelines Committee. Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Revista Espanola de Cardiologia* [english Ed.]. 2022 Jun;75(6):458-465. doi: 10.1016/j.rec.2021.11.023. PMID: 35190290
151. Arrarte V, Campuzano R, Duque J, Aldama G, Barrios V, Bonanad C, Conde A, Olmo R, Gamez J, Guzman-Martinez G, Rey C, Vivas D, Avanzas P, Congost G, Boraita A, Bueno H, Calvo D, Delgado V, Dos L, Ferreira-Gonzalez I, Doblas J, Figal D, Sambola A, Tejedor A, Ferreiro J, Alfonso F. Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. *Revista Espanola de Cardiologia*. 2022 May;75(5):364-369. doi: 10.1016/j.rec.2021.10.023. PMID: 35165071
152. Macera L, Spezia PG, Medici C, Rofi E, Del Re M, Focosi D, Mazzetti P, Navarro D, Antonelli G, Danesi R, Pistello M, Maggi F. Comparative evaluation of molecular methods for the quantitative measure of torquenavirus viremia, the new surrogate marker of immune competence. *Journal of*

# publication list

- Medical Virology. 2022 Feb;94(2):491-498. doi: 10.1002/jmv.25488. PMID: 31002743
153. Llacer P, Nunez J, Garcia M, Ruiz R, Lopez G, Fabbregate M, Fernandez C, Croset F, Del Hoyo B, Gomis A, Manzano L. Comparison of chlorthalidone and spironolactone as additional diuretic therapy in patients with acute heart failure and preserved ejection fraction. European Heart Journal Acute Cardiovascular Care. 2022 Jun 7;11(4):350-355. doi: 10.1093/ehjacc/zuac006. PMID: 35167653
154. Stabouli S, Chainoglou A, Evripidou K, Simao C, Antza C, Petrou P, Hamdani G, Calpe J, Lurbe E. Comparison of validation protocols for blood pressure measuring devices in children and adolescents. Frontiers in Cardiovascular Medicine. 2022 Nov 23;9:1001878. doi: 10.3389/fcvm.2022.1001878. PMID: 36505363
155. Biscaglia S, Erriquez A, Serenelli M, D'Ascenzo F, De Ferrari G, Ariza Sole A, Sanchis J, Giannini F, Gallo F, Scala A, Menozzi A, Pighi M, Moreno R, Iannopollo G, Menozzi M, Guiducci V, Tebaldi M, Campo G. Complete versus culprit-only strategy in older MI patients with multivessel disease. Catheterization and Cardiovascular Interventions. 2022 Mar;99(4):970-978. doi: 10.1002/ccd.30075. PMID: 35170844
156. Barrios V, Beato P, Brotons C, Campuzano R, Merino-Torres J, Mostaza J, Plana N, Rubio J, Comellas M. Comprehensive management of risk factors in peripheral vascular disease. Expert consensus. Revista Clinica Espanola. 2022 Feb;222(2):82-90. doi: 10.1016/j.rceng.2020.11.011. PMID: 34217671
157. Botello S, Fernandez R, Lozano C, Salher S, Arevalo J, Valdezate D, Marti V, Macias A. Concordance and survival implications of preoperative subclassification of T3 rectal cancers by depth of mesorectal invasion using a 5-mm cut-off point with endorectal ultrasound and magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery. 2022 Apr;12(4):2356-2367. doi: 10.21037/qims-21-880. PMID: 35371947
158. Nunez J, de la Espriella R, Rossignol P, Voors AA, Mullens W, Metra M, Chioncel O, Januzzi JL, Mueller C, Richards AM, de Boer RA, Thum T, Arfsten H, Gonzalez A, Abdelhamid M, Adamopoulos S, Anker SD, Gal TB, Biegus J, Cohen-Solal A, Boehm M, Emdin M, Jankowska EA, Gustafsson F, Hill L, Jaarsma T, Jhund PS, Lopatin Y, Lund LH, Milicic D, Moura B, Piepoli MF, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Tocchetti CG, Van Linthout S, Volterrani M, Seferovic P, Rosano G, Coats AJS, Bayes-Genis A. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. European Journal of Heart Failure. 2022 Oct;24(10):1751-1766. doi: 10.1002/ejhf.2664. PMID: 36039656
159. D'Marco L. Congestive nephropathy. International Journal of Environmental Research and Public Health. 2022 Feb 22;19(5):2499. doi: 10.3390/ijerph19052499. PMID: 35270191
160. Torres-Blanco A, Altable-Garcia M, Miralles-Hernandez M. Conservative surgical management of late carotid patch infection in a patient with subsequent stenting for restenosis. Vascular and Endovascular Surgery. 2022 Jan;56(1):112-116. doi: 10.1177/15385744211043329. PMID: 34601983
161. Peters S, Pujol J, Dafni U, Domine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Molla A, Gervais R, Lopez Vivanco G, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, Gonzalez Larriba J, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel R, Le Pechoux C, De Ruysscher D, ETOP/IFCT 4-12 STIMULI Collaborators. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Annals of Oncology. 2022 Jan;33(1):67-79. doi: 10.1016/j.annonc.2021.09.011. PMID: 34562610
162. Garcia-Arnaez I, Romero-Gavilan F, Cerqueira A, Elortza F, Azkargorta M, Munoz F, Mata M, de Llano J, Suay J, Gurruchaga M, Goni I. Correlation between biological responses in vitro and in vivo to Ca-doped sol-gel coatings assessed using proteomic analysis. Colloids and Surfaces B-Biointer-

# publication list

- faces. 2022 Oct 21;220:112962. doi: 10.1016/j.colsurfb.2022.112962. PMID: 36306698
163. Donat E, Roca M, Castillejo G, Sanchez-Valverde F, Garcia-Burriel JL, Martinez-Ojinaga E, Eizaguirre FJ, Barrio J, Cilleruelo ML, Perez-Solis D, Ochoa-Sangrador C, Vecino-Lopez R, Miranda-Cid MC, Garcia-Calatayud S, Torres-Peral R, Juste M, Armas H, Barros-Garcia P, Leis R, Solaguren R, Salazar JC, Garcia-Romero R, Ortigosa L, Pena-Quintana L, Urruzuno P, Codoner P, Garcia-Casales Z, Masiques ML, Galicia-Poblet G, Crehua-Gaudiza E, Balmaseda E, Rubio-Santiago J, Polanco-Allue I, Roman-Riechmann E, Ribes-Koninck C. Correlation of anti-tissue transglutaminase antibodies with the mucosal changes and IgA status of children with celiac disease. *Journal of Pediatric Gastroenterology and Nutrition*. 2022 Dec 1;75(6):743-748. doi: 10.1097/MPG.00000000000003620. PMID: 36123770
164. Pina-Camacho L, Martinez K, Diaz-Caneja C, Mezquida G, Cuesta M, Moreno C, Amoretti S, Gonzalez-Pinto A, Arango C, Vieta E, Castro-Fornieles J, Lobo A, Fraguas D, Bernardo M, Janssen J, Parellada M, PEPs Group. Cortical thinning over two years after first-episode psychosis depends on age of onset. *NPJ Schizophrenia*. 2022 Mar 11;8(1):20. doi: 10.1038/s41537-021-00196-7. PMID: 35277520
165. Ferri J, Martinez-Ibanez J, Terradez L, Savall E, Martinez-Hervas S, Oller M, Lorente R, Ascaso J, Real J. Corticotroph cell hyperplasia as a rare cause of ACTH-dependent Cushing syndrome. *Endocrinologia, Diabetes y Nutricion*. 2022 Nov;69(9):694-701. doi: 10.1016/j.endien.2022.11.004. PMID: 36470644
166. De Luca G, Algohwary M, Uguz B, Oliveira D, Ganukov V, Zimbakov Z, Cercek M, Jensen L, Loh P, Calmac L, Roura-Ferrer G, Quadros A, Milewski M, di Uccio F, von Birgelen C, Versaci F, Ten Berg J, Casella G, Wong A, Kala P, Gil J, Carrillo X, Dirksen M, Becerra-Munoz V, Lee M, Juzar D, Joaquim R, Paladino R, Milicic D, Davlouros P, Bakraceski N, Zilio F, Donazzan L, Kraaijeveld A, Galasso G, Lux A, Marinucci L, Guiducci V, Menichelli M, Scoccia A, Yamac A, Mert K, Rios X, Kovarnik T, Kidawa M, Moreu J, Flavien V, Fabris E, Martinez-Luengas I, Boccalatte M, Ojeda F, Arellano-Serrano C, Caiazzo G, Cirrincione G, Kao H, Fores J, Vignali L, Pereira H, Manzo-Silberman S, Ordonez S, Ozkan A, Scheller B, Lehtola H, Teles R, Mantis C, Ylitalo A, Silveira J, Zoni R, Bessonov I, Savonitto S, Kochiadakis G, Alexopoulos D, Uribe C, Kanakakis J, Faurie B, Gabrielli G, Gutierrez A, Bachini J, Rocha A, Tam F, Rodriguez A, Lukito A, Saint-Joy V, Pessah G, Tuccillo B, Cortese G, Parodi G, Bouraghda M, Kedhi E, Lamelas P, Suryapranata H, Nardin M, Verdoia M. COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. *Heart*. 2022 Mar;108(6):458-466. doi: 10.1136/heartjnl-2021-319750. PMID: 34711661
167. Garcia-Llana H, Panizo N, Gandia L, Orti M, Gimenez-Civera E, Forquet C, D'Marco L, Puchades M, Sargsyan M, Sanchis I, Ribera C, Marco M, Ferra C, Perez-Baylach C, Bonilla B, Frances F, Perez-Bernat E, Sancho A, Gorri J. COVID-19 vaccination improved psychological distress [anxiety and depression scores] in chronic kidney disease patients: a prospective study. *Vaccines*. 2022 Feb 16;10(2):299. doi: 10.3390/vaccines10020299. PMID: 35214757
168. Greenhalgh T, Griffin S, Gurdasani D, et al. Covid-19: an urgent call for global vaccines-plus action. *BMJ-British Medical Journal*. 2022 Jan 2;376:o1. doi: 10.1136/bmj.o1. PMID: 34980603
169. Balaguer Lopez E, Garcia-Molina P, Nunez F, Crehua-Gaudiza E, Montal Navarro M, Pedron Giner C, Vitoria Minana I, Jovani Casano C, Galera Martinez R, Gomez-Lopez L, Rodriguez Martinez G, Martinez-Costa C. Cross-cultural adaptation to Spanish and content validity of three nutritional risk scales. *Anales de Pediatría*. 2022 Jul;97(1):12-21. doi: 10.1016/j.anpede.2022.06.001. PMID: 35729061
170. Monaco E, Schoeps K, Valero-Moreno S, Castro-Calvo J, Montoya-Castilla I, del Rosario C, Coello F, Herrera S, Trujillo A, Munevar F, Esparza NA. Cross-cultural validation of the Worries about COVID-19 and its consequences Scale (W-COV) in adolescents and young people. *Archives of Psychiatric Nursing*. 2022 Oct;40:158-166. doi: 10.1016/j.apnu.2022.07.016. PMID: 36064240
171. Valles E, Jimenez J, Marti-Almor J, Toquero J, Ormaetxe JM, Barrera A, Garcia Alberola A, Rubio JM, Morina P, Grande C, Fe Arcocha M, Peinado R, Cozar R, Hernandez J, Perez-Alvarez L, Gazta-

# publication list

- naga L, Ferrero De Loma Osorio A, Ruiz Granell R, Villuendas R, Martinez-Alday JD. Cryoballoon ablation for persistent and paroxysmal atrial fibrillation: procedural differences and results from the Spanish Registry (RECABA). *Journal of Clinical Medicine*. 2022 Feb 22;11(5):1166. doi: 10.3390/jcm11051166. PMID: 35268259
172. Cabanero-Navalon M, Garcia-Bustos V, Nunez-Beltran M, Fernandez P, Mateu L, Solanich X, Carrillo-Linares J, Robles-Marhuenda A, Puchades-Gimeno F, Ballesta A, Lopez-Osle N, Torralba-Cabeza M, Masdeu A, Gil J, Gaya N, Castellanos G, Sanchez-Martinez R, Barragan-Casas J, Gonzalez-Garcia A, de la Pena J, Lopez-Wolf D, Rufete A, Mora A, Giner M, Moral P. Current clinical spectrum of common variable immunodeficiency in Spain: the multicentric nationwide GTEM-SEMI-CVID registry. *Frontiers in Immunology*. 2022 Oct 28;13:1033666. doi: 10.3389/fimmu.2022.1033666. PMID: 36389743
173. Vidal-Cortes P, Martin-Loeches I, Rodriguez A, Bou G, Canton R, Diaz E, De la Fuente C, Torre-Cisneros J, Nuvials FX, Salavert M, Aguilar G, Nieto M, Ramirez P, Borges M, Soriano C, Ferrer R, Maseda E, Zaragoza R. Current positioning against severe infections due to Klebsiella pneumoniae in hospitalized adults. *Antibiotics*. 2022 Aug 27;11(9):1160. doi: 10.3390/antibiotics11091160. PMID: 36139940
174. Martinez D, Quilez-Cutillas A, Jimenez-Labaig P, Sesma A, Tarazona N, Pacheco-Barcia V, Obispo B, Paez D, Quintanar T, Sanchez-Canoval M, Montes A, Felip E, Rodriguez-Lescure A, Elez E. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology+MIR section. *Clinical & Translational Oncology*. 2022 Nov 23;1-7. doi: 10.1007/s12094-022-02989-3. PMID: 36418642
175. Solomon S, McMurray J, Claggett B, de Boer R, DeMets D, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Jhund P, Belohlavek J, Chiang C, Borleffs C, Comin-Colet J, Dobreau D, Drozdz J, Fang J, Alcocer-Gamba M, Al Habeeb W, Han Y, Honorio J, Janssens S, Katovala T, Kitakaze M, Merkely B, O'Meara E, Saraiva J, Tereshchenko S, Thierer J, Vaduganathan M, Var- deny O, Verma S, Pham V, Wilderang U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde A. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *New England Journal of Medicine*. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. PMID: 36027570
176. Garrido Gomez T, Castillo Marco N, Cordero T, Simon Valles C. Decidualization resistance in the origin of preeclampsia. *American Journal of Obstetrics and Gynecology*. 2022 Feb;226(2S):S886-S894. doi: 10.1016/j.ajog.2020.09.039. PMID: 33007270
177. Espinosa-Espinosa J, Gonzalez-Barriga A, Lopez-Castel A, Artero R. Deciphering the complex molecular pathogenesis of myotonic dystrophy type 1 through omics studies. *International Journal of Molecular Sciences*. 2022 Jan 27;23(3):1441. doi: 10.3390/ijms23031441. PMID: 35163365
178. Mancebo F, Parras-Molto M, Garcia-Rios E, Perez-Romero P. Deciphering the potential coding of human cytomegalovirus: new predicted transmembrane proteome. *International Journal of Molecular Sciences*. 2022 Mar 2;23(5):2768. doi: 10.3390/ijms23052768. PMID: 35269907
179. Horiuchi Y, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Mueller GA, Birkhahn R, Taub P, Vilke GM, Barnett O, McDonald K, Mahon N, Nunez J, Briguori C, Passino C, Duff S, Maisel A, Murray PT. Decongestion, kidney injury and prognosis in patients with acute heart failure. *International Journal of Cardiology*. 2022 May 1;354:29-37. doi: 10.1016/j.ijcard.2022.02.026. PMID: 35202737
180. Mosquera-Zamudio A, Launet L, Tabatabaei Z, Parra-Medina R, Colomer A, Moll J, Monteagudo C, Janssen E, Naranjo V. Deep learning for skin melanocytic tumors in whole-slide images: a systematic review. *Cancers*. 2022 Dec 21;15(1):42. doi: 10.3390/cancers15010042. PMID: 36612037
181. Kroese T, van Hillegersberg R, Schoppmann S, Deseyne P, Nafteux P, Obermannova R, Nordström M, Pfeiffer P, Hawkings M, Smyth E, Markar S, Hanna G, Cheong E, Chaudry A, Elme A, Adenis A, Piessen G, Gani C, Bruns C, Moehler M, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, D'Ugo

# publication list

- D, Roviello F, Bencivenga M, de Manzoni G, Jeene P, van Sandick J, Muijs C, Slingerland M, Nieuwenhuijzen G, Wijnhoven B, Beerepoot L, Kolodziejczyk P, Polkowski W, Alsina M, Pera M, Kanonnikoff T, Nilsson M, Guckenberger M, Monig S, Wagner D, Wyrwicz L, Berbee M, Gockel I, Lordick F, Griffiths E, Verheij M, van Rossum P, van Laarhoven H, OMEC working group. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. *European Journal of Cancer*. 2022 Feb; 51:164:18-29. doi: 10.1016/j.ejca.2021.11.032. PMID: 35134666
182. Guerra-Ojeda S, Marchio P, Aldasoro M, Valles S, Genoves P, Mauricio M, Vila J. deleterious effects of levamisole, a cocaine adulterant, in rabbit aorta. *Vascular Pharmacology*. 2022 Jun;144:106992. doi: 10.1016/j.vph.2022.106992. PMID: 35358704
183. Torres-Durán M, López-Campos JL, Rodríguez-Hermosa JL, Esquinas C, Martínez-González C, Hernández-Pérez JM, Rodríguez C, Bustamante A, Casas-Maldonado F, Barrecheguren M, González C, Miravitles M. Demographic and clinical characteristics of patients with PI1-antitrypsin deficiency genotypes PI\*ZZ and PI\*SZ in the Spanish registry of EARCO. *ERJ Open Research*. 2022 Sep 26;8(3):00213-2022. doi: 10.1183/23120541.00213-2022. PMID: 36171983
184. Ocana A, Chacon J, Calvo L, Anton A, Mansutti M, Albalen J, Martinez M, Lahuerta A, Bisagni G, Bermejo B, Semiglavov V, Thill M, Chan A, Morales S, Herranz J, Tusquets I, Chiesa M, Caballero R, Valagussa P, Bianchini G, Alba E, Gianni L. Derived neutrophil-to-lymphocyte ratio predicts pathological complete response to neoadjuvant chemotherapy in breast cancer. *Frontiers in Oncology*. 2022 Feb 11;11:827625. doi: 10.3389/fonc.2021.827625. PMID: 35223459
185. Catala-Lopez F, Driver J, Page M, Hutton B, Ridao M, Berrozpe-Villabona C, Alonso-Arroyo A, Fraga-Medin C, Bernal-Delgado E, Valencia A, Tabares-Seisdedos R. Design and methodological characteristics of studies using observational routinely collected health data for investigating the link between cancer and neurodegenerative diseases: protocol for a meta-research study. *BMJ Open*. 2022 Apr 29;12(4):e058738. doi: 10.1136/bmjopen-2021-058738. PMID: 35487732
186. Megias J, San-Miguel T, Sanchez M, Navarro L, Monleon D, Calabuig-Farinás S, Morales J, Muñoz-Hidalgo L, Roldan P, Cerdá-Nicolás M, Lopez-Gines C. Desmoplastic infantile astrocytoma with atypical phenotype, PTEN homozygous deletion and BRAF V600E mutation. *Acta Neuropathologica Communications*. 2022 Jun 20;10(1):88. doi: 10.1186/s40478-022-01392-x. PMID: 35725578
187. Rodriguez-Perez M, Tung-Chen Y, Herrera-Cubas R. Detection and semiquantification of pneumothorax through lung ultrasound: case report of a COVID-19 patient. *Enfermedades Infecciosas y Microbiología Clínica*. 2022 Nov;40(9):524-525. doi: 10.1016/j.eimc.2021.12.004. PMID: 35017770
188. Rodriguez-Perez M, Tung-Chen Y, Herrera-Cubas R. Detection and semiquantification of pneumothorax through lung ultrasound: case report of a COVID-19 patient. *Enfermedades Infecciosas y Microbiología Clínica* [english Ed]. 2022 Nov;40(9):524-525. doi: 10.1016/j.eimc.2022.06.004. PMID: 35750584
189. Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Calderon E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Serrano M, Kusec R, Elorza B, Angona A, Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalecz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Ramaldi A, Vannucchi AM. Determinants of early triage for hospitalization in MPN patients with COVID-19. *American Journal of Hematology*. 2022 Dec;97(12):E470-E473. doi: 10.1002/ajh.26732. PMID: 36111658
190. Martinez-Hervas S, Morales-Suarez-Varela MM, Andres-Blasco I, Lara-Hernandez F, Peraita-Costa I, Real JT, Garcia-Garcia AB, Chaves FJ. Developing a simple and practical decision model to predict the risk of incident type 2 diabetes among the general

# publication list

- population: the Di@bet.es Study. *European Journal of Internal Medicine*. 2022 Aug;102:80-87. doi: 10.1016/j.ejim.2022.05.005. PMID: 35570127
191. Jimenez-Rodriguez B, Alba-Bernal A, Lopez-Lopez E, Quiros-Ortega ME, Carbajosa G, Garrido-Aranda A, Alvarez M, Godoy-Ortiz A, Queipo-Ortuno MI, Viccioso L, Diaz-Cordoba G, Roldan-Diaz MD, Velasco-Suelto J, Hernando C, Bermejo B, Julve-Parreno A, Lluch A, Pascual J, Comino-Mendez I, Alba E. Development of a Novel NGS methodology for ultrasensitive circulating tumor DNA detection as a tool for early-stage breast cancer diagnosis. *International Journal of Molecular Sciences*. 2022 Dec 21;24(1):146. doi: 10.3390/ijms24010146. PMID: 36613590
192. Danne T, Ampudia-Blasco FJ, Mathieu C. Diabetes and the WHO Model List of Essential Medicines. *Lancet Diabetes & Endocrinology*. 2022 Jan;10(1):18-19. doi: 10.1016/S2213-8587(21)00322-3. PMID: 34919865
193. Cousin E, Duncan B, Stein C, et al. Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019. *Lancet Diabetes & Endocrinology*. 2022 Mar;10(3):177-192. doi: 10.1016/S2213-8587(21)00349-1. PMID: 35143780
194. Paules C, Roche M, Marin M, Fayed N, Garcia-Marti G, Pison J, Oros D, Pueyo V. Different brain phenotypes in magnetic resonance imaging of healthy children after prenatal insults. *Diagnostics*. 2022 Nov 10;12(11):2748. doi: 10.3390/diagnostics12112748. PMID: 36359591
195. Lorente-Rovira E, Grasa E, Ochoa S, Corripio I, Pelaez T, Lopez-Carrilero R, Gutierrez-Gea A, Morano-Guillen M, Villagran J, Bartels-Velthuis A, Jenner J, Sanjuan J. Different measures for auditory hallucinations in populations with psychosis. The Validation of the Spanish versions of the Auditory Vocal Hallucination Rating Scale (AVHRS) and the Positive and Useful Voices Inquiry (PUVI). *Revista de Psiquiatria y Salud Mental*. 2022 Oct-Dec;15(4):259-271. doi: 10.1016/j.rpsmen.2020.03.002. PMID: 36513402
196. Salmeron-Villalobos J, Ramis-Zaldivar J, Balague O, Verdu-Amoros J, Celis V, Sabado C, Garrido M, Mato S, Uriz J, Ortega M, Gutierrez-Camino A, Sennett D, Illarregi U, Carron M, Regueiro A, Galera A, Gonzalez-Farre B, Campo E, Garcia N, Colomer D, Astigarraga I, Andres M, Llavador M, Martin-Guerrero I, Salaverria I. Diverse mutations and structural variations contribute to Notch signalling deregulation in paediatric T-cell lymphoblastic lymphoma. *Pediatric Blood & Cancer*. 2022 Nov;69(11):e29926. doi: 10.1002/pbc.29926. PMID: 36000950
197. Stankewicz T, Ruiz Alonso M, Soler Ibanez M, Simon C, Valbuena D. Do clinical outcomes differ for day-5 versus day-6 single embryo transfers controlled for endometrial factor?. *Reproductive Biomedicine Online*. 2022 Mar;44(3):478-485. doi: 10.1016/j.rbmo.2021.11.010. PMID: 35125295
198. Herrera J, Lacomba-Trejo L, Valero-Moreno S, Montoya-Castilla I, Perez-Marin M. Do COVID-19 worries, resilience and emotional distress influence life satisfaction? Outcomes in adolescents in Ecuador during the Pandemic: SEM vs. QCA. *Children*. 2022 Mar 21;9(3):439. doi: 10.3390/children9030439. PMID: 35327811
199. Machado I, Charville GW, Yoshida A, Navarro S, Righi A, Gambarotti M, Scotlandi K, Lopez-Guerrero JA, Llombart-Bosch A. Does PAX7 and NKX2.2 immunoreactivity in Ewing sarcoma have prognostic significance?. *Virchows Archiv*. 2022 Apr;480(4):909-917. doi: 10.1007/s00428-021-03254-8. PMID: 34985580
200. Troya J, Duenas C, Irazola I, de Los Santos I, de la Fuente S, Gil D, Hernandez C, Galindo M, Gomez J, Delgado E, Moreno-Garcia E, Posada G, Aldamiz T, Iribarren J, Guerra J, Moran M, Galera C, Fuente J, Pelaez A, Cervero M, Garcinuno M, Montero M, Ceballos F, Buzon L. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. *Medicine*. 2022 Jun 17;101(24):e29252. doi: 10.1097/MD.00000000000029252. PMID: 35713430
201. Gruevska A, Moragrega A, Galindo M, Esplugues J, Blas-Garcia A, Apostolova N. Down-regulation of the longevity-associated protein SIRT1 in peripheral blood mononuclear cells of treated HIV patients. *Cells*. 2022 Jan 20;11(3):348. doi: 10.3390/cells11030348. PMID: 35159154

# publication list

202. Sabater L, Sastre J, de Madaria E. Dr. Luis Aparisi Quereda In memoriam. *Gastroenterología y Hepatología*. 2022 Oct 12;S0210-5705(22)00218-7. doi: 10.1016/j.gastrohep.2022.08.011. PMID: 36243628
203. Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. *Lancet*. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. PMID: 36356632
204. Panizo N, Albert E, Gimenez-Civera E, Puchades M, D'Marco L, Gandia-Salmeron L, Gimenez E, Torre I, Sancho A, Gavela E, Gonzalez-Rico M, Montomoli M, Perez-Baylach C, Bonilla B, Solano C, Alvarado M, Torregrosa I, Alcaraz M, Gorrioz J, Navarro D. Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within 3 months after COVID-19 full vaccination. *Clinical Kidney Journal*. 2022 Apr 9;15(8):1562-1573. doi: 10.1093/ckj/sfac093. PMID: 35880064
205. Bayes-Genis A, Nunez J, Lupon J. Dysglycaemia and high natriuretic peptides: the prelude to heart failure. *European Journal of Heart Failure*. 2022 Feb;24(2):254-256. doi: 10.1002/ejhf.2410. PMID: 34957645
206. Saini S, Perez-Cremades D, Cheng H, Kosmac K, Peterson C, Li L, Tian L, Dong G, Wu K, Bouverat B, Wohlgemuth S, Ryan T, Sufit R, Ferrucci L, McDermott M, Leeuwenburgh C, Feinberg M. Dysregulated genes, MicroRNAs, biological pathways, and gastrocnemius muscle fiber types associated with progression of peripheral artery disease: a preliminary analysis. *Journal of the American Heart Association*. 2022 Nov;11(21):e023085. doi: 10.1161/JAHA.121.023085. PMID: 36300658
207. Moreno-Perez O, Nunez J, Sandin-Rollan M, Arrarte V, Boix V, Reus S, Pinargote-Celorio H, Ribes I, Alfayate R, Llorca-Santos M, Martinez-Garcia M, Chico-Sanchez P, Merino E. Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019. *Frontiers In Cardiovascular Medicine*. 2022 Oct 20;9:941512. doi: 10.3389/fcvm.2022.941512. PMID: 36337886
208. Zattera L, Veliziotis I, Benitez-Cano A, Ramos I, Larranaga L, Nunez M, Roman L, Adalid I, Ferriando C, Munoz G, Arruti E, Minini A, Bassas E, Hernandez M, Taccone F, Peluso L, Adalia R. Early procalcitonin to predict mortality in critically ill COVID-19 patients: a multicentric cohort study. *Minerva Anestesiologica*. 2022 Apr;88(4):259-271. doi: 10.23736/S0375-9393.22.15942-0. PMID: 35072432
209. Panach-Navarrete J, Martinez-Montava E, Gil-Viana R, Valls-Gonzalez L, Martinez-Jabaloyas J. Early ultrasound after endoscopic puncture of ureterocele: signs that show surgical treatment success. *Archivos Espanoles de Urologia*. 2022 Aug;75(6):567-571. doi: 10.37554/es-j.arch.esp.urol-20210119-3532-31. PMID: 36138507
210. Alonso J, Casans I, Gonzalez F, Fuster D, Rodriguez A, Sanchez N, Oyaguez I, Burgos R, Williams A, Espinoza N. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review. *BMC Gastroenterology*. 2022 Jul 2;22(1):326. doi: 10.1186/s12876-022-02396-6. PMID: 35780112
211. Robinson E, Novella S. Editorial: Genetic and gene regulation underlying sex differences in cardiovascular disease. *Frontiers in Cardiovascular Medicine*. 2022 Apr 11;9:881154. doi: 10.3389/fcvm.2022.881154. PMID: 35479282
212. Provenzano M, Garofalo C, Gorrioz J, Andreucci M. Editorial: management of patients with non-dialysis dependent chronic kidney disease (ND-CKD). *Frontiers in Medicine*. 2022 Feb 3;8:827245. doi: 10.3389/fmed.2021.827245. PMID: 35186981
213. Perez-Rando M, Castillo-Gomez E. Editorial: Neurotrophins and their importance on neural plasticity: new insights and potential therapeutic effects on brain pathology. *Frontiers in Molecular Neuroscience*. 2022 Nov 15;15:1082116. doi: 10.3389/fnmol.2022.1082116. PMID: 36458197
214. Browne C, Conant K, Lasek A, Nacher J. Editorial: perineuronal nets as therapeutic targets for the treatment of neuropsychiatric disorders. *Frontiers in Synaptic Neuroscience*. 2022 Jun 10;14:889800. doi: 10.3389/fnsyn.2022.889800. PMID: 35782789

# publication list

215. Novella S, Moreau K, Dantas A. Editorial: Sex differences in molecular mechanisms of cardiovascular aging. *Frontiers in Aging*. 2022 Mar 23;3:854714. doi: 10.3389/fragi.2022.854714. PMID: 35821829
216. Priego-Quesada J, Catala-Vilaplana I, Bermejo-Ruiz J, Gandia-Soriano A, Pellicer-Chenoll M, Encarnacion-Martinez A, Cibrian Ortiz de Anda R, Salvador-Palmer R. Effect of 10 km run on lower limb skin temperature and thermal response after a cold-stress test over the following 24 h. *Journal of Thermal Biology*. 2022 Apr;105:103225. doi: 10.1016/j.jtherbio.2022.103225. PMID: 35393059
217. Munoz-Gomez E, Ingles M, Aguilar-Rodriguez M, Molla-Casanova S, Sempere-Rubio N, Serra-Ano P, Espi-Lopez G. Effect of a craniosacral therapy protocol in people with migraine: a randomized controlled trial. *Journal of Clinical Medicine*. 2022 Jan 30;11(3):759. doi: 10.3390/jcm11030759. PMID: 35160211
218. Palau P, Dominguez E, Gonzalez C, Bondia E, Albiach C, Sastre C, Martinez M, Nunez J, Lopez L. Effect of a home-based inspiratory muscle training programme on functional capacity in postdischarged patients with long COVID: the InsCOVID trial. *BMJ Open Respiratory Research*. 2022 Dec;9(1):e001439. doi: 10.1136/bmjresp-2022-001439. PMID: 36549786
219. Palau P, Dominguez E, Sastre C, Martinez M, Gonzalez C, Bondia E, Albiach C, Nunez J, Lopez L. Effect of a home-based inspiratory muscular training programme on functional capacity in patients with chronic COVID-19 after a hospital discharge: protocol for a randomised control trial (InsCOVID trial). *BMJ Open Respiratory Research*. 2022 Jul;9(1):e001255. doi: 10.1136/bmjresp-2022-001255. PMID: 35790316
220. Gu Hong W, Ferri J, Ampudia-Blasco F, Martin-Bru-fau R, Peiro M, Benito E, Martinez-Hervas S, Sanz M, Real J. Effect of personality on blood glucose control in patients with type 1 diabetes. *Endocrinologia, Diabetes y Nutricion*. 2022 Nov;69(9):677-685. doi: 10.1016/j.endien.2021.11.034. PMID: 36470643
221. Espi-Lopez G, Ingles M, Carrasco-Fernandez J, Serra-Ano P, Copete-Fajardo L, Gonzalez-Gerez J, Saavedra-Hernandez M, Marques-Sule E. Effects of foam rolling vs. manual therapy in patients with tension-type headache: a randomized pilot study. *Journal of Clinical Medicine*. 2022 Mar 23;11(7):1778. doi: 10.3390/jcm11071778. PMID: 35407385
222. Tresguerres J, Fernandez-Tresguerres I, Vina J, Rancan L, Paredes S, Linillos-Pradillo B, Vara E. Effects of GH on the aging process in several organs: mechanisms of action. *International Journal of Molecular Sciences*. 2022 Jul 16;23(14):7848. doi: 10.3390/ijms23147848. PMID: 35887196
223. Garcia-de-la-Asuncion J, Moreno T, Duca A, Garcia-del-Olmo N, Perez-Griera J, Belda J, Soro M, Garcia-del-Olmo E. Effects of remote ischemic preconditioning on HIF-1 alpha and other markers in on-pump cardiac surgery. *General Thoracic and Cardiovascular Surgery*. 2022 Mar;70(3):239-247. doi: 10.1007/s11748-021-01690-6. PMID: 34378159
224. Gene-Morales J, Gene-Sampedro A, Salvador-Palmer R, Colado JC. Effects of squatting with elastic bands or conventional resistance-training equipment at different effort levels in post-exercise intraocular pressure of healthy men. *Biology of Sport*. 2022 Oct;39(4):895-903. doi: 10.5114/biolsport.2022.109955. PMID: 36247937
225. D'Erasmo L, Steward K, Cefalu A, Di Costanzo A, Boersma E, Bini S, Arca M, van Lenep J, Real Collado J, Italian and European Working Group on Lomitapide in HoFH. Efficacy and safety of lomitapide in homozygous familial hypercholesterolemia: the pan-European retrospective observational study. *European Journal of Preventive Cardiology*. 2022 May;5;29(5):832-841. doi: 10.1093/eurjpc/zwb229. PMID: 34971394
226. Civera J, de la Espriella R, Heredia R, Minana G, Santas E, Conesa A, Mollar A, Sastre C, Martinez A, Villaescusa A, Nunez J. Efficacy and safety of subcutaneous infusion of non-formulated furosemide in patients with worsening heart failure: a real-world study. *Journal of Cardiovascular Translational Research*. 2022 Jun;15(3):644-652. doi: 10.1007/s12265-021-10173-1. PMID: 34642870
227. Munoz-Rivas N, Aibar J, Gabara-Xanco C, Trueba-

# 9 publication list

- Vicente A, Urbelz-Perez A, Gomez-Del Olmo V, Demelo-Rodriguez P, Rivera-Gallego A, Bosch-Nicolau P, Perez-Pinar M, Rios-Prego M, Madridano-Cobo O, Ramos-Alonso L, Alonso-Carrillo J, Francisco-Albella I, Marti-Saez E, Maestre-Peiro A, Mendez-Bailon M, Hernandez-Rivas JA, Torres-Macho J. Efficacy and safety of tinzaparin in prophylactic, intermediate and therapeutic doses in non-critically ill patients hospitalized with COVID-19: the PROTHROMCOVID randomized controlled trial. *Journal of Clinical Medicine.* 2022 Sep 24;11(19):5632. doi: 10.3390/jcm11195632. PMID: 36233500
- 228.D'Erasmo L, Giammanco A, Suppressa P, Pavanello C, Iannuzzo G, Di Costanzo A, Tramontano D, Minicocci I, Bini S, Vogt A, Stewards K, Van Lennep J, Bertolini S, Arca M. Efficacy of long-term treatment of autosomal recessive hypercholesterolemia with lomitapide: a subanalysis of the Pan-European Lomitapide Study. *Frontiers in Genetics.* 2022 Aug 22;13:937750. doi: 10.3389/fgene.2022.937750. PMID: 36072671
- 229.O'Cearbhail R, Perez-Fidalgo J, Monk B, Tusquets I, McCormick C, Fuentes J, Moore R, Vulsteke C, Shahin M, Forget F, Bradley W, Hietanen S, O'Malley D, Dorum A, Slomovitz B, Baumann K, Selle F, Calvert P, Artioli G, Levy T, Kumar A, Malinowska I, Li Y, Gupta D, Gonzalez-Martin A. Efficacy of niraparib by time of surgery and postoperative residual disease status: a post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. *Gynecologic Oncology.* 2022 Jul;166(1):36-43. doi: 10.1016/j.ygyno.2022.04.012. PMID: 35550709
- 230.NIHR Global Health Unit on Global Surgery; COVID-Surg Collaborative. Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries. *Lancet.* 2022 Nov 5;400(10363):1607-1617. doi: 10.1016/S0140-6736(22)01846-3. PMID: 36328042
- 231.Mendoza N, Ramirez I, de la Viuda E, et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. *Maturitas.* 2022 Aug 30;166:65-85. doi: 10.1016/j.maturitas.2022.08.008. PMID: 36081216
- 232.Negueroles-Garcia M, Pastor-Hernandez F, Martinez-Jabaloyas J. Emergency radical nephrectomy in a polytrauma patient. *Archivos Espanoles de Urologia.* 2022 Oct;75(8):736-737. doi: 10.56434/j.arch.esp.urol.20227508.107. PMID: 36330577
- 233.Cuello M, Valero-Moreno S, Herrera J, Lacomba-Trejo L, Perez-Marin M. Emotional IMPACT IN ADOLESCENTS in Ecuador six months after the beginning of the COVID-19 Pandemic. *Journal of Psychology.* 2022;156(5):381-394. doi: 10.1080/00223980.2022.2054921. PMID: 35482962
- 234.Simon C. Endometrial factor testing is a useful tool in clinical infertility management. *Reproductive Biomedicine Online.* 2022 Jun;44(6):953-960. doi: 10.1016/j.rbmo.2021.12.014. PMID: 35221254
- 235.Moreno I, Garcia-Grau I, Perez-Villaroya D, Gonzalez-Monfort M, Bahceci M, Barrionuevo MJ, Taguchi S, Puente E, Dimattina M, Lim MW, Meneghini G, Aubuchon M, Leondires M, Izquierdo A, Perez-Olgiati M, Chavez A, Seethram K, Bau D, Gomez C, Valbuena D, Vilella F, Simon C. Endometrial microbiota composition is associated with reproductive outcome in infertile patients. *Microbiome.* 2022 Jan 4;10(1):1. doi: 10.1186/s40168-021-01184-w. PMID: 34980280
- 236.Yang D, Haemmig S, Chen J, McCoy M, Cheng H, Zhou H, Cheng X, Sun X, Haneo-Mejia J, Vellarakkal S, Gupta R, Barrera V, Perez Cremades D, Feinberg M. Endothelial cell-specific deletion of a microRNA accelerates atherosclerosis. *Atherosclerosis.* 2022 Jun;350:9-18. doi: 10.1016/j.atherosclerosis.2022.04.010. PMID: 35462240
- 237.Perez-Pelegrí M, Monmeneu J, Lopez-Lereu M, Maceira A, Bodi V, Moratal D. End-systole and end-diastole detection in short axis cine MRI using a fully convolutional neural network with dilated convolutions. *Computerized Medical Imaging and Graphics.* 2022 Jun 3;99:102085. doi: 10.1016/j.compmedimag.2022.102085. PMID: 35689982
- 238.Sobel M, Navas-Acien A, Powers M, Grau-Perez M, Goessler W, Best LG, Umans J, Oelsner EC, Podalanczuk A, Sanchez TR. Environmental-level

# publication list

- exposure to metals and metal-mixtures associated with spirometry-defined lung disease in American Indian adults: evidence from the Strong Heart Study. *Environmental Research.* 2022 May 1;207:112194. doi: 10.1016/j.envres.2021.112194. PMID: 34653410
239. Rios-Navarro C, Gavara J, Nunez J, Revuelta-Lopez E, Monmeneu JV, Lopez-Lereu MP, de Dios E, Perez-Sole N, Vila JM, Oltra R, Chorro FJ, Bayes-Genis A, Bodí V. EpCAM and microvascular obstruction in patients with STEMI: a cardiac magnetic resonance study. *Revista Espanola de Cardiologia* [English ed.]. 2022 May;75(5):384-391. doi: 10.1016/j.rec.2021.04.006. PMID: 34045168
240. Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Telez MJ, Dominguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero-Roman A, Santos I, Giner L, Arminanzas C, Montero M, Manzano C, Cifuentes C, Garcia C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodriguez C, Gaspar G, Perez L, Losa JE, Force L, Veloso S, Martinez-Alfaro E, Jarrin I, De Miguel M, Gonzalez Garcia J. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. *HIV Medicine.* 2022 Aug;23(7):705-716. doi: 10.1111/hiv.13229. PMID: 35037379
241. Quintana-Diaz M, Nanwani-Nanwani K, Marcos-Neira P, Serrano-Lazaro A, Juarez-Vela R, Andres-Esteban E. Epidemiology of blood transfusion in the Spanish Critical Care Units: «Transfusion Day». *Medicina Intensiva* [English ed]. 2022 Mar;46(3):123-131. doi: 10.1016/j.medine.2021.12.006. PMID: 34996742
242. Asensio A, Vallejo-Plaza A, Parra L, Orti-Bordas R, Salcedo I, Ramos A, Cantero M. Epidemiology of Clostridioides difficile infection in hospitalized patients in Spain: an eight-year review (2012-2019). *Enfermedades Infecciosas y Microbiología Clínica.* 2022 Mar;40(3):125-130. doi: 10.1016/j.eimc.2021.04.008. PMID: 35249672
243. Ortiz-Zapater E, Bagley D, Hernandez V, Roberts L, Maguire T, Voss F, Mertins P, Kirchner M, Peset-Martin I, Woszczeck G, Rosenblatt J, Gotthardt M, Santis G, Parsons M. Epithelial coxsackievirus adenovirus receptor promotes house dust mite-induced lung inflammation. *Nature Communications.* 2022 Oct 27;13(1):6407. doi: 10.1038/s41467-022-33882-w. PMID: 36302767
244. Fernandez-Domper L, Redondo M, De Dios M, Gonzalez H, Boixeda P. Erythema Ab Igne successfully treated with a 755-nm alexandrite picosecond laser. *Lasers in Medical Science.* 2022 Jun;37(4):2321-2322. doi: 10.1007/s10103-021-03459-y. PMID: 34750732
245. Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski R, Curigliano G, Felip E, Ferreira A, Ganz P, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge A, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. *Annals of Oncology.* 2022 Nov;33(11):1119-1133. doi: 10.1016/j.annonc.2022.07.1941. PMID: 35963481
246. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. *Annals of Oncology.* 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. PMID: 35809752
247. GBD 2019 Diabetes and Air Pollution Collaborators. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM<sub>2.5</sub> air pollution, 1990-2019: an analysis of data from the Global Burden of Disease Study 2019. *Lancet Planetary Health.* 2022 Jul;6(7):e586-e600. doi: 10.1016/S2542-5196(22)00122-X. PMID: 35809588
248. Nichols E, Steinmetz J, Vollset S, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease 2019. *Lancet Public Health.* 2022 Feb;7(2):e105-e125. doi: 10.1016/S2468-2667(21)00249-8. PMID: 34998485

# publication list

249. Perez-Rando M, Guirado R, Tellez-Merlo G, Carceler H, Nacher J. Estradiol regulates PSA-NCAM expression and connectivity of O-LM interneurons in the hippocampus of adult female mice. *Neuroendocrinology*. 2022;112(1):51-67. doi: 10.1159/000515052. PMID: 33550289
250. Ayesta A, Bonanad C, Diez-Villanueva P, Garcia-Blas S, Ariza-Sole A, Martinez-Selles M. Ethical considerations in elderly patients with acute coronary syndrome. *Reviews in Cardiovascular Medicine*. 2022 Feb 11;23(2):55. doi: 10.31083/j.rcm2302055. PMID: 35229546
251. Rodriguez Ruzafa M, Carrasco Picazo JP, Junqueira Fernandez G, Aguilar Garcia-Iturrospe EJ. EUROLD: preliminary results of the ecological study on suicide and its associated socioeconomic variables in people over 85 in Europe. *International Psychogeriatrics*. 2022 Feb 28;1-3. doi: 10.1017/S1041610222000072. PMID: 35225213
252. Bataller A, Garrido A, Guijarro F, Onate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, de Llano M, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Guinon A, Salamero O, Sampol A, Merchan B, Bargay J, Castano-Diez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, Lopez-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu J, Colomer D, Brunet S, Sierra J, Esteve J. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. *Blood Advances*. 2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585. PMID: 34911079
253. Machado I, Bujeda A, Giner F, Morales M, Cruz J, Lavernia J, Navarro S, Fernandez A, Ruiz-Sauri A, Llombart-Bosch A. Evaluation of alternative risk stratification systems in a large series of solitary fibrous tumors with molecular findings and Ki-67 Index Data: do they improve risk assessment?. *International Journal of Molecular Sciences*. 2022 Dec 27;24(1):439. doi: 10.3390/ijms24010439. PMID: 36613891
254. Roger I, Montero P, Garcia A, Milara J, Ribera P, Perez-Fidalgo JA, Cortijo J. Evaluation of antineoplastic delayed-type hypersensitivity skin reactions in vitro. *Pharmaceuticals*. 2022 Sep 6;15(9):1111. doi: 10.3390/ph15091111. PMID: 36145332
255. Miro O, Espinosa B, Gil V, Jacob J, Alquezar-Arbe A, Masip J, Llauger L, Tost J, Andueza J, Garrido J, Mojarror E, Urbano C, Nunez J, Chioncel O, Mullens W, Cotter G, Llorens P. Evaluation of the effect of intravenous nitroglycerine on short-term survival of patients with acute heart failure according to congestion and perfusion status at emergency department arrival. *European Journal of Emergency Medicine*. 2022 Dec 1;29(6):437-449. doi: 10.1097/MEJ.0000000000000964. PMID: 35861663
256. Cabrera L, Trapero I. Evaluation of the effectiveness of breastfeeding as a factor in the prevention of breast cancer. *Endocrine, Metabolic & Immune Disorders Drug Targets*. 2022;22(1):15-25. doi: 10.2174/1871530321666210427083707. PMID: 33906596
257. Stute P, Cano A, Thurston R, Small M, Lee L, Scott M, Siddiqui E, Schultz N. Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States. *Maturitas*. 2022 Jun 23;164:38-45. doi: 10.1016/j.maturitas.2022.06.008. PMID: 35785563
258. Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jimenez A, Brunet S, Casano J, Ojartzabal I, Diez-Campelo M, Ramos F, Romero R, Salido-Fierrez E, Pedro C, Bargay J, Munoz-Novas C, Lopez R, Rafel M, Valcarcel D. Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice. *Leukemia & Lymphoma*. 2022 Dec 28;1-12. doi: 10.1080/10428194.2022.2154604. PMID: 36577016
259. Bonanad C, Raposeiras-Roubin S, Garcia-Blas S, Nunez-Gil I, Vergara-Uzcategui C, Diez-Villanueva P, Baneras J, Molins C, Aboal J, Carreras J, Bodi V, Gabaldon-Perez A, Mateus-Porta G, Barcia J, Martinez-Selles M, Chorro F, Ariza-Sole A. Evaluation of the use of dual antiplatelet therapy beyond the first year after acute coronary syndrome. *Journal of Clinical Medicine*. 2022 Mar 17;11(6):1680. doi: 10.3390/jcm11061680. PMID: 35330004
260. Gimenez E, Alberola J, Torres I, Albert E, Alcaraz MJ, Botija P, Amat P, Remigia MJ, Beltran MJ,

# publication list

- Rodado C, Huntley D, Olea B, Navarro D. Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty COVID-19 vaccine. *Journal of Infection*. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.10.026. PMID: 34740744
261. Pata F, Di Martino M, Podda M, Di Saverio S, Ielpo B, Pellino G. Evolving trends in the management of acute appendicitis during COVID-19 waves: the ACIE Appy II Study. *World Journal of Surgery*. 2022 Sep;46(9):2021-2035. doi: 10.1007/s00268-022-06649-z. PMID: 35810215
262. Fusar-Poli L, Pries L, van Os J, Erzin G, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altinyazar V, Yalincetin B, Gumus-Akay G, Cihan B, Soygur H, Ulas H, Cankurtaran E, Kavymak S, Mihaljevic M, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, Garcia-Portilla M, Sanjuan J, Aguilar E, Santos J, Jimenez-Lopez E, Arrojo M, Carracedo A, Lopez G, Gonzalez-Penas J, Parellada M, Maric N, Atbasoglu C, Ucok A, Alptekin K, Saka M, Aguglia E, Arango C, O'Donovan M, Rutten B, Guloksuz S, Genetic Risk Outcome Psychosis Grp. Examining facial emotion recognition as an intermediate phenotype for psychosis: findings from the EUGEI study. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2022 Mar 8;113:110440. doi: 10.1016/j.pnpbp.2021.110440. PMID: 34536513
263. Rasulo F, Badenes R, Longhitano Y, Racca F, Zanza C, Marchesi M, Piva S, Beretta S, Nocivelli G, Matta B, Cunningham D, Cattaneo S, Savioli G, Franceschi F, Robba C, Latronico N. Excessive sedation as a risk factor for delirium: a comparison between two cohorts of ARDS critically ill patients with and without COVID-19. *Life*. 2022 Dec 5;12(12):2031. doi: 10.3390/life12122031. PMID: 36556396
264. Marcos-Garces V, Merenciano-Gonzalez H, Gabaldon-Perez A, Nunez-Marin G, Lorenzo-Hernandez M, Gavara J, Perez N, Rios-Navarro C, De Dios E, Bonanad C, Racugno P, Lopez-Lereu MP, Monmeneu JV, Chorro FJ, Bodi V. Exercise ECG Testing and stress cardiac magnetic resonance for risk prediction in patients with chronic coronary syndrome. *Journal of Cardiopulmonary Rehabilitation and Prevention*. 2022 Jan 1;42(1):E7-E12.
- doi: 10.1097/HCR.0000000000000621. PMID: 34561369
265. Dufresne S, Gueritat J, Wong CP, Isanejad A, Ho E, Serna E, Gomez-Cabrera MC, Rebillard A. Exercise training as a modulator of epigenetic events in prostate tumors. *Prostate cancer and prostatic diseases*. 2022 Mar;25(1):119-122. doi: 10.1038/s41391-021-00380-x. PMID: 34007020
266. Riffó-Campos A, Pérez-Hernández J, Ortega A, Martínez-Arroyo O, Flores-Chova A, Redón J, Cortés R. Exosomal and plasma non-coding RNA signature associated with urinary albumin excretion in hypertension. *International Journal of Molecular Sciences*. 2022 Jan 13;23(2):823. doi: 10.3390/ijms23020823. PMID: 35055008
267. Beltrán-García J, Osca-Verdegal R, Pérez-Cremades D, Novella S, Hermenegildo C, Pallardó FV, García-Giménez JL. Extracellular histones activate endothelial NLRP3 inflammasome and are associated with a severe sepsis phenotype. *Journal of Inflammation Research*. 2022 Jul 25;15:4217-4238. doi: 10.2147/JIR.S363693. PMID: 35915852
268. Pérez-Cremades D, Bueno-Beti C, García-Giménez J, Ibáñez-Cabellos J, Pallardo F, Hermenegildo C, Novella S. Extracellular histones trigger oxidative stress-dependent induction of the NF-κB/CAM pathway via TLR4 in endothelial cells. *Journal of Physiology and Biochemistry*. 2022 Dec 5. doi: 10.1007/s13105-022-00935-z. PMID: 36464762
269. Cinotti R, Mijangos JC, Pelosi P, Haenggi M, Gurjar M, Schultz MJ, Kaye C, Godoy DA, Alvarez P, Ioakeimidou A, Ueno Y, Badenes R, Elbuzidi AAS, Piagnerelli M, Elhadi M, Reza ST, Azab MA, McCredie V, Stevens RD, Digitale JC, Fong N, Asehnoune K. Extubation in neurocritical care patients: the ENIO international prospective study. *Intensive Care Medicine*. 2022 Nov;48(11):1539-1550. doi: 10.1007/s00134-022-06825-8. PMID: 36038713
270. Tripoli G, Quattrone D, Ferraro L, Gayer-Anderson C, La Cascia C, La Barbera D, Sartorio C, Semineiro F, Rodriguez V, Tarricone I, Berardi D, Jamain S, Arango C, Tortelli A, Llorca P, de Haan L, Velthorst E, Bobes J, Bernardo M, Sanjuan J, Santos J, Arrojo M, Del-Ben C, Menezes P, van der Ven E, Jones

# publication list

- P, Jongsma H, Kirkbride J, Tosato S, Lasalvia A, Richards A, O'Donovan M, Rutten B, van Os J, Morgan C, Sham P, Di Forti M, Murray R, Murray G. Facial emotion recognition in psychosis and associations with polygenic risk for schizophrenia: findings from the multi-center EU-GEI case-control study. *Schizophrenia Bulletin*. 2022 Sep; 148(5):1104-1114. doi: 10.1093/schbul/sbac022. PMID: 35325253
271. Jorda A, Aldasoro M, Campo-Palacio I, Vila JM, Aldasoro C, Campos-Campos J, Colmena C, Singh SK, Obrdor E, Valles SL. Facilitation of insulin effects by ranolazine in astrocytes in primary culture. *International Journal of Molecular Sciences*. 2022 Oct 9;23(19):11969. doi: 10.3390/ijms231911969. PMID: 36233271
272. Cabedo E, Prieto J, Quiles L, Arnaez S, Rivas M, Riveiro Y, Aguilar E, Renovell M. Factores asociados a impacto emocional de la pandemia por COVID-19 en profesionales sanitarios. *Behavioral Psychology*. 2022; 30(1): 69-91. doi: 10.51668/bp.8322104s
273. Mangas-Sanjuan C, Seoane A, Alvarez-Gonzalez M, Lue A, Suarez A, Alvarez-Garcia V, Bujanda L, Portillo I, Gonzalez N, Cid-Gomez L, Cubiella J, Rodriguez-Camacho E, Ponce M, Diez-Redondo P, Herranz M, Pellise M, Ono A, Baile-Maxia S, Medina-Prado L, Murcia O, Zapater P, Jover R. Factors associated with lesion detection in colonoscopy among different indications. *United European Gastroenterology Journal*. 2022 Nov;10(9):1008-1019. doi: 10.1002/ueg2.12325. PMID: 36300971
274. Blasco J, Perez-Maletzki J, Diaz-Diaz B, Silvestre-Munoz A, Martinez-Garrido I, Roig-Casasus S. Fall classification, incidence and circumstances in patients undergoing total knee replacement. *Scientific Reports*. 2022 Nov 18;12(1):19839. doi: 10.1038/s41598-022-23258-x. PMID: 36400816
275. Huguet J, Cortes X, Bosca-Watts M, Munoz M, Maroto N, Iborra M, Hinojosa E, Capilla M, Asencio C, Amoros C, Paredes J. Ferric carboxymaltose improves the quality of life of patients with inflammatory bowel disease and iron deficiency without anaemia. *Journal of Clinical Medicine*. 2022 May 15;11(10):2786. doi: 10.3390/jcm11102786. PMID: 35628914
276. Fell C, Hagelkruys A, Cicvaric A, Horrer M, Liu L, Li J, Stadlmann J, Polyansky A, Mereiter S, Tejada M, Kokotovic T, Achuta V, Scaramuzza A, Twyman K, Morrow M, Juusola J, Yan H, Wang J, Burmeister M, Choudhury B, Andersen T, Wirnsberger G, Holmskov U, Perrimon N, Aagrovic B, Monje F, Moeller J, Penninger J, Nagy V. FIBCD1 is an endocytic GAG receptor associated with a novel neurodevelopmental disorder. *EMBO Molecular Medicine*. 2022 Sep 7;14(9):e15829. doi: 10.15252/emmm.202215829. PMID: 35916241
277. Pérez Pérez A, Ortega Martínez de Victoria E, Arrieta Blanco F, Caixàs Pedragós A, Santos Mazo E, Fernandez-Catalina P, Martínez-Hervas S, López-Medina JA, Suárez-Gutiérrez L, Urgeles Planelles JR, Gatell Menchén S, Tinahones Madueño F. First clinical and efficacy data on evolocumab in routine clinical practice in endocrinology and nutrition services in Spain: a retrospective observational study [RETOSS-ENDO]. *Endocrinología, Diabetes y Nutrición*. 2022 Aug-Sep;69(7):540-542. doi: 10.1016/j.endien.2021.07.002. PMID: 35995680
278. Italiano A, Cassier PA, Lin C, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. *Cancer Immunotherapy*. 2022 Feb;71(2):417-431. doi: 10.1007/s00262-021-02973-w. PMID: 34216247
279. Kim T, Burris H, de Miguel Luken M, Pishvaian M, Bang Y, Gordon M, Awada A, Camidge D, Hodi F, McArthur G, Miller W, Cervantes A, Chow L, Lesokhin A, Rutten A, Sznol M, Rishipathak D, Chen S, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu L. First-in-human phase I Study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. *Clinical Cancer Research*. 2022 Aug 15;28(16):3452-3463. doi: 10.1158/1078-0432.CCR-21-4020. PMID: 35699599
280. Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Corstinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollyn

# publication list

- H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrerlimab (JNJ-63723283) in patients with advanced cancers. *Cancer Chemotherapy and Pharmacology*. 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6. PMID: 35298698
281. Moral R, Monteagudo C, Muriel J, Moreno L, Peiro A. Fluorescent in situ hybridization (FISH): a useful diagnostic tool for childhood conjunctival melanoma. *European Journal of Ophthalmology*. 2022 Nov;32(6):NP13-NP19. doi: 10.1177/11206721211030775. PMID: 34240653
282. Diaz-Garcia C, Herraiz S, Pamplona L, Subira J, Soriano M, Simon C, Seli E, Pellicer A. Follicular activation in women previously diagnosed with poor ovarian response: a randomized, controlled trial. *Fertility and Sterility*. 2022 Apr;117(4):747-755. doi: 10.1016/j.fertnstert.2021.12.034. PMID: 35367015
283. Marcos-Garces V, Rios-Navarro C, Gomez-Torres F, Gavara J, de Dios E, Diaz A, Minana G, Chorro F, Bodi V, Ruiz-Sauri A. Fourier analysis of collagen bundle orientation in myocardial infarction scars. *Histochemistry and Cell Biology*. 2022 Nov;158(5):471-483. doi: 10.1007/s00418-022-02132-x. PMID: 35948735
284. Mortier P, Vilagut G, Alayo I, Ferrer M, Amigo F, Aragonès E, Aragón-Peña A, Asúnsolo Del Barco A, Campos M, Espuga M, González-Pinto A, Haro JM, López Fresneña N, Martínez de Salazar A, Molina JD, Ortí-Lucas RM, Parellada M, Pelayo-Terán JM, Pérez-Gómez B, Pérez-Zapata A, Pijoan JI, Plana N, Polentinos-Castro E, Portillo-Van Diest A, Puig MT, Rius C, Sanz F, Serra C, Urreta-Barallobre I, Kessler RC, Bruffaerts R, Vieta E, Pérez-Solá V, Alonso J. Four-month incidence of suicidal thoughts and behaviors among healthcare workers after the first wave of the Spain COVID-19 pandemic. *Journal of Psychiatric Research*. 2022 May;149:10-17. doi: 10.1016/j.jpsychires.2022.02.009. PMID: 35217315
285. Jimenez-Mendez C, Diez-Villanueva P, Bonanad C, Ortiz-Cortes C, Barge-Caballero E, Goirigolzarri J, Esteban-Fernandez A, Perez-Rivera A, Cobo M, Lopez J, Sanz-Garcia A, Guerrero C, Pardo H, Robles C, Iglesias D, Manuel Garcia Pinilla J, Rodriguez L, Formiga F, Javier Martin-Sanchez F, Vidan M, Ariza A, Martinez-Selles M, Alfonso F. Fragilidad y pronostico de los pacientes mayores con insuficiencia cardiaca. *Revista Espanola de Cardiologia (English Ed.)*. 2022 Dec;75(12):1011-1019. doi: 10.1016/j.rec.2022.04.016. PMID: 35718066
286. Mollar A, Bonanad C, Diez-Villanueva P, Segarra D, Civera J, Sastre C, Conesa A, Villaescusa A, Fernández J, Miñana G, Navarro J, Sanchis J, Núñez J. Frailty and hospitalization burden in patients with chronic heart failure. *American Journal of Cardiology*. 2022 Nov 15;183:48-54. doi: 10.1016/j.amjcard.2022.08.013. PMID: 36153181
287. Munoz Lasso D, Molla B, Saenz Gamboa J, Insuasty E, de la Iglesia Vaya M, Pook M, Pallardo F, Palau F, Gonzalez-Cabo P. Frataxin deficit leads to reduced dynamics of growth cones in dorsal root ganglia neurons of Friedreich's Ataxia YG8sR model: a multilinear algebra approach. *Frontiers in Molecular Neuroscience*. 2022 Jun 13;15:912780. doi: 10.3389/fnmol.2022.912780. PMID: 35769335
288. Shi Z, Wulfkuhle J, Nowicka M, Gallagher RI, Saura C, Nuciforo PG, Calvo I, Andersen J, Passos Coelho JL, Gil Gil MJ, Bermejo B, Pratt DA, Ciruelos EM, Villagrasa P, Wongchenko MJ, Petricoin EF, Oliveira M, Isakoff SJ. Functional mapping of AKT signaling and biomarkers of response from the FAIRLANE Trial of neoadjuvant ipatasertib plus paclitaxel for triple-negative breast cancer. *Clinical Cancer Research*. 2022 Mar 1;28(5):993-1003. doi: 10.1158/1078-0432.CCR-21-2498. PMID: 34907082
289. Ingles M, Belenguer-Varea A, Serna E, Mas-Bargues C, Tarazona-Santabalbina F, Borrás C, Vina J. Functional transcriptomic analysis of centenarians' offspring reveals a specific genetic footprint that may explain that they are less frail than age-matched non-centenarians' offspring. *The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*. 2022 Oct 6;77(10):1931-1938. doi: 10.1093/gerona/glac119. PMID: 35640160
290. Abiétar DG, Beltrán Aguirre JL, García AM, García-Armesto S, Gutiérrez-Ibarluzea I, Segura-

# publication list

- Benedicto A, Franco M, Hernández-Aguado I, en nombre del Grupo de Trabajo de SESPAS sobre la Agencia Estatal de Salud Pública. Future National Public Health Agency: an opportunity for the public health system in Spain. *Gaceta Sanitaria*. 2022 May-Jun;36(3):265-269. doi: 10.1016/j.gaceta.2021.12.001. PMID: 35120795
291. Rio-Aige K, Girbal M, Selma-Royo M, Parra-Llorca A, Gonzalez S, Martinez-Costa C, Castell M, Collado M, Perez-Cano F, Rodriguez-Lagunas M. Galectins-1,3 and-9 are present in breast milk and have a role in early life development. *Nutrients*. 2022 Oct 17;14(20):4338. doi: 10.3390/nu14204338. PMID: 36297023
292. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth E. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology*. 2022 Oct;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. PMID: 35914639
293. Pereira F, Serrano A, Manzanedo I, Perez-Viejo E, Gonzalez-Moreno S, Gonzalez-Bayon L, Arjona-Sanchez A, Torres J, Ramos I, Barrios ME, Cascales P, Morales R, Boldo E, Garcia-Fadrique A, Arteaga X, Gutierrez-Calvo A, Sanchez-Garcia S, Asensio E, Ramirez CP, Artiles M, Vaque J, Parra PA, Villarejo P, Munoz-Casares C, Turienzo E, Calero A, Jaen Torrejimeno I, Prieto I, Galindo J, Borrego V, Marcelllo ME, Rihuete C, Carrasco J, Gomez-Quiles L. GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomycin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. *BMC Cancer*. 2022 May 12;22(1):536. doi: 10.1186/s12885-022-09572-7. PMID: 35549912
294. Galvez-Fernandez M, Sanchez-Saez F, Domingo-Reilloso A, Rodriguez-Hernandez Z, Tarazona S, Gonzalez-Marrachelli V, Grau-Perez M, Morales-Tatay J, Amigo N, Garcia-Barrera T, Gomez-Ariza J, Chaves F, Garcia-Garcia A, Melero R, Tellez-Plaza M, Martin-Escudero J, Redon J, Monleon D. Gene-environment interaction analysis of redox-related metals and genetic variants with plasma metabolic patterns in a general population from Spain: the Hortega Study. *Redox Biology*. 2022 Jun;52:102314. doi: 10.1016/j.
- redox.2022.102314. PMID: 35460952
295. Baptista MJ, Tapia G, Munoz-Marmol AM, Muncunill J, Garcia O, Montoto S, Gribben JG, Calaminici M, Martinez A, Veloza L, Martinez-Trillos A, Aldamiz T, Menarguez J, Terol MJ, Fernandez A, Alcoceba M, Briones J, Gonzalez-Barca E, Climent F, Muntanola A, Moraleda JM, Provencio M, Abrisqueta P, Abella E, Colomo L, Garcia-Ballesteros C, Garcia-Caro M, Sancho JM, Ribera JM, Mate JL, Navarro JT. Genetic and phenotypic characterization of HIV-associated aggressive B-cell non-Hodgkin lymphomas, that do not occur specifically in this population: diagnostic and prognostic implications. *Histopathology*. 2022 Dec;81(6):826-840. doi: 10.1111/his.14798. PMID: 36109172
296. Pignon B, Peyre H, Ayrolles A, Kirkbride JB, Jemain S, Ferchiou A, Richard JR, Baudin G, Tosato S, Jongsma H, de Haan L, Tarricone I, Bernardo M, Velthorst E, Braca M, Arango C, Arrojo M, Bobes J, Del-Ben CM, Di Forti M, Gayer-Anderson C, Jones PB, La Cascia C, Lasalvia A, Menezes PR, Quattrone D, Sanjuan J, Selten JP, Tortelli A, Llorca PM, van Os J, Rutten BPF, Murray RM, Morgan C, Leboyer M, Szoke A, Schurhoff F. Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study. *Epidemiology and Psychiatric Sciences*. 2022 Sep 27;31:e68. doi: 10.1017/S2045796022000464. PMID: 36165168
297. Usategui-Martin R, Perez-Castrillon J, Briongos-Figuero L, Abadia-Otero J, Lara-Hernandez F, Garcia-Sorribes S, Martin-Vallejo J, Garcia-Garcia A, Chaves F, Martin-Escudero J. Genetic variants in obesity-related genes and the risk of osteoporotic fracture. The Hortega Follow-up Study. *Frontiers in Bioscience-Landmark*. 2022 Jan 18;27(1):32. doi: 10.31083/j.fbl2701032. PMID: 35090337
298. Vina J, Escudero J, Baquero M, Cebrian M, Carbonell-Asins J, Munoz J, Satorres E, Melendez J, Ferrer-Rebolleda J, Cozar-Santiago M, Santabarbara-Gomez J, Jove M, Pamplona R, Tarazona-Santabalbina F, Borras C. Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial. *Alzheimers Research & Therapy*. 2022 Nov 4;14(1):164. doi: 10.1186/

# publication list

- s13195-022-01097-2. PMID: 36329553
- 299.Bargues C, Borras C, Vina J. Genistein, a tool for geroscience. Mechanisms of Ageing and Development. 2022 Jun;204:111665. doi: 10.1016/j.mad.2022.111665. PMID: 35307412
- 300.Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Garcia-Chica J, Zhao R, Montesinos P, Torrent A, Diaz-Beya M, Coll R, Hermosin L, Mercadal S, Gonzalez-Campos J, Zamora L, Artola T, Vall-Llovera F, Tormo M, Gil-Cortes C, Barba P, Novo A, Ribera J, Bernal T, De Ugarriza P, Queipo M, Martinez-Sanchez P, Gimenez A, Gonzalez-Martinez T, Cladera A, Cervera J, Fernandez-Martin R, Ardaiz M, Vidal M, Baena A, Lopez-Bigas N, Bigas A, Maciejewski J, Orfao A, Ribera J, Genesca E. Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials. Haematologica. 2022 Nov 3. doi: 10.3324/haematol.2022.281196. PMID: 36325893
- 301.Mondejar-Lopez P, Zolin A, Garcia-Marcos P, Pastor-Vivero M, Rosa-Silvestre M, Sanchez-Martinez F, Salvatore D, Cimino G, Majo F, Sole-Jover A, de la Cruz O, Calderazzo M, Pizzamiglio G, Castillo-Corullon S, Alvarez-Fernandez A, Gartner S, Padoan R, Carnovale V, Salvatore M, Moya-Quiles M, Orenti A, Glover G, Sanchez-Solis M. Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation. Respiratory Medicine. 2022 Feb;192:106736. doi: 10.1016/j.rmed.2022.106736. PMID: 35032736
- 302.Akulnik A, Kizyma R, Salek M, Włodarski M, Pogorelyy M, Oszer A, Yakimkova T, Nogovitsyna Y, Dutkiewicz M, Dalle J, Dirksen U, Eggert A, Fernandez-Teijeiro A, Greiner J, Kraal K, Mueller A, Sramkova L, Zecca M, Wise P, Mlynarski W, SAFER Ukraine Collaborative, SAFER Ukraine Collaborative. Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war. Lancet Haematology. 2022 Sep;9(9):e645-e647. doi: 10.1016/S2352-3026(22)00259-9. PMID: 36055331
- 303.Aimo A, Lupon J, Spitaleri G, Domingo M, Codina P, Santiago-Vacas E, Cediel G, Zamora E, Troya M, Santesmases J, Romero-Gonzalez G, Nuñez J, Martini N, Emdin M, Bayes-Genis A. Global warming, renal function and heart failure over 20 years. International Journal of Cardiology. 2022 Oct 15;365:100-105. doi: 10.1016/j.ijcard.2022.07.043. PMID: 35926642
- 304.GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. Gastroenterology & Hepatology. 2022 Jul;7(7):627-647. doi: 10.1016/S2468-1253(22)00044-9. PMID: 35397795
- 305.GBD 2019 Ageing Collaborators. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study. BMJ-British Medical Journal. 2022 Mar 10;376:e068208. doi: 10.1136/bmj-2021-068208. PMID: 35273014
- 306.Gorriz J, Romera I, Cobo A, O'Brien P, Merino-Torres J. Glucagon-like peptide-1 receptor agonist use in people living with Type 2 diabetes mellitus and chronic kidney disease: a narrative review of the key evidence with practical considerations. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders. 2022 Mar;13(3):389-421. doi: 10.1007/s13300-021-01198-5. PMID: 35175551
- 307.De la Rosa A, Olaso-Gonzalez G, Garcia-Dominguez E, Mastaloudis A, Hester S, Wood S, Gomez-Cabrera M, Vina J. Glucosamine supplementation improves physical performance in trained mice. Medicine and Science in Sports and Exercise. 2022 Mar 1;54(3):466-474. doi: 10.1249/MSS.0000000000002821. PMID: 34711707
- 308.Garcia-Dominguez E, Carretero A, Vina-Almunia A, Domenech-Fernandez J, Olaso-Gonzalez G, Vina J, Gomez-Cabrera MC. Glucose 6-P dehydrogenase—an antioxidant enzyme with regulatory functions in skeletal muscle during exercise. Cells. 2022 Sep 28;11(19):3041. doi: 10.3390/cells11193041. PMID: 36231003
- 309.Canet F, Christensen J, Victor V, Hustad K, Ottestad I, Rundblad A, Sather T, Dalen K, Ulven S, Holmen K, Telle-Hansen V. Glycated proteins, glycine, acetate, and monounsaturated fatty acids may

# publication list

- act as new biomarkers to predict the progression of type 2 diabetes: secondary analyses of a randomized controlled trial. *Nutrients*. 2022 Dec 5;14(23):5165. doi: 10.3390/nu14235165. PMID: 36501195
310. Diaz-Pozo P, Canet F, Grirrane A, Lopez-Domenech S, Herance J, Apostolova N, Luna-Marco C, Rovira-Llopis S, Marti M, Morillas C, Rocha M, Garcia H, Victor V. Gold nanoparticles supported on ceria nanoparticles modulate leukocyte-endothelium cell interactions and inflammation in Type 2 Diabetes. *Antioxidants*. 2022 Nov 20;11(11):2297. doi: 10.3390/antiox1112297. PMID: 36421483
311. Rocamora V, Crespi L, Ferran M, Llamas-Velasco M, del Alcazar E, Carrascosa J, Beltran E, Urruticoechea-Arana A, Estebaranz J, Vidal D, Riera J, Rodriguez L, Armesto S, Fernandez J, Aparicio G, Perez S, Porcar S, Montesinos E, Gallardo F. Gu selkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. *Dermatologic Therapy*. 2022 Nov;35(11):e15865. doi: 10.1111/dth.15865. PMID: 36175141
312. Di Meo S, Venditti P, Victor V, Napolitano G. Harmful and beneficial role of ROS 2020. *Oxidative Medicine and Cellular Longevity*. 2022 Jul 22;2022:9873652. doi: 10.1155/2022/9873652. PMID: 35910844
313. Bayes-Genis A, Aimo A, Metra M, Anker S, Seferovic P, Rapezzi C, Castiglione V, Nunez J, Emdin M, Rosano G, Coats AJs. Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines. *European Journal of Heart Failure*. 2022 Jun;24(6):916-926. doi: 10.1002/ejhf.2542. PMID: 35579428
314. Delgado-Velandia M, Gonzalez-Marrachelli V, Domingo-Relloso A, Galvez-Fernandez M, Grau-Perez M, Olmedo P, Galan I, Rodriguez-Artalejo F, Amigo N, Briongos-Figuero L, Redon J, Martin-Escudero J, Monleon-Salvado D, Tellez-Plaza M, Sotos-Prieto M. Healthy lifestyle, metabolomics and incident type 2 diabetes in a population-based cohort from Spain. *International Journal of Behavioral Nutrition and Physical Activity*. 2022 Jan 27;19(1):8. doi: 10.1186/s12966-021-01219-3. PMID: 35086546
315. Ferrer-Quintero M, Fernandez D, Lopez-Carrilero R, Diaz-Cutraro L, Verdaguer-Rodriguez M, Garcia-Mieres H, Huerta-Ramos E, Gomez-Benito J, Pelaez T, Birules I, Barajas A, Pousa E, Barrigon M, Gutierrez-Zotes A, Grasa E, Ruiz-Delgado I, Lorente-Rovira E, Cid J, Ochoa S. Heterogeneity in response to MCT and psychoeducation: a feasibility study using latent class mixed models in first-episode psychosis. *Healthcare*. 2022 Oct 28;10(11):2155. doi: 10.3390/healthcare10112155. PMID: 36360496
316. Mikulska M, Penack O, Wendel L, Knelange N, Cornelissen J, Blijlevens N, Passweg J, Kroger N, Bruns A, Koenecke C, Bierings M, Pinana J, Labussiere-Wallet H, Ghesquieres H, Diaz M, Sampol A, Averbuch D, de la Camara R, Styczynski J. HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party. *Bone Marrow Transplantation*. 2022 Feb;57(2):167-175. doi: 10.1038/s41409-021-01497-2. PMID: 34689177
317. Leite L, Matos P, Leon-Justel A, Espirito-Santo C, Rodriguez-Padial L, Rodrigues F, Orozco D, Redon J. High sensitivity troponins: a potential biomarkers of cardiovascular risk for primary prevention. *Frontiers In Cardiovascular Medicine*. 2022 Nov 30;9:1054959. doi: 10.3389/fcvm.2022.1054959. PMID: 36531726
318. Gomez R, Tejada M, Rodriguez-Garcia V, Burgues O, Santos-Llamas A, Martinez-Massa A, Marin-Montes A, Tarin J, Cano A. Histological grade and tumor stage are correlated with expression of receptor activator of nuclear factor Kappa b (Rank) in epithelial ovarian cancers. *International Journal of Molecular Sciences*. 2022 Feb 3;23(3):1742. doi: 10.3390/ijms23031742. PMID: 35163671
319. Osca-Verdegal R, Beltran-Garcia J, Paes A, Nacher-Sendra E, Novella S, Hermenegildo C, Carbonell N, Garcia-Gimenez J, Pallardo F. Histone citrullination mediates a protective role in endothelium and modulates inflammation. *Cells*. 2022 Dec 15;11(24):4070. doi: 10.3390/cells11244070. PMID: 36552833
320. Lauretta M, Melotti R, Sangermano C, George A, Badenes R, Bilotta F. Homocysteine plasma concentration in brain-injured neurocritical

# publication list

- care patients: systematic review of clinical evidence. *Journal of Clinical Medicine*. 2022 Jan 13;11(2):394. doi: 10.3390/jcm11020394. PMID: 35054087
321. Mollar A, Lorenzo M, Villaescusa A, Heredia R, Mianana G, Santas E, de la Espriella R, Sastre C, Civera J, Martinez A, Conesa A, Sanchis J, Nunez E, Bayes-Genis A, Nunez J. Hospitalization following an emergency-department visit for worsening heart failure: the role of left ventricular ejection fraction. *Medicina Clinica*. 2022 Aug 26;159(4):157-163. doi: 10.1016/j.medcli.2021.09.026. PMID: 35065819
322. Garcia-Bustos V, Peman J, Ruiz-Gaitan A, Cabanero-Navalon MD, Cabanilles-Boronat A, Fernandez-Calduch M, Marcilla-Barreda L, Sigena-Giangreco IA, Salavert M, Tormo-Mas MA, Ruiz-Sauri A. Host-pathogen interactions upon *Candida auris* infection: fungal behavior and immune response in *Galleria mellonella*. *Emerging Microbes & Infections*. 2022 Dec;11(1):136-146. doi: 10.1080/22221751.2021.2017756. PMID: 34890523
323. McLornan D, Hargreaves R, Hernandez-Boluda J, Harrison C. How I manage myeloproliferative neoplasm-unclassifiable: practical approaches for 2022 and beyond. *British Journal of Haematology*. 2022 May;197(4):407-416. doi: 10.1111/bjh.18087. PMID: 35191542
324. Etxeandia-Pradera J, Landeta J, Gonzalez-Such J, Aguilar E. How to improve training in descriptive psychopathology for psychiatry residents: a Delphi Study. *Psychopathology*. 2022 Jul 29;1-14. doi: 10.1159/000525691. PMID: 35908537
325. Gonzalez-Vivas C, Valdes-Florido MJ, Garcia-Marti G, Soldevila-Matias P, Marti-Bonmati L, Nacher J, Sanjuan J. How voices change the brain. Two fMRI follow-up case reports. *Schizophrenia Research*. 2022 Oct;248:329-330. doi: 10.1016/j.schres.2022.09.016. PMID: 36155306
326. Mata M, Peydro S, de Llano J, Sancho-Tello M, Carra C. Human dental pulp stem cells differentiate into cementoid-like-secreting cells on decellularized teeth scaffolds. *International Journal of Molecular Sciences*. 2022 Dec 9;23(24):15588. doi: 10.3390/ijms232415588. PMID: 36555228
327. Koel M, Krjutskov K, Saare M, Samuel K, Lubennets D, Katayama S, Einarsdottir E, Vargas E, Sola-Leyva A, Lalitkumar P, Gemzell-Danielsson K, Blesa D, Simon C, Lanner F, Kere J, Salumets A, Altmae S. Human endometrial cell-type-specific RNA sequencing provides new insights into the embryo-endometrium interplay. *Human Reproduction Open*. 2022 Oct 13;2022(4):hoac043. doi: 10.1093/hropen/hoac043. PMID: 36339249
328. Redondo N, Navarro D, Aguado JM, Fernandez-Ruiz M. Human genetic polymorphisms and risk of viral infection after solid organ transplantation. *Transplantation Reviews*. 2022 Jan;36(1):100669. doi: 10.1016/j.trre.2021.100669. PMID: 34688126
329. Giuffrida F, Fleith M, Goyer A, Samuel T, Elmelehy-Masserey I, Fontannaz P, Cruz-Hernandez C, Thakkar S, Monnard C, De Castro C, Lavalle L, Rakza T, Agosti M, Al-Jashi I, Pereira A, Costeira M, Marchini G, Vanpee M, Stiris T, Stoicescu S, Silva M, Picaud J, Martinez-Costa C, Domellof M, Billeaud C. Human milk fatty acid composition and its association with maternal blood and adipose tissue fatty acid content in a cohort of women from Europe. *European Journal of Nutrition*. 2022 Jun;61(4):2167-2182. doi: 10.1007/s00394-021-02788-6. PMID: 35072787
330. Fernandez-Ruiz M, Forque L, Albert E, Redondo N, Gimenez E, Lopez-Medrano F, Gonzalez E, Polanco N, Ruiz-Merlo T, Parra P, San Juan R, Andres A, Aguado J, Navarro D. Human pegivirus type 1 infection in kidney transplant recipients: replication kinetics and clinical correlates. *Transplant Infectious Disease*. 2022 Feb;24(1):e13771. doi: 10.1111/tid.13771. PMID: 34921747
331. Sancho-Alonso M, Taoro-Gonzalez L, Cabrera-Pastor A, Felipo V, Teruel-Marti V. Hyperammonemia alters the function of AMPA and NMDA receptors in hippocampus: extracellular cGMP reverses some of these alterations. *Neurochemical Research*. 2022 Jul;47(7):2016-2031. doi: 10.1007/s11064-022-03588-y. PMID: 35386048
332. de Simone G, Mancusi C, Hanssen H, Genovesi S, Lurbe E, Parati G, Sendzikaite S, Valerio G, Di Bonito P, Di Salvo G, Ferrini M, Leeson P, Moons P, Weismann C, Williams B. Hypertension in children and adolescents a consensus document

# publication list

- from ESC Council on Hypertension, European Association of Preventive Cardiology, European Association of Cardiovascular Imaging, Association of Cardiovascular Nursing & Allied Professions, ESC Council for Cardiology Practice and Association for European Paediatric and Congenital Cardiology. *European Heart Journal*. 2022 Sep 14;43(35):3290-3301. doi: 10.1093/eurheartj/ehac328. PMID: 35896123
333. Sancho JM, Marin-Niebla A, Fernandez S, Capote FJ, Canigral C, Grande C, Donato E, Zeberio I, Puer ta JM, Rivas A, Perez-Ceballos E, Vale A, Martin Garcia-Sancho A, Salar A, Gonzalez-Barca E, Teruel A, Pastoriza C, Conde-Royo D, Sanchez-Garcia J, Barrenetxea C, Arranz R, Hernandez-Rivas JA, Ramirez MJ, Jimenez A, Rubio-Azpeitia E. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice. *International Journal of Hematology*. 2022 Sep;116(3):381-392. doi: 10.1007/s12185-022-03367-z. PMID: 35551632
334. Giné E, de la Cruz F, Jiménez Ubieto A, López Jiménez J, Martín García-Sancho A, Terol MJ, González Barca E, Casanova M, de la Fuente A, Marín-Niebla A, Muntañola A, González-López TJ, Aymerich M, Setoain X, Cortés-Romera M, Rotger A, Rodríguez S, Medina Herrera A, García Sanz R, Nadeu F, Beà S, Campo E, López-Guillermo A. Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, Phase II Trial. *Journal of Clinical Oncology*. 2022 Apr 10;40(11):1196-1205. doi: 10.1200/JCO.21.02321. PMID: 35030036
335. Tejada MA, Santos Llamas A, Escrivá L, Tarin JJ, Cano A, Fernandez Ramirez MJ, Nunez Badinez P, De Leo B, Saunders PTK, Vidal V, Barthas F, Vincent K, Sweeney PJ, Sillito RR, Armstrong JD, Nagel J, Gomez R. Identification of altered evoked and non-evoked responses in a heterologous mouse model of endometriosis-associated pain. *Biomedicines*. 2022 Feb 21;10(2):501. doi: 10.3390/biomedicines10020501. PMID: 35203710
336. Garcia-Gimenez JL, Garcia-Trevijano ER, Aviles-Alia AI, Ibanez-Cabellos JS, Bovea-Marco M, Bas T, Paliardo FV, Vina JR, Zaragoza R. Identification of circulating miRNAs differentially expressed in patients with Limb-girdle, Duchenne or facioscapulohumeral muscular dystrophies. *Orphanet Journal of Rare Diseases*. 2022 Dec 27;17(1):450. doi: 10.1186/s13023-022-02603-3. PMID: 36575500
337. Herrera L, Martin-Inaraja M, Santos S, Ingles-Ferrandiz M, Azkarate A, Perez-Vaquero MA, Vesga MA, Vicario JL, Soria B, Solano C, De Paz R, Marcos A, Ferreras C, Perez-Martinez A, Eguizabal C. Identifying SARS-CoV-2 'memory' NK cells from COVID-19 convalescent donors for adoptive cell therapy. *Immunology*. 2022 Feb;165(2):234-249. doi: 10.1111/imm.13432. doi: 10.1111/imm.13432. PMID: 34775592
338. Mulet A, Signes-Costa J. Idiopathic pulmonary fibrosis and telomeres. *Journal of Clinical Medicine*. 2022 Nov 22;11(23):6893. doi: 10.3390/jcm11236893. PMID: 36498467
339. Macias-Ceja D, Coll S, Bauset C, Seco-Cervera M, Gisbert-Ferrandiz L, Navarro F, Cosin-Roger J, Calatayud S, Barrachina M, Ortiz-Masia D. IFN gamma-treated macrophages induce EMT through the WNT pathway: relevance in Crohn's disease. *Biomedicines*. 2022 May 8;10(5):1093. doi: 10.3390/biomedicines10051093. PMID: 35625832
340. Gutierrez A, Zapater P, Ricart E, et al. Immigrant IBD patients in Spain are younger, have more extraintestinal manifestations and use more biologics than native patients. *Frontiers in Medicine*. 2022 Feb 1;9:823900. doi: 10.3389/fmed.2022.823900. PMID: 35178413
341. Gares-Caballer M, Sanchez-Orti J, Correa-Ghisays P, Balanza-Martinez V, Selva-Vera G, Vila-Frances J, Magdalena-Benedito R, San-Martin C, Victor V, Escribano-Lopez I, Hernandez-Mijares A, Vivas-Lalinde J, Vieta E, Leza J, Tabares-Seisdedos R. Immune-inflammatory biomarkers predict cognition and social functioning in patients with Type 2 Diabetes Mellitus, major depressive disorder, bipolar disorder, and schizophrenia: a 1-year follow-up study. *Frontiers in Neurology*. 2022 Jun 2;13:883927. doi: 10.3389/fneur.2022.883927. PMID: 35720107
342. Alarcon Chulilla M, Avila Fuentes M, Casan Fernandez R, Muelas N, Real Collado J. Immune-mediated

# publication list

- necrotising inflammatory myopathy. A rare side effect of statins. *Endocrinologia, Diabetes y Nutricion.* 2022 Oct;69(8):648-649. doi: 10.1016/j.endien.2022.10.001. PMID: 36347793
- 343.Moragon S, Hernando C, Martinez-Martinez M, Tapia M, Ortega-Morillo B, Lluch A, Bermejo B, Cejalvo J. Immunological landscape of HER-2 positive breast cancer. *Cancers.* 2022 Jun 28;14(13):3167. doi: 10.3390/cancers14133167. PMID: 35804943
- 344.Albert E, Burgos JS, Peiro S, Salas D, Vanaclocha H, Gimenez E, Limon R, Alcaraz MJ, Sanchez-Paya J, Diez-Domingo J, Cervantes A, Navarro D. Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty COVID-19 vaccine in nursing home residents. *Clinical Microbiology and Infection.* 2022 Feb;28(2):279-284. doi: 10.1016/j.cmi.2021.09.031. PMID: 34619398
- 345.Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C, Bernal T, Tormo M, Mercadal S, Novoa S, Garcia-Cadenas I, Queipo de Llano MP, Cervera M, Coll R, Bermudez A, Amigo ML, Monsalvo S, Esteve J, Garcia-Boyero R, Novo A, Hernandez Rivas JM, Cladera A, Martinez-Sanchez P, Serrano J, Artola MT, Soria B, Abella E, Vall-Llovera F, Bergua J, Herrera P, Barrios D, Ribera JM. Impact of center-related characteristics and macroeconomic factors on the outcome of adult patients with acute lymphoblastic leukemia treated with pediatric-inspired protocols. *Hematphere.* 2022 Dec 23;7(1):e810. doi: 10.1097/HHS.0000000000000810. PMID: 36583094
- 346.De Luca G, Nardin M, Algohary M, Uguz B, Oliveira D, Ganyukov V, Zimbakov Z, Cercek M, Jensen L, Loh P, Calmac L, Ferrer G, Quadros A, Milewski M, di Uccio F, von Birgelen C, Versaci F, Ten Berg J, Casella G, Lung A, Kala P, Gil J, Carrillo X, Dirksen M, Becerra-Munoz V, Lee M, Juzar D, Joaquim R, Paladino R, Milicic D, Davlouros P, Bakraceski N, Zilio F, Donazzan L, Kraaijeveld A, Galasso G, Lux A, Marinucci L, Guiducci V, Menichelli M, Scoccia A, Yamac A, Mert K, Rios X, Kovarnik T, Kidawa M, Moreu J, Flavien V, Fabris E, Martinez-Luengas I, Boccalatte M, Ojeda F, Arellano-Serrano C, Caiazza G, Cirrincione G, Kao H, Fores J, Vignali L, Pereira H, Manzo S, Ordonez S, Ozkan A, Scheller B, Lehtola H, Teles R, Mantis C, Antti Y, Silveira J, Zoni R, Bessonov I, Savonitto S, Kochiadakis G, Alexopoulos D, Uribe C, Kanakakis J, Faurie B, Gabrielli G, Barrios A, Bachini J, Rocha A, Tam F, Rodriguez A, Lukito A, Saint-Joy V, Pessah G, Tuccillo A, Cortese G, Parodi G, Bouraghda M, Kedhi E, Lamelas P, Suryaprana H, Verdoia M. Impact of chronic obstructive pulmonary disease on short-term outcome in patients with ST-elevation myocardial infarction during COVID-19 pandemic: insights from the international multicenter ISACS-STEMI registry. *Respiratory Research.* 2022 Aug 15;23(1):207. doi: 10.1186/s12931-022-02128-0. PMID: 35971173
- 347.Palanca A, Quinones Torrelo C, Girbes J, Real JT, Ampudia Blasco FJ. Impact of COVID-19 lockdown on diabetes management and follow-up in a broad population in Spain. *European Journal of Clinical Investigation.* 2022 Jun;52(6):e13771. doi: 10.1111/eci.13771. PMID: 35313009
- 348.Czerw T, Iacobelli S, Malpassuti V, Koster L, Kroeger N, Robin M, Maertens J, Chevallier P, Watz E, Poire X, Snowden JA, Kuball J, Kinsella F, Blaise D, Remenyi P, Mear JB, Cammenga J, Rubio MT, Maury S, Dagquindau E, Finnegan D, Hayden P, Hernandez-Boluda JC, McLornan D, Yakoub-Agha I. Impact of donor-derived CD34+infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. *Bone Marrow Transplantation.* 2022 Feb;57(2):261-270. doi: 10.1038/s41409-021-01540-2. PMID: 34853433
- 349.Ayala R, Carreno-Tarragona G, Barragan E, Boluda B, Larrayoz M, Chillon M, Carrillo-Cruz E, Bilbao C, Sanchez-Garcia J, Bernal T, Martinez-Cuadron D, Gil C, Serrano J, Rodriguez-Medina C, Bergua J, Perez-Simon J, Calbacho M, Alonso-Dominguez J, Labrador J, Tormo M, Amigo M, Herrera-Puente P, Rapado I, Sargas C, Vazquez I, Calasanz M, Gomez-Casares T, Garcia-Sanz R, Sanz M, Martinez-Lopez J, Montesinos P. Impact of FLT3-ITD mutation status and its ratio in a cohort of 2901 patients undergoing upfront intensive chemotherapy: a PETHEMA Registry Study. *Cancers.* 2022 Nov 24;14(23):5799. doi: 10.3390/cancers14235799. PMID: 36497281

# publication list

350. Andreu Y, Soto-Rubio A, Ramos-Campos M, Escriche-Saura A, Martinez M, Gavila J. Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors. *Scientific Reports.* 2022 Nov 4;12(1):18673. doi: 10.1038/s41598-022-22971-x. PMID: 36333362
351. García-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, Fox L, Cuevas B, García-Hernández MC, Gómez-Casares MT, Ferrer-Marín F, Saavedra S, Cervantes F, García-Delgado R. Impact of individual comorbidities on survival of patients with myelofibrosis. *Cancers.* 2022 May 9;14(9):2331. doi: 10.3390/cancers14092331. PMID: 35565461
352. Guillen-Del-Castillo A, Meseguer M, Fonollosa-Pla V, Gimenez B, Colunga-Arguelles D, Revilla-Lopez E, Rubio-Rivas M, Ropero M, Argibay A, Mir J, Salas X, Menaca A, Vuelta A, Padron A, Comet L, Morera J, Gonzalez-Echavarri C, Mombiela T, Ortego-Centeno N, Gonzalez M, Tolosa-Vilella C, Blanco I, Subias P, Simeon-Aznar C, RESCLE Consortium, REHAP Consortium. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. *Scientific Reports.* 2022 Mar 28;12(1):5289. doi: 10.1038/s41598-022-09353-z. PMID: 35347225
- Guillen-Del-Castillo A, Meseguer M, Fonollosa-Pla V, Gimenez B, Colunga-Arguelles D, Revilla-Lopez E, Rubio-Rivas M, Ropero M, Argibay A, Barbera J, Salas X, Menaca A, Vuelta A, Padron A, Comet L, Morera J, Gonzalez-Echavarri C, Mombiela T, Ortego-Centeno N, Gonzalez M, Tolosa-Vilella C, Blanco I, Subias P, Simeon-Aznar C. Correction to: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension [vol 12, 5289, 2022]. *Scientific Reports.* 2022 Jul 28;12(1):12947. doi: 10.1038/s41598-022-17525-0. PMID: 35902683
353. Pastor-Galan I, Martin I, Ferrer B, Hernandez-Boluda J. Impact of molecular profiling on the management of patients with myelofibrosis. *Cancer Treatment Reviews.* 2022 Jul 8;109:102435. doi: 10.1016/j.ctrv.2022.102435. PMID: 35839532
354. Dios-Barbeito S, Gonzalez R, Cadenas M, Garcia L, Victor V, Padillo F, Muntan J. Impact of nitric oxide in liver cancer microenvironment. *Nitric Oxide-Biology and Chemistry.* 2022 Aug 5;128:1-11. doi: 10.1016/j.niox.2022.07.006. PMID: 35940533
355. Redondo N, Rodriguez-Goncer I, Parra P, Albert E, Gimenez E, Ruiz-Merlo T, Lopez-Medrano F, San Juan R, Gonzalez E, Sevillano A, Andres A, Navarro D, Aguado J, Fernandez-Ruiz M. Impact of polymorphisms in genes orchestrating innate immune responses on replication kinetics of Torque teno virus after kidney transplantation. *Frontiers in Genetics.* 2022 Nov 22;13:1069890. doi: 10.3389/fgene.2022.1069890. PMID: 36482892
356. Abad-Jimenez Z, Vezza T, Lopez-Domenech S, Fernandez-Reyes M, Canet F, Morillas C, Gomez-Abril S, Banuls C, Victor V, Rocha M. Impact of Roux-en-Y gastric bypass on mitochondrial biogenesis and dynamics in leukocytes of obese women. *Antioxidants.* 2022 Jun 29;11(7):1302. doi: 10.3390/antiox11071302. PMID: 35883794
357. De Luca G, Algohary M, Uguz B, Oliveira D, Ganukov V, Zimbakov Z, Cersek M, Jensen L, Loh P, Calmac L, Ferrer G, Quadros A, Milewski M, Scotto D'Uccio F, von Birgelen C, Versaci F, Ten Berg J, Casella G, Wong Sung Lung A, Kala P, Diez Gil J, Carrillo X, Dirksen M, Becerra-Munoz V, Lee M, Juizar D, Joaquim R, Paladino R, Milicic D, Davlouros P, Bakraceski N, Zilio F, Donazzan L, Kraaijeveld A, Galasso G, Arpad L, Lucia M, Vincenzo G, Menichelli M, Scoccia A, Yamac A, Ugur Mert K, Flores Rios X, Kovarnik T, Kidawa M, Moreu J, Vincent F, Fabris E, Martinez-Luengas I, Boccalatte M, Bosa Ojeda F, Arellano-Serrano C, Caiazzo G, Cirrincione G, Kao H, Sanchis Fores J, Vignali L, Pereira H, Manzo S, Ordonez S, Ozkan A, Scheller B, Lehtola H, Teles R, Mantis C, Antti Y, Silveira J, Zoni R, Bessonov I, Savonitto S, Kochiadakis G, Alexopoulos D, Uribe C, Kanakakis J, Faurie B, Gabrielli G, Barrios A, Bachini J, Rocha A, Tam F, Rodriguez A, Lukito A, Saint-Joy V, Pessah G, Tuccillo A, Cortese G, Parodi G, Bouraghda M, Kedhi E, Lamelas P, Suryapranata H, Nardin M, Verdoia M. Impact of Smoking Status on Mortality in STEMI patients undergoing mechanical reperfusion for STEMI: insights from the ISACS-STEMI COVID-19 Registry. *Journal of Clinical Medicine.* 2022 Nov 13;11(22):6722. doi: 10.3390/jcm11226722. PMID: 36431198

# publication list

- 358.Perez-Rando M, Carceller H, Castillo-Gomez E, Bueno-Fernandez C, Garcia-Mompo C, Gilabert-Juan J, Guirado R, Pesarico A, Nacher J. Impact of stress on inhibitory neuronal circuits, our tribute to Bruce McEwen. *Neurobiology of Stress*. 2022 May 13;19:100460. doi: 10.1016/j.jnstr.2022.100460. PMID: 35734023
- 359.Olaso-Gonzalez G, Inzitari M, Bellelli G, Morandi A, Barcons N, Vina J. Impact of supplementation with vitamins B6, B12, and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: a systematic review. *IUBMB Life*. 2022 Jan;74(1):74-84. doi: 10.1002/iub.2507. PMID: 34058062
- 360.Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Impact of the COVID-19 pandemic on a cancer fast-track programme. *Cancer Control*. 2022 Jan-Dec;29:10732748221131000. doi: 10.1177/10732748221131000. PMID: 36355430
- 361.De Michelena P, Torres I, Albert E, Bracho A, Gonzalez-Candelas F, Navarro D. Impact of time elapsed since full vaccination on SARS-CoV-2 RNA load in Delta-variant breakthrough COVID-19. *Journal of Infection*. 2022 Apr;84(4):579-613. doi: 10.1016/j.jinf.2022.01.006. PMID: 35016898
- 362.Fuentes M, Sales A, Charquero-Ballester M, Garcia-Marti G, Melendez J, Espert R, Scheel M, Bauknecht H, Simon K, Kopstein U, Gebauer S, Algarabel S. Impaired recollection and initially preserved familiarity in a patient with bilateral fornix transection following third ventricle colloid cyst removal: a two-year follow-up study. *Applied Neuropsychology-Adult*. 2022 Aug 2;1-13. doi: 10.1080/23279095.2022.2104162. PMID: 35917584
- 363.Calatayud J, Morera A, Ezzatvar Y, Lopez-Bueno R, Andersen LL, Cuenca-Martinez F, Suso-Marti L, Sanchis-Sanchez E, Lopez-Bueno L, Casana J. Importance of frequency and intensity of strength training for work ability among physical therapists. *Scientific Reports*. 2022 Sep 2;12(1):15016. doi: 10.1038/s41598-022-18539-4. PMID: 36056040
- 364.Scurt M, Balint L, Mijaica R. Improving body mass index in students with excess weight through a physical activity programme. *Children*. 2022 Oct 27;9(11):1638. doi: 10.3390/children9111638. PMID: 36360366
- 365.Ciardiello D, Roda D, Gambardella V, Cervantes A. In the literature: April 2022. *ESMO Open*. 2022 Apr 23;7(3):100479. doi: 10.1016/j.esmoop.2022.100479. PMID: 35472677
- 366.Montagut C, Gambardella V, Cabeza-Segura M, Fleitas T, Cervantes A. In the literature: December 2021. *ESMO Open*. 2022 Feb;7(1):100352. doi: 10.1016/j.esmoop.2021.100352. PMID: 34920292
- 367.Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. In the literature: February 2022. *ESMO open*. 2022 Feb 23;7(2):100411. doi: 10.1016/j.esmoop.2022.100411. PMID: 35219243
- 368.Gambardella V, Martinelli E, Tarazona N, Cervantes A. In the literature: July 2022. *ESMO Open*. 2022 Aug;7(4):100556. doi: 10.1016/j.esmoop.2022.100556. PMID: 35961192
- 369.Gambardella V, Cejalvo J, Cervantes A. In the literature: November 2022. *ESMO Open*. 2022 Nov 17;7(6):100643. doi: 10.1016/j.esmoop.2022.100643. PMID: 36403559
- 370.Milian L, Monleon-Guinot I, Sancho-Tello M, Galbis J, Cremades A, Almenar Ordaz M, Penaroya-Martinez J, Farras R, de Llano J, Carda C, Mata M. In vitro effect of delta 9-tetrahydrocannabinol and cannabidiol on cancer-associated fibroblasts isolated from lung cancer. *International Journal of Molecular Sciences*. 2022 Jun 17;23(12):6766. doi: 10.3390/ijms23126766. PMID: 35743206
- 371.Diaz J, Martinez F, Calderon JM, Fernandez A, Saure I, Uso R, Trillo JL, Redon J, Forner MJ. Incidence and impact of atrial fibrillation in heart failure patients: real-world data in a large community. *ESC Heart Failure*. 2022 Dec;9(6):4230-4239. doi: 10.1002/ehf2.14124. PMID: 36111519

# publication list

372. Torrent-Vernetta A, Gaboli M, Castillo-Corullon S, Mondejar-Lopez P, Santiago V, Costa-Colomer J, Osona B, Torres-Borrego J, De la Serna-Blazquez O, Alonso S, Aguilera P, De Atauri A, Soria A, Ayats R, de Vicente C, Gonzalez V, Gonzalez J, Calderin E, Pastor-Vivero M, Alvarez M, Rovira-Amigo S, Serrano I, Izquierdo A, Messa I, Gartner S, Navarro A, Baz-Redon N, Carmona R, Camats-Tarruela N, Fernandez-Cancio M, Rapp C, Dopazo J, Griese M, Moreno-Galdo A. Incidence and prevalence of children's diffuse lung disease in Spain. *Archivos de Bronconeumología*. 2022 Jan;58(1):22-29. doi: 10.1016/j.arbres.2021.06.001. PMID: 35249699
373. Alquézar-Arbé A, Miró Ò, Castillo JGD, Jiménez S, Llorens P, Martín A, Martín-Sánchez FJ, García-Lamberechts EJ, Piñera P, Jacob J, Porrino JMM, Jiménez B, Río RD, García CP, Aznar JVB, Ponce MC, Fernández ED, Tost J, Mojarro EM, García AH, Quirós AM, Noceda J, Cano MJC, Almela AFS, Bayarri MJF, Tejera MG, Rodriguez AD, Burillo-Putze G; Spanish Investigators on Emergency Situations TeAm [SIESTA] Network. Incidence, clinical characteristics, risk factors and outcomes of acute coronary syndrome in patients with COVID-19: results of the UMC-19-S1010. *Journal of Emergency Medicine*. 2022 Apr;62(4):443-454. doi: 10.1016/j.jemermed.2021.10.046. PMID: 35065863
374. Minana G, Lorenzo M, Ramirez de Arellano A, Wachter S, de la Espriella R, Sastre C, Mollar A, Nuñez E, Bodi V, Sanchis J, Bayes-Genis A, Nunez J. Incidence, treatment and clinical impact of iron deficiency in chronic heart failure: a longitudinal analysis. *Journal of Clinical Medicine*. 2022 May 2;11(9):2559. doi: 10.3390/jcm11092559. PMID: 35566684
375. Wang R, McLernon D, Lai S, Showell M, Chen Z, Wei D, Legro R, Wang Z, Sun Y, Wu K, Vuong L, Hardy P, Pinborg A, Stormlund S, Santamaria X, Simon C, Blockeel C, Mol F, Ferraretti A, Shapiro B, Garner F, Li R, Venetis C, Mol B, Bhattacharya S, Maheshwari A. Individual participant data meta-analysis of trials comparing frozen versus fresh embryo transfer strategy (INFORM): a protocol. *BMJ Open*. 2022 Jul 18;12(7):e062578. doi: 10.1136/bmjopen-2022-062578. PMID: 35851030
376. Escobar C, Luis-Bonilla J, Crespo-Leiro M, Este- ban-Fernandez A, Farre N, Garcia A, Nunez J. Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. *Expert Opinion on Pharmacotherapy*. 2022 Oct;23(14):1589-1599. doi: 10.1080/14656566.2022.2116275. PMID: 35995759
377. Moya-Gonzalvez E, Pena-Gil N, Rubio-del-Campo A, Coll-Marques J, Gozalbo-Rovira R, Monedero V, Rodriguez-Diaz J, Yebra M. Infant gut microbial metagenome mining of alpha-1-fucosidases with activity on fucosylated human milk oligosaccharides and glycoconjugates. *Microbiology Spectrum*. 2022 Aug 31;10(4):e0177522. doi: 10.1128/spec-trum.01775-22. PMID: 35943155
378. Carrascal M, Areny-Balaguero A, de-Madaria E, Cardenas-Jaen K, Garcia-Rayado G, Rivera R, Martin Mateos R, Pascual-Moreno I, Gironella M, Abian J, Closa D. Inflammatory capacity of exosomes released in the early stages of acute pancreatitis predicts the severity of the disease. *The Journal of Pathology*. 2022 Jan;256(1):83-92. doi: 10.1002/path.5811. PMID: 34599510
379. Botella Casas G, Cassinello Fernandez N, Perez Santiago L, Alfonso Ballester R, Ortega Serrano J. Influence of carotid anatomy anomaly in rescue surgery due to relapse of papillary thyroid cancer. *Cirugia Espanola*. 2022 Oct;100(10):657-659. doi: 10.1016/j.cireng.2022.06.035. PMID: 35753572
380. Serra-Navarro M, Amoretti S, Verdolini N, Forte M, Sanchez-Torres A, Vieta E, Clougher D, Lobo A, Gonzalez-Pinto A, Panadero R, Roldan A, Carvalho A, de la Serna E, Toll A, Ramos-Quiroga J, Torrent C, Cuesta M, Bernardo M, PEPs Group. Influence of clinical and neurocognitive factors in psychosocial functioning after a first episode non-affective psychosis: differences between males and females. *Frontiers in Psychiatry*. 2022 Oct 20;13:982583. doi: 10.3389/fpsyg.2022.982583. PMID: 36339856
381. Mendoza-Garcia S, Garcia-Mieres H, Lopez-Carriero R, Sevilla-Lewellyn-Jones J, Birules I, Barajas A, Lorente-Rovira E, Gutierrez-Zotes A, Grasa E, Pousa E, Pelaez T, Barrigon M, Gonzalez-Higueras F, Ruiz-Delgado I, Cid J, Montserrat R, Martin-Iñigo

# publication list

- L, Moreno-Kustner B, Vila-Bbadia R, Diaz-Cutraro L, Verdaguer-Rodriguez M, Ferrer-Quintero M, Punsoda-Puche P, Barrau-Sastre P, Moritz S, Ochoa S. Influence of maternal and paternal history of mental health in clinical, social cognition and metacognitive variables in people with first-episode psychosis. *Journal of Personalized Medicine*. 2022 Oct 18;12(10):1732. doi: 10.3390/jpm12101732. PMID: 36294871
- 382.Coupet R, Schlaepfer M, Neff TA, Boucher P, Baily P, Bellgardt M, Badenes R, Carbonell J, Becher T, Varillon C, Morand D, Blondonnet R, Constantin JM, Pereira B, O'Gara B, Jabaudon M. Inhaled sedation in patients with COVID-19-related acute respiratory distress syndrome: an international retrospective study. *Journal of Clinical Medicine*. 2022 Dec 20;12(1):12. doi: 10.3390/jcm12010012. PMID: 36614813
- 383.Costa R, Signes-Costa J, Olea B, Tarraso J, Carbonell N, Blasco M, Navarro D. Initial SARS-CoV-2 RNA load in nasopharyngeal specimens is not associated with severity and midterm resolution of pneumonia in COVID-19 patients. *Journal of Infection*. 2022 Dec;85(6):702-769. doi: 10.1016/j.jinf.2022.10.031. PMID: 36346264
- 384.Martin-Moreno J, Arenas A, Bengoa R, Borrell C, Franco M, Garcia-Basteiro A, Gestal J, Gonzalez Lopez-Valcarcel B, Hernandez Aguado I, Legido-Quigley H, March J, Minue S, Muntaner C, Vives-Cases C. Insight on how to assess and improve the response to the COVID-19 pandemic. *Gaceta Sanitaria*. 2022;36(1):32-36. doi: 10.1016/j.gaceta.2020.11.008. PMID: 33518411
- 385.Lurbe E, Redon J, Alvarez J, Grau-Perez M, Martinez F, Mancia G. Insights from matched office and ambulatory blood pressure in youth: clinical relevance. *Hypertension*. 2022 Mar 29;101161HYPERTENSIONAHA12218993. doi: 10.1161/HYPERTENSIONAHA.122.18993. PMID: 35345885
- 386.Cabanero-Navalon M, Garcia-Bustos V, Forero-Naranjo L, Baettig-Arriagada E, Nunez-Beltran M, Canada-Martinez A, Giner M, Catalan-Caceres N, Frances M, Moral P. Integrating clinics, laboratory, and imaging for the diagnosis of common variable immunodeficiency-related granulomatous-lymphocytic interstitial lung disease. *Frontiers in Immunology*. 2022 Feb 23;13:813491. doi: 10.3389/fimmu.2022.813491. PMID: 35281075
- 387.Sonzini G, Granados-Aparici S, Sanegre S, Diaz-Lagares A, Diaz-Martin J, de Andrea C, Eritja N, Bao-Caamano A, Costa-Fraga N, Garcia-Ros D, Salguero-Aranda C, Davidson B, Lopez-Lopez R, Melero I, Navarro S, Ramon Y Cajal S, de Alava E, Matias-Guiu X, Noguera R. Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness. *Frontiers in Cell and Developmental Biology*. 2022 Nov 18;10:1052098. doi: 10.3389/fcell.2022.1052098. PMID: 36467415
- 388.Machado Lopez A, Alonso R, Lago V, Jimenez Almazan J, Garcia M, Monleon J, Lopez S, Barcelo F, Torroba A, Ortiz S, Domingo S, Simon C, Mas A. Integrative genomic and transcriptomic profiling reveals a differential molecular signature in uterine leiomyoma versus leiomyosarcoma. *International Journal of Molecular Sciences*. 2022 Feb 16;23(4):2190. doi: 10.3390/ijms23042190. PMID: 35216305
- 389.Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. *British Journal of Cancer*. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523
- 390.Mediano O, Gonzalez Mangado N, Montserrat J, Alonso-Alvarez M, Almendros I, Alonso-Fernandez A, Barbe F, Borsini E, Caballero-Eraso C, Cano-Pumarega I, de Carlos Villafranca F, Carmona-Bernal C, Carrillo Alduenda J, Chiner E, Cordero Guevara J, de Manuel L, Duran-Cantolla J, Farre R, Franceschini C, Gaig C, Garcia Ramos P, Garcia-Rio F, Garmendia O, Gomez Garcia T, Gonzalez Pondal S, Hoyo Rodrigo M, Lecube A, Antonio Madrid J, Maniegas Lozano L, Martinez Carrasco J, Masa J, Masdeu Margalef M, Mayos Perez M, Mirabet Lis E, Monasterio C, Navarro Soriano N, Olea de

# publication list

- la Fuente E, Plaza G, Puertas Cuesta F, Rabec C, Resano P, Rigau D, Roncero A, Ruiz C, Salord N, Saltijeral A, Sampol Rubio G, Sanchez Quiroga M, Sans Capdevila O, Teixeira C, Tinahones Madueño F, Maria Togeiro S, Troncoso Acevedo M, Vargas Ramirez L, Winck J, Zabala Unionaguena N, Egea C. International consensus document on obstructive sleep apnea. *Archivos de Bronconeumología*. 2022 Jan;58(1):T52-T68. doi: 10.1016/j.arbres.2021.03.027. PMID: 35245183
391. Mediano O, Gonzalez Mangado N, Montserrat J, Alonso-Alvarez M, Almendros I, Alonso-Fernandez A, Barbe F, Borsini E, Caballero-Eraso C, Cano-Pumarega I, de Carlos Villafranca F, Carmona-Bernal C, Carrillo Alduenda J, Chiner E, Cordero Guevara J, de Manuel L, Duran-Cantolla J, Farre R, Franceschini C, Gaig C, Garcia Ramos P, Garcia-Rio F, Garmendia O, Gomez Garcia T, Gonzalez Ponal S, Hoyo Rodrigo M, Lecube A, Madrid J, Maniegas Lozano L, Martinez Carrasco J, Masa J, Masdeu Margalef M, Mayos Perez M, Mirabet Lis E, Monasterio C, Navarro Soriano N, Olea de la Fuente E, Plaza G, Puertas Cuesta F, Rabec C, Resano P, Rigau D, Roncero A, Ruiz C, Salord N, Saltijeral A, Sampol Rubio G, Sanchez Quiroga M, Sans Capdevila O, Teixeira C, Tinahones Madueno F, Maria Togeiro S, Troncos Acevedo M, Vargas Ramirez L, Winck J, Zabala Unionaguena N, Egea C, el Spanish Sleep Network. International Consensus Document on obstructive sleep apnea. *Archivos de Bronconeumología*. 2022 Jan;58(1):52-68. doi: 10.1016/j.arbres.2021.03.017. PMID: 33875282
392. Taoro-Gonzalez L, Cabrera-Pastor A, Sancho-Alonso M, Felipo V. Intracellular and extracellular cyclic GMP in the brain and the hippocampus. *Vitamins and Hormones*. 2022;118:247-288. doi: 10.1016/bs.vh.2021.11.006. PMID: 35180929
393. Amarenco P, Kim J, Labreuche J, Charles H, Giroud M, Lavallee P, Lee B, Mahagne M, Meseguer E, Nighoghossian N, Steg P, Vicaut E, Bruckert E. Intracranial hemorrhage in the TST Trial. *Stroke*. 2022 Feb;53(2):457-462. doi: 10.1161/STROKEAHA.121.035846. PMID: 34963300
394. Campos NS, Bluth T, Hemmes SNT, Librero J, Pozo N, Ferrando C, Ball L, Mazzinari G, Pelosi P, Gama de Abreu M, Schultz MJ, Serpa Neto A; REPEAT; investigators for the PROVHILO study; iPROVE study; PROBESE study investigators; PROVE Network. Intraoperative positive end-expiratory pressure and postoperative pulmonary complications: a patient-level meta-analysis of three randomised clinical trials. *British Journal of Anaesthesia*. 2022 Jun;128(6):1040-1051. doi: 10.1016/j.bja.2022.02.039. PMID: 35431038
395. Lopes H, McCallum A, Martin-Moreno J, Middleton J. Invest in primary healthcare and public health for the pandemic and beyond. *BMJ*. 2022 Feb 18;376:o425. doi: 10.1136/bmj.o425. PMID: 35181642
396. Bellver G, Buch E, Ripoll F, Adrianzen M, Bermejo B, Burgues O, Julve A, Ortega J. Is axillary assessment of ductal carcinoma in situ of the breast necessary in all cases?. *Journal of Surgical Research*. 2022 Mar;271:145-153. doi: 10.1016/j.jss.2021.10.006. PMID: 34902737
397. Ruiz-Delgado I, Moreno-Kuestner B, Garcia-Medina M, Barrigon M, Gonzalez-Higueras F, Lopez-Carrilero R, Barrios-Mellado I, Barajas A, Pousa E, Lorente-Rovira E, Grasa E, Cid J, Barrau-Sastre P, Moritz S, Ochoa S, Spanish Metacognition Group. Is metacognitive training effective for improving neurocognitive function in patients with a recent onset of psychosis?. *Psychiatry Research*. 2022 Dec;318:114941. doi: 10.1016/j.psychres.2022.114941. PMID: 36375331
398. Kosenko E, Tikhonova L, Alilova G, Montoliu C. Is NMDA-receptor-mediated oxidative stress in mitochondria of peripheral tissues the essential factor in the pathogenesis of hepatic encephalopathy?. *Journal of Clinical Medicine*. 2022 Feb 4;11(3):827. doi: 10.3390/jcm11030827. PMID: 35160278
399. Amoretti S, Verdolini N, Varo C, Mezquida G, Sanchez-Torres A, Vieta E, Garcia-Rizo C, Lobo A, Gonzalez-Pinto A, Abregu-Crespo R, Corripio I, Serra M, de la Serna E, Mane A, Ramos-Quiroga J, Ribases M, Cuesta M, Bernardo M. Is the effect of cognitive reserve in longitudinal outcomes in first-episode psychoses dependent on the use of cannabis?. *Journal of Affective Disorders*. 2022 Apr 1;302:83-93. doi: 10.1016/j.jad.2022.01.077. PMID: 35066012

# publication list

- 400.Chen J, Zhuang R, Cheng HS, Jamaiyar A, Assa C, McCoy M, Rawal S, Perez-Cremades D, Feinberg MW. Isolation and culture of murine aortic cells and RNA isolation of aortic intima and media: Rapid and optimized approaches for atherosclerosis research. *Atherosclerosis*. 2022 Mar 11;347:39-46. doi: 10.1016/j.atherosclerosis.2022.03.011. PMID: 35306416
- 401.Tarin J, Garcia-Perez M, Cano A. It is premature to use postmortem sperm for reproductive purposes: a data-driven opinion. *Reproductive Sciences*. 2022 Dec;29(12):3387-3393. doi: 10.1007/s43032-022-00874-6. PMID: 35146695
- 402.Pardavila-Belio M, Hershey M, Barberia-Latasa M, Toledo E, Martin-Moreno J, Martinez-Gonzalez M, Ruiz-Canela M. Joint association of the Mediterranean diet and smoking with all-cause mortality in the Seguimiento Universidad de Navarra (SUN) cohort. *Nutrition*. 2022 Jun 2;103-104:111761. doi: 10.1016/j.nut.2022.111761. PMID: 35843044
- 403.Bou G, Calbo E, Crespo M, Canton R, de Luna F, Rodriguez J, Goenaga M, Gonzalez-Garcia J, Gonzalez J, Larrosa N, Martinez-Martinez L, Navarro D, Pano J, Rivero A, Rodriguez J, Tomas M, Vilaj J. Justification for 24/7 clinical microbiology services. *Enfermedades Infecciosas y Microbiología Clínica*. 2022 Jan;40(1):1-4. doi: 10.1016/j.eimc.2021.08.014. PMID: 34991847
- 404.Wara AK, Rawal S, Yang X, Perez-Cremades D, Sachan M, Chen J, Feinberg MW. KLF10 deficiency in CD4+T cells promotes atherosclerosis progression by altering macrophage dynamics. *Atherosclerosis*. 2022 Oct;359:27-41. doi: 10.1016/j.atherosclerosis.2022.08.019. PMID: 36174463
- 405.Chofer-Sierra E, Perez-Ros P, Julian-Rochina I, Long C, Cauli O. Knowledge and attitudes towards palliative care: validation of the Spanish version of questionnaire on palliative care for advanced dementia. *Healthcare*. 2022 Mar 31;10(4):656. doi: 10.3390/healthcare10040656. PMID: 35455834
- 406.Lucas I, Puteikis K, Sinha M, Litwin M, Merkevicius K, Azukaitis K, Rus R, Pac M, Obrycki L, Bardsen T, Sladowska-Kozlowska J, Sagsak E, Lurbe E, Jimenez-Murcia S, Jankauskiene A, Fernandez-Aranda F. Knowledge gaps and future directions in cognitive functions in children and adolescents with primary arterial hypertension: a systematic review. *Frontiers in Cardiovascular Medicine*. 2022 Oct 20;9:973793. doi: 10.3389/fcvm.2022.973793. PMID: 36337900
- 407.Belles A, Aguirre-Ramirez D, Abad I, Parras-Molto M, Sanchez L, Grasa L. Lactoferrin modulates gut microbiota and Toll-like receptors (TLRs) in mice with dysbiosis induced by antibiotics. *Food & Function*. 2022 May 23;13(10):5854-5869. doi: 10.1039/d2fo00287f. PMID: 35545893
- 408.Lopez-Campos JL, Jimenez-Ruiz CA, Meneses Petersen ED, Rabade Castedo C, Asensio Sanchez S, Vaquero Lozano P, Ferrer Espinosa S, Perez Soriano MP, de Higes Martinez E, Garcia de Llanos C, Pastor Espla E, Cabrera Cesar E, Mogrovejo S, Riesco Miranda JA, Barrueco Ferrero M, Callejas Gonzalez FJ, Sandoval Contreras R, Pena Miguel T, Peris Cardells R, Gonzalez Dou MV, Guzman Aguilar JM, Amado CA, Gorordo Unzueta MI, Rois Seijas P, Martinez Muniz MA, Naval Sendra E, Granda-Orive JL, Signes-Costa J. Smoking Cessation Units as a Source of COPD Diagnoses: Project 1000-200. *Archivos de Bronconeumología*. 2022 Mar;58(3):264-267. doi: 10.1016/j.arbres.2021.05.013. PMID: 34158184
- 409.Perez-Nunez I, Rozalen C, Palomeque J, Sangrador I, Dalmau M, Comerma L, Hernandez-Prat A, Casadevall D, Menendez S, Liu D, Shen M, Berenguer J, Ruiz I, Pena R, Montanes J, Alba M, Bonnin S, Pononarenko J, Gomis R, Cejalvo J, Servitja S, Marzese D, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celia-Terrassa T. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. *Nature Cancer*. 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. PMID: 35301507
- 410.Lopes H, Baptista-Leite R, Franco D, Serra M, Escudero A, Martin-Moreno J. Let's end HepC: modelling public health epidemiological policies applied to Hepatitis C in Spain. *Frontiers in Public Health*. 2022 Jan 7;9:735572. doi: 10.3389/fpubh.2021.735572. PMID: 35071151

# publication list

411. Perez-Ros P, Cauli O, Julian-Rochina I, Long C, Chover-Sierra E. Level of knowledge and attitudes towards palliative care for people with advanced dementia in Spain: role of professional and academic factors. *Current Alzheimer Research.* 2022 Dec 21. doi: 10.2174/1567205020666221221145259. PMID: 36545733
412. Munoz J, Lope V, Fernandez de Larrea-Baz N, Gomez-Ariza J, Dierssen-Sotos T, Fernandez-Tardon G, Aragones N, Amiano P, Gomez-Acebo I, Tardon A, Grau-Perez M, Garcia-Barrera T, Kogevinas M, Pollan M, Perez-Gomez B. Levels and determinants of urinary cadmium in general population in Spain: Metal-MCC-Spain study. *Environmental Research.* 2022 Feb 19;210:112959. doi: 10.1016/j.envres.2022.112959. PMID: 35189102
413. Nunez J, de la Espriella R, Formiga F. Light at the end of the tunnel of preserved heart failure, although important improvements are still necessary. *Revista Portuguesa de Cardiologia.* 2022 Oct;41(10):897-898. doi: 10.1016/j.repc.2022.01.008. PMID: 36207070
414. Segura A, Mezquida G, Martinez-Pinteno A, Gasoso P, Rodriguez N, Moreno-Izco L, Amoretti S, Bioque M, Lobo A, Gonzalez-Pinto A, Garcia-Alcon A, Roldan-Bejarano A, Vieta E, de la Serna E, Toll A, Cuesta M, Mas S, Bernardo M. Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode. *Psychological Medicine.* 2022 Jun 9:1-14. doi: 10.1017/S0033291722001544. PMID: 35678455
415. Wei D, Marrachelli V, Melgarejo J, Liao C, Janssens S, Verhamme P, Vanassche T, Van Aelst L, Monleon D, Redon J, Zhang Z. Lipoprotein profiles of fat distribution and its association with insulin sensitivity. *Frontiers in Endocrinology.* 2022 Oct 25;13:978745. doi: 10.3389/fendo.2022.978745. PMID: 36387872
416. Guzzardi M, La Rosa F, Campani D, Collado M, Monleon D, Insilla A, Tripodi M, Zega A, Dattilo A, Brunetto M, Maffei M, Bonino F, Iozzo P. Liver and white/brown fat dystrophy associates with gut microbiota and metabolomic alterations in 3xTg Alzheimer's Disease mouse model. *Metabolites.* 2022 Mar 22;12(4):278. doi: 10.3390/metabo12040278. PMID: 35448465
417. Di Martino M, Dorcaratto D, Primavesi F, Syn N, Blanco-Teres L, Dupre A, Piardi T, Rhaiem R, Fernandez G, De Armas Conde N, Rodriguez Sanjuan J, Santiago R, Fernandez-Moreno M, Ferret G, Ben S, Suarez Munoz M, Perez-Alonso A, Koh Y, Jones R, Vennarecci G, Martin-Perez E. Liver resection in elderly patients with extensive CRLM: are we offering an adequate treatment?. A propensity score matched analysis. *European Journal of Surgical Oncology.* 2022 Jun;48(6):1331-1338. doi: 10.1016/j.ejso.2021.12.028. PMID: 35000821
418. Saadi W, Fatmi A, Pallardo FV, Garcia-Gimenez JL, Mena-Molla S. Long non-coding RNAs as epigenetic regulators of immune checkpoints in cancer immunity. *Cancers.* 2022 Dec 28;15(1):184. doi: 10.3390/cancers15010184. PMID: 36612180
419. Pesarico A, Carceller H, Guirado R, Coviello S, Nacher J. Long term effects of 24-h-restraint stress on the connectivity and structure of interneurons in the basolateral amygdala. *Progress in Neuro-Psychopharmacology & Biological Psychiatry.* 2022 Apr 20;115:110512. doi: 10.1016/j.pnpbp.2022.110512. PMID: 35066055
420. Jimenez-Rodriguez T, De la Barrera U, Schoeps K, Valero-Moreno S, Montoya-Castilla I. Longitudinal analysis of adolescent adjustment: the role of attachment and emotional competence. *Children.* 2022 Nov 8;9(11):1711. doi: 10.3390/children9111711. PMID: 36360439
421. Pradas I, Jove M, Huynh K, Ingles M, Borras C, Mota-Martorell N, Galo-Licona JD, Puig J, Vina J, Meikle PJ, Pamplona R. Long-lived humans have a unique plasma sphingolipidome. *The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences.* 2022 Apr 1;77(4):728-735. doi: 10.1093/gerona/glab360. PMID: 34871393
422. Martinez-Camprecios J, Riveiro-Barciela M, Munoz-Gomez R, Londono MC, Roget M, Serra MA, Escudero-Garcia D, Purchades L, Rodriguez M, Losa-Garcia JE, Gutierrez ML, Carmona I, Garcia-Samaniego J, Morano L, Martin-Granizo I, Montero-Alonso M, Prieto M, Delgado M, Ramos N, Azancot MA, Rodriguez-Frias F, Buti M. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy.

# publication list

- py. Gastroenterologia y Hepatologia. 2022 Dec 27;S0210-5705(22)00313-2. doi: 10.1016/j.gastrohep.2022.12.004. PMID: 36584754
- 423.Gorriz J, D'Marco L, Pastor-Gonzalez A, Molina P, Gonzalez-Rico M, Puchades M, Sanchis I, Escudero V, Estan N, de la Espriella R, Nunez E, Pallardo L, Nunez J. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalemia. *Nephrology, Dialysis, Transplantation*. 2022 Feb 25;37(3):522-530. doi: 10.1093/ndt/gfab003. PMID: 33508124
- 424.Guijarro F, Bataller A, Diaz-Beya M, Garrido A, Coll-Ferra C, Vives S, Salamero O, Valcarcel D, Tormo M, Arnan M, Sampol A, Castano-Diez S, Martinez C, Suarez-Lledo M, Fernandez-Aviles F, Hernandez-Boluda J, Ribera J, Rovira M, Brunet S, Sierra J, Esteve J. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. *Bone Marrow Transplantation*. 2022 Aug;57(8):1304-1312. doi: 10.1038/s41409-022-01703-9. PMID: 35643942
- 425.Tizon-Marcos H, Toloba A, Cachinero I, Elosua R, Sionis A, Fernandez-Aviles F, Bueno H, Carrillo A, Bayes A, Sanchez P, Roque M, Mila L, Elorriaga A, Vaquero J, Fernandez-Berges D, Bosch D, Alamedia J, Almor J, Jimenez-Navarro M, Martinez L, Sanchis J, Sanchez E, Rubert C, Ruiz-Valdepenas L, Rodriguez M, Lozano I, Abu-Assi E, Gonzalez V, Marrugat J. Long-term outcomes of extended DAPT in a real-life cohort of consecutive STEMI patients. *Revista Espanola de Cardiologia* [English Ed.]. 2022 Dec 17;S1885-5857(22)00324-3. doi: 10.1016/j.rec.2022.12.003. PMID: 36539185
- 426.Di Martino M, Primavesi F, Syn N, Dorcaratto D, de la Hoz Rodriguez A, Dupre A, Piardi T, Rhaiem R, Blanco Fernandez G, de Armas Conde N, Rodriguez Sanjuan J, Fernandez Santiago R, Fernandez-Moreno M, Ferret G, Lopez Ben S, Suarez Munoz M, Perez-Alonso A, Koh Y, Jones R, Martin-Perez E. Long-term outcomes of perioperative versus neoadjuvant chemotherapy for resectable colorectal liver metastases: an international multicentre propensity-score matched analysis with stratification by contemporary risk-scoring. *Annals of Surgical Oncology*. 2022 Oct;29(11):6829-6842. doi: 10.1245/s10434-022-12027-9. PMID: 35849284
- 427.de la Espriella R, Navarro J, Mollar A, D'Marco L, Palau P, Minana G, Llacer P, Santas E, Heredia R, Gonzalez M, Gorriz JL, Codina P, Diez J, Bayes-Genis A, Nunez J. Long-term prognostic impact of estimated glomerular filtration rate on admission in patients hospitalized for acute heart failure. *Cardiorenal Medicine*. 2022 Oct 25;1-9. doi: 10.1159/000526105. PMID: 36282062
- 428.Chaparro M, Baston-Rey I, Fernandez-Salgado E, Gonzalez Garcia J, Ramos L, Diz-Lois Palomares M, Arguelles-Arias F, Iglesias Flores E, Cabello M, Rubio Iturria S, Nunez Ortiz A, Charro M, Ginard D, Duenas Sadornil C, Merino Ochoa O, Busquets D, Iyo E, Gutierrez Casbas A, Ramirez de la Piscina P, Bosca-Watts M, Arroyo M, Garcia M, Hinojosa E, Gordillo J, Martinez Montiel P, Velayos Jimenez B, Quilez Ivorra C, Vazquez Moron J, Maria Huguet J, Gonzalez-Lama Y, Munagorri Santos A, Amo V, Martin-Arranz M, Bermejo F, Martinez Cadilla J, Rubin de Celix C, Fradejas Salazar P, San Roman A, Jimenez N, Garcia Lopez S, Figueroa A, Jimenez I, Martinez Cerezo F, Taxonera C, Varela P, de Francisco R, Monfort D, Molina Arriero G, Hernandez Camba A, Garcia-Alonso F, Van Domselaar M, Pajares Villarroya R, Nunez A, Rodriguez Moranta F, Marin-Jimenez I, Robles Alonso V, Martin Rodriguez M, Camo-Monterde P, Garcia Tercero I, Navarro Llavat M, Arias Garcia L, Hervas Cruz D, Silleiro S, Novella C, Vispo E, Barreiro-de Acosta M, Gisbert J. Long-term real-world effectiveness and safety of ustekinumab in Crohn's disease patients: the SUSTAIN Study. *Inflammatory Bowel Diseases*. 2022 Nov 2;28(11):1725-1736. doi: 10.1093/ibd/izab357. PMID: 35166347
- 429.Triguero A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, Velez P, Fox L, Gomez-Calafat M, Garcia-Delgado R, Gasior M, Ferrer-Marin F, Garcia-Gutierrez V, Angona A, Gomez-Casares MT, Cuevas B, Martinez C, Perez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernandez-Boluda JC, Sanz C, Alvarez-Larran A. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients

# publication list

- from the Spanish Registry of Polycythemia Vera. *Annals of Hematology.* 2022 Oct;101(10):2231-2239. doi: 10.1007/s00277-022-04963-z. PMID: 36042023
- Triguero A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, Velez P, Fox L, Gomez-Calafat M, Garcia-Delgado R, Gasior M, Ferrer-Marin F, Garcia-Gutierrez V, Angona A, Gomez-Casares MT, Cuevas B, Martinez C, Perez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernandez-Boluda JC, Sanz C, Alvarez-Larran A. Correction to: Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. *Annals of Hematology.* 2022 Dec;101(12):2819-2820. doi: 10.1007/s00277-022-05005-4. PMID: 36264368
- 430.Ortiz-Zapater E, Signes-Costa J, Montero P, Roiger I. Lung fibrosis and fibrosis in the lungs: is it all about myofibroblasts?. *Biomedicines.* 2022 Jun 15;10(6):1423. doi: 10.3390/biomedicines10061423. PMID: 35740444
- 431.Tarraso J, Safont B, Carbonell-Asins JA, Fernandez-Fabrellas E, Sancho-Chust JN, Naval E, Amat B, Herrera S, Ros JA, Soler-Cataluna JJ, Rodriguez-Portal JA, Andreu AL, Marin M, Rodriguez-Hermosa JL, Gonzalez-Villaescusa C, Soriano JB, Signes-Costa J. Lung function and radiological findings 1 year after COVID-19: a prospective follow-up. *Respiratory Research.* 2022 Sep 12;23(1):242. doi: 10.1186/s12931-022-02166-8. PMID: 36096801
- 432.Safont B, Tarraso J, Rodriguez-Borja E, Fernandez-Fabrellas E, Sancho-Chust JN, Molina V, Lopez-Ramirez C, Lope-Martinez A, Cabanes L, Andreu A, Herrera S, Lahosa C, Ros JA, Rodriguez-Hermosa JL, Soriano JB, Moret-Tatay I, Carbonell-Asins JA, Mulet A, Signes-Costa J. Lung function, radiological findings and biomarkers of fibrogenesis in a cohort of COVID-19 patients six months after hospital discharge. *Archivos de Bronconeumologia.* 2022 Feb;58(2):142-149. doi: 10.1016/j.arbres.2021.08.014. PMID: 34497426
- 433.Mosquera-Orgueira A, Perez-Encinas M, Hernandez-Sanchez A, Gonzalez-Martinez T, Arellano-Rodrigo E, Martinez-Elicegui J, Villaverde-Ramiro A, Raya JM, Ayala R, Ferrer-Marin F, Fox ML, Velez P, Mora E, Xicoy B, Mata-Vazquez MI, Garcia-Fortes M, Angona A, Cuevas B, Senin MA, Ramirez-Payer A, Ramirez MJ, Perez-Lopez R, Gonzalez de Villam-brosia S, Martinez-Valverde C, Gomez-Casares MT, Garcia-Hernandez C, Gasior M, Bellosillo B, Steegmann JL, Alvarez-Larran A, Hernandez-Rivas JM, Hernandez-Boluda JC. Machine learning improves risk stratification in myelofibrosis: an analysis of the Spanish registry of myelofibrosis. *Hemasphere.* 2022 Dec 20;7(1):e818. doi: 10.1097/HS9.0000000000000818. PMID: 36570691
- 434.Lopez-Lopez V, Maupoey J, Lopez-Andujar R, Ramos E, Mils K, Martinez P, Valdivieso A, Garces-Albir M, Sabater L, Valladares L, Perez S, Flores B, Brusadin R, Conesa A, Cayuela V, Cortijo S, Paterna S, Serrablo A, Sanchez-Cabus S, Gil A, Masia J, Loinaz C, Lucena J, Pastor P, Garcia-Zamora C, Calero A, Valiente J, Minguillon A, Rotellar F, Ramia J, Alcazar C, Aguiló J, Cutillas J, Kuemmerli C, Ruiperez-Valiente J, Robles-Campos R. Machine learning-based analysis in the management of iatrogenic bile duct injury during cholecystectomy: a nationwide multicenter study. *Journal of Gastrointestinal Surgery.* 2022 Aug;26(8):1713-1723. doi: 10.1007/s11605-022-05398-7. PMID: 35790677
- 435.Gavara J, Marcos-Garces V, Lopez-Lereu, MP, Monmeneu JV, Rios-Navarro C, de Dios E, Perez N, Merenciano H, Gabaldon A, Canoves J, Racugno P, Bonanad C, Minana G, Nunez J, Nunez E, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Rodriguez-Palomares JF, Ortiz-Perez JT, Bodi V. Magnetic resonance assessment of left ventricular ejection fraction at any time post-infarction for prediction of subsequent events in a large multicenter STEMI Registry. *Journal of Magnetic Resonance Imaging.* 2022 Aug;56(2):476-487. doi: 10.1002/jmri.27789. PMID: 34137478
- 436.Torres A, Motos A, Cilloniz C, Ceccato A, Fernandez-Barat L, Gabarrus A, Bermejo-Martin J, Ferrer R, Riera J, Perez-Arnal R, Garcia-Gasulla D, Penuelas O, Lorente J, de Gonzalo-Calvo D, Almansa R, Menendez R, Palomeque A, Villar R, Anon J, Marino A, Barbera C, Barberan J, Ortiz A, Boado M, Bustamante-Munguira E, Caballero

# publication list

- J, Canton-Bulnes M, Perez C, Carbonell N, Cata-lan-Gonzalez M, de Frutos R, Franco N, Galban C, Gumucio-Sanguino V, de la Torre M, Diaz E, Estella A, Gallego E, Garmendia J, Gomez J, Huerta A, Gar-cia R, Loza-Vazquez A, Marin-Corral J, Delgado M, de la Gandara A, Varela I, Messa J, Albaiceta G, Nieto M, Novo M, Penasco Y, Perez-Garcia F, Pozo-Laderas J, Ricart P, Sagredo V, Sanchez-Miralles A, Chinesta S, Serra-Fortuny M, Socias L, Sole-Violan J, Suarez-Sipmann F, Lomas L, Trenado J, Ubeda A, Valdivia L, Vidal P, Barbe F. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. *Intensive Care Medicine.* 2022 Jul;48(7):850-864. doi: 10.1007/s00134-022-06726-w. PMID: 35727348
437. Ferrer-Quintero M, Fernandez D, Lopez-Carrilero R, Birules I, Barajas A, Lorente-Rovira E, Luengo A, Diaz-Cutraro L, Verdaguera M, Garcia-Mieres H, Gu-tierrez-Zotes A, Grasa E, Pousa E, Huerta-Ramos E, Pelaez T, Barrigon M, Gomez-Benito J, Gonzalez-Higueras F, Ruiz-Delgado I, Cid J, Moritz S, Sevilla-Llewellyn-Jones J, Ochoa S. Males and females with first episode psychosis present distinct pro-files of social cognition and metacognition. *European Archives of Psychiatry and Clinical Neuro-scienece.* 2022 Oct;272(7):1169-1181. doi: 10.1007/s00406-022-01438-0. PMID: 35802165
438. Lorenzo Hernandez M, Sanchis J. Management of acute decompensated heart failure in Spain: whe-re are we now?. *Emergencias.* 2022 Apr;34(2):81-82. PMID: 35275457
439. Suria C, Bosca-Watts MM, Navarro P, Tosca J, An-ton R, Sanahuja A, Revaliente M, Minguez M. Ma-nagement of patients with Intestinal Bowel Disease and COVID-19: a review of current evidence and future perspectives. *Gastroenterologia y Hepato-logia.* 2022 May;45(5):383-389. doi: 10.1016/j.gastrohep.2021.06.005. PMID: 34171421
440. Local Burden of Disease Household Air Pollution Collaborators. Mapping development and health effects of cooking with solid fuels in low-income and middle-income countries, 2000-18: a geospatial modelling study. *Lancet. Global Health.* 2022 Oct;10(10):e1395-e1411. doi: 10.1016/S2214-109X(22)00332-1. PMID: 36113526
441. Trubetskoy V, Pardinas A, Qi T, Panagiotaropoulou G, Indonesia Schizophrenia Consortium, PsychEN-CODE, Psychosis Endophenotypes International Consortium, SynGO Consortium, Schizophrenia Working Group of the Psychiatric Genomics Consortium. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature.* 2022 Apr;604(7906):502-508. doi: 10.1038/s41586-022-04434-5. PMID: 35396580
442. San-Miguel T, Megias J, Monleon D, Navarro L, Munoz-Hidalgo L, Montoliu C, Meri M, Roldan P, Cerdá-Nicolas M, Lopez-Gines C. Matched paired primary and recurrent meningiomas points to cell-death program contributions to genomic and epigenomic instability along tumor progression. *Cancers.* 2022 Aug 19;14(16):4008. doi: 10.3390/cancers14164008. PMID: 36011000
443. Selma-Royo M, Gonzalez S, Gueimonde M, Chang M, Furst A, Martinez-Costa C, Bode L, Collado M. Maternal diet is associated with human milk oligosaccharide profile. *Molecular Nutrition & Food Research.* 2022 Aug;66(15):e2200058. doi: 10.1002/mnfr.202200058. PMID: 35612565
444. Capalbo A, Buonaiuto S, Figliuzzi M, Damaggio G, Gi-rardi L, Caroselli S, Poli M, Patassini C, Cetinkaya M, Yuksel B, Azad A, Grondahl M, Hoffmann E, Simon C, Colonna V, Kahraman S. Maternal exome analy-sis for the diagnosis of oocyte maturation defects and early embryonic developmental arrest. *Reproductive Biomedicine Online.* 2022 Sep;45(3):508-518. doi: 10.1016/j.rbmo.2022.05.009. PMID: 35798635
445. Alonso J, Vilagut G, Alayo I, Ferrer M, Amigo F, Ara-gon-Pena A, Aragones E, Campos M, Del Cura-Gon-zalez I, Urreta I, Espuga M, Pinto A, Haro J, Fres-nena N, de Salazar A, Molina J, Lucas R, Parellada M, Pelayo-Teran J, Zapata A, Pijoan J, Plana N, Puig M, Rius C, Rodriguez-Blazquez C, Sanz F, Serra C, Kessler R, Bruffaerts R, Vieta E, Perez-Sola V, Mor-tier P. Mental impact of COVID-19 among Spanish healthcare workers. A large longitudinal survey. *Epidemiology and Psychiatric Sciences.* 2022 Apr 29;31:e28. doi: 10.1017/S2045796022000130. PMID: 35485802
446. Palomar A, Gonzalez-Martin R, Perez-Deben S, Me-dina-Laver Y, Quinonero A, Dominguez F. Mercury

# publication list

- impairs human primary endometrial stromal cell function [dagger]. *Biology of Reproduction*. 2022 May 17;106(5):1022-1032. doi: 10.1093/biolre/ioac016. PMID: 35084015
447. Martinez-Arroyo O, Ortega A, Forner M, Cortes R. Mesenchymal stem cell-derived extracellular vesicles as non-coding RNA therapeutic vehicles in autoimmune diseases. *Pharmaceutics*. 2022 Mar 29;14(4):733. doi: 10.3390/pharmaceutics14040733. PMID: 35456567
448. Ortega M, Rios-Navarro C, Gavara J, de Dios E, Perez-Sole N, Marcos-Garcés V, Ferrandez-Izquierdo A, Bodi V, Ruiz-Sauri A. Meta-analysis of extracellular matrix dynamics after myocardial infarction using RNA-sequencing transcriptomic database. *International Journal of Molecular Sciences*. 2022 Dec 9;23(24):15615. doi: 10.3390/ijms232415615. PMID: 36555255
449. Segura A, Martinez-Pinteno A, Gasso P, Rodriguez N, Bioque M, Cuesta M, Gonzalez-Penas J, Garcia-Rizo C, Lobo A, Gonzalez-Pinto A, Garcia-Alcon A, Roldan A, Vista E, Castro-Fornieles J, Mane A, Saiz J, Bernardo M, Mas S. Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort. *Schizophrenia Research*. 2022 Jun;244:101-110. doi: 10.1016/j.schres.2022.05.021. PMID: 35659654
450. Ballester M, Gallego J, Fiorillo A, Casanova-Ferrer F, Gimenez-Garzo C, Escudero-Garcia D, Tosca J, Rios M, Monton C, Durban L, Ballester J, Benlloch S, Urios A, San-Miguel T, Kosenko E, Serra M, Felipe V, Montoliu C. Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. *Scientific Reports*. 2022 Feb 14;12(1):2463. doi: 10.1038/s41598-022-06416-z. PMID: 35165326
451. Pertusa C, Mifsut D, Morales J, Tarin J, Cano A, Monleon D, Garcia-Perez M. Metabolomic analysis of severe osteoarthritis in a Spanish population of women compared to healthy and osteoporotic subjects. *Metabolites*. 2022 Jul 24;12(8):677. doi: 10.3390/metabo12080677. PMID: 35893245
452. Arias-Borrego A, Soto Cruz FJ, Selma-Royo M, Bäuerl C, García Verdevio E, Pérez-Cano FJ, Lerin C, Velasco López I, Martínez-Costa C, Collado MC, García-Barrera T. Metallomic and untargeted metabolomic signatures of human milk from SARS-CoV-2 Positive mothers. *Molecular Nutrition & Food Research*. 2022 Aug;66(16):e2200071. doi: 10.1002/mnfr.202200071. PMID: 35687731
453. de Maranon A, Diaz-Pozo P, Canet F, Diaz-Morales N, Abad-Jimenez Z, Lopez-Domenech S, Vezza T, Apostolova N, Morillas C, Rocha M, Victor V. Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients. *Redox Biology*. 2022 Jul;53:102342. doi: 10.1016/j.redox.2022.102342. PMID: 35605453
454. Vezza T, Victor V. Metformin: an intriguing protective agent in hospitalized diabetic patients with sepsis. *Critical Care Medicine*. 2022 Jun 1;50(6):1018-1020. doi: 10.1097/CCM.0000000000005480. PMID: 35612442
455. Vidal Oliver L, Bayo Calduch P, Forque Rodriguez L, Navarro Ortega D, Duch Samper AM, Colomina Rodriguez J. Methicillin-resistant *Staphylococcus epidermidis* infectious keratitis: clinical and microbiological profile. *Revista Espanola de Quimioterapia*. 2022 Apr;35(2):171-177. doi: 10.37201/req/128.2021. PMID: 35067009
456. Correa-Ghisays P, Vicent Sanchez-Orti J, Balanza-Martinez V, Fuentes-Dura I, Martinez-Aran A, Ruiz-Bolo L, Correa-Estrada P, Ruiz-Ruiz J, Selva-Vera G, Vila-Frances J, Macias Saint-Gerons D, San-Martin C, Ayesa-Arriola R, Tabares-Seisdedos R. MICEmi: a method to identify cognitive endophenotypes of mental illnesses. *European Psychiatry*. 2022 Nov 28;65(1):e85. doi: 10.1192/j.eurpsy.2022.2348. PMID: 36440538
457. Medina-Gonzalez M, Panach-Navarrete J, Mata-Cano D, Jabaloyas J. Microbladder due to granulomatous cystitis secondary to BCG Treatment. *Archivos Espanoles de Urologia*. 2022 Oct;75(8):729-730. doi: 10.56434/j.arch.esp.urol.20227508.105. PMID: 36330575
458. Morales-Rosello J, Loscalzo G, Garcia-Lopez EM, Ibanez Cabellos JS, Garcia-Gimenez JL, Canada Martinez AJ, Perales Marin A. MicroRNA-185-5p: a marker of brain-sparing in

# publication list

- foetuses with late-onset growth restriction. *Epigenetics*. 2022 Nov;17(11):1345-1356. doi: 10.1080/15592294.2021.2023271. PMID: 34969362
- 459.Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. MicroRNAs as a clue to overcome breast cancer treatment resistance. *Cancer Metastasis Reviews*. 2022 Mar;41(1):77-105. doi: 10.1007/s10555-021-09992-0. PMID: 34524579
- 460.Rios-Navarro C, Gavara J, Bodi V. Microvascular injury after acute myocardial infarction. Focus on the catheterization laboratory. *Revista Espanola de Cardiologia* [English Ed.]. 2022 Oct;75(10):777-779. doi: 10.1016/j.rec.2022.05.011. PMID: 35676174
- 461.Casanova-Ferrer F, Garcia-Cena CE, Gallego JJ, Fiorillo A, Urios A, Calvo-Cordoba A, Ballester MP, Rios MP, Durban L, Hidalgo MR, Garcia F, Felipo V, Montoliu C. Minimal hepatic encephalopathy is associated to alterations in eye movements. *Scientific Reports*. 2022 Oct 7;12(1):16837. doi: 10.1038/s41598-022-21230-3. PMID: 36207472
- 462.Tarazona N, Gimeno-Valiente F, Cervantes A. Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible. *ESMO Open*. 2022 Aug;7(4):100547. doi: 10.1016/j.esmoop.2022.100547. PMID: 35849878
- 463.Zhou H, Yang D, Cheng H, McCoy M, Perez-Cremades D, Haemmig S, Wong D, Chen L, Feinberg M. miR-181b regulates vascular endothelial aging by modulating an MAP3K3 signaling pathway. *FASEB Journal*. 2022 Jun;36(6):e22353. doi: 10.1096/fj.202200046R. PMID: 35593587
- 464.Ferri C, Di Biase A, Bocchetti M, Zappavigna S, Wagner S, Le Vu P, Luce A, Cossu A, Vadakekolathu J, Miles A, Boocock D, Robinson A, Schwerdtfeger M, Tirino V, Papaccio F, Caraglia M, Regad T, Desiderio V. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. *Journal of Experimental & Clinical Cancer Research*. 2022 Jan 11;41(1):20. doi: 10.1186/s13046-021-02233-w. PMID: 35016717
- 465.Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gurpide J, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies. *Cancer Communications*. 2022 Dec;42(12):1412-1416. doi: 10.1002/cac2.12352. PMID: 35997029
- 466.Canet F, Diaz-Pozo P, Luna-Marco C, Fernandez-Reyes M, Vezza T, Marti M, Salazar J, Roldan I, Morillas C, Rovira-Llopis S, Rocha M, Victor V. Mitochondrial redox impairment and enhanced autophagy in peripheral blood mononuclear cells from type 1 diabetic patients. *Redox Biology*. 2022 Dec;58:102551. doi: 10.1016/j.redox.2022.102551. PMID: 36455476
- 467.Samuel T, Thielecke F, Lavalle L, Chen C, Fogel P, Giuffrida F, Dubascoux S, Martinez-Costa C, Halaland K, Marchini G, Agosti M, Rakza T, Costeira M, Picaud J, Billeaud C, Thakkar S. Mode of neonatal delivery influences the nutrient composition of human milk: results from a multicenter European cohort of lactating women. *Frontiers in Nutrition*. 2022 Apr 6;9:834394. doi: 10.3389/fnut.2022.834394. PMID: 35464009
- 468.Punzon-Jimenez P, Lago V, Domingo S, Simon C, Mas A. Molecular management of high-grade serous ovarian carcinoma. *International Journal of Molecular Sciences*. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777. PMID: 36430255
- 469.Forque L, Albert E, Gimenez E, Torres I, Carbonell N, Ferreres J, Blasco M, Navarro D. Monitoring of Torque Teno virus DNAemia in critically ill COVID-19 patients: may it help to predict clinical outcomes?. *Journal of Clinical Virology*. 2022 Jan 23;148:105082. doi: 10.1016/j.jcv.2022.105082. PMID: 35091226
- 470.Cordero A, Nunez J, Bertomeu-Gonzalez V, Facila L, Quintanilla M, Rodriguez-Manero M, Escribano D, Valle A, de la Espriella R, Torres-Llergo J, Bayes-Genis A, Gonzalez-Juanatey J. Mortality and heart failure risk reductions in patients treated with sacubitril-valsartan in clinical trials. *American Journal of Therapeutics*. 2022 Sep-Oct 01;29(5):e572-e575. doi: 10.1097/MJT.0000000000001503. PMID: 36074989

# publication list

471. Gebran A, Gaitanidis A, Argandykov D, Maurer L, Gallastegi A, Bokenkamp M, Alser O, Nepogodiev D, Bhangu A, Kaafarani H. Mortality and pulmonary complications in emergency general surgery patients with COVID-19: a large international multicenter study. *Journal of Trauma and Acute Care Surgery.* 2022 Jul 1;93(1):59-65. doi: 10.1097/TA.00000000000003577. PMID: 35195098
472. Catala-Lopez F, Hutton B, Page M, Driver J, Ridao M, Alonso-Arroyo A, Valencia A, Macias Saint-Gerons D, Tabares-Seisdedos R. Mortality in persons with autism spectrum disorder or attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. *JAMA Pediatrics.* 2022 Apr 1;176(4):e216401. doi: 10.1001/jamapedia-trics.2021.6401. PMID: 35157020
473. Codina P, Zamora E, Levy W, Revuelta-Lopez E, Borrellas A, Spitaleri G, Cediol G, Ruiz-Cueto M, Canedo E, Santiago-Vacas E, Domingo M, Buchaca D, Subirana I, Santesmases J, de la Espriella R, Nunez J, Lupon J, Bayes-Genis A. Mortality risk prediction dynamics after heart failure treatment optimization: repeat risk assessment using online risk calculators. *Frontiers In Cardiovascular Medicine.* 2022 Apr 12;9:836451. doi: 10.3389/fcvm.2022.836451. PMID: 35498033
474. Januel C, Menduti G, Mamchaoui K, Martinat C, Artero R, Konieczny P, Boido M. Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model. *Cellular and Molecular Life Sciences.* 2022 Jul 22;79(8):441. doi: 10.1007/s00018-022-04450-8. PMID: 35864358
475. Casadevall D, Hernandez-Prat A, Garc A-Alonso S, Arpi-Llucia O, Menendez S, Qin M, Guardia C, Morrancho B, Sanchez-Mart N F, Zazo S, Gavilan E, Sabbagh M, Eroles P, Cejalvo J, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. *Molecular Cancer Research.* 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. PMID: 35348729
476. Torres I, Huntley D, Tormo M, Calabuig M, Hernandez-Boluda J, Terol M, Carretero C, de Michelena P, Perez A, Pinana J, Colomina J, Solano C, Navarro D. Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients. *BMC Infectious Diseases.* 2022 Feb 21;22(1):172. doi: 10.1186/s12879-022-07154-3. PMID: 35189833
477. Garcia Sumalla A, Loras C, Sanchiz V, Sanz R, Vazquez Sequeiros E, Aparicio J, De la Serna Higuera C, Luna Rodriguez D, Andujar X, Capilla M, Barbera T, Foruny Olcina J, Martinez B, Dura M, Salord S, Laquente B, Tebe C, Videla S, Perez-Miranda M, Gornals J. Multicenter study of lumen-apposing metal stents with or without pigtail in endoscopic ultrasound-guided biliary drainage for malignant obstruction-BAMPI TRIAL: an open-label, randomized controlled trial protocol. *Trials.* 2022 Feb 25;23(1):181. doi: 10.1186/s13063-022-06106-1. PMID: 35216619
- Garcia-Sumalla A, Loras C, Sanchiz V, Sanz R, Vazquez-Sequeiros E, Aparicio J, de la Serna-higuera C, Luna-Rodriguez D, Andujar X, Capilla M, Barbera T, Foruny-Olcina J, Martinez B, Dura M, Salord S, Laquente B, Tebe C, Videla S, Perez-Miranda M, Gornals J, Spanish Working Grp Endoscopic. Correction to: Multicenter study of lumen-apposing metal stents with or without pigtail in endoscopic ultrasound-guided biliary drainage for malignant obstruction-BAMPI TRIAL: an open-label, randomized controlled trial protocol. *Trials.* 2022 Mar 14;23(1):214. doi: 10.1186/s13063-022-06138-7. PMID: 35287708
478. Cunnane SC, Swerdlow RH, Inzitari M, Olaso-Gonzalez G, Vina J. Multimodal strategy to rescue the brain in mild cognitive impairment: ketogenic oral nutrition supplementation with B vitamins and aerobic exercise. *European Journal of Clinical Investigation.* 2022 Sep;52(9):e13806. doi: 10.1111/eci.13806. PMID: 35488743
479. Bergeron A, Mikulska M, De Greef J, Bondeelle L, Franquet T, Herrmann J, Lange C, Spriet I, Akova M, Donnelly J, Maertens J, Maschmeyer G, Rovira M, Goletti D, de la Camara R. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia. *Lancet Infectious Diseases.* 2022 Dec;22(12):e359-e369. doi: 10.1016/

# publication list

- S1473-3099(22)00227-4. PMID: 35636446
- 480.Obrador E, Salvador-Palmer R, Lopez-Blanch R, Oriol-Caballo M, Moreno-Murciano P, Estrella J. N-Acetylcysteine promotes metastatic spread of melanoma in mice. *Cancers.* 2022 Jul 25;14[15]:3614. doi: 10.3390/cancers14153614. PMID: 35892873
- 481.Redon J, Seeman T, Pall D, Suuorog L, Kamperis K, Erdine S, Wuhl E, Mancia G. Narrative update of clinical trials with antihypertensive drugs in children and adolescents. *Frontiers In Cardiovascular Medicine.* 2022 Nov 21;9:1042190. doi: 10.3389/fcvm.2022.1042190. PMID: 36479567
- 482.Zabana Y, Marin-Jimenez I, Rodriguez-Lago I, et al. Nationwide COVID-19-EII study: incidence, environmental risk factors and long-term follow-up of patients with inflammatory bowel disease and COVID-19 of the ENEIDA Registry. *Journal of Clinical Medicine.* 2022 Jan 14;11[2]:421. doi: 10.3390/jcm11020421. PMID: 35054116
- 483.Garcia-Gausi M, Garcia-Armengol J, Pellino G, Muñas C, Roig J, Garcia-Granero A, Moro D, Valverde A. Navigating surgical anatomy of the Denonvilliers' fascia and dissection planes of the anterior mesorectum with a cadaveric simulation model. *Updates in Surgery.* 2022 Apr;74[2]:629-636. doi: 10.1007/s13304-022-01252-2. PMID: 35286602
- 484.Lorente-Pozo S, Boronat N, Parra-Llorca A, Lara-Canton I, Solaz-Garcia A, Soler J, Buso E, Casabó-Valles G, Garcia-Gimenez J, Pallardo F, Vento M. Neurodevelopmental outcome and epigenetic changes at 2 years associated with the oxygen load received upon postnatal stabilization: a pilot study. *Neonatology.* 2022;119[5]:575-584. doi: 10.1159/000525305. PMID: 35760056
- 485.Sánchez-Sendra B, Albert E, Zulaica J, Torres I, Giménez E, Botija P, Beltrán MJ, Rodado C, Geller R, Navarro D. Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. *Scientific Reports.* 2022 Mar 8;12[1]:3788. doi: 10.1038/s41598-022-07849-2. PMID: 35260713
- 486.Bioque M, Matias-Martins A, Llorca-Bofi V, Mezquida G, Cuesta M, Vieta E, Amorette S, Lobo A, Gonzalez-Pinto A, Moreno C, Roldan A, Martinez-Aran A, Baeza I, Berge D, Garcia-Rizo C, Herrero S, Bernardo M, 2EPs GROUP. Neutrophil to lymphocyte ratio in patients with a first episode of psychosis: a two-year longitudinal follow-up study. *Schizophrenia Bulletin.* 2022 Nov 18;48[6]:1327-1335. doi: 10.1093/schbul/sbac089. PMID: 35876785
- 487.Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. *Cellular & Molecular Immunology.* 2022 Feb;19[2]:177-191. doi: 10.1038/s41423-021-00832-3. PMID: 35039631
- 488.Orti Lucas R, Luciano E. New immunomagnetic separation method to analyze risk factors for Legionella colonization in health care centres. *Journal of Exposure Science and Environmental Epidemiology.* 2022 Sep;32[5]:744-750. doi: 10.1038/s41370-022-00421-0. PMID: 35264765
- 489.Redon J. New insights of cardiovascular and renal protection in diabetic chronic kidney disease with finerenone. *Cardiovascular Research.* 2022 Mar 25;118[5]:e36-e37. doi: 10.1093/cvr/cvac024. PMID: 35333317
- 490.Perez-Benavente B, Fathinajafabadi A, de la Fuente L, Gandia C, Martinez-Ferriz A, Pardo-Sanchez J, Milian L, Conesa A, Romero O, Carretero J, Matthiesen R, Jariel-Encontre I, Piechaczyk M, Farras R. New roles for AP-1/JUNB in cell cycle control and tumorigenic cell invasion via regulation of cyclin E1 and TGF-beta2. *Genome Biology.* 2022 Dec 9;23[1]:252. doi: 10.1186/s13059-022-02800-0. PMID: 36494864
- 491.Talens-Visconti R, Perra M, Ruiz-Sauri A, Nacher A. New vechicalation systems of mometasone furoate for the treatment of inflammatory skin diseases. *Pharmaceutics.* 2022 Nov 22;14[12]:2558. doi: 10.3390/pharmaceutics14122558. PMID: 36559053
- 492.Battaglini D, Premraj L, Huth S, Fanning J, Whitman G, Arora R, Bellapart J, Porto D, Taccone F, Suen J, Li Bassi G, Fraser J, Badenes R, Cho S, Robba C. Non-invasive multimodal neuromonitoring in non-critically ill hospitalized adult patients with COVID-19: a systematic review and meta-analysis. *Frontiers in Neurology.* 2022 Apr 14;13:814405. doi: 10.3389/fneur.2022.814405. PMID: 35493827

# publication list

493. Navarro-Sanchez L, Garcia-Pascual C, Rubio C, Simon C. Non-invasive preimplantation genetic testing for aneuploidies: an update. *Reproductive Biomedicine Online*. 2022 May;44(5):817-828. doi: 10.1016/j.rbmo.2022.01.012. PMID: 35307298
494. Tornero C, Pastor E, Garzando M, Orduna J, Forner M, Bocigas I, Cedeno D, Vallejo R, McClure C, Czura C, Liebler E, Staats P. Non-invasive vagus nerve stimulation for COVID-19: results from a randomized controlled trial [SAVIOR I]. *Frontiers in Neurology*. 2022 Apr 8;13:820864. doi: 10.3389/fneur.2022.820864. PMID: 35463130
495. Garcia-Vigara A, Cano A, Fernandez-Garrido J, Carbonell-Asins J, Tarin J, Sanchez-Sanchez M. Non-use of information and communication technology as a predictor of frailty in postmenopausal midlife and older women. *Maturitas*. 2022 Feb;156:60-64. doi: 10.1016/j.maturitas.2021.05.010. PMID: 34275701
496. Bayona J, Garcia C, Palop N, Martin A, Padron C, Rodriguez J, Peman J, Cardona C. Novel chromogenic medium CHROMagar TM candida plus for detection of candida auris and other candida species from surveillance and environmental samples: a multicenter study. *Journal of Fungi*. 2022 Mar 9;8(3):281. doi: 10.3390/jof8030281. PMID: 35330283
497. Jimenez-Marti E, Hurtado-Genoves G, Aguilar-Ballester M, Martinez-Hervas S, Gonzalez-Navarro H. Novel therapies for cardiometabolic disease: recent findings in studies with hormone peptide-derived G protein coupled receptor agonists. *Nutrients*. 2022 Sep 13;14(18):3775. doi: 10.3390/nu14183775. PMID: 36145148
498. Buigues C, Trapero I, Velasco JA, Salvador Sanz A, Jennings C, Wood D, Queralt A. Nurse-led and interdisciplinary secondary cardiovascular prevention programmes: Spanish cohort of the EUROACTION Project. *Endocrine, Metabolic & Immune Disorders Drug Targets*. 2022;22(13):1319-1329. doi: 10.2174/1871530322666220331154354. PMID: 35362378
499. Sosa-Palanca E, Saus-Ortega C, Gea-Caballero V, Andani-Cervera J, Garcia-Martinez P, Orti-Lucas R. Nurses' perception of patient safety culture in a referral hospital: a cross-sectional study. *International Journal of Environmental Research and Public Health*. 2022 Aug 16;19(16):10131. doi: 10.3390/ijerph191610131. PMID: 36011763
500. Bauset C, Martinez-Aspas A, Smith-Ballester S, Garcia-Vigara A, Monllor-Tormos A, Kadi F, Nilsson A, Cano A. Nuts and metabolic syndrome: reducing the burden of metabolic syndrome in menopause. *Nutrients*. 2022 Apr 18;14(8):1677. doi: 10.3390/nu14081677. PMID: 35458240
501. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology*. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. PMID: 35914638
502. Moya-Alarcon C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, Barretina-Ginesta M, Perez-Fidalgo J, Redondo A. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: is it cost-effective in Spain. *Gynecologic Oncology*. 2022 Feb;164(2):406-414. doi: 10.1016/j.ygyno.2021.11.011. PMID: 34844775
503. Vicente C, Lacruz L, Gascon F, Carratala S, Quintanilla-Bordas C, Sanz M, Carcelen-Gadea M, Maldada J, Carreres J, Torres L, Dominguez J, Canizares E, Gil-Perotin S, Cubas L, Rubio R, Castillo-Villalba J, Perez-Miralles F, Casanova B. Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis. *Frontiers in Neurology*. 2022 Oct 28;13:991596. doi: 10.3389/fneur.2022.991596. PMID: 36388220
504. Cejalvo JM, Falato C, Villanueva L, Tolosa P, Gonzalez X, Pascal M, Canes J, Gavila J, Manso L, Pascual T, Prat A, Salvador F. Oncolytic viruses: a new immunotherapeutic approach for breast cancer treatment?. *Cancer Treatment Reviews*. 2022 May;106:102392. doi: 10.1016/j.ctrv.2022.102392. PMID: 35436729
505. Belltall A, Mazzinari G, Garrido-Cano I, Giner F, Mari A, Eroles P, Argente-Navarro M, Cata J, Diaz-Cambronero O. Opioid receptor expression in colorectal cancer: a nested matched case-control study. *Frontiers in Oncology*. 2022 Apr 6;12:801714. doi:

# publication list

- 10.3389/fonc.2022.801714. PMID: 35463331
506. Garcia-Oriola G, Tomasi S, Gallardo F, Umana G, Lawton M, Winkler P. Optic tract as an upper limit in amygdalectomy: microsurgical study. *Operative Neurosurgery*. 2022 Jul 1;23(1):e42-e48. doi: 10.1227/ons.0000000000000000208. PMID: 35486869
507. Nunez J, Bayes-Genis A, Revuelta-Lopez E, Minana G, Santas E, Ter Maaten J, de la Espriella R, Carratala A, Lorenzo M, Palau P, Llacer P, Valle A, Bodí V, Nunez E, Lupón J, Lang C, Ng L, Metra M, Sanchis J, Voors A. Optimal carbohydrate antigen 125 cut-point for identifying low-risk patients after admission for acute heart failure. *Revista Espanola de Cardiologia (English Ed.)*. 2022 Apr;75(4):316-324. doi: 10.1016/j.rec.2021.02.002. PMID: 33745912
508. Sanchez Vega JD, Alonso Salinas GL, Vieitez Flores JM, Ariza Sole A, Lopez de Sa E, Sanz-Ruiz R, Burgos Palacios V, Raposeiras Roubin S, Gomez Varela S, Sanchis Fores J, Silva Melchor L, Martinez-Seara X, Malagon Lopez L, Viana Tejedor A, Corbi Pascual M, Zamorano Gomez JL, Sanmartin-Fernandez M. Optimal surgical timing after post-infarction ventricular septal rupture. *Cardiology Journal*. 2022;29(5):773-781. doi: 10.5603/CJ.a2022.0035. PMID: 35578757
509. Bonanad C, Formiga F, Anguita M, Petidier R, Guillón A. Oral anticoagulant use and appropriateness in elderly patients with atrial fibrillation in complex clinical conditions: ACONVENIENCE Study. *Journal of Clinical Medicine*. 2022 Dec 14;11(24):7423. doi: 10.3390/jcm11247423. PMID: 36556039
510. Montomoli M, Roca L, Rivera M, Fernandez-Prado R, Redondo B, Camacho R, Moyano C, Pampa S, Gonzalez A, Casas J, Kislikova M, Sanchez Horrillo A, Cabrera Cardena A, Quiroga B, Rabasco C, Piquerias S, Suso A, Reque J, Villa J, Ojeda R, Arroyo D. Oral anticoagulation in patients with chronic kidney disease and non-valvular atrial fibrillation: the FAERC Study. *Healthcare*. 2022 Dec 17;10(12):2566. doi: 10.3390/healthcare10122566. PMID: 36554089
511. McLornan D, Gras L, Martin I, Sirait T, Schroeder T, Blau I, Kuball J, Byrne J, Collin M, Stadler M, Desmier D, Salmenniemi U, Jindra P, Mikhailova N, Lenhoff S, Rifon J, Robin M, Rovira M, Veelken H, Sadowska-Klasa A, Zecca M, Hayden P, Czerw T, Hernandez-Boluda J, Yakoub-Agha I. Outcome of allogeneic hematopoietic cell transplantation in eosinophilic disorders: a retrospective study by the chronic malignancies working party of the EBMT. *British Journal of Haematology*. 2022 Jul;198(1):209-213. doi: 10.1111/bjh.18219. PMID: 35482558
512. Cimci M, Polad J, Mamas M, Iniguez-Romo A, Chevalier B, Abhaichand R, Aminian A, Roguin A, Maluenda G, Angioi M, Cassel G, Kuramitsu S, Jacobs L, Debrus R, Malik F, Hildick-Smith D, Laanmets P, Roffi M, Sanchis Fores J, e-ULTIMASTER investigators. Outcomes and regional differences in practice in a worldwide coronary stent registry. *Heart*. 2022 Jul 27;108(16):1310-1318. doi: 10.1136/heartjnl-2021-320116. PMID: 35012960
513. Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hernandez-Boluda J, Czerw T, Hayden P, Kansagra A, Ho V, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani B, McLornan D, Yakoub-Agha I, Saber W. Outcomes of allogeneic hematopoietic cell transplantation for chronic neutrophilic leukaemia: a combined CIBMTR/CMWP of EBMT analysis. *British Journal of Haematology*. 2022 Aug;198(4):785-789. doi: 10.1111/bjh.18297. PMID: 35658101
514. Fotopoulos C, Khan T, Bracik J, Glasbey J, Abu-Rustum N, Chiva L, Fagotti A, Fujiwara K, Ghebre R, Gutelkin M, Konney TO, Ng J, Pareja R, Kottayam Seenivasagam R, Sehouli J, Surappa STS, Bhangu A, Leung E, Sundar S, CovidSurg Gynecological Cancer Collaborators. Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study. *American Journal of Obstetrics and Gynecology*. 2022 Nov;227(5):735.e1-735.e25. doi: 10.1016/j.ajog.2022.06.052. PMID: 35779589
515. McKay S, COVIDSurg Collaborative. Outcomes of patients undergoing elective liver and pancreas cancer surgery during the SARS-CoV-2 pandemic: an international, multicentre, prospective cohort study. *HPB*. 2022 Oct;24(10):1668-1678. doi: 10.1016/j.hpb.2022.03.002. PMID: 35562256

# publication list

516. Provencio M, Serna-Blasco R, Nadal E, Insa A, Garcia-Campelo MR, Casal Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Calvo V, Martin-Lopez J, Garcia-Garcia F, Casarrubios M, Franco F, Sanchez-Herrero E, Massuti B, Cruz-Bermudez A, Romero A. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA Non-Small-Cell Lung Cancer [NADIM phase II trial]. *Journal of Clinical Oncology*. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. PMID: 35576508
517. Geyer C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong A, Arnedos M, Balmana J, Bergh J, Bliss J, Delaloge S, Domchek S, Eisen A, Elsafty F, Fein L, Fielding A, Ford J, Friedman S, Gelmon K, Gianni L, Ghant M, Hollingsworth S, Im S, Jager A, Lakhani S, Janni W, Linderholm B, Liu T, Loman N, Korde L, Loibl S, Lucas P, Marme F, de Duenas E, McConnell R, Phillips K, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer C, Spanic T, Stickeler E, Toi M, Traina T, Viale G, Zoppoli G, Park Y, Yerushalmi R, Yang H, Pang D, Jung K, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke G, Sun Q, Parton M, Colleoni M, Schmidt M, Brufsky A, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt A, Johannsson O. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. *Annals of Oncology*. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. PMID: 36228963
518. Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Munoz M, Bermejo B, Margeli M, Csoszi T, Anton A, Turner N, Casas MI, Morales S, Alba E, Calvo L, de la Haba-Rodriguez J, Ramos M, Murillo L, Santaballa A, Alonso-Romero JL, Sanchez-Rovira P, Corsaro M, Huang X, Thallinger C, Kahan Z, Gil-Gil M. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. *European Journal of Cancer*. 2022 Jun;168:12-24. doi: 10.1016/j.ejca.2022.03.006.
- PMID: 35429901
519. Gambini J, Stromsnes K. Oxidative stress and inflammation: from mechanisms to therapeutic approaches. *Biomedicines*. 2022 Mar 23;10(4):753. doi: 10.3390/biomedicines10040753. PMID: 35453503
520. Robba C, Badenes R, Battaglini D, Ball L, Sanfilippo F, Brunetti I, Jakobsen JC, Lilja G, Friberg H, Wendel-Garcia PD, Young PJ, Eastwood G, Chew MS, Uden J, Thomas M, Joannidis M, Nichol A, Lundin A, Hollenberg J, Hammon N, Saxena M, Martin A, Solar M, Taccone FS, Dankiewicz J, Nielsen N, Grejs AM, Ebner F, Pelosi P. Oxygen targets and 6-month outcome after out of hospital cardiac arrest: a pre-planned sub-analysis of the targeted hypothermia versus targeted normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial. *Critical Care*. 2022 Oct 21;26(1):323. doi: 10.1186/s13054-022-04186-8. PMID: 36271410
521. Gross DA, Cheng HS, Zhuang R, McCoy MG, Perez-Cremades D, Salyers Z, Wara AKMK, Haemming S, Ryan TE, Feinberg MW. p Deficiency of lncRNA SNHG12 impairs ischemic limb neovascularization by altering an endothelial cell cycle pathway. *JCI Insight*. 2022 Jan 11;7(1):e150761. doi: 10.1172/jci.insight.150761. PMID: 34793334
522. Saura S, Benavent M. Pachydermodactyly. *Journal of Cutaneous Medicine and Surgery*. 2022;26(3):310. doi: 10.1177/12034754211003523. doi: 10.1177/12034754211003523. PMID: 33779338
523. Montero P, Perez-Leal M, Perez-Fidalgo JA, Sanz C, Estornut C, Roger I, Milara J, Cervantes A, Cortijo J. Paclitaxel induces epidermal molecular changes and produces subclinical alterations in the skin of gynecological cancer patients. *Cancers*. 2022 Feb 23;14(5):1146. doi: 10.3390/cancers14051146. PMID: 35267454
524. Blanco-Fernandez G, Fondevila-Campo C, Sanjuanbenito A, Fabregat-Prous J, Secanella-Medayo L, Rotellar-Sastre F, Pardo-Sanchez F, Prieto-Calvo M, Marin-Ortega H, Sanchez-Cabus S, Diez-Valladares L, Alonso-Casado O, Gonzalez-Serrano C, Rodriguez-Sanjuan J, Garcia-Plaza G, Jaen-Torrijimo I, Suarez-Munoz M, Becerra-Massare A,

# publication list

- 528.Rio P, Pando E, Lopez-Andujar R, Munoz-Forner E, Rodriguez-Lopez M, Pereira F, Serrablo-Requejo A, Turron V, Garrido M, Burdio F, Martin-Perez E, Estevan-Estevan R, Lopez-Guerra D, Castell-Gomez J, Salinas-Gomez J, Lopez-Baena J, Lopez-Ben S, Solar-Garcia L, Perez-Alonso A, Martinez-Insfran L, Blas J, Cornejo M, Gutierrez-Calvo A, Pozo C, Ochando-Cerdan F, Munoz-Bellvis L, Rebollar-Saenz J, Sanchez B, Jover J, Gomez-Bravo M, Ramia J, Rojas-Holguin A. Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study [PANMEKID]. *European Journal of Surgical Oncology*. 2022 Jan;48(1):133-141. doi: 10.1016/j.ejso.2021.08.011. PMID: 34417061
- 525.Ramia J, Martin J, Blanco-Fernandez G, Canta-lejo-Diaz M, Pardo F, Munoz-Forner E, Carabias A, Manuel-Vazquez A, Hernandez-Rivera P, Jaen-Torrejimeno I, Kalvainen-Mejia H, Rotellar-Sastre F, Garces-Albir M, Latorre R, Longoria-Dubocq T, De Armas-Conde N, Serrablo-Requejo A, Gordillo S, Sabater L, Serradilla-Martin M. Pancreatic mucinous cystic neoplasms located in the distal pancreas: a multicenter study. *Gland Surgery*. 2022 May;11(5):795-804. doi: 10.21037/gs-21-703. PMID: 35694091
- 526.Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffei I, Valagussa P, Viale G. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. *Annals of Oncology*. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. PMID: 35182721
- 527.Kroeze E, Padilla L, Bakker M, Boer J, Hagleitner M, Burkhardt B, Mori T, Attarbaschi A, Verdu-Amoros J, Pillon M, Anderzhanova L, Kabickova E, Chiang A, Kebudi R, Mellgren K, Lazic J, Jazbec J, Meijerink J, Beishuizen A, Loeffen J. Pediatric precursor B-Cell lymphoblastic malignancies: from extramedullary to medullary involvement. *Cancers*. 2022 Aug 12;14(16):3895. doi: 10.3390/cancers14163895. PMID: 36010889
- 528.Cortes J, Rugo H, Cescon D, Im S, Yusof M, Gallardo C, Lipatov O, Barrios C, Perez-Garcia J, Iwata H, Masuda N, Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. *New England Journal of Medicine*. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. PMID: 35857659
- 529.Valero-Moreno S, Montoya-Castilla I, Schoeps K, Postigo-Zegarra S, Perez-Marin M. Perceived stress in the primary caregivers of adolescents with asthma: a cross-sectional study. *Children*. 2022 Oct 25;9(11):1614. doi: 10.3390/children9111614. PMID: 36360342
- 530.Lele A, Wahlster S, Alunpipachathai B, Gebrewold M, Chou S, Crabtree G, English S, Der-Nigoghossian C, Gagnon D, Kim-Tenser M, Karanjia N, Kirkman M, Lamperti M, Livesay S, Mejia-Mantilla J, Melmed K, Prabhakar H, Tumino L, Rao C, Udy A, Videtta W, Moheet A. Perceptions regarding the SARS-CoV-2 pandemic's impact on neurocritical care delivery: results from a global survey. *Journal of Neurosurgical Anesthesiology*. 2022 Apr 1;34(2):209-220. doi: 10.1097/ANA.0000000000000825. PMID: 34882104
- 531.Tormo N, Gimenez E, Martinez-Navarro M, Albert E, Navalpotro D, Torres I, Gimeno C, Navarro D. Performance comparison of a flow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON SARS-CoV-2 test for detection and quantification of SARS-CoV-2-Spike-reactive-IFN-gamma-producing T cells after COVID-19 vaccination. *European Journal of Clinical Microbiology & Infectious Diseases*. 2022 Apr;41(4):657-662. doi: 10.1007/s10096-022-04422-7. PMID: 35165804
- 532.Valdivia A, Tarin F, Alcaraz M, Pinero P, Torres I, Marco F, Albert E, Navarro D. Performance of a flow cytometry-based immunoassay for detection of antibodies binding to SARS-CoV-2 spike protein. *Scientific Reports*. 2022 Jan 12;12(1):586. doi: 10.1038/s41598-021-04565-1. PMID: 35022478
- 533.POSE-Study group. Peri-interventional outcome study in the elderly in Europe: a 30-day prospective cohort study. *European Journal of Anaesthesiology*. 2022 Mar 1;39(3):198-209. doi: 10.1097/EJA.0000000000001639. PMID: 34799496

# publication list

- 534.Carceller H, Gramuntell Y, Klimczak P, Nacher J. Perineuronal nets: subtle structures with large implications. *Neuroscientist*. 2022 Jul 23;10738584221106346. doi: 10.1177/10738584221106346. PMID: 35872660
- 535.Zhuang R, Chen J, Cheng HS, Assa C, Jamaiyar A, Pandey AK, Perez-Cremades D, Zhang B, Tzani A, Khyrul Wara A, Plutzky J, Barrera V, Bhetariya P, Mitchell RN, Liu Z, Feinberg MW. Perivascular fibrosis is mediated by a KLF10-IL-9 signaling axis in CD4+ T Cells. *Circulation Research*. 2022 May 27;130(11):1662-1681. doi: 10.1161/CIRCRESAHA.121.320420. PMID: 35440172
- 536.Calvo-Lerma J, Bueno-Llamoga P, Bauerl C, Cortes-Macias E, Selma-Royo M, Perez-Cano F, Lerin C, Martinez-Costa C, Collado M. Persistence of Anti SARS-CoV-2 antibodies in breast milk from infected and vaccinated women after in vitro-simulated gastrointestinal digestion. *Nutrients*. 2022 May 19;14(10):2117. doi: 10.3390/nu14102117. PMID: 35631258
- 537.Leigh D, Cram D, Rechitsky S, Handyside A, Wells D, Munne S, Kahraman S, Grifo J, Katz-Jaffe M, Rubio C, Viotti M, Forman E, Xu K, Gordon T, Madjunkova S, Qiao J, Chen Z, Harton G, Gianaroli L, Simon C, Scott R, Simpson J, Kuliev A. PGDIS position statement on the transfer of mosaic embryos 2021. *Reproductive Biomedicine Online*. 2022 Jul;45(1):19-25. doi: 10.1016/j.rbmo.2022.03.013. PMID: 35523707
- 538.Wermke M, Felip E, Gambardella V, Kuboki Y, Morgenstern D, Hamed Z, Liu M, Studeny M, Owonikoko T. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. *Future Oncology*. 2022 Aug;18(24):2639-2649. doi: 10.2217/fon-2022-0196. PMID: 35815644
- 539.Coviello S, Gramuntell Y, Klimczak P, Varea E, Blasco-Ibanez J, Crespo C, Gutierrez A, Nacher J. Phenotype and distribution of immature neurons in the human cerebral cortex layer II. *Frontiers in Neuroanatomy*. 2022 Apr 8;16:851432. doi: 10.3389/fnana.2022.851432. PMID: 35464133
- 540.Mouron S, Bueno MJ, Lluch A, Manso L, Calvo I, Cortes J, Garcia-Saenz JA, Gil-Gil M, Martinez-Janez N, Apala JV, Caleiras E, Ximénez-Eembún P, Muñoz J, Gonzalez-Cortijo L, Murillo R, Sánchez-Bayona R, Cejalvo JM, Gómez-López G, Fuster-Torre C, Sabroso-Lasa S, Malats N, Martínez M, Moreno A, Megias D, Malumbres M, Colomer R, Quintela-Fandino M. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. *Nature Communications*. 2022 Dec 7;13(1):7529. doi: 10.1038/s41467-022-35065-z. PMID: 36477027
- 541.Agud-Dios M, Perandones-Gonzalez H, Fernández-Domper L, Dominguez Santas M, Boixeda de Miquel P. Picosecond 755-nm alexandrite laser treatment for oral lentiginosis in Peutz-Jeghers disease. *Lasers in Surgery and Medicine*. 2022 Aug;54(6):823-824. doi: 10.1002/lsm.23553. PMID: 35485783
- 542.Delgado-Arana J, Rumoroso J, Regueiro A, Martin-Moreiras J, Minana G, Mohandes M, Pan M, Salinas P, Caballero-Borrego J, Fernandez-Diaz J, Jurado-Roman A, Lacunza J, Vaquerizo B, Rivero F, Abellan-Huerta J, Rondan J, Gomez Menchero A, Santos-Martinez S, Subinas A, Arevalos V, Diego Nieto A, Sanchis J, Rojas S, Ojeda S, Gonzalo N, Lopez-Perez M, Goicolea J, Sadaba M, Gomez-Salvador I, Sabate M, Nunez Garcia J, Amat-Santos I. Plaque modification in calcified chronic total occlusions: the PLACCTON study. *Revista Espanola de Cardiologia (English Ed.)*. 2022 Mar;75(3):213-222. doi: 10.1016/j.rec.2021.06.011. PMID: 34301507
- 543.Tranah T, Ballester M, Carbonell-Asins J, Ampuero J, Alexandrino G, Caracostea A, Sanchez-Torrijos Y, Thomsen K, Kerbert A, Capilla-Lozano M, Romero-Gomez M, Escudero-Garcia D, Montoliu C, Jalan R, Shawcross D. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. *Journal of Hepatology*. 2022 Dec;77(6):1554-1563. doi: 10.1016/j.jhep.2022.07.014. PMID: 35872326
- 544.Gallego J, Fiorillo A, Casanova-Ferrer F, Urios A, Ballester M, Durban L, Megias J, Rubio T, Cabrera-Pastor A, Escudero-Garcia D, Felipo V, Montoliu C. Plasma extracellular vesicles play a role in immu-

# publication list

- ne system modulation in minimal hepatic encephalopathy. International Journal of Molecular Sciences. 2022 Oct 15;23(20):12335. doi: 10.3390/ijms232012335. PMID: 36293192
- 545.Andreu-Bernabeu Á, Díaz-Caneja CM, Costas J, De Hoyos L, Stella C, Gurriarán X, Alloza C, Fañanás L, Bobes J, González-Pinto A, Crespo-Facorro B, Martorell L, Vilella E, Muntané G, Nacher J, Molto MD, Aguilar EJ, Parellada M, Arango C, González-Peñas J. Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia. Nature Communications. 2022 Jan 10;13(1):51. doi: 10.1038/s41467-021-27598-6. PMID: 35013163
- 546.Castellano J, Pocock S, Bhatt D, Quesada A, Owen R, Fernandez-Ortiz A, Sanchez P, Ortuno F, Rodriguez J, Domingo-Fernandez A, Lozano I, Roncalion M, Baviera M, Foresta A, Ojeda-Fernandez L, Colivicchi F, Di Fusco S, Doechner W, Meyer A, Schiele F, Ecarnot F, Linhart A, Lubanda J, Barczi G, Merkely B, Ponikowski P, Kasprzak M, Alvira J, Andres V, Bueno H, Collier T, Van de Werf F, Perel P, Rodriguez-Manero M, Garcia A, Proietti M, Schoos M, Simon T, Ferro J, Lopez N, Beghi E, Bejot Y, Vivas D, Cordero A, Ibanez B, Fuster V. Polypill strategy in secondary cardiovascular prevention. New England Journal of Medicine. 2022 Sep 15;387(11):967-977. doi: 10.1056/NEJMoa2208275. PMID: 36018037
- 547.De Pascale G, Antonelli M, Deschepper M, Arvaniti K, Blot K, Brown B, de Lange D, De Waele J, Dikmen Y, Dimopoulos G, Eckmann C, Francois G, Giarridis M, Koulenti D, Labeau S, Lipman J, Lipovsky F, Maseda E, Montravers P, Mikstacki A, Paiva J, Pereyra C, Rello J, Timsit J, Vogelaers D, Blot S. Poor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitis. Intensive Care Medicine. 2022 Nov;48(11):1593-1606. doi: 10.1007/s00134-022-06883-y. PMID: 36151335
- 548.Cancino-Munoz I, Lopez M, Torres-Puente M, Villamayor L, Borras R, Borras-Manez M, Bosque M, Camarena J, Colijn C, Colomer-Roig E, Colomina J, Escribano I, Esparcia-Rodriguez O, Garcia-Garcia F, Gil-Brusola A, Gimeno C, Gimeno-Gascon A, Gomila-Sard B, Gonzales-Granda D, Gonzalo-Jimenez N,
- Guna-Serrano M, Lopez-Hontangas J, Martin-Gonzalez C, Moreno-Munoz R, Navarro D, Navarro M, Orta N, Perez E, Prat J, Rodriguez J, Ruiz-Garcia M, Vanaclocha H, Comas I. Population-based sequencing of Mycobacterium tuberculosis reveals how current population dynamics are shaped by past epidemics. eLife. 2022 Jul 26;11:e76605. doi: 10.7554/eLife.76605. PMID: 35880398
- 549.GBD 2020 Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet. 2022 Jul 16;400(10347):185-235. doi: 10.1016/S0140-6736(22)00847-9. PMID: 35843246
- 550.Lazzari L, Balaguer-Rosello A, Montoro J, Greco R, Hernani R, Lupo-Stanghellini M, Villalba M, Giglio F, Facal A, Lorentino F, Guerreiro M, Bruno A, Perez A, Xue E, Clerici D, Piemontese S, Pinana J, Sanz M, Solano C, de la Rubia J, Ciceri F, Peccatori J, Sanz J. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation. 2022 Sep;57(9):1389-1398. doi: 10.1038/s41409-022-01725-3. PMID: 35680995
- 551.Munoz-Gomez E, Serra-Ano P, Molla-Casanova S, Sempere-Rubio N, Aguilar-Rodriguez M, Espi-Lopez G, Ingles M. Potential add-on effects of manual therapy techniques in migraine patients: a randomised controlled trial. Journal of Clinical Medicine. 2022 Aug 11;11(16):4686. doi: 10.3390/jcm11164686. PMID: 36012924
- 552.Sangerman M, Moreno A, Quintana A, Garcia-Vidal C, Rubio M, Diaz M, Vendranas M, Macias G. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. Expert Review of Hematology. 2022 Mar;15(3):203-214. doi: 10.1080/17474086.2022.2054801. PMID: 35332831
- 553.Soldevila-Matías P, Albajes-Eizagirre A, Radua J, García-Martí G, Rubio JM, Tordesillas-Gutierrez D, Fuentes-Durá I, Solanes A, Fortea L, Oliver D, Sanjuán J. Precuneus and insular hypoactivation during cognitive processing in first-episode psychosis: systematic review and meta-analysis of fMRI studies. Revista de Psiquiatria y Salud Mental.

# publication list

- tal. 2022 Apr-Jun;15(2):101-116. doi: 10.1016/j.rpsmen.2022.06.004. PMID: 35840277
554. Lluis N, Parra J, Villodre C, Zapater P, Jalali A, Canto M, Mena L, Ramia J, Lluis F. Prediction of peritoneal soiling in acute appendicitis with simple clinical and laboratory data. Prospective, multicenter, cohort study of 2,645 adult patients nationwide. *International Journal of Surgery*. 2022 Aug;104:106741. doi: 10.1016/j.ijsu.2022.106741. PMID: 35772594
555. Martin-Moreno JM, Alegre-Martinez A, Martin-Gorgojo V, Alfonso-Sanchez JL, Torres F, Pallares-Carratala V. Predictive models for forecasting public health scenarios: practical experiences applied during the first wave of the COVID-19 Pandemic. *International Journal of Environmental Research and Public Health*. 2022 May 3;19(9):5546. doi: 10.3390/ijerph19095546. PMID: 35564940
556. Alvarez H, Rava M, Martinez C, Portilla J, Peraire J, Rivero A, Cervero M, Marino A, Poveda E, Llibre J, CoRIS Study Group, Ferrer Ribera A, CoRIS Study Group. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: a Spanish nationwide cohort. *HIV. Medicine*. 2022 Sep;23(8):825-836. doi: 10.1111/hiv.13265. PMID: 35234328
557. Hernandez-Boluda JC, Pastor-Galan I, Arellano-Rodrigo E, Raya JM, Perez-Escinas M, Ayala R, Ferrer-Marin F, Velez P, Mora E, Fox ML, Hernandez-Rivas JM, Xicoy B, Mata-Vazquez MI, Garcia-Fortes M, Perez-Lopez R, Angona A, Cuevas B, Senin A, Ramirez MJ, Ramirez-Payer A, Gomez-Casares MT, Martinez-Valverde C, Magro E, Steegmann JL, Duran MA, Garcia-Hernandez C, Gasior M, de Villambrosia S, Alvarez-Larran A, Pereira A. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis. *British Journal of Haematology*. 2022 Nov;199(4):529-538. doi: 10.1111/bjh.18440. PMID: 36089912
558. Simic G, Krsnik Z, Knezovic V, Kelovic Z, Mathiasen M, Junakovic A, Rados M, Mulc D, Spanic E, Quattrocolo G, Hall V, Zaborszky L, Vuksic M, Bordonau F, Kostovic I, Witter M, Hof P. Prenatal development of the human entorhinal cortex. *Journal of Comparative Neurology*. 2022 Oct;530(15):2711-2748. doi: 10.1002/cne.25344. PMID: 35603771
559. Villacampa G, Falato C, Pare L, Hernando C, Arumi M, Saura C, Gomez G, Munoz M, Gil-Gil M, Izarzugaza Y, Ferrer N, Najera-Zuloaga J, Montano A, Ciruelos E, Gonzalez-Santiago S, Villagraña P, Gavila J, Prat A, Pascual T. Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. *European Journal of Cancer*. 2022 Oct;174:232-242. doi: 10.1016/j.ejca.2022.07.028. PMID: 36067616
560. Castro A, Cassinello N, Alfonso R, Ortega J. Preoperative risk factors for early hemorrhagic complications in bariatric surgery: a case-control study. *Surgical Endoscopy*. 2022 Jan;36(1):430-434. doi: 10.1007/s00464-021-08302-7. PMID: 33523271
561. Puche-Roses M, Blasco-Serra A, Valverde-Navarro A, Puche-Torres M. Prevalence and morphometric analysis of the retromolar canal in a Spanish population sample: a helical CT scan study. *Medicina Oral Patologia Oral y Cirugia Bucal*. 2022 Mar 1;27(2):e142-e149. doi: 10.4317/medoral.25069. PMID: 34704980
562. Calleja J, Rivera-Esteban J, Aller R, Hernandez-Conde M, Abad J, Pericas J, Benito H, Serra M, Escudero A, Ampuero J, Lucena A, Sanchez Y, Arias-Loste M, Irizubietta P, Romero-Gomez M, Augustin S, Crespo J. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology. *Liver International*. 2022 Aug;42(8):1783-1792. doi: 10.1111/liv.15323. PMID: 35643936
563. Sinha M, Azukaitis K, Sladowska-Kozlowska J, Bardsen T, Merkevicius K, Sletten I, Obrycki L, Pac M, Fernandez-Aranda F, Bjelakovic B, Jankauskienė A, Litwin M, HyperChildNet Working Grp. Prevalence of left ventricular hypertrophy in children and young people with primary hypertension: meta-analysis and meta-regression. *Frontiers in Cardiovascular Medicine*. 2022 Oct 31;9:993513. doi: 10.3389/fcvm.2022.993513. PMID: 36386367
564. Ribera J, Granada I, Morgades M, Gonzalez T, Ciudad J, Such E, Calasanz M, Mercadal S, Coll R, Gonzalez-Campos J, Tormo M, Garcia-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermudez A, Orfao A, Ribera J, Programa Tratamiento He-

# publication list

- mopatias Ma, Spanish Soc Hematology, SEHH. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t[1;19](q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. *British Journal of Haematology*. 2022 Feb;196(3):670-675. doi: 10.1111/bjh.17844. PMID: 34549416
565. Onate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol MA, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. *Blood Advances*. 2022 Feb 8;6(3):882-890. doi: 10.1182/bloodadvances.2020004136. PMID: 34516636
566. Gabaldón-Pérez A, Marcos-Garcés V, Gavara J, López-Lereu MP, Monmeneu JV, Pérez N, Ríos-Navarro C, De Dios E, Merenciano-González H, Cànoves J, Racugno P, Bonanad C, Minana G, Núñez J, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Ortiz-Pérez JT, Rodríguez-Palomares JF, Bodí V. Prognostic value of cardiac magnetic resonance early after ST-segment elevation myocardial infarction in older patients. *Age and Ageing*. 2022 Nov 2;51(11):afac248. doi: 10.1093/ageing/afac248. PMID: 36436010
567. Sanchez-Sendra B, Perez-Deben S, Gonzalez-Munoz JF, Murgui A, Monteagudo C. Prognostic value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) intratumoral expression in melanoma patients at the time of diagnosis: comparative analysis of RT-qPCR versus immunohistochemistry. *Cancers*. 2022 May 7;14(9):2319. doi: 10.3390/cancers14092319. PMID: 35565448
568. De la Espriella R, Bayes-Genis A, Llacer P, Palau P, Minana G, Santas E, Pellicer M, Gonzalez M, Gorri JL, Bodí V, Sanchis J, Nunez J. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. *European Journal of Internal Medicine*. 2022 Jan;95:67-73. doi: 10.1016/j.ejim.2021.08.024. PMID: 34507853
569. Overby SJ, Cerro Herreros E, Gonzalez Martinez I, Varela MA, Seoane Miraz D, Jad Y, Raz R, Moller T, Perez Alonso M, Wood MJ, Llamusi B, Artero R. Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model. *Molecular Therapy. Nucleic Acids*. 2022 Feb 10;27:1146-1155. doi: 10.1016/j.omtn.2022.02.003. PMID: 35282418
570. Silva-Rodriguez J, Schmidt A, Sales M, Molina R, Naranco V. Proportion constrained weakly supervised histopathology image classification. *Computers in Biology and Medicine*. 2022 Aug;147:105714. doi: 10.1016/j.combiomed.2022.105714. PMID: 35753089
571. De la Torre Hernandez J, Palop R, Jimenez Mazuecos J, Saez P, Gutierrez-Barrios A, Pinar E, Cid B, Fernandez L, Camarero T, Urbano-Carrillo C, Oteo Dominguez J, Jimenez Diaz V, Gomez Menchero A, Fernandez E, Cordoba Soriano J, Ocaranza R, Ucar E, Roman K, Leal S, Caceres G, Linares Vicente J, Ferre G, Carrillo X, Rama Merchan J, Costa C, Sanchis J, Fernandes R, Rodrigues A, Vegas Valle J, Pereira H, de Prado A. Prospective application of a bleeding and ischemic risks-adjusted antithrombotic protocol in elderly patients revascularized with everolimus-eluting stents: EPICO5-Sierra75 study. *Journal of Geriatric Cardiology*. 2022 May 28;19(5):354-366. doi: 10.11909/j.issn.1671-5411.2022.05.009. PMID: 35722037
572. Lopez-Guerrero J, Mendiola M, Perez-Fidalgo J, Romero I, Torres A, Recalde D, Molina E, Gomez-Raposo C, Levin A, Herrero A, Alarcon J, Esteban C, Marquina G, Rubio M, Guerra E, Sanchez-Lorenzo L, Galvez-Montosa F, de Juan A, Churruca C, Gallejo A, Gonzalez-Martin A. Prospective real-world gynaecological cancer clinical registry with associated biospecimens: a collaborative model to promote translational research between GEICO and the Spanish Biobank Network. *Cancers*. 2022 Apr 13;14(8):1965. doi: 10.3390/cancers14081965. PMID: 35454870
573. Buhre W, de Korte-de Boer D, de Abreu MG, Scheeren T, Gruenewald M, Hoeft A, Spahn DR, Zarbock A, Daamen S, Westphal M, Brauer U, Dehnhardt T, Schmier S, Baron JF, De Hert S, Gavranovic I, Cholley B, Vymazal T, Szczechlik W, Bornemann-Cimenti H, Soro Domingo MB, Grintescu I, Jankovic R, Belada J. Prospective, randomized, controlled, double-blind, multi-center, multinational study on the safety and efficacy of 6% Hydroxyethyl starch (HES)

# publication list

- sOlution versus an Electrolyte solutioN In patients undergoing eleCtive abdominal Surgery: study protocol for the PHOENICS study. *Trials.* 2022 Feb 22;23(1):168. doi: 10.1186/s13063-022-06058-6. PMID: 35193648
574. Jorda A, Campos-Campos J, Aldasoro C, Colmena C, Aldasoro M, Alvarez K, Valles SL. Protective action of ultrasound-guided electrolysis technique on the muscle damage induced by notexin in rats. *PLoS One.* 2022 Nov 28;17(11):e0276634. doi: 10.1371/journal.pone.0276634. PMID: 36441673
575. Lopez-Miralles M, Lacomba-Trejo L, Valero-Moreno S, Benavides G, Perez-Marin M. Psychological aspects of pre-adolescents or adolescents with precocious puberty: a systematic review. *Journal of Pediatric Nursing.* 2022 May-Jun;64:e61-e68. doi: 10.1016/j.pedn.2022.01.002. PMID: 35033399
576. Ruiz J, Fuentes-Dura I, Lopez-Gilberte M, Dasi C, Pardo-Garcia C, Fuentes-Duran M, Perez-Gonzalez F, Salmeron L, Soldevila-Matias P, Vila-Frances J, Balanza-Martinez V. Public stigma profile toward mental disorders across different university degrees in the University of Valencia (Spain). *Frontiers in Psychiatry.* 2022 Aug 12;13:951894. doi: 10.3389/fpsyg.2022.951894. PMID: 36032229
577. Miró Ò, Jiménez S, Llorens P, Roussel M, Gorlicki J, García-Lamberechts EJ, Le Borgne P, Jacob J, Chauvin A, Lucidarme O, Burillo-Putze G, Aguirre A, Brigant F, Lozano L, González Del Castillo J, Freund Y; SIESTA and PEPCOV research teams. Pulmonary embolism severity and in-hospital mortality: an international comparative study between COVID-19 and non-COVID patients. *European Journal of Internal Medicine.* 2022 Apr;98:69-76. doi: 10.1016/j.ejim.2022.01.035. PMID: 35115232
578. Miravitlles M, Gonzalez-Torralba F, Represas-Represas C, Pomares X, Marquez-Martin E, Gonzalez C, Amado C, Forne C, Alonso S, Alcazar B, Barrecheguren M, Mirete J, Naval E. Pulmonologists' opinion on the use of inhaled corticosteroids in chronic obstructive pulmonary disease patients in Spain: a cross-sectional survey. *International Journal of Chronic Obstructive Pulmonary Disease.* 2022 Jul 12;17:1577-1587. doi: 10.2147/COPD.S369118. PMID: 35855745
579. Andreu Y, Martinez P, Soto-Rubio A, Perez-Marin M, Cervantes A, Arribas L. Quality of life in cancer survivorship: sociodemographic and disease-related moderators. *European Journal of Cancer Care.* 2022 Nov;31(6):e13692. doi: 10.1111/ecc.13692. PMID: 36069249
580. Garcia-Fadrique A, Estevan Estevan R, Sabater Ortí L. Quality standards for surgery of colorectal peritoneal metastasis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Annals of Surgical Oncology.* 2022 Jan;29(1):188-202. doi: 10.1245/s10434-021-10642-6. PMID: 34435297
581. Sánchez-Velázquez P, Pueyo-Périz E, Álamo JM, Suárez Artacho G, Gómez Bravo MÁ, Marcello M, Vicente E, Quijano Y, Ferri V, Caruso R, Dorcaratto D, Sabater L, González Chávez P, Noguera J, Navarro Gonzalo A, Bellido-Luque J, Téllez-Marques C, Ielpo B, Burdio F. Radiofrequency-assisted transection of the pancreas versus stapler in distal pancreatectomy: study protocol for a multicentric randomised clinical trial [TRANSPaire]. *BMJ Open.* 2022 Nov 4;12(11):e062873. doi: 10.1136/bmjopen-2022-062873. PMID: 36332946
582. Albanell J, Martinez M, Ramos M, O'Connor M, de la Cruz-Merino L, Santaballa A, Martinez-Janez N, Moreno F, Fernandez I, Alarcon J, Virizuela J, de la Haba-Rodriguez J, Sanchez-Rovira P, Gonzalez-Cortijo L, Margeli M, Sanchez-Munoz A, Anton A, Casas M, Bezares S, Rojo F. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). *European Journal of Cancer.* 2022 Jan;161:26-37. doi: 10.1016/j.ejca.2021.11.010. PMID: 34902765
583. Amat-Santos I, Sanchez-Luna J, Abu-Assi E, Melendo Viu M, Cruz-Gonzalez I, Nombela-Franco L, Munoz Garcia A, Garcia Blas S, de la Torre Hernandez J, Romaguera R, Sanchez-Recalde A, Diez Gil J, Lopez Otero D, Gheorge L, Ibanez B, Iniguez Romo A, Raposeiras-Roubin S, Dapagliflozin after Transcatheter Aortic Valve Implantation (Dapa-TAVI), investigators. Rationale and design of the dapagliflozin after transcatheter aortic valve implantation (DapaTAVI) randomized trial. *European*

# publication list

- Journal of Heart Failure. 2022 Mar;24(3):581-588. doi: 10.1002/ejhf.2370. PMID: 34693613
584. Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabes J, Sanchez P, Anguita M, Fernandez-Vazquez F, Pascual-Figal D, Hernandez J, Ferraro S, Vetrano A, Perez-Rivera J, Prada-Delgado O, Escalera N, Staszewsky L, Pizarro G, Aguero J, Pocock S, Ottani F, Fuster V, Ibanez B, SANCHIS FORES J, REBOOT-CNIC investigators. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fractIon (RE-BOOT). European Heart Journal-Cardiovascular Pharmacotherapy. 2022 May 5;8(3):291-301. doi: 10.1093/ejhcvp/pvab060. PMID: 34351426
585. Menendez Rodriguez M, Garau Ramirez J, Traver Salvador A, Hervas Jimenez Y, Garcia Morales N, Seoane Pillado T, Pin Vieito N, Vega Villaamil P, Montes Martinez A, Cubilla J. Rawl's questionnaire spanish validation for colorectal cancer screening with faecal occult blood testing. Gastroenterologia y Hepatologia. 2022 Feb;45(2):106-113. doi: 10.1016/j.gastrohep.2021.04.001. PMID: 34023478
586. Manuel-Vazquez A, Latorre-Fragua R, Alcazar C, Requena P, de la Plaza R, Fernandez G, Serradilla-Martin M, Ramia J. Reaching a consensus on the definition of "difficult" cholecystectomy among Spanish experts. A Delphi project. A qualitative study. International Journal of Surgery. 2022 Jun;102:106649. doi: 10.1016/j.ijsu.2022.106649. PMID: 35525412
587. Calderon J, Martinez F, Fernandez A, Sauri I, Diaz J, Uso R, Trillo J, Redon J, Forner M. Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status. Scientific Reports. 2022 Apr 12;12(1):6123. doi: 10.1038/s41598-022-10164-5. PMID: 35414001
588. Luna A, Perez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuno C, Vega M, Alvarez-Larran A, Salamanca A, Garcia-Noblejas A, Vall-Llovera F, Villalon L, De Las Heras N, Ramila E, Perez-Encinas M, Cuevas B, Perez-Lopez R, Sanchez-Guijo F, Jimenez-Velasco A, Lakhwani S, Casado L, Rosell A, Escola A, Fernandez M, Garcia-Hernandez C, Cervero C, Mora E, Sagues M, Suarez-Varela S, Velez P, Ca-rrascosa Mastell P, Bitaube R, Serrano L, Cortes M, Vera Goni J, Steegmann J, de Soria V, Alonso-Dominguez J, Araujo M, Coll A, Hernandez-Boluda J, Garcia-Gutierrez V. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Annals of Hematology. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. PMID: 35997804
589. Millan-Domingo F, Tarazona-Santabalbina F, Cartero A, Olaso-Gonzalez G, Vina J, Gomez-Cabrera M. Real-life outcomes of a multicomponent exercise intervention in community-dwelling frail older adults and its association with nutritional-related factors. Nutrients. 2022 Dec 3;14(23):5147. doi: 10.3390/nu14235147. PMID: 36501177
590. De Michelena P, Torres I, Ramos Garcia A, Gozalbes V, Ruiz N, Sanmartin A, Botija P, Poujois S, Huntley D, Albert E, Navarro D. Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant. Journal of Infection. 2022 May;84(5):e64-e66. doi: 10.1016/j.jinf.2022.02.022. PMID: 35217106
591. Alvarez-Larran A, Garrote M, Ferrer-Marin F, Perez-Encinas M, Mata-Vazquez M, Bellosillo B, Arellano-Rodrigo E, Gomez M, Garcia R, Garcia-Gutierrez V, Gasior M, Cuevas B, Angona A, Gomez-Casares M, Martinez C, Magro E, Ayala R, del Orbe-Barreto R, Perez-Lopez R, Fox M, Raya J, Guerrero L, Garcia-Hernandez C, Caballero G, Murillo I, Xicoy B, Ramirez M, Carreno-Tarragona G, Hernandez-Boluda J, Pereira A. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. PMID: 35417564
592. Calderon J, Martinez F, Diaz J, Fernandez A, Sauri I, Uso R, Trillo J, Vela S, Bea C, Redon J, Forner M. Real-world data of anticoagulant treatment in non-valvular atrial fibrillation. Frontiers In Cardiovascular Medicine. 2022 Jan 21;8:733300. doi: 10.3389/fcvm.2021.733300. PMID: 35127843
593. Pascual Izquierdo M, Mingot-Castellano M, Kerguelen Fuentes A, Garcia-Arroba Peinado J, Cid J, Jimenez M, Valcarcel D, Gomez-Segui I, de la Rubia

# publication list

- J, Martin P, Goterris R, Hernandez-Mateo L, Tallon Ruiz I, Varea S, Fernandez-Docampp M, Garcia-Munoz N, Vara M, Fernandez Zarzoso M, Garcia-Candel F, Paciello M, Garcia-Garcia I, Zalba S, Campuzano Saavedra V, Garcia-Gala J, Vidan J, Moreno G, Lopez Lorenzo J, Gonzalez Arias E, Freiria C, Sole M, Avila Idrovo L, Hernandez Castellet J, Cruz N, Lavilla E, Perez-Montana A, Atucha J, Moreno Beltran M, Romero Macias J, Salinas Argente R, Del Rio-Garma J. Real-world effectiveness of caplizumab vs standard of care in immune thrombotic thrombocytopenic purpura. *Blood Advances*. 2022 Dec 27;6(24):6219-6227. doi: 10.1182/bloodadvances.2022008028. PMID: 35930694
594. Palanca A, van Nes F, Pardo F, Ampudia Blasco FJ, Mathieu C. Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with Type 1 Diabetes: an European two-center experience. *Diabetes Care*. 2022 Mar 1;45(3):650-658. doi: 10.2337/dc21-1584. PMID: 35061022
595. Mas-Bargues C, Garcia-Dominguez E, Borras C. Recent approaches to determine static and dynamic redox state-related parameters. *Antioxidants*. 2022 Apr 28;11(5):864. doi: 10.3390/antiox11050864. PMID: 35624728
596. Navarro-Lleó N, Santiso-Bellón C, Vila-Vicent S, Carmona-Vicente N, Gozalbo-Rovira R, Cárcamo-Calvo R, Rodríguez-Díaz J, Buesa J. Recombinant noroviruses circulating in Spain from 2016 to 2020 and proposal of two novel genotypes within genogroup I. *Microbiology Spectrum*. 2022 Aug 31;10(4):e0250521. doi: 10.1128/specrum.02505-21. PMID: 35862999
597. Mingot Castellano M, Pascual Izquierdo C, Gonzalez A, Viejo Llorente A, Valcarcel Ferreiras D, Sebastian E, Garcia Candel F, Sarmiento Palao H, Gomez Segui I, de la Rubia J, Cid J, Martinez Nieto J, Hernandez Mateo L, Goterris Viciedo R, Fidalgo T, Salinas R, Del Rio-Garma J, Grupo Espanol de Aferesis (GEA). Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura. *Medicina Clinica*. 2022 Jun 24;158(12):630.e1-630.e14. doi: 10.1016/j.medcli.2021.03.040. PMID: 34266669
598. Luis Recuero Diaz J, Almanzar S, Munoz C, Sierra J, Porras M, Medina D, Vicuna M, Moreno L, Cantalejo M, Porcel J. Recommendations of the Spanish Society of Thoracic Surgery for the management of malignant pleural effusion. *Cirugia Espanola*. 2022 Nov;100(11):673-683. doi: 10.1016/j.cireng.2022.06.009. PMID: 35667609
599. Abad Gonzalez AL, Civera Andres M, Argente Pla M, Garcia Malpartida K, Olivares Alcolea J, Dominguez Escribano JR, Ferrer Gomez M, Gonzalez Boillo M, Hervas Abad E, Negueruela Avella GI, Urgeles Planella JR, Veses Martin S, Sanchez JC. Recommendations on the use of telemedicine as applied to nutritional pathology. *Nutricion Hospitalaria*. 2022 Aug 25;39(4):863-875. doi: 10.20960/nh.03923. PMID: 35312336
600. Garcia-Herraiz A, Marquez-Can Combining Tilde Ada J, Tejerina-Botella C. Reconstruction of a large columellar defect. *Dermatologic Surgery*. 2022 Sep 1;48(9):993-995. doi: 10.1097/DSS.0000000000003174. PMID: 34334619
601. Ejarque Domenech I, Marin Reina P, Garcia-Minaur Rica S, Chirivella Gonzalez I, Martinez Martinez M, Garcia Rodriguez A, Alvarez de Andres S, Telleira Orriols J. Referral criteria to clinical genetics from primary care: consensus document. *Atencion Primaria*. 2022 Nov 11;54(12):102501. doi: 10.1016/j.aprim.2022.102501. PMID: 36375295
602. Cuesta MJ, Ballesteros A, Sanchez-Torres AM, Amoretti S, Lopez-Illundain JM, Merchan-Naranjo J, Gonzalez-Ortega I, Salgado P, Rodriguez-Jimenez R, Roldan-Bejarano A, Sarro S, Ibanez A, Usall J, Escartí MJ, Moreno-Izco L, Mezquida G, Parellada M, Gonzalez-Pinto A, Berrocoso E, Bernardo M. Relapse of first-episode schizophrenia patients and neurocognitive impairment: the role of dopaminergic and anticholinergic burden. *Schizophrenia Research*. 2022 Oct;248:331-340. doi: 10.1016/j.schres.2022.09.014. PMID: 36155307
603. Juarez-Vela R, Andres-Esteban E, Gea-Caballero V, Sanchez-Gonzalez J, Marcos-Neira P, Serrano-Lazaro A, Tirado-Angles G, Ruiz-Rodriguez J, Durante A, Santolalla-Arnedo I, Garcia-Erce J, Quintana-Diaz M. Related factors of anemia in critically ill patients: a prospective multicenter study. *Journal of Clinical Medicine*. 2022 Feb 16;11(4):1031. doi: 10.3390/jcm11041031. PMID: 35207301

# publication list

604. Lopez-Medina J, Lopez-Rodriguez C, Estornell-Gualde M, Rey-Fernandez L, Gomez-Senent S, Joaquin-Ortiz C, Fernandez-Soto M, Hurtado-Garcia R, Martin-Martin M, Barrera-Martin A, Vitales-Farrero M, Martinez-Ortega A, Blanca-Martinez-Barbeito M, Vazquez-Vizcaino B, Tasende-Fernandez C, Penacho-Lazaro M, Jorda-Sorolla E, Sanchez-Sanchez R, Diaz-Gomez L, Baos-Fernandez S, Guzman-Rolo G, Ballesteros-Pomar M. Relationship between nutritional treatment compliance and nutritional status improvements in patients with gastrointestinal impairment taking an oral peptide-based supplement. *Nutrition*. 2022 Oct;102:111734. doi: 10.1016/j.nut.2022.111734. PMID: 35839658
605. Esteva M, Leiva A, Ramos-Monserrat M, Espí A, González-Luján L, Macià F, Murta-Nascimento C, Sánchez-Calavera MA, Magallón R, Balboa-Burreiro V, Seoane-Pillado T, Pertega-Díaz S. Relationship between time from Symptom's onset to diagnosis and prognosis in patients with symptomatic colorectal cancer. *BMC Cancer*. 2022 Aug 22;22(1):910. doi: 10.1186/s12885-022-09990-7. PMID: 35996104
606. Blasiak A, Gugula A, Gundlach A, Olucha-Bordonau F, Aniello F, Donizetti A. Relaxin ligand/receptor systems in the developing teleost fish brain: conserved features with mammals and a platform to address neuropeptide system functions. *Frontiers in Molecular Neuroscience*. 2022 Oct 5;15:984524. doi: 10.3389/fnmol.2022.984524. PMID: 36277494
607. Vilorio-Marques L, Fernandez CC, Mora E, Gutierrez L; Rey Bua B, Jimenez Lorenzo MJ, Diaz Beya M, Vara Pampliega M, Molero A, Sanchez-Garcia J, Calabuig M, Cedena MT, Chen-Liang T, Diaz Santa JA, Padilla I, Hernandez F, Diez R, Asensi P, Xicoy B, Sanz G, Valcarcel D, Diez-Campelo M, Bernal T. Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD. *Therapeutic Advances in Hematology*. 2022 Sep 29;13:20406207221127547. doi: 10.1177/20406207221127547. PMID: 36199837
608. San Martin Valenzuela C, Duenas L, Tomas J, Correa-Ghisays P, Serra-Ano P. Relevance of sociodemographics and clinical tests in single- and dual-task conditions as gait speed predictors of Parkinson's disease. *Journal of Clinical Medicine*. 2022 Jan 30;11(3):757. doi: 10.3390/jcm11030757. PMID: 35160208
609. Viderman D, Seri E, Aubakirova M, Abdildin Y, Badenes R, Bilotta F. Remote monitoring of chronic critically ill patients after hospital discharge: a systematic review. *Journal of Clinical Medicine*. 2022 Feb 15;11(4):1010. doi: 10.3390/jcm11041010. PMID: 35207287
610. Panach-Navarrete J, Valls-Gonzalez L, Gil-Viana R, Martinez-Jabaloyas J. Renal cyst after heminephrectomy in a pediatric patient: complication or normality?. *Archivos Espanoles de Urologia*. 2022 Nov;75(9):803-806. doi: 10.56434/j.arch.esp.urol.20227509.117. PMID: 36472064
611. D'Marco L, Puchades M, Escudero-Saiz V, Gimenez-Civera E, Terradez L, Moscardo A, Carbonell-Asins J, Perez-Bernat E, Torregrosa I, Moncho F, Navarro J, Gorri J. Renal histologic findings in necropsies of Type 2 Diabetes Mellitus patients. *Journal of Diabetes Research*. 2022 Sep 6;2022:3893853. doi: 10.1155/2022/3893853. PMID: 36110834
612. Santiso-Bellon C, Gozalbo-Rovira R, Buesa J, Rubio-Del-Campo A, Pena-Gil N, Navarro-Lleo N, Carcamo-Calvo R, Yebra MJ, Monedero V, Rodriguez-Diaz J. Replication of human norovirus in mice after antibiotic-mediated intestinal bacteria depletion. *International Journal of Molecular Sciences*. 2022 Sep 13;23(18):10643. doi: 10.3390/ijms231810643. PMID: 36142552
613. De la Espriella R, Bayes-Genis A, Nunez J. Reply to the Letter regarding the article 'Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure'. *European Journal of Heart Failure*. 2022 Dec;24(12):2391-2392. doi: 10.1002/ejhf.2717. PMID: 36225111
614. Llacer P, Manzano L, Nunez J. Reply to the Letter to the Editor to the article Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure. *Medicina Clinica*. 2022 Jul 8;159(1):e2. doi: 10.1016/j.medcli.2022.01.023. PMID: 35545477

# publication list

615. Palau P, Seller J, Domínguez E, Bayés-Genís A, Núñez J. Reply: Beta-blocker withdrawal and chronotropic incompetence in heart failure with preserved ejection fraction. *Journal of the American College of Cardiology*. 2022 Mar 8;79(9):e197-e198. doi: 10.1016/j.jacc.2022.01.002. PMID: 35241230
616. Merenciano-Gonzalez H, Marcos-Garces V, Gavara J, Pedro-Tudela A, Lopez-Lereu M, Monmeneu J, Perez N, Rios-Navarro C, de Dios E, Gabaldon-Perez A, Albiach C, Racugno P, Bonanad C, Canoves J, Chorro F, Bodi V. Residual ST-segment elevation to predict long-term clinical and CMR-derived outcomes in STEMI. *Scientific Reports*. 2022 Dec 17;12(1):21813. doi: 10.1038/s41598-022-26082-5. PMID: 36528716
617. Triguero A, Xicoy B, Zamora L, Jimenez M, Garcia O, Calabuig M, Diaz-Beya M, Arzuaga J, Ramos F, Medina A, Bernal T, Talarin C, Coll R, Collado R, Chen T, Borras J, Brunet S, Marchante I, Marco V, Lopez-Cadenas F, Calbacho M, Simiele A, Cortes M, Cedenia M, Pedreno M, Aguilar C, Pedro C, Fernandez M, Stoica C, Ribera J, Sanz G. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria. *Leukemia Research*. 2022 May;116:106836. doi: 10.1016/j.leukres.2022.106836. PMID: 35405632
618. Corro Moron M, Granell A, Ivanova V, Domingo E, Beltran Debon R, Barril X, Sanz MJ, Matheu MI, Castillon S, Diaz Y. Revealing 2-dimethylhydrazino-2-alkyl alkynyl sphingosine derivatives as sphingosine kinase 2 inhibitors: some hints on the structural basis for selective inhibition. *Bioorganic Chemistry*. 2022 Apr;121:105668. doi: 10.1016/j.bioorg.2022.105668. PMID: 35219046
619. Zabana Y, Marin-Jimenez I, Rodriguez-Lago I, Vera I, Martin-Arranz M, Guerra I, P Gisbert J, Mesonero F, Benitez O, Taxonera C, Ponferrada-Diaz A, Piqueiras M, J Lucendo A, Caballol B, Manosa M, Martinez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Mancenido N, Martinez-Perez T, Lopez A, Rodriguez-Gutierrez C, Garcia-Lopez S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de Acosta M, Sicilia B, Barrio J, Perez Calle J, Busquets D, Perez-Martinez I, Navarro-Llavat M, Hernandez V, Arguelles-Arias F, Ramirez Esteso F, Meijide S, Ramos L, Gomollon F, Munoz F, Suris G, Ortiz de Zarate J, Huguet J, Liao J, Garcia-Sepulcre M, Sierra M, Dura M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutierrez A, Varela P, Rull N, Gilabert P, Hernandez-Camba A, Brotons A, Gignard D, Sese E, Carpio D, Aceituno M, Cabriada J, Gonzalez-Lama Y, Jimenez L, Chaparro M, Lopez-San Roman A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastian S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galan H, Pajares R, Olcina P, Manzano P, Domenech E, Esteve M, on behalf of the Eneida Registry Of Geteccu. Risk factors for COVID-19 in inflammatory bowel disease: a national, ENEIDA-based case-control study [COVID-19-EII]. *Journal of Clinical Medicine*. 2022 Dec 19;11[24]:7540. doi: 10.3390/jcm11247540. PMID: 36556155
620. Calafat M, Manosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, Lopez-SanRoman A, Guardiola J, Taxonera C, Minguez M, Martin-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, Garcia-Lopez S, Marquez L, Gomollon F, Barrio J, Esteve M, Munoz F, Gisbert JP, Gutierrez A, Hinojosa J, Arguelles-Arias F, Busquets D, Bujanda L, Perez-Calle JL, Sicilia B, Merino O, Martinez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodriguez C, Garcia-Sepulcre MF, Monfort D, Canete F, Domenech E. Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. *Journal of Crohn's & Colitis*. 2022 Jul 14;16(6):946-953. doi: 10.1093/ecco-jcc/jjab213. PMID: 34864947
621. Marcos-Garces V, Perez N, Gavara J, Lopez-Lereu MP, Monmeneu JV, Rios-Navarro C, de Dios E, Merenciano-Gonzalez H, Gabaldon-Perez A, Canoves J, Racugno P, Bonanad C, Minana G, Nunez J, Moratal D, Chorro FJ, Valente F, Lorenzatti D, Ortiz-Perez JT, Rodriguez-Palomares JF, Bodi V. Risk score for early risk prediction by cardiac magnetic resonance after acute myocardial infarction. *International Journal of Cardiology*. 2022 Feb 15;349:150-154. doi: 10.1016/j.ijcard.2021.11.050. PMID: 34826497
622. Guzmán Morais B, Ordóñez Álvarez FÁ, Santos Rodríguez F, Martín Ramos S, Fernández Novo G. Rituximab treatment in pediatric patients with

# publication list

- steroid-dependent nephrotic syndrome: a tertiary hospital. *Anales de Pediatría*. 2022 Feb;96(2):83-90. doi: 10.1016/j.anpede.2020.12.019. PMID: 35144901
- 623.Costa R, Olea B, Bracho M, Albert E, de Michelena P, Martinez-Costa C, Gonzalez-Candelas F, Navarro D. RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status. *Journal of Infection*. 2022 Apr;84(4):579-613. doi: 10.1016/j.jinf.2021.12.018. PMID: 34953901
- 624.Pattanayak B, Lameirinhas A, Torres-Ruiz S, Burgues O, Rovira A, Martinez M, Tapia M, Zazo S, Albañell J, Rojo F, Bermejo B, Eroles P. Role of SALL4 in HER2+breast cancer progression: regulating PI3K/AKT Pathway. *International Journal of Molecular Sciences*. 2022 Oct 31;23(21):13292. doi: 10.3390/ijms232113292. PMID: 36362083
- 625.Parra Cotanda C, Munoz Lozon A, Botifoll Garcia E. Role of the pediatric emergency department during SARS-CoV-2 pandemic. *Anales de Pediatría*. 2022 Jan;96(1):64-65. doi: 10.1016/j.anpede.2020.11.011. PMID: 34872882
- 626.Albañell-Fernandez M, Oltra S, Orts-Arroyo M, Ibarrola-Villava M, Carrasco F, Jimenez-Martí E, Cervantes A, Castro I, Martinez-Lillo J, Ribas G. RUNAT-BI: a Ruthenium (III) complex as a selective anti-tumor drug candidate against highly aggressive cancer cell lines. *Cancers*. 2022 Dec 22;15(1):69. doi: 10.3390/cancers15010069. PMID: 36612065
- 627.Codina P, Domingo M, Barcelo E, Gastelurrutia P, Casquette D, Vila J, Altisent O, Spitaleri G, Cendiel G, Santiago-Vacas E, Zamora E, Ruiz-Cueto M, Santesmases J, de la Espriella R, Pascual-Figal D, Nunez J, Lupon J, Bayes-Genis A. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. *ESC Heart Failure*. 2022 Aug;9(4):2170-2180. doi: 10.1002/ehf2.13952. PMID: 35588235
- 628.Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, Kristeleit R, Hiret S, Bajor DL, Cruz P, Beck JT, Ghosh S, Dabrowski C, Antony G, Duan T, Veneris J, Zografos E, Subramanian J. Safety and efficacy of dostarlimab in patients with recurrent/advanced non-small cell lung cancer: results from cohort E of the Phase I GARNET Trial. *Clinical Lung Cancer*. 2022 Nov;23(7):e415-e427. doi: 10.1016/j.cllc.2022.05.013. PMID: 35729005
- 629.Salvador Bofill J, Moreno Anton F, Rodriguez Sanchez CA, Galve Calvo E, Hernando Melia C, Ciruelos Gil EM, Vidal M, Jimenez-Rodriguez B, De la Cruz Merino L, Martinez Janez N, Villanueva Vazquez R, de Toro Salas R, Anton Torres A, Alvarez Lopez IM, Gavila Gregori J, Quiroga Garcia V, Vicente Rubio E, De la Haba-Rodriguez J, Gonzalez-Santiago S, Diaz Fernandez N, Barnadas Molins A, Cantos Sanchez de Ibarguen B, Delgado Mingorance JI, Bellet Ezquerra M, de Casa S, Gimeno A, Martin M. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. *Breast*. 2022 Sep 28;66:77-84. doi: 10.1016/j.breast.2022.09.006. PMID: 36206609
- 630.Rejeski K, Burchert A, Iacoboni G, Sesques P, Franssensky L, Bucklein V, Trenker C, Hernani R, Naumann R, Schafer J, Blumenberg V, Schmidt C, Sohlbach K, von Bergwelt-Baildon M, Bachy E, Barba P, Subklewe M. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. *Blood Advances*. 2022 Aug 23;6(16):4719-4725. doi: 10.1182/bloodadvances.2022007776. PMID: 35793454
- 631.Jacob J, Albert-Casado A, Del-Castillo J, Llorens-Soriano P, Jimenez-Hernandez S, Burillo-Putze G, Martin-Martinez A, Martin-Sanchez F, Garcia-Lamberechts E, Pinera-Salmeron P, Alquezar-Arbe A, Ferre-Losa C, Juan-Gomez M, Serrano-Lazaro L, Noceda-Bermejo J, Salido-Mota M, Fortuny-Bayarri M, Gonzalez-Tejera M, Ferreras-Amez J, Diaz-Fernandez E, Quero-Motto E, Peiro-Gomez A, Martin-Mojarro E, Llopis-Roca F, Huerta-Garcia A, Pedraza-Garcia J, Melendez-Calix N, Brazo-Aznar J, Cano-Cano M, Miro O. Safety and revisit related to discharge the sixty-one Spanish emergency department medical centers without hospitalization in patients with COVID-19 pneumonia. A prospective cohort study UMC-Pneumonia COVID-19. *Revista de Investigacion Clinica-Clinical and Transla-*

# publication list

- tional Investigation. 2022 May 2;74(3):135-146. doi: 10.24875/RIC.22000021. PMID: 35240755
632. Gomez-Rubio P, Trapero I, Cauli O, Buigues C. Salivary IL-6 concentration is associated with frailty syndrome in older individuals. *Diagnostics*. 2022 Jan 5;12(1):117. doi: 10.3390/diagnostics12010117. PMID: 35054284
633. Gimenez E, Albert E, Zulaica J, Torres I, Rusu L, Rodriguez Moreno A, Burgos JS, Peiro S, Salas D, Vanaclocha H, Limon R, Alcaraz MJ, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzales Candelas F, Geller R, Navarro D. SARS-CoV-2 adaptive immunity in nursing home residents following a third dose of the Comirnaty COVID-19 vaccine. *Clinical Infectious Diseases*. 2022 Aug 24;75(1):e865-e868. doi: 10.1093/cid/ciac223. PMID: 35314856
634. Gimenez E, Albert E, Burgos JS, Peiro S, Salas D, Vanaclocha H, Limon R, Alcaraz MJ, Sanchez-Paya J, Diez Domingo J, Comas I, Gonzales Candelas F. SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty COVID-19 vaccine. *Journal of Infection*. 2022 Jun;84(6):834-872. doi: 10.1016/j.jinf.2022.02.035. PMID: 35245583
635. Torres I, Bellido-Blasco JB, Gimeno C, Burgos JS, Albert E, Moya-Malo R, Gasco-Laborda JC, Tornero A, Soriano J, Meseguer-Ferrer N, Martinez-Serrano M, Ortiz-Rambla J, Buj H, Hernandez N, Peiro S, Salas D, Limon R, Vanaclocha H, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzalez-Candelas F, Navarro D. SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty (R) COVID-19 vaccination. *Journal of Medical Virology*. 2022 Aug;94(8):3776-3782. doi: 10.1002/jmv.27799. PMID: 35445415
636. COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. *Medical Journal of Australia*. 2022 Jan;77(1):28-39. doi: 10.1111/ajae.15563. PMID: 34428858
637. Olea B, Albert E, Torres I, Gozalbo-Rovira R, Carbonell N, Ferreres J, Poujois S, Costa R, Colomina J, Rodriguez J, Blasco M, Navarro D. SARS-CoV-2 N-antigenemia in critically ill adult COVID-19 patients: frequency and association with inflammatory and tissue-damage biomarkers. *Journal of Medical Virology*. 2022 Jan;94(1):222-228. doi: 10.1002/jmv.27300. PMID: 34449894
638. Torres I, Gimenez E, Albert E, Zulaica J, Alvarez-Rodriguez B, Burgos J, Peiro S, Limon R, Vanaclocha H, Rodado C, Botija P, Sifre A, Tur B, Lozano R, Orosa I, Vicente-Ruiz M, Carrion R, Clari M, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzalez-Candelas F, Geller R, Navarro D. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty (R) COVID-19 vaccine: looking for correlates of protection. *Journal of Medical Virology*. 2022 Sep;94(9):4216-4223. doi: 10.1002/jmv.27867. PMID: 35585782
639. De Luca G, Algohary M, Uguz B, et al. SARS-CoV-2 positivity, stent thrombosis, and 30-day mortality in STEMI patients undergoing mechanical reperfusion. *Angiology*. 2022 Oct 12;33197221129351. doi: 10.1177/00033197221129351. PMID: 36222189
640. Bauerl C, Randazzo W, Sanchez G, Selma-Royo M, Garcia-Verdevio E, Martinez L, Parra-Llorca A, Lerin C, Fumado V, Crovetto F, Crispi F, Perez-Cano F, Rodriguez G, Ruiz-Redondo G, Campoy C, Martinez-Costa C, Collado M, MilkCORONA study team. Archives of Disease in Childhood. SARS-CoV-2 RNA and antibody detection in breast milk from a prospective multicentre study in Spain. *Fetal and Neonatal Edition*. 2022 Mar;107(2):216-221. doi: 10.1136/archdischild-2021-322463. PMID: 34417223
641. De Michelena P, Olea B, Torres I, Gonzalez-Candelas F, Navarro D. SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2. *Journal of Medical Virology*. 2022 Dec;94(12):5836-5840. doi: 10.1002/jmv.28079. PMID: 35986484
642. Pinana JL, Lopez-Corral L, Martino R, Vazquez L, Perez A, Martin-Martin G, Gago B, Sanz-Linares G, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave MT, Corona M, Marcos-Corrales S, Tormo M, Hernandez-Rivas JA, Montoro J, Rodriguez-Fernandez A, Risco-Galvez I, Rodriguez-Belenguer

# publication list

- P, Hernandez-Boluda JC, Garcia-Cadenas I, Ruiz-Garcia M, Munoz-Bellido JL, Solano C, Cedillo A, Sureda A, Navarro D. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. *Journal of Hematology & Oncology*. 2022 May 7;15(1):54. doi: 10.1186/s13045-022-01275-7. PMID: 35526045
643. Pinana J, Lopez-Corral L, Martino R, Montoro J, Vazquez L, Perez A, Martin-Martin G, Facal-Malvar A, Ferrer E, Pascual M, Sanz-Linares G, Gago B, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave M, Lopez-Jimenez J, Marcos-Corrales S, Garcia-Blazquez M, Garcia-Gutierrez V, Hernandez-Rivas J, Saus A, Espigado I, Alonso C, Hernani R, Solano C, Ferrer-Lores B, Guerreiro M, Ruiz-Garcia M, Munoz-Bellido J, Navarro D, Cedillo A, Sureda A, Infectious Complications Subcommittee of the Spanish Hematopoietic Stem, Cell Transplantation and Cell Therapy Group [GETH-TC]. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group [GETH-TC]. *American Journal of Hematology*. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. PMID: 34695229
644. Olea B, Albert E, Gimenez E, Torres I, Amat P, Remigia M, Alberola J, Carbonell N, Ferreres J, Blasco M, Navarro D. SARS-CoV-2-reactive IFN-gamma-producing CD4+ and CD8+ T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID-19 patients. *Scientific Reports*. 2022 Aug 22;12(1):14271. doi: 10.1038/s41598-022-18659-x. PMID: 35995830
645. Panizo N, Gimenez E, Albert E, Zulaica J, Rodriguez-Moreno A, Rusu L, Gimenez-Civera E, Puchades M, D'Marco L, Gandia-Salmeron L, Torres I, Sancho A, Gavela E, Gonzalez-Rico M, Montomoli M, Perez-Baylach C, Bonilla B, Solano C, Alvarado M, Torregrosa I, Gonzales-Candia B, Alcaraz M, Geller R, Gorri J, Navarro D. SARS-CoV-2-spike antibody and T-Cell responses elicited by a homologous third mRNA COVID-19 dose in hemodialysis and kidney transplant recipients. *Microorganisms*. 2022 Nov 16;10(11):2275. doi: 10.3390/microorganisms10112275. PMID: 36422345
646. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas M, Elli E, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Kabat M, Cuevas B, Fox M, Andrade-Campos M, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas M, Bonifacio M, Alvarez-Larran A, Kiladjian J, Calderon E, Patriarca A, Cervantes K, Griessammer M, Garcia-Gutierrez V, Sanchez A, Mazo E, Ruggeri M, Hernandez-Boluda J, Osorio S, Carreno-Tarragona G, Serrano M, Kusec R, Elorza B, Angona A, Cirici B, Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalecz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi A. Second versus first wave of COVID-19 in patients with MPN. *Leukemia*. 2022 Mar;36(3):897-900. doi: 10.1038/s41375-022-01507-2. PMID: 35064223
647. Baneras J, Jorge-Perez P, Bonanad C, Lopez Lluva M, Moll I, Fidel Kinori S. Second victims and quality of support resources among cardiology professionals. *Revista Espanola de Cardiologia* [English ed.]. 2022 Aug;75(8):686-688. doi: 10.1016/j.rec.2022.01.012. PMID: 35337779
648. Ximenez E, Ruiperez A. Selective neoadjuvant therapy in locally advanced rectal cancer: who and why? *Cirugia Espanola*. 2022 Nov 21;S2173-5077(22)00414-8. doi: 10.1016/j.cireng.2022.11.007. PMID: 36423876
649. Lorras C, Andujar X, Gornals JB, Sanchiz V, Brullet E, Sicilia B, Martin Arranz MD, Naranjo A, Barrio J, Duenas C, Foruny JR, Busquets D, Monfort D, Pineda JR, Gonzalez Huix F, Perez Roldan F, Pons V, Gonzalez B, Reyes Moreno J, Sainz E, Guardiola J, Bosca Watts MM, Fernandez Banares F, Mayor V, Esteve M. Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease [ProtDilat study]: an open-label, multicentre, randomised trial. *Lancet. Gastroenterology & Hepatology*. 2022 Apr;7(4):332-341. doi: 10.1016/S2468-1253(21)00386-1. PMID: 35065738
650. Barretina Ginesta MP, Quindos M, Alarcon JD, Esteban C, Gaba L, Gomez C, Perez Fidalgo JA, Romero I, Santaballa A, Rubio Perez MJ. SEOM-GEICO clinical guidelines on endometrial cancer (2021). *Clinical & Translational Oncology*. 2022

# publication list

- Apr;24(4):625-634. doi: 10.1007/s12094-022-02799-7. PMID: 35312947
651. Capdevila J, Gomez MA, Guillot M, Paez D, Pericay C, Safont MJ, Tarazona N, Vera R, Vidal J, Sastre J. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer [2021]. *Clinical & Translational Oncology*. 2022 Apr;24(4):646-657. doi: 10.1007/s12094-022-02816-9. PMID: 35303269
- Capdevila J, Gomez M, Guillot M, Paez D, Pericay C, Safont M, Tarazona N, Vera R, Vidal J, Sastre J. Correction to: SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer [2021] [vol 24, pg 646, 2022]. *Clinical & Translational Oncology*. 2022 Jul;24(7):1443-1444. doi: 10.1007/s12094-022-02855-2. PMID: 35596046
652. Caravaca Perez P, Gonzalez-Juanatey J, Nuche J, Moran Fernandez L, Lora Pablos D, Alvarez-Garcia J, Bascompte Claret R, Martinez Selles M, Vazquez Garcia R, Martinez Dolz L, Cobo-Marcos M, Pascual Figal D, Crespo-Leiro M, Nunez Villota J, Cinca Cuscullo J, Delgado J. Serum potassium dynamics during acute heart failure hospitalization. *Clinical Research in Cardiology*. 2022 Apr;111(4):368-379. doi: 10.1007/s00392-020-01753-3. PMID: 33070219
653. Lago-Sampedro A, Lhamyani S, Valdes S, Colomo N, Maldonado-Araque C, Gonzalez-Molero I, Doulatram-Gamgaram V, Delgado E, Chaves F, Castano L, Calle-Pascual A, Franch-Nadal J, Rojo-Martinez G, Garcia-Serrano S, Garcia-Escobar E. Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study. *International Journal of Obesity*. 2022 Nov;46(11):2013-2020. doi: 10.1038/s41366-022-01212-1. PMID: 35987953
654. Diez-Villanueva P, Jimenez-Mendez C, Bonanad C, Ortiz-Cortes C, Barge-Caballero E, Goirigolzarri J, Esteban-Fernandez A, Perez-Rivera A, Cobo M, Sanz-Garcia A, Formiga F, Ariza-Sole A, Martinez-Selles M, Alfonso F. Sex differences in the impact of frailty in elderly outpatients with heart failure. *Frontiers In Cardiovascular Medicine*. 2022 Sep 12;9:1000700. doi: 10.3389/fcvm.2022.1000700. PMID: 36172583
655. Pisoni S, Marrachelli V, Morales J, Maestrini S, Di Blasio A, Monleon D. Sex dimorphism in the metabolome of metabolic syndrome in morbidly obese individuals. *Metabolites*. 2022 May 6;12(5):419. doi: 10.3390/metabo12050419. PMID: 35629923
656. Palau P, Nunez J, Monmeneu J, Lopez-Lereu M, Gavara J, Rios-Navarro C, de Dios E, Perez-Sole N, Marcos-Garces V, Dominguez E, Moratal D, Canoves J, Minana G, Chorro F, Bodí V. Sex effect in the decision to perform invasive coronary angiography in patients with chronic coronary syndrome after undergoing vasodilator stress MRI. *Journal of Magnetic Resonance Imaging*. 2022 Dec;56(6):1680-1690. doi: 10.1002/jmri.28163. PMID: 35344231
657. Santas E, Palau P, Llacer P, de la Espriella R, Minana G, Nunez-Marin G, Lorenzo M, Heredia R, Sanchis J, Chorro FJ, Bayes-Genis A, Nunez J. Sex-related differences in mortality following admission for acute heart failure across the left ventricular ejection fraction spectrum. *Journal of the American Heart Association*. 2022 Jan 4;11(1):e022404. doi: 10.1161/JAHA.121.022404. PMID: 34927464
658. Teira R, Diaz-Cuervo H, Aragao F, Castano M, Romero A, Roca B, Montero M, Galindo M, Munoz-Sanchez M, Espinosa N, Peraire J, Martinez E, De la Fuente B, Domingo P, Deig E, Merino M, Geijo P, Estrada V, Sepulveda M, Garcia J, Berenguer J, Curran A. Shorter time to discontinuation due to treatment failure in people living with HIV switched to dolutegravir plus either rilpivirine or lamivudine compared with integrase inhibitor-based triple therapy in a large Spanish cohort. *Infectious Diseases and Therapy*. 2022 Jun;11(3):1177-1192. doi: 10.1007/s40121-022-00630-y. PMID: 35399147
659. Del Canto I, Santas E, Cardells I, Minana G, Palau P, Llacer P, Facila L, Lopez-Vilella R, Almenar L, Bodí V, Lopez-Lereu M, Monmeneu J, Sanchis J, Moratal D, Maceira A, de la Espriella R, Chorro F, Bayes-Genis A, Nunez J. Short-term changes in left and right ventricular cardiac magnetic resonance feature tracking strain following ferric carboxymaltose in patients with heart failure: a substudy of the

# publication list

- Myocardial-IRON Trial. *Journal of the American Heart Association.* 2022 Apr 5;11(7):e022214. doi: 10.1161/JAHA.121.022214. PMID: 35301854
- 660.Palau P, Amiguet M, Dominguez E, Sastre C, Mollar A, Seller J, Pinilla J, Larumbe A, Valle A, Doblas J, de la Espriella R, Minana G, Mezcua A, Santas E, Bodi V, Sanchis J, Pascual-Figal D, Gorri J, Bayes-Genis A, Nunez J. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO<sub>2</sub>): a randomized clinical trial. *European Journal of Heart Failure.* 2022 Oct;24(10):1816-1826. doi: 10.1002/ejhf.2560. PMID: 35604416
- 661.Moro-Valdezate D, Martin-Arevalo J, Ferro-Echevarria O, Pla-Martí V, García-Botello S, Pérez-Santiago L, Gadea-Mateo R, Tarazona N, Roda D, Rosello-Keranen S, Espí-Macías A. Short-term outcomes of colorectal cancer surgery in older patients: a novel nomogram predicting postoperative morbi-mortality. *Langenbeck's Archives of Surgery.* 2022 Dec;407(8):3587-3597. doi: 10.1007/s00423-022-02688-1. PMID: 36129528
- 662.Lacueva FJ, Escrig-Sos J, Martí-Obiol R, Zaragoza C, Mingol F, Oviedo M, Peris N, Civera J, Roig A. Short-term postoperative outcomes of gastric adenocarcinoma patients treated with curative intent in low-volume centers. *World Journal of Surgical Oncology.* 2022 Oct 17;20(1):344. doi: 10.1186/s12957-022-02804-x. PMID: 36253780
- 663.Cicinelli E, McQueen DB, Huepfel B, Vitagliano A, Moreno I, Simon C, Pirtea P, Scott RTJ, Bellavia M, de Ziegler D. Should patients be screened for chronic endometritis before assisted reproductive technology?. *Fertility and Sterility.* 2022 Oct;118(4):639-652. doi: 10.1016/j.fertnstert.2022.08.846. PMID: 36182261
- 664.Sánchez-Saez F, Peiro S, Cuenca L, Vanaclocha H, Limón R, Salas D, Burgos JS, Sanchez-Paya J, Meneu R, Diez J, García-Sempere A, Navarro I, Rodríguez-Bernal C, Sanfelix-Gimeno G, Navarro D. Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain. *Vaccine.* 2022 Sep 29;40(41):5942-5949. doi: 10.1016/j.vaccine.2022.08.028. PMID: 36068110
- 665.Moro-Valdezate D, Martín-Arévalo J, Pla-Martí V, García-Botello S, Izquierdo-Moreno A, Pérez-Santiago L, Pedrós-Giménez JM, Villagrasa R, Peña A, Espí-Macías A. Sigmoid volvulus. *Langenbeck's Archives of Surgery.* 2022 May;407(3):1161-1171. doi: 10.1007/s00423-022-02428-5. PMID: 35028738
- 666.Bover J, Trinidad P, Jara A, Soler Majoral J, Martín-Malo A, Torres A, Frazao J, Urena P, Dusso A, Arana C, Graterol F, Romero Gonzalez G, Troya M, Samaniego D, D'Marco L, Valdivielso J, Fernandez E, Arenas M, Torregrosa V, Navarro Gonzalez J, Lloret M, Ballarin J, Bosch R, Gorri J, de Francisco A, Gutierrez O, Ara J, Felsenfeld A, Canalejo A, Almaden Y. Silver jubilee: 25 years of the first demonstration of the direct effect of phosphate on the parathyroid cell. *Nefrologia.* 2022 Nov-Dec;42(6):645-655. doi: 10.1016/j.nefroe.2023.02.008. PMID: 36925324
- 667.Villodre C, Taccogna L, Zapater P, Canto M, Mena L, Ramia J, Lluis F. Simplified risk-prediction for benchmarking and quality improvement in emergency general surgery. Prospective, multicenter, observational cohort study. *International Journal of Surgery.* 2022 Jan;97:106168. doi: 10.1016/j.ijsu.2021.106168. PMID: 34785344
- 668.Villalba A, Gonzalez-Rodriguez A, Arzuaga-Mendez J, Puig N, Arnao M, Arguinano J, Jimenez M, Canet M, Teruel A, Sola M, Diaz F, Encinas C, Garcia A, Rosinol L, Suarez A, Gonzalez M, Izquierdo I, Hernandez M, Infante M, Sanchez M, Sampol A, de la Rubia J. Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM). *Leukemia & Lymphoma.* 2022 Dec;63(14):3438-3447. doi: 10.1080/10428194.2022.2123229. PMID: 36124538
- 669.Sánchez-Jiménez JL, Aparicio I, Romero-Avila JL, Bellot-Arcís C, Cibrián Ortiz de Anda RM, Priego-Quesada JI. Skin temperature measurement in individuals with spinal cord injury during and after exercise: systematic review. *Journal of Thermal Biology.* 2022 Apr;105:103146. doi: 10.1016/j.jtherbio.2021.103146. PMID: 35393040

# publication list

670. Sanz-Ros J, Romero-Garcia N, Mas-Bargues C, Monleon D, Gordevicius J, Brooke RT, Dromant M, Diaz A, Derevyanko A, Guio-Carrion A, Roman-Dominguez A, Ingles M, Blasco MA, Horvath S, Vina J, Borras C. Small extracellular vesicles from young adipose-derived stem cells prevent frailty, improve health span, and decrease epigenetic age in old mice. *Science Advances*. 2022 Oct 21;8(42):eabq2226. doi: 10.1126/sciadv.abq2226. PMID: 36260670
- 10;12:801411. doi: 10.3389/fonc.2022.801411. PMID: 35359418
671. Llorca-Cardenosa MJ, Aronson LI, Krastev DB, Nieminuszczy J, Alexander J, Song F, Dylewska M, Broderick R, Brough R, Zimmermann A, Zenke FT, Gurel B, Riisnaes R, Ferreira A, Roumeliotis T, Choudhary J, Pettitt SJ, de Bono J, Cervantes A, Haider S, Niedzwiedz W, Lord CJ, Chong IY. SMG8/SMG9 heterodimer loss modulates SMG1 kinase to drive ATR inhibitor resistance. *Cancer Research*. 2022 Nov 2;82(21):3962-3973. doi: 10.1158/0008-5472.CAN-21-4339. PMID: 36273494
672. Lopez-Campos J, Jimenez-Ruiz C, Meneses Petersen E, Rabade Castedo C, Asensio Sanchez S, Vaquero Lozano P, Ferrer Espinosa S, Perez Soriano M, de Higes Martinez E, Garcia de Llanos C, Pastor Espla E, Cabrera Cesar E, Mogrovejo S, Riesco Miranda J, Barrueco Ferrero M, Callejas Gonzalez F, Sandoval Contreras R, Pena Miguel T, Peris Cardells R, Gonzalez Dou M, Guzman Aguilar J, Amado C, Gorordo Unzueta M, Rois Seijas P, Martinez Muniz M, Naval Sendra E, Granda-Orive J, Signes-Costa J. Smoking cessation units as a source of COPD diagnoses: project 1000-200. *Archivos de Bronconeumologia*. 2022 Mar;58(3):T264-T267. doi: 10.1016/j.arbres.2021.05.031. PMID: 35312495
673. Carrion Valero F, Martinez Gonzalez D, Bobes-Bascaran M, Galan Gil G, Ortega Serrano J, Chorro Gasco F, Bobes J, Jimenez Ruiz C. Smoking in hospitalized patients. A great opportunity. *Adicciones*. 2022 Feb 16;34(1):13-22. doi: 10.20882/adicciones.1358. PMID: 32677696
674. Belltall A, Zuniga-Trejos S, Garrido-Cano I, Eroles P, Argente-Navarro M, Buggy D, Diaz-Cambronero O, Mazzinari G. Solid tumor opioid receptor expression and oncologic outcomes: analysis of the cancer genome atlas and genotype tissue expression Project. *Frontiers in Oncology*. 2022 Mar
675. Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Miguel Cejalvo J, Izarzugaza Y, Amillano K, Garcia Corbacho J, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. *Future Oncology*. 2022 Oct 6. doi: 10.2217/fon-2022-0660. PMID: 36200668
676. Solis D, Pascual M, Sangrador C, Burriel J, Visus F, Arocena F, Calatayud S, Nodal E, Aliaga E, Torres J, de Villasante G, Cid M, Peral R, Lopez R, Ruiz M, Ramos H, Garcia P, Leis R, Alberdi R, Quero J, Romero R, del Clastillo L, Quintana L, Telleria P, Franch P, Casales Z, Mas M, Poblet G, Costa C, Serrano E, Allue I, Koninck C, Riechmann E. Spanish National Registry of paediatric coeliac disease: changes in the clinical presentation in the 21st century. *Journal of Pediatric Gastroenterology and Nutrition*. 2022 Jun 1;74(6):805-811. doi: 10.1097/MPG.0000000000003424. PMID: 35192578
677. Pinana J, Vazquez L, Martino R, de la Camara R, Sureda A, Rodriguez-Veiga R, Garrido A, Sierra J, Ribera J, Torrent A, Mateos M, de la Rubia J, Tormo M, Diez-Campelo M, Garcia-Gutierrez V, Alvarez-Larran A, Sancho J, MartinGarcia-Sancho A, Yanez L, Simon J, Barba P, Abrisqueta P, Alvarez-Twose I, Bonanad S, Lecumberri R, Ruiz-Camps I, Navarro D, Hernandez-Rivas J, Cedillo A, Garcia-Sanz R, Bosch F. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. *Leukemia & Lymphoma*. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. PMID: 34668835
678. Cilleruelo Ramos Á, Figueroa Almánzar S, López Castro R, Martínez Hernández NJ, Mezquita Pérez L, Moreno Casado P, Zabaleta Jiménez J. Spanish Society of Thoracic Surgery (SECT) consensus document. Long-term follow-up for operated patients with lung cancer. *Cirugia Es-*

# publication list

- panola. 2022 Jun;100(6):320-328. doi: 10.1016/j.cireng.2022.05.024. PMID: 35643357
679. Mas-Bargues C, Alique M, Barrús-Ortiz MT, Bo rrás C, Rodrigues-Díez R. Special issue "Oxidative stress in aging and associated chronic diseases". *Antioxidants*. 2022 Apr 2;11(4):701. doi: 10.3390/antiox11040701. PMID: 35453386
680. Sanchez-Orti J, Balanza-Martinez V, Correa-Ghissays P, Selva-Vera G, Vila-Frances J, Magdalena-Benedito R, San-Martin C, Victor V, Escribano-Lopez I, Hernandez-Mijares A, Vivas-Lalinde J, Crespo-Facorro B, Tabares-Seisdedos R. Specific metabolic syndrome components predict cognition and social functioning in people with type 2 diabetes mellitus and severe mental disorders. *Acta Psychiatrica Scandinavica*. 2022 Sep;146(3):215-226. doi: 10.1111/acps.13433. PMID: 35359023
681. Saint-Gerons D, Rodovalho S, Dias A, de Carvalho A, Beratarrechea A, Monteiro W, Machado M, da Costa C, Wada M, de Almeida M, Fonseca R, Cordeiro J, Antolini A, Nepomuceno J, Fleck K, Gasparotto F, Lacerda M, Rojas-Cortes R, Pal S, Porras A, Ade M, Castro J. Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth. *Malaria Journal*. 2022 Jan 29;21(1):28. doi: 10.1186/s12936-022-04047-3. PMID: 35093070
682. Gabaldon-Perez A, Bonanad C, Garcia-Blas S, Gavara J, Rios-Navarro C, Perez-Sole N, de Dios E, Marcos-Garces V, Merenciano-Gonzalez H, Monmeneu J, Lopez-Lereu M, Nunez J, Chorro F, Bodí V. Stress cardiac magnetic resonance for mortality prediction and decision-making: registry of 2496 elderly patients with chronic coronary syndrome. *Revista Espanola de Cardiologia* [English Ed.]. 2022 Mar;75(3):223-231. doi: 10.1016/j.rec.2021.08.004. PMID: 34548244
683. Giancotti G, Nannetti G, Padalino G, Landini M, Santos-Ferreira N, Van Dycke J, Naccarato V, Patel U, Silvestri R, Neyts J, Gozalbo-Rovira R, Rodriguez-Diaz J, Rocha-Pereira J, Brancale A, Ferla S, Bassetto M. Structural investigations on novel non-nucleoside inhibitors of human norovirus polymerase. *Viruses*. 2022 Dec 27;15(1):74. doi: 10.3390/v15010074. PMID: 36680114
684. Huguet JM, Garcia-Lorenzo V, Martí L, Paredes JM, Ramirez JJ, Pastor M, Ruiz L, Sanahuja A, Timoneda P, Sanchis L, Perez GA, Bosca-Watts MM. Subcutaneous Infliximab [CT-P13], a true biologic 2.0. real clinical practice multicentre study. *Biomedicines*. 2022 Aug 30;10(9):2130. doi: 10.3390/biomedicines10092130. PMID: 36140230
685. Bauset C, Lis-Lopez L, Coll S, Gisbert-Ferrandiz L, Macias-Ceja D, Seco-Cervera M, Navarro F, Esplugués J, Calatayud S, Ortiz-Masia D, Barrachina M, Cosin-Roger J. SUCNR1 mediates the priming step of the inflammasome in intestinal epithelial cells: relevance in ulcerative colitis. *Biomedicines*. 2022 Feb 24;10(3):532. doi: 10.3390/biomedicines10030532. PMID: 35327334
686. Vila L, Cabedo N, Villarroel-Vicente C, Garcia A, Bernabeu A, Hennuyer N, Staels B, Franck X, Figgadere B, Sanz MJ, Cortes D. Synthesis and biological studies of polycerasoidol and trans-delta-tocotrienolic acid derivatives as PPARalpha and/or PPARgamma agonists. *Bioorganic & Medicinal Chemistry*. 2022 Jan 1;53:116532. doi: 10.1016/j.bmc.2021.116532. PMID: 34863066
687. Rivas El, Linares J, Zwick M, Gomez-Llonin A, Guiu M, Labernadie A, Badia-Ramentol J, Llado A, Baridia L, Perez-Nunez I, Martinez-Ciarpaglini C, Tarazona N, Sallent-Aragay A, Garrido M, Celia-Terrassa T, Burgues O, Gomis RR, Albanell J, Calon A. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+breast tumors. *Nature Communications*. 2022 Sep 9;13(1):5310. doi: 10.1038/s41467-022-32782-3. PMID: 36085201
688. Adam-Artigues A, Arenas E, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, Hernando C, Martinez M, Carbonell-Asins J, Simon S, Poveda J, Moragon S, Zazo S, Martinez D, Rovira A, Burgues O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo J. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. *Science Advances*. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. PMID: 35594351
689. Lacomba-Trejo L, Schoeps K, Valero-Moreno S, Del Rosario C, Montoya-Castilla I. Teachers' response to stress, anxiety and depression during

# publication list

- COVID-19 lockdown: what have we learned from the pandemic?. *Journal of School Health*. 2022 Sep;92(9):864-872. doi: 10.1111/josh.13192. PMID: 35610141
- 690.Barrero A, Carrasco Chinchilla F, Benito Gonzalez T, Pascual I, Arzamendi D, Estevez Loureiro R, Nombela Franco L, Pan M, Freixa X, Trillo Nouche R, Sanchez Recalde A, Andraka L, Cruz Gonzalez I, Lopez Minguez JR, Diez Gil JL, Urbano Carrillo C, Sanmiguel Cervera D, Sanchis J, Bosa F, Ruiz V, Del Trigo M, Molina E, Serrador AM, Alonso Briales JH, Garrote C, Avanzas P, Li CH, Baz JA, Jimenez Quevedo P, Mesa D, Regueiro A, Cid B, Carrasco Mora-leja M, Rodriguez Gabella T, Hernandez Garcia JM, Fernandez Vazquez F, Amat Santos IJ. Temporal trend and potential impact of angiotensin receptor-neprilysin inhibitors on transcatheter edge-to-edge mitral valve repair. *Revista Espanola de Cardiologia* [English ed.]. 2022 Dec;75(12):1001-1010. doi: 10.1016/j.rec.2022.02.001. PMID: 35272968
- 691.Ruiz-Alguero M, Hernando V, Riero M, Blanco Ramos J, de Zarraga Fernandez M, Galindo P, Perez-Gonzalez A, Diaz A, Suarez-Garcia I, Jarrin I, CoRIS Cohort. Temporal trends and geographic variability in the prescription of antiretroviral treatments in people living with HIV in Spain, 2004-2020. *Journal of Clinical Medicine*. 2022 Mar 29;11(7):1896. doi: 10.3390/jcm11071896. PMID: 35407504
- 692.Di Filippo S, Godoy DA, Manca M, Paolessi C, Bi-lotta F, Meseguer A, Severgnini P, Pelosi P, Badenes R, Robba C. Ten rules for the management of moderate and severe traumatic brain injury during pregnancy: an expert viewpoint. *Frontiers in Neurology*. 2022 Jun 9;13:911460. doi: 10.3389/fneur.2022.911460. PMID: 35756939
- 693.Romero-Gonzalez G, Bover J, Arrieta J, Salera D, Troya M, Graterol F, Urena-Torres P, Cozzolino M, Di Lullo L, Cippa P, Urrutia M, Paul-Martinez J, Boixeda R, Gorri J, Ara J, Bayes-Genis A, Bellasi A, Ronco C. The "FIFTY SHADOWS" of the RALES Trial: lessons about the potential risk of dietary potassium supplementation in patients with chronic kidney disease. *Journal of Clinical Medicine*. 2022 Jul 8;11(14):3970. doi: 10.3390/jcm11143970. PMID: 35887733
- 694.Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pence AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altinyazar V, Yalince-tin B, Gumus-Akay G, Cihan B, Soygur H, Ulus H, Cankurtaran ES, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, Garcia-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jimenez-Lopez E, Arrojo M, Carracedo A, Lopez G, Gonzalez-Penas J, Parellada M, Maric NP, Atbasoglu C, Ucok A, Alptekin K, Saka MC, Aguglia E, Arango C, Rutten BP, Guloksuz S. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: results from the EUGEI study. *European Neuropsychopharmacology*. 2022 Aug 30;63:47-59. doi: 10.1016/j.euro.2022.08.003. PMID: 36055075
- 695.Haagsma J, Charalampous P, Ariani F, et al. The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study. *Archives of Public Health*. 2022 May 20;80(1):142. doi: 10.1186/s13690-022-00891-6. PMID: 35590340
- 696.Vieco-Marti I, Lopez-Carrasco A, de la Cruz-Merino L, Noguera R, Alvaro Naranjo T. The complexity of cancer immunotherapy illustrated through skin tumors. *International Journal of Biological Markers*. 2022 Jun;37(2):113-122. doi: 10.1177/03936155221088884. PMID: 35473449
- 697.Mas-Bargues C, Borras C, Alique M. The contribution of extracellular vesicles from senescent endothelial and vascular smooth muscle cells to vascular calcification. *Frontiers in Cardiovascular Medicine*. 2022 Apr 15;9:854726. doi: 10.3389/fcvm.2022.854726. PMID: 35498012
- 698.Gil-Nagel A, Falip M, Sanchez-Carpintero R, Abad-Sazatornil M, Poveda J, Aibar J, Cardenal-Munoz E, Aras L, Sanchez R, Sancho-Lopez A, Trillo-Mata J, Torrejon M, Gil A. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through multi-criteria decision analysis. *Epilepsy & Behavior*. 2022 Jul;132:108711. doi: 10.1016/j.yebeh.2022.108711. PMID: 35588562
- 699.Palanca A, Ampudia-Blasco F, Real J. The controversial role of vitamin D in thyroid cancer pre-

# publication list

- vention. *Nutrients*. 2022 Jun 23;14(13):2593. doi: 10.3390/nu14132593. PMID: 35807774
- 700.Afeiche M, Iroz A, Thielecke F, De Castro A, Lefebvre G, Draper C, Martinez-Costa C, Haaland K, Marchini G, Agosti M, Domellof M, Rakza T, Costeira M, Vanpee M, Billeaud C, Picaud J, Hian D, Liu G, Shivappa N, Hebert J, Samuel T. The dietary inflammatory index is associated with subclinical mastitis in lactating European women. *Nutrients*. 2022 Nov 8;14(22):4719. doi: 10.3390/nu14224719. PMID: 36432405
- 701.Raidt J, Maitre B, Pennekamp P, Altenburg J, Anagnostopoulou P, Armengot M, Bloemsma L, Boon M, Borrelli M, Brinkmann F, Carr S, Carroll M, Castillo-Corullon S, Coste A, Cutrera R, Dehlink E, Desouches D, Di Cicco M, Dixon L, Emiralioglu N, Eralp E, Haarman E, Hogg C, Karadag B, Kobbernagel H, Lorent N, Mall M, Marthin J, Martinu V, Narayanan M, Ozcelik U, Peckham D, Pifferi M, Pohunek P, Polverino E, Range S, Ringshausen F, Robson E, Roehmel J, Rovira-Amigo S, Santamaria F, Schlegtenthal A, Szepfalusi Z, Tempels P, Thouvenin G, Ullmann N, Walker W, Wetzk M, Yiallouros P, Omran H, Nielsen K. The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN. *ERJ Open Research*. 2022 Aug 15;8(3):00139-2022. doi: 10.1183/23120541.00139-2022. PMID: 35983540
- 702.Cantarero-Prieto D, Lera J, Lanza-Leon P, Barreda-Gutierrez M, Guillem-Porta V, Castelo-Branco L, Martin-Moreno JM. The economic burden of localized prostate cancer and insights derived from cost-effectiveness studies of the different treatments. *Cancers*. 2022 Aug 24;14(17):4088. doi: 10.3390/cancers14174088. PMID: 36077625
- 703.Garcia-Rizo C, Cabrera B, Bioque M, Mezquida G, Lobo A, Gonzalez-Pinto A, Diaz-Caneja C, Corripio I, Vieta E, Baeza I, Garcia-Portilla M, Gutierrez-Fraile M, Rodriguez-Jimenez R, Garriga M, Fernandez-Egea E, Bernardo M. The effect of early life events on glucose levels in first-episode psychosis. *Frontiers in Endocrinology*. 2022 Dec 5;13:983792. doi: 10.3389/fendo.2022.983792. PMID: 36545332
- 704.Chico-Sanchez P, Gras-Valenti P, Algado-Selles N, Jimenez-Sepulveda N, Vanaclocha H, Peiro S, Burgos J, Berenguer A, Navarro D, Sanchez-Paya J. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain). *Preventive Medicine*. 2022 Oct;163:107237. doi: 10.1016/j.ypmed.2022.107237. PMID: 36057393
- 705.Toson B, Simon C, Moreno I. The endometrial microbiome and its impact on human conception. *International Journal of Molecular Sciences*. 2022 Jan 1;23(1):485. doi: 10.3390/ijms23010485. PMID: 35008911
- 706.Fatmi A, Saadi W, Beltran-Garcia J, Garcia-Gimenez JL, Pallardo FV. The endothelial glycocalyx and neonatal sepsis. *International Journal of Molecular Sciences*. 2022 Dec 26;24(1):364. doi: 10.3390/ijms24010364. PMID: 36613805
- 707.Iborra M, Moret I, Buso E, Garcia-Gimenez J, Ricart E, Gisbert J, Cabre E, Esteve M, Marquez-Mosquera L, Garcia-Planella E, Guardiola J, Pallardo F, Serena C, Algaba-Chueca F, Domenech E, Nos P, Beltran B. The genetic diversity and dysfunctionality of catalase associated with a worse outcome in Crohn's Disease. *International Journal of Molecular Sciences*. 2022 Dec 14;23(24):15881. doi: 10.3390/ijms232415881. PMID: 36555526
- 708.GBD 2019 Adolescent Young Adult Cancer Collaborators. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet. Oncology*. 2022 Jan;23(1):27-52. doi: 10.1016/S1470-2045(21)00581-7. PMID: 34871551
- 709.GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2022 Aug 20;400(10352):563-591. doi: 10.1016/S0140-6736(22)01438-6. PMID: 35988567
- 710.Tonet E, Ariza-Sole A, Serenelli M, Formiga F, Sanchis J, Pavasini R, Diez-Villanueva P, Vitali F, Bonanad C, Grazzi G, Carol A, Chiaranda G, Pompei G, Cardelli LS, Caglioni S, Gibiino F, Volpatto S, Campo G. The impact of sex and physical performance on long-term mortality in older patients with

# publication list

- myocardial infarction. *BMC Medicine*. 2022 Jan 20;20(1):15. doi: 10.1186/s12916-021-02211-1. PMID: 35045843
711. Adamina M, Ademuyiwa A, Adisa A, et al. The impact of surgical delay on resectability of colorectal cancer: an international prospective cohort study. *Colorectal Disease*. 2022 Mar 14;24(6):708-726. doi: 10.1111/codi.16117. PMID: 35286766
712. Fons-Badal C, Agustin-Panadero R, Labaig-Rueda C, Sola-Ruiz M, Garcia-Selva M, Font A. The influence of keratinized mucosa on the nonsurgical therapeutic treatment of peri-implantitis. *Journal of Clinical Medicine*. 2022 Jul 15;11(14):4118. doi: 10.3390/jcm11144118. PMID: 35887880
713. Pujol N, Berge D, Mane A, Bioque M, Mezquida G, Amoretti S, Baeza I, Gonzalez-Pinto A, Lobo A, Cuesta M, Ribeiro M, Sanchez-Tomico G, Perez-Sola V, Verdolini N, Vieta E, Parellada M, Roldan A, Bernardo M. The influence of modifiable cardiovascular risk factors on cognition, functioning, and inflammatory markers in first-episode psychosis: results from a 2-year follow-up study. *Psychiatry Research*. 2022 Oct;316:114760. doi: 10.1016/j.psychres.2022.114760. PMID: 35977447
714. Van Schooten T, Derkx S, Jimenez-Marti E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O'Connor J, Esteso F, Farres J, Mas J, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T. The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. *BMC Cancer*. 2022 Jun 13;22(1):646. doi: 10.1186/s12885-022-09689-9. PMID: 35692051
715. Mas-Bargues C, Borras C, Vina J. The multimodal action of genistein in Alzheimer's and other age-related diseases. *Free Radical Biology & Medicine*. 2022 Apr;183:127-137. doi: 10.1016/j.freeradbiomed.2022.03.021. PMID: 35346775
716. Sanchez-Torres A, Peralta V, Gil-Berrozpe G, Mezquida G, Ribeiro M, Molina-Garcia M, Amoretti S, Lobo A, Gonzalez-Pinto A, Merchan-Naranjo J, Corripio I, Vieta E, de la Serna E, Berge D, Bernardo M, Cuesta M, Aguilar Garcia Iturrospe E, PEPs Group. The network structure of cognitive deficits in first episode psychosis patients. *Schizophrenia Research*. 2022 Jun;244:46-54. doi: 10.1016/j.schres.2022.05.005. PMID: 35594732
717. Ahullo-Fuster MA, Ortiz T, Varela-Donoso E, Nacher J, Sanchez-Sanchez ML. The parietal lobe in Alzheimer's disease and blindness. *Journal of Alzheimer's Disease*. 2022;89(4):1193-1202. doi: 10.3233/JAD-220498. PMID: 36093700
718. Wilding JPH, Evans M, Fernando K, Gorrioz JL, Cebrian A, Diggle J, Hicks D, James J, Newland Jones P, Ali A, Bain S, Da Porto A, Patel D, Viljoen A, Wheeler DC, Del Prato S. The place and value of sodium-glucose cotransporter 2 inhibitors in the evolving treatment paradigm for type 2 diabetes mellitus: a narrative review. *Diabetes Therapy*. 2022 May;13(5):847-872. doi: 10.1007/s13300-022-01228-w. PMID: 35307801
719. Soua S, Ghammam R, Maatoug J, Zammit N, Ben Fredj S, Martinez F, Ghannem H. The prevalence of high blood pressure and its determinants among Tunisian adolescents. *Journal of Human Hypertension*. 2022 Apr 8. doi: 10.1038/s41371-022-00677-x. PMID: 35396537
720. Sanchez-Sendra B, Gonzalez-Munoz J, Perez-Deben S, Monteagudo C. The prognostic value of miR-125b, miR-200c and miR-205 in primary cutaneous malignant melanoma is independent of BRAF mutational status. *Cancers*. 2022 Mar 16;14(6):1532. doi: 10.3390/cancers14061532. PMID: 35326682
721. Marques P, Fernandez-Presa L, Carretero A, Gomez-Cabrera MC, Viña J, Signes-Costa J, Sanz MJ. The radiographic assessment of lung edema score of lung edema severity correlates with inflammatory parameters in patients with coronavirus disease 2019-Potential new admission biomarkers to predict coronavirus disease 2019 worsening. *Frontiers in Medicine*. 2022 Aug 11;9:871714. doi: 10.3389/fmed.2022.871714. PMID: 36035415
722. Martinez-Redondo M, Prados Sanchez C, Garcia-Rio F, Quintana Gallego E, Castillo Corullon S, Salcedo Posadas A, Giron Moreno R, Martinez Martinez M, Maiz Carro L, de Vicente C, Costa

# publication list

- Colomer J, Alvarez-Sala Walther R. The relation of CFTR-genotype and associated comorbidities to development of pulmonary atelectasis in cystic fibrosis patients. *Archivos de Bronconeumología*. 2022 Sep;58(9):666-668. doi: 10.1016/j.arbres.2022.02.009. PMID: 35644710
- 723.Cano J, Facila L, Gracia-Baena J, Zangroniz R, Alcaraz R, Rieta J. The relevance of calibration in machine learning-based hypertension risk assessment combining photoplethysmography and electrocardiography. *Biosensors-Basel*. 2022 May 1;12(5):289. doi: 10.3390/bios12050289. PMID: 35624590
- 724.Martinez Pinteno A, Mezquida G, Bioque M, Lopez Ilundain JM, Andreu Bernabeu A, Zorrilla I, Mane A, Rodriguez Jimenez R, Corripio I, Sarro S, Ibanez A, Usall J, Rivero O, Gasso P, Leza JC, Cuesta MJ, Parellada M, Gonzalez Pinto A, Berrocoso E, Mas S, Bernardo M. The role of BDNF and NGF plasma levels in first-episode schizophrenia: a longitudinal study. *European Neuropsychopharmacology*. 2022 Feb 23;57:105-117. doi: 10.1016/j.euroneuro.2022.02.003. PMID: 35219096
- 725.Wandschneider L, Namer Y, Davidovitch N, Nitzan D, Otok R, Leighton L, Signorelli C, Middleton J, Martin-Moreno JM, Chambaud L, Lopes H, Razum O. The Role of Europe's Schools of Public Health in Times of War: ASPHER Statement on the War Against Ukraine. *Public Health Reviews*. 2022 Mar 16;43:1604880. doi: 10.3389/phrs.2022.1604880. PMID: 35371592
- 726.Cuvry A, Gozalbo-Rovira R, Strubbe D, Neyts J, de Witte P, Rodriguez-Diaz J, Rocha-Pereira J. The role of histo-blood group antigens and microbiota in human norovirus replication in zebrafish larvae. *Microbiology Spectrum*. 2022 Dec 21;10(6):e0315722. doi: 10.1128/specrum.03157-22. PMID: 36314930
- 727.Vezza T, Diaz-Pozo P, Canet F, Maranon AM, Abad Jimenez Z, Garcia-Gargallo C, Roldan I, Sola E, Banuls C, Lopez-Domenech S, Rocha M, Victor VM. The role of mitochondrial dynamic dysfunction in age-associated type 2 diabetes. *World Journal of Mens Health*. 2022 Jul;40(3):399-411. doi: 10.5534/wjmh.210146. PMID: 35021300
- 728.Martorell-Llobregat C, Gonzalez-Lopez P, Luna E, Asensio-Asensio M, Jadraque-Rodriguez R, Garcia-March G, Moreno-Lopez P. The role of vagus nerve stimulation in the treatment of refractory epilepsy: clinical outcomes and impact on quality of life. *Neurologia*. 2022 Jul-Aug;37(6):450-458. doi: 10.1016/j.nrleng.2019.04.004. PMID: 34088638
- 729.Mendibe Bilbao M, Ezpeleta Echavarri D, Lainez Andres J. The SEN and the Spanish model of recertification promoted by the Spanish Federation of Medical and Scientific Associations and its members. *Neurologia*. 2022 Sep 29;S2173-5808(22)00102-X. doi: 10.1016/j.nrleng.2022.09.001. PMID: 36183954
- 730.Porcellato E, Gonzalez-Sanchez J, Ahlmann Eltze C, Elsakka M, Shapira I, Fritsch J, Navarro J, Anders S, Russell R, Wieland F, Metzendorf C. The S-palmitoylome and DHHC-PAT interactome of *Drosophila melanogaster* S2R+cells indicate a high degree of conservation to mammalian palmitoylomes. *PLoS One*. 2022 Aug 12;17(8):e0261543. doi: 10.1371/journal.pone.0261543. PMID: 35960718
- 731.Ginex T, Marco-Marín C, Wieczór M, Mata CP, Krieger J, Ruiz-Rodríguez P, López-Redondo ML, Francés-Gómez C, Melero R, Sánchez-Sorzano CÓ, Martínez M, Gougeard N, Forcada-Nadal A, Zamora-Caballero S, Gozalbo-Rovira R, Sanz-Frasquet C, Arranz R, Bravo J, Rubio V, Marina A, Geller R, Comas I, Gil C, Coscolla M, Orozco M, Llácer JL, Carazo JM. The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: the case of the spike A222V mutation. *PLoS Pathogens*. 2022 Jul 11;18(7):e1010631. doi: 10.1371/journal.ppat.1010631. PMID: 35816514
- Ginex T, Marco-Marín C, Wieczór M, Mata CP, Krieger J, Ruiz-Rodríguez P, López-Redondo ML, Francés-Gómez C, Melero R, Sánchez-Sorzano CÓ, Martínez M, Gougeard N, Forcada-Nadal A, Zamora-Caballero S, Gozalbo-Rovira R, Sanz-Frasquet C, Arranz R, Bravo J, Rubio V, Marina A, Geller R, Comas I, Gil C, Coscolla M, Orozco M, Llácer JL, Carazo JM. Correction to: The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: the case of the spike A222V mutation. *PLoS Pathogens*. 2022 Nov

# publication list

- 23;18(11):e1010995. doi: 10.1371/journal.ppat.1010995. PMID: 36417341
732. Gonzalez-Darder J, Capilla-Guasch P. The temporary resection of the cranial vault by Wilhelm Wagner (1848-1900) instead of trepanation: the cornerstone of the modern craniotomy. *Journal of Neurosurgery.* 2022 Dec 9;1-6. doi: 10.3171/2022.11.JNS221680. PMID: 36681976
733. Zamora-Sanchez J, Urpi-Fernandez A, Sastre-Rus M, Lumillo-Gutierrez I, Gea-Caballero V, Jodar-Fernandez L, Julian-Rochina I, Zabaleta-Del-Olmo E. The Tilburg Frailty Indicator: a psychometric systematic review. *Ageing Research Reviews.* 2022 Apr;76:101588. doi: 10.1016/j.arr.2022.101588. PMID: 35150901
734. Villar S, Ariceta B, Agirre X, Urribarri A, Ayala R, Martinez-Cuadron D, Bergua J, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Simoes C, Herrera P, Calasanz M, Alfonso-Pierola A, Paiva B, Martinez-Lopez J, San Miguel J, Prosper F, Montesinos P. The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients. *Frontiers in Oncology.* 2022 Nov 24;12:1054458. doi: 10.3389/fonc.2022.1054458. PMID: 36505804
735. Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Valeria Bianchi G, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglavov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. *Molecular Oncology.* 2022 Jun;16(12):2355-2366. doi: 10.1002/1878-0261.13141. PMID: 34816585
736. Negueroles-Garcia M, Panach-Navarrete J, Martinez-Jabaloyas J. The use of urokinase in urinary catheter obstructed by clots. *Archivos Espanoles de Urologia.* 2022 Jan;75(1):82-86. doi: 10.37554/es-j.arch.esp.urol-20210317-3534-33. PMID: 35173068
737. Usach I, Di Marco S, Díez O, Alós M, Peris JE. The usefulness of in vitro percutaneous absorption experiments applying the infinite dose technique to predict in vivo plasma levels: comparison of model-predicted and observed plasma concentrations of nortriptyline in rats. *Pharmaceutics.* 2022 Jul 12;14(7):1457. doi: 10.3390/pharmaceutics14071457. PMID: 35890351
738. Vazquez J, Pinero A, de Castro F, Lluch A, Martin M, Barnadas A, Alba E, Rodriguez-Lescure A, Rojo F, Gimenez J, Sola I, Quintana M, Bonfill X, Urrutia G, Sanchez-Rovira P. The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview. *Clinical & Translational Oncology.* 2022 Sep;24(9):1744-1754. doi: 10.1007/s12094-022-02824-9. PMID: 35414152
739. Sanz-Ros J, Mas-Bargues C, Romero-Garcia N, Huete-Acevedo J, Dromant M, Borras C. Therapeutic potential of extracellular vesicles in aging and age-related diseases. *International Journal of Molecular Sciences.* 2022 Nov 23;23(23):14632. doi: 10.3390/ijms232314632. PMID: 36498960
740. Rodríguez LR, Lapeña-Luzón T, Benetó N, Beltran-Beltran V, Pallardó FV, Gonzalez-Cabo P, Navarro JA. Therapeutic strategies targeting mitochondrial calcium signaling: a new hope for neurological diseases?. *Antioxidants.* 2022 Jan 15;11(1):165. doi: 10.3390/antiox11010165. PMID: 35052668
741. Gomez-Medina C, Capilla-Lozano M, Ballester Ferre M, Martí-Aguado D, Crespo A, Bosca-Watts M, Navarro Cortes P, Anton R, Pascual Moreno I, Tosca Cuquerella J, Minguez Perez M. Thiopurine adherence: high prevalence with low impact in UC outcomes. *Revista Espanola de Enfermedades Digestivas.* 2022 Feb;114(2):76-82. doi: 10.17235/reed.2021.7630/2020. PMID: 33733802
742. Domper L, Redondo M, Hernandez J, Diaz E. Thoracic frog roes with zosteriform distribution. *Dermatology Practical & Conceptual.* 2022 Apr 1;12(2):e2022047. doi: 10.5826/dpc.1202a47. PMID: 35646439
743. Garcia-Botello S, Martín-Arévalo J, Martí-Fernández R, Moro-Valdezate D, Pla-Martí V, Espí-Macías A. Three-dimensional endoanal ultrasound to assess the validity of Goodsall's Rule and the Midline Rule in predicting the path of perianal fistula-in-anal and the location of the internal opening. *Techniques in Coloproctology.* 2022 May;26(5):351-

# publication list

361. doi: 10.1007/s10151-022-02592-2. PMID: 35217938
744. Burn E, Li X, Delmestri A, Jones N, Duarte-Salles T, Reyes C, Martinez-Hernandez E, Martí E, Verhamme K, Rijnbeek P, Strauss V, Prieto-Alhambra D. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom. *Nature Communications*. 2022 Nov 23;13(1):7167. doi: 10.1038/s41467-022-34668-w. PMID: 36418291
745. Ontoria-Oviedo I, Amaro-Prellezo E, Castellano D, Venegas-Venegas E, Gonzalez-Santos F, Ruiz-Sauri A, Pelacho B, Prosper F, Perez del Caz MD, Sepulveda P. Topical administration of a marine oil rich in pro-resolving lipid mediators accelerates wound healing in diabetic db/db mice through angiogenesis and macrophage polarization. *International Journal of Molecular Sciences*. 2022 Aug 31;23(17):9918. doi: 10.3390/ijms23179918. PMID: 36077316
746. Mari-Alexandre J, Garcia-Oms J, Agababyan C, Belda-Montesinos R, Royo-Bolea S, Varo-Gomez B, Diaz-Sierra C, Gonzalez-Canto E, Gilabert-Estelles J. Toward an improved assessment of quality of life in endometriosis: evaluation of the Spanish version of the Endometriosis Health Profile 30. *Journal of Psychosomatic Obstetrics & Gynecology*. 2022 Sep;43(3):251-257. doi: 10.1080/0167482X.2020.1795827. PMID: 32735156
747. Grau-Perez M, Caballero-Mateos MJ, Domingo-Rellosa A, Navas-Acien A, Gomez-Ariza JL, Garcia-Barrera T, Leon-Latre M, Soriano-Gil Z, Jarauta E, Cenarro A, Moreno-Franco B, Laclaustra M, Civeira F, Casasnovas JA, Guallar E, Tellez-Plaza M. Toxic metals and subclinical atherosclerosis in carotid, femoral, and coronary vascular territories: the Aragon workers health study. *Arteriosclerosis, Thrombosis, And Vascular Biology*. 2022 Jan;42(1):87-99. doi: 10.1161/ATVBAHA.121.316358. PMID: 34879710
748. Hernani R, Benzaquen A, Solano C. Toxicities following CAR-T therapy for hematological malignancies. *Cancer Treatment Reviews*. 2022 Dec;111:102479. doi: 10.1016/j.ctrv.2022.102479. PMID: 36308910
749. Raposeiras-Roubin S, Abu-Assi E, Cespon Fernandez M, Blanco Prieto S, Barreiro Pardal C, Dominguez-Erquicia P, Melendo Viu M, Bonanad Lozano C, Rossello X, Ibanez B, Iniguez Romo A. Trade-off between the effects of embolic versus bleeding events on mortality in elderly patients with atrial fibrillation. *Revista Espanola de Cardiologia (English Ed.)*. 2022 Apr;75(4):334-342. doi: 10.1016/j.rec.2021.02.003. PMID: 33839062
750. Rasulo F, Calza S, Robba C, Taccone F, Biasucci D, Badenes R, Piva S, Savo D, Citerio G, Dibu J, Curto F, Merciadri M, Gritti P, Fassini P, Park S, Lamperti M, Bouzat P, Malacarne P, Chieregato A, Bertuetti R, Aspide R, Cantoni A, McCredie V, Guadrini L, Latronico N. Transcranial Doppler as a screening test to exclude intracranial hypertension in brain-injured patients: the IMPRESSIT-2 prospective multicenter international study. *Critical Care*. 2022 Apr 15;26(1):110. doi: 10.1186/s13054-022-03978-2. PMID: 35428353
751. Jimenez N, Reig O, Marin-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, Rodriguez-Vida A, Climent MA, Cros S, Chirivella I, Domenech M, Figols M, Gonzalez-Billalabeitia E, Jimenez Peralta D, Rodriguez-Carunchio L, Garcia-Esteve S, Garcia de Herreros M, Ribal MJ, Prat A, Mellado B. Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel. *Cancers*. 2022 Sep 29;14(19):4757. doi: 10.3390/cancers14194757. PMID: 36230681
752. Ruiz-Herrero J, Olaso-Gonzalez G, Serna E, Canedo-Villarroya E, Correas A, Gambini J, Gomez-Cabrera M, Pedron-Giner C, Vina J. Transcriptomic profile of epileptic children treated with ketogenic therapies. *Journal of Integrative Neuroscience*. 2022 Jan 28;21(1):31. doi: 10.31083/j.jin2101031. PMID: 35164467
753. Correa-Ghisays P, Sanchez-Orti JV, Balanza-Martinez V, Selva-Vera G, Vila-Frances J, Magdalena-Benedito R, Victor VM, Escribano-Lopez I, Hernandez-Mijares A, Vivas-Lalinde J, San-Martin C, Crespo-Facorro B, Tabares-Seisdedos R. Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: a

# publication list

- 1-year follow-up study. *Journal of Affective Disorders.* 2022 Mar 1;300:99-108. doi: 10.1016/j.jad.2021.12.074. PMID: 34965401
754. Bastida G, Marin-Jimenez I, Fores A, Garcia-Planella E, Arguelles-Arias F, Tagarro I, Fernandez-Nistal A, Montoto C, Aparicio J, Aguas M, Santos-Fernandez J, Bosca-Watts M, Ferreiro-Iglesias R, Merino O, Aldeguer X, Cortes X, Sicilia B, Mesonero F, Barreiro-de Acosta M. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNF $\alpha$  used for the treatment of IBD: results from the VERNE study. *Digestive and Liver Disease.* 2022 Jan;54(1):76-83. doi: 10.1016/j.dld.2021.06.005. PMID: 34244110
755. Martinez-Cuadron D, Megias-Vericat JE, Serrano J, Martinez-Sanchez P, Rodriguez-Arboli E, Gil C, Aguiar E, Bergua Burgues JM, Lopez-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodriguez-Medina C, Lopez-Pavia M, Tormo M, Algarra JL, Amigo ML, Sayas MJ, Labrador J, Rodriguez-Gutierrez JI, Benavente C, Costilla-Barriga L, Garcia-Boyero R, Lavilla E, Vives S, Herrera P, Garcia D, Herraez-Albendea MM, Esteves GV, Gomez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MA, Montesinos P. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. *Blood Advances.* 2022 Feb 22;6(4):1278-1295. doi: 10.1182/bloodadvances.2021005335. PMID: 34794172
756. Casarrubios M, Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Lazaro-Quintela M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe R, Vinolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernandez-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermudez A. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. *Journal for Immunotherapy of Cancer.* 2022 Sep;10(9):e005320. doi: 10.1136/jitc-2022-005320. PMID: 36171009
757. Donat-Vargas C, Guerrero-Zotano A, Lope V, Bermejo B, Casas A, Baena-Canada J, Antolin S, Sanchez-Rovira P, Anton A, Garcia-Saenz J, Ramos M, Munoz M, de Juan A, Sanchez C, Chacon J, Gil-Gil M, Conejero R, Llombart A, Bezares S, de Larrea-Baz N, Perez-Gomez B, Martin M, Pollan M. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study. *European Journal of Clinical Nutrition.* 2022 Sep;76(9):1343-1346. doi: 10.1038/s41430-022-01101-w. PMID: 35194197
758. Mosquera Orgueira A, Gonzalez Perez MS, Diaz Arias J, Rosinol L, Oriol A, Teruel AI, Martinez Lopez J, Palomera L, Granell M, Blanchard MJ, de la Rubia J, Lopez de la Guia A, Rios R, Sureda A, Hernandez MT, Bengoechea E, Calasanz MJ, Gutierrez N, Martin ML, Blade J, Lahuerta JJ, San Miguel J, Mateos MV. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. *Blood Cancer Journal.* 2022 Apr 25;12(4):76. doi: 10.1038/s41408-022-00647-z. PMID: 35468898
759. Verdonk F, Feyaerts D, Badenes R, Bastarache J, Bougle A, Ely W, Gaudilliere B, Howard C, Kotfis K, Lautrette A, Le Dorze M, Mankidy B, Matthay M, Morgan C, Mazeraud A, Patel B, Pattnaik R, Reuter J, Schultz M, Sharshar T, Shrestha G, Verdonk C, Ware L, Pirracchio R, Jabaudon M. Upcoming and urgent challenges in critical care research based on COVID-19 pandemic experience. *Anaesthesia, Critical Care & Pain Medicine.* 2022 Jun 30;41(5):101121. doi: 10.1016/j.acpm.2022.101121. PMID: 35781076
760. Borghi C, Agnoletti D, Cicero A, Lurbe E, Virdis A. Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk. *Hypertension.* 2022 Sep;79(9):1927-1936. doi: 10.1161/HYPERTENSIONHA.122.17956. PMID: 35658505
761. Galvez-Fernandez M, Powers M, Grau-Perez M, Domingo-Rellosa A, Lolacono N, Goessler W, Zhang Y, Fretts A, Umans JG, Maruthur N, Navas-Acien A. Urinary zinc and incident type 2 Diabetes: prospective evidence from the Strong Heart Study. *Diabetes Care.* 2022 Nov 1;45(11):2561-2569. doi: 10.2337/dc22-1152. PMID: 36134919
762. Osca Verdegal R, Beltran Garcia J, Gorri J, Jaboloyas J, Pallardo F, Garcia Gimenez J. Use of circular RNAs in diagnosis, prognosis and therapeutics

# publication list


- of renal cell carcinoma. *Frontiers in Cell and Developmental Biology*. 2022 Jun 22;10:879814. doi: 10.3389/fcell.2022.879814. PMID: 35813211
- 763.Ruiz-Alguero M, Alejos B, Yubero C, Jaume M, Iribarren J, Asensi V, Pasquau F, Galera C, Pascual-Carrasco M, Munoz A, Jarrin I, Ferrer Ribera A, Galindo Puerto M, Suarez-Garcia I. Use of generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection in Spain. *AIDS Research and Human Retroviruses*. 2022 Jun;38(6):433-440. doi: 10.1089/aid.2021.0122. PMID: 35357907
- 764.Labrador J, Saiz-Rodriguez M, de Miguel D, de Laiglesia A, Rodriguez-Medina C, Vidriales M, Perez-Encinas M, Sanchez-Sanchez M, Cuello R, Roldan-Perez A, Vives S, Benzo-Callejo G, Colorado M, Garcia-Fortes M, Sayas M, Olivier C, Recio I, Conde-Royo D, Bienert-Garcia A, Vahi M, Munoz-Garcia C, Seri-Merino C, Tormo M, Vall-Llovera F, Foncillas M, Martinez-Cuadron D, Sanz M, Montesinos P. Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: the PETHEMA Registry Experience. *Cancers*. 2022 Mar 29;14(7):1734. doi: 10.3390/cancers14071734. PMID: 35406512
- 765.Chaparro M, Baston-Rey I, Salgado E, Garcia J, Ramos L, Palomares M, Arguelles-Arias F, Flores E, Cabello M, Iturria S, Ortiz A, Charro M, Ginard D, Sadornil C, Ochoa O, Busquets D, Iyo E, Casbas A, de la Piscina P, Bosca-Watts M, Arroyo M, Garcia M, Hinojosa E, Gordillo J, Montiel P, Jimenez B, Iborra C, Moron J, Huguet J, Gonzalez-Lama Y, Santos A, Amo V, Arranz M, Bermejo F, Cadilla J, de Celis C, Salazar P, San Roman A, Jimenez N, Garcia-Lopez S, Figuerola A, Jimenez I, Cerezo F, Taxonera C, Varela P, de Francisco R, Monfort D, Arriero G, Hernandez-Camba A, Alonso F, Van Domselaar M, Pajares-Villarroya R, Nunez A, Moranta F, Marin-Jimenez I, Alonso V, Rodriguez M, Camo-Monterde P, Tercero I, Navarro-Llavat M, Garcia L, Cruz D, Kloss S, Passey A, Novella C, Vispo E, Barreiro-de Acosta M, Gisbert J. Using interpretable machine learning to identify baseline predictive factors of remission and drug durability in Crohn's disease patients on ustekinumab. *Journal of Clinical Medicine*. 2022 Aug 3;11(15):4518. doi: 10.3390/jcm11154518. PMID: 35956133
- 766.Rubio-Gracia J, Crespo-Aznarez S, De la Espriella R, Nunez G, Sanchez-Martes M, Garcés-Horna V, Yanguas-Barea N, Josa-Laorden C, Cobo-Marcos M, Gimenez-Lopez I, Perez-Calvo JL, Nunez J. Utility of plasma CA125 as a proxy of intra-abdominal pressure in patients with acute heart failure. *European Heart Journal-Acute Cardiovascular Care*. 2022 Jun 22;11(6):453-460. doi: 10.1093/ehjacc/zuc046. PMID: 35512321
- 767.Rodriguez-Manero M, Baluja A, Hernandez J, Munoz C, Calvo D, Fernandez-Armenta J, Garcia-Fernandez A, Zorio E, Arce-Leon A, Sanchez-Gomez J, Mosquera-Perez I, Arias M, Diaz-Infante E, Exposito V, Jimenez-Ramos V, Teijeira E, Canadas-Godoy M, Guerra-Ramos J, Oloriz T, Basterra N, Sousa P, Elices-Teja J, Garcia-Bolao I, Gonzalez-Juanatey J, Brugada R, Gimeno J, Brugada J, Arbelo E. Validation of multiparametric approaches for the prediction of sudden cardiac death in patients with Brugada syndrome and electrophysiological study. *Revista Espanola de Cardiologia (English Ed.)*. 2022 Jul;75(7):559-567. doi: 10.1016/j.rec.2021.07.007. PMID: 34479845
- 768.Ribera J, Garcia O, Buendia-Urena B, Terol M, Vincent A, Vall-Llovera F, Bergua J, Garcia-Cadenas I, Esteve J, Ribera J, Acuna-Cruz E, Herrera P, Hernandez-Rivas J, Abriesqueta P, Gonzalez-Campos J, Rodriguez C, Bastos-Oreiro M, Genesca E, Caminos N, de Llano M, Cladera A, Sancho J. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. *Leukemia & Lymphoma*. 2022 Aug;63(8):1993-1996. doi: 10.1080/10428194.2022.2053531. PMID: 35343365
- 769.Ahmed W, Bhatia S, McLean K, et al. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery. *BJS Open*. 2022 Jan 6;6(1):zrab150. doi: 10.1093/bjsopen/zrab150. PMID: 35179188
- 770.Terres-Jimenez B, Dominguez-Cabanero EM, Gonzalez-Vivas C, Garcia-Parreno B, Diego-Castano S, Aiko Gesler M, De Entrambasaguas M, Lorente-Rovira E. Variables associated with the success of group cognitive behavioral therapy for insomnia: preliminary results. *Actas Espanolas de Psiquiatria*. 2022 Sep;50(5):233-240. PMID: 36273383
- 771.Lopez-Lopez V, Kuemmerli C, Cutillas J, Maupoej

# publication list

- J, Lopez-Andujar R, Ramos E, Mils K, Valdivieso A, Valero A, Martinez P, Paterna S, Serrablo A, Re ese T, Oldhafer K, Brusadin R, Conesa A, Valladares L, Loinaz C, Garc es-Albir M, Sabater L, Moc chegiani F, Vivarelli M, Perez S, Flores B, Lucena J, Sanchez-Cabus S, Calero A, Minguillon A, Ramia J, Alcazar C, Aguiló J, Ruiperez-Valiente J, Grochola L, Clavien P, Petrowsky H, Robles-Campos R. Vascular injury during cholecystectomy: a multicenter critical analysis behind the drama. *Surgery*. 2022 Oct;172(4):1067-1075. doi: 10.1016/j.surg.2022.06.020. PMID: 35965144
772. Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T, Lee KH, Nakagawa K, Hansen O, Biesma B, Kundu MG, Dunbar M, He L, Ansell P, Sehgal V, Huang X, Glasgow J, Bach BA. Veliparib plus carboplatin and paclitaxel versus investigator's choice of standard chemotherapy in patients with advanced non-squamous non-small cell lung cancer. *Clinical Lung Cancer*. 2022 May;23(3):214-225. doi: 10.1016/j.cllc.2022.01.005. PMID: 35331641
773. Civera J, Minana G, de la Espriella R, Santas E, Sasstre C, Mollar A, Conesa A, Martinez A, Nunez E, Bayes-Genis A, Nunez J. Venous leg compression for tissue decongestion in patients with worsening congestive heart failure. *Frontiers In Cardiovascular Medicine*. 2022 Jul 8;9:847450. doi: 10.3389/fcvm.2022.847450. PMID: 35872894
774. Robba C, Nielsen N, Dankiewicz J, Badenes R, Battaglini D, Ball L, Brunetti I, Wendel Garcia P, Young P, Eastwood G, Chew MS, Jakobsen J, Unden J, Thomas M, Joannidis M, Nichol A, Lundin A, Hollenberg J, Lilja G, Hammond NE, Saxena M, Martin A, Solar M, Taccone FS, Friberg HA, Pelosi P. Ventilation management and outcomes in out-of-hospital cardiac arrest: a protocol for a preplanned secondary analysis of the TTM2 trial. *BMJ Open* 2022 Mar 3;12(3):e058001. doi: 10.1136/bmjopen-2021-058001. PMID: 35241476
775. Robba C, Badenes R, Battaglini D, Ball L, Brunetti I, Jakobsen J, Lilja G, Friberg H, Wendel-Garcia P, Young P, Eastwood G, Chew M, Unden J, Thomas M, Joannidis M, Nichol A, Lundin A, Hollenberg J, Hammond N, Saxena M, Annborn M, Solar M, Taccone F, Dankiewicz J, Nielsen N, Pelosi P. Ventilatory settings in the initial 72h and their association with outcome in out-of-hospital cardiac arrest patients: a preplanned secondary analysis of the targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest (TTM2) trial. *Intensive Care Medicine*. 2022 Aug;48(8):1024-1038. doi: 10.1007/s00134-022-06756-4. PMID: 35780195
776. Redondo N, Navarro D, Aguado J, Fernandez-Ruiz M. Viruses, friends, and foes: the case of Torque Teno Virus and the net state of immunosuppression. *Transplant Infectious Disease*. 2022 Apr;24(2):e13778. doi: 10.1111/tid.13778. PMID: 34933413
777. Benavent M, Saura S. Visual dermatology: annular elastolytic giant cell granuloma. *Journal of Cutaneous Medicine and Surgery*. 2022;26(1):98. doi: 10.1177/1203475420962047. PMID: 32988233
778. Henn M, Martin-Gorgojo V, Martin-Moreno J. Vitamin D in cancer prevention: gaps in current knowledge and room for hope. *Nutrients*. 2022 Oct 27;14(21):4512. doi: 10.3390/nu14214512. PMID: 36364774
779. Monferrer E, Dobre O, Trujillo S, Oliva M, Trubert-Paneli A, Acevedo-Leon D, Noguera R, Salmeron-Sanchez M. Vitronectin-based hydrogels recapitulate neuroblastoma growth conditions. *Frontiers in Cell and Developmental Biology*. 2022 Oct 11;10:988699. doi: 10.3389/fcell.2022.988699. PMID: 36425532
780. Sancho J, Ferrer S, Bures E, Fernandez-Presa L, Banuls P, Gonzalez MC, Signes-Costa J. Waveforms analysis in patients with amyotrophic lateral sclerosis for enhanced efficacy of mechanically assisted coughing. *Respiratory Care*. 2022 Oct;67(10):1226-1235. doi: 10.4187/resp-care.09978. PMID: 35790394
781. Mombiela R, Arildskov A, Bruun F, Hasselbalch L, Holst K, Rasmussen S, Borras C. What genetics can do for oncological imaging: a systematic review of the genetic validation data used in radiomics studies. *International Journal of Molecular Sciences*. 2022 Jun 10;23(12):6504. doi: 10.3390/ijms23126504. PMID: 35742947
782. Fernandez-Moreno M, Carvajal M, Mozos F, Albir M, Obiol R, Ortega J. When laparoscopic repair is feasible for diaphragmatic hernia in adults?. *A*

# publication list

- retrospective study and literature review. *Surgical Endoscopy and Other Interventional Techniques.* 2022 May;36(5):3347-3355. doi: 10.1007/s00464-021-08651-3. PMID: 34312729
783. Guarque-Chabrera J, Gil-Miravet I, Olucha-Bordona F, Melchor-Eixe I, Miquel M. When the front fails, the rear wins. Cerebellar correlates of prefrontal dysfunction in cocaine-induced memory in male rats. *Progress in Neuropsychopharmacology & Biological Psychiatry.* 2022 Jan 10;112:110429. doi: 10.1016/j.pnpbp.2021.110429. PMID: 34416354
784. Insa A, Martin-Martorell P, Di Liello R, Fasano M, Martini G, Napolitano S, Vicedomini G, Cappabianca S, Franco R, Morgillo F, Della Corte CM. Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? *Critical Reviews in Oncology/Hematology.* 2022 Jan;169:103538. doi: 10.1016/j.critrevonc.2021.103538. PMID: 34801700
785. Papaccio F, Cabeza-Segura M, Garcia-Mico B, Tarazona N, Roda D, Castillo J, Cervantes A. Will organoids fill the gap towards functional precision medicine? *Journal of Personalized Medicine.* 2022 Nov 21;12(11):1939. doi: 10.3390/jpm12111939. PMID: 36422115
786. Einstein AJ, Hirschfeld C, Williams MC, Vitola JV, Better N, Villines TC, Cerci R, Shaw LJ, Choi AD, Dorbala S, Karthikeyan G, Lu B, Sinitzyn V, Ansheles AA, Kudo T, Buccicarelli-Ducci C, Nørgaard BL, Maurovich-Horvat P, Campisi R, Milan E, Louw L, Allam AH, Bhatia M, Sewanan L, Malkovskiy E, Cohen Y, Randazzo M, Narula J, Morozova O, Pascual TNB, Pynda Y, Dondi M, Paez D. Worldwide disparities in recovery of cardiac testing 1 year into COVID-19. *Journal of the American College of Cardiology.* 2022 May 24;79(20):2001-2017. doi: 10.1016/j.jacc.2022.03.348. PMID: 35589162
- Ferrer-Quintero M, Fernandez D, Lopez-Carrilero R, Birules I, Barajas A, Lorente-Rovira E, Diaz-Cutraro L, Verdaguer M, Garcia-Mieres H, Sevilla-Llewellyn-Jones J, Gutierrez-Zotes A, Grasa E, Pousa E, Huerta-Ramos E, Pelaez T, Barrigon M, Gonzalez-Higueras F, Ruiz-Delgado I, Cid J, Moritz S, Ochoa S, Spanish Metacognition Grp. Correction to: Persons with first episode psychosis have distinct profiles of social cognition and metacognition. *NPJ Schizophrenia.* 2022 Feb 24;8(1):3. doi: 10.1038/s41537-021-00199-4. PMID: 35210466
- Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee. Correction to: Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. *Annals of Oncology.* 2022 Jun;33(6):666. doi: 10.1016/j.annonc.2022.03.009. PMID: 35365377
- Rahman I, Sánchez AC, Davies J, Rzeniewicz K, Abuksem S, Joachim J, Hoskins Green HL, Killock D, Sanz MJ, Charras G, Parsons M, Ivetic A. Correction to: L-selectin regulates human neutrophil transendothelial migration. *Journal of Cell Science.* 2022 Oct 15;135(20):jcs.260658. doi: 10.1242/jcs.260658. PMID: 36259426
- Marco J, Canabate M, Martinez C, Banos R, Guillen V, Perez S. Correction to: Meaning in life mediates between emotional deregulation and eating disorders psychopathology: a research from the meaning-making model of eating disorders. *Frontiers in Psychology.* 2022 Feb 15;13:849974. doi: 10.3389/fpsyg.2022.849974. PMID: 35242091
- Chaparro et al.; on behalf of the EpidemiBD Study Group of Geteccu. Correction to: Chaparro et al. Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study. *J. Clin. Med.* 2021, 10, 2885. *Journal of Clinical Medicine.* 2022 Sep 30;11(19):5816. doi: 10.3390/jcm11195816. PMID: 36233844



# INCLIVA | VLC

Biomedical Research Institute

**Avda. Menéndez Pelayo, 4 accesorio · 46010 Valencia (España)**

**Tel. 34 96 197 35 17 Fax 34 96 197 35 40**

**[www.incliva.es](http://www.incliva.es) [incliva@incliva.es](mailto:incliva@incliva.es)**